FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Streiff, MB
Holmstrom, B
Ashrani, A
Bockenstedt, PL
Chesney, C
Eby, C
Fanikos, J
Fenninger, RB
Fogerty, AE
Gao, SW
Goldhaber, SZ
Hendrie, P
Kuderer, N
Lee, A
Lee, JT
Lovrincevic, M
Millenson, MM
Neff, AT
Ortel, TL
Paschal, R
Shattil, S
Siddiqi, T
Smock, KJ
Soff, G
Wang, TF
Yee, GC
Zakarija, A
McMillian, N
Engh, AM
AF Streiff, Michael B.
Holmstrom, Bjorn
Ashrani, Aneel
Bockenstedt, Paula L.
Chesney, Carolyn
Eby, Charles
Fanikos, John
Fenninger, Randolph B.
Fogerty, Annemarie E.
Gao, Shuwei
Goldhaber, Samuel Z.
Hendrie, Paul
Kuderer, Nicole
Lee, Alfred
Lee, Jason T.
Lovrincevic, Mirjana
Millenson, Michael M.
Neff, Anne T.
Ortel, Thomas L.
Paschal, Rita
Shattil, Sanford
Siddiqi, Tanya
Smock, Kristi J.
Soff, Gerald
Wang, Tzu-Fei
Yee, Gary C.
Zakarija, Anaadriana
McMillian, Nicole
Engh, Anita M.
TI Cancer-Associated Venous Thromboembolic Disease, Version 1.2015 Featured
Updates to the NCCN Guidelines
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Review
ID LAPAROSCOPIC BARIATRIC SURGERY; CHRONIC KIDNEY-DISEASE; BODY-MASS INDEX;
DEEP-VEIN THROMBOSIS; Y GASTRIC BYPASS; MOLECULAR-WEIGHT HEPARIN;
MORBIDLY OBESE-PATIENTS; RANDOMIZED DOUBLE-BLIND; MEDICALLY-ILL
PATIENTS; ANTI-XA LEVELS
AB The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease outline strategies for treatment and prevention of venous thromboembolism (VTE) in adult patients with a diagnosis of cancer or for whom cancer is clinically suspected. VTE is a common complication in patients with cancer, which places them at greater risk for morbidity and mortality. Therefore, risk-appropriate prophylaxis is an essential component for the optimal care of inpatients and outpatients with cancer. Critical to meeting this goal is ensuring that patients get the most effective medication in the correct dose. Body weight has a significant impact on blood volume and drug clearance. Because obesity is a common health problem in industrialized societies, cancer care providers are increasingly likely to treat obese patients in their practice. Obesity is a risk factor common to VTE and many cancers, and may also impact the anticoagulant dose needed for safe and effective prophylaxis. These NCCN Guidelines Insights summarize the data supporting new dosing recommendations for VTE prophylaxis in obese patients with cancer.
C1 [Streiff, Michael B.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA.
[Holmstrom, Bjorn] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
[Ashrani, Aneel] Mayo Clin, Ctr Canc, Rochester, MN USA.
[Bockenstedt, Paula L.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
[Chesney, Carolyn] Univ Tennessee, St Jude Childrens Res Hosp, Hlth Sci Ctr, Knoxville, TN 37996 USA.
[Eby, Charles] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA.
[Eby, Charles] Washington Univ, Sch Med, St Louis, MO 63130 USA.
[Fanikos, John; Goldhaber, Samuel Z.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA.
[Fenninger, Randolph B.] Natl Blood Clot Alliance, Strockville, MD USA.
[Fogerty, Annemarie E.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Gao, Shuwei] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Hendrie, Paul; Kuderer, Nicole] Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA.
[Lee, Alfred] Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA.
[Lee, Jason T.] Stanford Canc Inst, Stanford, CA USA.
[Lovrincevic, Mirjana] Roswell Pk Canc Inst, Buffalo, NY USA.
[Millenson, Michael M.] Fox Chase Canc Ctr, Philadelphia, PA USA.
[Neff, Anne T.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
[Ortel, Thomas L.] Duke Canc Inst, Durham, NC USA.
[Paschal, Rita] Univ Alabama, Birmingham Comprehens Canc Ctr, Tuscaloosa, AL 35487 USA.
[Shattil, Sanford] UC San Diego Moores Canc Ctr, San Diego, CA USA.
[Siddiqi, Tanya] City Hope Comprehens Canc Ctr, Duarte, CA USA.
[Smock, Kristi J.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.
[Soff, Gerald] Mem Sloan Kettering Canc Ctr, New York, NY USA.
[Wang, Tzu-Fei] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA.
[Wang, Tzu-Fei] Ohio State Univ, Solove Res Inst, Columbus, OH 43210 USA.
[Yee, Gary C.] Fred & Pamela Buffett Canc Ctr, Omaha, NE USA.
[Zakarija, Anaadriana] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA.
[McMillian, Nicole; Engh, Anita M.] Natl Comprehens Canc Network, Washington, DC USA.
RP Streiff, MB (reprint author), Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA.
RI Wang, Tzu-Fei/F-2519-2016
FU Eisai; Bristol-Myers Squibb; Genentech; BioOncology; Merck; Novartis
Oncology; Novocure; Boehringer Ingelheim Pharmaceuticals, Inc.
FX Supported by an educational grant from Eisai; a contribution from
Exelixis Inc.; educational grants from Bristol-Myers Squibb, Genentech
BioOncology, Merck, Novartis Oncology, Novocure; and by an independent
educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
NR 110
TC 11
Z9 12
U1 0
U2 1
PU HARBORSIDE PRESS
PI COLD SPRING HARBOR
PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA
SN 1540-1405
EI 1540-1413
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD SEP
PY 2015
VL 13
IS 9
BP 1079
EP 1096
PG 18
WC Oncology
SC Oncology
GA CR5YH
UT WOS:000361419800007
PM 26358792
ER
PT J
AU Abdollah, F
Sammon, JD
Majumder, K
Reznor, G
Gandaglia, G
Sood, A
Hevelone, N
Kibel, AS
Nguyen, PL
Choueiri, TK
Selvaggi, KJ
Menon, M
Trinh, QD
AF Abdollah, Firas
Sammon, Jesse D.
Majumder, Kaustav
Reznor, Gaily
Gandaglia, Giorgio
Sood, Akshay
Hevelone, Nathanael
Kibel, Adam S.
Nguyen, Paul L.
Choueiri, Toni K.
Selvaggi, Kathy J.
Menon, Mani
Quoc-Dien Trinh
TI Racial Disparities in End-of-Life Care Among Patients With Prostate
Cancer: A Population-Based Study
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Article
ID MEDICARE BENEFICIARIES; AFRICAN-AMERICAN; ETHNIC-DIFFERENCES; HOSPICE
CARE; LUNG-CANCER; NEAR-DEATH; ASSOCIATION; INDICATORS; INTENSITY;
SURVIVAL
AB Objective: To examine racial disparities in end-of-life (EOL) care among black and white patients dying of prostate cancer (PCa). Methods: Relying on the SEER-Medicare database, 3789 patients who died of metastatic PCa between 1999 and 2009 were identified. Information was assessed regarding diagnostic care, therapeutic interventions, hospitalizations, intensive care unit (ICU) admissions, and emergency department visits in the last 12 months, 3 months, and 1 month of life. Logistic regression tested the relationship between race and the receipt of diagnostic care, therapeutic interventions, and high-intensity EOL care. Results: Overall, 729 patients (19.24%) were black. In the 12-months preceding death, laboratory tests (odds ratio [OR], 0.51; 95% Cl, 0.36-0.72), prostate-specific antigen test (OR, 0.54; 95% Cl, 0.43-0.67), cystourethroscopy (OR, 0.71; 95% Cl, 0.56-0.90), imaging procedure (OR, 0.58; 95% Cl, 0.41-0.81), hormonal therapy (OR, 0.53; 95% Cl, 0.44-0.65), chemotherapy (OR, 0.59; 95% Cl, 0.48-0.72), radiotherapy (OR, 0.74; 95% Cl, 0.61-0.90), and office visit (OR, 0.38; 95% Cl, 0.28-0.50) were less frequent in black versus white patients. Conversely, high-intensity EOL care, such as ICU admission (OR, 1.27; 95% Cl, 1.04-1.58), inpatient admission (OR, 1.49; 95% Cl, 1.09-2.05), and cardiopulmonary resuscitation (OR, 1.72; 95% Cl, 1.40-2.11), was more frequent in black versus white patients. Similar trends for EOL care were observed at 3-month and 1-month end points. Conclusions: Although diagnostic and therapeutic interventions are less frequent in black patients with end-stage PCa, the rate of high-intensity and aggressive EOL care is higher in these individuals. These disparities may indicate that race plays an important role in the quality of care for men with end-stage PCa.
C1 [Abdollah, Firas; Sammon, Jesse D.; Sood, Akshay; Menon, Mani] Henry Ford Hlth Syst, Vattikuti Urol Inst, Ctr Outcomes Res Analyt & Evaluat, Detroit, MI 48202 USA.
[Majumder, Kaustav] Univ Minnesota, Dept Surg, Minneapolis, MN 55455 USA.
[Reznor, Gaily; Gandaglia, Giorgio; Hevelone, Nathanael; Kibel, Adam S.; Quoc-Dien Trinh] Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Div Urol Surg, Boston, MA 02115 USA.
[Reznor, Gaily; Gandaglia, Giorgio; Hevelone, Nathanael; Kibel, Adam S.; Quoc-Dien Trinh] Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Ctr Surg & Publ Hlth, Boston, MA 02115 USA.
[Nguyen, Paul L.] Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
[Choueiri, Toni K.] Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Selvaggi, Kathy J.] Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Boston, MA 02115 USA.
RP Abdollah, F (reprint author), Henry Ford Hlth Syst, Vattikuti Urol Inst, 2799 West Grand Blvd, Detroit, MI 48202 USA.
EM firas.abdollah@gmail.com
NR 33
TC 6
Z9 6
U1 1
U2 1
PU HARBORSIDE PRESS
PI COLD SPRING HARBOR
PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA
SN 1540-1405
EI 1540-1413
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD SEP
PY 2015
VL 13
IS 9
BP 1131
EP 1138
PG 8
WC Oncology
SC Oncology
GA CR5YH
UT WOS:000361419800012
PM 26358797
ER
PT J
AU Haddad, RI
Lydiatt, WM
Ball, DW
Busaidy, NL
Byrd, D
Callender, G
Dickson, P
Duh, QY
Ehya, H
Haymart, M
Hoh, C
Hunt, JP
Iagaru, A
Kandeel, F
Kopp, P
Lamonica, DM
McCaffrey, JC
Moley, JF
Parks, L
Raeburn, CD
Ridge, JA
Ringel, MD
Scheri, RP
Shah, JP
Smallridge, RC
Sturgeon, C
Wang, TN
Wirth, LJ
Hoffmann, KG
Hughes, M
AF Haddad, Robert I.
Lydiatt, William M.
Ball, Douglas W.
Busaidy, Naifa Lamki
Byrd, David
Callender, Glenda
Dickson, Paxton
Duh, Quan-Yang
Ehya, Hormoz
Haymart, Megan
Hoh, Carl
Hunt, Jason P.
Iagaru, Andrei
Kandeel, Fouad
Kopp, Peter
Lamonica, Dominick M.
McCaffrey, Judith C.
Moley, Jeffrey F.
Parks, Lee
Raeburn, Christopher D.
Ridge, John A.
Ringel, Matthew D.
Scheri, Randall P.
Shah, Jatin P.
Smallridge, Robert C.
Sturgeon, Cord
Wang, Thomas N.
Wirth, Lori J.
Hoffmann, Karin G.
Hughes, Miranda
TI Anaplastic Thyroid Carcinoma, Version 2.2015
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Review
ID FINE-NEEDLE-ASPIRATION; PHASE-II TRIAL; PROGNOSTIC-FACTORS;
UNITED-STATES; SINGLE-INSTITUTION; CANCER STATISTICS; CONSECUTIVE
PATIENTS; INCREASING INCIDENCE; TREATMENT OUTCOMES; RADIATION-THERAPY
AB This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Thyroid Carcinoma focuses on anaplastic carcinoma because substantial changes were made to the systemic therapy recommendations for the 2015 update. Dosages and frequency of administration are now provided, docetaxel/doxorubicin regimens were added, and single-agent cisplatin was deleted because it is not recommended for patients with advanced or metastatic anaplastic thyroid cancer.
C1 [Haddad, Robert I.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA.
[Lydiatt, William M.] Fred & Pamela Buffett Canc Ctr, Omaha, NE USA.
[Ball, Douglas W.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA.
[Busaidy, Naifa Lamki] Univ Texas MD Anderson Canc Ctr, Houston, TX USA.
[Byrd, David] Seattle Canc Care Alliance, Fred Hutchinson Canc Res Ctr, Seattle, WA USA.
[Callender, Glenda] Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA.
[Dickson, Paxton] Univ Tennessee, Hlth Sci Ctr, St Jude Childrens Res Hosp, Knoxville, TN 37996 USA.
[Duh, Quan-Yang] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA.
[Ehya, Hormoz; Ridge, John A.] Fox Chase Canc Ctr, Philadelphia, PA USA.
[Haymart, Megan] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
[Hoh, Carl] UC San Diego Moores Canc Ctr, San Diego, CA USA.
[Hunt, Jason P.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.
[Iagaru, Andrei] Stanford Canc Inst, Stanford, CA USA.
[Kandeel, Fouad] City Hope Comprehens Canc Ctr, Duarte, CA USA.
[Kopp, Peter; Sturgeon, Cord] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA.
[Lamonica, Dominick M.] Roswell Pk Canc Inst, Buffalo, NY USA.
[McCaffrey, Judith C.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
[Moley, Jeffrey F.] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA.
[Moley, Jeffrey F.] Washington Univ, Sch Med, St Louis, MO 63130 USA.
[Parks, Lee] Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
[Raeburn, Christopher D.] Univ Colorado, Ctr Canc, Boulder, CO 80309 USA.
[Ringel, Matthew D.] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA.
[Scheri, Randall P.] Duke Canc Inst, Durham, NC USA.
[Shah, Jatin P.] Mem Sloan Kettering Canc Ctr, New York, NY USA.
[Smallridge, Robert C.] Mayo Clin, Ctr Canc, Rochester, MN USA.
[Wang, Thomas N.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL USA.
[Wirth, Lori J.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
RP Haddad, RI (reprint author), Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA.
OI Shah, Jatin/0000-0002-6444-6592
FU NCI NIH HHS [P30 CA008748]
NR 104
TC 7
Z9 7
U1 0
U2 5
PU HARBORSIDE PRESS
PI COLD SPRING HARBOR
PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA
SN 1540-1405
EI 1540-1413
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD SEP
PY 2015
VL 13
IS 9
BP 1140
EP 1150
PG 11
WC Oncology
SC Oncology
GA CR5YH
UT WOS:000361419800013
PM 26358798
ER
PT J
AU McCauley, HL
Blosnich, JR
Dichter, ME
AF McCauley, Heather L.
Blosnich, John R.
Dichter, Melissa E.
TI Adverse Childhood Experiences and Adult Health Outcomes Among Veteran
and Non-Veteran Women
SO JOURNAL OF WOMENS HEALTH
LA English
DT Article
ID MILITARY SEXUAL TRAUMA; MENTAL-HEALTH; HOUSEHOLD DYSFUNCTION; US ADULTS;
LIFE-SPAN; ABUSE; RISK; MORTALITY; VIOLENCE; SERVICE
AB Background: Women veterans represent a vulnerable population with unique health needs and disparities in access to care. One constellation of exposures related to subsequent poor health includes adverse childhood experiences (ACEs; e.g., physical and sexual child abuse), though research on impacts of ACEs among women veterans is limited. Methods: Data were drawn from the 2010 Behavioral Risk Factor Surveillance System for the 11 states that included the ACE module (n=36,485). Weighted chi-squared tests and multivariable logistic regression were used to assess the prevalence of ACEs among women veterans compared with women non-veterans and differences in the following outcomes, controlling for ACEs: social support, inadequate sleep, life satisfaction, mental distress, smoking, heavy alcohol use, obesity, diabetes, cardiovascular disease symptoms, asthma, and disability. Results: Women veterans (1.6% of the total sample) reported a higher prevalence of 7 out of 11 childhood adversities and higher mean ACE score than women non-veterans. Women veterans were more likely to be current smokers and report a disability, associations which were attenuated when controlling for ACE. Conclusions: Despite women veterans' higher prevalence of ACE, their health outcomes did not differ substantially from non-veterans. Further research is needed to understand the intersections of traumatic experiences and sources of resilience over the lifecourse among women veterans.
C1 [McCauley, Heather L.] Univ Pittsburgh, Div Adolescent & Young Adult Med, Childrens Hosp Pittsburgh UPMC, Dept Pediat,Sch Med, Pittsburgh, PA 15213 USA.
[Blosnich, John R.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Dichter, Melissa E.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
RP McCauley, HL (reprint author), Univ Pittsburgh, Sch Med, Dept Pediat, 3414 Fifth Ave,CHOB Room 109, Pittsburgh, PA 15213 USA.
EM heather.mccauley@chp.edu
FU National Institutes of Health/Office of Research on Women's Health
Building Interdisciplinary Research Careers in Women's Health
[K12HD043441]; Office of Academic Affiliations in the Department of
Veterans Affairs; Department of Veterans Affairs, Veterans Health
Administration, Health Service Research and Development Service (CDA)
[10-202]
FX This work was supported by National Institutes of Health/Office of
Research on Women's Health Building Interdisciplinary Research Careers
in Women's Health K12HD043441 scholar funds to HLM; a postdoctoral
fellowship to JRB from the Office of Academic Affiliations in the
Department of Veterans Affairs; and a career development award from the
Department of Veterans Affairs, Veterans Health Administration, Health
Service Research and Development Service to MED (CDA No. 10-202).
NR 43
TC 1
Z9 1
U1 5
U2 16
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-9996
EI 1931-843X
J9 J WOMENS HEALTH
JI J. Womens Health
PD SEP 1
PY 2015
VL 24
IS 9
BP 723
EP 729
DI 10.1089/jwh.2014.4997
PG 7
WC Public, Environmental & Occupational Health; Medicine, General &
Internal; Obstetrics & Gynecology; Women's Studies
SC Public, Environmental & Occupational Health; General & Internal
Medicine; Obstetrics & Gynecology; Women's Studies
GA CR6RT
UT WOS:000361475700005
PM 26390379
ER
PT J
AU Berger, D
Bradley, KA
AF Berger, Douglas
Bradley, Katharine A.
TI Primary Care Management of Alcohol Misuse
SO MEDICAL CLINICS OF NORTH AMERICA
LA English
DT Article
DE Alcohol misuse; Unhealthy alcohol use; Alcohol use disorder; Alcohol
abuse; Alcohol dependence; Alcohol screening; Brief intervention;
Alcohol treatment
ID NATIONAL EPIDEMIOLOGIC SURVEY; SERVICES TASK-FORCE; SUBSTANCE USE
DISORDERS; CHRONIC NONCANCER PAIN; PREVENTIVE SERVICES; UNITED-STATES;
RISK DRINKING; CONTROLLED-TRIAL; DSM-IV; RECOMMENDATION STATEMENT
AB More than one in four American adults consume alcohol in quantities exceeding recommended limits. One in 12 have an alcohol use disorder marked by harmful consequences. Both types of alcohol misuse contribute to acute injury and chronic disease, making alcohol the third largest cause of preventable death in the United States. Alcohol misuse alters the management of common conditions from insomnia to anemia. Primary care providers should screen adult patients to identify the full spectrum of alcohol misuse. A range of effective treatments are available from brief counselling interventions and mutual help groups to medications and behavioral therapies.
C1 [Berger, Douglas] VA Puget Sound, Gen Med Serv, Seattle, WA 98108 USA.
[Berger, Douglas; Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA 98101 USA.
[Bradley, Katharine A.] Univ Washington, Dept Hlth Serv, Seattle, WA 98101 USA.
[Bradley, Katharine A.] Grp Hlth Res Inst, Seattle, WA USA.
[Bradley, Katharine A.] VA Hlth Serv Res & Dev HSR&D, Seattle, WA USA.
[Bradley, Katharine A.] CESATE, Seattle, WA USA.
RP Berger, D (reprint author), S-123 PCC,1660 S Columbian Way, Seattle, WA 98108 USA.
EM douglas.berger@va.gov
NR 144
TC 3
Z9 3
U1 2
U2 13
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0025-7125
EI 1557-9859
J9 MED CLIN N AM
JI Med. Clin. N. Am.
PD SEP
PY 2015
VL 99
IS 5
BP 989
EP +
DI 10.1016/j.mcna.2015.05.004
PG 29
WC Medicine, General & Internal
SC General & Internal Medicine
GA CS0TW
UT WOS:000361776100007
PM 26320043
ER
PT J
AU Klein, JW
Reddy, S
AF Klein, Jared Wilson
Reddy, Simha
TI Care of the Homeless Patient
SO MEDICAL CLINICS OF NORTH AMERICA
LA English
DT Article
DE Homelessness; Harm reduction; Housing first; Respite
ID SERIOUS MENTAL-ILLNESS; HEALTH-CARE; ADULTS; PEOPLE; BARRIERS; DISEASE;
PERCEPTIONS; MANAGEMENT; PROGRAMS; SAMPLE
AB This article discusses the unique considerations when caring for patients who lack housing, one of the most essential human needs. Special attention is provided to diseases and conditions that are affected by homelessness as well as to particularly vulnerable populations of homeless patients.
C1 [Klein, Jared Wilson] Univ Washington, Harborview Med Ctr, Dept Med, Div Gen Internal Med, Seattle, WA 98104 USA.
[Reddy, Simha] Univ Washington, Dept Med, Div Gen Internal Med, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
RP Klein, JW (reprint author), Univ Washington, Harborview Med Ctr, Dept Med, Div Gen Internal Med, 325 Ninth Ave,Box 359780, Seattle, WA 98104 USA.
EM jaredwk@uw.edu
NR 57
TC 0
Z9 0
U1 2
U2 13
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0025-7125
EI 1557-9859
J9 MED CLIN N AM
JI Med. Clin. N. Am.
PD SEP
PY 2015
VL 99
IS 5
BP 1017
EP +
DI 10.1016/j.mcna.2015.05.011
PG 23
WC Medicine, General & Internal
SC General & Internal Medicine
GA CS0TW
UT WOS:000361776100008
PM 26320044
ER
PT J
AU Iverson, GL
Gardner, AJ
McCrory, P
Zafonte, R
Castellani, RJ
AF Iverson, Grant L.
Gardner, Andrew J.
McCrory, Paul
Zafonte, Ross
Castellani, Rudy J.
TI A critical review of chronic traumatic encephalopathy
SO NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
LA English
DT Review
DE Brain injury; Dementia pugilistica; Athletes; Dementia; Concussion
ID MILD COGNITIVE IMPAIRMENT; FOOTBALL LEAGUE PLAYERS; VARIANT
FRONTOTEMPORAL DEMENTIA; ALZHEIMERS ASSOCIATION GUIDELINES; MAJOR
DEPRESSIVE DISORDER; REPETITIVE BRAIN TRAUMA; AMYLOID-BETA-PROTEIN;
HIGH-SCHOOL FOOTBALL; QUALITY-OF-LIFE; HEAD-INJURY
AB Chronic traumatic encephalopathy (CTE) has been described in the literature as a neurodegenerative disease with: (i) localized neuronal and glial accumulations of phosphorylated tau (p-tau) involving perivascular areas of the cerebral cortex, sulcal depths, and with a preference for neurons within superficial cortical laminae; (ii) multifocal axonal varicosities and axonal loss involving deep cortex and subcortical white matter; (iii) relative absence of beta-amyloid deposits; (iv) TDP-43 immunoreactive inclusions and neurites; and (v) broad and diverse clinical features. Some of the pathological findings reported in the literature may be encountered with age and other neurodegenerative diseases. However, the focality of the p-tau cortical findings in particular, and the regional distribution, are believed to be unique to CTE. The described clinical features in recent cases are very similar to how depression manifests in middle-aged men and with frontotemporal dementia as the disease progresses. It has not been established that the described tau pathology, especially in small amounts, can cause complex changes in behavior such as depression, substance abuse, suicidality, personality changes, or cognitive impairment. Future studies will help determine the extent to which the neuropathology is causally related to the diverse clinical features. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Iverson, Grant L.] Harvard Univ, Spaulding Rehabil Hosp, MassGeneral Hosp Children,Med Sch, Dept Phys Med & Rehabil,Sports Concuss Program, Boston, MA USA.
[Iverson, Grant L.; Zafonte, Ross] Red Sox Fdn, Boston, MA USA.
[Iverson, Grant L.; Zafonte, Ross] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA.
[Gardner, Andrew J.] Univ Newcastle, Hunter New England Local Hlth Dist Sports Concuss, Sch Med & Publ Hlth, Callaghan, NSW 2308, Australia.
[Gardner, Andrew J.] Univ Newcastle, Ctr Translat Neurosci & Mental Hlth, Sch Med & Publ Hlth, Callaghan, NSW 2308, Australia.
[McCrory, Paul] Melbourne Brain Ctr, Florey Inst Neurosci & Mental Hlth, Heidelberg, Vic, Australia.
[Castellani, Rudy J.] Univ Maryland, Sch Med, Div Neuropathol, Baltimore, MD USA.
[Zafonte, Ross] Harvard Univ, Dept Phys Med & Rehabil, Sch Med, Boston, MA USA.
[Zafonte, Ross] Spaulding Rehabil Hosp, Boston, MA USA.
[Zafonte, Ross] Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Iverson, GL (reprint author), Harvard Univ, Ctr Hlth & Rehabil Res, Dept Phys Med & Rehabil, Sch Med, 79-96 Thirteenth St, Charlestown, MA 02129 USA.
EM giverson@mgh.harvard.edu
RI Gardner, Andrew/J-5162-2013
FU INTRuST Posttraumatic Stress Disorder and Traumatic Brain Injury
Clinical Consortium - Department of Defense Psychological
Health/Traumatic Brain Injury Research Program [X81XWH-07-CC-CSDoD];
Harvard Integrated Program to Protect and Improve the Health of NFLPA;
NICHD Brain and Tissue Bank at the University of Maryland; New South
Wales Sporting Injuries Committee; Brain Foundation, Australia; National
Health and Medical Research Council of Australia; Florey Institute of
Neuroscience and Mental Health; Victorian Government
FX GLI and RZ note that this work was supported in part by the INTRuST
Posttraumatic Stress Disorder and Traumatic Brain Injury Clinical
Consortium funded by the Department of Defense Psychological
Health/Traumatic Brain Injury Research Program (X81XWH-07-CC-CSDoD). RZ
also was supported in part by the Harvard Integrated Program to Protect
and Improve the Health of NFLPA Members. RJC acknowledges support from
the NICHD Brain and Tissue Bank at the University of Maryland. AJG has
received funding from the New South Wales Sporting Injuries Committee,
and the Brain Foundation, Australia to conduct research in current and
retired rugby league players. PM receives ongoing funding from the
National Health and Medical Research Council of Australia and the Florey
Institute of Neuroscience and Mental Health. The Florey Institute of
Neuroscience and Mental Health acknowledges support from the Victorian
Government, in particular the funding from the Operational
Infrastructure Support Grant.
NR 220
TC 23
Z9 23
U1 10
U2 65
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0149-7634
EI 1873-7528
J9 NEUROSCI BIOBEHAV R
JI Neurosci. Biobehav. Rev.
PD SEP
PY 2015
VL 56
BP 276
EP 293
DI 10.1016/j.neubiorev.2015.05.008
PG 18
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA CR8CK
UT WOS:000361578500021
PM 26183075
ER
PT J
AU Halpern, SD
French, B
Small, DS
Saulsgiver, K
Harhay, MO
Audrain-McGovern, J
Loewenstein, G
Brennan, TA
Asch, DA
Volpp, KG
AF Halpern, Scott D.
French, Benjamin
Small, Dylan S.
Saulsgiver, Kathryn
Harhay, Michael O.
Audrain-McGovern, Janet
Loewenstein, George
Brennan, Troyen A.
Asch, David A.
Volpp, Kevin G.
TI Randomized Trial of Four Financial-Incentive Programs for Smoking
Cessation
SO OBSTETRICAL & GYNECOLOGICAL SURVEY
LA English
DT Editorial Material
AB In the 50 years since the release of the first Surgeon General's report on the harmful effects of smoking, national policies and behavioral programs as well as pharmacologic approaches have helped reduce smoking rates in the United States. Despite these interventions, the need for new approaches is clear because smoking is still the leading cause of preventable illness and death. Previous studies have demonstrated that financial incentives can promote a variety of health behaviors. However, effective ways to deliver health incentives are uncertain. A number of online and employer-based behavioral-change programs have been used. One of these programs involves use of deposit (commitment) contracts, whereby participants put some of their own money at risk and recover it if they are successful in changing their behavior. Deposit contracts should be more successful than reward programs because people are usually more motivated to avoid losses than to seek gains. The need to make deposits, however, may deter people from participating in such programs. No studies have directly compared the overall effectiveness of deposit and reward programs. This randomized controlled trial compared 4 financial-incentive programs for smoking cessation. Participants were CVS Caremark employees and their relatives and friends. The incentive programs were compared with usual care (which included informational resources and free smoking-cessation aids). Two of the incentive programs (reward based and deposit based) targeted individuals, whereas the other 2 targeted groups of 6 participants. One individual-oriented program and 1 group-oriented program provided rewards of approximately $800 for smoking cessation; the other 2 entailed refundable deposits of $150 plus $650 for successful participants. Levels of acceptance, overall effectiveness, and efficacy were assessed. The primary efficacy outcome was sustained abstinence for 6 months after the target quit date. A total of 2538 participants were randomized to 1 of the 4 incentive programs or to usual care. Participants in the 2 reward-based incentive programs were much more likely to accept the assignment (combined acceptance rate, 90.0%) than those in the 2 deposit-based programs (combined acceptance rate, 13.7%; P < 0.001). Intention-to-treat analyses using logistic regression showed that rates of sustained abstinence from smoking through 6 months were higher for each of the 4 incentive programs (range, 9.4%-16.0%) than usual care (6.0%) (P < 0.05 for all comparisons). Moreover, the superiority of reward-based programs was sustained through 12 months. The proportion of participants with sustained abstinence was similar at 6 months for participants assigned to group-oriented and individual-oriented programs (13.7% and 12.1%, respectively; P = 0.29). At 6 months, the proportion of participants with sustained abstinence was greater with reward-based incentives than with deposit-based incentives (15.7% vs 10.2%, P < 0.001). However, the rate of abstinence at 6 months in instrumental-variable analyses (accounting for differential acceptance) was 13.2 percentage points higher (95% confidence interval, 3.1-22.8) in the deposit-based programs than in the reward-based programs among the 13.7% of smokers who would accept participation in either type of program. These findings show that, among several financial-incentive programs for smoking cessation, rewards for smoking cessation achieve higher rates of sustained abstinence from smoking than deposit-based contracts owing to much higher rates of acceptance.
Group-oriented programs are no more effective than the programs for individuals.
C1 [Halpern, Scott D.; Asch, David A.; Volpp, Kevin G.] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA.
[Halpern, Scott D.; French, Benjamin; Saulsgiver, Kathryn; Harhay, Michael O.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
[Halpern, Scott D.; Volpp, Kevin G.] Univ Penn, Perelman Sch Med, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA.
[Audrain-McGovern, Janet] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA.
[Halpern, Scott D.; French, Benjamin; Small, Dylan S.; Saulsgiver, Kathryn; Audrain-McGovern, Janet; Loewenstein, George; Asch, David A.; Volpp, Kevin G.] Univ Penn, Perelman Sch Med, Leonard Davis Inst Hlth Econ, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA.
[Small, Dylan S.] Univ Penn, Wharton Sch, Ctr Hlth Equ Res & Promot, Dept Stat, Philadelphia, PA 19104 USA.
[Asch, David A.; Volpp, Kevin G.] Univ Penn, Wharton Sch, Ctr Hlth Equ Res & Promot, Dept Hlth Care Management, Philadelphia, PA 19104 USA.
[Asch, David A.; Volpp, Kevin G.] Univ Penn Hlth Syst, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Asch, David A.; Volpp, Kevin G.] Univ Penn Hlth Syst, Ctr Hlth Care Innovat, Philadelphia, PA USA.
[Loewenstein, George] Carnegie Mellon Univ, Ctr Behav Decis Res, Pittsburgh, PA 15213 USA.
[Brennan, Troyen A.] CVS Caremark, Woonsocket, RI USA.
RP Halpern, SD (reprint author), Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA.
OI Harhay, Michael/0000-0002-0553-674X
NR 0
TC 0
Z9 0
U1 3
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0029-7828
EI 1533-9866
J9 OBSTET GYNECOL SURV
JI Obstet. Gynecol. Surv.
PD SEP
PY 2015
VL 70
IS 9
BP 566
EP 567
DI 10.1097/01.ogx.0000470840.40563.9a
PG 2
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA CS0LE
UT WOS:000361749900012
ER
PT J
AU Grady, CD
Dehlendorf, C
Cohen, ED
Schwarz, EB
Borrero, S
AF Grady, Cynthia D.
Dehlendorf, Christine
Cohen, Elan D.
Schwarz, E. Bimla
Borrero, Sonya
TI Racial and Ethnic Differences in Contraceptive use Among Women Who
Desire No Future Children, 2006-2010 National Survey of Family Growth
SO OBSTETRICAL & GYNECOLOGICAL SURVEY
LA English
DT Editorial Material
AB Uynintended pregnancies are either mistimed pregnancies occurring sooner than desired or unwanted pregnancies occurring when no children (or no more children) are desired. Unwanted pregnancies appear to be associated with poor pregnancy outcomes, specifically higher risk of preterm delivery and premature rupture of membranes. Women from racial and ethnic minority groups are more likely than white women to experience an unwanted pregnancy. Racial/ethnic differences in contraceptive use patterns among black and Hispanic women are the most likely proximal cause of observed disparities in unintended pregnancy. Several studies have reported that black women are more likely than white women to not use contraceptives or use contraception inconsistently, to have more contraceptive failures, and to less frequently use some prescription methods. Little is known about disparities in contraceptive use among the specific subset of women who do not want any (more) children and who may be at particularly high risk for having an unwanted pregnancy. This study evaluated racial/ethnic differences in contraceptive use among women who do not desire future pregnancy. Nationally representative data were obtained from the 2006-2010 National Survey of Family Growth (NSFG) to examine the relationships between race/ethnicity and contraceptive use among a sample of sexually active, reproductive-age women who stated that they do not desire any (more) children. The primary study outcome measures were (1) use of any contraceptive method and (2) the effectiveness of contraceptive methods used by women using any method at last heterosexual intercourse. Multivariable logistic regression models were used to assess the independent effect of race/ethnicity on contraceptive use patterns, adjusting for sociodemographic factors, reproductive characteristics, and indicators of health care access and utilization. The study sample comprised 2900 sexually active women, aged 15 to 44 years, who were at risk of an unwanted pregnancy. The vast majority (91.2%) used contraception at last sex, although use varied significantly by race/ethnicity; 93.2% of white women reported use of any method, compared with 84.7% of black and 90.5% of Hispanic women; P < 0.01. In the fully adjusted model, black women were significantly less likely than whites to use any contraception at last sex (odds ratio [OR], 0.43; 95% confidence interval, 0.27-0.73); in contrast, there was no significant difference among Hispanic women (OR, 0.95; 95% confidence interval, 0.52-1.72). In bivariate analysis, the type of contraceptive method used at last sex among women who used a method at last sex varied significantly by race/ethnicity (P < 0.01), although most women (59%) used a highly effective method. In the fully adjusted model, however, racial/ethnic differences were no longer significant: There were no significant differences between white women and black or Hispanic women with regard to use of highly/moderately effective contraception. Among the subset of women who report that they do not want (more) children, black women are significantly less likely than white women to use any contraception at last intercourse; this disparity does not appear to be due to differences in sociodemographic characteristics, reproductive factors, or utilization of health care.
C1 [Grady, Cynthia D.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA.
[Dehlendorf, Christine] Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA.
[Dehlendorf, Christine] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA USA.
[Dehlendorf, Christine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Cohen, Elan D.] Univ Pittsburgh, Ctr Res Hlth, Care Data Ctr, Pittsburgh, PA USA.
[Schwarz, E. Bimla] Univ Calif Davis, Sch Med, Div Gen Internal Med, Sacramento, CA 95817 USA.
[Borrero, Sonya] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA USA.
[Borrero, Sonya] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
RP Grady, CD (reprint author), Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA.
NR 0
TC 0
Z9 0
U1 3
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0029-7828
EI 1533-9866
J9 OBSTET GYNECOL SURV
JI Obstet. Gynecol. Surv.
PD SEP
PY 2015
VL 70
IS 9
BP 574
EP 576
DI 10.1097/01.ogx.0000470841.16800.60
PG 3
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA CS0LE
UT WOS:000361749900017
ER
PT J
AU del Carmen, MG
AF del Carmen, Marcela G.
TI Evidence for the Relationship Between Endometriosis and Epithelial
Ovarian Cancer
SO OBSTETRICAL & GYNECOLOGICAL SURVEY
LA English
DT Review
ID CLEAR-CELL CARCINOMA; HOSPITAL DISCHARGE DIAGNOSIS;
DISTINCT-HISTOLOGIC-TYPE; ESTROGEN-RECEPTOR-ALPHA;
MALIGNANT-TRANSFORMATION; ATYPICAL ENDOMETRIOSIS; BREAST-CANCER;
POSTMENOPAUSAL ENDOMETRIOSIS; CLINICAL CHARACTERISTICS; POOR-PROGNOSIS
AB Endometriosis may be a precursor lesion for some epithelial ovarian cancers (EOCs), especially those of clear cell and endometrioid histologies. The causality of this relationship remains controversial and in need of further investigation because the high prevalence of endometriosis and high mortality of EOC carry significant public health implications if the association is real. Endometriosis-associated ovarian cancer (EAOC) often presents at an earlier stage and with lower-grade lesions than non-EAOC. After surgical resection, these patients also tend to have less residual disease than do patients with non-EAOC. Survival has been reported to be better for women with EAOC. The tumor suppression gene, ARID1A, is frequently disrupted in EAOC. The ARID1A mutation has been reported in preneoplastic lesions and may be an early marker in the transformation of endometriosis into cancer. The current evidence in respect to critical molecular pathways underscores the need to investigate possible role of targeted therapies in the treatment of EAOC. Target Audience Obstetricians and gynecologists, family physicians
Learning Objectives Endometriosis may be a precursor lesion for some EOCs, especially those of clear cell and endometrioid histologies. We review the epidemiology, pathology, pathogenesis, clinical presentation, and management of patients with EAOC. After completing this CME, physicians should be able to able to discuss the epidemiologic data supporting the association of endometriosis to certain histological subtypes of EOC, as well as describe the pathogenesis of this association. In addition, they should be able to discuss the clinical presentation and optimal management of these patients.
C1 [del Carmen, Marcela G.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Gynecol Oncol,Vincent Obstet & Gynecol, Boston, MA USA.
RP del Carmen, MG (reprint author), Massachusetts Gen Hosp, Div Gynecol Oncol, 55 Fruit St,Yawkey 9E, Boston, MA 02114 USA.
EM mdelcarmen@partners.org
NR 117
TC 0
Z9 1
U1 2
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0029-7828
EI 1533-9866
J9 OBSTET GYNECOL SURV
JI Obstet. Gynecol. Surv.
PD SEP
PY 2015
VL 70
IS 9
BP 587
EP 595
DI 10.1097/OGX.0000000000000218
PG 9
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA CS0LE
UT WOS:000361749900020
PM 26403563
ER
PT J
AU Campbell, AA
Cunnane, ME
Dunn, GP
Gray, ST
Lefebvre, DR
AF Campbell, Ashley A.
Cunnane, Mary Elizabeth
Dunn, Gavin P.
Gray, Stacy Tutt
Lefebvre, Daniel R.
TI Spontaneous Resorption of a Penetrating Orbital Bone Fracture Fragment
SO OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY
LA English
DT Article
AB The authors describe a 20-year-old man who sustained multiple facial fractures in a high-speed motor vehicle crash, including a bone fragment from a skull base fracture that penetrated the orbital soft tissues superomedially. Serial CT scans documented spontaneous resorption over a 6-month period. While it is known that autologous bone grafts used in craniofacial reconstruction exhibit variable amounts of bone resorption, the complete resorption of an intraorbital fracture fragment has not been documented in the literature. His clinical care and the report of his case were undertaken in a fashion in accordance with the principles of the Health Insurance Portability and Accountability Act regulations.
C1 [Campbell, Ashley A.; Lefebvre, Daniel R.] Massachusetts Eye & Ear Infirm, Ophthalm Plast Surg, Boston, MA 02114 USA.
[Campbell, Ashley A.; Lefebvre, Daniel R.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA.
[Cunnane, Mary Elizabeth] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
[Cunnane, Mary Elizabeth] Harvard Univ, Sch Med, Dept Radiol Neuroradiol, Boston, MA USA.
[Dunn, Gavin P.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
[Dunn, Gavin P.] Harvard Univ, Sch Med, Dept Neurosurg, Boston, MA USA.
[Gray, Stacy Tutt] Massachusetts Eye & Ear Infirm, Dept Otolaryngol Head & Neck Surg, Boston, MA 02114 USA.
[Gray, Stacy Tutt] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
RP Campbell, AA (reprint author), Mass Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA.
EM Ashley_Campbell@MEEI.Harvard.edu
NR 6
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0740-9303
EI 1537-2677
J9 OPHTHAL PLAST RECONS
JI Ophthalmic Plast. Reconstr. Surg.
PD SEP-OCT
PY 2015
VL 31
IS 5
BP E123
EP E125
DI 10.1097/IOP.0000000000000146
PG 3
WC Ophthalmology; Surgery
SC Ophthalmology; Surgery
GA CR5LJ
UT WOS:000361383500003
PM 24833452
ER
PT J
AU Jakobiec, FA
Rai, R
Rashid, A
Sutula, FC
AF Jakobiec, Frederick A.
Rai, Ruju
Rashid, Alia
Sutula, Francis C.
TI Bilateral Eyelid Pseudoptosis From Lipogranulomas of the Preaponeurotic
Fat Pads
SO OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY
LA English
DT Article
ID HYALURONIC-ACID GEL; CUTANEOUS GRANULOMATOUS REACTION;
MELKERSSON-ROSENTHAL-SYNDROME; INTRAOCULAR SILICONE OIL; SOFT-TISSUE
AUGMENTATION; SCLEROSING LIPOGRANULOMATOSIS; INVOLUTIONAL
BLEPHAROPTOSIS; PERIORBITAL LIPOGRANULOMA; ADVERSE-REACTIONS; INJECTION
AB Lipogranulomas of the periocular tissues with fulminant fibrotic and lymphohistiocytic responses were initially described in cases of exogenous paraffin or petrolatum jelly injections (paraffinomas). A 49-year-old Cambodian woman slowly developed bilateral pseudoptosis with intact levator function and redundant, taut upper eyelid skin. At surgery, vesiculations or bubbles in the preaponeurotic fat were encountered and were demonstrated histopathologically to be empty locules surrounded by a thin collagenous lamina. Outside these extracellular spaces were CD68/CD163-positive mononucleated and univacuolated histiocytes simulating damaged fat cells or neoplastic lipoblasts in hematoxylin and eosin sections. Giant cells and chronic sclerosing inflammation were absent. The patient denied any previous injections. The bland character of the lipogranulomas in comparison with that of other injectable agents, the absence of any residual particles associated with other cosmetic fillers, and the distinctive histiocytic response of lipoblast-like cells that were sufficiently characteristic to compel the diagnosis of surreptitious silicone injections. Other conditions were excluded based on comparative clinicopathologic criteria.
C1 [Jakobiec, Frederick A.; Rai, Ruju; Rashid, Alia] Massachusetts Eye & Ear Infirm, David G Cogan Lab Ophthalm Pathol, Dept Ophthalmol, Boston, MA 02114 USA.
[Sutula, Francis C.] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Ophthalm Plast Surg, Boston, MA 02114 USA.
[Jakobiec, Frederick A.; Rai, Ruju; Rashid, Alia; Sutula, Francis C.] Harvard Univ, Sch Med, Boston, MA USA.
RP Jakobiec, FA (reprint author), Massachusetts Eye & Ear Infirm, David G Cogan Lab Ophthalm Pathol, 243 Charles St,Suite 328, Boston, MA 02114 USA.
EM Fred_Jakobiec@meei.harvard.edu
NR 57
TC 3
Z9 3
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0740-9303
EI 1537-2677
J9 OPHTHAL PLAST RECONS
JI Ophthalmic Plast. Reconstr. Surg.
PD SEP-OCT
PY 2015
VL 31
IS 5
BP E125
EP E131
DI 10.1097/IOP.0000000000000157
PG 7
WC Ophthalmology; Surgery
SC Ophthalmology; Surgery
GA CR5LJ
UT WOS:000361383500004
PM 24841730
ER
PT J
AU Costa-Mallen, P
Zabetian, CP
Agarwal, P
Hu, SC
Yearout, D
Samii, A
Leverenz, JB
Roberts, JW
Checkoway, H
AF Costa-Mallen, Paola
Zabetian, Cyrus P.
Agarwal, Pinky
Hu, Shu-Ching
Yearout, Dora
Samii, Ali
Leverenz, James B.
Roberts, John W.
Checkoway, Harvey
TI Haptoglobin phenotype modifies serum iron levels and the effect of
smoking on Parkinson disease risk
SO PARKINSONISM & RELATED DISORDERS
LA English
DT Article
DE Idiopathic Parkinson disease; Tobacco smoking; Serum iron; Serum
ferritin; Haptoglobin phenotype
ID NEURODEGENERATIVE DISEASES; SUBSTANTIA-NIGRA; FERRITIN; SUSCEPTIBILITY;
POLYMORPHISM; ASSOCIATION; METABOLISM
AB Introduction: Haptoglobin is a hemoglobin-binding protein that exists in three functionally different phenotypes, and haptoglobin phenotype 2-1 has previously been associated with Parkinson disease (PD) risk, with mechanisms not elucidated. Some evidence is emerging that low levels of serum iron may increase PD risk. In this study we investigated whether PD patients have lower serum iron and ferritin than controls, and whether this is dependent on haptoglobin phenotype. We also investigated the effect of Hp phenotype as a modifier of the effect of smoking on PD risk.
Methods: The study population consisted of 128 PD patients and 226 controls. Serum iron, ferritin, and haptoglobin phenotype were determined, and compared between PD cases and controls. Stratified analysis by haptoglobin phenotype was performed to determine effect of haptoglobin phenotype on serum iron parameter differences between PD cases and controls and to investigate its role in the protective effect of smoking on PD risk.
Results: PD cases had lower serum iron than controls (83.28 ug/100 ml vs 94.00 ug/100 ml, p 0.006), and in particular among subjects with phenotype 2-1. The protective effect of smoking on PD risk resulted stronger in subjects with phenotype 1-1 and 2-2, and weakest among subjects with phenotype 2-1. Ferritin levels were higher in PD cases than controls among subjects of White ethnicity.
Conclusions: Our results report for the first time that the haptoglobin phenotype may be a contributor of iron levels abnormalities in PD patients. The mechanisms for these haptoglobin-phenotype specific effects will have to be further elucidated. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Costa-Mallen, Paola] Bastyr Univ, Res Inst, Kenmore, WA 98028 USA.
[Zabetian, Cyrus P.; Yearout, Dora; Samii, Ali] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
[Zabetian, Cyrus P.; Hu, Shu-Ching; Samii, Ali] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA.
[Agarwal, Pinky] Evergreen Hlth, Booth Gardner Parkinsons Care Ctr, Kirkland, WA USA.
[Leverenz, James B.] Cleveland Clin, Neurol Inst, Lou Ruvo Ctr Brain Hlth, Cleveland, OH 44106 USA.
[Roberts, John W.] Virginia Mason Med Ctr, Seattle, WA 98101 USA.
[Checkoway, Harvey] Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA.
RP Costa-Mallen, P (reprint author), Bastyr Univ, Res Inst, 14500 Juanita Dr NE, Kenmore, WA 98028 USA.
EM pcostamallen@bastyr.edu
FU NIH [R21 NS070202-01A1, P50 NS062684, R01 NS065070]; Department of
Veterans Affairs [1I01BX000531]; Bastyr University [3, 4]
FX This study was funded by grants from the NIH (R21 NS070202-01A1, P50
NS062684, R01 NS065070), Department of Veterans Affairs (1I01BX000531),
and Bastyr University (Faculty Seed Grants #3 and #4 2009-2011).
NR 29
TC 7
Z9 7
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1353-8020
EI 1873-5126
J9 PARKINSONISM RELAT D
JI Parkinsonism Relat. Disord.
PD SEP
PY 2015
VL 21
IS 9
BP 1087
EP 1092
DI 10.1016/j.parkreldis.2015.07.006
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA CR8BR
UT WOS:000361576600013
PM 26228081
ER
PT J
AU Chou, JJ
Wang, JH
AF Chou, James J.
Wang, Jia-huai
TI Transmembrane signaling: A multiplex problem with converging solutions
SO PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY
LA English
DT Editorial Material
ID RECEPTOR; CELLS
C1 [Chou, James J.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Wang, Jia-huai] Peking Univ, Sch Life Sci, Beijing 100871, Peoples R China.
[Wang, Jia-huai] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Wang, JH (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.
EM jwang@crystal.harvard.edu
FU NHLBI NIH HHS [P01 HL103526]; NIGMS NIH HHS [U54 GM094608]
NR 9
TC 0
Z9 0
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0079-6107
J9 PROG BIOPHYS MOL BIO
JI Prog. Biophys. Mol. Biol.
PD SEP
PY 2015
VL 118
IS 3
BP 87
EP 88
DI 10.1016/j.pbiomolbio.2015.06.006
PG 2
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA CS0UA
UT WOS:000361776500001
PM 26140997
ER
PT J
AU Finci, L
Zhang, Y
Meijers, R
Wang, JH
AF Finci, L.
Zhang, Y.
Meijers, R.
Wang, J. -H.
TI Signaling mechanism of the netrin-1 receptor DCC in axon guidance
SO PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY
LA English
DT Review
DE DCC; Netrin-1; Axon guidance; Structure; UNC5
ID C-ELEGANS; COLORECTAL-CANCER; CRYSTAL-STRUCTURE; TYROSINE
PHOSPHORYLATION; STRUCTURAL BASIS; SPINAL-CORD; BINDING; ADHESION;
FAMILY; IMMUNOGLOBULIN
AB DCC (Deleted in Colorectal Cancer) is a single-pass transmembrane protein that belongs to the immunoglobulin superfamily. It was originally identified as a prognostic tumor marker and then subsequently found to be a receptor for netrin-1. DCC plays a key role in axon guidance and also in a number of other important cellular processes. This review describes the current progress of the structural biology of DCC with an emphasis on how DCC is involved in the dual functionality of netrin-1 as a chemo-attractant as well as a repellent in axon guidance, referred to as hi-functionality. A perspective about other DCC ligands and the signaling mechanism of the cytoplasmic tail of DCC is also recapitulated. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Finci, L.; Zhang, Y.; Wang, J. -H.] Peking Univ, Coll Life Sci, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100871, Peoples R China.
[Finci, L.; Wang, J. -H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02215 USA.
[Meijers, R.] European Mol Biol Lab, Hamburg Outstn, D-22607 Hamburg, Germany.
RP Wang, JH (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02215 USA.
EM r.meijers@embl-hamburg.de; jwang@crystal.harvard.edu
OI Meijers, Rob/0000-0003-2872-6279
FU Ministry of Education of China; National Science Foundation of China
(NSFC) [91132718]; NIH [HL48675]; Peking-Tsinghua Center for Life
Sciences; short-term EMBO postdoctoral fellowship
FX This work was supported by the Ministry of Education of China to J.-H.W.
and Y.Z., the National Science Foundation of China (NSFC) Major Research
Grant (91132718) to Y.Z., an NIH grant (HL48675) and funds from the
Peking-Tsinghua Center for Life Sciences to J-H W, and a short-term EMBO
postdoctoral fellowship to L. I. F.
NR 48
TC 5
Z9 6
U1 0
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0079-6107
J9 PROG BIOPHYS MOL BIO
JI Prog. Biophys. Mol. Biol.
PD SEP
PY 2015
VL 118
IS 3
BP 153
EP 160
DI 10.1016/j.pbiomolbio.2015.04.001
PG 8
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA CS0UA
UT WOS:000361776500009
PM 25881791
ER
PT J
AU LaChance, H
Cioe, PA
Tooley, E
Colby, SM
O'Farrell, TJ
Kahler, CW
AF LaChance, Heather
Cioe, Patricia A.
Tooley, Erin
Colby, Suzanne M.
O'Farrell, Timothy J.
Kahler, Christopher W.
TI Behavioral Couples Therapy for Smoking Cessation: A Pilot Randomized
Clinical Trial
SO PSYCHOLOGY OF ADDICTIVE BEHAVIORS
LA English
DT Article
DE smoking cessation; couples therapy; tobacco dependence; behavioral
couples therapy
ID SOCIAL SUPPORT; PARTNER SUPPORT; QUITTING SMOKING; UNITED-STATES; USE
DISORDERS; SMOKERS; RELAPSE; METAANALYSIS; PREGNANCY; INTERVENTIONS
AB Behavioral couples therapy (BCT) has been found to improve long-term abstinence rates in alcohol-and substance-dependent populations but has not been tested for smoking cessation. This pilot study examined the feasibility and acceptability of BCT for smoking-discordant couples. Forty-nine smokers (smoking >10 cigarettes/day) with nonsmoking partners were randomized to receive a couples social support (BCT-S) intervention or an individually delivered, standard smoking cessation treatment (ST). The couples were married or had been cohabiting for at least 1 year, with partners who had never smoked or had not used tobacco in 1 year. Both treatments included 7 weekly sessions and 8 weeks of nicotine replacement therapy. Participants were followed for 6 months posttreatment. The Partner Interaction Questionnaire was used to measure perceived smoking-specific partner support. Participants were 67% male and 88% White. Biochemically verified cessation rates were 40.9%, 50%, and 45% in BCT-S and 59.1%, 50%, and 55% in ST at end of treatment, after 3 month, and after 6 months, respectively, and did not differ significantly between treatment conditions at any time point. Perceived smoking-specific partner support at posttreatment did not significantly differ between treatment groups. Results of this pilot study do not provide support for the efficacy of BCT in smoking-discordant couples.
C1 [LaChance, Heather] Natl Jewish Hlth, Denver, CO USA.
[Cioe, Patricia A.; Colby, Suzanne M.; Kahler, Christopher W.] Brown Univ, Ctr Alcohol & Addict Studies, Sch Publ Hlth, Providence, RI 02912 USA.
[Tooley, Erin] Brown Univ, Ctr Behav & Preventat Med, Warren Alpert Med Sch, Providence, RI 02912 USA.
[Tooley, Erin] Miriam Hosp, Dept Psychiat & Human Behav, Providence, RI 02906 USA.
[O'Farrell, Timothy J.] VA Boston Healthcare Syst, Families & Addict Program, Brockton, MA USA.
[O'Farrell, Timothy J.] Harvard Univ, Sch Med, Dept Psychiat, Cambridge, MA 02138 USA.
RP Cioe, PA (reprint author), Brown Univ, Ctr Alcohol & Addict Studies, Sch Publ Hlth, 121 South Main St, Providence, RI 02912 USA.
EM Patricia_Cioe@brown.edu
OI CIOE, PATRICIA/0000-0003-3599-7819
FU National Institute on Drug Abuse (NIDA) at the National Institutes of
Health [R01 DA021265]; NIDA [T32 DA016184]; National Heart Lung and
Blood Institute at the National Institutes of Health [T32 HL076134-07];
Department of Veterans Affairs
FX This work was supported by the National Institute on Drug Abuse (NIDA)
at the National Institutes of Health (Grant R01 DA021265 to Heather
LaChance). This work was partially supported by NIDA (Grant T32 DA016184
to Patricia A. Cioe), the National Heart Lung and Blood Institute at the
National Institutes of Health (Grant T32 HL076134-07 to Erin Tooley),
and the Department of Veterans Affairs (award to Timothy J. O'Farrell).
We gratefully acknowledge Suzanne Sales for her assistance with data
management and data analyses.
NR 55
TC 2
Z9 2
U1 3
U2 9
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 0893-164X
EI 1939-1501
J9 PSYCHOL ADDICT BEHAV
JI Psychol. Addict. Behav.
PD SEP
PY 2015
VL 29
IS 3
BP 643
EP 652
DI 10.1037/adb0000051
PG 10
WC Substance Abuse; Psychology, Multidisciplinary
SC Substance Abuse; Psychology
GA CS1NT
UT WOS:000361833900016
PM 25642582
ER
PT J
AU Seltzer, EK
Jean, NS
Kramer-Golinkoff, E
Asch, DA
Merchant, RM
AF Seltzer, E. K.
Jean, N. S.
Kramer-Golinkoff, E.
Asch, D. A.
Merchant, R. M.
TI The content of social media's shared images about Ebola: a retrospective
study
SO PUBLIC HEALTH
LA English
DT Article
DE Ebola; Social media; Public opinion; Public health; Communication
ID EMERGENCY; EPIDEMIC; HEALTH
AB Objective: Social media have strongly influenced awareness and perceptions of public health emergencies, but a considerable amount of social media content is now carried through images, rather than just text. This study's objective is to explore how image-sharing platforms are used for information dissemination in public health emergencies.
Study design: Retrospective review of images posted on two popular image-sharing platforms to characterize public discourse about Ebola.
Methods: Using the keyword '#ebola' we identified a 1% sample of images posted on Instagram and Flickr across two sequential weeks in November 2014. Images from both platforms were independently coded by two reviewers and characterized by themes. We reviewed 1217 images posted on Instagram and Flickr and identified themes.
Results: Nine distinct themes were identified. These included: images of health care workers and professionals [308 (25%)], West Africa [75 (6%)], the Ebola virus [59 (5%)], and artistic renderings of Ebola [64 (5%)]. Also identified were images with accompanying embedded text related to Ebola and associated: facts [68 (6%)], fears [40 (3%)], politics [46 (4%)], and jokes [284 (23%)]. Several [273 (22%)] images were unrelated to Ebola or its sequelae. Instagram images were primarily coded as jokes [255 (42%)] or unrelated [219 (36%)], while Flickr images primarily depicted health care workers and other professionals [281 (46%)] providing care or other services for prevention or treatment.
Conclusion: Image sharing platforms are being used for information exchange about public health crises, like Ebola. Use differs by platform and discerning these differences can help inform future uses for health care professionals and researchers seeking to assess public fears and misinformation or provide targeted education/awareness interventions. (C) 2015 The Royal Institute of Public Health. All rights reserved.
C1 [Seltzer, E. K.; Jean, N. S.; Kramer-Golinkoff, E.; Asch, D. A.; Merchant, R. M.] Univ Penn, Penn Med Social Media & Hlth Innovat Lab, Philadelphia, PA 19104 USA.
[Asch, D. A.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA.
RP Seltzer, EK (reprint author), 423 Blockley Hall, Philadelphia, PA 19104 USA.
EM seltzer@uphs.upenn.edu
FU NIH, NHLBI [K23: 10714038, R01: HL122457-01A1]
FX Seltzer, Saint Jean, Kramer-Golinkoff: No conflicts to disclose; Asch:
US Government employee, no conflicts to disclose; Merchant:
Grant/Research support: NIH, NHLBI K23: 10714038, NIH, NHLBI, R01:
HL122457-01A1.
NR 23
TC 9
Z9 9
U1 6
U2 19
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0033-3506
EI 1476-5616
J9 PUBLIC HEALTH
JI Public Health
PD SEP
PY 2015
VL 129
IS 9
BP 1273
EP 1277
DI 10.1016/j.puhe.2015.07.025
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA CR8VI
UT WOS:000361631800019
PM 26285825
ER
PT J
AU Sripada, RK
Bohnert, ASB
Teo, AR
Levine, DS
Pfeiffer, PN
Bowersox, NW
Mizruchi, MS
Chermack, ST
Ganoczy, D
Walters, H
Valenstein, M
AF Sripada, Rebecca K.
Bohnert, Amy S. B.
Teo, Alan R.
Levine, Debra S.
Pfeiffer, Paul N.
Bowersox, Nicholas W.
Mizruchi, Mark S.
Chermack, Stephen T.
Ganoczy, Dara
Walters, Heather
Valenstein, Marcia
TI Social networks, mental health problems, and mental health service
utilization in OEF/OIF National Guard veterans
SO SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY
LA English
DT Article
DE Social support; Social network; PTSD; Depression; Veteran; National
Guard
ID POSTTRAUMATIC-STRESS-DISORDER; OPERATIONS ENDURING FREEDOM; VIETNAM
VETERANS; PTSD SYMPTOMS; TREATMENT-SEEKING; CARE UTILIZATION; SUPPORT
NETWORKS; PHYSICAL HEALTH; SEXUAL ASSAULT; DEPRESSED MOOD
AB Low social support and small social network size have been associated with a variety of negative mental health outcomes, while their impact on mental health services use is less clear. To date, few studies have examined these associations in National Guard service members, where frequency of mental health problems is high, social support may come from military as well as other sources, and services use may be suboptimal.
Surveys were administered to 1448 recently returned National Guard members. Multivariable regression models assessed the associations between social support characteristics, probable mental health conditions, and service utilization.
In bivariate analyses, large social network size, high social network diversity, high perceived social support, and high military unit support were each associated with lower likelihood of having a probable mental health condition (p < .001). In adjusted analyses, high perceived social support (OR .90, CI .88-.92) and high unit support (OR .96, CI .94-.97) continued to be significantly associated with lower likelihood of mental health conditions. Two social support measures were associated with lower likelihood of receiving mental health services in bivariate analyses, but were not significant in adjusted models.
General social support and military-specific support were robustly associated with reduced mental health symptoms in National Guard members. Policy makers, military leaders, and clinicians should attend to service members' level of support from both the community and their units and continue efforts to bolster these supports. Other strategies, such as focused outreach, may be needed to bring National Guard members with need into mental health care.
C1 [Sripada, Rebecca K.; Bohnert, Amy S. B.; Levine, Debra S.; Pfeiffer, Paul N.; Bowersox, Nicholas W.; Chermack, Stephen T.; Ganoczy, Dara; Walters, Heather; Valenstein, Marcia] VA Serious Mental Illness Treatment Resource & Ev, Ann Arbor, MI 48105 USA.
[Sripada, Rebecca K.; Bohnert, Amy S. B.; Levine, Debra S.; Pfeiffer, Paul N.; Bowersox, Nicholas W.; Chermack, Stephen T.; Walters, Heather; Valenstein, Marcia] VA Ann Arbor Hlth Care Syst, Ann Arbor, MI USA.
[Sripada, Rebecca K.; Bohnert, Amy S. B.; Levine, Debra S.; Pfeiffer, Paul N.; Bowersox, Nicholas W.; Chermack, Stephen T.; Walters, Heather; Valenstein, Marcia] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA.
[Teo, Alan R.] Portland VA Med Ctr, Portland, OR USA.
[Teo, Alan R.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Mizruchi, Mark S.] Univ Michigan, Dept Sociol, Ann Arbor, MI 48109 USA.
RP Sripada, RK (reprint author), VA Serious Mental Illness Treatment Resource & Ev, 2800 Plymouth Rd Bldg 16, Ann Arbor, MI 48105 USA.
EM rekaufma@umich.edu
OI Sripada, Rebecca/0000-0002-2844-3458
FU Department of Veterans Affairs Health Services Research and Development
Service [RRP 09-420, SDP 10-047]; Welcome Back Veterans Initiative;
McCormick Foundation; Families and Communities Together Coalition of
Michigan State University
FX This work was supported by the Department of Veterans Affairs Health
Services Research and Development Service, RRP 09-420 and SDP 10-047;
the Welcome Back Veterans Initiative, the McCormick Foundation, and
Families and Communities Together Coalition of Michigan State
University. Writing of this manuscript was supported by the Department
of Veterans Affairs Office of Academic Affiliations, Advanced Fellowship
Program in Mental Illness Research and Treatment, the Veterans Affairs
Serious Mental Illness Treatment Resource and Evaluation Center
(SMITREC) and the Mental Health Service of the VA Ann Arbor Healthcare
System.
NR 104
TC 1
Z9 1
U1 5
U2 14
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0933-7954
EI 1433-9285
J9 SOC PSYCH PSYCH EPID
JI Soc. Psychiatry Psychiatr. Epidemiol.
PD SEP
PY 2015
VL 50
IS 9
BP 1367
EP 1378
DI 10.1007/s00127-015-1078-2
PG 12
WC Psychiatry
SC Psychiatry
GA CS1KA
UT WOS:000361821700006
PM 26032182
ER
PT J
AU Liang, SH
Southon, AG
Fraser, BH
Krause-Heuer, AM
Zhang, B
Shoup, TM
Lewis, R
Volitakis, I
Han, YF
Greguric, I
Bush, AI
Vasdev, N
AF Liang, Steven H.
Southon, Adam G.
Fraser, Benjamin H.
Krause-Heuer, Anwen M.
Zhang, Bo
Shoup, Timothy M.
Lewis, Rebecca
Volitakis, Irene
Han, Yifeng
Greguric, Ivan
Bush, Ashley I.
Vasdev, Neil
TI Novel Fluorinated 8-Hydroxyquinoline Based Metal Ionophores for
Exploring the Metal Hypothesis of Alzheimer's Disease
SO ACS MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE 8-Hydroxyquinoline; metal ionophore; positron emission tomography;
Alzheimer's disease
ID A-BETA; TRANSGENIC MICE; ZINC; PLAQUES; COPPER; BIOMARKER; PROTEIN;
AGENTS
AB Zinc, copper, and iron ions are involved in amyloid-beta (A beta) deposition and stabilization in Alzheimer's disease (AD). Consequently, metal binding agents that prevent metal-A beta interaction and lead to the dissolution of A beta deposits have become well sought therapeutic and diagnostic targets. However, direct intervention between diseases and metal abnormalities has been challenging and is partially attributed to the lack of a suitable agent to determine and modify metal concentration and distribution in vivo. In the search of metal ionophores, we have identified several promising chemical entities by strategic fluorination of 8-hydroxyquinoline drugs, clioquinol, and PBT2. Compounds 15-17 and 28-30 showed exceptional metal ionophore ability (6-40-fold increase of copper uptake and >2-fold increase of zinc uptake) and inhibition of zinc induced A beta oligomerization (EC(50)s < similar to 5 mu M). These compounds are suitable for further development as drug candidates and/or positron emission tomography (PET) biomarkers if radiolabeled with F-18.
C1 [Liang, Steven H.; Shoup, Timothy M.; Lewis, Rebecca; Vasdev, Neil] Massachusetts Gen Hosp, Div Nucl Med & Mol Imaging, Boston, MA 02114 USA.
[Liang, Steven H.; Shoup, Timothy M.; Vasdev, Neil] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Southon, Adam G.; Volitakis, Irene; Bush, Ashley I.] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Parkville, Vic 3010, Australia.
[Fraser, Benjamin H.; Krause-Heuer, Anwen M.; Zhang, Bo; Greguric, Ivan] Australian Nucl Sci & Technol Org, Life Sci, Radiopharmaceut Res & Dev, Kirrawee, NSW 2232, Australia.
[Han, Yifeng] Zhejiang Sci Tech Univ, Dept Chem, Key Lab Adv Text Mat & Mfg Technol, Hangzhou 310018, Zhejiang, Peoples R China.
RP Bush, AI (reprint author), Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Parkville, Vic 3010, Australia.
EM ashleyib@unimelb.edu.au; vasdev.neil@mgh.harvard.edu
FU NIDA NIH HHS [K01 DA038000]
NR 24
TC 4
Z9 4
U1 9
U2 30
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-5875
J9 ACS MED CHEM LETT
JI ACS Med. Chem. Lett.
PD SEP
PY 2015
VL 6
IS 9
BP 1025
EP 1029
DI 10.1021/acsmedchemlett.5b00281
PG 5
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA CR3UY
UT WOS:000361259800016
PM 26396692
ER
PT J
AU Yaremchuk, MJ
AF Yaremchuk, Michael J.
TI Commentary on: The Role of Microfat Grafting in Facial Contouring
SO AESTHETIC SURGERY JOURNAL
LA English
DT Editorial Material
C1 [Yaremchuk, Michael J.] Harvard Univ, Sch Med, Surg, Boston, MA USA.
[Yaremchuk, Michael J.] Massachusetts Gen Hosp, Craniofacial Surg, Boston, MA 02114 USA.
[Yaremchuk, Michael J.] Harvard Plast Surg Training Program, Boston, MA USA.
RP Yaremchuk, MJ (reprint author), 170 Commonwealth Ave, Boston, MA 02116 USA.
EM dr.y@dryaremchuk.com
NR 2
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1090-820X
EI 1527-330X
J9 AESTHET SURG J
JI Aesthet. Surg. J.
PD SEP-OCT
PY 2015
VL 35
IS 7
BP 772
EP 773
DI 10.1093/asj/sjv084
PG 2
WC Surgery
SC Surgery
GA CR5PJ
UT WOS:000361395100011
PM 26141672
ER
PT J
AU Khera, AV
Qamar, A
Murphy, SA
Cannon, CP
Sabatine, MS
Rader, DJ
AF Khera, Amit V.
Qamar, Arman
Murphy, Sabina A.
Cannon, Christopher P.
Sabatine, Marc S.
Rader, Daniel J.
TI On-Statin Resistin, Leptin, and Risk of Recurrent Coronary Events After
Hospitalization for an Acute Coronary Syndrome (from the Pravastatin or
Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial
Infarction 22 Study)
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID RECEPTOR; ADIPONECTIN; DISEASE; OBESITY; HUMANS; WOMEN
AB Resistin is an adipokine secreted by macrophages and inflammatory cells linked to insulin resistance and inflammation. Leptin is an adipokine regulator of appetite and obesity. Although circulating levels of both have been associated with atherosclerosis, few data have reported their relation to coronary events in the context of statin therapy. This study measured on-statin levels of both resistin and leptin through enzyme-linked immunosorbent assay in a nested case control cohort (n = 176 cases with coronary death, myocardial infarction, or unstable angina pectoris observed in follow-up matched 1:1 to 176 controls) derived from the Pravastatin or, Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 study, a randomized controlled trial of atorvastatin 80 mg/day versus pravastatin 40 mg/day in patients with a recent acute coronary syndrome. Resistin demonstrated a moderate association with high-sensitivity C-reactive protein (hsCRP; Spearman rho = 0.25, p <0.0001). On-statin resistin levels were linked to recurrent coronary events in conditional logistic regression analysis adjusted for additional risk factors including hsCRP and history of diabetes (tertile 3 vs 1 adjusted odds ratio 2.08; 95% confidence interval [CI] 1.04 to 4.19). An additive risk was noted when patients were stratified by resistin and glycated hemoglobin levels. In contrast, leptin levels were associated with obesity, diabetes, triglycerides, and hsCRP (p <0.001 for each) but demonstrated no association with recurrent coronary events (tertile 3 vs 1 adjusted odds ratio 0.72; 95% CI 0.28 to 1.83). In conclusion, on-statin resistin, but not leptin, is an independent marker of residual risk for recurrent coronary events in patients after hospitalization for an acute coronary syndrome. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Khera, Amit V.] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA.
[Qamar, Arman; Rader, Daniel J.] 11 125 Smillow Ctr Translat Res, Perelman Sch Med, Dept Med & Cardiovasc Inst, Philadelphia, PA USA.
[Murphy, Sabina A.; Cannon, Christopher P.; Sabatine, Marc S.] Brigham & Womens Hosp, Dept Med, TIMI Study Grp, Boston, MA 02115 USA.
[Murphy, Sabina A.; Cannon, Christopher P.; Sabatine, Marc S.] Harvard Univ, Sch Med, Boston, MA USA.
RP Khera, AV (reprint author), Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA.
EM avkhera@mgh.harvard.edu
FU Bristol-Myers Squibb (New York, New York); Sankyo Pharmaceuticals
(Parsippany, New Jersey); ACCF/Merck (Kenilworth, NJ) Research
Fellowship in Cardiovascular Disease; Merck; Boehringer Ingelheim
(Ridgefield, CT); Bristol-Myers Squibb; CSL Behring (King of Prussia,
PA); Essentialis (Carlsbad, CA); GlaxoSmithKline (Middlesex, UK); Kowa
(Montgomery, AL); Takeda (Deerfield, IL); Lipimedix (Jerusalem, Israel);
Pfizer (New York, NY); Regeneron (Tarrytown, NJ); Sanofi (Bridgewater,
NJ); Accumetrics (San Diego, CA); Arisaph (Boston, MA); Astra Zeneca
(London, UK); Boehringer-Ingelheim; GlaxoSmithKline; Janssen (New
Brunswick, NJ); Takeda; Alnylam (Cambridge, MA); Amgen (Thousand Oaks,
CA); Cubist (Lexington, MA); CVS Caremark (Woonsocket, RI); Intarcia
(Boston, MA); MyoKardia (San Francisco, CA); Abbott Laboratories
(Chicago, IL); Amgen; AstraZeneca; Critical Diagnostics (San Diego, CA);
Daiichi-Sankyo (Tokyo, Japan); Eisai (Woodcliff Lake, NJ); Gilead
(Forest City, CA); Intarcia; Roche Diagnostics (Indianapolis, Indiana);
Sanofi-Aventis
FX The PROVE IT-TIMI 22 Study was funded by Bristol-Myers Squibb (New York,
New York) and Sankyo Pharmaceuticals (Parsippany, New Jersey). The
companies had no role in the analysis presented, manuscript preparation,
or decision to submit for publication. An ACCF/Merck (Kenilworth, NJ)
Research Fellowship in Cardiovascular Disease (awarded to AVK) provided
additional project support.; Dr. Khera has received consulting
fees/honoraria from Merck. Dr. Cannon has received consulting
fees/honoraria from Boehringer Ingelheim (Ridgefield, CT), Bristol-Myers
Squibb, CSL Behring (King of Prussia, PA), Essentialis (Carlsbad, CA),
GlaxoSmithKline (Middlesex, UK), Kowa (Montgomery, AL), Merck, Takeda
(Deerfield, IL), Lipimedix (Jerusalem, Israel), Pfizer (New York, NY),
Regeneron (Tarrytown, NJ), and Sanofi (Bridgewater, NJ) and research
grants from Accumetrics (San Diego, CA), Arisaph (Boston, MA), Astra
Zeneca (London, UK), Boehringer-Ingelheim, GlaxoSmithKline, Janssen (New
Brunswick, NJ), Merck, and Takeda. Dr. Sabatine has received consulting
fees/honoraria from Alnylam (Cambridge, MA), Amgen (Thousand Oaks, CA),
AstraZeneca, Cubist (Lexington, MA), CVS Caremark (Woonsocket, RI),
Intarcia (Boston, MA), Merck, and MyoKardia (San Francisco, CA) and
research grant support from Abbott Laboratories (Chicago, IL), Amgen,
AstraZeneca, Critical Diagnostics (San Diego, CA), Daiichi-Sankyo
(Tokyo, Japan), Eisai (Woodcliff Lake, NJ), Gilead (Forest City, CA),
GlaxoSmithKline, Intarcia, Merck, Roche Diagnostics (Indianapolis,
Indiana), Sanofi-Aventis, and Takeda.
NR 20
TC 3
Z9 3
U1 0
U2 4
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
EI 1879-1913
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD SEP 1
PY 2015
VL 116
IS 5
BP 694
EP 698
DI 10.1016/j.amjcard.2015.05.038
PG 5
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CR3YX
UT WOS:000361270100004
PM 26119654
ER
PT J
AU Tabtabai, S
Yeh, DD
Stefanescu, A
Kennedy, K
Yeh, RW
Bhatt, AB
AF Tabtabai, Sara
Yeh, Doreen DeFaria
Stefanescu, Ada
Kennedy, Kevin
Yeh, Robert W.
Bhatt, Ami B.
TI National Trends in Hospitalizations for Patients With Single-Ventricle
Anatomy
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID CONGENITAL HEART-DISEASE; UNITED-STATES; ADULTS; COMORBIDITY;
PHYSIOLOGY; OUTCOMES; IMPACT; DEATH; RISK
AB Patients with single-ventricle (SV) anatomy now live to adulthood. Little is known about the cost of care and outcomes for patients with SV anatomy, especially those who develop heart failure (HF) cared for in adult hospitals in the United States. We analyzed the Nationwide Inpatient Sample from 2000 to 2011 for patients >14 years admitted to adult hospitals with the International Classifications of Diseases, Ninth Revision, codes for SV anatomy. Demographics, outcomes, co-morbidities, and cost were assessed. From 2000 to 2011, the number of SV admissions was stable with a trend toward increased cost per admission over time. Coexistent hypertension, obesity, and liver, pulmonary, and renal diseases significantly increased over time. The most common reason for admission was atrial arrhythmia followed by HF. Patients with SV with HF had significantly higher inhospital mortality, length of stay, and more medical co-morbidities than those with SV and without HF. In conclusion, the cohort of patients with SV admitted to adult hospitals has changed in the modern era. Patients with SV have medical co-morbidities including renal and liver diseases, hypertension, and obesity at a surprisingly young age. Aggressive and proactive management of HF and arrhythmia may reduce cost of care for this challenging population. Patients with SV with HE have particularly high mortality, more medical co-morbidities, and increased cost of care and deserve more focused attention to improve outcomes. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Tabtabai, Sara; Yeh, Doreen DeFaria; Stefanescu, Ada; Kennedy, Kevin; Yeh, Robert W.; Bhatt, Ami B.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
RP Bhatt, AB (reprint author), Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
EM abhatt@mgh.harvard.edu
OI Stefanescu Schmidt, Ada/0000-0002-5692-2616
NR 19
TC 2
Z9 2
U1 0
U2 0
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
EI 1879-1913
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD SEP 1
PY 2015
VL 116
IS 5
BP 773
EP 778
DI 10.1016/j.amjcard.2015.05.053
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CR3YX
UT WOS:000361270100017
PM 26100589
ER
PT J
AU Hirko, KA
Kantor, ED
Cohen, SS
Blot, WJ
Stampfer, MJ
Signorello, LB
AF Hirko, Kelly A.
Kantor, Elizabeth D.
Cohen, Sarah S.
Blot, William J.
Stampfer, Meir J.
Signorello, Lisa B.
TI Body Mass Index in Young Adulthood, Obesity Trajectory, and Premature
Mortality
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE body mass index; mortality; obesity; young adulthood
ID SOUTHERN COMMUNITY COHORT; INTENTIONAL WEIGHT-LOSS;
CORONARY-HEART-DISEASE; ALL-CAUSE MORTALITY; BIRTH COHORT; HEALTH
DISPARITIES; CHILDHOOD OBESITY; BLACK ADULTS; US WHITE; OVERWEIGHT
AB Although much research has been conducted on the role adult body mass index (BMI) plays in mortality, there have been fewer studies that evaluated the associations of BMI in young adulthood and adult weight trajectory with mortality, and it remains uncertain whether associations differ by race or sex. We prospectively examined the relationships of BMI in young adulthood (21 years of age) and adult obesity trajectory with later-life mortality rates among 75,881 men and women in the Southern Community Cohort Study. Study participants were enrolled between 2002 and 2009 at ages 40-79 years and were followed through December, 2011. Multivariable Cox proportional hazards models were used to estimate hazard ratios and 95% confidence intervals. There were 7,301 deaths in the 474,970 person-years of follow-up. Participants who reported being overweight or obese as young adults had mortality rates that were 19% (95% confidence interval: 12, 27) and 64% (95% confidence interval: 52, 78) higher, respectively, than those of their normal weight counterparts. The results did not significantly differ by race or sex. Participants who reported being obese in young adulthood only or in both young and middle adulthood experienced mortality rates that were 40%-90% higher than those of participants who were nonobese at either time. These results suggest that obesity in young adulthood is associated with higher mortality risk regardless of race, sex, and obesity status in later life.
C1 [Hirko, Kelly A.; Stampfer, Meir J.; Signorello, Lisa B.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA.
[Hirko, Kelly A.; Stampfer, Meir J.; Signorello, Lisa B.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Hirko, Kelly A.; Kantor, Elizabeth D.; Stampfer, Meir J.; Signorello, Lisa B.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Cohen, Sarah S.] EpidStat Inst, Ann Arbor, MI USA.
[Blot, William J.] Int Epidemiol Inst, Rockville, MD USA.
[Blot, William J.] Vanderbilt Univ, Med Ctr, Div Epidemiol, Dept Med, Nashville, TN 37235 USA.
[Signorello, Lisa B.] Dana Farber Harvard Canc Ctr, Boston, MA USA.
RP Hirko, KA (reprint author), Harvard Univ, Sch Publ Hlth, Dept Epidemiol, 677 Huntington Ave, Boston, MA 02115 USA.
EM khirko@hsph.harvard.edu
FU National Cancer Institute [R01 CA092447]; [R25T CA098566]
FX The Southern Community Cohort Study is funded by grant R01 CA092447 from
the National Cancer Institute. K.A.H. is supported by the R25T CA098566
training grant.
NR 50
TC 9
Z9 9
U1 2
U2 12
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
EI 1476-6256
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD SEP 1
PY 2015
VL 182
IS 5
BP 441
EP 450
DI 10.1093/aje/kwv084
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA CR5NB
UT WOS:000361388700009
PM 25977515
ER
PT J
AU Gradus, JL
Antonsen, S
Svensson, E
Lash, TL
Resick, PA
Hansen, JG
AF Gradus, Jaimie L.
Antonsen, Sussie
Svensson, Elisabeth
Lash, Timothy L.
Resick, Patricia A.
Hansen, Jens Georg
TI Trauma, Comorbidity, and Mortality Following Diagnoses of Severe Stress
and Adjustment Disorders: A Nationwide Cohort Study
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE cohort studies; stress disorders; traumatic; suicide
ID SEXUAL REVICTIMIZATION; PSYCHIATRIC-ILLNESS; COMPLETED SUICIDE; PTSD;
REGISTER; VETERANS; SYMPTOMATOLOGY; POPULATION; SYMPTOMS; MEDIATOR
AB Longitudinal outcomes following stress or trauma diagnoses are receiving attention, yet population-based studies are few. The aims of the present cohort study were to examine the cumulative incidence of traumatic events and psychiatric diagnoses following diagnoses of severe stress and adjustment disorders categorized using International Classification of Diseases, Tenth Revision, codes and to examine associations of these diagnoses with all-cause mortality and suicide. Data came from a longitudinal cohort of all Danes who received a diagnosis of reaction to severe stress or adjustment disorders (International Classification of Diseases, Tenth Revision, code F43.x) between 1995 and 2011, and they were compared with data from a general-population cohort. Cumulative incidence curves were plotted to examine traumatic experiences and psychiatric diagnoses during the study period. A Cox proportional hazards regression model was used to examine the associations of the disorders with mortality and suicide. Participants with stress diagnoses had a higher incidence of traumatic events and psychiatric diagnoses than did the comparison group. Each disorder was associated with a higher rate of all-cause mortality than that seen in the comparison cohort, and strong associations with suicide were found after adjustment. This study provides a comprehensive assessment of the associations of stress disorders with a variety of outcomes, and we found that stress diagnoses may have long-lasting and potentially severe consequences.
C1 [Gradus, Jaimie L.] Boston Univ, VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA 02130 USA.
[Gradus, Jaimie L.] Boston Univ, Dept Psychiat, Boston, MA 02215 USA.
[Gradus, Jaimie L.] Boston Univ, Dept Epidemiol, Boston, MA 02215 USA.
[Antonsen, Sussie; Svensson, Elisabeth; Hansen, Jens Georg] Aarhus Univ Hosp, Dept Clin Epidemiol, DK-8000 Aarhus, Denmark.
[Lash, Timothy L.] Emory Univ, Dept Epidemiol, Atlanta, GA 30322 USA.
[Resick, Patricia A.] Duke Univ, Dept Psychiat, Durham, NC 27706 USA.
[Resick, Patricia A.] Duke Univ, Dept Behav Sci, Durham, NC USA.
RP Gradus, JL (reprint author), VA Boston Healthcare Syst, Natl Ctr PTSD, 150 South Huntington Ave 116B-3, Boston, MA 02130 USA.
EM jaimie.gradus@va.gov
OI Gradus, Jaimie/0000-0003-1459-5327
FU National Institute of Mental Health [1R21MH094551-01A1]
FX This work was supported by a National Institute of Mental Health (grant
1R21MH094551-01A1) to J.L.G.
NR 27
TC 2
Z9 2
U1 1
U2 9
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
EI 1476-6256
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD SEP 1
PY 2015
VL 182
IS 5
BP 451
EP 458
DI 10.1093/aje/kwv066
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA CR5NB
UT WOS:000361388700010
PM 26243737
ER
PT J
AU Chenelle, CT
Fisher, DF
Kacmarek, RM
Berra, L
AF Chenelle, Christopher T.
Fisher, Daniel F.
Kacmarek, Robert M.
Berra, Lorenzo
TI Procedural Considerations on the Use of Polyurethane and/or Conical
Cuffs
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Letter
ID VENTILATOR-ASSOCIATED PNEUMONIA; CRITICALLY-ILL PATIENTS; PRESSURE
C1 [Chenelle, Christopher T.; Fisher, Daniel F.; Kacmarek, Robert M.; Berra, Lorenzo] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Chenelle, Christopher T.; Fisher, Daniel F.; Kacmarek, Robert M.; Berra, Lorenzo] Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Chenelle, CT (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 6
TC 0
Z9 0
U1 1
U2 1
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD SEP 1
PY 2015
VL 192
IS 5
BP 639
EP 640
PG 2
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA CR4XX
UT WOS:000361344500020
PM 26561679
ER
PT J
AU Dieras, V
Campone, M
Yardley, DA
Romieu, G
Valero, V
Isakoff, SJ
Koeppen, H
Wilson, TR
Xiao, Y
Shames, DS
Mocci, S
Chen, M
Schmid, P
AF Dieras, V.
Campone, M.
Yardley, D. A.
Romieu, G.
Valero, V.
Isakoff, S. J.
Koeppen, H.
Wilson, T. R.
Xiao, Y.
Shames, D. S.
Mocci, S.
Chen, M.
Schmid, P.
TI Randomized, phase II, placebo-controlled trial of onartuzumab and/or
bevacizumab in combination with weekly paclitaxel in patients with
metastatic triple-negative breast cancer
SO ANNALS OF ONCOLOGY
LA English
DT Article
DE bevacizumab; MET; triple-negative breast cancer; onartuzumab;
paclitaxel; phase II
ID SOLID TUMORS; C-MET; EXPRESSION; CHEMOTHERAPY; CARCINOMAS; SUBTYPES
AB Increased hepatocyte growth factor/MET signaling is associated with an aggressive phenotype and poor prognosis in triple-negative breast cancer (TNBC). We evaluated the benefit of adding onartuzumab, a monoclonal anti-MET antibody, to paclitaxel with/without bevacizumab in patients with TNBC.
Women with metastatic TNBC were randomized to receive onartuzumab plus placebo plus weekly paclitaxel (OP; n = 60) or onartuzumab plus bevacizumab plus paclitaxel (OBP; n = 63) or placebo plus bevacizumab plus paclitaxel (BP; n = 62). The primary end point was progression-free survival (PFS); additional end points included overall survival (OS), objective response rate (ORR), and safety. This trial was hypothesis generating and did not have power to detect minimum clinically meaningful differences between treatment arms.
There was no improvement in PFS with the addition of onartuzumab to BP [hazard ratio (HR), 1.08; 95% confidence interval (CI) 0.69-1.70]; the risk of a PFS event was higher with OP than with BP (HR, 1.74; 95% CI 1.13-2.68). Most patients had MET-negative tumors (88%); PAM50 subtype analysis showed basal-like tumors in 68% of samples. ORR was higher in the bevacizumab arms (OBP: 42.2%; 95% CI 28.6-57.1; BP: 54.7%; 95% CI 41.0-68.4) compared with OP (27.5%; 95% CI 15.9-40.6). Median OS was shorter with OBP (HR, 1.36; 95% CI 0.75-2.46) and OP (HR, 1.92; 95% CI 1.03-3.59), than with BP. Peripheral edema was more frequent in the onartuzumab arms (OBP, 51.8%; OP, 58.6%) versus BP (17.7%).
This study did not show a clinical benefit of the addition of onartuzumab to paclitaxel with/without bevacizumab in patients with predominantly MET-negative TNBC.
C1 [Dieras, V.] Inst Curie Paris & St Cloud, Dept Clin Res, F-75248 Paris 05, France.
[Campone, M.] Ctr Reg Lutte Canc CRLC Nantes, Ctr Rene Gauducheau, Atlantique, France.
[Yardley, D. A.] PLLC, Sarah Cannon Res Inst & Tennessee Oncol, Nashville, TN USA.
[Romieu, G.] ICM, Montpellier, France.
[Valero, V.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Isakoff, S. J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Koeppen, H.; Wilson, T. R.; Xiao, Y.; Shames, D. S.; Mocci, S.] Genentech Inc, San Francisco, CA 94080 USA.
[Chen, M.] Roche Prod Dev, Shanghai, Peoples R China.
[Schmid, P.] Queen Mary Univ London, Barts Canc Inst, London, England.
RP Dieras, V (reprint author), Inst Curie Paris & St Cloud, Dept Clin Res, 26 Rue Ulm, F-75248 Paris 05, France.
EM veronique.dieras@curie.fr
RI campone, mario/L-4880-2015
FU Genentech, Inc.
FX This study was supported by Genentech, Inc. Support for third-party
writing assistance for this manuscript was provided by Genentech, Inc.
Grant numbers are not applicable.
NR 20
TC 15
Z9 16
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD SEP
PY 2015
VL 26
IS 9
BP 1904
EP 1910
DI 10.1093/annonc/mdv263
PG 7
WC Oncology
SC Oncology
GA CR5ON
UT WOS:000361392700015
PM 26202594
ER
PT J
AU Ausiello, D
Lipnick, S
AF Ausiello, Dennis
Lipnick, Scott
TI Real-Time Assessment of Wellness and Disease in Daily Life
SO BIG DATA
LA English
DT Article
DE big data industry standards; big data architecture; big data analytics
ID GUT MICROBIOTA; METAGENOME
AB The next frontier in medicine involves better quantifying human traits, known as "phenotypes." Biological markers have been directly associated with disease risks, but poor measurement of behaviors such as diet and exercise limits our understanding of preventive measures. By joining together an uncommonly wide range of disciplines and expertise, the Kavli HUMAN Project will advance measurement of behavioral phenotypes, as well as environmental factors that impact behavior. By following the same individuals over time, KHP will liberate new understanding of dynamic links between behavioral phenotypes, disease, and the broader environment. As KHP advances understanding of the bio-behavioral complex, it will seed new approaches to the diagnosis, prevention, and treatment of human disease.
C1 [Ausiello, Dennis; Lipnick, Scott] Massachussetts Gen Hosp, Ctr Assessment Technol & Continuous Hlth, Boston, MA USA.
RP Ausiello, D (reprint author), Dept Med, 55 Fruit St, Boston, MA 02114 USA.
EM Ausiello.Dennis@mgh.harvard.edu
NR 9
TC 3
Z9 3
U1 5
U2 7
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2167-6461
EI 2167-647X
J9 BIG DATA
JI Big Data
PD SEP 1
PY 2015
VL 3
IS 3
BP 203
EP 208
DI 10.1089/big.2015.0016
PG 6
WC Computer Science, Interdisciplinary Applications; Computer Science,
Theory & Methods
SC Computer Science
GA CR5FC
UT WOS:000361364900010
ER
PT J
AU Kim, KS
Hyun, H
Yang, JA
Lee, MY
Kim, H
Yun, SH
Choi, HS
Hahn, SK
AF Kim, Ki Su
Hyun, Hoon
Yang, Jeong-A
Lee, Min Young
Kim, Hyemin
Yun, Seok-Hyun
Choi, Hak Soo
Hahn, Sei Kwang
TI Bioimaging of Hyaluronate-Interferon alpha Conjugates Using a
Non-Interfering Zwitterionic Fluorophore
SO BIOMACROMOLECULES
LA English
DT Article
ID HEPATITIS-C VIRUS; NEAR-INFRARED FLUOROPHORES; QUANTUM DOTS; IN-VIVO;
ACID DERIVATIVES; DELIVERY; TARGET; CELLS; CLEARANCE; DRUGS
AB We conducted real-time bioimaging of the hyaluronate-interferon alpha (HA-IFN alpha) conjugate using a biologically inert zwitterionic fluorophore of ZW800-1 for the treatment of hepatitis C virus (HCV) infection. ZW800-1 was labeled on the IFN alpha molecule of the HA-IFN alpha conjugate to investigate its bio distribution and clearance without altering its physicochemical and targeting characteristics. Confocal microscopy clearly visualized the effective in vitro cellular uptake of the HA-IFN alpha conjugate to HepG2 cells. After verifying the biological activity in Daudi cells, we conducted the pharmacokinetic analysis of the HA-IFN alpha conjugate, which confirmed its target-specific delivery to the liver with a prolonged residence time longer than that of PEGylated IFN alpha. In vivo and ex vivo bioimaging of the ZW800-1-labeled HA-IFN alpha conjugate directly showed real-time biodistribution and clearance of the conjugate that are consistent with the biological behaviors analyzed by an enzyme-linked immunosorbent assay. Furthermore, the elevated level of OAS1 mRNA in the liver confirmed in vivo antiviral activity of HA-IFN alpha conjugates. With the data taken together, we could confirm the feasibility of ZW800-1 as a biologically inert fluorophore and target-specific HA-IFN alpha conjugate for the treatment of HCV infection.
C1 [Kim, Ki Su; Yun, Seok-Hyun; Hahn, Sei Kwang] Massachusetts Gen Hosp, Wellman Ctr Photomed, Cambridge, MA 02139 USA.
[Kim, Ki Su; Yun, Seok-Hyun; Hahn, Sei Kwang] Harvard Univ, Sch Med, Cambridge, MA 02139 USA.
[Yang, Jeong-A; Lee, Min Young; Kim, Hyemin; Hahn, Sei Kwang] Pohang Univ Sci & Technol POSTECH, Dept Mat Sci & Engn, Pohang 790784, Kyungbuk, South Korea.
[Hyun, Hoon; Choi, Hak Soo] Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Boston, MA 02215 USA.
[Hyun, Hoon; Choi, Hak Soo] Harvard Univ, Sch Med, Boston, MA 02215 USA.
[Hyun, Hoon] Chonnam Natl Univ, Sch Med, Dept Biomed Sci, Kwangju 501746, South Korea.
RP Choi, HS (reprint author), Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, 330 Brookline Ave, Boston, MA 02215 USA.
EM hchoi@bidmc.harvard.edu; skhanb@postech.ac.kr
RI Choi, Hak Soo/C-9954-2011
FU Converging Research Center Program through the National Research
Foundation of Korea (NRF) - Ministry of Education, Science and
Technology [2009-0081871]; Midcareer Researcher Program through an NRF
grant - MEST [2012R1A2A2A06045773]; National Institute of Biomedical
Imaging and Bioengineering [R01-EB-011523]
FX This work was supported by the Converging Research Center Program
through the National Research Foundation of Korea (NRF) funded by the
Ministry of Education, Science and Technology (2009-0081871). This study
was also supported by the Midcareer Researcher Program through an NRF
grant funded by the MEST (2012R1A2A2A06045773) and a National Institute
of Biomedical Imaging and Bioengineering grant (R01-EB-011523).
NR 35
TC 3
Z9 3
U1 0
U2 10
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1525-7797
EI 1526-4602
J9 BIOMACROMOLECULES
JI Biomacromolecules
PD SEP
PY 2015
VL 16
IS 9
BP 3054
EP 3061
DI 10.1021/acs.biomac.5b00933
PG 8
WC Biochemistry & Molecular Biology; Chemistry, Organic; Polymer Science
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA CR4WV
UT WOS:000361341700052
PM 26258264
ER
PT J
AU Wang, C
Dominici, F
Parmigiani, G
Zigler, CM
AF Wang, Chi
Dominici, Francesca
Parmigiani, Giovanni
Zigler, Corwin Matthew
TI Accounting for Uncertainty in Confounder and Effect Modifier Selection
When Estimating Average Causal Effects in Generalized Linear Models
SO BIOMETRICS
LA English
DT Article
DE Average causal effect; Bayesian adjustment for confounding; Confounder
selection; Treatment effect heterogeneity
ID PROPENSITY SCORE; VARIABLE SELECTION; ADJUSTMENT UNCERTAINTY;
BAYESIAN-ADJUSTMENT; INFERENCE; REGRESSION; BOOTSTRAP; ALGORITHM
AB Confounder selection and adjustment are essential elements of assessing the causal effect of an exposure or treatment in observational studies. Building upon work by Wang et al. (2012, Biometrics 68, 661-671) and Lefebvre et al. (2014, Statistics in Medicine 33, 2797-2813), we propose and evaluate a Bayesian method to estimate average causal effects in studies with a large number of potential confounders, relatively few observations, likely interactions between confounders and the exposure of interest, and uncertainty on which confounders and interaction terms should be included. Our method is applicable across all exposures and outcomes that can be handled through generalized linear models. In this general setting, estimation of the average causal effect is different from estimation of the exposure coefficient in the outcome model due to noncollapsibility. We implement a Bayesian bootstrap procedure to integrate over the distribution of potential confounders and to estimate the causal effect. Our method permits estimation of both the overall population causal effect and effects in specified subpopulations, providing clear characterization of heterogeneous exposure effects that may vary considerably across different covariate profiles. Simulation studies demonstrate that the proposed method performs well in small sample size situations with 100-150 observations and 50 covariates. The method is applied to data on 15,060 US Medicare beneficiaries diagnosed with a malignant brain tumor between 2000 and 2009 to evaluate whether surgery reduces hospital readmissions within 30 days of diagnosis.
C1 [Wang, Chi] Univ Kentucky, Dept Biostat, Lexington, KY 40506 USA.
[Wang, Chi] Univ Kentucky, Markey Canc Ctr, Lexington, KY USA.
[Dominici, Francesca; Parmigiani, Giovanni; Zigler, Corwin Matthew] Harvard Univ, TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Parmigiani, Giovanni] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
RP Wang, C (reprint author), Univ Kentucky, Dept Biostat, Lexington, KY 40506 USA.
EM chi.wang@uky.edu
FU NIH/NCI [P01 CA134294, 5P30 CA006516-46]; HEI [4909]; AHRQ [K18
HS021991]; NIH [R21 ES022585-01, R01 ES019560, R01 GM111339]
FX We thank Dr Nils Arvold and Dr Yun Wang for input on the construction
and analysis of the brain cancer data. We also thank the Co-Editor, the
Associate Editor, and three referees for insightful comments. The work
of Drs Dominici and Zigler was supported by NIH/NCI P01 CA134294, and
HEI 4909, Dr Dominici was supported by AHRQ K18 HS021991, NIH R21
ES022585-01, NIH R01 ES019560, and NIH R01 GM111339, and Dr Parmigiani
was supported by NIH/NCI 5P30 CA006516-46.
NR 28
TC 0
Z9 0
U1 4
U2 13
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0006-341X
EI 1541-0420
J9 BIOMETRICS
JI Biometrics
PD SEP
PY 2015
VL 71
IS 3
BP 654
EP 665
DI 10.1111/biom.12315
PG 12
WC Biology; Mathematical & Computational Biology; Statistics & Probability
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
Biology; Mathematics
GA CR7JY
UT WOS:000361527000010
PM 25899155
ER
PT J
AU Nakagawa, A
Von Alt, K
Lillemoe, KD
Fernandez-del Castillo, C
Warshaw, AL
Liss, AS
AF Nakagawa, Akifumi
Von Alt, Kate
Lillemoe, Keith D.
Fernandez-del Castillo, Carlos
Warshaw, Andrew L.
Liss, Andrew S.
TI A method for fixing and paraffin embedding tissue to retain the natural
fluorescence of reporter proteins
SO BIOTECHNIQUES
LA English
DT Article
DE FFPE; GFP; natural fluorescence
ID MARKER; MOUSE; GFP
AB Green fluorescent protein (GFP) and its derivatives are routinely employed as surrogate markers for gene expression and lineage tracing in genetically engineered mice. Tissues from these mice are commonly formalin fixed and paraffin embedded (FFPE) for histological studies. However, this results in inactivation of the natural fluorescence of these proteins, requiring their detection by immunological techniques. Here we present an ethanol fixation protocol that allows for the direct visualization of the natural fluorescence of reporter proteins while maintaining excellent tissue histology. We demonstrate the utility of this method for visualizing green and red fluorescent proteins in a wide range of murine tissues using both cytoplasmic and membrane-localized fluorescent reporter proteins. Tissues fixed by this method also allow for immunohistochemical studies, providing a single method to visualize the natural fluorescence of reporter proteins with subsequent detection of cellular proteins.
C1 [Liss, Andrew S.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Andrew L Warshaw MD Inst Pancreat Canc Res, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
RP Liss, AS (reprint author), Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
EM aliss@mgh.harvard.edu
FU Institute for Pancreatic Cancer Research; NIH [P01CA117969]
FX We would like to thank Patricia Della Pelle for her advice and technical
support. This work was supported in part by the Andrew L Warshaw, MD,
Institute for Pancreatic Cancer Research and a grant from the NIH:
P01CA117969. This paper is subject to the NIH Public Access Policy.
NR 10
TC 1
Z9 1
U1 2
U2 4
PU BIOTECHNIQUES OFFICE
PI NEW YORK
PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA
SN 0736-6205
EI 1940-9818
J9 BIOTECHNIQUES
JI Biotechniques
PD SEP
PY 2015
VL 59
IS 3
BP 153
EP 155
DI 10.2144/000114328
PG 3
WC Biochemical Research Methods; Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA CR3RE
UT WOS:000361250000010
PM 26345508
ER
PT J
AU Locascio, JJ
Eberly, S
Liao, ZX
Liu, GQ
Hoesing, AN
Duong, K
Trisini-Lipsanopoulos, A
Dhima, K
Hung, AY
Flaherty, AW
Schwarzschild, MA
Hayes, MT
Wills, AM
Sohur, US
Mejia, NI
Selkoe, DJ
Oakes, D
Shoulson, I
Dong, XJ
Marek, K
Zheng, B
Ivinson, A
Hyman, BT
Growdon, JH
Sudarsky, LR
Schlossmacher, MG
Ravina, B
Scherzer, CR
AF Locascio, Joseph J.
Eberly, Shirley
Liao, Zhixiang
Liu, Ganqiang
Hoesing, Ashley N.
Duong, Karen
Trisini-Lipsanopoulos, Ana
Dhima, Kaltra
Hung, Albert Y.
Flaherty, Alice W.
Schwarzschild, Michael A.
Hayes, Michael T.
Wills, Anne-Marie
Sohur, U. Shivraj
Mejia, Nicte I.
Selkoe, Dennis J.
Oakes, David
Shoulson, Ira
Dong, Xianjun
Marek, Ken
Zheng, Bin
Ivinson, Adrian
Hyman, Bradley T.
Growdon, John H.
Sudarsky, Lewis R.
Schlossmacher, Michael G.
Ravina, Bernard
Scherzer, Clemens R.
TI Association between alpha-synuclein blood transcripts and early,
neuroimaging-supported Parkinson's disease
SO BRAIN
LA English
DT Article
DE alpha-synuclein; biomarker; gene expression; biobank; mitochondria;
cognitive decline
ID GENE-EXPRESSION; RNA; BIOMARKERS; DISCOVERY; PROTEIN; RISK;
STABILIZATION; PHLEBOTOMY; OPINION; MARKERS
AB There are no cures for neurodegenerative diseases and this is partially due to the difficulty of monitoring pathogenic molecules in patients during life. The Parkinson's disease gene a-synuclein (SNCA) is selectively expressed in blood cells and neurons. Here we show that SNCA transcripts in circulating blood cells are paradoxically reduced in early stage, untreated and dopamine transporter neuroimaging-supported Parkinson's disease in three independent regional, national, and international populations representing 500 cases and 363 controls and on three analogue and digital platforms with P50.0001 in meta-analysis. Individuals with SNCA transcripts in the lowest quartile of counts had an odds ratio for Parkinson's disease of 2.45 compared to individuals in the highest quartile. Disease-relevant transcript isoforms were low even near disease onset. Importantly, low SNCA transcript abundance predicted cognitive decline in patients with Parkinson's disease during up to 5 years of longitudinal follow-up. This study reveals a consistent association of reduced SNCA transcripts in accessible peripheral blood and early-stage Parkinson's disease in 863 participants and suggests a clinical role as potential predictor of cognitive decline. Moreover, the three independent biobank cohorts provide a generally useful platform for rapidly validating any biological marker of this common disease.
C1 [Locascio, Joseph J.; Liao, Zhixiang; Liu, Ganqiang; Hoesing, Ashley N.; Duong, Karen; Trisini-Lipsanopoulos, Ana; Dhima, Kaltra; Dong, Xianjun; Zheng, Bin; Scherzer, Clemens R.] Harvard Univ, Sch Med, Neurogen Lab, Cambridge, MA 02139 USA.
[Locascio, Joseph J.; Liao, Zhixiang; Liu, Ganqiang; Hoesing, Ashley N.; Duong, Karen; Trisini-Lipsanopoulos, Ana; Dhima, Kaltra; Dong, Xianjun; Zheng, Bin; Scherzer, Clemens R.] Harvard Univ, Sch Med, Parkinson Personalized Med Program, Cambridge, MA 02139 USA.
[Locascio, Joseph J.; Liao, Zhixiang; Liu, Ganqiang; Hoesing, Ashley N.; Duong, Karen; Trisini-Lipsanopoulos, Ana; Dhima, Kaltra; Dong, Xianjun; Zheng, Bin; Scherzer, Clemens R.] Brigham & Womens Hosp, Cambridge, MA 02139 USA.
[Locascio, Joseph J.; Hung, Albert Y.; Flaherty, Alice W.; Schwarzschild, Michael A.; Wills, Anne-Marie; Sohur, U. Shivraj; Mejia, Nicte I.; Hyman, Bradley T.; Growdon, John H.; Scherzer, Clemens R.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Eberly, Shirley; Oakes, David] Univ Rochester, Med Ctr, Dept Biostat & Computat Biol, Rochester, NY 14642 USA.
[Liao, Zhixiang; Liu, Ganqiang; Hoesing, Ashley N.; Duong, Karen; Trisini-Lipsanopoulos, Ana; Dhima, Kaltra; Selkoe, Dennis J.; Dong, Xianjun; Zheng, Bin; Ivinson, Adrian; Scherzer, Clemens R.] Brigham & Womens Hosp, Ann Romney Ctr Neurol Dis, Boston, MA 02115 USA.
[Hoesing, Ashley N.; Duong, Karen; Trisini-Lipsanopoulos, Ana; Dhima, Kaltra; Wills, Anne-Marie; Ivinson, Adrian; Hyman, Bradley T.; Scherzer, Clemens R.] Harvard NeuroDiscovery Ctr, Biomarkers Program, Boston, MA 02115 USA.
[Flaherty, Alice W.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Hayes, Michael T.; Selkoe, Dennis J.; Sudarsky, Lewis R.; Scherzer, Clemens R.] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA.
[Shoulson, Ira] Georgetown Univ, Dept Neurol, Program Regulatory Sci & Med, Washington, DC 20007 USA.
[Marek, Ken] Inst Neurodegenerat Disorders, New Haven, CT 06510 USA.
[Schlossmacher, Michael G.] Univ Ottawa, Ottawa Hosp Res Inst, Program Neurosci, Ottawa, ON K1H 8M5, Canada.
[Ravina, Bernard] Voyager Therapeut, Clin Dev, Cambridge, MA 02142 USA.
RP Scherzer, CR (reprint author), Harvard Univ, Sch Med, Neurogen Lab, 65 Landsdowne St,Suite 307A, Cambridge, MA 02139 USA.
EM cscherzer@rics.bwh.harvard.edu
FU NIH [U01 NS082157, U01 NS082080]; Harvard NeuroDiscovery Center; U.S.
Department of Defense [W81XWH-1-0007, W81XWH-13-1-0115,
W81XWH-11-1-0150]; Michael J. Fox Foundation; M.E.M.O. Hoffman
Foundation; Harvard NeuroDiscovery Center (HNDC); Parkinson's Disease
Biomarkers Program (PDBP) of the NINDS [U01 NS082157]; Massachusetts
Alzheimer's Disease Research Center (ADRC) of the National Institute on
Aging [P50 AG005134]; Department of Defense Neurotoxin Exposure
Treatment Parkinson's Research Program [W23RRYX7022N606]; NINDS PD-DOC
[NS050095]; Parkinson's Disease Foundation (New York, NY); Cephalon Inc;
Lundbeck; Michael J. Fox Foundation for Parkinson's Research; Abbott;
Avid; Biogen Idec; Bristol-Myers Squibb; Covance; Elan; GE Healthcare;
Genentech; GlaxoSmithKline; Lilly; Merck; Meso Scale Discovery; Pfizer;
Roche; UCB
FX This study was made possible by NIH grants U01 NS082157 (C.R.S.), U01
NS082080 (C.R.S.) the Harvard NeuroDiscovery Center (to A. I., C.R.S.,
and B.T.H.), U.S. Department of Defense grants W81XWH-1-0007 (B.R.) and
W81XWH-13-1-0115 (C.R.S), and the Michael J. Fox Foundation (C.R.S. and
M.G.S.). Additional funding was provided by the M.E.M.O. Hoffman
Foundation (C.R.S.) and U.S. Department of Defense grant
W81XWH-11-1-0150 (M.A.S.).; The Harvard Biomarker Study is supported by
the Harvard NeuroDiscovery Center (HNDC), the Parkinson's Disease
Biomarkers Program (PDBP) grant U01 NS082157 of the NINDS, and the
Massachusetts Alzheimer's Disease Research Center (ADRC) P50 AG005134
grant of the National Institute on Aging.; The PROBE cohort was funded
by Department of Defense Neurotoxin Exposure Treatment Parkinson's
Research Program (W23RRYX7022N606), NINDS PD-DOC (NS050095), the
Parkinson's Disease Foundation (New York, NY), with initial funding from
Cephalon Inc and Lundbeck for the parent PRECEPT clinical trial and
follow-up PostCEPT cohort, from which the nested PROBE cohort was
derived.; PPMI, a public-private partnership, is funded by the Michael
J. Fox Foundation for Parkinson's Research and funding partners,
including Abbott, Avid, Biogen Idec, Bristol-Myers Squibb, Covance,
Elan, GE Healthcare, Genentech, GlaxoSmithKline, Lilly, Merck, Meso
Scale Discovery, Pfizer, Roche, UCB.
NR 47
TC 10
Z9 10
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 1460-2156
J9 BRAIN
JI Brain
PD SEP 1
PY 2015
VL 138
BP 2659
EP 2671
DI 10.1093/brain/awv202
PN 9
PG 13
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA CR5PS
UT WOS:000361396200026
PM 26220939
ER
PT J
AU Toledo, JB
Zetterberg, H
van Harten, AC
Glodzik, L
Martinez-Lage, P
Bocchio-Chiavetto, L
Rami, L
Hansson, O
Sperling, R
Engelborghs, S
Osorio, RS
Vanderstichele, H
Vandijck, M
Hampel, H
Teipl, S
Moghekar, A
Albert, M
Hu, WT
Argiles, JAM
Gorostidi, A
Teunissen, CE
De Deyn, PP
Hyman, BT
Molinuevo, JL
Frisoni, GB
Linazasoro, G
de Leon, MJ
van der Flier, WM
Scheltens, P
Blennow, K
Shaw, LM
Trojanowski, JQ
AF Toledo, Jon B.
Zetterberg, Henrik
van Harten, Argonde C.
Glodzik, Lidia
Martinez-Lage, Pablo
Bocchio-Chiavetto, Luisella
Rami, Lorena
Hansson, Oskar
Sperling, Reisa
Engelborghs, Sebastiaan
Osorio, Ricardo S.
Vanderstichele, Hugo
Vandijck, Manu
Hampel, Harald
Teipl, Stefan
Moghekar, Abhay
Albert, Marilyn
Hu, William T.
Argiles, Jose A. Monge
Gorostidi, Ana
Teunissen, Charlotte E.
De Deyn, Peter P.
Hyman, Bradley T.
Molinuevo, Jose L.
Frisoni, Giovanni B.
Linazasoro, Gurutz
de Leon, Mony J.
van der Flier, Wiesje M.
Scheltens, Philip
Blennow, Kaj
Shaw, Leslie M.
Trojanowski, John Q.
CA Alzheimer's Dis Neuroimaging
TI Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal
subjects
SO BRAIN
LA English
DT Article
DE Alzheimer's disease; dementia; biomarkers; cognitive ageing; imaging
ID BETA-AMYLOID 1-42; 2 ANALYTICAL PLATFORMS; ADULT LIFE-SPAN;
NEUROPATHOLOGIC ASSESSMENT; ASSOCIATION GUIDELINES; NATIONAL INSTITUTE;
CSF BIOMARKERS; TAU PROTEINS; AGING BRAIN; AGE
AB In a large multicentre study, Toledo et al. examine core Alzheimer's disease CSF biomarkers in 1233 cognitively normal subjects aged 40-85 years. Alzheimer disease-like changes in A beta 1-42 are seen as early as middle age, while APOE genotype strongly modifies age-related effects on both A beta 1-42 and phosphorylated/total tau.In a large multicentre study, Toledo et al. examine core Alzheimer's disease CSF biomarkers in 1233 cognitively normal subjects aged 40-85 years. Alzheimer disease-like changes in A beta 1-42 are seen as early as middle age, while APOE genotype strongly modifies age-related effects on both A beta 1-42 and phosphorylated/total tau.In a large multicentre sample of cognitively normal subjects, as a function of age, gender and APOE genotype, we studied the frequency of abnormal cerebrospinal fluid levels of Alzheimer's disease biomarkers including: total tau, phosphorylated tau and amyloid-beta(1-42). Fifteen cohorts from 12 different centres with either enzyme-linked immunosorbent assays or LuminexA (R) measurements were selected for this study. Each centre sent nine new cerebrospinal fluid aliquots that were used to measure total tau, phosphorylated tau and amyloid-beta(1-42) in the Gothenburg laboratory. Seven centres showed a high correlation with the new Gothenburg measurements; therefore, 10 cohorts from these centres are included in the analyses here (1233 healthy control subjects, 40-84 years old). Amyloid-beta amyloid status (negative or positive) and neurodegeneration status (negative or positive) was established based on the pathological cerebrospinal fluid Alzheimer's disease cut-off values for cerebrospinal fluid amyloid-beta(1-42) and total tau, respectively. While gender did not affect these biomarker values, APOE genotype modified the age-associated changes in cerebrospinal fluid biomarkers such that APOE epsilon 4 carriers showed stronger age-related changes in cerebrospinal fluid phosphorylated tau, total tau and amyloid-beta(1-42) values and APOE epsilon 2 carriers showed the opposite effect. At 40 years of age, 76% of the subjects were classified as amyloid negative, neurodegeneration negative and their frequency decreased to 32% at 85 years. The amyloid-positive neurodegeneration-negative group remained stable. The amyloid-negative neurodegeneration-positive group frequency increased slowly from 1% at 44 years to 16% at 85 years, but its frequency was not affected by APOE genotype. The amyloid-positive neurodegeneration-positive frequency increased from 1% at 53 years to 28% at 85 years. Abnormally low cerebrospinal fluid amyloid-beta(1-42) levels were already frequent in midlife and APOE genotype strongly affects the levels of cerebrospinal fluid amyloid-beta(1-42), phosphorylated tau and total tau across the lifespan without influencing the frequency of subjects with suspected non-amyloid pathology.
C1 [Toledo, Jon B.; Shaw, Leslie M.; Trojanowski, John Q.] Univ Penn, Perelman Sch Med, Ctr Neurodegenerat Dis Res, Dept Pathol & Lab Med,Inst Aging, Philadelphia, PA 19104 USA.
[Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Sahlgrenska Acad, Dept Psychiat & Neurochem, Inst Neurosci & Physiol, Gothenburg, Sweden.
[Zetterberg, Henrik] UCL Inst Neurol, Dept Mol Neurosci, London, England.
[van Harten, Argonde C.; van der Flier, Wiesje M.; Scheltens, Philip] Vrije Univ Amsterdam Med Ctr, Alzheimer Ctr, Amsterdam, Netherlands.
[van Harten, Argonde C.; van der Flier, Wiesje M.; Scheltens, Philip] Vrije Univ Amsterdam Med Ctr, Dept Neurol, Amsterdam, Netherlands.
[Glodzik, Lidia; Osorio, Ricardo S.; de Leon, Mony J.] NYU, Sch Med, Dept Psychiat, Ctr Brain Hlth, New York, NY USA.
[Martinez-Lage, Pablo] Fdn CITA Alzheimer Fundazioa, Ctr Res & Adv Therapies, Dept Neurol, Donostia San Sebastian, Spain.
[Bocchio-Chiavetto, Luisella; Frisoni, Giovanni B.] IRCCS Ctr San Giovanni di Dio FBF, Brescia, Italy.
[Bocchio-Chiavetto, Luisella] eCampus Univ, Fac Psychol, Novedrate, Como, Italy.
[Rami, Lorena; Molinuevo, Jose L.] Hosp Clin & Univ, Alzheimers Dis & Other Cognit Disorders Unit, Barcelona, Spain.
[Hansson, Oskar] Lund Univ, Dept Clin Sci, Lund, Sweden.
[Hansson, Oskar] Skane Univ Hosp, Memory Clin, Lund, Sweden.
[Sperling, Reisa; Hyman, Bradley T.] Harvard Univ, Massachusetts Gen Hosp, Massachusetts Alzheimers Dis Res Ctr, Harvard Aging Brain Study,Dept Neurol,Med Sch, Boston, MA USA.
[Engelborghs, Sebastiaan; De Deyn, Peter P.] Hosp Network Antwerp Middelheim & Hoge Beuken, Dept Neurol, Antwerp, Belgium.
[Engelborghs, Sebastiaan; De Deyn, Peter P.] Hosp Network Antwerp Middelheim & Hoge Beuken, Memory Clin, Antwerp, Belgium.
[Engelborghs, Sebastiaan; De Deyn, Peter P.] Univ Antwerp, Dept Biomed Sci, Reference Ctr Biol Markers Dementia BIODEM, Lab Neurochem & Behav,Inst Born Bunge, B-2020 Antwerp, Belgium.
[Vanderstichele, Hugo] ADx NeuroSci, Ghent, Belgium.
[Vandijck, Manu] Fujirebio Europe Nv, Ghent, Belgium.
[Hampel, Harald] AXA Res Fund, Paris, France.
[Hampel, Harald] Univ Paris 06, Paris, France.
[Hampel, Harald] Univ Paris 06, Sorbonne Univ, Inst Memoire & Maladie Alzheimer IM2A, Paris, France.
[Hampel, Harald] Hop La Pitie Salpetriere, Dept Neurol, Inst Cerveau & Moelle Epiniere ICM, Paris, France.
[Teipl, Stefan] Univ Med Rostock, Dept Psychosomat Med, Rostock, Germany.
[Teipl, Stefan] German Ctr Neurodegenerat Dis, DZNE, Rostock, Germany.
[Moghekar, Abhay; Albert, Marilyn] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA.
[Hu, William T.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA.
[Argiles, Jose A. Monge] Univ Gen Hosp Alicante, Dept Neurol, Alicante, Spain.
[Gorostidi, Ana] Biodonostia Res Inst, Neurosci Unit, San Sebastian, Spain.
[Teunissen, Charlotte E.] VU Univ Med Ctr Amsterdam, Dept Clin Chem, Neurochem Lab, Amsterdam, Netherlands.
[Teunissen, Charlotte E.] VU Univ Med Ctr Amsterdam, Dept Clin Chem, Biobank, Amsterdam, Netherlands.
[Frisoni, Giovanni B.] Univ Hosp Geneva, Geneva, Switzerland.
[Frisoni, Giovanni B.] Univ Geneva, Geneva, Switzerland.
[van der Flier, Wiesje M.] VU Univ Med Ctr, Dept Epidemiol Biostat, New York, NY USA.
[Blennow, Kaj] Royal Swedish Acad Sci, Torsten Soderberg Professorship Med, Stockholm, Sweden.
RP Trojanowski, JQ (reprint author), Univ Penn, Med Ctr, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
EM trojanow@mail.med.upenn.edu
RI Kowall, Neil/G-6364-2012; Hansson, Oskar/A-7134-2013; Frisoni, Giovanni
B/K-1360-2016;
OI Kowall, Neil/0000-0002-6624-0213; Hansson, Oskar/0000-0001-8467-7286;
Frisoni, Giovanni B/0000-0002-6419-1753; Molinuevo, Jose
Luis/0000-0003-0485-6001; de Leon, Mony/0000-0003-2245-4380; Toledo,
Jon/0000-0003-4366-9268; Preda, Adrian /0000-0003-3373-2438; Bocchio
Chiavetto, Luisella/0000-0002-9801-603X
FU NIH [AG022374, AG13616, AG1210]; University of Antwerp Research Fund;
Alzheimer Research Foundation (SAO-FRA); central Biobank facility of the
Institute Born-Bunge / University Antwerp; Research Foundation Flanders
(FWO); Agency for Innovation by Science and Technology (IWT); Belgian
Science Policy Office Interuniversity Attraction Poles (IAP) program;
Flemish Government; EU/EFPIA Innovative Medicines Initiative Joint
Undertaking (EMIF) [115372]; European Research Council; Swedish Research
Council; Swedish Brain Foundation; Swedish federal government under the
ALF; Miguel Servet program [CP 08/00147]; AXA Research Fund; Fondation
Universite Pierre et Marie Curie; 'Fondation pour la Recherche sur
Alzheimer', Paris, France; program 'Investissements d'avenir'
[ANR-10-IAIHU-06]; ADNI (National Institutes of Health) [U01 AG024904];
DOD ADNI (Department of Defense) [W81XWH-12-2-0012]; National Institute
on Aging; National Institute of Biomedical Imaging and Bioengineering;
Canadian Institutes of Health Research; Michael J. Fox Foundation for
Parkinson's Research; abbvie; Avid Radiopharmaceuticals; Biogen Idec;
Bristol-Myers Squibb; Covance; GE Healthcare; Genentech;
GlaxoSmithKline; Lilly; Lundbeck; Merck; Meso Scale Discovery; Piramal;
La Roche Ltd; Pfizer Inc; UCB Pharma SA; [P01 AG032953]; [PO1
AG017586]; [P30 AG010124]; [P50 NS053488]; [K23 AG042856]; [R21
AG043885]; [P50 AG016976]
FX J.B.T. is supported by P01 AG032953, PO1 AG017586, P30 AG010124 and P50
NS053488. J.Q.T. is the William Maul Measey-Truman G. Schnabel, Jr.,
Professor of Geriatric Medicine and Gerontology. H.Z.: The Swedish
Research Council, the Knut and Alice Wallenberg Foundation and Swedish
State Support for Clinical Research. The NYU CSF studies were supported
by the following NIH grants to MdeL (PI): AG022374, AG13616, and AG1210.
The Antwerp centre was supported by the University of Antwerp Research
Fund; the Alzheimer Research Foundation (SAO-FRA); the central Biobank
facility of the Institute Born-Bunge / University Antwerp; the Research
Foundation Flanders (FWO); the Agency for Innovation by Science and
Technology (IWT); the Belgian Science Policy Office Interuniversity
Attraction Poles (IAP) program; the Flemish Government initiated
Methusalem excellence grant; the EU/EFPIA Innovative Medicines
Initiative Joint Undertaking (EMIF grant no 115372) and this work is
part of the BIOMARKAPD project within the EU Joint Programme for
Neurodegenerative Disease Research (JPND). W.T.H. is supported by K23
AG042856, R21 AG043885, and P50 AG016976. O.H. is supported by the
European Research Council, the Swedish Research Council, the Swedish
Brain Foundation, and the Swedish federal government under the ALF
agreement. This publication is part of the Consolider-Ingenio 2010 (CSD
2010-00045 PI: Jose L Molinuevo), FIS-Fondo europeo de desarrollo
regional, una manera de hacer Europa (PI11/01071 PI: Lorena Rami) and
Miguel Servet program (CP 08/00147; PI: Lorena Rami). H.H. is supported
by the AXA Research Fund, the Fondation Universite Pierre et Marie Curie
and the 'Fondation pour la Recherche sur Alzheimer', Paris, France. The
research leading to these results has received funding from the program
'Investissements d'avenir' ANR-10-IAIHU-06. Data collection and sharing
for this project was funded ADNI (National Institutes of Health Grant
U01 AG024904) and DOD ADNI (Department of Defense award number
W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging,
the National Institute of Biomedical Imaging and Bioengineering, and
through generous contributions from the following: Alzheimer's
Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech;
BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai
Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F.
Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.;
Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy
Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research
& Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale
Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis
Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier;
Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes
of Health Research is providing funds to support ADNI clinical sites in
Canada. Private sector contributions are facilitated by the Foundation
for the National Institutes of Health (www.fnih.org). The grantee
organization is the California Institute for Research and Education, and
the study is coordinated by the Alzheimer's Disease Cooperative Study at
the University of California, San Diego. ADNI data are disseminated by
the Laboratory for Neuro Imaging at the University of Southern
California. Supported by the Michael J.; Fox Foundation for Parkinson's
Research and funding partners: abbvie, Avid Radiopharmaceuticals, Biogen
Idec, Bristol-Myers Squibb, Covance, GE Healthcare, Genentech,
GlaxoSmithKline, Lilly, Lundbeck, Merck, Meso Scale Discovery, Piramal,
La Roche Ltd, Pfizer Inc and UCB Pharma SA.
NR 60
TC 16
Z9 16
U1 2
U2 18
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 1460-2156
J9 BRAIN
JI Brain
PD SEP 1
PY 2015
VL 138
BP 2701
EP 2715
DI 10.1093/brain/awv199
PN 9
PG 15
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA CR5PS
UT WOS:000361396200029
PM 26220940
ER
PT J
AU Gardner, AJ
Iverson, GL
Quinn, TN
Makdissi, M
Levi, CR
Shultz, SR
Wright, DK
Stanwell, P
AF Gardner, Andrew J.
Iverson, Grant L.
Quinn, Tanya N.
Makdissi, Michael
Levi, Christopher R.
Shultz, Sandy R.
Wright, David K.
Stanwell, Peter
TI A preliminary video analysis of concussion in the National Rugby League
SO BRAIN INJURY
LA English
DT Article
DE Athletes; brain concussion; epidemiology; injury surveillance
ID INCIDENT ANALYSIS; PROFESSIONAL FOOTBALL; INJURY; MATCH; SITUATIONS; NHL
AB Primary objective: To conduct the first video analysis of concussion in the Australian National Rugby League (NRL) and describe player and injury characteristics, situational factors and time to return to play.
Research design: Descriptive, observational case series.
Methods and procedures: Video analysis of 20 medically diagnosed concussions for three consenting clubs during the 2013 NRL season.
Main outcome and results: Most concussions (83%) occurred during a high tackle, and all injured ball carriers were hit high. Loss of consciousness was observed in 30% of cases. Common observable signs of injury included clutching of the head, balance problems or wobbly legs and a blank or vacant state. There were no post-concussive seizures. All players with loss of consciousness were removed from play. However, only half of the total sample was removed from play and one athlete who was removed returned to play in the same match. Of the players who were removed from play, the large majority returned the following week. Illegal play accounted for 25% of all concussions.
Conclusions: Video analysis may be a useful method to study the incidence, mechanism and management of concussion in sports such as Rugby League. Future studies may include larger numbers to validate this preliminary data and may also investigate other levels of play and age ranges.
C1 [Gardner, Andrew J.; Levi, Christopher R.] Univ Newcastle, Sch Med & Publ Hlth, Ctr Translat Neurosci & Mental Hlth, Callaghan, NSW 2308, Australia.
[Iverson, Grant L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA.
[Iverson, Grant L.] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Boston, MA USA.
[Iverson, Grant L.] MGHfC Sports Concuss Program, Boston, MA USA.
[Iverson, Grant L.] Red Sox Fdn, Boston, MA USA.
[Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA.
[Quinn, Tanya N.] Univ Newcastle, Dept Psychol, Callaghan, NSW 2308, Australia.
[Makdissi, Michael] Melbourne Brain Ctr, Florey Inst Neurosci & Mental Hlth, Heidelberg, Vic, Australia.
[Makdissi, Michael] Federat Univ, Australian Ctr Res Injury Sport & Its Prevent, Ballarat, Vic, Australia.
[Shultz, Sandy R.] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic, Australia.
[Wright, David K.] Univ Melbourne, Dept Anat & Neurosci, Parkville, Vic 3052, Australia.
[Stanwell, Peter] Univ Newcastle, Fac Hlth, Sch Hlth Sci, Ctr Translat Neurosci & Mental Hlth, Callaghan, NSW 2308, Australia.
RP Gardner, AJ (reprint author), Calvary Mater Hosp, Ctr Translat Neurosci & Mental Hlth, Level 5,McAuley Bldg, Waratah, NSW 2298, Australia.
EM andrew.gardner@neurogard.com.au
RI Gardner, Andrew/J-5162-2013; Stanwell, Peter/F-9136-2012;
OI Stanwell, Peter/0000-0002-4780-0393
FU New South Wales Sporting Injuries Committee-Sports Research & Injury
Prevention Scheme Grant; Brain Foundation, Australia-Brain Injury Award;
Hunter Medical Research Institute; Mooney-Reed Charitable Foundation
FX Andrew J. Gardner, Peter Stanwell and Christopher R. Levi have been
funded to conduct research into concussion in rugby league through a New
South Wales Sporting Injuries Committee-Sports Research & Injury
Prevention Scheme Grant, and a Brain Foundation, Australia-Brain Injury
Award. Andrew J. Gardner acknowledges sport concussion research
fellowship funding from Jennie Thomas, Life Governor of the Hunter
Medical Research Institute. Grant L. Iverson acknowledges sport
concussion research funding from the Mooney-Reed Charitable Foundation.
NR 15
TC 4
Z9 4
U1 2
U2 16
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0269-9052
EI 1362-301X
J9 BRAIN INJURY
JI Brain Inj.
PD SEP
PY 2015
VL 29
IS 10
BP 1182
EP 1185
DI 10.3109/02699052.2015.1034179
PG 4
WC Neurosciences; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA CR3UK
UT WOS:000361258400006
ER
PT J
AU Suarez, C
Puente, J
Gallardo, E
Mendez-Vidal, MJ
Climent, MA
Leon, L
Olmos, D
del Muro, XG
Gonzalez-Billalabeitia, E
Grande, E
Bellmunt, J
Mellado, B
Maroto, P
del Alba, AG
AF Suarez, C.
Puente, J.
Gallardo, E.
Mendez-Vidal, M. J.
Climent, M. A.
Leon, L.
Olmos, D.
Garcia del Muro, X.
Gonzalez-Billalabeitia, E.
Grande, E.
Bellmunt, J.
Mellado, B.
Maroto, P.
Gonzalez del Alba, A.
TI New advances in genitourinary cancer: evidence gathered in 2014
SO CANCER AND METASTASIS REVIEWS
LA English
DT Review
DE Genitourinary cancer; Bladder cancer; Renal cancer; Prostate cancer;
Molecular research; Germ cell tumors
ID RENAL-CELL CARCINOMA; RESISTANT PROSTATE-CANCER; PHASE-III TRIAL;
ADVANCED UROTHELIAL CARCINOMA; INVASIVE BLADDER-CANCER; MITOXANTRONE
PLUS PREDNISONE; LONG-TERM SURVIVAL; ANDROGEN RECEPTOR; OPEN-LABEL;
DOUBLE-BLIND
AB This review provides updated information published in 2014 regarding advances and major achievements in genitourinary cancer. Sections include the best in prostate cancer, renal cancer, bladder cancer, and germ cell tumors. In the field of prostate cancer, data related to treatment approach of hormone-sensitive disease, castrate-resistant prostate cancer, mechanisms of resistance, new drugs, and molecular research are presented. In relation to renal cancer, relevant aspects in the treatment of advanced renal cell carcinoma, immunotherapy, and molecular research, including angiogenesis and von Hippel-Lindau gene, molecular biology of non-clear cell histologies, and epigenetics of clear renal cell cancer are described. New strategies in the management of muscle-invasive localized bladder cancer and metastatic disease are reported as well as salient findings of biomolecular research in urothelial cancer. Some approaches intended to improve outcomes in poor prognosis patients with metastatic germ cell cancer are also reported. Results of clinical trials in these areas are discussed.
C1 [Suarez, C.] Univ Autonoma Barcelona, Vall Hebron Univ Hosp, E-08193 Barcelona, Spain.
[Suarez, C.] Univ Autonoma Barcelona, Inst Oncol, E-08193 Barcelona, Spain.
[Puente, J.] Hosp Clin Univ San Carlos, Dept Med Oncol, Madrid, Spain.
[Gallardo, E.] Hosp Univ Parc Tauli, Dept Med Oncol, Barcelona, Spain.
[Mendez-Vidal, M. J.] Hosp Univ Reina Sofia, Inst Maimonides Invest Biomed IMIBIC, Dept Med Oncol, Cordoba, Spain.
[Climent, M. A.] Fdn Inst Valenciano Oncol, Dept Med Oncol, Valencia, Spain.
[Leon, L.] Hosp Clin, Dept Med Oncol, Santiago De Compostela, A Coruna, Spain.
[Olmos, D.] Spanish Natl Canc Res Ctr CNIO, Prostate Canc Clin Res Unit, Madrid, Spain.
[Olmos, D.] Hosp Univ Virgen Victoria & Reg Malaga, CNIO IBIMA Genitourinary Canc Res Unit, Madrid, Spain.
[Olmos, D.] Ctr Integral Oncol Clara Campal, Madrid, Spain.
[Garcia del Muro, X.] Oncol Hosp, Inst Catala, Barcelona, Spain.
[Gonzalez-Billalabeitia, E.] Hosp GU Morales Meseguer, Med Oncol & Hematol Dept, Murcia, Spain.
[Grande, E.] Ramon & Cajal Univ Hosp, Dept Med Oncol, GI Endocrine & Translat Res Unit, Early Drug Dev Unit IRYCIS, Madrid, Spain.
[Bellmunt, J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Bladder Canc Ctr,Dana Farber Brigham & Womens Can, Boston, MA 02115 USA.
[Mellado, B.] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain.
[Maroto, P.] Hosp La Santa Creu & St Pau, Dept Med Oncol, Barcelona, Spain.
[Gonzalez del Alba, A.] Hosp Univ Son Espases, Dept Med Oncol, Palma De Mallorca 07010, Spain.
RP del Alba, AG (reprint author), Hosp Univ Son Espases, Dept Med Oncol, Carretera Valldemosa 79, Palma De Mallorca 07010, Spain.
EM aranzazu.gonzalezdelalba@ssib.es
FU Astellas
FX The authors thank Marta Pulido, MD, PhD, freelance author's editor for
assistance in writing of the manuscript and Content Ed Net
Communications, Madrid (Spain) for editorial assistance with funding
from Astellas.
NR 155
TC 1
Z9 1
U1 1
U2 7
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0167-7659
EI 1573-7233
J9 CANCER METAST REV
JI Cancer Metastasis Rev.
PD SEP
PY 2015
VL 34
IS 3
BP 443
EP 464
DI 10.1007/s10555-015-9577-x
PG 22
WC Oncology
SC Oncology
GA CR7UL
UT WOS:000361556900006
PM 26227584
ER
PT J
AU Khalili, H
Gong, J
Brenner, H
Austin, TR
Hutter, CM
Baba, Y
Baron, JA
Berndt, SI
Bezieau, S
Caan, B
Campbell, PT
Chang-Claude, J
Chanock, SJ
Chen, C
Hsu, L
Jiao, S
Conti, DV
Duggan, D
Fuchs, CS
Gala, M
Gallinger, S
Haile, RW
Harrison, TA
Hayes, R
Hazra, A
Henderson, B
Haiman, C
Hoffmeister, M
Hopper, JL
Jenkins, MA
Kolonel, LN
Kury, S
LaCroix, A
Le Marchand, L
Lemire, M
Lindor, NM
Ma, J
Manson, JE
Morikawa, T
Nan, H
Ng, K
Newcomb, PA
Nishihara, R
Potter, JD
Qu, CH
Schoen, RE
Schumacher, FR
Seminara, D
Taverna, D
Thibodeau, S
Wactawski-Wende, J
White, E
Wu, K
Zanke, BW
Casey, G
Hudson, TJ
Kraft, P
Peters, U
Slattery, ML
Ogino, S
Chan, AT
AF Khalili, Hamed
Gong, Jian
Brenner, Hermann
Austin, Thomas R.
Hutter, Carolyn M.
Baba, Yoshifumi
Baron, John A.
Berndt, Sonja I.
Bezieau, Stephane
Caan, Bette
Campbell, Peter T.
Chang-Claude, Jenny
Chanock, Stephen J.
Chen, Constance
Hsu, Li
Jiao, Shuo
Conti, David V.
Duggan, David
Fuchs, Charles S.
Gala, Manish
Gallinger, Steven
Haile, Robert W.
Harrison, Tabitha A.
Hayes, Richard
Hazra, Aditi
Henderson, Brian
Haiman, Chris
Hoffmeister, Michael
Hopper, John L.
Jenkins, Mark A.
Kolonel, Laurence N.
Kuery, Sebastien
LaCroix, Andrea
Le Marchand, Loic
Lemire, Mathieu
Lindor, Noralane M.
Ma, Jing
Manson, Joann E.
Morikawa, Teppei
Nan, Hongmei
Ng, Kimmie
Newcomb, Polly A.
Nishihara, Reiko
Potter, John D.
Qu, Conghui
Schoen, Robert E.
Schumacher, Fredrick R.
Seminara, Daniela
Taverna, Darin
Thibodeau, Stephen
Wactawski-Wende, Jean
White, Emily
Wu, Kana
Zanke, Brent W.
Casey, Graham
Hudson, Thomas J.
Kraft, Peter
Peters, Ulrike
Slattery, Martha L.
Ogino, Shuji
Chan, Andrew T.
CA GECCO
CGFR
TI Identification of a common variant with potential pleiotropic effect on
risk of inflammatory bowel disease and colorectal cancer
SO CARCINOGENESIS
LA English
DT Article
ID ISLAND METHYLATOR PHENOTYPE; GENOME-WIDE ASSOCIATION; POPULATION-BASED
SAMPLE; MICROSATELLITE INSTABILITY; ULCERATIVE-COLITIS; COLON-CANCER;
SUSCEPTIBILITY LOCI; MOLECULAR-FEATURES; CROHNS-DISEASE; MAIT CELLS
AB We identified the minor allele (T) in SNP rs11676348 to have pleiotropic effect on risk of UC and CRC, particularly in tumors with an inflammatory component. Our findings offer the promise of risk stratification of UC patients for developing CRC.Although genome-wide association studies (GWAS) have separately identified many genetic susceptibility loci for ulcerative colitis (UC), Crohn's disease (CD) and colorectal cancer (CRC), there has been no large-scale examination for pleiotropy, or shared genetic susceptibility, for these conditions. We used logistic regression modeling to examine the associations of 181 UC and CD susceptibility variants previously identified by GWAS with risk of CRC using data from the Genetics and Epidemiology of Colorectal Cancer Consortium and the Colon Cancer Family Registry. We also examined associations of significant variants with clinical and molecular characteristics in a subset of the studies. Among 11794 CRC cases and 14190 controls, rs11676348, the susceptibility single nucleotide polymorphism (SNP) for UC, was significantly associated with reduced risk of CRC (P = 7E-05). The multivariate-adjusted odds ratio of CRC with each copy of the T allele was 0.93 (95% CI 0.89-0.96). The association of the SNP with risk of CRC differed according to mucinous histological features (P (heterogeneity) = 0.008). In addition, the (T) allele was associated with lower risk of tumors with Crohn's-like reaction but not tumors without such immune infiltrate (P (heterogeneity) = 0.02) and microsatellite instability-high (MSI-high) but not microsatellite stable or MSI-low tumors (P (heterogeneity) = 0.03). The minor allele (T) in SNP rs11676348, located downstream from CXCR2 that has been implicated in CRC progression, is associated with a lower risk of CRC, particularly tumors with a mucinous component, Crohn's-like reaction and MSI-high. Our findings offer the promise of risk stratification of inflammatory bowel disease patients for complications such as CRC.
C1 [Khalili, Hamed; Gala, Manish; Chan, Andrew T.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
[Gong, Jian; Hsu, Li; Jiao, Shuo; Harrison, Tabitha A.; LaCroix, Andrea; Newcomb, Polly A.; Potter, John D.; Qu, Conghui; White, Emily; Peters, Ulrike] Fred Hutchinson Canc Res Ctr, Publ Hlth Sci Div, Seattle, WA 98104 USA.
[Brenner, Hermann; Hoffmeister, Michael] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, Germany.
[Brenner, Hermann] German Canc Cosortium DKTK, Heidelberg, Germany.
[Austin, Thomas R.] Whitman Coll, Walla Walla, WA 99362 USA.
[Hutter, Carolyn M.; Seminara, Daniela] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA.
[Baba, Yoshifumi] Kumamoto Univ, Dept Surg Gastroenterol, Kumamoto, Japan.
[Baron, John A.] Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC USA.
[Berndt, Sonja I.; Chanock, Stephen J.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
[Bezieau, Stephane; Kuery, Sebastien] CHU Nantes, Serv Genet Med, F-44035 Nantes 01, France.
[Caan, Bette] Univ Ottawa, Fac Med, Div Hematol, Ottawa, ON, Canada.
[Campbell, Peter T.] Amer Canc Soc, Epidemiol Res Program, Atlanta, GA 30329 USA.
[Chang-Claude, Jenny] German Canc Res Ctr, Div Canc Epidemiol, Heidelberg, Germany.
[Chen, Constance; Kraft, Peter] Harvard TH Chan Sch Publ Hlth, Program Mol & Genet Epidemiol, Boston, MA USA.
[Conti, David V.; Henderson, Brian; Haiman, Chris; Schumacher, Fredrick R.; Casey, Graham] Univ So Calif, Keck Sch Med, Los Angeles, CA USA.
[Duggan, David; Taverna, Darin] Syst Imaginat, Computat Biol, Phoenix, AZ USA.
[Fuchs, Charles S.; Ng, Kimmie; Nishihara, Reiko; Ogino, Shuji] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Fuchs, Charles S.; Hazra, Aditi; Ma, Jing; Nan, Hongmei; Kraft, Peter; Chan, Andrew T.] Indiana Univ, Dept Epidemiol, Sch Publ Hlth, Indianapolis, IN 46204 USA.
[Gallinger, Steven] Toronto Gen Hosp, Dept Surg, Univ Hlth Network, Toronto, ON, Canada.
[Haile, Robert W.] Stanford Canc Inst, Palo Alto, CA USA.
[Hayes, Richard; Jenkins, Mark A.] NYU, Div Epidemiol, Sch Med, New York, NY USA.
[Hopper, John L.] Univ Melbourne, Melbourne Sch Populat Hlth, Melbourne, Australia.
[Kolonel, Laurence N.; Le Marchand, Loic] Univ Hawaii, Epidemiol Program, Ctr Canc, Honolulu, HI 96822 USA.
[Lemire, Mathieu; Hudson, Thomas J.] Ontario Inst Canc Res, Toronto, ON, Canada.
[Lindor, Noralane M.] Mayo Clin, Dept Hlth Sci Serv, Scottsdale, AZ USA.
[Manson, Joann E.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Morikawa, Teppei] Tokyo Univ Hosp, Dept Pathol, Tokyo 113, Japan.
[Nishihara, Reiko; Wu, Kana] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Potter, John D.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Potter, John D.] Massey Univ, Ctr Publ Hlth Res, Wellington, New Zealand.
[Schoen, Robert E.] Univ Pittsburgh, Dept Med & Epidemiol, Med Ctr, Pittsburgh, PA USA.
[Thibodeau, Stephen] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA.
[Wactawski-Wende, Jean] SUNY Buffalo, Dept Social & Prevent Med, Buffalo, NY 14260 USA.
[Zanke, Brent W.] Ottawa Hosp, Clin Epidemiol Program, Res Inst, Ottawa, OK USA.
[Hudson, Thomas J.] Univ Toronto, Dept Med Biophys, Toronto, OK USA.
[Slattery, Martha L.] Univ Utah, Dept Internal Med, Hlth Sci Ctr, Salt Lake City, UT 84112 USA.
[Ogino, Shuji] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Ogino, Shuji] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
RP Chan, AT (reprint author), Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
EM shuji_ogino@dfci.harvard.edu; achan@mgh.harvard.edu
RI Bezieau, stephane/G-5621-2015; Jenkins, Mark/P-7803-2015; Gallinger,
Steven/E-4575-2013; Brenner, Hermann/B-4627-2017;
OI Bezieau, stephane/0000-0003-0095-1319; Jenkins,
Mark/0000-0002-8964-6160; Brenner, Hermann/0000-0002-6129-1572; KURY,
Sebastien/0000-0001-5497-0465; Potter, John/0000-0001-5439-1500; Hayes,
Richard/0000-0002-0918-661X; Hoffmeister, Michael/0000-0002-8307-3197
FU Crohn's and Colitis Foundation of America (CCFA); American
Gastroenterological Association (AGA); National Institute of Diabetes
and Digestive and Kidney Diseases [K23 DK099681]; National Cancer
Institute, National Institutes of Health, U.S. Department of Health and
Human Services [U01 CA137088, R01 CA059045]; Regional Council of Pays de
la Loire; Groupement des Entreprises Francaises dans la Lutte contre le
Cancer (GEFLUC); Association Anne de Bretagne Genetique; Ligue Regionale
Contre le Cancer (LRCC); National Institutes of Health [R01 CA60987, UM1
CA167551, R01 CA48998, CA61757, U01 CA074783, CA42182, R01 CA076366, K05
CA154337]; National Cancer Institute, National Institutes of Health [U01
CA122839, R01 CA143237]; National Institutes of Health: Australasian
Colorectal Cancer Family Registry [U01/U24 CA097735]; National
Institutes of Health: Familial Colorectal Neoplasia Collaborative Group
[U01/U24 CA074799]; National Institutes of Health: Mayo Clinic
Cooperative Family Registry for Colon Cancer Studies [U01/U24 CA074800];
National Institutes of Health: Ontario Registry for Studies of Familial
Colorectal Cancer [U01/U24 CA074783]; National Institutes of Health:
Seattle Colorectal Cancer Family Registry [U01/U24 CA074794]; National
Institutes of Health: University of Hawaii Colorectal Cancer Family
Registry [U01/U24 CA074806]; German Research Council (Deutsche
Forschungsgemeinschaft) [BR 1704/6-1, BR 1704/6-3, BR 1704/6-4, CH
117/1-1]; German Federal Ministry of Education and Research [01KH0404,
01ER0814]; National Institutes of Health; Ontario Research Fund;
Canadian Institutes of Health Research; Ontario Institute for Cancer
Research; Ontario Ministry of Research and Innovation; Intramural
Research Program of the Division of Cancer Epidemiology and Genetics;
Division of Cancer Prevention, National Cancer Institute, NIH, DHHS;
National Institutes of Health (NIH), Genes, Environment and Health
Initiative (GEI) [Z01 CP 010200]; NIH [U01 HG004446]; NIH GEI [U01 HG
004438]; National Heart, Lung, and Blood Institute, National Institutes
of Health, U.S. Department of Health and Human Services
[HHSN268201100046C, HHSN268201100001C, HHSN268201100002C,
HHSN268201100003C, HHSN268201100004C, HHSN271201100004C]; [R01
CA137178]; [R01 CA050385]; [R01 CA151993]; [P01 CA87969]; [P30
DK043351]; [P50 CA127003]; [UM1 CA 167552]; [UM1 CA186107]; [K24
[DK]098311]; [K07 CA190673]; [K07 CA148894]
FX Funded by R01 CA137178, R01 CA050385, R01 CA151993, P01 CA87969, P30
DK043351, P50 CA127003, UM1 CA 167552, UM1 CA186107, K23 DK099681, K24
[DK]098311, K07 CA190673 and K07 CA148894. Senior investigator grant
from the Crohn's and Colitis Foundation of America (CCFA) to A.T.C. A
career development award from the American Gastroenterological
Association (AGA) and by National Institute of Diabetes and Digestive
and Kidney Diseases (K23 DK099681 to H.K.).; GECCO: National Cancer
Institute, National Institutes of Health, U.S. Department of Health and
Human Services (U01 CA137088; R01 CA059045).; ASTERISK: a Hospital
Clinical Research Program (PHRC) and supported by the Regional Council
of Pays de la Loire, the Groupement des Entreprises Francaises dans la
Lutte contre le Cancer (GEFLUC), the Association Anne de Bretagne
Genetique and the Ligue Regionale Contre le Cancer (LRCC).; COLO2&3:
National Institutes of Health (R01 CA60987).; CCFR: National Institutes
of Health (UM1 CA167551) and through cooperative agreements with members
of the Colon Cancer Family Registry and P.I.s. This genome wide scan was
supported by the National Cancer Institute, National Institutes of
Health by U01 CA122839 and R01 CA143237 to G.C. The content of this
manuscript does not necessarily reflect the views or policies of the
National Cancer Institute or any of the collaborating centers in the
CFRs, nor does mention of trade names, commercial products or
organizations imply endorsement by the US Government or the CFR. The
following CFR centers contributed data to this manuscript and were
supported by National Institutes of Health: Australasian Colorectal
Cancer Family Registry (U01/U24 CA097735), Familial Colorectal Neoplasia
Collaborative Group (U01/U24 CA074799), Mayo Clinic Cooperative Family
Registry for Colon Cancer Studies (U01/U24 CA074800), Ontario Registry
for Studies of Familial Colorectal Cancer (U01/U24 CA074783), Seattle
Colorectal Cancer Family Registry (U01/U24 CA074794) and the University
of Hawaii Colorectal Cancer Family Registry (U01/U24 CA074806).; DACHS:
German Research Council (Deutsche Forschungsgemeinschaft, BR 1704/6-1,
BR 1704/6-3, BR 1704/6-4 and CH 117/1-1), and the German Federal
Ministry of Education and Research (01KH0404 and 01ER0814).; DALS:
National Institutes of Health (R01 CA48998 and CA61757 to M.L.S.);;
OFCCR: National Institutes of Health, through funding allocated to the
Ontario Registry for Studies of Familial Colorectal Cancer (U01
CA074783); see CCFR section. Additional funding toward genetic analyses
of OFCCR includes the Ontario Research Fund, the Canadian Institutes of
Health Research and the Ontario Institute for Cancer Research, through
generous support from the Ontario Ministry of Research and Innovation.;
PLCO: Intramural Research Program of the Division of Cancer Epidemiology
and Genetics and supported by contracts from the Division of Cancer
Prevention, National Cancer Institute, NIH, DHHS. Additionally, a subset
of control samples were genotyped as part of the Cancer Genetic Markers
of Susceptibility (CGEMS) Prostate Cancer GWAS (Yeager,M. et al. (2007)
Genome-wide association study of prostate cancer identifies a second
risk locus at 8q24. Nat. Genet., 39, 645-649), Colon CGEMS pancreatic
cancer scan (PanScan) (Amundadottir, L et al. (2009) Genome-wide
association study identifies variants in the ABO locus associated with
susceptibility to pancreatic cancer. Nat. Genet., 41, 986-990, and
Petersen, G.M. et al. (2010) A genome-wide association study identifies
pancreatic cancer susceptibility locion chromosomes 13q22.1, 1q32.1 and
5p15.33. Nat. Genet., 42, 224-228), and the Lung Cancer and Smoking
study (Landi,M.T. et al. (2009) A genome-wide association study of lung
cancer identifies a region of chromosome 5p15 associated with risk for
adenocarcinoma. Am. J. Hum. Genet., 85, 679-691). The prostate and
PanScan study datasets were accessed with appropriate approval through
the dbGaP online resource (http://cgems.cancer.gov/data/) accession
numbers phs000207v.1p1 and phs000206.v3.p2, respectively, and the lung
datasets were accessed from the dbGaP website
(http://www.ncbi.nlm.nih.gov/gap) through accession number phs000093
v2.p2. Funding for the Lung Cancer and Smoking study was provided by
National Institutes of Health (NIH), Genes, Environment and Health
Initiative (GEI) Z01 CP 010200, NIH U01 HG004446 and NIH GEI U01 HG
004438. For the lung study, the GENEVA Coordinating Center provided
assistance with genotype cleaning and general study coordination, and
the Johns Hopkins University Center for Inherited Disease Research
conducted genotyping.; PHS: National Institutes of Health (CA42182).;
PMH: National Institutes of Health (R01 CA076366 to P.A.N.).; VITAL:
National Institutes of Health (K05 CA154337).; WHI: The WHI program is
funded by the National Heart, Lung, and Blood Institute, National
Institutes of Health, U.S. Department of Health and Human Services
through contracts HHSN268201100046C, HHSN268201100001C,
HHSN268201100002C, HHSN268201100003C, HHSN268201100004C and
HHSN271201100004C.
NR 50
TC 4
Z9 4
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD SEP
PY 2015
VL 36
IS 9
BP 999
EP 1007
DI 10.1093/carcin/bgv086
PG 9
WC Oncology
SC Oncology
GA CR5QA
UT WOS:000361397000008
PM 26071399
ER
PT J
AU Stone, JR
Bruneval, P
Angelini, A
Bartoloni, G
Basso, C
Batoroeva, L
Buja, LM
Butany, J
d'Amati, G
Fallon, JT
Gittenberger-de Groot, AC
Gouveia, RH
Halushka, MK
Kelly, KL
Kholova, I
Leone, O
Litovsky, SH
Maleszewski, JJ
Miller, DV
Mitchell, RN
Preston, SD
Pucci, A
Radio, SJ
Rodriguez, ER
Sheppard, MN
Suvarna, SK
Tan, CD
Thiene, G
van der Wal, AC
Veinot, JP
AF Stone, James R.
Bruneval, Patrick
Angelini, Annalisa
Bartoloni, Giovanni
Basso, Cristina
Batoroeva, Lubov
Buja, L. Maximilian
Butany, Jagdish
d'Amati, Giulia
Fallon, John T.
Gittenberger-de Groot, Adriana C.
Gouveia, Rosa H.
Halushka, Marc K.
Kelly, Karen L.
Kholova, Ivana
Leone, Ornella
Litovsky, Silvio H.
Maleszewski, Joseph J.
Miller, Dylan V.
Mitchell, Richard N.
Preston, Stephen D.
Pucci, Angela
Radio, Stanley J.
Rodriguez, E. Rene
Sheppard, Mary N.
Suvarna, S. Kim
Tan, Carmela D.
Thiene, Gaetano
van der Wal, Allard C.
Veinot, John P.
TI Consensus statement on surgical pathology of the aorta from the Society
for Cardiovascular Pathology and the Association for European
Cardiovascular Pathology: I. Inflammatory diseases
SO CARDIOVASCULAR PATHOLOGY
LA English
DT Review
DE Atherosclerosis; Aortitis; Inflammatory aneurysm; Aorta
ID GIANT-CELL ARTERITIS; LARGE-VESSEL VASCULITIS; IGG4-RELATED
SYSTEMIC-DISEASE; AMERICAN-HEART-ASSOCIATION; TERM-FOLLOW-UP; ASCENDING
AORTA; TAKAYASU ARTERITIS; ATHEROSCLEROTIC LESIONS; NATURAL-HISTORY;
LYMPHOPLASMACYTIC AORTITIS
AB Inflammatory diseases of the aorta include routine atherosclerosis, aortitis, periaortitis, and atherosclerosis with excessive inflammatory responses, such as inflammatory atherosclerotic aneurysms. The nomenclature and histologic features of these disorders are reviewed and discussed. In addition, diagnostic criteria are provided to distinguish between these disorders in surgical pathology specimens. An initial classification scheme is provided for aortitis and periaortitis based on the pattern of the inflammatory infiltrate: granulomatous/giant cell pattern, lymphoplasmacytic pattern, mixed inflammatory pattern, and the suppurative pattern. These inflammatory patterns are discussed in relation to specific systemic diseases including giant cell arteritis, Takayasu arteritis, granulomatosis with polyangiitis (Wegener's), rheumatoid arthritis, sarcoidosis, ankylosing spondylitis, Cogan syndrome, Behcet's disease, relapsing polychondritis, syphilitic aortitis, and bacterial and fungal infections. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Stone, James R.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Bruneval, Patrick] Univ Paris 05, Paris, France.
[Angelini, Annalisa; Basso, Cristina; Thiene, Gaetano] Univ Padua, Sch Med, Padua, Italy.
[Bartoloni, Giovanni] Univ Catania, Catania, Italy.
[Batoroeva, Lubov] Russian Acad Med Sci, Irkutsk, Russia.
[Buja, L. Maximilian] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA.
[Butany, Jagdish] Toronto Gen Hosp, Toronto, ON, Canada.
[d'Amati, Giulia] Univ Roma La Sapienza, I-00185 Rome, Italy.
[Fallon, John T.] New York Med Coll, Valhalla, NY 10595 USA.
[Gittenberger-de Groot, Adriana C.] Leiden Univ, Leiden, Netherlands.
[Gouveia, Rosa H.] Hosp Santa Cruz, Carnaxide, Portugal.
[Halushka, Marc K.] Johns Hopkins Univ, Baltimore, MD USA.
[Kelly, Karen L.] E Carolina Univ, Greenville, NC USA.
[Kholova, Ivana] Fimlab Labs, Tampere, Finland.
[Leone, Ornella] Univ Bologna, St Orsola Malpighi Hosp, Bologna, Italy.
[Litovsky, Silvio H.] Univ Alabama Birmingham, Birmingham, AL USA.
[Maleszewski, Joseph J.] Mayo Clin, Rochester, MN USA.
[Miller, Dylan V.] Univ Utah, Salt Lake City, UT 84112 USA.
[Mitchell, Richard N.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Preston, Stephen D.] Papworth Hosp, Papworth Everard, Cambs, England.
[Pucci, Angela] Pisa Univ Hosp, Pisa, Italy.
[Radio, Stanley J.] Univ Nebraska, Lincoln, NE 68583 USA.
[Rodriguez, E. Rene; Tan, Carmela D.] Cleveland Clin, Cleveland, OH 44106 USA.
[Sheppard, Mary N.] Univ London, St George Med Sch, London, England.
[Suvarna, S. Kim] Sheffield Teaching Hosp, Sheffield, S Yorkshire, England.
[van der Wal, Allard C.] Univ Amsterdam, Amsterdam, Netherlands.
[Veinot, John P.] Univ Ottawa, Ottawa, ON, Canada.
RP Stone, JR (reprint author), Massachusetts Gen Hosp, Simches Bldg Room 8236, Boston, MA 02114 USA.
EM jrstone@partners.org; patrick.bruneval@egp.aphp.fr
OI leone, ornella/0000-0001-6412-3294; Buja, Louis
Maximilian/0000-0001-8386-7029; Halushka, Marc/0000-0002-7112-7389
NR 115
TC 11
Z9 11
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1054-8807
EI 1879-1336
J9 CARDIOVASC PATHOL
JI Cardiovasc. Pathol.
PD SEP-OCT
PY 2015
VL 24
IS 5
BP 267
EP 278
DI 10.1016/j.carpath.2015.05.001
PG 12
WC Cardiac & Cardiovascular Systems; Pathology
SC Cardiovascular System & Cardiology; Pathology
GA CR2TL
UT WOS:000361183400001
PM 26051917
ER
PT J
AU Song, JW
Mitchell, PD
Kolasinski, J
Grant, PE
Galaburda, AM
Takahashi, E
AF Song, Jae W.
Mitchell, Paul D.
Kolasinski, James
Grant, P. Ellen
Galaburda, Albert M.
Takahashi, Emi
TI Asymmetry of White Matter Pathways in Developing Human Brains
SO CEREBRAL CORTEX
LA English
DT Article
DE asymmetry; brain; development; diffusion imaging; human tractography;
white matter
ID HUMAN FETAL-BRAIN; DIFFUSION TENSOR; DEVELOPMENTAL DYSLEXIA; CEREBRAL
ASYMMETRY; CORPUS-CALLOSUM; VISUAL-CORTEX; HUMAN FETUS; IN-UTERO;
TRACTOGRAPHY; LATERALIZATION
AB Little is known about the emergence of structural asymmetry of white matter tracts during early brain development. We examined whether and when asymmetry in diffusion parameters of limbic and association white matter pathways emerged in humans in 23 brains ranging from 15 gestational weeks (GW) up to 3 years of age (11 ex vivo and 12 in vivo cases) using high-angular resolution diffusion imaging tractography. Age-related development of laterality was not observed in a limbic connectional pathway (cingulum bundle or fornix). Among the studied cortico-cortical association pathways (inferior longitudinal fasciculus [ILF], inferior fronto-occipital fasciculus, and arcuate fasciculus), only the ILF showed development of age-related laterality emerging as early as the second trimester. Comparisons of ages older and younger than 40 GW revealed a leftward asymmetry in the cingulum bundle volume and a rightward asymmetry in apparent diffusion coefficient and leftward asymmetry in fractional anisotropy in the ILF in ages older than 40 GW. These results suggest that morphometric asymmetry in cortical areas precedes the emergence of white matter pathway asymmetry. Future correlative studies will investigate whether such asymmetry is anatomically/genetically driven or associated with functional stimulation.
C1 [Song, Jae W.; Grant, P. Ellen; Takahashi, Emi] Harvard Univ, Sch Med, Dept Med, Div Newborn Med,Boston Childrens Hosp, Boston, MA 02115 USA.
[Song, Jae W.; Grant, P. Ellen; Takahashi, Emi] Harvard Univ, Sch Med, Boston Childrens Hosp, Fetal Neonatal Neuroimaging & Dev Sci Ctr, Boston, MA 02115 USA.
[Grant, P. Ellen] Harvard Univ, Sch Med, Boston Childrens Hosp, Dept Radiol, Boston, MA 02115 USA.
[Mitchell, Paul D.] Boston Childrens Hosp, Clin Res Ctr, Boston, MA 02115 USA.
[Kolasinski, James; Grant, P. Ellen; Takahashi, Emi] Harvard Univ, Sch Med, Athinoula A Martinos Ctr Biomed Imaging, Massachusetts Gen Hosp, Charlestown, MA 02129 USA.
[Galaburda, Albert M.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Neurol,Div Cognit Neurol, Boston, MA 02115 USA.
RP Takahashi, E (reprint author), Harvard Univ, Sch Med, Dept Med, Div Newborn Med,Boston Childrens Hosp, Boston, MA 02115 USA.
EM emi@nmr.mgh.harvard.edu
OI Kolasinski, James/0000-0002-1599-6440
FU Eunice Shriver Kennedy National Institute of Child Health and
Development (NICHD) [NIH R01HD078561, R21HD069001]; Ruth L. Kirschstein
National Research Service Awards [NIH F32 AR058105]; Biomedical
Technology Program of the National Center for Research Resources (NCRR),
National Institutes of Health [NIH P41RR14075]; NCRR Shared
Instrumentation Grant Program [NIH S10RR023401, S10RR019307,
S10RR023043]; High-End Instrumentation Grant Program [NIH S10RR016811];
Women's Hospital; Boston Children's Hospital; Harvard Medical School;
[NIH MH081896]
FX This work was supported the Eunice Shriver Kennedy National Institute of
Child Health and Development (NICHD) (NIH R01HD078561, R21HD069001)
(E.T.) and the Ruth L. Kirschstein National Research Service Awards for
Individual Postdoctoral Fellows (NIH F32 AR058105) (J.W.S.). This
research was carried out in part at the Athinoula A. Martinos Center for
Biomedical Imaging at the Massachusetts General Hospital, using
resources provided by the Center for Functional Neuroimaging
Technologies, NIH P41RR14075, a P41 Regional Resource supported by the
Biomedical Technology Program of the National Center for Research
Resources (NCRR), National Institutes of Health. This work also involved
the use of instrumentation supported by the NCRR Shared Instrumentation
Grant Program (NIH S10RR023401, S10RR019307, and S10RR023043) and
High-End Instrumentation Grant Program (NIH S10RR016811). This study was
conducted partly using postmortem human brain specimens from the tissue
collection at the Department of Neurobiology at Yale University School
of Medicine (supported by grant NIH MH081896), which form a part of the
BrainSpan Consortium collection (http://www.brainspan.org). The other
brain specimens were provided by Dr Rebecca D. Folkerth, Brigham and
Women's Hospital, Boston Children's Hospital, and Harvard Medical
School.
NR 59
TC 6
Z9 6
U1 0
U2 15
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1047-3211
EI 1460-2199
J9 CEREB CORTEX
JI Cereb. Cortex
PD SEP
PY 2015
VL 25
IS 9
BP 2883
EP 2893
DI 10.1093/cercor/bhu084
PG 11
WC Neurosciences
SC Neurosciences & Neurology
GA CR6NK
UT WOS:000361464000048
PM 24812082
ER
PT J
AU Sharma, J
Sugihara, H
Katz, Y
Schummers, J
Tenenbaum, J
Sur, M
AF Sharma, Jitendra
Sugihara, Hiroki
Katz, Yarden
Schummers, James
Tenenbaum, Joshua
Sur, Mriganka
TI Spatial Attention and Temporal Expectation Under Timed Uncertainty
Predictably Modulate Neuronal Responses in Monkey V1
SO CEREBRAL CORTEX
LA English
DT Article
DE hazard rate; neural responses; reaction time; top-down influences
ID PRIMARY VISUAL-CORTEX; SACCADIC EYE-MOVEMENTS; SELECTIVE ATTENTION;
HEMODYNAMIC SIGNALS; NEURAL MECHANISMS; TASK-DIFFICULTY; HAZARD RATE;
AREAS V1; DAS 2009; MACAQUE
AB The brain uses attention and expectation as flexible devices for optimizing behavioral responses associated with expected but unpredictably timed events. The neural bases of attention and expectation are thought to engage higher cognitive loci; however, their influence at the level of primary visual cortex (V1) remains unknown. Here, we asked whether single-neuron responses in monkey V1 were influenced by an attention task of unpredictable duration. Monkeys covertly attended to a spot that remained unchanged for a fixed period and then abruptly disappeared at variable times, prompting a lever release for reward. We show that monkeys responded progressively faster and performed better as the trial duration increased. Neural responses also followed monkey's task engagement-there was an early, but short duration, response facilitation, followed by a late but sustained increase during the time monkeys expected the attention spot to disappear. This late attentional modulation was significantly and negatively correlated with the reaction time and was well explained by a modified hazard function. Such bimodal, time-dependent changes were, however, absent in a task that did not require explicit attentional engagement. Thus, V1 neurons carry reliable signals of attention and temporal expectation that correlate with predictable influences on monkeys' behavioral responses.
C1 [Sharma, Jitendra; Sugihara, Hiroki; Schummers, James; Sur, Mriganka] MIT, Picower Inst Learning & Memory, Cambridge, MA 01239 USA.
[Katz, Yarden; Tenenbaum, Joshua; Sur, Mriganka] MIT, Dept Brain & Cognit Sci, Cambridge, MA 01239 USA.
[Sharma, Jitendra] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
[Schummers, James] Max Planck Florida Inst Neurosci, Jupiter, FL 33458 USA.
RP Sur, M (reprint author), MIT, Dept Brain & Cognit Sci, Simons Ctr Social Brain, 43 Vassar St,Room 46-6237, Cambridge, MA 02139 USA.
EM msur@mit.edu
FU US National Institutes for Health; Simon Foundations
FX Supported by grants from the US National Institutes for Health and the
Simon Foundations to M.S.
NR 83
TC 3
Z9 3
U1 2
U2 9
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1047-3211
EI 1460-2199
J9 CEREB CORTEX
JI Cereb. Cortex
PD SEP
PY 2015
VL 25
IS 9
BP 2894
EP 2906
DI 10.1093/cercor/bhu086
PG 13
WC Neurosciences
SC Neurosciences & Neurology
GA CR6NK
UT WOS:000361464000049
PM 24836689
ER
PT J
AU He, S
Chousterman, BG
Fenn, A
Anzai, A
Nairz, M
Brandt, M
Hilgendorf, I
Sun, Y
Ye, YX
Iwamoto, Y
Tricot, B
Weissleder, R
Macphee, C
Libby, P
Nahrendorf, M
Swirski, FK
AF He, Shun
Chousterman, Benjamin G.
Fenn, Ashley
Anzai, Atsushi
Nairz, Manfred
Brandt, Martin
Hilgendorf, Ingo
Sun, Yuan
Ye, Yu-Xiang
Iwamoto, Yoshiko
Tricot, Benoit
Weissleder, Ralph
Macphee, Colin
Libby, Peter
Nahrendorf, Matthias
Swirski, Filip K.
TI Lp-PLA(2) Antagonizes Left Ventricular Healing After Myocardial
Infarction by Impairing the Appearance of Reparative Macrophages
SO CIRCULATION-HEART FAILURE
LA English
DT Article
DE heart failure; inflammation; macrophages; monocytes; myocardial
infarction
ID CORONARY-HEART-DISEASE; ACTIVATING-FACTOR ACETYLHYDROLASE; PHOSPHOLIPASE
A(2); ATHEROSCLEROTIC PLAQUE; MONOCYTE SUBSETS; LIPOPROTEIN; DARAPLADIB;
TRIAL; STABILIZATION; INHIBITION
AB Background Healing after myocardial infarction (MI) involves the biphasic accumulation of inflammatory Ly-6C(high) and reparative Ly-6C(low) monocytes/macrophages. Excessive inflammation disrupts the balance between the 2 phases, impairs infarct healing, and contributes to left ventricle remodeling and heart failure. Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)), a member of the phospholipase A(2) family of enzymes, produced predominantly by leukocytes, participates in host defenses and disease. Elevated Lp-PLA(2) levels associate with increased risk of cardiovascular events across diverse patient populations, but the mechanisms by which the enzyme elicits its effects remain unclear. This study tested the role of Lp-PLA(2) in healing after MI.
Methods and Results In response to MI, Lp-PLA(2) levels markedly increased in the circulation. To test the functional importance of Lp-PLA(2), we generated chimeric mice whose bone marrow-derived leukocytes were Lp-PLA(2)-deficient (bmLp-PLA(2)(-/-)). Compared with wild-type controls, bmLp-PLA(2)(-/-) mice subjected to MI had lower serum levels of inflammatory cytokines tumor necrosis factor-, interleukin (IL)-1, and IL-6, and decreased number of circulating inflammatory myeloid cells. Accordingly, bmLp-PLA(2)(-/-) mice developed smaller and less inflamed infarcts with reduced numbers of infiltrating neutrophils and inflammatory Ly-6C(high) monocytes. During the later, reparative phase, infarcts of bmLp-PLA(2)(-/-) mice contained Ly-6C(low) macrophages with a skewed M2-prone gene expression signature, increased collagen deposition, fewer inflammatory cells, and improved indices of angiogenesis. Consequently, the hearts of bmLp-PLA(2)(-/-) mice healed more efficiently, as determined by improved left ventricle remodeling and ejection fraction.
Conclusions Lp-PLA(2) augments the inflammatory response after MI and antagonizes healing by disrupting the balance between inflammation and repair, providing a rationale for focused study of ventricular function and heart failure after targeting this enzyme acutely in MI.
C1 [He, Shun; Chousterman, Benjamin G.; Fenn, Ashley; Anzai, Atsushi; Nairz, Manfred; Hilgendorf, Ingo; Sun, Yuan; Ye, Yu-Xiang; Iwamoto, Yoshiko; Tricot, Benoit; Weissleder, Ralph; Nahrendorf, Matthias; Swirski, Filip K.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
[Brandt, Martin] GlaxoSmithKline, Biol Sci, Collegeville, PA USA.
[Weissleder, Ralph] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02114 USA.
[Macphee, Colin] GlaxoSmithKline, King Of Prussia, PA USA.
[Libby, Peter] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA.
RP Swirski, FK (reprint author), Massachusetts Gen Hosp, Ctr Syst Biol, Simches Res Bldg,185 Cambridge St, Boston, MA 02114 USA.
EM fswirski@mgh.harvard.edu
FU GSK; National Institutes of Health [1R01HL095612, R56AI104695]
FX This work was supported, in part, by GSK funding (GlaxoSmithKline:
Targeting Lp-PLA2 in Inflammatory Cardiovascular Disease) and
by National Institutes of Health grants 1R01HL095612 and R56AI104695 (to
Dr Swirski).
NR 27
TC 0
Z9 0
U1 2
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1941-3289
EI 1941-3297
J9 CIRC-HEART FAIL
JI Circ.-Heart Fail.
PD SEP
PY 2015
VL 8
IS 5
BP 980
EP 987
DI 10.1161/CIRCHEARTFAILURE.115.002334
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CR2UL
UT WOS:000361186000019
PM 26232205
ER
PT J
AU Anderson, KC
AF Anderson, Kenneth C.
TI New insights into therapeutic targets in multiple myeloma.
SO CLINICAL CANCER RESEARCH
LA English
DT Meeting Abstract
CT AACR Special Conference on Hematologic Malignancies - Translating
Discoveries to Novel Therapies
CY SEP 20-23, 2014
CL Philadelphia, PA
SP Amer Assoc Canc Res
C1 [Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD SEP 1
PY 2015
VL 21
SU 17
MA IA27
DI 10.1158/1557-3265.HEMMAL14-IA27
PG 1
WC Oncology
SC Oncology
GA CR5ME
UT WOS:000361386200094
ER
PT J
AU Blackburn, J
Molodtsov, A
Lobbardi, R
Moore, F
Langenau, D
AF Blackburn, Jessica
Molodtsov, Aleksey
Lobbardi, Riadh
Moore, Finola
Langenau, David
TI The tyrosine phosphatase PRL3 as a novel drug target in T-cell acute
lymphoblastic leukemia.
SO CLINICAL CANCER RESEARCH
LA English
DT Meeting Abstract
CT AACR Special Conference on Hematologic Malignancies - Translating
Discoveries to Novel Therapies
CY SEP 20-23, 2014
CL Philadelphia, PA
SP Amer Assoc Canc Res
C1 [Blackburn, Jessica; Molodtsov, Aleksey; Lobbardi, Riadh; Moore, Finola; Langenau, David] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD SEP 1
PY 2015
VL 21
SU 17
MA A16
DI 10.1158/1557-3265.HEMMAL14-A16
PG 1
WC Oncology
SC Oncology
GA CR5ME
UT WOS:000361386200014
ER
PT J
AU Cottini, F
Hideshima, T
Richardson, P
Anderson, K
Tonon, G
AF Cottini, Francesca
Hideshima, Teru
Richardson, Paul
Anderson, Kenneth
Tonon, Giovanni
TI Exploiting oncogene-induced DNA replicative stress as synthetic lethal
approach to target myeloma.
SO CLINICAL CANCER RESEARCH
LA English
DT Meeting Abstract
CT AACR Special Conference on Hematologic Malignancies - Translating
Discoveries to Novel Therapies
CY SEP 20-23, 2014
CL Philadelphia, PA
SP Amer Assoc Canc Res
C1 [Cottini, Francesca; Hideshima, Teru; Richardson, Paul; Anderson, Kenneth] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Tonon, Giovanni] Ist Sci San Raffaele, I-20132 Milan, Italy.
NR 2
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD SEP 1
PY 2015
VL 21
SU 17
MA PR04
DI 10.1158/1557-3265.HEMMAL14-PR04
PG 2
WC Oncology
SC Oncology
GA CR5ME
UT WOS:000361386200109
ER
PT J
AU Cottini, F
Hideshima, T
Richardson, P
Anderson, K
Tonon, G
AF Cottini, Francesca
Hideshima, Teru
Richardson, Paul
Anderson, Kenneth
Tonon, Giovanni
TI Exploiting oncogene-induced DNA replicative stress as synthetic lethal
approach to target myeloma.
SO CLINICAL CANCER RESEARCH
LA English
DT Meeting Abstract
CT AACR Special Conference on Hematologic Malignancies - Translating
Discoveries to Novel Therapies
CY SEP 20-23, 2014
CL Philadelphia, PA
SP Amer Assoc Canc Res
C1 [Cottini, Francesca; Hideshima, Teru; Richardson, Paul; Anderson, Kenneth] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Tonon, Giovanni] Ist Sci San Raffaele, I-20132 Milan, Italy.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD SEP 1
PY 2015
VL 21
SU 17
MA B09
DI 10.1158/1557-3265.HEMMAL14-B09
PG 1
WC Oncology
SC Oncology
GA CR5ME
UT WOS:000361386200047
ER
PT J
AU Ghobrial, I
AF Ghobrial, Irene
TI Multiple myeloma as a model of bone metastasis.
SO CLINICAL CANCER RESEARCH
LA English
DT Meeting Abstract
CT AACR Special Conference on Hematologic Malignancies - Translating
Discoveries to Novel Therapies
CY SEP 20-23, 2014
CL Philadelphia, PA
SP Amer Assoc Canc Res
C1 [Ghobrial, Irene] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD SEP 1
PY 2015
VL 21
SU 17
MA IA07
DI 10.1158/1557-3265.HEMMAL14-IA07
PG 1
WC Oncology
SC Oncology
GA CR5ME
UT WOS:000361386200079
ER
PT J
AU Hogdal, L
Chyla, B
McKeegan, E
Leverson, J
Potluri, J
Humerickhouse, R
Mack, M
DeAngelo, D
Galinsky, I
Stone, R
Letai, A
AF Hogdal, Leah
Chyla, Brenda
McKeegan, Evelyn
Leverson, Joel
Potluri, Jalaja
Humerickhouse, Rod
Mack, Mabry
DeAngelo, Daniel
Galinsky, Ilene
Stone, Richard
Letai, Anthony
TI Studying BCL-2 dependence using BH3 profiling in a phase 2 clinical
trial of ABT-199 in acute myeloid leukemia.
SO CLINICAL CANCER RESEARCH
LA English
DT Meeting Abstract
CT AACR Special Conference on Hematologic Malignancies - Translating
Discoveries to Novel Therapies
CY SEP 20-23, 2014
CL Philadelphia, PA
SP Amer Assoc Canc Res
C1 [Hogdal, Leah; DeAngelo, Daniel; Galinsky, Ilene; Stone, Richard; Letai, Anthony] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Chyla, Brenda; McKeegan, Evelyn; Leverson, Joel; Potluri, Jalaja; Humerickhouse, Rod] AbbVie Inc, N Chicago, IL USA.
[Mack, Mabry] AbbVie Inc, Redwood City, CA USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD SEP 1
PY 2015
VL 21
SU 17
MA B10
DI 10.1158/1557-3265.HEMMAL14-B10
PG 2
WC Oncology
SC Oncology
GA CR5ME
UT WOS:000361386200048
ER
PT J
AU Karreth, FA
Reschke, M
Bjoern, C
Shipp, M
Chiarle, R
Pandolfi, PP
AF Karreth, Florian A.
Reschke, Markus
Bjoern, Chapuy
Shipp, Margaret
Chiarle, Roberto
Pandolfi, Pier Paolo
TI The BRAF pseudogene is a proto-oncogenic competitive endogenous RNA.
SO CLINICAL CANCER RESEARCH
LA English
DT Meeting Abstract
CT AACR Special Conference on Hematologic Malignancies - Translating
Discoveries to Novel Therapies
CY SEP 20-23, 2014
CL Philadelphia, PA
SP Amer Assoc Canc Res
C1 [Karreth, Florian A.] Weill Cornell Med Coll, New York, NY USA.
[Reschke, Markus; Pandolfi, Pier Paolo] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Bjoern, Chapuy; Shipp, Margaret] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Chiarle, Roberto] Childrens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD SEP 1
PY 2015
VL 21
SU 17
MA A37
DI 10.1158/1557-3265.HEMMAL14-A37
PG 1
WC Oncology
SC Oncology
GA CR5ME
UT WOS:000361386200030
ER
PT J
AU Letai, A
Hogdal, L
Chonghaile, T
Gutierrez, A
Roderick, J
Kelliher, M
Konopleva, M
AF Letai, Anthony
Hogdal, Leah
Chonghaile, Triona
Gutierrez, Alejandro
Roderick, Justine
Kelliher, Michelle
Konopleva, Marina
TI Using mitochondria to guide leukemia therapy.
SO CLINICAL CANCER RESEARCH
LA English
DT Meeting Abstract
CT AACR Special Conference on Hematologic Malignancies - Translating
Discoveries to Novel Therapies
CY SEP 20-23, 2014
CL Philadelphia, PA
SP Amer Assoc Canc Res
C1 [Letai, Anthony; Hogdal, Leah; Chonghaile, Triona] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Gutierrez, Alejandro] Childrens Hosp, Boston, MA 02115 USA.
[Roderick, Justine; Kelliher, Michelle] Univ Massachusetts, Sch Med, Worcester, MA USA.
[Konopleva, Marina] Univ Texas MD Anderson Med Ctr, Houston, TX USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD SEP 1
PY 2015
VL 21
SU 17
MA IA29
DI 10.1158/1557-3265.HEMMAL14-IA29
PG 1
WC Oncology
SC Oncology
GA CR5ME
UT WOS:000361386200095
ER
PT J
AU Li, LS
Kopp, N
Wu, SC
Van Der Zwet, J
Layer, JV
Weigert, O
Christie, AL
Christodoulou, AN
Liu, HY
Yoda, A
Radimerski, T
Weinstock, DM
AF Li, Loretta S.
Kopp, Nadja
Wu, Shuo-Chieh
Van Der Zwet, Jordy
Layer, Jacob V.
Weigert, Oliver
Christie, Amanda L.
Christodoulou, Alexandra N.
Liu, Huiyun
Yoda, Akinori
Radimerski, Thomas
Weinstock, David M.
TI Type II JAK2 inhibitor NVP-CHZ868 has potent activity in JAK2-dependent
B-cell acute lymphoblastic leukemias (B-ALLs) in vivo.
SO CLINICAL CANCER RESEARCH
LA English
DT Meeting Abstract
CT AACR Special Conference on Hematologic Malignancies - Translating
Discoveries to Novel Therapies
CY SEP 20-23, 2014
CL Philadelphia, PA
SP Amer Assoc Canc Res
C1 [Li, Loretta S.; Kopp, Nadja; Wu, Shuo-Chieh; Van Der Zwet, Jordy; Layer, Jacob V.; Christie, Amanda L.; Christodoulou, Alexandra N.; Liu, Huiyun; Yoda, Akinori; Weinstock, David M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Weigert, Oliver] Univ Hosp Grosshadern LMU, Munich, Germany.
[Radimerski, Thomas] Novartis Inst Biomed Res, Basel, Switzerland.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD SEP 1
PY 2015
VL 21
SU 17
MA A23
DI 10.1158/1557-3265.HEMMAL14-A23
PG 2
WC Oncology
SC Oncology
GA CR5ME
UT WOS:000361386200019
ER
PT J
AU Moore, FE
Esain, V
Lobbardi, R
Blackburn, JS
North, TE
Langenau, DM
AF Moore, Finola E.
Esain, Virginie
Lobbardi, Riadh
Blackburn, Jessica S.
North, Trista E.
Langenau, David M.
TI Role for the tumor suppressor phf6 in hematopoiesis.
SO CLINICAL CANCER RESEARCH
LA English
DT Meeting Abstract
CT AACR Special Conference on Hematologic Malignancies - Translating
Discoveries to Novel Therapies
CY SEP 20-23, 2014
CL Philadelphia, PA
SP Amer Assoc Canc Res
C1 [Moore, Finola E.; Lobbardi, Riadh; Blackburn, Jessica S.; Langenau, David M.] Massachusetts Gen Hosp, Charlestown, MA USA.
[Esain, Virginie; North, Trista E.] Beth Israel Deaconess, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD SEP 1
PY 2015
VL 21
SU 17
MA A33
DI 10.1158/1557-3265.HEMMAL14-A33
PG 1
WC Oncology
SC Oncology
GA CR5ME
UT WOS:000361386200027
ER
PT J
AU Nicholson, B
Kodrasov, MP
LaRocque, JP
Eddins, MJ
Kumar, S
Chauhan, D
Anderson, KC
Mattern, MR
AF Nicholson, Benjamin
Kodrasov, Matthew P.
LaRocque, James P.
Eddins, Michael J.
Kumar, Suresh
Chauhan, Dharminder
Anderson, Kenneth C.
Mattern, Michael R.
TI Inhibition of USP7 for the treatment of multiple myeloma and other
malignancies.
SO CLINICAL CANCER RESEARCH
LA English
DT Meeting Abstract
CT AACR Special Conference on Hematologic Malignancies - Translating
Discoveries to Novel Therapies
CY SEP 20-23, 2014
CL Philadelphia, PA
SP Amer Assoc Canc Res
C1 [Nicholson, Benjamin; Kodrasov, Matthew P.; LaRocque, James P.; Eddins, Michael J.; Kumar, Suresh; Mattern, Michael R.] Progenra Inc, Malvern, PA USA.
[Chauhan, Dharminder; Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 4
U2 10
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD SEP 1
PY 2015
VL 21
SU 17
MA A21
DI 10.1158/1557-3265.HEMMAL14-A21
PG 1
WC Oncology
SC Oncology
GA CR5ME
UT WOS:000361386200018
ER
PT J
AU Shipp, M
AF Shipp, Margaret
TI Identification of targetable vulnerabilities in lymphoma.
SO CLINICAL CANCER RESEARCH
LA English
DT Meeting Abstract
CT AACR Special Conference on Hematologic Malignancies - Translating
Discoveries to Novel Therapies
CY SEP 20-23, 2014
CL Philadelphia, PA
SP Amer Assoc Canc Res
C1 [Shipp, Margaret] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD SEP 1
PY 2015
VL 21
SU 17
MA IA38
DI 10.1158/1557-3265.HEMMAL14-IA38
PG 1
WC Oncology
SC Oncology
GA CR5ME
UT WOS:000361386200101
ER
PT J
AU Shirai, CL
Ley, JN
White, B
Tibbitts, J
Shao, J
Ndonwi, M
Kim, S
Okeyo-Owuor, T
Graubert, TA
Walter, MJ
AF Shirai, Cara Lunn
Ley, James N.
White, Brian
Tibbitts, Justin
Shao, Jin
Ndonwi, Matthew
Kim, Sanghyun
Okeyo-Owuor, Theresa
Graubert, Timothy A.
Walter, Matthew J.
TI Mutant U2AF1 alters hematopoiesis and pre-mRNA splicing in transgenic
mice.
SO CLINICAL CANCER RESEARCH
LA English
DT Meeting Abstract
CT AACR Special Conference on Hematologic Malignancies - Translating
Discoveries to Novel Therapies
CY SEP 20-23, 2014
CL Philadelphia, PA
SP Amer Assoc Canc Res
C1 [Shirai, Cara Lunn; Ley, James N.; White, Brian; Tibbitts, Justin; Shao, Jin; Ndonwi, Matthew; Kim, Sanghyun; Okeyo-Owuor, Theresa; Walter, Matthew J.] Washington Univ, St Louis, MO USA.
[Graubert, Timothy A.] Dana Farber Harvard Canc Ctr, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD SEP 1
PY 2015
VL 21
SU 17
MA PR06
DI 10.1158/1557-3265.HEMMAL14-PR06
PG 2
WC Oncology
SC Oncology
GA CR5ME
UT WOS:000361386200110
ER
PT J
AU Shirai, CL
Ley, JN
White, B
Tibbitts, J
Shao, J
Ndonwi, M
Kim, S
Okeyo-Owuor, T
Graubert, TA
Walter, MJ
AF Shirai, Cara Lunn
Ley, James N.
White, Brian
Tibbitts, Justin
Shao, Jin
Ndonwi, Matthew
Kim, Sanghyun
Okeyo-Owuor, Theresa
Graubert, Timothy A.
Walter, Matthew J.
TI Mutant U2AF1 alters hematopoiesis and pre-mRNA splicing in transgenic
mice.
SO CLINICAL CANCER RESEARCH
LA English
DT Meeting Abstract
CT AACR Special Conference on Hematologic Malignancies - Translating
Discoveries to Novel Therapies
CY SEP 20-23, 2014
CL Philadelphia, PA
SP Amer Assoc Canc Res
C1 [Shirai, Cara Lunn; Ley, James N.; White, Brian; Tibbitts, Justin; Shao, Jin; Ndonwi, Matthew; Kim, Sanghyun; Okeyo-Owuor, Theresa; Walter, Matthew J.] Washington Univ, St Louis, MO USA.
[Graubert, Timothy A.] Dana Farber Harvard Canc Ctr, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD SEP 1
PY 2015
VL 21
SU 17
MA B41
DI 10.1158/1557-3265.HEMMAL14-B41
PG 1
WC Oncology
SC Oncology
GA CR5ME
UT WOS:000361386200071
ER
PT J
AU Stegmaier, K
AF Stegmaier, Kimberly
TI Integrating chemical and functional genomics for leukemia discovery.
SO CLINICAL CANCER RESEARCH
LA English
DT Meeting Abstract
CT AACR Special Conference on Hematologic Malignancies - Translating
Discoveries to Novel Therapies
CY SEP 20-23, 2014
CL Philadelphia, PA
SP Amer Assoc Canc Res
C1 [Stegmaier, Kimberly] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD SEP 1
PY 2015
VL 21
SU 17
MA IA23
DI 10.1158/1557-3265.HEMMAL14-IA23
PG 1
WC Oncology
SC Oncology
GA CR5ME
UT WOS:000361386200090
ER
PT J
AU Weir, M
Hellwig, S
Gray, NS
Smithgall, TE
AF Weir, Mark
Hellwig, Sabine
Gray, Nathanael S.
Smithgall, Thomas E.
TI Dual inhibition of Flt3 and Fes tyrosine kinases potently blocks
proliferation of AML cells expressing an active Flt3 mutant.
SO CLINICAL CANCER RESEARCH
LA English
DT Meeting Abstract
CT AACR Special Conference on Hematologic Malignancies - Translating
Discoveries to Novel Therapies
CY SEP 20-23, 2014
CL Philadelphia, PA
SP Amer Assoc Canc Res
C1 [Weir, Mark; Hellwig, Sabine; Smithgall, Thomas E.] Univ Pittsburgh, Sch Med, Microbiol & Mol Genet, Pittsburgh, PA USA.
[Gray, Nathanael S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD SEP 1
PY 2015
VL 21
SU 17
MA A25
DI 10.1158/1557-3265.HEMMAL14-A25
PG 1
WC Oncology
SC Oncology
GA CR5ME
UT WOS:000361386200021
ER
PT J
AU Wu, CJ
AF Wu, Catherine J.
TI The evolutionary landscape of chronic lymphocytic leukemia.
SO CLINICAL CANCER RESEARCH
LA English
DT Meeting Abstract
CT AACR Special Conference on Hematologic Malignancies - Translating
Discoveries to Novel Therapies
CY SEP 20-23, 2014
CL Philadelphia, PA
SP Amer Assoc Canc Res
C1 [Wu, Catherine J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Wu, Catherine J.] Broad Inst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD SEP 1
PY 2015
VL 21
SU 17
MA IA19
DI 10.1158/1557-3265.HEMMAL14-IA19
PG 1
WC Oncology
SC Oncology
GA CR5ME
UT WOS:000361386200087
ER
PT J
AU Blumenthal, KG
Parker, RA
Shenoy, ES
Walensky, RP
AF Blumenthal, Kimberly G.
Parker, Robert A.
Shenoy, Erica S.
Walensky, Rochelle P.
TI Improving Clinical Outcomes in Patients With Methicillin-Sensitive
Staphylococcus aureus Bacteremia and Reported Penicillin Allergy
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE decision analysis; vancomycin; allergy; penicillin; Staphylococcus
aureus
ID HEMODIALYSIS-DEPENDENT PATIENTS; ADVERSE DRUG-REACTIONS;
HOSPITALIZED-PATIENTS; BETA-LACTAMS; SKIN; VANCOMYCIN; INFECTIONS;
RESISTANT; HISTORY; CEPHALOSPORINS
AB Background. Methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia is a morbid infection. First-line MSSA therapies (nafcillin, oxacillin, cefazolin) are generally avoided in the 10% of patients reporting penicillin (PCN) allergy, but most of these patients are not truly allergic. We used a decision tree with sensitivity analyses to determine the optimal evaluation and treatment for patients with MSSA bacteremia and reported PCN allergy.
Methods. Our model simulates 3 strategies: (1) no allergy evaluation, give vancomycin (Vanc); (2) allergy history-guided treatment: if history excludes anaphylactic features, give cefazolin (Hx-Cefaz); and (3) complete allergy evaluation with history-appropriate PCN skin testing: if skin test negative, give cefazolin (ST-Cefaz). Model outcomes included 12-week MSSA cure, recurrence, and death; allergic reactions including major, minor, and potentially iatrogenic; and adverse drug reactions.
Results. Vanc results in the fewest patients achieving MSSA cure and the highest rate of recurrence (67.3%/14.8% vs 83.4%/9.3% for Hx-Cefaz and 84.5%/8.9% for ST-Cefaz) as well as the greatest frequency of allergic reactions (3.0% vs 2.4% for Hx-Cefaz and 1.7% for ST-Cefaz) and highest rates of adverse drug reactions (5.2% vs 4.6% for Hx-Cefaz and 4.7% for ST-Cefaz). Even in a "best case for Vanc" scenario, Vanc yields the poorest outcomes. ST-Cefaz is preferred to Hx-Cefaz although sensitive to input variations.
Conclusions. Patients with MSSA bacteremia and a reported PCN allergy should have the allergy addressed for optimal treatment. Full allergy evaluation with skin testing seems to be preferred, although more data are needed.
C1 [Blumenthal, Kimberly G.] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Dept Med, Boston, MA 02114 USA.
[Blumenthal, Kimberly G.; Parker, Robert A.; Shenoy, Erica S.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Med Practice Evaluat Ctr, Boston, MA 02114 USA.
[Blumenthal, Kimberly G.; Parker, Robert A.; Shenoy, Erica S.; Walensky, Rochelle P.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Shenoy, Erica S.] Massachusetts Gen Hosp, Infect Control Unit, Boston, MA 02114 USA.
[Shenoy, Erica S.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Div Infect Dis, Dept Med, Boston, MA 02114 USA.
[Parker, Robert A.] Massachusetts Gen Hosp, Ctr Biostat, Dept Med, Boston, MA 02114 USA.
RP Blumenthal, KG (reprint author), Massachusetts Gen Hosp, Med Practice Evaluat Ctr, 50 Staniford St,9th Flr, Boston, MA 02114 USA.
EM kblumenthal1@partners.org
FU NIH [T32 HL116275]
FX This work was supported by the NIH (grant number T32 HL116275 to K. G.
B.).
NR 66
TC 9
Z9 9
U1 0
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD SEP 1
PY 2015
VL 61
IS 5
BP 741
EP 749
DI 10.1093/cid/civ394
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA CR6PD
UT WOS:000361468700011
PM 25991471
ER
PT J
AU Evans, SR
Rubin, D
Follmann, D
Pennello, G
Huskins, WC
Powers, JH
Schoenfeld, D
Chuang-Stein, C
Cosgrove, SE
Fowler, VG
Lautenbach, E
Chambers, HF
AF Evans, Scott R.
Rubin, Daniel
Follmann, Dean
Pennello, Gene
Huskins, W. Charles
Powers, John H.
Schoenfeld, David
Chuang-Stein, Christy
Cosgrove, Sara E.
Fowler, Vance G., Jr.
Lautenbach, Ebbing
Chambers, Henry F.
TI Desirability of Outcome Ranking (DOOR) and Response Adjusted for
Duration of Antibiotic Risk (RADAR)
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE DOOR; RADAR; antibiotic use strategies
ID EQUIVALENCE TRIALS; ANTIMICROBIAL USE; NON-INFERIORITY; SAMPLE-SIZE
AB Clinical trials that compare strategies to optimize antibiotic use are of critical importance but are limited by competing risks that distort outcome interpretation, complexities of noninferiority trials, large sample sizes, and inadequate evaluation of benefits and harms at the patient level. The Antibacterial Resistance Leadership Group strives to overcome these challenges through innovative trial design. Response adjusted for duration of antibiotic risk (RADAR) is a novel methodology utilizing a superiority design and a 2-step process: (1) categorizing patients into an overall clinical outcome (based on benefits and harms), and (2) ranking patients with respect to a desirability of outcome ranking (DOOR). DOORs are constructed by assigning higher ranks to patients with (1) better overall clinical outcomes and (2) shorter durations of antibiotic use for similar overall clinical outcomes. DOOR distributions are compared between antibiotic use strategies. The probability that a randomly selected patient will have a better DOOR if assigned to the new strategy is estimated. DOOR/RADAR represents a new paradigm in assessing the risks and benefits of new strategies to optimize antibiotic use.
C1 [Evans, Scott R.] Harvard Univ, Boston, MA 02115 USA.
[Rubin, Daniel] US FDA, Ctr Drug Evaluat & Res, Silver Spring, MD USA.
[Follmann, Dean] NIAID, NIH, Bethesda, MD 20892 USA.
[Pennello, Gene] US FDA, Ctr Devices & Radiol Hlth, Silver Spring, MD USA.
[Huskins, W. Charles] Mayo Clin, Div Pediat Infect Dis, Rochester, MN USA.
[Powers, John H.] George Washington Univ, Sch Med, Washington, DC USA.
[Powers, John H.] NIH, Leidos Biomed Res, Div Clin Res, Bethesda, MD 20892 USA.
[Schoenfeld, David] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Chuang-Stein, Christy] Pfizer Inc, Groton, CT 06340 USA.
[Cosgrove, Sara E.] Johns Hopkins Univ, Baltimore, MD USA.
[Fowler, Vance G., Jr.] Duke Univ, Durham, NC USA.
[Lautenbach, Ebbing] Univ Penn, Philadelphia, PA 19104 USA.
[Chambers, Henry F.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
RP Evans, SR (reprint author), Harvard Univ, Sch Publ Hlth, CBAR Biostat, FXB 513,651 Huntington Ave, Boston, MA 02115 USA.
EM evans@sdac.harvard.edu
FU National Institute of Allergy and Infectious Diseases of the NIH
[UM1AI104681]; National Cancer Institute, NIH [HHSN261200800001E]
FX This work was supported by the National Institute of Allergy and
Infectious Diseases of the NIH (award number UM1AI104681) and in part
with federal funds from the National Cancer Institute, NIH (contract
number HHSN261200800001E).
NR 14
TC 16
Z9 16
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD SEP 1
PY 2015
VL 61
IS 5
BP 800
EP 806
DI 10.1093/cid/civ495
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA CR6PD
UT WOS:000361468700021
PM 26113652
ER
PT J
AU Sparger, K
Deschmann, E
Sola-Visner, M
AF Sparger, Katherine
Deschmann, Emoke
Sola-Visner, Martha
TI Platelet Transfusions in the Neonatal Intensive Care Unit
SO CLINICS IN PERINATOLOGY
LA English
DT Article
DE Platelet transfusions; Neonatal intensive care unit; Thrombocytopenia
ID FUNCTION ANALYZER; CORD BLOOD; PRIMARY HEMOSTASIS; PREMATURE-INFANTS;
NEWBORN PLATELETS; CONTROLLED-TRIAL; REFERENCE RANGES; BLEEDING TIMES;
THROMBOCYTOPENIA; CHILDREN
AB There is significant world-wide variability in platelet transfusion thresholds used to transfuse thrombocytopenic neonates. A large multicenter randomized controlled trial comparing 2 different platelet transfusion thresholds in neonates is currently ongoing, and should provide data to guide transfusion practice. However, several studies have found that factors other than the degree of thrombocytopenia determine the bleeding risk. Thus, it will be important to develop better tests to assess primary hemostasis and bleeding risk in neonates.
C1 [Sparger, Katherine] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA.
[Deschmann, Emoke] Karolinska Univ Hosp, Dept Neonatol, Astrid Lindgren Childrens Hosp, S-17176 Stockholm, Sweden.
[Sola-Visner, Martha] Boston Childrens Hosp, Div Newborn Med, Boston, MA 02115 USA.
RP Sola-Visner, M (reprint author), Boston Childrens Hosp, Div Newborn Med, Enders Res Bldg,Room 961,300 Longwood Ave, Boston, MA 02115 USA.
EM Martha.Sola-Visner@childrens.harvard.edu
FU NHLBI NIH HHS [P01 HL046925, R21 HL087150]
NR 43
TC 2
Z9 2
U1 0
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0095-5108
EI 1557-9840
J9 CLIN PERINATOL
JI Clin. Perinatol.
PD SEP
PY 2015
VL 42
IS 3
BP 613
EP +
DI 10.1016/j.clp.2015.04.009
PG 12
WC Obstetrics & Gynecology; Pediatrics
SC Obstetrics & Gynecology; Pediatrics
GA CR2LY
UT WOS:000361162700013
PM 26250921
ER
PT J
AU Kojic, M
Milosevic, M
Kojic, N
Starosolski, Z
Ghaghada, K
Serda, R
Annapragada, A
Ferrari, M
Ziemys, A
AF Kojic, M.
Milosevic, M.
Kojic, N.
Starosolski, Z.
Ghaghada, K.
Serda, R.
Annapragada, A.
Ferrari, M.
Ziemys, A.
TI A multi-scale FE model for convective-diffusive drug transport within
tumor and large vascular networks
SO COMPUTER METHODS IN APPLIED MECHANICS AND ENGINEERING
LA English
DT Article
DE Pipe finite element; Coupling fluid and solid; Homogenization;
Multiscale; Tumor model; Brain model
ID BLOOD-FLOW; NEOPLASTIC TISSUES; MICROVASCULAR ARCHITECTURE; VISCOUS
RESISTANCE; SOLID TUMORS; PERMEABILITY; MICROENVIRONMENT; CARCINOMA;
FLUID; CAPILLARIES
AB Mass transport within an organ occurs through networks of blood vessels and surrounding tissue. This convective-diffusive transport is a very complex process which spans several different scales, from nano-to micro-to macro-scale. The blood vessel network is usually very intricate and irregular with respect to size and geometry, with mass transport being directly coupled to the neighboring tissue. Due to such complexity, development of a comprehensive transport model remains a challenge. The primary focus of this study is on solid tumors which are extremely complex autonomous systems with regard to mass transport. Additionally, tumors develop various biological barriers which hinder effective delivery of drug molecules into cancer tissue. We introduce a multi-scale tumor transport model where larger tumor vessels are modeled by simple 1D finite elements, whereas the capillary bed is replaced by equivalent 3D continuum finite elements. The model couples convective-diffusive transport within capillaries (fluid domain) and tissue (solid domain). These fluid and solid domains are connected by fictitious 1D elements. The proposed tumor model incorporates the imaged inhomogeneous tumor tissue and blood vessel network-from larger vessels to the smallest capillary bed. The tumor model is also applicable to transport within organs, such as the mouse brain, which is presented here as an example. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Kojic, M.; Ferrari, M.; Ziemys, A.] Houston Methodist Res Inst, Dept Nanomed, Houston, TX 77030 USA.
[Kojic, M.; Milosevic, M.] Belgrade Metropolitan Univ, Bioengn Res & Dev Ctr BioIRC Kragujevac, Kragujevac 34000, Serbia.
[Kojic, M.] Serbian Acad Arts & Sci, Belgrade 11000, Serbia.
[Kojic, N.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Engn Med & Surg Serv, Boston, MA 02114 USA.
[Starosolski, Z.; Ghaghada, K.; Annapragada, A.] Texas Childrens Hosp, Singleton Dept Pediat Radiol, Houston, TX 77030 USA.
[Serda, R.] Baylor Coll Med, Houston, TX 77030 USA.
RP Kojic, M (reprint author), Houston Methodist Res Inst, Dept Nanomed, 6670 Bertner Ave,R7-117, Houston, TX 77030 USA.
EM mkojic42@gmail.com
FU State of Texas Emerging Technology Fund; Alliance of NanoHealth (ANH);
Ministry of Education and Science of Serbia [OI 174028, III 41007]; City
of Kragujevac; Ernest Cockrell Jr. Presidential Distinguished Chair
FX This study has been supported from funds of State of Texas Emerging
Technology Fund, Alliance of NanoHealth (ANH), and the Ernest Cockrell
Jr. Presidential Distinguished Chair (M.F.).; The authors acknowledge
support from Ministry of Education and Science of Serbia, grants OI
174028 and III 41007, and City of Kragujevac.
NR 53
TC 1
Z9 1
U1 0
U2 4
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0045-7825
EI 1879-2138
J9 COMPUT METHOD APPL M
JI Comput. Meth. Appl. Mech. Eng.
PD SEP 1
PY 2015
VL 294
BP 100
EP 122
DI 10.1016/j.cma.2015.06.002
PG 23
WC Engineering, Multidisciplinary; Mathematics, Interdisciplinary
Applications; Mechanics
SC Engineering; Mathematics; Mechanics
GA CR6YD
UT WOS:000361493600005
ER
PT J
AU Singbrant, S
van Galen, P
Lucas, D
Challen, G
Rossi, DJ
Daley, GQ
AF Singbrant, Sofie
van Galen, Peter
Lucas, Daniel
Challen, Grant
Rossi, Derrick J.
Daley, George Q.
TI Two new routes to make blood: Hematopoietic specification from
pluripotent cell lines versus reprogramming of somatic cells
SO EXPERIMENTAL HEMATOLOGY
LA English
DT Article
ID STEM-CELLS; INDUCTION; PROGENITORS; FIBROBLASTS
AB Transplantation of hematopoietic stem cells (HSCs) to treat hematologic disorders is routinely used in the clinic. However, HSC therapy is hindered by the requirements of finding human leukocyte antigen (HLA)-matched donors and attaining sufficient numbers of long-term HSCs in the graft. Therefore, ex vivo expansion of transplantable HSCs remains one of the "holy grails" of hematology. Without the ability to maintain and expand human HSCs in vitro, two complementary approaches involving cellular reprogramming to generate transplantable HSCs have emerged. Reprogrammed HSCs represent a potentially inexhaustible supply of autologous tissue. On March 18th, 2015, Dr. George Q. Daley and Dr. Derrick J. Rossi, two pioneers in the field, presented and discussed their most recent research on these topics in a webinar organized by the International Society for Experimental Hematology (ISEH). Here, we summarize these seminars and discuss the possibilities and challenges in the field of hematopoietic specification. Copyright (C) 2015 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc.
C1 [Singbrant, Sofie] Lund Univ, Lund Stem Cell Ctr, Dept Mol Med, Lund, Sweden.
[van Galen, Peter] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[van Galen, Peter] Harvard Univ, Sch Med, Boston, MA USA.
[Lucas, Daniel] Univ Michigan, Sch Med, Dept Cell & Dev Biol, Ann Arbor, MI USA.
[Challen, Grant] Washington Univ, Sch Med, Div Dev Regenerat & Stem Cell Biol, St Louis, MO USA.
[Challen, Grant] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA.
[Rossi, Derrick J.] Harvard Univ, Sch Med, Harvard Stem Cell Inst,Div Hematol & Oncol,Boston, Program Cellular & Mol Med,Dept Stem Cell & Regen, Cambridge, MA 02138 USA.
[Daley, George Q.] Harvard Univ, Sch Med, Div Hematol & Oncol,Harvard Stem Cell Inst, Stem Cell Transplantat Program,Boston Childrens H, Cambridge, MA 02138 USA.
RP Singbrant, S (reprint author), Lund Univ, Lund Stem Cell Ctr, Dept Mol Med, Lund, Sweden.
EM sofie.singbrant@med.lu.se
NR 12
TC 4
Z9 4
U1 3
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0301-472X
EI 1873-2399
J9 EXP HEMATOL
JI Exp. Hematol.
PD SEP
PY 2015
VL 43
IS 9
BP 756
EP 759
DI 10.1016/j.exphem.2015.05.007
PG 4
WC Hematology; Medicine, Research & Experimental
SC Hematology; Research & Experimental Medicine
GA CR5XH
UT WOS:000361417200002
PM 26143581
ER
PT J
AU D'Andrea, AD
AF D'Andrea, Alan D.
TI FANCONI ANEMIA AND BONE MARROW FAILURE
SO EXPERIMENTAL HEMATOLOGY
LA English
DT Meeting Abstract
CT 44th Annual Scientific Meeting of the
International-Society-for-Experimental-Hematology (ISEH)
CY SEP 17-19, 2015
CL Kyoto, JAPAN
SP Int Soc Expt Hematol
C1 [D'Andrea, Alan D.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0301-472X
EI 1873-2399
J9 EXP HEMATOL
JI Exp. Hematol.
PD SEP
PY 2015
VL 43
IS 9
SU 1
MA 1031
BP S40
EP S40
PG 1
WC Hematology; Medicine, Research & Experimental
SC Hematology; Research & Experimental Medicine
GA CR5XJ
UT WOS:000361417400031
ER
PT J
AU Kwan, W
Cortes, M
Liu, SY
Goessling, W
North, TE
AF Kwan, Wanda
Cortes, Mauricio
Liu, Sarah Y.
Goessling, Wolfram
North, Trista E.
TI SEROTONIN REGULATES HSC FORMATION VIA GLUCOCORTICOID PRODUCTION FROM THE
HYPOTHALAMIC-PITUITARY-INTERRENAL AXIS
SO EXPERIMENTAL HEMATOLOGY
LA English
DT Meeting Abstract
CT 44th Annual Scientific Meeting of the
International-Society-for-Experimental-Hematology (ISEH)
CY SEP 17-19, 2015
CL Kyoto, JAPAN
SP Int Soc Expt Hematol
C1 [Kwan, Wanda; Cortes, Mauricio; Liu, Sarah Y.; North, Trista E.] Harvard Univ, Sch Med, BIDMC, Boston, MA USA.
[Goessling, Wolfram] Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0301-472X
EI 1873-2399
J9 EXP HEMATOL
JI Exp. Hematol.
PD SEP
PY 2015
VL 43
IS 9
SU 1
MA 2007
BP S46
EP S46
PG 1
WC Hematology; Medicine, Research & Experimental
SC Hematology; Research & Experimental Medicine
GA CR5XJ
UT WOS:000361417400042
ER
PT J
AU Lin, CP
AF Lin, Charles P.
TI OPTICAL TECHNIQUES FOR CHARACTERIZING THE BONE MARROW MICROENVIRONMENT
SO EXPERIMENTAL HEMATOLOGY
LA English
DT Meeting Abstract
CT 44th Annual Scientific Meeting of the
International-Society-for-Experimental-Hematology (ISEH)
CY SEP 17-19, 2015
CL Kyoto, JAPAN
SP Int Soc Expt Hematol
C1 [Lin, Charles P.] Harvard Univ, Sch Med, Boston, MA USA.
[Lin, Charles P.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0301-472X
EI 1873-2399
J9 EXP HEMATOL
JI Exp. Hematol.
PD SEP
PY 2015
VL 43
IS 9
SU 1
MA 1009
BP S29
EP S29
PG 1
WC Hematology; Medicine, Research & Experimental
SC Hematology; Research & Experimental Medicine
GA CR5XJ
UT WOS:000361417400010
ER
PT J
AU Park, SY
Han, EYA
Jung, Y
Lin, CP
Silberstein, LE
AF Park, Shin-Young
Han, Eun Young Anna
Jung, Yookyung
Lin, Charles P.
Silberstein, Leslie E.
TI DECLINED PRESENTATION INFLAMMATORY MODULATION OF HEMATOPOIETIC STROMAL
NICHE CELLS BY TNF-alpha LEADS TO RAPID MOBILIZATION OF HEMATOPOIETIC
STEM/PROGENITOR CELLS (HSPC) AND NEUTROPHILS
SO EXPERIMENTAL HEMATOLOGY
LA English
DT Meeting Abstract
CT 44th Annual Scientific Meeting of the
International-Society-for-Experimental-Hematology (ISEH)
CY SEP 17-19, 2015
CL Kyoto, JAPAN
SP Int Soc Expt Hematol
C1 [Park, Shin-Young; Han, Eun Young Anna; Silberstein, Leslie E.] Boston Childrens Hosp, Boston, MA USA.
[Jung, Yookyung; Lin, Charles P.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0301-472X
EI 1873-2399
J9 EXP HEMATOL
JI Exp. Hematol.
PD SEP
PY 2015
VL 43
IS 9
SU 1
MA 3059
BP S65
EP S65
PG 1
WC Hematology; Medicine, Research & Experimental
SC Hematology; Research & Experimental Medicine
GA CR5XJ
UT WOS:000361417400116
ER
PT J
AU van Galen, P
Ram, O
Ryan, RJ
Cotton, MJ
Donohue, L
Drier, Y
Sievers, C
Gillespie, SM
Bernstein, BE
AF van Galen, Peter
Ram, Oren
Ryan, Russel J.
Cotton, Matthew J.
Donohue, Laura
Drier, Yotam
Sievers, Cem
Gillespie, Shawn M.
Bernstein, Bradley E.
TI A LOW-INPUT, MULTIPLEXED ASSAY FOR QUANTITATIVE COMPARISON OF CHROMATIN
LANDSCAPES
SO EXPERIMENTAL HEMATOLOGY
LA English
DT Meeting Abstract
CT 44th Annual Scientific Meeting of the
International-Society-for-Experimental-Hematology (ISEH)
CY SEP 17-19, 2015
CL Kyoto, JAPAN
SP Int Soc Expt Hematol
C1 [van Galen, Peter; Ram, Oren; Ryan, Russel J.; Cotton, Matthew J.; Donohue, Laura; Drier, Yotam; Sievers, Cem; Gillespie, Shawn M.; Bernstein, Bradley E.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[van Galen, Peter; Ram, Oren; Ryan, Russel J.; Cotton, Matthew J.; Donohue, Laura; Drier, Yotam; Sievers, Cem; Gillespie, Shawn M.; Bernstein, Bradley E.] Harvard Univ, Sch Med, Boston, MA USA.
[van Galen, Peter; Ram, Oren; Ryan, Russel J.; Cotton, Matthew J.; Donohue, Laura; Drier, Yotam; Sievers, Cem; Gillespie, Shawn M.; Bernstein, Bradley E.] Broad Inst MIT & Harvard, Cambridge, MA USA.
[van Galen, Peter; Ram, Oren; Ryan, Russel J.; Cotton, Matthew J.; Donohue, Laura; Drier, Yotam; Sievers, Cem; Gillespie, Shawn M.; Bernstein, Bradley E.] Massachusetts Gen Hosp, Ctr Canc Res, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0301-472X
EI 1873-2399
J9 EXP HEMATOL
JI Exp. Hematol.
PD SEP
PY 2015
VL 43
IS 9
SU 1
MA 3194
BP S99
EP S99
PG 1
WC Hematology; Medicine, Research & Experimental
SC Hematology; Research & Experimental Medicine
GA CR5XJ
UT WOS:000361417400250
ER
PT J
AU Nicolay, BN
Danielian, PS
Kottakis, F
Lapek, JD
Sanidas, I
Miles, WO
Dehnad, M
Tschop, K
Gierut, JJ
Manning, AL
Morris, R
Haigis, K
Bardeesy, N
Lees, JA
Haas, W
Dyson, NJ
AF Nicolay, Brandon N.
Danielian, Paul S.
Kottakis, Filippos
Lapek, John D., Jr.
Sanidas, Ioannis
Miles, Wayne O.
Dehnad, Mantre
Tschoep, Katrin
Gierut, Jessica J.
Manning, Amity L.
Morris, Robert
Haigis, Kevin
Bardeesy, Nabeel
Lees, Jacqueline A.
Haas, Wilhelm
Dyson, Nicholas J.
TI Proteomic analysis of pRb loss highlights a signature of decreased
mitochondrial oxidative phosphorylation
SO GENES & DEVELOPMENT
LA English
DT Article
DE pRB; mitochondria; metabolism; proteomics; OXPHOS; C-13-glucose
ID RETINOBLASTOMA TUMOR-SUPPRESSOR; CELL LUNG-CANCER; DEFICIENT CELLS;
TRANSCRIPTIONAL REPRESSION; MOUSE MODEL; RB MUTANT; PROTEIN; METABOLISM;
EXPRESSION; INHIBITION
AB The retinoblastoma tumor suppressor (pRb) protein associates with chromatin and regulates gene expression. Numerous studies have identified Rb-dependent RNA signatures, but the proteomic effects of Rb loss are largely unexplored. We acutely ablated Rb in adult mice and conducted a quantitative analysis of RNA and proteomic changes in the colon and lungs, where Rb-KO was sufficient or insufficient to induce ectopic proliferation, respectively. As expected, Rb-KO caused similar increases in classic pRb/E2F-regulated transcripts in both tissues, but, unexpectedly, their protein products increased only in the colon, consistent with its increased proliferative index. Thus, these protein changes induced by Rb loss are coupled with proliferation but uncoupled from transcription. The proteomic changes in common between Rb-KO tissues showed a striking decrease in proteins with mitochondrial functions. Accordingly, RB1 inactivation in human cells decreased both mitochondrial mass and oxidative phosphorylation (OXPHOS) function. RBKO cells showed decreased mitochondrial respiratory capacity and the accumulation of hypopolarized mitochondria. Additionally, RB/Rb loss altered mitochondrial pyruvate oxidation from C-13-glucose through the TCA cycle in mouse tissues and cultured cells. Consequently, RBKO cells have an enhanced sensitivity to mitochondria' stress conditions. In summary, proteomic analyses provide a new perspective on Rb/RB1 mutation, highlighting the importance of pRb for mitochondrial function and suggesting vulnerabilities for treatment.
C1 [Nicolay, Brandon N.; Kottakis, Filippos; Lapek, John D., Jr.; Sanidas, Ioannis; Miles, Wayne O.; Dehnad, Mantre; Tschoep, Katrin; Gierut, Jessica J.; Manning, Amity L.; Morris, Robert; Haigis, Kevin; Bardeesy, Nabeel; Haas, Wilhelm; Dyson, Nicholas J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA.
[Danielian, Paul S.; Lees, Jacqueline A.] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA.
[Dehnad, Mantre] Univ Med Ctr Utrecht, NL-3584 CX Utrecht, Netherlands.
RP Dyson, NJ (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA.
EM dyson@helix.mgh.harvard.edu
FU National Institutes of Health [P30-CA14051, 2-P01-CA42063, R01-CA163698,
F32-CA165856]; American Cancer Society [PF-13-081-01-TBG]
FX We thank Cambridge Isotope Laboratories (Cambridge, MA) for generously
supplying the 13C-glucose for all metabolic fate-mapping
studies. We thank S. Gygi (Harvard Medical School) for access to the
computational platform to perform the proteomics data analysis, T. Jacks
(Massachusetts Institute of Technology) for providing the conditional Rb
and the RosaCreERT2 alleles, and the Hope Babette Tang
Histology Facility at the Koch Institute for technical support. We thank
K. Birsoy, J. Coloff, B. Drapkin, I. Harris, L. Gallegos, A.
Guarner-Peralta, M. Liesa, S. McBrayer, K. Patra, G. Smolen, and D.
Ulanet for discussions and critical reading of the manuscript, and E.
Benevolenskaya for sharing data prior to publication. Funding for this
work was provided in part by National Institutes of Health P30-CA14051
to the Koch Institute, National Institutes of Health 2-P01-CA42063 to
J.A.L., National Institutes of Health R01-CA163698 to N.J.D., National
Institutes of Health F32-CA165856 to B.N.N., and American Cancer Society
PF-13-081-01-TBG to J.J.G. J.A.L. is a Ludwig scholar, and N.J.D. is a
James and Shirley Curvey Massachusetts General Hospital Research
Scholar.
NR 59
TC 10
Z9 10
U1 0
U2 2
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 0890-9369
EI 1549-5477
J9 GENE DEV
JI Genes Dev.
PD SEP 1
PY 2015
VL 29
IS 17
BP 1875
EP 1889
DI 10.1101/gad.264127.115
PG 15
WC Cell Biology; Developmental Biology; Genetics & Heredity
SC Cell Biology; Developmental Biology; Genetics & Heredity
GA CR5WS
UT WOS:000361415700009
PM 26314710
ER
PT J
AU Cohn, DE
Havrilesky, LJ
Osann, K
Lipscomb, J
Hsieh, S
Walker, JL
Wright, AA
Alvarez, RD
Karlan, BY
Bristow, RE
DiSilvestro, PA
Wakabayashi, MT
Morgan, R
Mukamel, DB
Wenzel, L
AF Cohn, David E.
Havrilesky, Laura J.
Osann, Kathryn
Lipscomb, Joseph
Hsieh, Susie
Walker, Joan L.
Wright, Alexi A.
Alvarez, Ronald D.
Karlan, Beth Y.
Bristow, Robert E.
DiSilvestro, Paul A.
Wakabayashi, Mark T.
Morgan, Robert
Mukamel, Dana B.
Wenzel, Lari
TI Consensus in controversy: The modified Delphi method applied to
Gynecologic Oncology practice
SO GYNECOLOGIC ONCOLOGY
LA English
DT Article
DE Ovarian cancer; Intraperitoneal (IP); Delphi technique; Opinion
ID DECISION-MAKING; OVARIAN-CANCER; BREAST-CANCER
AB Objectives. To determine the degree of consensus regarding the probabilities of outcomes associated with IP/IV and IV chemotherapy.
Methods. A survey was administered to an expert panel using the Delphi method. Ten ovarian cancer experts were asked to estimate outcomes for patients receiving IP/IV or IV chemotherapy. The clinical estimates were: 1) probability of completing six cycles of chemotherapy, 2) probability of surviving five years, 3) median survival, and 4) probability of ER/hospital visits during treatment Estimates for two patients, one with a low comorbidity index (patient 1) and the other with a moderate index (patient 2), were included. The survey was administered in three rounds, and panelists could revise their subsequent responses based on review of the anonymous opinions of their peers.
Results. The ranges were smaller for IV compared with IP/IV therapy. Ranges decreased with each round. Consensus converged around outcomes related to IP/IV chemotherapy for: 1) completion of 6 cycles of therapy (type 1 patient, 62%, type 2 patient, 43%); 2) percentage of patients surviving 5 years (type 1 patient, 66%, type 2 patient, 47%); and 3) median survival (type 1 patient, 83 months, type 2 patient, 58 months). The group required three rounds to achieve consensus on the probabilities of ER/hospital visits (type 1 patient, 24%, type 2 patient, 35%).
Conclusions. Initial estimates of survival and adverse events associated with IP/IV chemotherapy differ among experts. The Delphi process works to build consensus and may be a pragmatic tool to inform patients of their expected outcomes. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Cohn, David E.] Ohio State Univ, Columbus, OH 43210 USA.
[Havrilesky, Laura J.] Duke Univ, Sch Med, Durham, NC USA.
[Osann, Kathryn; Hsieh, Susie; Bristow, Robert E.; Wenzel, Lari] Univ Calif Irvine, Irvine, CA USA.
[Lipscomb, Joseph] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
[Lipscomb, Joseph] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
[Walker, Joan L.] Univ Oklahoma, Oklahoma City, OK USA.
[Wright, Alexi A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Alvarez, Ronald D.] Univ Alabama Birmingham, Birmingham, AL USA.
[Karlan, Beth Y.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
[DiSilvestro, Paul A.] Brown Univ, Women & Infants Hosp, Providence, RI 02912 USA.
[Wakabayashi, Mark T.; Morgan, Robert] City Hope Natl Med Ctr, Duarte, CA USA.
[Mukamel, Dana B.] Univ Calif Irvine, Sch Med, Orange, CA 92668 USA.
RP Cohn, DE (reprint author), 320 West 10th Ave,M210 Starling Loving Hall, Columbus, OH 43210 USA.
EM david.cohn@osumc.edu
FU NCI NIH HHS [K07 CA166210, P30 CA062203]
NR 13
TC 0
Z9 0
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0090-8258
EI 1095-6859
J9 GYNECOL ONCOL
JI Gynecol. Oncol.
PD SEP
PY 2015
VL 138
IS 3
BP 712
EP 716
DI 10.1016/j.ygyno.2015.07.014
PG 5
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA CR3YP
UT WOS:000361269300037
PM 26177553
ER
PT J
AU Kishore, SP
Kolappa, K
Jarvis, JD
Park, PH
Belt, R
Balasubramaniam, T
Kiddell-Monroe, R
AF Kishore, Sandeep P.
Kolappa, Kavitha
Jarvis, Jordan D.
Park, Paul H.
Belt, Rachel
Balasubramaniam, Thirukumaran
Kiddell-Monroe, Rachel
TI Overcoming Obstacles To Enable Access To Medicines For Noncommunicable
Diseases In Poor Countries
SO HEALTH AFFAIRS
LA English
DT Article
AB The modern access-to-medicines movement grew largely out of the civil-society reaction to the HIV/AIDS pandemic three decades ago. While the movement was successful with regard to HIV/AIDS medications, the increasingly urgent challenge to address access to medicines for noncommunicable diseases has lagged behind-and, in some cases, has been forgotten. In this article we first ask what causes the access gap with respect to lifesaving essential noncommunicable disease medicines and then what can be done to close the gap. Using the example of the push for access to antiretrovirals for HIV/AIDS patients for comparison, we highlight the problems of inadequate global financing and procurement for noncommunicable disease medications, intellectual property barriers and concerns raised by the pharmaceutical industry, and challenges to building stronger civil-society organizations and a patient and humanitarian response from the bottom up to demand treatment. We provide targeted policy recommendations, specific to the public sector, the private sector, and civil society, with the goal of improving access to noncommunicable disease medications globally.
C1 [Kishore, Sandeep P.] Yale Univ, New Haven, CT 06520 USA.
[Kishore, Sandeep P.; Jarvis, Jordan D.] Young Profess Chron Dis Network, Boston, MA USA.
[Kolappa, Kavitha] Massachusetts Gen Hosp, Psychiat, Boston, MA 02114 USA.
[Jarvis, Jordan D.] Harvard Global Equ Initiat, Boston, MA USA.
[Park, Paul H.] Noncommunicable Dis Partners Hlth Rwanda, Kigali, Rwanda.
[Balasubramaniam, Thirukumaran] Knowledge Ecol Int, Zurich, Switzerland.
Univ Allied Essential Med, Berkeley, CA USA.
RP Kishore, SP (reprint author), Yale Univ, New Haven, CT 06520 USA.
EM sunny.kishore@gmail.com
FU Open Society Institute
FX This work was partially supported by the Open Society Institute. The
views of author Rachel Kiddell-Monroe do not represent those of Medecins
sans Frontieres.
NR 38
TC 3
Z9 3
U1 1
U2 5
PU PROJECT HOPE
PI BETHESDA
PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA
SN 0278-2715
J9 HEALTH AFFAIR
JI Health Aff.
PD SEP
PY 2015
VL 34
IS 9
BP 1569
EP 1577
DI 10.1377/hlthaff.2015.0375
PG 9
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA CR2FQ
UT WOS:000361142100018
PM 26355060
ER
PT J
AU Manian, FA
AF Manian, Farrin A.
TI Medical Myths: Unprepared For The End Stages Of End-Stage Kidney Disease
SO HEALTH AFFAIRS
LA English
DT Editorial Material
C1 Massachusetts Gen Hosp, Med, Boston, MA 02114 USA.
RP Manian, FA (reprint author), Massachusetts Gen Hosp, Med, Boston, MA 02114 USA.
EM fmanian@partners.org
NR 5
TC 0
Z9 0
U1 0
U2 0
PU PROJECT HOPE
PI BETHESDA
PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA
SN 0278-2715
J9 HEALTH AFFAIR
JI Health Aff.
PD SEP
PY 2015
VL 34
IS 9
BP 1599
EP 1602
DI 10.1377/HLTHAFF.2014.0992
PG 4
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA CR2FQ
UT WOS:000361142100022
PM 26355064
ER
PT J
AU Kaafarani, HMA
Lee, J
Masiakos, PT
AF Kaafarani, Haytham M. A.
Lee, Jarone
Masiakos, Peter T.
TI Massachusetts Graduated Driver-Licensing Program
SO HEALTH AFFAIRS
LA English
DT Letter
C1 [Kaafarani, Haytham M. A.; Lee, Jarone; Masiakos, Peter T.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Kaafarani, HMA (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 3
TC 0
Z9 0
U1 1
U2 1
PU PROJECT HOPE
PI BETHESDA
PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA
SN 0278-2715
J9 HEALTH AFFAIR
JI Health Aff.
PD SEP
PY 2015
VL 34
IS 9
BP 1609
EP 1609
DI 10.1377/hlthaff.2015.0851
PG 1
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA CR2FQ
UT WOS:000361142100028
PM 26355069
ER
PT J
AU Viana, LM
O'Malley, JT
Burgess, BJ
Jones, DD
Oliveira, CACP
Santos, F
Merchant, SN
Liberman, LD
Liberman, MC
AF Viana, Lucas M.
O'Malley, Jennifer T.
Burgess, Barbara J.
Jones, Dianne D.
Oliveira, Carlos A. C. P.
Santos, Felipe
Merchant, Saumil N.
Liberman, Leslie D.
Liberman, M. Charles
TI Cochlear neuropathy in human presbycusis: Confocal analysis of hidden
hearing loss in post-mortem tissue
SO HEARING RESEARCH
LA English
DT Article
ID INNER HAIR-CELLS; SPIRAL GANGLION NEURONS; GUINEA-PIG COCHLEA;
INNERVATION DENSITIES; SYNAPTIC RIBBONS; SERIAL SECTIONS;
AFFERENT-FIBERS; USHERS SYNDROME; HENSENS CELLS; CAT COCHLEA
AB Recent animal work has suggested that cochlear synapses are more vulnerable than hair cells in both noise-induced and age-related hearing loss. This synaptopathy is invisible in conventional histopathological analysis, because cochlear nerve cell bodies in the spiral ganglion survive for years, and synaptic analysis requires special immunostaining or serial-section electron microscopy. Here, we show that the same quadruple-immunostaining protocols that allow synaptic counts, hair cell counts, neuronal counts and differentiation of afferent and efferent fibers in mouse can be applied to human temporal bones, when harvested within 9 h post-mortem and prepared as dissected whole mounts of the sensory epithelium and osseous spiral lamina. Quantitative analysis of five "normal" ears, aged 54-89 yrs, without any history of otologic disease, suggests that cochlear synaptopathy and the degeneration of cochlear nerve peripheral axons, despite a near-normal hair cell population, may be an important component of human presbycusis. Although primary cochlear nerve degeneration is not expected to affect audiometric thresholds, it may be key to problems with hearing in noise that are characteristic of declining hearing abilities in the aging ear. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Santos, Felipe; Merchant, Saumil N.; Liberman, M. Charles] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
[Merchant, Saumil N.; Liberman, Leslie D.; Liberman, M. Charles] Massachusetts Eye & Ear Infirm, Eaton Peabody Labs, Boston, MA 02114 USA.
[O'Malley, Jennifer T.; Burgess, Barbara J.; Jones, Dianne D.; Santos, Felipe; Merchant, Saumil N.; Liberman, Leslie D.; Liberman, M. Charles] Massachusetts Eye & Ear, Dept Otolaryngol, Boston, MA USA.
[Viana, Lucas M.; Oliveira, Carlos A. C. P.] Univ Brasilia, Fac Hlth Sci, Brasilia, DF, Brazil.
RP Liberman, MC (reprint author), Massachusetts Eye & Ear Infirm, Eaton Peabody Labs, 243 Charles St, Boston, MA 02114 USA.
EM Charles_Liberman@meei.harvard.edu
OI Viana, Lucas/0000-0001-5872-4915; Santos, Felipe/0000-0002-3523-665X
FU [NIDCD: R01 DC 0188]; [P30 DC 05209]; [U24 DC 011943]
FX Research supported by grants from the NIDCD: R01 DC 0188, P30 DC 05209
and U24 DC 011943.
NR 52
TC 20
Z9 21
U1 6
U2 15
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5955
EI 1878-5891
J9 HEARING RES
JI Hear. Res.
PD SEP
PY 2015
VL 327
BP 78
EP 88
DI 10.1016/j.heares.2015.04.014
PG 11
WC Audiology & Speech-Language Pathology; Neurosciences;
Otorhinolaryngology
SC Audiology & Speech-Language Pathology; Neurosciences & Neurology;
Otorhinolaryngology
GA CR3RX
UT WOS:000361251900009
PM 26002688
ER
PT J
AU Zou, B
Mittal, R
Grati, M
Lu, ZM
Shu, YL
Tao, Y
Feng, Y
Xie, DH
Kong, WJ
Yang, SM
Chen, ZY
Liu, XZ
AF Zou, Bing
Mittal, Rahul
Grati, M'hamed
Lu, Zhongmin
Shu, Yilai
Tao, Yong
Feng, Youg
Xie, Dinghua
Kong, Weijia
Yang, Shiming
Chen, Zheng-Yi
Liu, Xuezhong
TI The application of genome editing in studying hearing loss
SO HEARING RESEARCH
LA English
DT Review
ID ZINC-FINGER NUCLEASES; HOMOLOGOUS RECOMBINATION; MAMMALIAN-CELLS;
CHIMERIC NUCLEASES; DNA RECOGNITION; GENE-REGULATION; CAS9 NUCLEASE; TAL
EFFECTORS; III EFFECTORS; STEM-CELLS
AB Targeted genome editing mediated by clustered, regularly interspaced, short palindromic repeat (CRISPR)/CRISPR-associated nuclease 9 (Cas9) technology has emerged as one of the most powerful tools to study gene functions, and with potential to treat genetic disorders. Hearing loss is one of the most common sensory disorders, affecting approximately 1 in 500 newborns with no treatment. Mutations of inner ear genes contribute to the largest portion of genetic deafness. The simplicity and robustness of CRISPR/Cas9-directed genome editing in human cells and model organisms such as zebrafish, mice and primates make it a promising technology in hearing research. With CRISPR/Cas9 technology, functions of inner ear genes can be studied efficiently by the disruption of normal gene alleles through non-homologous-end-joining (NHEJ) mechanism. For genetic hearing loss, CRISPR/Cas9 has potential to repair gene mutations by homology-directed-repair (HDR) or to disrupt dominant mutations by NHEJ, which could restore hearing. Our recent work has shown CRISPR/Cas9-mediated genome editing can be efficiently performed in the mammalian inner ear in vivo. Thus, application of CRISPR/Cas9 in hearing research will open up new avenues for understanding the pathology of genetic hearing loss and provide new routes in the development of treatment to restore hearing. In this review, we describe major methodologies currently used for genome editing. We will highlight applications of these technologies in studies of genetic disorders and discuss issues pertaining to applications of CRISPR/Cas9 in auditory systems implicated in genetic hearing loss. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Zou, Bing; Mittal, Rahul; Grati, M'hamed; Liu, Xuezhong] Univ Miami, Miller Sch Med, Dept Otolaryngol, Miami, FL 33136 USA.
[Lu, Zhongmin] Univ Miami, Dept Biol, Miami, FL 33146 USA.
[Shu, Yilai; Tao, Yong; Chen, Zheng-Yi] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02114 USA.
[Shu, Yilai; Tao, Yong; Chen, Zheng-Yi] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA.
[Shu, Yilai] Fudan Univ, Shanghai Med Coll, Eye Ear Nose & Throat Hosp, Dept Otol & Skull Base Surg, Shanghai 200433, Peoples R China.
[Tao, Yong; Kong, Weijia] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Otolaryngol, Wuhan 430074, Peoples R China.
[Feng, Youg; Liu, Xuezhong] Cent S Univ, Xiangya Hosp, Dept Otolaryngol, Changsha, Hunan, Peoples R China.
[Xie, Dinghua; Liu, Xuezhong] Cent S Univ, Xiangya Hosp 2, Dept Otolaryngol Head & Neck Surg, Changsha, Hunan, Peoples R China.
[Yang, Shiming; Liu, Xuezhong] Chinese Peoples Liberat Army Gen Hosp, Dept Otolaryngol Head & Neck Surg, Beijing, Peoples R China.
RP Liu, XZ (reprint author), Univ Miami, Miller Sch Med, Dept Otolaryngol, 1601 NW 12th Ave, Miami, FL 33136 USA.
EM zheng-yi_chen@meei.harvard.edu; xliu@med.miami.edu
FU National Institutes of Health/National Institute on Deafness and Other
Communication Disorders [R01 DC05575, R01 DC01246,
2P50DC000422-Sub-Project 6432, R01 DC012115]; NIH [R01 DC006908];
Bertarelli Foundation; David-Shulsky Foundation; Frederick and Ines
Yeatts Hair Cell Regeneration grants; University of Miami Provost's
Research Award; College of Arts and Sciences Gabelli Fellowship;
National Basic Research Program of China (973 program) [2012CB 967904,
2012CB 967900]; National Nature Science Foundation of China
[NSFC81300824]
FX This work was supported by grants R01 DC05575, R01 DC01246,
2P50DC000422-Sub-Project 6432, and R01 DC012115 from the National
Institutes of Health/National Institute on Deafness and Other
Communication Disorders to Xue Zhong Liu; NIH (R01 DC006908), the
Bertarelli Foundation, and the David-Shulsky Foundation, and the
Frederick and Ines Yeatts Hair Cell Regeneration grants to Zheng-Yi
Chen; the University of Miami Provost's Research Award and College of
Arts and Sciences Gabelli Fellowship to Zhongmin Lu; the National Basic
Research Program of China (973 program number 2012CB 967904 and 2012CB
967900) to Shiming Yang and Dinghua Xie and the National Nature Science
Foundation of China NSFC81300824 to Yilai Shu. We are thankful to Drs.
Robert Gerring and Christopher Lisi for the critical reading of the
manuscript.
NR 82
TC 8
Z9 9
U1 5
U2 20
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5955
EI 1878-5891
J9 HEARING RES
JI Hear. Res.
PD SEP
PY 2015
VL 327
BP 102
EP 108
DI 10.1016/j.heares.2015.04.016
PG 7
WC Audiology & Speech-Language Pathology; Neurosciences;
Otorhinolaryngology
SC Audiology & Speech-Language Pathology; Neurosciences & Neurology;
Otorhinolaryngology
GA CR3RX
UT WOS:000361251900011
PM 25987504
ER
PT J
AU Minguez-Alarcon, L
Gaskins, AJ
Chiu, YH
Williams, PL
Ehrlich, S
Chavarro, JE
Petrozza, JC
Ford, JB
Calafat, AM
Hauser, R
AF Minguez-Alarcon, Lidia
Gaskins, Audrey J.
Chiu, Yu-Han
Williams, Paige L.
Ehrlich, Shelley
Chavarro, Jorge E.
Petrozza, John C.
Ford, Jennifer B.
Calafat, Antonia M.
Hauser, Russ
CA EARTH Study Team
TI Urinary bisphenol A concentrations and association with in vitro
fertilization outcomes among women from a fertility clinic
SO HUMAN REPRODUCTION
LA English
DT Article
DE bisphenol A; IVF outcomes; epidemiology; reproductive health; endocrine
disruptor
ID ESTROGEN-RECEPTOR-ALPHA; INTRAUTERINE IMPLANTATION; LACTATIONAL
EXPOSURE; NEONATAL EXPOSURE; ETHINYL ESTRADIOL; DIETARY EXPOSURE; SEMEN
QUALITY; MICE; VARIABILITY; CELLS
AB Are urinary BPA concentrations associated with in vitro fertilization (IVF) outcomes among women attending an academic fertility center?
Urinary BPA concentrations were not associated with adverse reproductive and pregnancy outcomes among women from a fertility clinic.
Bisphenol A (BPA), an endocrine disruptor, is detected in the urine of most Americans. Although animal studies have demonstrated that BPA reduces female fertility through effects on the ovarian follicle and uterus, data from human populations are scarce and equivocal.
This prospective cohort study between 2004 and 2012 at the Massachusetts General Hospital Fertility Center included 256 women (n = 375 IVF cycles) who provided up to two urine samples prior to oocyte retrieval (total N = 673).
Study participants were women enrolled in the Environment and Reproductive Health (EARTH) Study. Intermediate and clinical end-points of IVF treatments were abstracted from electronic medical records. We used generalized linear mixed models with random intercepts to evaluate the association between urinary BPA concentrations and IVF outcomes adjusted by age, race, body mass index, smoking status and infertility diagnosis.
The specific gravity-adjusted geometric mean of BPA was 1.87 A mu g/l, which is comparable to that for female participants in the National Health and Nutrition Examination Survey, 2011-2012. Urinary BPA concentrations were not associated with endometrial wall thickness, peak estradiol levels, proportion of high quality embryos or fertilization rates. Furthermore, there were no associations between urinary BPA concentrations and implantation, clinical pregnancy or live birth rates per initiated cycle or per embryo transfer. Although we did not find any associations between urinary BPA concentrations and IVF outcomes, the relation between BPA and endometrial wall thickness was modified by age. Younger women (< 37 years old) had thicker endometrial thickness across increasing quartiles of urinary BPA concentrations, while older women (a parts per thousand yen37 years old) had thinner endometrial thickness across increasing quartiles of urinary BPA concentrations.
Limitations to this study include a possible misclassification of BPA exposure and difficulties in extrapolating the findings to the general population.
Data on the relation between urinary BPA concentrations and reproductive outcomes remain scarce and additional research is needed to clarify its role in human reproduction.
C1 [Minguez-Alarcon, Lidia; Ford, Jennifer B.; Hauser, Russ] Harvard Univ, TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
[Gaskins, Audrey J.; Chiu, Yu-Han; Chavarro, Jorge E.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Gaskins, Audrey J.; Williams, Paige L.; Chavarro, Jorge E.; Hauser, Russ] Harvard Univ, TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Williams, Paige L.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Ehrlich, Shelley] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Dept Environm Hlth, Div Biostat & Epidemiol, Cincinnati, OH USA.
[Chavarro, Jorge E.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA.
[Chavarro, Jorge E.; Petrozza, John C.; Hauser, Russ] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Petrozza, John C.] Massachusetts Gen Hosp, Vincent Obstet & Gynecol, Boston, MA 02114 USA.
[Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA.
RP Minguez-Alarcon, L (reprint author), Harvard Univ, TH Chan Sch Publ Hlth, Dept Environm Hlth, 665 Huntington Ave, Boston, MA 02115 USA.
EM lminguez@hsph.harvard.edu
RI Ehrlich , Shelley/L-6991-2015
FU NIH from National Institute of Environmental Health Sciences (NIEHS)
[R01ES022955, R01ES009718, R01ES000002]; National Institute of Child
Health and Human Development (NICHD) [T32DK00770316]
FX This work was supported by NIH grants R01ES022955, R01ES009718, and
R01ES000002 from the National Institute of Environmental Health Sciences
(NIEHS) and grant T32DK00770316 from the National Institute of Child
Health and Human Development (NICHD).
NR 52
TC 8
Z9 8
U1 3
U2 21
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0268-1161
EI 1460-2350
J9 HUM REPROD
JI Hum. Reprod.
PD SEP
PY 2015
VL 30
IS 9
BP 2120
EP 2128
DI 10.1093/humrep/dev183
PG 9
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA CR3FV
UT WOS:000361217300018
PM 26209788
ER
PT J
AU Chiu, YH
Afeiche, MC
Gaskins, AJ
Williams, PL
Petrozza, JC
Tanrikut, C
Hauser, R
Chavarro, JE
AF Chiu, Y. H.
Afeiche, M. C.
Gaskins, A. J.
Williams, P. L.
Petrozza, J. C.
Tanrikut, C.
Hauser, R.
Chavarro, J. E.
TI Reply: Pesticide residues and semen quality
SO HUMAN REPRODUCTION
LA English
DT Letter
ID ANTIOXIDANT INTAKE; MEN
C1 [Chiu, Y. H.; Gaskins, A. J.; Chavarro, J. E.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Afeiche, M. C.; Hauser, R.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
[Williams, P. L.; Hauser, R.; Chavarro, J. E.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Williams, P. L.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Petrozza, J. C.] Massachusetts Gen Hosp, Vincent Dept Obstet & Gynecol, Boston, MA 02114 USA.
[Tanrikut, C.] Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA.
[Chavarro, J. E.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA.
[Chavarro, J. E.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Chavarro, JE (reprint author), 665 Huntington Ave, Boston, MA USA.
EM jchavarr@hsph.harvard.edu
NR 9
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0268-1161
EI 1460-2350
J9 HUM REPROD
JI Hum. Reprod.
PD SEP
PY 2015
VL 30
IS 9
BP 2241
EP 2242
DI 10.1093/humrep/dev165
PG 2
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA CR3FV
UT WOS:000361217300032
PM 26141708
ER
PT J
AU Banerji, J
AF Banerji, Julian
TI Asparaginase treatment side-effects may be due to genes with
homopolymeric Asn codons (Review-Hypothesis)
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Review
DE asparaginase; diabetes; lipodystrophy; leukemia; lymphoma; immune
response; pancreatitis; cystic fibrosis; insulin regulatory substrate-2;
Salmonella
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; GENOME-WIDE ASSOCIATION;
TRANSFER-RNA-SYNTHETASE; CORONARY-ARTERY-DISEASE;
AMYOTROPHIC-LATERAL-SCLEROSIS; SINGLE NUCLEOTIDE POLYMORPHISM;
INSULIN-RECEPTOR SUBSTRATE-2; AMINO-ACID REPEATS; TRANSMEMBRANE
CONDUCTANCE REGULATOR; HIGH-DENSITY-LIPOPROTEIN
AB The present treatment of childhood T-cell leukemias involves the systemic administration of prokaryotic L-asparaginase (ASNase), which depletes plasma Asparagine (Asn) and inhibits protein synthesis. The mechanism of therapeutic action of ASNase is poorly understood, as are the etiologies of the side-effects incurred by treatment. Protein expression from genes bearing Asn homopolymeric coding regions (N-hCR) may be particularly susceptible to Asn level fluctuation. In mammals, N-hCR are rare, short and conserved. In humans, misfunctions of genes encoding N-hCR are associated with a cluster of disorders that mimic ASNase therapy side-effects which include impaired glycemic control, dislipidemia, pancreatitis, compromised vascular integrity, and neurological dysfunction. This paper proposes that dysregulation of Asn homeostasis, potentially even by ASNase produced by the microbiome, may contribute to several clinically important syndromes by altering expression of N-hCR bearing genes. By altering amino acid abundance and modulating ribosome translocation rates at codon repeats, the microbiomic environment may contribute to genome decoding and to shaping the proteome. We suggest that impaired translation at poly Asn codons elevates diabetes risk and severity.
C1 Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Simches Res Ctr, Boston, MA 02114 USA.
RP Banerji, J (reprint author), Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Simches Res Ctr, Seventh Floor,185 Cambridge St, Boston, MA 02114 USA.
EM jbanerji@molbio.mgh.harvard.edu
NR 393
TC 1
Z9 1
U1 2
U2 17
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107-3756
EI 1791-244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD SEP
PY 2015
VL 36
IS 3
BP 607
EP 626
DI 10.3892/ijmm.2015.2285
PG 20
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA CR2DH
UT WOS:000361134700001
PM 26178806
ER
PT J
AU Jochum, JR
Begley, AE
Dew, MA
Weiner, DK
Karp, JF
AF Jochum, John R.
Begley, Amy E.
Dew, Mary Amanda
Weiner, Debra K.
Karp, Jordan F.
TI Advancing the screening of fibromyalgia in late-life depression:
practical implications for psychiatric settings
SO INTERNATIONAL PSYCHOGERIATRICS
LA English
DT Article
DE fibromyalgia; screening; aging; pain; depression
ID COGNITIVE IMPAIRMENT; PAIN; MANAGEMENT; DISORDERS; CRITERIA; CARE;
POPULATION; DIAGNOSIS; SEVERITY
AB Background: Fibromyalgia (FM) is common in older adults suffering from mood disorders. However, clinical diagnosis of FM is challenging, particularly in psychiatric settings. We examined the prevalence of FM and the sensitivity of three simple screeners for FM.
Methods: Using cross-sectional data, we evaluated three tests against the American College of Rheumatology (ACR) 1990 Criteria for the Classification of FM: a "Do you often feel like you hurt all over?" question, a pain map score, and the Pope and Hudson (PH) interview for FM. Participants were 185 community-dwelling adults >= 60 years old with comorbid depression and chronic low back pain evaluated at a late-life mental health clinic.
Results: Fifty three of 185 participants (29%) met the ACR 1990 FM criteria. Compared to those without FM, the FM group had more "yes" answers to the "hurt all over?" question and higher pain map scores. To reach a sensitivity of at least 0.90, the cut-off score for the pain map was 8. The sensitivity of the pain map, "hurt all over?" question, and PH criteria were 0.92 [95% CI 0.82-0.98], 0.91 [95% CI 0.79-0.97], and 0.94 [95% CI 0.843-0.99] respectively.
Conclusions: Nearly one in three older adults suffering from depression and chronic low back pain met ACR 1990 FM criteria. Three short screening tests showed high sensitivity when compared to the ACR 1990 FM criteria. Implementation of one of the simple screeners for FM in geriatric psychiatry settings may guide the need for further diagnostic evaluation.
C1 [Jochum, John R.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
[Begley, Amy E.; Dew, Mary Amanda; Weiner, Debra K.; Karp, Jordan F.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA.
[Dew, Mary Amanda] Univ Pittsburgh, Dept Epidemiol, Sch Med, Pittsburgh, PA 15261 USA.
[Dew, Mary Amanda] Univ Pittsburgh, Dept Biostat, Sch Med, Pittsburgh, PA 15261 USA.
[Dew, Mary Amanda] Univ Pittsburgh, Dept Psychol, Sch Med, Pittsburgh, PA 15260 USA.
[Dew, Mary Amanda; Weiner, Debra K.; Karp, Jordan F.] Clin & Translat Sci Inst, Pittsburgh, PA USA.
[Weiner, Debra K.; Karp, Jordan F.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15261 USA.
[Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA.
[Weiner, Debra K.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
RP Karp, JF (reprint author), Western Psychiat Inst & Clin, 3811 OHara St, Pittsburgh, PA 15213 USA.
EM karpjf@upmc.edu
FU M-STREAM program: Medical Student Training and Research Experience in
Aging and Mental Health [AG033575, R25 MH071544]; [P30 MH090333]; [UL1
RR024153]; [UL1TR000005]
FX Supported in part by AG033575 (Karp) and R25 MH071544 through the
M-STREAM program: Medical Student Training and Research Experience in
Aging and Mental Health (Jochum). The project also received support by
P30 MH090333, UL1 RR024153, and UL1TR000005. The content is solely the
responsibility of the authors.
NR 36
TC 1
Z9 1
U1 1
U2 2
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1041-6102
EI 1741-203X
J9 INT PSYCHOGERIATR
JI Int. Psychogeriatr.
PD SEP
PY 2015
VL 27
IS 9
BP 1513
EP 1521
DI 10.1017/S1041610215000666
PG 9
WC Psychology, Clinical; Geriatrics & Gerontology; Gerontology; Psychiatry;
Psychology
SC Psychology; Geriatrics & Gerontology; Psychiatry
GA CR5LS
UT WOS:000361384600011
PM 25907254
ER
PT J
AU Pomerantz, H
Hogan, D
Eilers, D
Swetter, SM
Chen, SC
Jacob, SE
Warshaw, EM
Stricklin, G
Dellavalle, RP
Sidhu-Malik, N
Konnikov, N
Werth, VP
Keri, J
Lew, R
Weinstock, MA
AF Pomerantz, Hyemin
Hogan, Daniel
Eilers, David
Swetter, Susan M.
Chen, Suephy C.
Jacob, Sharon E.
Warshaw, Erin M.
Stricklin, George
Dellavalle, Robert P.
Sidhu-Malik, Navjeet
Konnikov, Nellie
Werth, Victoria P.
Keri, Jonette
Lew, Robert
Weinstock, Martin A.
CA Vet Affairs Keratinocyte Carcinoma
TI Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating
Actinic Keratosis A Randomized Clinical Trial
SO JAMA DERMATOLOGY
LA English
DT Article
ID TRETINOIN CHEMOPREVENTION TRIAL; 0.5-PERCENT FLUOROURACIL; 1-WEEK
AB IMPORTANCE Topical fluorouracil was demonstrated to be effective in reducing the number of actinic keratoses (AKs) for up to 6 months, but no randomized trials studied its long-term efficacy.
OBJECTIVE To evaluate the long-term efficacy of a single course of fluorouracil cream, 5%, for AK treatment.
DESIGN, SETTING, AND PARTICIPANTS The Veterans Affairs Keratinocyte Carcinoma Chemoprevention (VAKCC) trial was a randomized, double-blinded, placebo-controlled trial with patients from dermatology clinics at 12 VA medical centers recruited from 2009 to 2011 and followed up until 2013. Our study population comprised 932 veterans with 2 or more keratinocyte carcinomas in the 5 years prior to enrollment. The mean follow-up duration was 2.6 years in both treatment and control groups.
INTERVENTIONS Participants applied either topical fluorouracil cream, 5%(n = 468), or vehicle control cream (n = 464) to the face and ears twice daily for up to 4 weeks.
MAIN OUTCOMES AND MEASURES This study reports on AK counts and treatments, which were secondary outcomes of the VAKCC trial. Actinic keratoses on the face and ears were counted by study dermatologists at enrollment and at study visits every 6 months. The number of spot treatments for AKs on the face and ears at semiannual study visits and in between study visits was recorded.
RESULTS The number of AKs on the face and ears per participant was not different between the fluorouracil and control groups at randomization (11.1 vs 10.6, rho > .10). After randomization, the fluorouracil group had fewer AKs compared with the control group at 6 months (3.0 vs 8.1, rho < .001) and for the overall study duration (rho < .001). The fluorouracil group also had higher complete AK clearance rates (38% vs 17% at 6 months) and fewer spot treatments at 6-month intervals, at study visits, and in between study visits during the trial (rho < .01 for all). The fluorouracil group took longer to require the first spot AK treatment (6.2 months) compared with the control group (6.0 months) (hazard ratio, 0.69; 95% CI, 0.60-0.79). The number of hypertrophic AKs was not different between the 2 groups overall (rho = .60), although there were fewer hypertrophic AKs in the fluorouracil group at 6 months (0.23 vs 0.41) (rho = .05).
CONCLUSIONS AND RELEVANCE Our results indicate that a single course of fluorouracil cream, 5%, effectively reduces AK counts and the need for spot treatments for longer than 2 years.
C1 [Pomerantz, Hyemin; Weinstock, Martin A.] Vet Affairs VA Med Ctr, Ctr Dermatoepidemiol, Providence, RI USA.
[Pomerantz, Hyemin; Weinstock, Martin A.] Brown Univ, Dept Dermatol, Providence, RI 02912 USA.
[Hogan, Daniel] Bay Pines VA Healthcare Syst, Dermatol, Bay Pines, FL USA.
[Hogan, Daniel] Nova SE Univ, Coll Osteopath Med, Dept Internal Med Dermatol, Davie, FL USA.
[Eilers, David] Edward Hines Jr VA Hosp, Dermatol, Hines, IL USA.
[Swetter, Susan M.] VA Palo Alto Hlth Care Syst, Dermatol, Palo Alto, CA USA.
[Swetter, Susan M.] Stanford Univ, Med Ctr, Dept Dermatol, Palo Alto, CA 94304 USA.
[Chen, Suephy C.] Atlanta VA Med Ctr, Dermatol, Atlanta, GA USA.
[Chen, Suephy C.] Emory Univ, Dept Dermatol, Atlanta, GA 30322 USA.
[Jacob, Sharon E.] VA San Diego Healthcare Syst, Dermatol, San Diego, CA USA.
[Warshaw, Erin M.] Minneapolis VA Hlth Care Syst, Dermatol, Minneapolis, MN USA.
[Warshaw, Erin M.] Univ Minnesota, Dept Dermatol, Minneapolis, MN 55455 USA.
[Stricklin, George] Tennessee Valley Healthcare Syst, Dermatol, Nashville, TN USA.
[Stricklin, George] Vanderbilt Univ, Div Dermatol, Nashville, TN 37235 USA.
[Dellavalle, Robert P.] VA Med Ctr, Dermatol, Denver, CO USA.
[Sidhu-Malik, Navjeet] Durham VA Med Ctr, Dermatol, Durham, NC USA.
[Sidhu-Malik, Navjeet] Duke Univ, Dept Dermatol, Durham, NC USA.
[Konnikov, Nellie] Boston VA Med Ctr, Dermatol, Boston, MA USA.
[Werth, Victoria P.] Philadelphia VA Med Ctr, Dermatol, Philadelphia, PA USA.
[Keri, Jonette] Miami VA Hosp, Dermatol, Miami, FL USA.
[Keri, Jonette] Univ Miami, Miller Sch Med, Dept Dermatol & Cutaneous Surg, Miami, FL 33136 USA.
[Lew, Robert] VA Cooperat Studies Coordinating Ctr, Boston, MA USA.
[Weinstock, Martin A.] Rhode Isl Hosp, Dept Dermatol, Providence, RI USA.
[Weinstock, Martin A.] Brown Univ, Dept Epidemiol, Providence, RI 02912 USA.
RP Pomerantz, H (reprint author), Providence VA Med Ctr, Ctr Dermatoepidemiol, 830 Chalkstone Ave, Providence, RI 02908 USA.
EM hyemin.pomerantz@gmail.com
OI Swan, James/0000-0002-9438-6391
FU Office of Research and Development Cooperative Studies Program, US
Department of Veterans Affairs
FX The study was supported by the Office of Research and Development
Cooperative Studies Program, US Department of Veterans Affairs.
NR 18
TC 9
Z9 9
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6068
EI 2168-6084
J9 JAMA DERMATOL
JI JAMA Dermatol.
PD SEP
PY 2015
VL 151
IS 9
BP 952
EP 960
DI 10.1001/jamadermatol.2015.0502
PG 9
WC Dermatology
SC Dermatology
GA CR5HG
UT WOS:000361371100007
PM 25950503
ER
PT J
AU Asgari, MM
Moffet, HH
Ray, GT
Quesenberry, CP
AF Asgari, Maryam M.
Moffet, Howard H.
Ray, G. Thomas
Quesenberry, Charles P.
TI Trends in Basal Cell Carcinoma Incidence and Identification of High-Risk
Subgroups, 1998-2012
SO JAMA DERMATOLOGY
LA English
DT Article
ID NONMELANOMA SKIN-CANCER; UNITED-STATES; NEW-MEXICO; MELANOMA;
DISPARITIES; POPULATION; BEHAVIORS
AB IMPORTANCE The incidence of basal cell carcinomas (BCCs) is increasing globally, but incidence rates in the United States are difficult to quantify because BCCs are not reportable tumors.
OBJECTIVE To estimate annual BCC incidence rates by age, sex, and race/ethnicity to identify demographically distinct high-risk subgroups and to assess changes in rates over time.
DESIGN, SETTING, AND PARTICIPANTS In this retrospective cohort study (January 1, 1998, through December 31, 2012), we studied 147 093 patients with BCC from Kaiser Permanente Northern California, a large, integrated health care provision system, identified using a previously validated BCC registry.
MAIN OUTCOMES AND MEASURES We estimated annual BCC incidence rates by age, sex, and race/ethnicity and assessed changes in rates over time. The BCC incidence rates were standardized to the age, sex, and race/ethnicity distribution of the 2010 US Census population.
RESULTS In models adjusting for age, sex, and race, male patients had higher rates than female patients (incidence rate ratio [IRR], 1.65; 95% CI, 1.60-1.70). Persons 65 through 79 years of age and those 80 years and older had higher rates than persons 40 through 64 years of age (IRR, 2.96; 95% CI, 2.86-3.06; and IRR, 5.14; 95% CI, 4.94-5.35, respectively). Whites had higher rates than multiracial persons (IRR, 1.96; 95% CI, 1.80-2.13), Hispanics (IRR, 8.56; 95% CI, 7.79-9.41), Asians (IRR, 33.13; 95% CI, 27.84-39.42), and blacks (IRR, 72.98; 95% CI, 49.21-108.22).
CONCLUSIONS AND RELEVANCE We estimate that BCCs occur in approximately 2 million Americans annually. Our findings provide an updated estimate of the incidence of BCCs, highlight the changing epidemiologic findings, and better identify demographically distinct high-risk subgroups.
C1 [Asgari, Maryam M.; Moffet, Howard H.; Ray, G. Thomas; Quesenberry, Charles P.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA.
[Asgari, Maryam M.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA.
[Asgari, Maryam M.] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA.
[Asgari, Maryam M.] Harvard Univ, Sch Med, Boston, MA USA.
RP Asgari, MM (reprint author), Massachusetts Gen Hosp, Dept Dermatol, 50 Staniford St,Ste 270, Boston, MA 02114 USA.
RI Asgari, Maryam/O-4947-2016
FU National Cancer Institute at the National Institutes of Health [U19
CA79689, R01 CA166672]
FX This work was supported by grants U19 CA79689 and R01 CA166672 from the
National Cancer Institute at the National Institutes of Health (Dr
Asgari).
NR 22
TC 9
Z9 9
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6068
EI 2168-6084
J9 JAMA DERMATOL
JI JAMA Dermatol.
PD SEP
PY 2015
VL 151
IS 9
BP 976
EP 981
DI 10.1001/jamadermatol.2015.1188
PG 6
WC Dermatology
SC Dermatology
GA CR5HG
UT WOS:000361371100012
PM 26039887
ER
PT J
AU Shen, LQ
Kloek, CE
Turalba, AV
AF Shen, Lucy Q.
Kloek, Carolyn E.
Turalba, Angela V.
TI Assessing the Effect of a Glaucoma Surgical Curriculum in Resident
Physicians
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID SURGERY
AB IMPORTANCE Subspecialty surgical training is an important part of resident education. We changed the glaucoma rotation in which postgraduate year 4 residents worked with multiple attending physicians with varying teaching styles to a structured surgical curriculum led by 2 dedicated preceptors, and we evaluated the effect on residents' surgical performance prospectively.
OBSERVATIONS A curriculum consisting of preoperative training, intraoperative teaching, postoperative feedback, and repetition was implemented for postgraduate year 4 residents between July 2, 2012, and June 30, 2014. In a class of 8 residents per year, the mean (SD) glaucoma surgical volume increased from 8.9 (0.8) cases in the prior year to 13.6 (2.5) in 2013 (mean difference, 4.8 cases; 95% CI, 2.4-7.1; P = .001) and 14.8 (4.2) in 2014 (mean difference, 5.9 cases; 95% CI, 2.1-9.6; P = .007). A self-assessment survey showed improvement in suturing (scores for each section range from 1 [worst] to 5 [best]; mean rating, 3.9 in the prior year vs 4.4 in 2013 [P = .04] and 4.5 in 2014 [P = .02]). A validated survey assessing overall surgical competency revealed improvement in handling adverse events (mean rating, 4.1 in the prior year vs 5.0 for both 2013 and 2014; both P < .001).
CONCLUSIONS AND RELEVANCE Despite the small sample size and nonrandomized study design, these data suggest that a structured surgical curriculum has advantages in teaching subspecialty surgery and might be considered by other ophthalmology training programs.
C1 [Shen, Lucy Q.; Kloek, Carolyn E.; Turalba, Angela V.] Harvard Univ, Sch Med, Dept Ophthalmol, Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
RP Shen, LQ (reprint author), Harvard Univ, Sch Med, Dept Ophthalmol, Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA.
EM lucy_shen@meei.harvard.edu
FU Harvard Glaucoma Center of Excellence; Glaucoma Service; Residency
Committee at Massachusetts Eye and Ear Infirmary
FX This study was supported by the Harvard Glaucoma Center of Excellence,
the Glaucoma Service, and the Residency Committee at Massachusetts Eye
and Ear Infirmary.
NR 7
TC 3
Z9 3
U1 1
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD SEP
PY 2015
VL 133
IS 9
BP 1077
EP 1080
DI 10.1001/jamaophthalmol.2015.1846
PG 4
WC Ophthalmology
SC Ophthalmology
GA CR5JJ
UT WOS:000361377100019
PM 26086738
ER
PT J
AU Leskov, I
Rasool, N
Cestari, DM
AF Leskov, Ilya
Rasool, Nailyn
Cestari, Dean M.
TI Hypometabolic Lateral Recti Due to Bilateral Cranial Nerve VI Palsy
SO JAMA OPHTHALMOLOGY
LA English
DT Editorial Material
C1 [Leskov, Ilya; Rasool, Nailyn; Cestari, Dean M.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
RP Leskov, I (reprint author), Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA.
EM ilya_leskov@meei.harvard.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD SEP
PY 2015
VL 133
IS 9
AR e151490
DI 10.1001/jamaophthalmol.2015.1490
PG 1
WC Ophthalmology
SC Ophthalmology
GA CR5JJ
UT WOS:000361377100004
PM 26356005
ER
PT J
AU Sonnenberg, A
Genta, RM
AF Sonnenberg, Amnon
Genta, Robert M.
TI Epithelial Dysplasia and Cancer in IBD Strictures
SO JOURNAL OF CROHNS & COLITIS
LA English
DT Article
DE Colon cancer; dysplasia; epidemiology; histopathology of inflammatory
bowel disease; intestinal strictures
ID INFLAMMATORY-BOWEL-DISEASE; MALIGNANT COLORECTAL STRICTURES;
HELICOBACTER-PYLORI; CROHNS-DISEASE; ESOPHAGEAL EOSINOPHILIA; VIENNA
CLASSIFICATION; PATHOLOGY DATABASE; ULCERATIVE-COLITIS; RISK-FACTOR;
NEOPLASIA
AB Colonic strictures and epithelial dysplasia are both known risk factors for the occurrence of colorectal cancer in inflammatory bowel disease (IBD) patients. The aim of the present work was to study colonic stricture as a risk factor for the occurrence of epithelial dysplasia and colonic adenocarcinoma.
In a case-control study among 53568 IBD patients undergoing colonoscopy, we compared the prevalence of strictures among cases with dysplasia or adenocarcinoma and controls without such complications by calculating odds ratios (ORs) and their 95% confidence intervals (CIs). Multivariate logistic regressions were used to assess the joint influence of multiple predictor variables (age, sex, IBD type and stricture) on the occurrence of colonic dysplasia or adenocarcinoma.
The prevalence of strictures was 1.06% in ulcerative colitis (UC) and 8.71% in Crohn's disease (CD, OR 11.09, 95% CI 9.72-12.70). The prevalence of dysplasia was 3.22% in UC and 2.08% in CD (OR 0.75, 95% CI 0.65-0.86). The prevalence of dysplasia was similar in IBD patients with and without stricture: 2.82 and 2.41%, respectively. The prevalence of cancer was higher in IBD patients with than without stricture: 0.78 and 0.11%, respectively (OR 6.87, 95% CI 3.30-12.89). In the multivariate analysis, old age, male sex and UC, but not stricture, were all significantly and independently associated with dysplasia. Old age, dysplasia and stricture were significantly and independently associated with cancer.
The prevalence of epithelial dysplasia is not generally increased in IBD patients with strictures.
C1 [Sonnenberg, Amnon; Genta, Robert M.] Miraca Life Sci, Irving, TX USA.
[Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Genta, Robert M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3-GI, Portland, OR 97239 USA.
EM sonnenbe@ohsu.edu
NR 22
TC 1
Z9 1
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1873-9946
EI 1876-4479
J9 J CROHNS COLITIS
JI J. Crohns Colitis
PD SEP 1
PY 2015
VL 9
IS 9
BP 769
EP 775
DI 10.1093/ecco-jcc/jjv108
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CR6PY
UT WOS:000361470800011
PM 26079724
ER
PT J
AU Kachooei, AR
Rivlin, M
Wu, F
Faghfouri, A
Eberlin, KR
Ring, D
AF Kachooei, Amir Reza
Rivlin, Michael
Wu, Fei
Faghfouri, Aram
Eberlin, Kyle R.
Ring, David
TI Intraoperative Physical Examination for Diagnosis of Interosseous
Ligament Rupture - Cadaveric Study
SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME
LA English
DT Article
DE Interosseous ligament; interosseous membrane; joystick test; pull-push
test; reliability
ID FOREARM INSTABILITY; MEMBRANE; RADIUS
AB Purpose To study the intraobserver and interobserver reliability of the diagnosis of interosseous ligament (TOL) rupture in a cadaver model.
Methods On 12 fresh frozen cadavers, radial heads were cut using an identical incision and osteotomy. After randomization, the soft tissues of the limbs were divided into 4 groups: both IOL and triangular fibrocartilage (TFCC) intact; IOL disruption but TFCC intact; both IOL and TFCC divided; and IOL intact but TFCC divided. All incisions had identical suturing. After standard instruction and demonstration of radius pull-push and radius lateral pull tests, 10 physician evaluators with different levels of experience examined the cadaver limbs in a standardized way (elbow at 90 with the forearm held in both supination and pronation) and were asked to classify them into one of the 4 groups. Next, the same examiners were asked to reexamine the limbs after randomly changing the order of examination.
Results The interobserver reliability of agreement for the diagnosis of IOL injury (groups 2 and 3) was fair in both rounds of examination and the intraobserver reliability was moderate. The intra- and interobserver reliabilities of agreement for the 4 groups of injuries among the examiners were fair in both rounds of examination. The sensitivity, specificity, accuracy, positive, and negative predictive Values were all around 70%. The likelihood of a positive test corresponding with the presence of IOL rupture (positive likelihood ratio) was 2.2. The likelihood of a negative test correctly diagnosing an intact IOL was 0.40.
Conclusions In cadavers, intraoperative tests had fair reliability and 70% accuracy for the diagnosis of IOL rupture using the push-pull and lateral pull maneuvers. The level of experience did not have any effect on the correct diagnosis of intact versus disrupted IOL. Clinical relevance Although not common, some failure of surgeries for traumatic elbow fracture-dislocations is because of failure in timely diagnosis of IOL disruption. Copyright (C) 2015 by the American Society for Surgery of the Hand. All rights reserved.
C1 [Kachooei, Amir Reza; Faghfouri, Aram; Eberlin, Kyle R.; Ring, David] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Orthopaed Hand & Upper Extrem Serv, Boston, MA 02114 USA.
[Kachooei, Amir Reza] Mashhad Univ Med Sci, Orthoped Res Ctr, Mashhad, Iran.
[Rivlin, Michael] Thomas Jefferson Univ, Rothman Inst, Philadelphia, PA 19107 USA.
[Wu, Fei] Wuhan Univ, Renmin Hosp, Dept Orthoped Surg, Wuhan 430072, Peoples R China.
RP Ring, D (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Orthopaed Hand & Upper Extrem Serv,Yawkey Ctr, 55 Fruit St,Suite 2100, Boston, MA 02114 USA.
EM dring@mgh.harvard.edu
OI Ring, David/0000-0002-6506-4879
NR 12
TC 6
Z9 6
U1 0
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0363-5023
EI 1531-6564
J9 J HAND SURG-AM
JI J. Hand Surg.-Am. Vol.
PD SEP
PY 2015
VL 40
IS 9
BP 1785
EP 1790
DI 10.1016/j.jhsa.2015.06.004
PG 6
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA CR3ZG
UT WOS:000361271000008
PM 26231483
ER
PT J
AU Menendez, ME
Chen, NC
Mudgal, CS
Jupiter, JB
Ring, D
AF Menendez, Mariano E.
Chen, Neal C.
Mudgal, Chaitanya S.
Jupiter, Jesse B.
Ring, David
TI Physician Empathy as a Driver of Hand Surgery Patient Satisfaction
SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME
LA English
DT Article
DE Empathy; communication; patient satisfaction; health literacy;
reimbursement
ID PRIMARY-CARE PHYSICIANS; SHARED DECISION-MAKING; CARPAL-TUNNEL RELEASE;
HEALTH-CARE; EMERGENCY-DEPARTMENT; CONSUMER ASSESSMENT; CENTERED CARE;
HOSPITAL-CARE; ITEM BANK; LITERACY
AB Purpose To examine the relationship between patient-rated physician empathy and patient satisfaction after a single new hand surgery office visit.
Methods Directly after the office visit, 112 consecutive new patients rated their overall satisfaction with the provider and completed the Consultation and Relational Empathy Measure, the Newest Vital Sign health literacy test, a sociodemographic survey, and 3 Patient-Reported Outcomes Measurement Information System-based questionnaires: Pain Interference, Upper-Extremity Function, and Depression. We also measured the waiting time in the office to see the physician, the duration of the visit, and the time from booking until appointment. Multivariable logistic and linear regression models were used to identify factors independently associated with patient satisfaction.
Results Patient-rated physician empathy correlated strongly with the degree of overall satisfaction with the provider. After controlling for confounding effects, greater empathy was independently associated with patient satisfaction, and it alone accounted for 65% of the variation in satisfaction scores. Older patient age was also associated with satisfaction. There were no differences between satisfied and dissatisfied patients with regard to waiting time in the office, duration of the appointment, time from booking until appointment, and health literacy.
Conclusions Physician empathy was the strongest driver of patient satisfaction in the hand surgery office setting. As patient satisfaction plays a growing role in reimbursement, targeted educational programs to enhance empathic communication skills in hand surgeons merit consideration. Copyright (C) 2015 by the American Society for Surgery of the Hand. All rights reserved.
C1 [Menendez, Mariano E.; Chen, Neal C.; Mudgal, Chaitanya S.; Jupiter, Jesse B.; Ring, David] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Orthopaed Surg, Boston, MA USA.
RP Ring, D (reprint author), Massachusetts Gen Hosp, Dept Orthopaed Surg, Yawkey Ctr, 55 Fruit St,Suite 2100, Boston, MA 02114 USA.
EM dring@partners.org
OI Ring, David/0000-0002-6506-4879
NR 48
TC 7
Z9 7
U1 4
U2 12
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0363-5023
EI 1531-6564
J9 J HAND SURG-AM
JI J. Hand Surg.-Am. Vol.
PD SEP
PY 2015
VL 40
IS 9
BP 1860
EP 1865
DI 10.1016/j.jhsa.2015.06.105
PG 6
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA CR3ZG
UT WOS:000361271000019
PM 26231482
ER
PT J
AU Marjoua, Y
Eberlin, KR
Mudgal, CS
AF Marjoua, Youssra
Eberlin, Kyle R.
Mudgal, Chaitanya S.
TI Multiple Displaced Metacarpal Fractures
SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME
LA English
DT Editorial Material
ID FIXATION; HAND
C1 [Marjoua, Youssra; Eberlin, Kyle R.; Mudgal, Chaitanya S.] Massachusetts Gen Hosp, Hand Surg Serv, Boston, MA 02114 USA.
RP Mudgal, CS (reprint author), Massachusetts Gen Hosp, Hand & Upper Extrem Serv, 55 Fruit St, Boston, MA 02114 USA.
EM cmudgal@partners.org
NR 13
TC 1
Z9 1
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0363-5023
EI 1531-6564
J9 J HAND SURG-AM
JI J. Hand Surg.-Am. Vol.
PD SEP
PY 2015
VL 40
IS 9
BP 1869
EP 1870
DI 10.1016/j.jhsa.2015.04.032
PG 2
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA CR3ZG
UT WOS:000361271000023
PM 26096220
ER
PT J
AU Ivers, LC
Charles, RC
Hilaire, IJ
Mayo-Smith, LM
Teng, JE
Jerome, JG
Rychert, J
LaRocque, RC
Xu, P
Kovac, P
Ryan, ET
Qadri, F
Almazor, CP
Franke, MF
Harris, JB
AF Ivers, Louise C.
Charles, Richelle C.
Hilaire, Isabelle J.
Mayo-Smith, Leslie M.
Teng, Jessica E.
Jerome, J. Gregory
Rychert, Jenna
LaRocque, Regina C.
Xu, Peng
Kovac, Pavol
Ryan, Edward T.
Qadri, Firdausi
Almazor, Charles P.
Franke, Molly F.
Harris, Jason B.
TI Immunogenicity of the Bivalent Oral Cholera Vaccine Shanchol in Haitian
Adults With HIV Infection
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Cholera vaccine; HIV; Shanchol (BivWC); immunogenicity
ID PNEUMOCOCCAL DISEASE; MOZAMBIQUE; CHILDREN; O1
AB We evaluated immune responses following bivalent oral cholera vaccination (Shanchol [Shantha Biotechnics]; BivWC) in a cohort of 25 human immunodeficiency virus (HIV)-infected adults in Haiti. Compared with adults without HIV infection, vaccination in HIV-infected individuals resulted in lower vibriocidal responses against Vibrio cholerae O1, and there was a positive relationship between the CD4(+) T-cell count and vibriocidal responses following vaccination. Nevertheless, seroconversion occurred at a rate of 65% against the Ogawa serotype and 74% against the Inaba serotype in adults with HIV infection. These results suggest that the vaccine retains substantial immunogenicity in adults with HIV infection and may benefit this population by protecting against cholera.
C1 [Ivers, Louise C.; Teng, Jessica E.] Brigham & Womens Hosp, Div Global Hlth Equ, Boston, MA 02115 USA.
[Ivers, Louise C.; Franke, Molly F.] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Boston, MA USA.
[Charles, Richelle C.; LaRocque, Regina C.; Ryan, Edward T.; Harris, Jason B.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Harris, Jason B.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Ivers, Louise C.; Hilaire, Isabelle J.; Teng, Jessica E.; Jerome, J. Gregory; Almazor, Charles P.; Franke, Molly F.] Massachusetts Gen Hosp, Partners Hlth, Boston, MA 02114 USA.
[Charles, Richelle C.; Mayo-Smith, Leslie M.; Rychert, Jenna; LaRocque, Regina C.; Ryan, Edward T.; Harris, Jason B.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
[Xu, Peng; Kovac, Pavol] NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA.
[Qadri, Firdausi] Int Ctr Diarrhoeal Dis Res, Dhaka, Bangladesh.
RP Harris, JB (reprint author), Massachusetts Gen Hosp, Div Infect Dis, GRJ 504,55 Fruit St, Boston, MA 02114 USA.
EM jbharris@mgh.harvard.edu
RI Xu, Peng/K-7036-2012
FU National Institute of Allergy and Infectious Diseases, National
Institutes of Health (NIH) [R01 AI099243, R01 AI106878, U01 AI AI058935,
R01 AI10355]; NIH [K08 AI089721]; Massachusetts General Hospital
FX This work was supported by the National Institute of Allergy and
Infectious Diseases, National Institutes of Health (NIH; R01 AI099243 to
J. B. H. and L. C. I.; R01 AI106878 to E. T. R., P. K., and F. Q.; U01
AI AI058935 to E. T. R. and F. Q.; and R01 AI10355); an NIH Career
Development Award (K08 AI089721 to R. C. C.); and Massachusetts General
Hospital (Massachusetts General Hospital physician scientist development
award to R. C. C.).
NR 12
TC 1
Z9 1
U1 1
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD SEP 1
PY 2015
VL 212
IS 5
BP 779
EP 783
DI 10.1093/infdis/jiv108
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA CR4EO
UT WOS:000361284800014
PM 25722294
ER
PT J
AU Scherrer-Crosbie, M
AF Scherrer-Crosbie, Marielle
TI Losartan: A new treatment for cardiac cachexia?
SO JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
LA English
DT Editorial Material
ID GROWTH-FACTOR-I; ANGIOTENSIN-II; CANCER CACHEXIA; PROSTATE-CANCER;
HEART-FAILURE; PATHWAY; RISK
C1 Massachusetts Gen Hosp, Div Cardiol, Cardiac Ultrasound Lab, Boston, MA 02114 USA.
RP Scherrer-Crosbie, M (reprint author), Massachusetts Gen Hosp, Div Cardiol, Cardiac Ultrasound Lab, Blake 254,55 Fruit St, Boston, MA 02114 USA.
EM marielle@crosbie.com
NR 21
TC 0
Z9 0
U1 2
U2 9
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2828
EI 1095-8584
J9 J MOL CELL CARDIOL
JI J. Mol. Cell. Cardiol.
PD SEP
PY 2015
VL 86
BP 12
EP 13
DI 10.1016/j.yjmcc.2015.06.018
PG 2
WC Cardiac & Cardiovascular Systems; Cell Biology
SC Cardiovascular System & Cardiology; Cell Biology
GA CR5YA
UT WOS:000361419100003
PM 26141529
ER
PT J
AU Billmire, DF
Rescorla, FJ
Ross, JH
Schlatter, MG
Dicken, BJ
Krailo, MD
Rodriguez-Galindo, C
Olson, TA
Cullen, JW
Frazier, AL
AF Billmire, Deborah F.
Rescorla, Frederick J.
Ross, Jonathan H.
Schlatter, Marc G.
Dicken, Bryan J.
Krailo, Mark D.
Rodriguez-Galindo, Carlos
Olson, Thomas A.
Cullen, John W.
Frazier, A. Lindsay
TI Impact of central surgical reviewin a study of malignant germcell tumors
SO JOURNAL OF PEDIATRIC SURGERY
LA English
DT Article
DE Malignant germ cell tumors; Surgical quality; Surgical clinical trials
ID NATIONAL WILMS-TUMOR; PEDIATRIC-ONCOLOGY-GROUP; CELL TUMORS; OVARY
AB Background: Verification of surgical staging has received little attention in clinical oncology trials. Central surgical review was undertaken during a study of malignant pediatric germ cell tumors.
Methods: Children's Oncology Group study AGCT0132 included central surgical review during the study. Completeness of submitted data and confirmation of assigned stage were assessed. Review responses were: assigned status confirmed, assignment withheld pending review of additional information requested, or institutional assignment of stage disputed with explanation given. Changes in stage assignment were at the discretion of the enrolling institution.
Results: A total of 206 patients underwent central review. Failure to submit required data elements or need for clarification was noted in 40%. Disagreement with stage assignment occurred in 10% with 17/21 discordant patients reassigned to stage recommended by central review. Four ovarian tumor patients not meeting review criteria for Stage I remained in that stratum by institutional decision. Two-year event free survival in Stage I ovarian patients was 25% for discordant patients compared to 57% for those meeting Stage I criteria by central review.
Conclusions: Central review of stage assignment improved complete data collection and assignment of correct tumor stage at study entry, and allowed for prompt initiation of chemotherapy in patients determined not to have Stage I disease. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Billmire, Deborah F.; Rescorla, Frederick J.] Indiana Univ Sch Med, Dept Surg, Riley Hosp Children, Indianapolis, IN 46202 USA.
[Ross, Jonathan H.] Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Div Urol, Cleveland, OH 44106 USA.
[Schlatter, Marc G.] Spectrum Hlth, Helen DeVos Childrens Hosp, Grand Rapids, MI USA.
[Dicken, Bryan J.] Univ Alberta, Dept Surg, Stollery Childrens Hosp, Edmunton, AB, Canada.
[Krailo, Mark D.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
[Rodriguez-Galindo, Carlos; Frazier, A. Lindsay] Boston Childrens Hosp, Dana Farber Canc Inst, Boston, MA USA.
[Olson, Thomas A.] Emory Univ, Sch Med, Childrens Healthcare Atlanta, Aflac Canc & Blood Disorders Ctr, Atlanta, GA USA.
[Cullen, John W.] Rocky Mt Hosp Children, Presbyterian St Lukes Med, Denver, CO USA.
RP Billmire, DF (reprint author), Indiana Univ, Div Pediat Surg, Dept Surg, Riley Hosp Children, 705 Riley Hosp Dr,Suite 2500, Indianapolis, IN 46202 USA.
EM dbillmir@iupui.edu
FU NCI NIH HHS [U10 CA098413, U10 CA098543, U10 CA180886, U10 CA180899]
NR 12
TC 1
Z9 1
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0022-3468
EI 1531-5037
J9 J PEDIATR SURG
JI J. Pediatr. Surg.
PD SEP
PY 2015
VL 50
IS 9
BP 1502
EP 1505
DI 10.1016/j.jpedsurg.2014.12.008
PG 4
WC Pediatrics; Surgery
SC Pediatrics; Surgery
GA CR7AK
UT WOS:000361499500012
PM 25783295
ER
PT J
AU Meng, F
Morioka, C
AF Meng, Frank
Morioka, Craig
TI Automating the generation of lexical patterns for processing free text
in clinical documents
SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION
LA English
DT Article
DE information extraction; natural language processing; text mining
ID INFORMATION EXTRACTION; SYSTEM; EXPRESSIONS; NARRATIVES; CRITERIA; RULES
AB Objective Many tasks in natural language processing utilize lexical pattern-matching techniques, including information extraction (IE), negation identification, and syntactic parsing. However, it is generally difficult to derive patterns that achieve acceptable levels of recall while also remaining highly precise.
Materials and Methods We present a multiple sequence alignment (MSA)-based technique that automatically generates patterns, thereby leveraging language usage to determine the context of words that influence a given target. MSAs capture the commonalities among word sequences and are able to reveal areas of linguistic stability and variation. In this way, MSAs provide a systemic approach to generating lexical patterns that are generalizable, which will both increase recall levels and maintain high levels of precision.
Results The MSA-generated patterns exhibited consistent F1-, F.5-, and F2- scores compared to two baseline techniques for IE across four different tasks. Both baseline techniques performed well for some tasks and less well for others, but MSA was found to consistently perform at a high level for all four tasks.
Discussion The performance of MSA on the four extraction tasks indicates the method's versatility. The results show that the MSA-based patterns are able to handle the extraction of individual data elements as well as relations between two concepts without the need for large amounts of manual intervention.
Conclusion We presented an MSA-based framework for generating lexical patterns that showed consistently high levels of both performance and recall over four different extraction tasks when compared to baseline methods.
C1 [Meng, Frank; Morioka, Craig] Univ Calif Los Angeles, Dept Radiol Sci, Med Imaging Informat Grp, Los Angeles, CA 90024 USA.
[Meng, Frank] VA Boston Healthcare Syst, MAVERIC, Boston, MA USA.
[Morioka, Craig] VA Greater Los Angeles Healthcare Syst, Dept Radiol, Los Angeles, CA USA.
RP Meng, F (reprint author), 924 Westwood Blvd,Ste 420, Los Angeles, CA 90024 USA.
EM fmeng@mii.ucla.edu
FU National Institutes of Health (National Cancer Institute) [R01
CA1575533]; National Institutes of Health (National Institute of
Neurological Disorders and Stroke) [R01 NS076534]; National Institutes
of Health (National Library of Medicine) [R01 LM011333]
FX This work was supported by the following National Institutes of Health
grants: R01 CA1575533 (National Cancer Institute), R01 NS076534
(National Institute of Neurological Disorders and Stroke), and R01
LM011333 (National Library of Medicine).
NR 38
TC 0
Z9 0
U1 3
U2 12
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1067-5027
EI 1527-974X
J9 J AM MED INFORM ASSN
JI J. Am. Med. Inf. Assoc.
PD SEP
PY 2015
VL 22
IS 5
BP 980
EP 986
DI 10.1093/jamia/ocv012
PG 7
WC Computer Science, Information Systems; Computer Science,
Interdisciplinary Applications; Health Care Sciences & Services;
Information Science & Library Science; Medical Informatics
SC Computer Science; Health Care Sciences & Services; Information Science &
Library Science; Medical Informatics
GA CR4DS
UT WOS:000361282600007
PM 25977405
ER
PT J
AU Yu, S
Liao, KP
Shaw, SY
Gainer, VS
Churchill, SE
Szolovits, P
Murphy, SN
Kohane, IS
Cai, TX
AF Yu, Sheng
Liao, Katherine P.
Shaw, Stanley Y.
Gainer, Vivian S.
Churchill, Susanne E.
Szolovits, Peter
Murphy, Shawn N.
Kohane, Isaac S.
Cai, Tianxi
TI Toward high-throughput phenotyping: unbiased automated feature
extraction and selection from knowledge sources
SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION
LA English
DT Article
ID ELECTRONIC MEDICAL-RECORDS; RHEUMATOID-ARTHRITIS; HEALTH RECORDS; EMERGE
NETWORK; PHENOME-WIDE; RETROSPECTIVE ANALYSIS; ELASTIC-NET; RISK;
DISEASE; MORTALITY
AB Objective Analysis of narrative (text) data from electronic health records (EHRs) can improve population-scale phenotyping for clinical and genetic research. Currently, selection of text features for phenotyping algorithms is slow and laborious, requiring extensive and iterative involvement by domain experts. This paper introduces a method to develop phenotyping algorithms in an unbiased manner by automatically extracting and selecting informative features, which can be comparable to expert-curated ones in classification accuracy.
Materials and methods Comprehensive medical concepts were collected from publicly available knowledge sources in an automated, unbiased fashion. Natural language processing (NLP) revealed the occurrence patterns of these concepts in EHR narrative notes, which enabled selection of informative features for phenotype classification. When combined with additional codified features, a penalized logistic regression model was trained to classify the target phenotype.
Results The authors applied our method to develop algorithms to identify patients with rheumatoid arthritis and coronary artery disease cases among those with rheumatoid arthritis from a large multi-institutional EHR. The area under the receiver operating characteristic curves (AUC) for classifying RA and CAD using models trained with automated features were 0.951 and 0.929, respectively, compared to the AUCs of 0.938 and 0.929 by models trained with expert-curated features.
Discussion Models trained with NLP text features selected through an unbiased, automated procedure achieved comparable or slightly higher accuracy than those trained with expert-curated features. The majority of the selected model features were interpretable.
Conclusion The proposed automated feature extraction method, generating highly accurate phenotyping algorithms with improved efficiency, is a significant step toward high-throughput phenotyping.
C1 [Yu, Sheng] Partners Hlth Care Personalized Med, Boston, MA 02139 USA.
[Yu, Sheng; Liao, Katherine P.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Yu, Sheng; Liao, Katherine P.; Kohane, Isaac S.] Harvard Univ, Sch Med, Boston, MA USA.
[Shaw, Stanley Y.; Murphy, Shawn N.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Gainer, Vivian S.; Churchill, Susanne E.; Murphy, Shawn N.] Partners Hlth Care, Res Comp, Charlestown, MA USA.
[Szolovits, Peter] MIT, Cambridge, MA 02139 USA.
[Kohane, Isaac S.] Boston Childrens Hosp, Boston, MA USA.
[Cai, Tianxi] Harvard TH Chan Sch Publ Hlth, Boston, MA USA.
RP Yu, S (reprint author), Partners Hlth Care Personalized Med, Boston, MA 02139 USA.
EM syu7@partners.org
OI Szolovits, Peter/0000-0001-8411-6403; Yu, Sheng/0000-0002-6347-0507
FU NIH [U54-H6007963, U54-LM008748, R01-GM079330, AR-060257]; Harold and
Duval Bowen Fund; Partners HealthCare
FX This work was supported by NIH grants U54-H6007963, U54-LM008748,
R01-GM079330, and AR-060257, as well as Harold and Duval Bowen Fund and
internal funds from Partners HealthCare.
NR 57
TC 9
Z9 9
U1 3
U2 14
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1067-5027
EI 1527-974X
J9 J AM MED INFORM ASSN
JI J. Am. Med. Inf. Assoc.
PD SEP
PY 2015
VL 22
IS 5
BP 993
EP 1000
DI 10.1093/jamia/ocv034
PG 8
WC Computer Science, Information Systems; Computer Science,
Interdisciplinary Applications; Health Care Sciences & Services;
Information Science & Library Science; Medical Informatics
SC Computer Science; Health Care Sciences & Services; Information Science &
Library Science; Medical Informatics
GA CR4DS
UT WOS:000361282600009
PM 25929596
ER
PT J
AU Luo, Y
Xin, Y
Hochberg, E
Joshi, R
Uzuner, O
Szolovits, P
AF Luo, Yuan
Xin, Yu
Hochberg, Ephraim
Joshi, Rohit
Uzuner, Ozlem
Szolovits, Peter
TI Subgraph augmented non-negative tensor factorization (SANTF) for
modeling clinical narrative text
SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION
LA English
DT Article
DE non-negative tensor factorization; unsupervised learning; subgraph
mining; natural language processing
ID 3-MODE FACTOR-ANALYSIS; MATRIX FACTORIZATION; PATTERN DISCOVERY;
MICROARRAY DATA; MUTATIONS; CANCER
AB Objective Extracting medical knowledge from electronic medical records requires automated approaches to combat scalability limitations and selection biases. However, existing machine learning approaches are often regarded by clinicians as black boxes. Moreover, training data for these automated approaches at often sparsely annotated at best. The authors target unsupervised learning for modeling clinical narrative text, aiming at improving both accuracy and interpretability.
Methods The authors introduce a novel framework named subgraph augmented non-negative tensor factorization (SANTF). In addition to relying on atomic features (e.g., words in clinical narrative text), SANTF automatically mines higher-order features (e.g., relations of lymphoid cells expressing antigens) from clinical narrative text by converting sentences into a graph representation and identifying important subgraphs. The authors compose a tensor using patients, higher-order features, and atomic features as its respective modes. We then apply non-negative tensor factorization to cluster patients, and simultaneously identify latent groups of higher-order features that link to patient clusters, as in clinical guidelines where a panel of immunophenotypic features and laboratory results are used to specify diagnostic criteria.
Results and Conclusion SANTF demonstrated over 10% improvement in averaged F-measure on patient clustering compared to widely used non-negative matrix factorization (NMF) and k-means clustering methods. Multiple baselines were established by modeling patient data using patient-by-features matrices with different feature configurations and then performing NMF or k-means to cluster patients. Feature analysis identified latent groups of higher-order features that lead to medical insights. We also found that the latent groups of atomic features help to better correlate the latent groups of higher-order features.
C1 [Luo, Yuan; Xin, Yu; Joshi, Rohit; Szolovits, Peter] MIT, Comp Sci & Artificial Intelligence Lab, Cambridge, MA 02139 USA.
[Hochberg, Ephraim] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Lymphoma, Cambridge, MA 02138 USA.
[Hochberg, Ephraim] Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA.
[Uzuner, Ozlem] SUNY Albany, Dept Informat Studies, Albany, NY 12222 USA.
RP Luo, Y (reprint author), MIT, Comp Sci & Artificial Intelligence Lab, Cambridge, MA 02139 USA.
EM yuanluo@mit.edu
OI Szolovits, Peter/0000-0001-8411-6403
FU National Library of Medicine [U54LM008748]; Scullen Center for Cancer
Data Analysis
FX The work described was supported in part by Grant Number U54LM008748
from the National Library of Medicine and by the Scullen Center for
Cancer Data Analysis.
NR 50
TC 4
Z9 4
U1 3
U2 12
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1067-5027
EI 1527-974X
J9 J AM MED INFORM ASSN
JI J. Am. Med. Inf. Assoc.
PD SEP
PY 2015
VL 22
IS 5
BP 1009
EP 1019
DI 10.1093/jamia/ocv016
PG 11
WC Computer Science, Information Systems; Computer Science,
Interdisciplinary Applications; Health Care Sciences & Services;
Information Science & Library Science; Medical Informatics
SC Computer Science; Health Care Sciences & Services; Information Science &
Library Science; Medical Informatics
GA CR4DS
UT WOS:000361282600011
PM 25862765
ER
PT J
AU Manchikanti, L
Benyamin, R
Kaye, AD
Hirsch, JA
AF Manchikanti, Laxmaiah
Benyamin, Ramsin
Kaye, Alan David
Hirsch, Joshua A.
TI RE: Efficacy of Cervical Intelaminar Epidural Steroid Injections
SO KOREAN JOURNAL OF RADIOLOGY
LA English
DT Letter
DE Cervical; Epidural; Radiculopathy
C1 [Manchikanti, Laxmaiah] Univ Louisville, Dept Anesthesiol & Perioperat Med, Louisville, KY 40292 USA.
[Manchikanti, Laxmaiah] Pain Management Ctr Paducah, Paducah, KY 42003 USA.
[Benyamin, Ramsin] Millennium Pain Ctr, Bloomington, IL USA.
[Benyamin, Ramsin] Univ Illinois, Dept Surg, Coll Med, Urbana, IL 61701 USA.
[Kaye, Alan David] LSU Hlth Sci Ctr, Dept Anesthesia, New Orleans, LA 70112 USA.
[Hirsch, Joshua A.] Harvard Univ, Massachusetts Gen Hosp, NeuroIntervent Spine Serv,Intervent Care, Dept Radiol,Med Sch, Boston, MA 02114 USA.
RP Manchikanti, L (reprint author), Univ Louisville, Dept Anesthesiol & Perioperat Med, Louisville, KY 40292 USA.
EM drlm@thepainmd.com
NR 4
TC 0
Z9 0
U1 0
U2 2
PU KOREAN RADIOLOGICAL SOC
PI SEOUL
PA 121-8 YANGJAE-DONG, SEOCHO-GU, SEOUL 137-130, SOUTH KOREA
SN 1229-6929
EI 2005-8330
J9 KOREAN J RADIOL
JI Korean J. Radiol.
PD SEP-OCT
PY 2015
VL 16
IS 5
BP 1171
EP 1171
DI 10.3348/kjr.2015.16.5.1171
PG 1
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CR7BX
UT WOS:000361504000025
PM 26357508
ER
PT J
AU Jeong, D
Kim, J
Nam, J
Sun, H
Lee, YH
Lee, TJ
Aguiar, RCT
Kim, SW
AF Jeong, D.
Kim, J.
Nam, J.
Sun, H.
Lee, Y-H
Lee, T-J
Aguiar, R. C. T.
Kim, S-W
TI MicroRNA-124 links p53 to the NF-kappa B pathway in B-cell lymphomas
SO LEUKEMIA
LA English
DT Article
ID RITUXIMAB PLUS CYCLOPHOSPHAMIDE; PHOSPHODIESTERASE 4B; CANCER; MYC;
EXPRESSION; NETWORK; PATHOGENESIS; VINCRISTINE; DOXORUBICIN; PREDNISONE
AB The contribution of microRNAs to lymphoma biology is not fully understood. In particular, it remains untested whether microRNA dysregulation could contribute to the emergence of the aggressive subset of B-cell lymphomas that coexpress MYC and BCL2. Here, we identify microRNA-124 (miR-124) as a negative regulator of MYC and BCL2 expression in B-cell lymphomas. Concordantly, stable or transient ectopic expression of miR-124 suppressed cell proliferation and survival, whereas genetic inhibition of this miRNA enhanced the fitness of these tumors. Mechanistically, the activities of miR-124 towards MYC and BCL2 intersect with both oncogenic and tumor-suppressive pathways. In respect to the former, we show that miR-124 directly targets nuclear factor-kappa B (NF-kappa B) p65, and using genetic approaches, we demonstrate that this interaction accounts for the miR-124-mediated suppression of MYC and BCL2. We also characterized miR-124 promoter region and identified a functional p53 binding site. In agreement with this finding, endogenous or ectopic expression of wild-type, but not mutant, p53 increased miR-124 levels and suppressed p65, MYC and BCL2. Our data unveil an miRNA-dependent regulatory circuitry that links p53 to the NF-kappa B pathway, which when disrupted in B-cell lymphoma may be associated with aberrant coexpression of MYC and BCL2 and poor prognosis.
C1 [Jeong, D.; Kim, J.; Nam, J.; Kim, S-W] Pusan Natl Univ, Dept Biol Sci, Pusan 609735, South Korea.
[Sun, H.] Pusan Natl Univ, Dept Stat, Pusan 609735, South Korea.
[Lee, Y-H] Yonsei Univ, Dept Radiat Oncol, Seoul 120749, South Korea.
[Lee, T-J] Yeungnam Univ, Dept Anat, Daegu, South Korea.
[Aguiar, R. C. T.] Univ Texas Hlth Sci Ctr San Antonio, Div Hematol & Med Oncol, Dept Med, San Antonio, TX 78229 USA.
[Aguiar, R. C. T.] Audie Murphy VA Hosp, South Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Kim, SW (reprint author), Pusan Natl Univ, Dept Biol Sci, 63 Beon Gil 2, Pusan 609735, South Korea.
EM kimsw@pusan.ac.kr
FU Basic Science Research Program through the National Research Foundation
of Korea (NRF) - Ministry of Education, Science and Technology
[2013R1A1A2008838]; NCI/NIH [R01-CA138747]; Veterans Administration
Merit Award [I01-BX001882]
FX We thank Dr Kyung Lib Jang (Pusan National University) for the WT and
MUT (R248Q) p53 constructs. This work was supported by Basic Science
Research Program through the National Research Foundation of Korea (NRF)
funded by the Ministry of Education, Science and Technology
(2013R1A1A2008838) to S-WK and RCTA was funded by NCI/NIH R01-CA138747
and Veterans Administration Merit Award (I01-BX001882).
NR 28
TC 5
Z9 7
U1 1
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887-6924
EI 1476-5551
J9 LEUKEMIA
JI Leukemia
PD SEP
PY 2015
VL 29
IS 9
BP 1868
EP 1874
DI 10.1038/leu.2015.101
PG 7
WC Oncology; Hematology
SC Oncology; Hematology
GA CQ9MA
UT WOS:000360937800008
PM 25915824
ER
PT J
AU Kikuchi, S
Suzuki, R
Ohguchi, H
Yoshida, Y
Lu, D
Cottini, F
Jakubikova, J
Bianchi, G
Harada, T
Gorgun, G
Tai, YT
Richardson, PG
Hideshima, T
Anderson, KC
AF Kikuchi, S.
Suzuki, R.
Ohguchi, H.
Yoshida, Y.
Lu, D.
Cottini, F.
Jakubikova, J.
Bianchi, G.
Harada, T.
Gorgun, G.
Tai, Y-T
Richardson, P. G.
Hideshima, T.
Anderson, K. C.
TI Class IIa HDAC inhibition enhances ER stress-mediated cell death in
multiple myeloma
SO LEUKEMIA
LA English
DT Article
ID UNFOLDED PROTEIN RESPONSE; TRANSCRIPTION FACTOR XBP-1; HISTONE
DEACETYLASES; TRANSLATION INITIATION; ENDOPLASMIC-RETICULUM; OXIDATIVE
STRESS; GENE-EXPRESSION; BORTEZOMIB; APOPTOSIS; COMBINATION
AB Histone deacetylase (HDAC) inhibitors have been extensively investigated as therapeutic agents in cancer. However, the biological role of class IIa HDACs (HDAC4, 5, 7 and 9) in cancer cells, including multiple myeloma (MM), remains unclear. Recent studies show HDAC4 interacts with activating transcription factor 4 (ATF4) and inhibits activation of endoplasmic reticulum (ER) stress-associated proapoptotic transcription factor C/EBP homologous protein (CHOP). In this study, we hypothesized that HDAC4 knockdown and/or inhibition could enhance apoptosis in MM cells under ER stress condition by upregulating ATF4, followed by CHOP. HDAC4 knockdown showed modest cell growth inhibition; however, it markedly enhanced cytotoxicity induced by either tunicamycin or carfilzomib (CFZ), associated with upregulating ATF4 and CHOP. For pharmacological inhibition of HDAC4, we employed a novel and selective class IIa HDAC inhibitor TMP269, alone and in combination with CFZ. As with HDAC4 knockdown, TMP269 significantly enhanced cytotoxicity induced by CFZ in MM cell lines, upregulating ATF4 and CHOP and inducing apoptosis. Conversely, enhanced cytotoxicity was abrogated by ATF4 knockdown, confirming that ATF4 has a pivotal role mediating cytotoxicity in this setting. These results provide the rationale for novel treatment strategies combining class IIa HDAC inhibitors with ER stressors, including proteasome inhibitors, to improve patient outcome in MM.
C1 [Kikuchi, S.; Suzuki, R.; Ohguchi, H.; Yoshida, Y.; Lu, D.; Cottini, F.; Jakubikova, J.; Bianchi, G.; Harada, T.; Gorgun, G.; Tai, Y-T; Richardson, P. G.; Hideshima, T.; Anderson, K. C.] Harvard Univ, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Dana Farber Canc Inst,Med Sch, Boston, MA 02215 USA.
RP Anderson, KC (reprint author), Harvard Univ, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Dana Farber Canc Inst,Med Sch, 450 Brookline Ave,Mayer 557, Boston, MA 02215 USA.
EM kenneth_anderson@dfci.harvard.edu
FU ITO Foundation for the Promotion of Medical Science; National Institutes
of Health [RO-1 CA 178264]
FX This study was supported by ITO Foundation for the Promotion of Medical
Science (to SK) and the National Institutes of Health (RO-1 CA 178264).
KCA is an American Cancer Society Clinical Research Professor.
NR 43
TC 10
Z9 10
U1 0
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887-6924
EI 1476-5551
J9 LEUKEMIA
JI Leukemia
PD SEP
PY 2015
VL 29
IS 9
BP 1918
EP 1927
DI 10.1038/leu.2015.83
PG 10
WC Oncology; Hematology
SC Oncology; Hematology
GA CQ9MA
UT WOS:000360937800014
PM 25801913
ER
PT J
AU Dahlberg, A
Woo, S
Delaney, C
Boyle, P
Gnirke, A
Bock, C
Bernstein, BE
Meissner, A
Gottardo, R
Bernstein, ID
AF Dahlberg, A.
Woo, S.
Delaney, C.
Boyle, P.
Gnirke, A.
Bock, C.
Bernstein, B. E.
Meissner, A.
Gottardo, R.
Bernstein, I. D.
TI Notch-mediated expansion of cord blood progenitors: maintenance of
transcriptional and epigenetic fidelity
SO LEUKEMIA
LA English
DT Letter
ID LARGE GENE LISTS; BIOINFORMATICS; METHYLATION; PLURIPOTENT; CELLS;
CANCER; BEX2; MAPS
C1 [Dahlberg, A.; Delaney, C.; Bernstein, I. D.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Pediat Oncol, Seattle, WA 98104 USA.
[Dahlberg, A.; Delaney, C.; Bernstein, I. D.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA.
[Woo, S.; Gottardo, R.] Fred Hutchinson Canc Res Ctr, PS Stat Vaccine & Infect Dis Div, Seattle, WA 98104 USA.
[Boyle, P.; Gnirke, A.; Bock, C.; Bernstein, B. E.; Meissner, A.] Broad Inst MIT & Harvard, Cambridge, MA USA.
[Bernstein, B. E.] Howard Hughes Med Inst, Chevy Chase, MD USA.
[Bernstein, B. E.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Bernstein, B. E.] Harvard Univ, Sch Med, Boston, MA USA.
RP Dahlberg, A (reprint author), Fred Hutchinson Canc Res Ctr, Div Clin Res, Pediat Oncol, 1124 Columbia St, Seattle, WA 98104 USA.
EM ibernste@fhcrc.org
OI Bock, Christoph/0000-0001-6091-3088
FU NCI NIH HHS [K12CA076930, K12 CA076930, T32CA009351, P30 CA015704, T32
CA009351]; NHLBI NIH HHS [U01 HL100395, U01HL100395]
NR 13
TC 2
Z9 2
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887-6924
EI 1476-5551
J9 LEUKEMIA
JI Leukemia
PD SEP
PY 2015
VL 29
IS 9
BP 1948
EP 1951
DI 10.1038/leu.2015.61
PG 5
WC Oncology; Hematology
SC Oncology; Hematology
GA CQ9MA
UT WOS:000360937800019
PM 25742749
ER
PT J
AU Ahlfors, SP
Wreh, C
AF Ahlfors, Seppo P.
Wreh, Christopher, II
TI Modeling the effect of dendritic input location on MEG and EEG source
dipoles
SO MEDICAL & BIOLOGICAL ENGINEERING & COMPUTING
LA English
DT Article
DE Magnetoencephalography; Electroencephalography; Postsynaptic current;
Pyramidal cells
ID NEOCORTICAL NEURONS; EXTRASTRIATE CORTEX; CEREBRAL-CORTEX;
MAGNETOENCEPHALOGRAPHY; POTENTIALS; CURRENTS; SIGNALS;
ELECTROENCEPHALOGRAPHY; ORIGINS; CANCELLATION
AB The cerebral sources of magneto- and electroencephalography (MEG, EEG) signals can be represented by current dipoles. We used computational modeling of realistically shaped passive-membrane dendritic trees of pyramidal cells from the human cerebral cortex to examine how the spatial distribution of the synaptic inputs affects the current dipole. The magnitude of the total dipole moment vector was found to be proportional to the vertical location of the synaptic input. The dipole moment had opposite directions for inputs above and below a reversal point located near the soma. Inclusion of shunting-type inhibition either suppressed or enhanced the current dipole, depending on whether the excitatory and inhibitory synapses were on the same or opposite side of the reversal point. Relating the properties of the macroscopic current dipoles to dendritic current distributions can help to provide means for interpreting MEG and EEG data in terms of synaptic connection patterns within cortical areas.
C1 [Ahlfors, Seppo P.; Wreh, Christopher, II] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Athinoula A Martinos Ctr Biomed Imaging, Cambridge, MA 02135 USA.
[Ahlfors, Seppo P.] Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02135 USA.
RP Ahlfors, SP (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Athinoula A Martinos Ctr Biomed Imaging, Cambridge, MA 02135 USA.
EM seppo@nmr.mgh.harvard.edu
RI Ahlfors, Seppo/P-3644-2016
FU National Institutes of Health [NS57500, NS037462]; National Center for
Research Resources [P41RR14075]
FX This work was supported by National Institutes of Health Grants NS57500
and NS037462, and by The National Center for Research Resources
(P41RR14075).
NR 71
TC 1
Z9 1
U1 0
U2 5
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0140-0118
EI 1741-0444
J9 MED BIOL ENG COMPUT
JI Med. Biol. Eng. Comput.
PD SEP
PY 2015
VL 53
IS 9
BP 879
EP 887
DI 10.1007/s11517-015-1296-5
PG 9
WC Computer Science, Interdisciplinary Applications; Engineering,
Biomedical; Mathematical & Computational Biology; Medical Informatics
SC Computer Science; Engineering; Mathematical & Computational Biology;
Medical Informatics
GA CR6XO
UT WOS:000361491900010
PM 25863693
ER
PT J
AU Stein, BD
Pacula, RL
Gordon, AJ
Burns, RM
Leslie, DL
Sorbero, MJ
Bauhoff, S
Mandell, TW
Dick, AW
AF Stein, Bradley D.
Pacula, Rosalie Liccardo
Gordon, Adam J.
Burns, Rachel M.
Leslie, Douglas L.
Sorbero, Mark J.
Bauhoff, Sebastian
Mandell, Todd W.
Dick, Andrew W.
TI Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role
of Private Offices, Opioid Treatment Programs, and Substance Abuse
Treatment Facilities in Urban and Rural Counties
SO MILBANK QUARTERLY
LA English
DT Article
DE opioid-related disorders; health policy; substance abuse treatment;
buprenorphine
ID CLINICAL-TRIALS NETWORK; 1ST 3 YEARS; MAINTENANCE THERAPY;
METHADONE-MAINTENANCE; DEPENDENT PATIENTS; AGONIST TREATMENT; OPIATE
ADDICTION; UNITED-STATES; NALOXONE; PHYSICIANS
AB Context: Opioid use disorders are a significant public health problem. In 2002, the FDA approved buprenorphine as an opioid use disorder treatment when prescribed by waivered physicians who were limited to treating 30 patients at a time. In 2006, federal legislation raised this number to 100 patients. Although federal legislators are considering increasing these limits further and expanding prescribing privileges to nonphysicians, little information is available regarding the impact of such changes on buprenorphine use. We therefore examined the impact of the 2006 legislation- as well as the association between urban and rural waivered physicians, opioid treatment programs, and substance abuse treatment facilities- on buprenorphine distributed per capita over the past decade. Methods: Using 2004- 2011 state- level data on buprenorphine dispensed and county- level data on the number of buprenorphine- waivered physicians and substance abuse treatment facilities using buprenorphine, we estimated a multivariate ordinary least squares regression model with state fixed effects of a state's annual total buprenorphine dispensed per capita as a function of the state's number of buprenorphine providers. Findings: The amount of buprenorphine dispensed has been increasing at a greater rate than the number of buprenorphine providers. The number of physicians waivered to treat 100 patients with buprenorphine in both rural and urban settings was significantly associated with increased amounts of buprenorphine dispensed per capita. There was no significant association in the growth of buprenorphine distributed and the number of physicians with 30- patient waivers. Conclusions: The greater amounts of buprenorphine dispensed are consistent with the potentially greater use of opioid agonists for opioid use disorder treatment, though they also make their misuse more likely. The changes after the 2006 legislation suggest that policies focused on increasing the number of patients that a single waivered physician could safely and effectively treat could bemore effective in increasing buprenorphine use than would alternatives such as opening new substance abuse treatment facilities or raising the overall number of waivered physicians.
C1 [Stein, Bradley D.; Pacula, Rosalie Liccardo; Burns, Rachel M.; Sorbero, Mark J.; Bauhoff, Sebastian; Dick, Andrew W.] RAND Corp, Pittsburgh, PA 15213 USA.
[Stein, Bradley D.; Gordon, Adam J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA.
[Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Leslie, Douglas L.] Penn State Coll Med, Hershey, PA USA.
[Mandell, Todd W.] Community Substance Abuse Ctr, Chicopee, MA USA.
RP Stein, BD (reprint author), RAND Corp, 4570 Fifth Ave, Pittsburgh, PA 15213 USA.
EM stein@rand.org
FU National Institute on Drug Abuse of the National Institutes of Health
(NIH) [1R01DA032881-01A1]
FX The National Institute on Drug Abuse of the National Institutes of
Health (NIH) provided support (award 1R01DA032881-01A1) for this study.
NR 67
TC 4
Z9 4
U1 8
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0887-378X
EI 1468-0009
J9 MILBANK Q
JI Milbank Q.
PD SEP
PY 2015
VL 93
IS 3
BP 561
EP 583
DI 10.1111/1468-0009.12137
PG 23
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA CR3FQ
UT WOS:000361216700011
PM 26350930
ER
PT J
AU Kabekkodu, SP
Chakrabarty, S
Shukla, V
Varghese, VK
Singh, KK
Thangaraj, K
Satyamoorthy, K
AF Kabekkodu, Shama Prasada
Chakrabarty, Sanjiban
Shukla, Vaibhav
Varghese, Vinay Koshy
Singh, Keshav K.
Thangaraj, Kumarasamy
Satyamoorthy, Kapaettu
TI Mitochondrial biology: From molecules to diseases
SO MITOCHONDRION
LA English
DT Article
DE Mitochondria; Clinical perspective; Mitochondrial biomarker;
Mitochondrial database; Signaling and metabolism; Mitochondrial genetics
ID TYPE-2 DIABETIC-RETINOPATHY; KEARNS-SAYRE SYNDROME; SODIUM-BUTYRATE;
OXIDATIVE-PHOSPHORYLATION; POPULATION-GENETICS; COLORECTAL-CANCER;
CERVICAL-CANCER; GENOME DATABASE; CELLS; APOPTOSIS
AB As an integral part of the cell, mitochondria play a pivotal role in the regulation of energy metabolism, signaling pathways, cell differentiation, cell proliferation and cell death. Mitochondrion with its own genetic material has characteristics distinct from those of the nuclear counterpart and its dysregulation is associated with a myriad of diseases. The discovery of interplay between the nuclear and mitochondrial genes, and various post-transcriptional modifications associated with their products has added excitement in the field. This has led to a better understanding of the basic mitochondrial function in normal and disease states, and is important for diagnosis and prognosis of a large number of disorders. The Fourth Annual Conference of Society for Mitochondrial Research and Medicine - India (SMRM) was titled "Mitochondrial Biology: from Molecules to Disease". The conference was organized by K. Satyamoorthy and K. Thangaraj at School of Life Sciences, Manipal University, Manipal, India, during 8-9 December, 2014. The aim of the conference was to bring researchers and clinicians to a common platform; create an opportunity for networking between laboratories; and to discuss about the recent development in mitochondrial biology, diagnosis, and therapy. This review summarizes the key outcomes of the conference. (C) 2015 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 [Kabekkodu, Shama Prasada; Chakrabarty, Sanjiban; Shukla, Vaibhav; Varghese, Vinay Koshy; Satyamoorthy, Kapaettu] Manipal Univ, Sch Life Sci, Dept Biotechnol, Manipal 576104, Karnataka, India.
[Singh, Keshav K.] Univ Alabama Birmingham, Dept Genet, Birmingham, AL USA.
[Singh, Keshav K.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
[Singh, Keshav K.] Univ Alabama Birmingham, Dept Environm Hlth, Birmingham, AL USA.
[Singh, Keshav K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Thangaraj, Kumarasamy] Ctr Cellular & Mol Biol, CSIR, Hyderabad 500007, Andhra Pradesh, India.
RP Satyamoorthy, K (reprint author), Manipal Univ, Sch Life Sci, Manipal 576104, Karnataka, India.
EM ksatyamoorthy@manipal.edu
OI shukla, Vaibhav/0000-0003-4881-9894; Thangaraj,
Kumarasamy/0000-0002-0075-0106
NR 50
TC 3
Z9 4
U1 4
U2 22
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD SEP
PY 2015
VL 24
BP 93
EP 98
DI 10.1016/j.mito.2015.07.008
PG 6
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA CR5YD
UT WOS:000361419400010
PM 26210788
ER
PT J
AU Sanchez, JR
Reddick, TL
Perez, M
Centonze, VE
Mitra, S
Izumi, T
McMahan, CA
Walter, CA
AF Sanchez, Jamila R.
Reddick, Traci L.
Perez, Marissa
Centonze, Victoria E.
Mitra, Sankar
Izumi, Tadahide
McMahan, C. Alex
Walter, Christi A.
TI Increased human AP endonuclease 1 level confers protection against the
paternal age effect in mice
SO MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
LA English
DT Article
DE Paternal Age; DNA repair; APEX1; Mutagenesis; LacI; Spermatogenesis
ID BASE EXCISION-REPAIR; DE-NOVO MUTATIONS; APURINIC APYRIMIDINIC SITES;
PROGRAMMED CELL-DEATH; DNA-POLYMERASE-BETA; HETEROZYGOUS MICE;
SPERMATOGENIC CELLS; ALTERED EXPRESSION; NUCLEAR EXTRACTS; ABASIC SITES
AB Increased paternal age is associated with a greater risk of producing children with genetic disorders originating from de novo germline mutations. Mice mimic the human condition by displaying an age-associated increase in spontaneous mutant frequency in spermatogenic cells. The observed increase in mutant frequency appears to be associated with a decrease in the DNA repair protein, AP endonuclease 1 (APEX1) and Apex1 heterozygous mice display an accelerated paternal age effect as young adults. In this study, we directly tested if APEX1 over-expression in cell lines and transgenic mice could prevent increases in mutagenesis. Cell lines with ectopic expression of APEX1 had increased APEX1 activity and lower spontaneous and induced mutations in the lad reporter gene relative to the control. Spermatogenic cells obtained from mice transgenic for human APEX1 displayed increased APEX1 activity, were protected from the age-dependent increase in spontaneous germline mutagenesis, and exhibited increased apoptosis in the spermatogonial cell population. These results directly indicate that increases in APEXI level confer protection against the murine paternal age effect, thus highlighting the role of APEX1 in preserving reproductive health with increasing age and in protection against genotoxin-induced mutagenesis in somatic cells. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Walter, Christi A.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
[Sanchez, Jamila R.; Perez, Marissa; Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
[Reddick, Traci L.] Duke Univ, Duke Canc Inst, Durham, NC 27710 USA.
[Centonze, Victoria E.] St Jude Childrens Res Hosp, Cell & Tissue Imaging Ctr, Memphis, TN 38105 USA.
[Mitra, Sankar] Houston Methodist Res Inst, Dept Radiat Oncol, Houston, TX 77030 USA.
[Izumi, Tadahide] Grad Ctr Toxicol, Lexington, KY 40536 USA.
[McMahan, C. Alex] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
[Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA.
[Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
RP Walter, CA (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, MC 7762 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM walter@uthscsa.edu
FU National Institutes of Health [AG024364, AG021163]
FX National Institutes of Health grants [AG024364 and AG021163].
NR 55
TC 2
Z9 2
U1 1
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0027-5107
EI 1873-135X
J9 MUTAT RES-FUND MOL M
JI Mutat. Res.-Fundam. Mol. Mech. Mutagen.
PD SEP
PY 2015
VL 779
BP 124
EP 133
DI 10.1016/j.mrfmmm.2015.06.008
PG 10
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
GA CR3RT
UT WOS:000361251500013
PM 26201249
ER
PT J
AU Danovitch, GM
Delmonico, FL
AF Danovitch, Gabriel M.
Delmonico, Francis L.
TI A path of hope for organ transplantation in China?
SO NEPHROLOGY DIALYSIS TRANSPLANTATION
LA English
DT Article
ID DONATION
AB "aEuro broken vertical bar we declare solemnly that the use of executed prisoner organs has totally stopped in our center and that none of the cases reported in this study were from executed prisoner organs". The content of the study itself reflects the struggle by the authors to rid themselves of the curse of executed prisoner organs at a time when death by neurologic critera ("brain death") has not been ratified by Chinese Law and is thought to be contrary to Chinese cultural values.aEuro broken vertical bar.
C1 [Danovitch, Gabriel M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Danovitch, Gabriel M.] Univ Calif Los Angeles, Ronald Reagan Med Ctr, Div Nephrol, Kidney Transplant Program, Los Angeles, CA 90095 USA.
[Delmonico, Francis L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, Boston, MA USA.
RP Danovitch, GM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
EM gdanovitch@mednet.ucla.edu
NR 9
TC 0
Z9 0
U1 4
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0931-0509
EI 1460-2385
J9 NEPHROL DIAL TRANSPL
JI Nephrol. Dial. Transplant.
PD SEP
PY 2015
VL 30
IS 9
BP 1413
EP 1414
DI 10.1093/ndt/gfv206
PG 2
WC Transplantation; Urology & Nephrology
SC Transplantation; Urology & Nephrology
GA CR4LL
UT WOS:000361303800001
PM 26044833
ER
PT J
AU Ellingson, BM
Bendszus, M
Boxerman, J
Barboriak, D
Erickson, BJ
Smits, M
Nelson, SJ
Gerstner, E
Alexander, B
Goldmacher, G
Wick, W
Vogelbaum, M
Weller, M
Galanis, E
Kalpathy-Cramer, J
Shankar, L
Jacobs, P
Pope, WB
Yang, DW
Chung, C
Knopp, MV
Cha, S
van den Bent, MJ
Chang, S
Al Yung, WK
Cloughesy, TF
Wen, PY
Gilbert, MR
AF Ellingson, Benjamin M.
Bendszus, Martin
Boxerman, Jerrold
Barboriak, Daniel
Erickson, Bradley J.
Smits, Marion
Nelson, Sarah J.
Gerstner, Elizabeth
Alexander, Brian
Goldmacher, Gregory
Wick, Wolfgang
Vogelbaum, Michael
Weller, Michael
Galanis, Evanthia
Kalpathy-Cramer, Jayashree
Shankar, Lalitha
Jacobs, Paula
Pope, Whitney B.
Yang, Dewen
Chung, Caroline
Knopp, Michael V.
Cha, Soonme
van den Bent, Martin J.
Chang, Susan
Al Yung, W. K.
Cloughesy, Timothy F.
Wen, Patrick Y.
Gilbert, Mark R.
CA Jumpstarting Brain Tumor Drug Dev
TI Consensus recommendations for a standardized Brain Tumor Imaging
Protocol in clinical trials
SO NEURO-ONCOLOGY
LA English
DT Review
DE Brain Tumor Imaging Protocol; clinical trials; glioblastoma; MRI
ID NEWLY-DIAGNOSED GLIOBLASTOMA; NUCLEAR MAGNETIC-RESONANCE; RANDOMIZED
PHASE-III; HIGH-GRADE GLIOMAS; MP-RAGE; RESPONSE ASSESSMENT;
INTEROBSERVER VARIABILITY; GADODIAMIDE INJECTION; ADJUVANT TEMOZOLOMIDE;
MALIGNANT GLIOMAS
AB A recent joint meeting was held on January 30, 2014, with the US Food and Drug Administration (FDA), National Cancer Institute (NCI), clinical scientists, imaging experts, pharmaceutical and biotech companies, clinical trials cooperative groups, and patient advocate groups to discuss imaging endpoints for clinical trials in glioblastoma. This workshop developed a set of priorities and action items including the creation of a standardized MRI protocol for multicenter studies. The current document outlines consensus recommendations for a standardized Brain Tumor Imaging Protocol (BTIP), along with the scientific and practical justifications for these recommendations, resulting from a series of discussions between various experts involved in aspects of neuro-oncology neuroimaging for clinical trials. The minimum recommended sequences include: (i) parameter-matched precontrast and postcontrast inversion recovery-prepared, isotropic 3D T1-weighted gradient-recalled echo; (ii) axial 2D T2-weighted turbo spin-echo acquired after contrast injection and before postcontrast 3D T1-weighted images to control timing of images after contrast administration; (iii) precontrast, axial 2D T2-weighted fluid-attenuated inversion recovery; and (iv) precontrast, axial 2D, 3-directional diffusion-weighted images. Recommended ranges of sequence parameters are provided for both 1.5 T and 3 T MR systems.
C1 [Ellingson, Benjamin M.; Cloughesy, Timothy F.] Univ Calif Los Angeles, David Geffen Sch Med, Neuro Oncol Program, Los Angeles, CA 90095 USA.
[Ellingson, Benjamin M.; Cloughesy, Timothy F.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Tumor Imaging Lab, Los Angeles, CA 90095 USA.
[Ellingson, Benjamin M.; Pope, Whitney B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol Sci, Los Angeles, CA 90095 USA.
[Bendszus, Martin] Univ Heidelberg Hosp, Dept Neuroradiol, Heidelberg, Germany.
[Boxerman, Jerrold] Brown Univ, Warrne Alpert Med Sch, Dept Diagnost Imaging, Providence, RI 02912 USA.
[Barboriak, Daniel] Duke Univ, Sch Med, Dept Neuroradiol, Durham, NC USA.
[Erickson, Bradley J.] Mayo Clin, Dept Radiol, Rochester, MN USA.
[Smits, Marion] Erasmus MC Univ, Dept Radiol, Rotterdam, Netherlands.
[Nelson, Sarah J.; Cha, Soonme] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA.
[Gerstner, Elizabeth] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA USA.
[Alexander, Brian; Wen, Patrick Y.] Harvard Univ, Dana Farber Brigham & Womens Canc Ctr, Ctr Neurooncol, Boston, MA USA.
[Goldmacher, Gregory; Wick, Wolfgang] ICON Med Imaging, Med & Sci Affairs, Warrington, PA USA.
[Wick, Wolfgang] Univ Clin Heidelberg, Dept Neurooncol, Natl Ctr Tumor Dis, Heidelberg, Germany.
[Vogelbaum, Michael] Cleveland Clin, Dept Neurol Surg, Brain Tumor & Neurooncol Ctr, Cleveland, OH 44106 USA.
[Weller, Michael] Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland.
[Galanis, Evanthia] Mayo Clin, Dept Oncol, Div Med Oncol, Rochester, MN USA.
[Kalpathy-Cramer, Jayashree] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Kalpathy-Cramer, Jayashree] Harvard Univ, Sch Med, Boston, MA USA.
[Shankar, Lalitha; Jacobs, Paula] NCI, Div Canc Treatment & Diag, Bethesda, MD 20892 USA.
[Chung, Caroline] Univ Toronto, Dept Radiat Oncol, Toronto, ON, Canada.
[Chung, Caroline] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada.
[Knopp, Michael V.] Ohio State Univ, Wright Ctr Innovat Biomed Imaging, Div Imaging Sci, Wexner Med Ctr, Columbus, OH 43210 USA.
[van den Bent, Martin J.] Erasmus MC Canc Inst, Dept Neurooncol, Rotterdam, Netherlands.
[Cha, Soonme; Chang, Susan] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.
[Al Yung, W. K.] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Neurooncol, Houston, TX 77030 USA.
[Cloughesy, Timothy F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
[Gilbert, Mark R.] NCI, Neurooncol Branch, Bethesda, MD USA.
[Ellingson, Benjamin M.; Gerstner, Elizabeth; Wen, Patrick Y.] ABTC, Baltimore, MD USA.
[Ellingson, Benjamin M.; Nelson, Sarah J.] Ivy Consortium Early Phase Clin Trials, Garden City, NY USA.
[Ellingson, Benjamin M.; Boxerman, Jerrold; Barboriak, Daniel] ACRIN, Philadelphia, PA USA.
[Bendszus, Martin; Smits, Marion; Wick, Wolfgang; van den Bent, Martin J.] EORTC, Brussels, Belgium.
[Erickson, Bradley J.; Gerstner, Elizabeth] Alliance Clin Trials Oncol, Duarte, CA USA.
[Ellingson, Benjamin M.; Barboriak, Daniel; Erickson, Bradley J.; Goldmacher, Gregory; Knopp, Michael V.] RSNA Quantitat Imaging Biomarker Alliance QIBA, Arlington, VA USA.
[Ellingson, Benjamin M.; Boxerman, Jerrold; Barboriak, Daniel; Erickson, Bradley J.; Pope, Whitney B.] Amer Soc Neuroradiol ASNR, Oak Brook, IL USA.
[Boxerman, Jerrold] Amer Soc Funct Neuroradiol ASFNR, Austin, TX USA.
[Vogelbaum, Michael; Gilbert, Mark R.] RTOG, Atlanta, GA USA.
RP Ellingson, BM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Radiol Sci, 924 Westwood Blvd,Suite 650, Los Angeles, CA 90095 USA.
EM bellingson@mednet.ucla.edu
RI Gilbert, Mark/J-7494-2016; Smits, Marion/E-4795-2011;
OI Gilbert, Mark/0000-0003-2556-9722; Kalpathy-Cramer,
Jayashree/0000-0001-8906-9618
FU Roche/Genentech Research Grant; Siemens Healthcare Research Grant;
National Brain Tumor Society Research Grant
FX Roche/Genentech Research Grant (B.M.E.), Siemens Healthcare Research
Grant (B.M.E.), National Brain Tumor Society Research Grant (B.M.E.).
NR 62
TC 31
Z9 31
U1 3
U2 11
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
EI 1523-5866
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD SEP
PY 2015
VL 17
IS 9
BP 1188
EP 1198
DI 10.1093/neuonc/nov095
PG 11
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA CR4MH
UT WOS:000361306400004
PM 26250565
ER
PT J
AU Ma, DJ
Galanis, E
Anderson, SK
Schiff, D
Kaufmann, TJ
Peller, PJ
Giannini, C
Brown, PD
Uhm, JH
McGraw, S
Jaeckle, KA
Flynn, PJ
Ligon, KL
Buckner, JC
Sarkaria, JN
AF Ma, Daniel J.
Galanis, Evanthia
Anderson, S. Keith
Schiff, David
Kaufmann, Timothy J.
Peller, Patrick J.
Giannini, Caterina
Brown, Paul D.
Uhm, Joon H.
McGraw, Steven
Jaeckle, Kurt A.
Flynn, Patrick J.
Ligon, Keith L.
Buckner, Jan C.
Sarkaria, Jann N.
TI A phase II trial of everolimus, temozolomide, and radiotherapy in
patients with newly diagnosed glioblastoma: NCCTG N057K
SO NEURO-ONCOLOGY
LA English
DT Article
DE everolimus; FLT-PET; glioblastoma; mTOR
ID PANCREATIC NEUROENDOCRINE TUMORS; TUBEROUS SCLEROSIS COMPLEX; RENAL-CELL
CARCINOMA; RADIATION-THERAPY; 3'-DEOXY-3'-F-18-FLUOROTHYMIDINE PET;
RAD001 EVEROLIMUS; MTOR INHIBITION; MULTIFORME; COMBINATION; VARIABILITY
AB The mammalian target of rapamycin (mTOR) functions within the phosphatidylinositol-3 kinase (PI3K)/Akt pathway as a critical modulator of cell survival. This clinical trial evaluated the combination of the mTOR inhibitor everolimus with conventional temozolomide (TMZ)-based chemoradiotherapy.
Newly diagnosed patients with glioblastoma multiforme were eligible for this single arm, phase II study. Everolimus (70 mg/wk) was started 1 week prior to radiation and TMZ, followed by adjuvant TMZ, and continued until disease progression. The primary endpoint was overall survival at 12 months, and secondary endpoints were toxicity and time to progression. Eleven patients were imaged with 3'-deoxy-3'-F-18-fluorothymidine ((FLT)-F-18)-PET/CT before and after the initial 2 doses of everolimus before initiating radiation/TMZ. Imaged patients with sufficient tumor samples also underwent immunohistochemical and focused exon sequencing analysis.
This study accrued 100 evaluable patients. Fourteen percent of patients had grade 4 hematologic toxicities. Twelve percent had at least one grade 4 nonhematologic toxicity, and there was one treatment-related death. Overall survival at 12 months was 64% and median time to progression was 6.4 months. Of the patients who had (FLT)-F-18-PET data, 4/9 had a partial response after 2 doses of everolimus. Focused exon sequencing demonstrated that (FLT)-F-18-PET responders were less likely to have alterations within the PI3K/Akt/mTOR or tuberous sclerosis complex/neurofibromatosis type 1 pathway compared with nonresponders.
Combining everolimus with conventional chemoradiation had moderate toxicity. (FLT)-F-18-PET studies suggested an initial antiproliferative effect in a genetically distinct subset of tumors, but this did not translate into an appreciable survival benefit compared with historical controls treated with conventional therapy.
C1 [Ma, Daniel J.; Galanis, Evanthia; Kaufmann, Timothy J.; Peller, Patrick J.; Giannini, Caterina; Brown, Paul D.; Uhm, Joon H.; Buckner, Jan C.; Sarkaria, Jann N.] Mayo Clin, Rochester, MN 55905 USA.
[Anderson, S. Keith] Mayo Clin, Alliance Stat & Data Ctr, Rochester, MN 55905 USA.
[Schiff, David] Univ Virginia, Charlottesville, VA USA.
[Brown, Paul D.] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA.
[McGraw, Steven] Sioux Community Canc Consortium, Sioux Falls, SD USA.
[Jaeckle, Kurt A.] Mayo Clin, Jacksonville, FL 32224 USA.
[Flynn, Patrick J.] Metro Minnesota Community Clin Oncol Program, St Louis Pk, MN USA.
[Ligon, Keith L.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Ligon, Keith L.] Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Dept Med Oncol, Boston, MA 02115 USA.
RP Sarkaria, JN (reprint author), Mayo Clin, Dept Radiat Oncol, 200 First St SW, Rochester, MN 55905 USA.
EM sarkaria.jann@mayo.edu
FU Public Health Service [CA-25224, CA-37404, CA-35103, CA-35267]; CTSA
from the National Center for Advancing Translational Sciences (NCATS)
[UL1 TR000135]; National Cancer Institute, Department of Health and
Human Services [CA-108961, CA-165962]; National Cancer Institute
[CA31946]; Alliance for Clinical Trials in Oncology; Alliance Statistics
and Data Center [CA33601]; Novartis
FX This study was conducted as a collaborative trial of the North Central
Cancer Treatment Group and Mayo Clinic and was supported in part by
Public Health Service grants CA-25224, CA-37404, CA-35103, CA-35267,
CTSA grant no. UL1 TR000135 from the National Center for Advancing
Translational Sciences (NCATS), and Brain SPORE grant no. CA-108961 and
CA-165962 from the National Cancer Institute, Department of Health and
Human Services. The study was also supported, in part, by grants from
the National Cancer Institute (CA31946) to the Alliance for Clinical
Trials in Oncology (Monica M. Bertagnolli, MD, Chair) and to the
Alliance Statistics and Data Center (Daniel J. Sargent, PhD, CA33601).
This study was also supported by Novartis and presented at the ASCO 2012
Annual Meeting in Chicago, IL.
NR 50
TC 17
Z9 17
U1 3
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
EI 1523-5866
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD SEP
PY 2015
VL 17
IS 9
BP 1261
EP 1269
DI 10.1093/neuonc/nou328
PG 9
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA CR4MH
UT WOS:000361306400011
PM 25526733
ER
PT J
AU Wen, PY
Omuro, A
Ahluwalia, MS
Fathallah-Shaykh, HM
Mohile, N
Lager, JJ
Laird, AD
Tang, JL
Jiang, J
Egile, C
Cloughesy, TF
AF Wen, Patrick Y.
Omuro, Antonio
Ahluwalia, Manmeet S.
Fathallah-Shaykh, Hassan M.
Mohile, Nimish
Lager, Joanne J.
Laird, A. Douglas
Tang, Jiali
Jiang, Jason
Egile, Coumaran
Cloughesy, Timothy F.
TI Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib
(SAR245409, XL765) plus temozolomide with or without radiotherapy in
patients with high-grade glioma
SO NEURO-ONCOLOGY
LA English
DT Article
DE glioblastoma; pharmacodynamics; pharmacokinetics; PI3K; mTOR;
temozolomide
ID PI3K PATHWAY; GLIOBLASTOMA-MULTIFORME; ADJUVANT TEMOZOLOMIDE; CONFERS
RESISTANCE; MALIGNANT GLIOMA; CANCER; RADIATION; TRIAL; CONCOMITANT;
KINASE
AB This phase I study aimed to evaluate safety, maximum tolerated dose, pharmacokinetics, pharmacodynamics, and preliminary efficacy of voxtalisib (SAR245409, XL765), a pan-class I phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor, in combination with temozolomide (TMZ), with or without radiation therapy (RT), in patients with high-grade glioma.
Patients received voxtalisib 30-90 mg once daily (q.d.) or 20-50 mg twice daily (b.i.d.), in combination with 200 mg/m(2) TMZ (n = 49), or voxtalisib 20 mg q.d. with 75 mg/m(2) TMZ and RT (n = 5). A standard 3 + 3 dose-escalation design was used to determine the maximum tolerated dose. Patients were evaluated for adverse events (AEs), plasma pharmacokinetics, pharmacodynamic effects in skin biopsies, and tumor response.
The maximum tolerated doses were 90 mg q.d. and 40 mg b.i.d. for voxtalisib in combination with TMZ. The most frequently reported treatment-related AEs were nausea (48%), fatigue (43%), thrombocytopenia (26%), and diarrhea (24%). The most frequently reported treatment-related grade a parts per thousand yen3 AEs were lymphopenia (13%), thrombocytopenia, and decreased platelet count (9% each). Pharmacokinetic parameters were similar to previous studies with voxtalisib monotherapy. Moderate inhibition of PI3K signaling was observed in skin biopsies. Best response was partial response in 4% of evaluable patients, with stable disease observed in 68%.
Voxtalisib in combination with TMZ with or without RT in patients with high-grade gliomas demonstrated a favorable safety profile and a moderate level of PI3K/mTOR pathway inhibition.
C1 [Wen, Patrick Y.] Dana Farber Canc Inst, Ctr Neurooncol, Boston, MA 02215 USA.
[Omuro, Antonio] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Ahluwalia, Manmeet S.] Cleveland Clin, Cleveland, OH 44106 USA.
[Fathallah-Shaykh, Hassan M.] Univ Alabama Birmingham, Birmingham, AL USA.
[Mohile, Nimish] Univ Rochester, Med Ctr, Rochester, NY 14642 USA.
[Lager, Joanne J.] Sanofi, Cambridge, MA USA.
[Laird, A. Douglas] Exelixis Inc, San Francisco, CA USA.
[Tang, Jiali] Quintiles, Durham, NC USA.
[Jiang, Jason] Sanofi, Bridgewater, NJ USA.
[Egile, Coumaran] Sanofi, Vitry Sur Seine, France.
[Cloughesy, Timothy F.] Univ Calif Los Angeles, Los Angeles, CA USA.
RP Wen, PY (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM pwen@partners.org
OI Omuro, Antonio/0000-0003-4299-3664
FU Sanofi; Exelixis
FX This study was sponsored by Sanofi and Exelixis. Exelixis was the study
sponsor until March 2011, when Sanofi became the sponsor.
NR 29
TC 2
Z9 2
U1 2
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
EI 1523-5866
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD SEP
PY 2015
VL 17
IS 9
BP 1275
EP 1283
DI 10.1093/neuonc/nov083
PG 9
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA CR4MH
UT WOS:000361306400013
PM 26019185
ER
PT J
AU Mason, DJ
Jones, DA
Roy, C
Sullivan, CG
Wood, LJ
AF Mason, Diana J.
Jones, Dorothy A.
Roy, Callista
Sullivan, Cheryl G.
Wood, Laura J.
TI Commonalities of nurse-designed models of health care
SO NURSING OUTLOOK
LA English
DT Article
DE Community; Family centered; Health care financing; Health policy;
Innovation; Nursing; Patient engagement; Payment; Relationship-based
care; Social determinants; Value-based health care
ID ALL-INCLUSIVE CARE; AGING IN-PLACE; OLDER-ADULTS; CREATING
OPPORTUNITIES; PATIENT ACTIVATION; PARENT EMPOWERMENT; CONTROLLED-TRIAL;
YOUNG-CHILDREN; MANAGED CENTER; BIRTH CENTER
AB The American Academy of Nursing has identified examples of care-redesign developed by nurses who address the health needs of diverse populations. These models show important clinical and financial outcomes as summarized in the Select Edge Runner Models of Care table included in this article. A study team appointed by the Academy explored the commonalities across these models. Four commonalities emerged: health holistically defined; individual-, family-, and community-centric approaches to care; relationship-based care that enables partnerships and builds patient engagement and activation; and a shift from episodic individual care to continuous group and public health approaches. The policy implications include examining measures of an expanded definition of health, paying for visionary care, and transparency and rewards for community-level engagement.
C1 [Mason, Diana J.] CUNY Hunter Coll, Ctr Hlth Media & Policy, Amer Acad Nursing, New York, NY 10021 USA.
[Jones, Dorothy A.] Boston Coll, William F Connell Sch Nursing, Chestnut Hill, MA 02167 USA.
[Jones, Dorothy A.; Roy, Callista] Massachusetts Gen Hosp, Ctr Nursing Res, Boston, MA 02114 USA.
[Sullivan, Cheryl G.] Amer Acad Nursing, Washington, DC USA.
[Wood, Laura J.] Boston Childrens Hosp, Boston, MA USA.
RP Mason, DJ (reprint author), 455 W 44th St,22, New York, NY 10036 USA.
EM djmasonm@gmail.com
NR 50
TC 5
Z9 5
U1 5
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0029-6554
EI 1528-3968
J9 NURS OUTLOOK
JI Nurs. Outlook
PD SEP-OCT
PY 2015
VL 63
IS 5
BP 540
EP 553
DI 10.1016/j.outlook.2015.04.009
PG 14
WC Nursing
SC Nursing
GA CR3YH
UT WOS:000361268500003
PM 26211847
ER
PT J
AU Geng, TY
Xia, LL
Russo, S
Kamara, D
Cawart, LA
AF Geng, Tuoyu
Xia, Lili
Russo, Sarah
Kamara, Davida
Cawart, Lauren Ashley
TI Prosteatotic genes are associated with unsaturated fat suppression of
saturated fat-induced hepatic steatosis in C57BL/6 mice
SO NUTRITION RESEARCH
LA English
DT Article
DE Saturated fatty acid; Unsaturated fatty acid; Obese mice; Hepatic
steatosis; Hepatic cells
ID SKELETAL-MUSCLE CELLS; COA DESATURASE-1 GENE; BILE-ACID METABOLISM;
PREGNANE-X-RECEPTOR; INSULIN-RESISTANCE; MEDIATED INDUCTION; NUCLEAR
RECEPTORS; PPAR-GAMMA; LXR-ALPHA; LIVER
AB Both high sugar and fat diets can induce prosteatotic genes, leading to obesity and obesity-associated diseases, including hepatic steatosis. Unsaturated fat/fatty acid (USFA) reduces high sugar-induced hepatic steatosis by inhibiting the induced prosteatotic genes. In contrast, it is still unclear how USFA ameliorates saturated fat/fatty acid (SFA)-induced hepatic steatosis. As sugar and fat have different transport and metabolic pathways, we hypothesized that USFA suppressed SFA-induced hepatic steatosis via a different set of prosteatotic genes. To test this, we implemented high SFA vs USFA diets and a control diet in C57BL/6 mice for 16 weeks. Severe hepatic steatosis was induced in mice fed the SPA diet. Among a nearly complete set of prosteatotic genes, only the stearoyl-coenzyme a desaturase 1 (Scd1), cluster of differentiation 36 (Cd36), and peroxisome proliferator-activated receptor gamma (Ppar gamma) genes that were differentially expressed in the liver could contribute to SPA-induced steatosis or the alleviative effect of USFA. That is, the SPA diet induced the expression of Cd36 and Ppar gamma but not Scd1, and the USFA diet suppressed Scd1 expression and the induction of Cd36 and Ppar gamma. These findings were mainly recapitulated in cultured hepatocytes. The essential roles of SCD1 and CD36 were confirmed by the observation that the suppression of SCD1 and CD36 with small interfering RNA or drug treatment ameliorated SPA-induced lipid accumulation in hepatocytes. We thus concluded that SCD1, CD36, and PPAR gamma were essential to the suppression of SFA-induced hepatic steatosis by main dietary USFA, which may provide different therapeutic targets for reducing high-fat vs sugar-induced hepatic steatosis. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Geng, Tuoyu] Yangzhou Univ, Inst Epigenet & Epigen, Yangzhou 225009, Jiangsu, Peoples R China.
[Geng, Tuoyu; Xia, Lili] Yangzhou Univ, Coll Anim Sci & Technol, Yangzhou 225009, Jiangsu, Peoples R China.
[Geng, Tuoyu; Russo, Sarah; Cawart, Lauren Ashley] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
[Cawart, Lauren Ashley] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29403 USA.
[Kamara, Davida] Union Hosp Cecil Cty, Elkton, MD 21921 USA.
RP Geng, TY (reprint author), Yangzhou Univ, Inst Epigenet & Epigen, 48 Wenhui Rd, Yangzhou 225009, Jiangsu, Peoples R China.
EM tygeng@yzu.edu.cn
FU Natural Sciences Foundation of China [31472086]; Priority Academic
Program Development of Jiangsu Higher Education Institutions; VA Merit
Award [1R01HL117233]
FX This work was financially supported by the Natural Sciences Foundation
of China (31472086) and the Priority Academic Program Development of
Jiangsu Higher Education Institutions through awards to TG as well as by
a VA Merit Award and 1R01HL117233 awarded to LAC. TG and LAC designed
the research and wrote the article; TG, LX, and SBR conducted the
research and analyzed the data. DK contributed to writing and editing of
the article.
NR 52
TC 4
Z9 4
U1 0
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0271-5317
J9 NUTR RES
JI Nutr. Res.
PD SEP
PY 2015
VL 35
IS 9
BP 812
EP 822
DI 10.1016/j.nutres.2015.06.012
PG 11
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA CR5XE
UT WOS:000361416900008
PM 26277244
ER
PT J
AU Stevens, JR
Coffey, MJ
Fojtik, M
Kurtz, K
Stern, TA
AF Stevens, Jonathan R.
Coffey, M. Justin
Fojtik, Megan
Kurtz, Kristina
Stern, Theodore A.
TI The Use of Transdermal Therapeutic Systems in Psychiatric Care: A Primer
on Patches
SO PSYCHOSOMATICS
LA English
DT Review
ID ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; RANDOMIZED CONTROLLED-TRIAL;
PLACEBO-CONTROLLED TRIAL; MAJOR DEPRESSIVE DISORDER; HEALTH INITIATIVE
MEMORY; ESTROGEN PLUS PROGESTIN; RESTLESS LEGS SYNDROME; MODERATE
ALZHEIMERS-DISEASE; CHEMOTHERAPY-INDUCED NAUSEA; MILD COGNITIVE
IMPAIRMENT
AB Background: Numerous currently available medications that act in the central nervous system can be delivered transdermally. Such medications include cholinesterase inhibitors for dementia, methylphenidate (MPH),for attention-deficit hyperactivity disorder, monoamine oxidase inhibitors (MAOIs) for depression, dopamine agonists for Parkinson disease and restless leg syndrome, and clonidine for attention-deficit hyperactivity disorder and impulse-control disorders. Objective: This article aims to review the literature related to transdermal delivery systems from the perspective of clinical practice and research related to their use in the treatment of psychiatric conditions. Results: Most of the currently available transdermal systems have psychotropic properties or utility in the behavioral health arena and, therefore, are of clinical relevance to consultation-liaison psychiatrists or practitioners of psychosomatic medicine. We discuss their efficacy and safety profiles. We provide a table of these agents and their uses. Conclusions: Transdermal delivery (i.e., patches) for medicines with psycho tropic properties allows mental health providers to customize therapy for patients by altering the duration of therapy, minimizing first-pass metabolism and the potential for drug drug interactions, and decreasing the risk for gastrointestinal irritation.
C1 [Stevens, Jonathan R.] Menninger Clin, Outpatient Serv, Houston, TX 77035 USA.
[Stevens, Jonathan R.; Coffey, M. Justin] Baylor Coll Med, Psychiat & Behav Sci, Houston, TX 77030 USA.
[Coffey, M. Justin] Menninger Clin, Neurostimulat & Clin Informat, Houston, TX 77035 USA.
[Fojtik, Megan; Kurtz, Kristina] Henry Ford Hlth Syst, Detroit, MI USA.
[Stern, Theodore A.] Massachusetts Gen Hosp, Psychiat Consultat Serv, Boston, MA 02114 USA.
[Stern, Theodore A.] Harvard Univ, Sch Med, Psychosomat Med Consultat, Boston, MA USA.
RP Stevens, JR (reprint author), Menninger Clin, 12301 Main St, Houston, TX 77035 USA.
EM jonstevens@menninger.edu
NR 133
TC 0
Z9 1
U1 4
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0033-3182
J9 PSYCHOSOMATICS
JI Psychosomatics
PD SEP-OCT
PY 2015
VL 56
IS 5
BP 423
EP 444
PG 22
WC Psychiatry; Psychology
SC Psychiatry; Psychology
GA CR0KD
UT WOS:000361006500001
PM 26211981
ER
PT J
AU Freudenreich, O
Huffman, JC
Sharpe, M
Beach, SR
Celano, CM
Chwastiak, LA
Cohen, MA
Dickerman, A
Fitz-Gerald, MJ
Kontos, N
Mittal, L
Nejad, SH
Niazi, S
Novak, M
Philbrick, K
Rasimas, JJ
Shim, J
Simpson, SA
Walker, A
Walker, J
Wichman, CL
Zimbrean, P
Sollner, W
Stern, TA
AF Freudenreich, Oliver
Huffman, Jeff C.
Sharpe, Michael
Beach, Scott R.
Celano, Christopher M.
Chwastiak, Lydia A.
Cohen, Mary Ann
Dickerman, Anne
Fitz-Gerald, Mary Joe
Kontos, Nicholas
Mittal, Leena
Nejad, Shamim H.
Niazi, Shehzad
Novak, Marta
Philbrick, Kemuel
Rasimas, Joseph J.
Shim, Jewel
Simpson, Scott A.
Walker, Audrey
Walker, Jane
Wichman, Christina L.
Zimbrean, Paula
Soellner, Wolfgang
Stern, Theodore A.
TI Updates in Psychosomatic Medicine: 2014
SO PSYCHOSOMATICS
LA English
DT Article
ID RANDOMIZED-CONTROLLED-TRIAL; QUALITY-OF-LIFE; PSYCHOGENIC NONEPILEPTIC
SEIZURES; INTEGRATED COLLABORATIVE CARE; ACUTE CORONARY SYNDROME;
SERIOUS MENTAL-ILLNESS; CHRONIC KIDNEY-DISEASE; CLINICAL-TRIAL;
LIVER-TRANSPLANTATION; MAJOR DEPRESSION
AB Background: The amount of literature published annually related to psychosomatic medicine is vast; this poses a challenge for practitioners to keep up-to-date in all but a small area of expertise. Objectives: To introduce how a group process using volunteer experts can be harnessed to provide clinicians with a manageable selection of important publications in psychosomatic medicine, organized by specialty area, for 2014. Methods: We used quarterly annotated abstracts selected by experts from the Academy of Psychosomatic Medicine and the European Association of Psychosomatic Medicine in 15 subspecialties to create a list of important articles. Results: In 2014, subspecialty experts selected 88 articles of interest for practitioners of psychosomatic medicine. For this review, 14 articles were chosen. Conclusions: A group process can he used to whittle clown the vast literature in psychosomatic medicine and compile a list of important articles for individual practitioners. Such an approach is consistent with the idea of physicians as lifelong learners and educators.
C1 [Freudenreich, Oliver; Huffman, Jeff C.; Beach, Scott R.; Celano, Christopher M.; Kontos, Nicholas; Nejad, Shamim H.; Stern, Theodore A.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Sharpe, Michael; Walker, Jane] Univ Oxford, Dept Psychiat, Psychol Med Res, Oxford, England.
[Chwastiak, Lydia A.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Cohen, Mary Ann] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.
[Dickerman, Anne] Weill Cornell Med Coll, New York Presbyterian Hosp, Consultat Liaison Serv, Dept Psychiat, New York, NY USA.
[Fitz-Gerald, Mary Joe] Louisiana State Univ, Hlth Sci Ctr, Dept Psychiat, Shreveport, LA 71105 USA.
[Mittal, Leena] Brigham & Womens Hosp, Dept Psychiat, Div Med Psychiat, Boston, MA 02115 USA.
[Mittal, Leena] Brigham & Womens Hosp, Dept Psychiat, Div Womens Mental Hlth, Boston, MA 02115 USA.
[Niazi, Shehzad] Mayo Clin, Dept Psychiat & Psychol, Jacksonville, FL 32224 USA.
[Novak, Marta] Univ Hlth Network, Dept Psychiat, Toronto, ON, Canada.
[Novak, Marta] Univ Toronto, Toronto, ON, Canada.
[Novak, Marta] Semmelweis Univ, Inst Behav Sci, H-1085 Budapest, Hungary.
[Philbrick, Kemuel] Mayo Clin, Dept Psychiat & Psychol, Rochester, MN USA.
[Rasimas, Joseph J.] HealthPartners Reg Hosp, St Paul, MN USA.
[Shim, Jewel] Kaiser Oakland Med Ctr, Dept Psychiat, San Francisco, CA USA.
[Shim, Jewel] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Simpson, Scott A.] Univ Colorado, Sch Med, Denver Hlth Med Ctr, Denver, CO USA.
[Walker, Audrey] Montefiore Med Ctr, Albert Einstein Coll Med, Div Child & Adolescent Psychiat, Bronx, NY 10467 USA.
[Wichman, Christina L.] Med Coll Wisconsin, Dept Psychiat & Behav Med, Milwaukee, WI 53226 USA.
[Zimbrean, Paula] Yale New Haven Med Ctr, Dept Psychiat & Surg Transplant, New Haven, CT 06504 USA.
[Soellner, Wolfgang] Paracelsus Med Univ, Nuremberg Gen Hosp, Dept Psychosomat Med & Psychotherapy, Nurnberg, Germany.
RP Freudenreich, O (reprint author), Erich Lindemann Mental Hlth Ctr, MGH Schizophrenia Program, 25 Staniford St, Boston, MA 02114 USA.
EM ofreudenreich@partners.org
FU Psychogenics; Forum; Beacon Health Strategies; Optimal Medicine
FX Oliver Freudenreich has received grant support from Psychogenics and
Forum, has received honoraria from Global Medical Education and the MGH
Psychiatry Academy, has received consultant fees from Beacon Health
Strategies and Optimal Medicine, and has received royalties from
UpToDate. Theodore A. Stern is an employee of the Academy of
Psychosomatic Medicine for serving as the editor in chief of
Psychosomatics. The other authors had no disclosures.
NR 89
TC 0
Z9 0
U1 5
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0033-3182
J9 PSYCHOSOMATICS
JI Psychosomatics
PD SEP-OCT
PY 2015
VL 56
IS 5
BP 445
EP 459
PG 15
WC Psychiatry; Psychology
SC Psychiatry; Psychology
GA CR0KD
UT WOS:000361006500002
PM 26032045
ER
PT J
AU O'Cleirigh, C
Magidson, JF
Skeer, MR
Mayer, KH
Safren, SA
AF O'Cleirigh, Conall
Magidson, Jessica F.
Skeer, Margie R.
Mayer, Kenneth H.
Safren, Steven A.
TI Prevalence of Psychiatric and Substance Abuse Symptomatology Among
HIV-Infected Gay and Bisexual Men in HIV Primary Care
SO PSYCHOSOMATICS
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SOCIAL ANXIETY; TRANSMISSION RISK;
SUICIDAL IDEATION; UNITED-STATES; DISORDERS; SEX; WOMEN; HIV/AIDS; PTSD
AB Background: The presence of psychiatric symptoms in gay/bisexual men managing HIV are underidentified and undertreated and can interfere with optimal HIV disease management. There is a paucity of prevalence reports of these symptoms in this group, identified in the primary HIV care setting. Few studies have compared prevalence rates based on empirically supported screening tools in relation to diagnoses made in primary care. Objective: The purpose of this study was to identify the prevalence of psychiatric symptoms and substance abuse in HI V-infected gay/bisexual men and to estimate the proportion of those who had been diagnosed within their primary medical care setting. Method: Participants (n = 503) were HIV-infected gayl bisexual men screened for participation in a HIV prevention trial and completed psychosocial assessment. Data were also extracted from patients' electronic medical record. Results: More than 47% of participants met diagnostic screen-in criteria for any anxiety disorder, of whom approximately one-third were identified in primary care. More than 22% screened in for a depressive mood disorder, approximately 50% of whom had been identified in primary care. A quarter of the sample had elevated substance abuse symptoms, 19.4% of whom were identified in primary care. Of those with symptoms of alcohol abuse (19.9%), 9.0% of those were identified in primary care. Conclusion: These results provide some evidence suggesting that mood, anxiety, and substance abuse symptomatology are prevalent among HIV-injected gay/bisexual men and are underidentified in primary care. Increased mental health and substance use screening integrated into HIV primary care treatment settings may help to identify more gay/bisexual men in need of treatment.
C1 [O'Cleirigh, Conall; Magidson, Jessica F.; Safren, Steven A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Fenway Inst, Boston, MA USA.
[Skeer, Margie R.] Tufts Med Sch, Boston, MA USA.
[Mayer, Kenneth H.] Harvard Univ, Beth Israel Deaconess Med Ctr, Fenway Inst, Sch Med, Boston, MA 02215 USA.
RP O'Cleirigh, C (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 1 Bowdoin Sq BS-07B, Boston, MA 02114 USA.
EM cocleirigh@partners.org
FU NIMH, USA [5R01MH068746-05]; HRSA, USA [H97HA01293]
FX This study was supported by NIMH, USA Grant no. 5R01MH068746-05 and
HRSA, USA Grant no. H97HA01293 awarded to Drs. Kenneth H. Mayer and
Steven A. Safren.
NR 50
TC 9
Z9 9
U1 6
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0033-3182
J9 PSYCHOSOMATICS
JI Psychosomatics
PD SEP-OCT
PY 2015
VL 56
IS 5
BP 470
EP 478
PG 9
WC Psychiatry; Psychology
SC Psychiatry; Psychology
GA CR0KD
UT WOS:000361006500004
PM 25656425
ER
PT J
AU Nota, SPFT
Spit, SA
Voskuyl, T
Bot, AGJ
Hageman, MGJS
Ring, D
AF Nota, Sjoerd P. F. T.
Spit, Silke A.
Voskuyl, Timothy
Bot, Arjan G. J.
Hageman, Michiel G. J. S.
Ring, David
TI Opioid Use, Satisfaction, and Pain Intensity After Orthopedic Surgery
SO PSYCHOSOMATICS
LA English
DT Article
ID TOTAL KNEE ARTHROPLASTY; POSTOPERATIVE PAIN; OPERATIVE TREATMENT;
MANAGEMENT; CARE; QUESTIONNAIRE; DEPRESSION; MORPHINE; FRACTURE; RELIEF
AB Background: Patients in other countries use fewer opioids than patients in the United States with satisfactory pain relief. Objective: This study tested the null hypothesis that opioid intake after orthopedic surgery does not influence satisfaction with pain management. Methods: A total of 232 orthopedic surgical inpatients' completed measures of pain self-efficacy and symptoms of depression at enrollment and commonly used measures of pain intensity, satisfaction with pain relief and satisfaction with hospital staff attention to pain approximately 14 days after surgery. Inpatient (Third intake per 24-hour period was quantified. Results: At a phone evaluation approximately 2 weeks after discharge from the hospital, patients who were always satisfied with their pain relief in hospital and always satisfied with stuff attention to pain used significantly less opioids on day 1 compared with patients who were not always satisfied There were no differences in satisfaction by type of surgery. The final multivariable model for not always satisfied with pain relief included greater opioid use on day 1 ( odds ratio = 1.2), and preadmission diagnosis of depression (odds ratio = 2.6). Greater opioid use on day I was the only factor associated with less than always satisfied with the staff attention to pain relief ( odds ratio = 1.3). Conclusions: Patients who take more opioids report less satisfaction with pain relief and greater pain intensity. Evidence-based interventions to increase self-efficacy merit additional study for the management of postoperative pain.
C1 [Nota, Sjoerd P. F. T.; Spit, Silke A.; Voskuyl, Timothy; Bot, Arjan G. J.; Hageman, Michiel G. J. S.; Ring, David] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Orthopaed Hand & Upper Extrem Serv, Boston, MA 02114 USA.
RP Ring, D (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Orthopaed Hand & Upper Extrem Serv,Yawkey Ctr, Suite 2100,55 Fruit St, Boston, MA 02114 USA.
EM dring@partners.org
NR 28
TC 5
Z9 5
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0033-3182
J9 PSYCHOSOMATICS
JI Psychosomatics
PD SEP-OCT
PY 2015
VL 56
IS 5
BP 479
EP 485
PG 7
WC Psychiatry; Psychology
SC Psychiatry; Psychology
GA CR0KD
UT WOS:000361006500005
PM 25624183
ER
PT J
AU Goldzweig, G
Abramovitch, A
Brenner, B
Perry, S
Peretz, T
Baider, L
AF Goldzweig, Gil
Abramovitch, Amitai
Brenner, Baruch
Perry, Shlomit
Peretz, Tamar
Baider, Lea
TI Expectations and Level of Satisfaction of Patients and Their Physicians:
Concordance and Discrepancies
SO PSYCHOSOMATICS
LA English
DT Article
ID CANCER-PATIENTS; INFORMATION; CARE; FAMILY; COMMUNICATION; PERCEPTIONS;
INVOLVEMENT; PROGNOSIS; ONCOLOGY; QUALITY
AB Background: Identifying discrepancies between patients expectations for support provided by their physicians, and physicians' appraisal of the support they provide to their patients, is a key factor in constructing effective doctor-patient communication. Objective: The current study proposes and explores a paradigm for assessing possible gaps and overlaps between perceptions of patients with cancer and physicians about the "actual" and the "ideal" (desired) emotional and cognitive support oncologists. provide to patients. Methods: Participants included 1027 patients' with cancer and 47 senior oncologists. Patients' and physicians' levels of expectations and satisfaction with the emotional and cognitive support offered by physicians were assessed using a quantitative measure of discrepancy between the actual and the ideal situation. The measure was developed for this study and tested on a random sample of 200 patients and 17 oncologists. Results: The results indicated consistency between physicians' and patients' perceptions of the needs and support that the patients received, Nevertheless, oncologists (lid not feel highly trusted by their patients, oncologists desired less involvement of patients in the treatment plan than the patients expected. Oncologists thought that they actually provided the desired levels of explanation to patients' families, whereas patients thought their flamilies got less explanations than expected. Conclusion: Actual and ideal levels of communication should be described from the points of view of both physicians and patients to better understand the complex picture of patient satisfaction. Oncologists should consider patients' expectations for support vs their own expectations to effectively address patients needs.
C1 [Goldzweig, Gil] Acad Coll Tel Aviv Yaffo, Sch Behav Sci, Tel Aviv, Israel.
[Abramovitch, Amitai] Harvard Univ, Massachusetts Gen Hosp, Sch Med, OCD & Related Disorders Program, Boston, MA USA.
[Brenner, Baruch; Perry, Shlomit] Beilinson Med Ctr, Inst Oncol, Rabin Med Ctr, Petah Tiqwa, Israel.
[Peretz, Tamar] Hadassah Univ Hosp, Sharctt Inst Oncol, IL-91120 Jerusalem, Israel.
[Baider, Lea] Assuta Med Ctr, Inst Oncol, Tel Aviv, Israel.
RP Goldzweig, G (reprint author), Acad Coll Tel Aviv Yaffo, Sch Behav Sci, Tel Aviv, Israel.
EM giligold@mta.ac.il
FU Israel Cancer Association, Israel [98003570-C]
FX Supported by research Grant no. 98003570-C from the Israel Cancer
Association, Israel.
NR 35
TC 0
Z9 1
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0033-3182
J9 PSYCHOSOMATICS
JI Psychosomatics
PD SEP-OCT
PY 2015
VL 56
IS 5
BP 521
EP 529
PG 9
WC Psychiatry; Psychology
SC Psychiatry; Psychology
GA CR0KD
UT WOS:000361006500010
PM 25596021
ER
PT J
AU Lokko, HN
Stern, TA
AF Lokko, Hermioni N.
Stern, Theodore A.
TI Confrontations with Difficult Patients: The Good, the Bad, and the Ugly
SO PSYCHOSOMATICS
LA English
DT Article
ID FAMILY PHYSICIANS; ENCOUNTERS; CARE
C1 [Lokko, Hermioni N.; Stern, Theodore A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Lokko, HN (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM hlokko@partners.org
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0033-3182
J9 PSYCHOSOMATICS
JI Psychosomatics
PD SEP-OCT
PY 2015
VL 56
IS 5
BP 556
EP 560
PG 5
WC Psychiatry; Psychology
SC Psychiatry; Psychology
GA CR0KD
UT WOS:000361006500014
PM 26117725
ER
PT J
AU Murugesan, N
Utunkaya, T
Feener, EP
AF Murugesan, Nivetha
Utunkaya, Tuna
Feener, Edward P.
TI Thrombosis and Hemorrhage in Diabetic Retinopathy: A Perspective from an
Inflammatory Standpoint
SO SEMINARS IN THROMBOSIS AND HEMOSTASIS
LA English
DT Article
DE thrombosis; hemorrhage; diabetic retinopathy; inflammation
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL VASCULAR-PERMEABILITY; PLASMA
KALLIKREIN; ACTIVATION; RECEPTOR; PLATELET; DYSFUNCTION; MICROPARTICLES;
PATHOGENESIS; LEUKOSTASIS
AB Retinal ischemia and hemorrhage are hallmarks of worsening diabetic retinopathy, which can lead to neovascularization, macular edema, and severe vision loss. Although diabetes alters expression of clotting factors and their activities, and increases retinal microthromboses, the effects of thrombotic processes on the pathogenesis of diabetic retinopathy are not fully understood. In addition to the roles of coagulation and fibrinolytic cascades in thrombosis and hemostasis, components in these systems also mediate multiple effects on the vasculature that promote inflammation. Plasma kallikrein, thrombin, and urokinase are increased in diabetic retinopathy, and exert proinflammatory effects that contribute to retinal vascular dysfunction. The accumulation and activation of these and additional coagulation factors in the vitreous due to hemorrhage and chronic retinal injury in the diabetic retina may contribute to worsening of retinal inflammation and capillary dysfunction, which lead to retinal ischemia and edema. Further understanding of the role for specific coagulation factors in diabetic retinopathy may suggest new therapeutic opportunities for this vision-threatening disease.
C1 [Murugesan, Nivetha; Feener, Edward P.] Joslin Diabet Ctr, Div Res, Sect Vasc Cell Biol, Boston, MA 02215 USA.
[Murugesan, Nivetha; Feener, Edward P.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Utunkaya, Tuna] Hacettepe Univ, Sch Med, Ankara, Turkey.
RP Feener, EP (reprint author), Joslin Diabet Ctr, Div Res, Sect Vasc Cell Biol, One Joslin Pl, Boston, MA 02215 USA.
EM Edward.Feener@joslin.harvard.edu
FU National Institutes of Health (NIH) [EY019029, DK36836, T32EY007145]
FX This article was supported by the National Institutes of Health (NIH)
Award Numbers EY019029, DK36836, and T32EY007145. The content is solely
the responsibility of the authors and does not necessarily represent the
official views of the NIH.
NR 42
TC 2
Z9 2
U1 0
U2 5
PU THIEME MEDICAL PUBL INC
PI NEW YORK
PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA
SN 0094-6176
EI 1098-9064
J9 SEMIN THROMB HEMOST
JI Semin. Thromb. Hemost.
PD SEP
PY 2015
VL 41
IS 6
BP 659
EP 664
DI 10.1055/s-0035-1556731
PG 6
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA CR6ZY
UT WOS:000361498300014
PM 26305236
ER
PT J
AU Kim, ND
Luster, AD
AF Kim, Nancy D.
Luster, Andrew D.
TI The role of tissue resident cells in neutrophil recruitment
SO TRENDS IN IMMUNOLOGY
LA English
DT Review
ID INNATE LYMPHOID-CELLS; GROWTH-STIMULATORY ACTIVITY; BLOOD-BRAIN-BARRIER;
MAST-CELLS; IN-VIVO; PULMONARY INFLAMMATION; RHEUMATOID-ARTHRITIS;
ENDOTHELIAL-CELLS; IMAGING REVEALS; COCULTURE MODEL
AB Neutrophils are first responders of the immune system, rapidly migrating into affected tissues in response to injury or infection. To effectively call in this first line of defense, strategically placed cells within the vasculature and tissue respond to noxious stimuli by sending out coordinated signals that recruit neutrophils. Regulation of organ-specific neutrophil entry occurs at two levels. First, the vasculature supplying the organ provides cues for neutrophil egress out of the bloodstream in a manner dependent upon its unique cellular composition and architectural features. Second, resident immune cells and stromal cells within the organ send coordinated signals that guide neutrophils to their final destination. Here, we review recent findings that highlight the importance of these tissue-specific responses in the regulation of neutrophil recruitment and the initiation and resolution of inflammation.
C1 [Kim, Nancy D.; Luster, Andrew D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Immunol & Inflammatory Dis,Div Rheumatol Alle, Boston, MA 02114 USA.
RP Luster, AD (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Immunol & Inflammatory Dis,Div Rheumatol Alle, Boston, MA 02114 USA.
EM aluster@mgh.harvard.edu
FU Rheumatology Research Foundation; National Institutes of Health
FX N.D.K. was supported by a grant from the Rheumatology Research
Foundation and A.D.L. was supported by grants from the National
Institutes of Health.
NR 77
TC 14
Z9 14
U1 4
U2 16
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471-4906
EI 1471-4981
J9 TRENDS IMMUNOL
JI Trends Immunol.
PD SEP
PY 2015
VL 36
IS 9
BP 547
EP 555
DI 10.1016/j.it.2015.07.007
PG 9
WC Immunology
SC Immunology
GA CR5TI
UT WOS:000361406600007
PM 26297103
ER
PT J
AU Frias-Lopez, J
AF Frias-Lopez, Jorge
TI Targeting specific bacteria in the oral microbiome
SO TRENDS IN MICROBIOLOGY
LA English
DT Editorial Material
DE oral microbiome; antimicrobial peptide; microbial ecology
ID ANTIMICROBIAL PEPTIDES
AB A lack of tools that kill selected members of the oral microbiome has hampered the ability to study specific roles of bacteria within bacterial communities. Work by Guo et al. shows the potential of antimicrobial peptides as a tool to assess the role of individual species in the microbial community.
C1 Forsyth Inst, Cambridge, MA 02142 USA.
RP Frias-Lopez, J (reprint author), Forsyth Inst, 245 First St, Cambridge, MA 02142 USA.
EM jfrias@forsyth.org
NR 10
TC 2
Z9 2
U1 1
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0966-842X
EI 1878-4380
J9 TRENDS MICROBIOL
JI Trends Microbiol.
PD SEP
PY 2015
VL 23
IS 9
BP 527
EP 528
DI 10.1016/j.tim.2015.07.004
PG 2
WC Biochemistry & Molecular Biology; Microbiology
SC Biochemistry & Molecular Biology; Microbiology
GA CR5WA
UT WOS:000361413900004
PM 26215711
ER
PT J
AU Asch, DA
Rader, DJ
Merchant, RM
AF Asch, David A.
Rader, Daniel J.
Merchant, Raina M.
TI Mining the social mediome
SO TRENDS IN MOLECULAR MEDICINE
LA English
DT Editorial Material
DE communication; health information technology; health services research;
social media
ID FACEBOOK; HEALTH; DEPRESSION; SCALE; USERS
AB The experiences and behaviors revealed in our everyday lives provide as much insight into health and disease as any analysis of our genome could ever produce. These characteristics are not found in the genome, but may be revealed in our online activities, which make up our social mediome.
C1 [Asch, David A.; Merchant, Raina M.] Univ Penn, Ctr Hlth Care Innovat, Philadelphia, PA 19104 USA.
[Asch, David A.; Rader, Daniel J.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
[Asch, David A.] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA.
[Asch, David A.] Philadelphia VA Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA.
[Rader, Daniel J.] Univ Penn, Dept Med Genet, Philadelphia, PA 19104 USA.
[Merchant, Raina M.] Univ Penn, Dept Emergency Med, Perelman Sch Med, Philadelphia, PA 19104 USA.
RP Merchant, RM (reprint author), Univ Penn, Ctr Hlth Care Innovat, Philadelphia, PA 19104 USA.
EM raina.merchant@uphs.upenn.edu
FU NHLBI NIH HHS [K23 HL109083, R01 HL122457, R01 HL122457-01A1]; PHS HHS
[NHLBI K23 109083-01]
NR 15
TC 2
Z9 2
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471-4914
EI 1471-499X
J9 TRENDS MOL MED
JI Trends Mol. Med
PD SEP
PY 2015
VL 21
IS 9
BP 528
EP 529
DI 10.1016/j.molmed.2015.06.004
PG 2
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
Medicine
GA CR5TP
UT WOS:000361407500002
PM 26341614
ER
PT J
AU Sheykhkarimli, D
Yachie, N
Petsalaki, E
Cote, A
Knapp, J
Roth, FP
AF Sheykhkarimli, Dayag
Yachie, Nozomu
Petsalaki, Evangelia
Cote, Atina
Knapp, Jennifer
Roth, Frederick P.
TI Towards a platform for global mapping of binary protein interactions
under diverse conditions
SO YEAST
LA English
DT Meeting Abstract
CT 27th International Conference on Yeast Genetics and Molecular Biology
(ICYGMB)
CY SEP 06-12, 2015
CL Fondazione Edmund Mach, Levico Terme, ITALY
SP Inst Cell Biol Nas Ukraine, Roche, Singer Instruments, Tema Ric, EMBO, Wiley Blackwell, Federat European Microbiol Soc, Assoc Genetica Italiana, Stanford Univ, DSB, Athesina Studiorum Univ, Soc Italiana Microbiologia Generale & Biotecnologie Microbiche, Saccharomyces Genome Database, Fondazione Bruno Kessler, Prov Autonoma Trento
HO Fondazione Edmund Mach
C1 [Sheykhkarimli, Dayag; Petsalaki, Evangelia; Cote, Atina; Knapp, Jennifer; Roth, Frederick P.] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G 1X5, Canada.
[Sheykhkarimli, Dayag; Petsalaki, Evangelia; Cote, Atina; Knapp, Jennifer; Roth, Frederick P.] Univ Toronto, Donelly Ctr Cellular & Biomol Res, Toronto, ON, Canada.
[Sheykhkarimli, Dayag; Roth, Frederick P.] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada.
[Yachie, Nozomu] Univ Tokyo, Adv Sci & Technol Res Ctr, Tokyo, Japan.
[Yachie, Nozomu] Keio Univ, Inst Adv Biosci, Tsuruoka, Yamagata, Japan.
[Yachie, Nozomu] Japan Sci & Technol Agcy JST, PRESTO, Tokyo, Japan.
[Roth, Frederick P.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Roth, Frederick P.] Univ Toronto, Dept Comp Sci, Toronto, ON, Canada.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0749-503X
EI 1097-0061
J9 YEAST
JI Yeast
PD SEP
PY 2015
VL 32
SU 1
MA PS1-13
BP S99
EP S99
PG 1
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Microbiology; Mycology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Microbiology; Mycology
GA CR6OF
UT WOS:000361466200137
ER
PT J
AU Rasmussen, DD
Kincaid, CL
Froehlich, JC
AF Rasmussen, Dennis D.
Kincaid, Carrie L.
Froehlich, Janice C.
TI Prazosin plus Naltrexone Decreases Alcohol Drinking More Effectively
Than Does Either Drug Alone in P Rats with a Protracted History of
Extensive Voluntary Alcohol Drinking, Dependence, and Multiple
Withdrawals
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
DE Prazosin; Naltrexone; Alcohol; Alcoholism Treatment; Noradrenergic;
Opioid
ID ALPHA(1)-ADRENERGIC RECEPTOR ANTAGONIST; RANDOMIZED CONTROLLED-TRIAL;
ETHANOL-CONSUMPTION; NOREPINEPHRINE; STRESS; BRAIN; INHIBITION;
PREFERENCE; ADDICTION; BEHAVIORS
AB BackgroundPrazosin (PRZ; an (1)-adrenergic receptor antagonist) and naltrexone (NTX; a nonspecific opioid receptor antagonist) each decrease alcohol drinking when administered to rats selectively bred for high voluntary alcohol drinking (alcohol-preferring or P), and the combination of PRZ+NTX decreases alcohol drinking more effectively than does either drug alone. As drug responsiveness can depend on history of alcohol drinking and dependence, we investigated whether various schedules of PRZ and NTX administration, alone or in combination, are effective in decreasing alcohol drinking in male P rats with a history of protracted voluntary alcohol drinking, dependence, and repeated withdrawals closely resembling human alcoholism.
MethodsMale P rats became alcohol-dependent during 1year of adlibitum 24h/d access to food, water, and 20% alcohol with repetitive temporary alcohol withdrawals. Four sequential studies then addressed effects of oral PRZ (2mg/kg) and NTX (10mg/kg), alone or together, on alcohol drinking during: (i) daily alcohol access with daily drug treatment, (ii) intermittent alcohol access with daily drug treatment, (iii) intermittent alcohol access with occasional drug treatment, and (iv) postdeprivation reinstatement of alcohol access.
ResultsThe combination of PRZ+NTX consistently suppressed alcohol drinking during daily or intermittent alcohol access conditions and when drug treatment was either daily or occasional. PRZ+NTX was consistently more effective than either drug alone. The reduction in alcohol drinking was not due to sedation, motor effects, or malaise.
ConclusionsBoth daily and as-needed treatment with PRZ+NTX are highly effective in suppressing daily, intermittent, and postdeprivation alcohol drinking in male P rats with a protracted history of alcohol dependence and repeated withdrawals. This drug combination may be especially effective for treating individuals with long histories of heavy alcohol abuse, dependence, and repeated relapse, as commonly encountered in clinical practice.
C1 [Rasmussen, Dennis D.] VISN 20 Mental Illness Res Educ & Clin Ctr, Seattle, WA USA.
[Rasmussen, Dennis D.; Kincaid, Carrie L.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Rasmussen, Dennis D.; Kincaid, Carrie L.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Froehlich, Janice C.] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA.
RP Rasmussen, DD (reprint author), VA Puget Sound Hlth Care Syst Med Ctr, 116 MIRECC,1660 S Columbian Way, Seattle, WA 98108 USA.
EM drasmuss@u.washington.edu
FU VA Puget Sound Health Care System; VA VISN 20 Mental Illness Research,
Education and Clinical Center (MIRECC); NIH [R01 AA018604, P20 AA017839,
P60 AA007611, R24 AA015512]
FX This material is based on work supported in part by resources from the
VA Puget Sound Health Care System, the VA VISN 20 Mental Illness
Research, Education and Clinical Center (MIRECC), and NIH grants R01
AA018604, P20 AA017839, and P60 AA007611. P rats provided by the Indiana
Alcohol Research Resource Center supported by NIH grant R24 AA015512.
NR 53
TC 5
Z9 5
U1 2
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD SEP
PY 2015
VL 39
IS 9
BP 1832
EP 1841
DI 10.1111/acer.12828
PG 10
WC Substance Abuse
SC Substance Abuse
GA CQ7ZB
UT WOS:000360824300030
PM 26260061
ER
PT J
AU Solus, JF
Goyal, A
Duncan, LM
Nazarian, RM
AF Solus, Jason F.
Goyal, Amrita
Duncan, Lyn M.
Nazarian, Rosalynn M.
TI Basaloid Carcinoma of the Breast Mimicking Cutaneous Basaloid Neoplasms
SO AMERICAN JOURNAL OF DERMATOPATHOLOGY
LA English
DT Article
DE basaloid carcinoma of the breast; nipple; basal cell carcinoma; CK17
ID ADENOID CYSTIC CARCINOMA; SQUAMOUS-CELL-CARCINOMA; NIPPLE-AREOLA
COMPLEX; ECCRINE SPIRADENOMA; DIAGNOSTIC PITFALL; FEATURES;
DIFFERENTIATION; TRICHOBLASTOMA; PREVALENCE; CANCERS
AB Basaloid carcinoma of the breast (BCB) is a rare, triple-negative aggressive primary breast tumor that can closely mimic cutaneous basal cell carcinoma (BCC), neuroendocrine tumors, adnexal neoplasms, and other primary breast tumors. Accurate diagnosis of this tumor is critical for appropriate clinical management. We add to the literature 2 female patients with BCB presenting with a nipple mass. Histopathologic findings from both patients showed dermal nests and cords of atypical basaloid cells with epidermal involvement, closely resembling cutaneous BCC. A panel of immunohistochemical stains, including the novel use of CK17, is essential for differentiating BCB from mimickers. BCB is a rare primary breast tumor that follows an aggressive clinical course and closely mimics many basaloid neoplasms, including cutaneous BCC clinicopathologically. Increased awareness of BCB among dermatologists and dermatopathologists is critical for accurate diagnosis and patient care.
C1 Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Dermatopathol Unit, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Nazarian, RM (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dermatopathol Unit,Pathol Serv, 55 Fruit St,WRN 829A, Boston, MA 02114 USA.
EM rmnazarian@partners.org
NR 36
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0193-1091
EI 1533-0311
J9 AM J DERMATOPATH
JI Am. J. Dermatopathol.
PD SEP
PY 2015
VL 37
IS 9
BP e102
EP e106
DI 10.1097/DAD.0000000000000209
PG 5
WC Dermatology
SC Dermatology
GA CQ9BY
UT WOS:000360907100001
PM 25229570
ER
PT J
AU Hwang, AS
Liu, SW
Ashburner, JM
Auerbach, BJ
Atlas, SJ
Hong, CS
AF Hwang, Andrew S.
Liu, Shan W.
Ashburner, Jeffrey M.
Auerbach, Brandon J.
Atlas, Steven J.
Hong, Clemens S.
TI Outcomes of primary care patients who are frequent and persistent users
of the ED
SO AMERICAN JOURNAL OF EMERGENCY MEDICINE
LA English
DT Letter
ID EMERGENCY-DEPARTMENT USE; ACCESS; VISITS
C1 [Hwang, Andrew S.; Ashburner, Jeffrey M.; Auerbach, Brandon J.; Atlas, Steven J.; Hong, Clemens S.] Massachusetts Gen Hosp, Div Gen Internal Med, Boston, MA 02114 USA.
[Liu, Shan W.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
RP Hwang, AS (reprint author), Massachusetts Gen Hosp, Div Gen Internal Med, Boston, MA 02114 USA.
EM ahwang1@partners.org
NR 11
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0735-6757
EI 1532-8171
J9 AM J EMERG MED
JI Am. J. Emerg. Med.
PD SEP
PY 2015
VL 33
IS 9
BP 1320
EP 1322
DI 10.1016/j.ajem.2015.05.042
PG 6
WC Emergency Medicine
SC Emergency Medicine
GA CQ9GG
UT WOS:000360920700056
PM 26092675
ER
PT J
AU Raslau, FD
Augustinack, JC
Klein, AP
Ulmer, JL
Mathews, VP
Mark, LP
AF Raslau, F. D.
Augustinack, J. C.
Klein, A. P.
Ulmer, J. L.
Mathews, V. P.
Mark, L. P.
TI Memory Part 3: The Role of the Fornix and Clinical Cases
SO AMERICAN JOURNAL OF NEURORADIOLOGY
LA English
DT Editorial Material
ID FREQUENT MARIJUANA USE; ALZHEIMERS-DISEASE; COLLOID CYST; REMOVAL;
HIPPOCAMPUS; DAMAGE
C1 [Raslau, F. D.] Univ Kentucky, Dept Radiol, Lexington, KY USA.
[Augustinack, J. C.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Augustinack, J. C.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA.
[Augustinack, J. C.] Harvard Univ, Sch Med, Boston, MA USA.
[Klein, A. P.; Ulmer, J. L.; Mathews, V. P.; Mark, L. P.] Med Coll Wisconsin, Dept Radiol, Milwaukee, WI 53226 USA.
RP Mark, LP (reprint author), Froedtert Hosp, Dept Radiol, Neuroradiol Sect, 9200 West Wisconsin Ave, Milwaukee, WI 53226 USA.
EM lmark@mcw.edu
NR 16
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC NEURORADIOLOGY
PI DENVILLE
PA PO BOX 3000, DENVILLE, NJ 07834-9349 USA
SN 0195-6108
EI 1936-959X
J9 AM J NEURORADIOL
JI Am. J. Neuroradiol.
PD SEP
PY 2015
VL 36
IS 9
BP 1604
EP 1608
DI 10.3174/ajnr.A4371
PG 5
WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA CR0WO
UT WOS:000361044500008
PM 26045575
ER
PT J
AU Prah, MA
Stufflebeam, SM
Paulson, ES
Kalpathy-Cramer, J
Gerstner, ER
Batchelor, TT
Barboriak, DP
Rosen, BR
Schmainda, KM
AF Prah, M. A.
Stufflebeam, S. M.
Paulson, E. S.
Kalpathy-Cramer, J.
Gerstner, E. R.
Batchelor, T. T.
Barboriak, D. P.
Rosen, B. R.
Schmainda, K. M.
TI Repeatability of Standardized and Normalized Relative CBV in Patients
with Newly Diagnosed Glioblastoma
SO AMERICAN JOURNAL OF NEURORADIOLOGY
LA English
DT Article
ID CEREBRAL BLOOD-VOLUME; HIGH-GRADE GLIOMA; PERFUSION MRI; ADJUVANT
TEMOZOLOMIDE; RESPONSE ASSESSMENT; LEAKAGE-CORRECTION; SURVIVAL;
HISTOPATHOLOGY; BEVACIZUMAB; PREDICT
AB BACKGROUND AND PURPOSE: For more widespread clinical use advanced imaging methods such as relative cerebral blood volume must be both accurate and repeatable. The aim of this study was to determine the repeatability of relative CBV measurements in newly diagnosed glioblastoma multiforme by using several of the most commonly published estimation techniques.
MATERIALS AND METHODS: The relative CBV estimates were calculated from dynamic susceptibility contrast MR imaging in double-baseline examinations for 33 patients with treatment-naive and pathologically proved glioblastoma multiforme (men = 20; mean age = 55 years). Normalized and standardized relative CBV were calculated by using 6 common postprocessing methods. The repeatability of both normalized and standardized relative CBV, in both tumor and contralateral brain, was examined for each method with metrics of repeatability, including the repeatability coefficient and within-subject coefficient of variation. The minimum sample size required to detect a parameter change of 10% or 20% was also determined for both normalized relative CBV and standardized relative CBV for each estimation method.
RESULTS: When ordered by the repeatability coefficient, methods using postprocessing leakage correction and Delta R2*(t) techniques offered superior repeatability. Across processing techniques, the standardized relative CBV repeatability in normal-appearing brain was comparable with that in tumor (P = .31), yet inferior in tumor for normalized relative CBV (P = .03). On the basis of the within-subject coefficient of variation, tumor standardized relative CBV estimates were less variable (13%-20%) than normalized relative CBV estimates (24%-67%). The minimum number of participants needed to detect a change of 10% or 20% is 118-643 or 30-161 for normalized relative CBV and 109-215 or 28-54 for standardized relative CBV.
CONCLUSIONS: The Delta R2* estimation methods that incorporate leakage correction offer the best repeatability for relative CBV, with standardized relative CBV being less variable and requiring fewer participants to detect a change compared with normalized relative CBV.
C1 [Prah, M. A.; Paulson, E. S.; Schmainda, K. M.] Med Coll Wisconsin, Dept Radiol, Milwaukee, WI 53226 USA.
[Paulson, E. S.] Med Coll Wisconsin, Dept Radiat Oncol, Milwaukee, WI 53226 USA.
[Stufflebeam, S. M.; Kalpathy-Cramer, J.; Gerstner, E. R.; Batchelor, T. T.; Rosen, B. R.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Barboriak, D. P.] Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27710 USA.
RP Schmainda, KM (reprint author), Med Coll Wisconsin, Dept Radiol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.
EM kathleen@mcw.edu
OI Kalpathy-Cramer, Jayashree/0000-0001-8906-9618
FU National Institutes of Health/National Institute of Neurological
Disorders and Stroke [RO1 NS060918]; National Institutes of
Health/National Cancer Institute [RO1 CA082500, U01 CA176110, U01
CA154601]
FX This work was supported by National Institutes of Health/National
Institute of Neurological Disorders and Stroke RO1 NS060918, National
Institutes of Health/National Cancer Institute RO1 CA082500, National
Institutes of Health/National Cancer Institute U01 CA176110 (Medical
College of Wisconsin), and National Institutes of Health/National Cancer
Institute U01 CA154601 (Massachusetts General Hospital).
NR 37
TC 2
Z9 2
U1 0
U2 0
PU AMER SOC NEURORADIOLOGY
PI DENVILLE
PA PO BOX 3000, DENVILLE, NJ 07834-9349 USA
SN 0195-6108
EI 1936-959X
J9 AM J NEURORADIOL
JI Am. J. Neuroradiol.
PD SEP
PY 2015
VL 36
IS 9
BP 1654
EP 1661
DI 10.3174/ajnr.A4374
PG 8
WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA CR0WO
UT WOS:000361044500017
PM 26066626
ER
PT J
AU Ducharme, S
Price, BH
Larvie, M
Dougherty, DD
Dickerson, BC
AF Ducharme, Simon
Price, Bruce H.
Larvie, Mykol
Dougherty, Darin D.
Dickerson, Bradford C.
TI Clinical Approach to the Differential Diagnosis Between Behavioral
Variant Frontotemporal Dementia and Primary Psychiatric Disorders
SO AMERICAN JOURNAL OF PSYCHIATRY
LA English
DT Article
ID PRIMARY PROGRESSIVE APHASIA; LOBAR DEGENERATION; BIPOLAR DISORDER;
NEUROPSYCHOLOGICAL FUNCTION; HEXANUCLEOTIDE REPEAT; ALZHEIMER-DISEASE;
MAJOR DEPRESSION; SOCIAL COGNITION; CONTROLLED-TRIAL; MOOD DISORDERS
C1 [Ducharme, Simon] Massachusetts Gen Hosp, Frontotemporal Disorders Unit, Boston, MA 02114 USA.
McGill Univ, Montreal Neurol Inst & Hosp, Montreal, PQ, Canada.
McGill Univ, Ctr Hlth, Montreal, PQ, Canada.
McGill Univ, Dept Psychiat, Montreal, PQ, Canada.
McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ, Canada.
Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
RP Ducharme, S (reprint author), Massachusetts Gen Hosp, Frontotemporal Disorders Unit, Boston, MA 02114 USA.
EM simon.ducharme@mcgill.ca
FU Sidney R. Baer, Jr., Foundation; Fonds de Recherche du Quebec-Sante;
McGill University Health Centre Research Institute (Frank McGill Travel
Fellowship); Cyberonics; Eli Lilly; Medtronic; Roche
FX Dr. Ducharme's fellowship was supported by the Sidney R. Baer, Jr.,
Foundation, the Fonds de Recherche du Quebec-Sante, and the McGill
University Health Centre Research Institute (Frank McGill Travel
Fellowship).; Dr. Dougherty has received research support from
Cyberonics, Eli Lilly, Medtronic, and Roche and honoraria or travel
support from Insys, Johnson & Johnson, Medtronic, and Roche. Dr.
Dickerson has served as a consultant for Best Doctors, Forum, Isis,
Inc., Haymarket Media, and Piramal, has served on a data safety
monitoring board for Merck, and receives royalties from Oxford
University Press. The other authors report no financial relationships
with commercial interests.
NR 76
TC 4
Z9 4
U1 3
U2 8
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0002-953X
EI 1535-7228
J9 AM J PSYCHIAT
JI Am. J. Psychiat.
PD SEP
PY 2015
VL 172
IS 9
BP 827
EP 837
DI 10.1176/appi.ajp.2015.14101248
PG 11
WC Psychiatry
SC Psychiatry
GA CR1SA
UT WOS:000361103900005
PM 26324301
ER
PT J
AU Greenberg, T
Chase, HW
Almeida, JR
Stiffler, R
Zevallos, CR
Aslam, HA
Deckersbach, T
Weyandt, S
Cooper, C
Toups, M
Carmody, T
Kurian, B
Peltier, S
Adams, P
McInnis, MG
Oquendo, MA
McGrath, PJ
Fava, M
Weissman, M
Parsey, R
Trivedi, MH
Phillips, ML
AF Greenberg, Tsafrir
Chase, Henry W.
Almeida, Jorge R.
Stiffler, Richelle
Zevallos, Carlos R.
Aslam, Haris A.
Deckersbach, Thilo
Weyandt, Sarah
Cooper, Crystal
Toups, Marisa
Carmody, Thomas
Kurian, Benji
Peltier, Scott
Adams, Phillip
McInnis, Melvin G.
Oquendo, Maria A.
McGrath, Patrick J.
Fava, Maurizio
Weissman, Myrna
Parsey, Ramin
Trivedi, Madhukar H.
Phillips, Mary L.
TI Moderation of the Relationship Between Reward Expectancy and Prediction
Error-Related Ventral Striatal Reactivity by Anhedonia in Unmedicated
Major Depressive Disorder: Findings From the EMBARC Study
SO AMERICAN JOURNAL OF PSYCHIATRY
LA English
DT Article
ID DOPAMINE; RESPONSES; SCALE; ACTIVATION; FRAMEWORK
AB Objective: Anhedonia, disrupted reward processing, is a core symptom of major depressive disorder. Recent findings demonstrate altered reward-related ventral striatal reactivity in depressed individuals, but the extent to which this is specific to anhedonia remains poorly understood. The authors examined the effect of anhedonia on reward expectancy (expected outcome value) and prediction error(discrepancy between expected and actual outcome) related ventral striatal reactivity, as well as the relationship between these measures.
Method: A total of 148 unmedicated individuals with major depressive disorder and 31 healthy comparison individuals recruited for the multisite EMBARC (Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care) study underwent functional MRI during a well-validated reward task. Region of interest and whole-brain data were examined in the first- (N=78) and second- (N=70) recruited cohorts, as well as the total sample, of depressed individuals, and in healthy individuals.
Results: Healthy, but not depressed, individuals showed a significant inverse relationship between reward expectancy and prediction error-related right ventral striatal reactivity. Across all participants, and in depressed individuals only, greater anhedonia severity was associated with a reduced reward expectancy-prediction error inverse relationship, even after controlling for other symptoms.
Conclusions: The normal reward expectancy and prediction error-related ventral striatal reactivity inverse relationship concords with conditioning models, predicting a shift in ventral striatal responding from reward outcomes to reward cues. This study shows, for the first time, an absence of this relationship in two cohorts of unmedicated depressed individuals and a moderation of this relationship by anhedonia, suggesting reduced reward contingency learning with greater anhedonia. These findings help elucidate neural mechanisms of anhedonia, as a step toward identifying potential biosignatures of treatment response.
C1 [Greenberg, Tsafrir] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15260 USA.
Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA.
Univ Michigan, Funct MRI Lab, Ann Arbor, MI 48109 USA.
Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA.
New York State Psychiat Inst & Hosp, New York, NY 10032 USA.
Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI USA.
SUNY Stony Brook, Dept Psychiat, Stony Brook, NY 11794 USA.
SUNY Stony Brook, Dept Behav Sci, Stony Brook, NY 11794 USA.
SUNY Stony Brook, Dept Radiol, Stony Brook, NY 11794 USA.
RP Greenberg, T (reprint author), Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15260 USA.
EM greenbergt@upmc.edu
RI Parsey, Ramin/J-8254-2014; Greenberg, Tsafrir /Q-7831-2016
FU NIMH NIH HHS [U01 MH092250, R25 MH101076, U01 MH092221, U01MH092221,
U01MH092250]
NR 34
TC 9
Z9 9
U1 6
U2 10
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0002-953X
EI 1535-7228
J9 AM J PSYCHIAT
JI Am. J. Psychiat.
PD SEP
PY 2015
VL 172
IS 9
BP 881
EP 891
DI 10.1176/appi.ajp.2015.14050594
PG 11
WC Psychiatry
SC Psychiatry
GA CR1SA
UT WOS:000361103900011
PM 26183698
ER
PT J
AU Wortzel, HS
AF Wortzel, Hal S.
TI Psychiatric Expert Testimony: Emerging Applications
SO AMERICAN JOURNAL OF PSYCHIATRY
LA English
DT Book Review
C1 [Wortzel, Hal S.] Denver VA Med Ctr, Rocky Mt Mental Illness Res Educ & Clin Care Ctr, Neuropsychiat Consultat Serv, Denver, CO 80220 USA.
[Wortzel, Hal S.] Denver VA Med Ctr, Rocky Mt Mental Illness Res Educ & Clin Care Ctr, Psychiat Fellowship Program, Denver, CO USA.
RP Wortzel, HS (reprint author), Denver VA Med Ctr, Rocky Mt Mental Illness Res Educ & Clin Care Ctr, Neuropsychiat Consultat Serv, Denver, CO 80220 USA.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0002-953X
EI 1535-7228
J9 AM J PSYCHIAT
JI Am. J. Psychiat.
PD SEP
PY 2015
VL 172
IS 9
BP 915
EP 916
DI 10.1176/appi.ajp.2015.15040480
PG 3
WC Psychiatry
SC Psychiatry
GA CR1SA
UT WOS:000361103900022
PM 26324312
ER
PT J
AU Mackenzie, DC
Khan, NA
Blehar, D
Glazier, S
Chang, YC
Stowell, CP
Noble, VE
Liteplo, AS
AF Mackenzie, David C.
Khan, Noman A.
Blehar, David
Glazier, Scott
Chang, Yuchiao
Stowell, Christopher P.
Noble, Vicki E.
Liteplo, Andrew S.
TI Carotid Flow Time Changes With Volume Status in Acute Blood Loss
SO ANNALS OF EMERGENCY MEDICINE
LA English
DT Article
ID FLUID RESPONSIVENESS; VENTILATED PATIENTS; SEPTIC SHOCK; WAVE-FORM;
TRIAL
AB Study objective: Noninvasive predictors of volume responsiveness may improve patient care in the emergency department. Doppler measurements of arterial blood flow have been proposed as a predictor of volume responsiveness. We seek to determine the effect of acute blood loss and a passive leg raise maneuver on corrected carotid artery flow time.
Methods: In a prospective cohort of blood donors, we obtained a Doppler tracing of blood flow through the carotid artery before and after blood loss. Measurements of carotid flow time, cardiac cycle time, and peak blood velocity were obtained in supine position and after a passive leg raise. Measurements of flow time were corrected for pulse rate.
Results: Seventy-nine donors were screened for participation; 70 completed the study. Donors,had a mean blood loss of 452 mL. Mean corrected carotid artery flow time before blood loss was 320 ms (95% confidence interval [Cl] 315 to 325 ms); this decreased after blood loss to 299 ms (95% Cl 294 to 304 ms). A passive leg raise had little effect on mean corrected carotid artery flow time before blood loss (mean increase 4 ms; 95% Cl -1 to 9 ms), but increased mean corrected carotid artery flow time after blood loss (mean increase 23 ms; 95% Cl 18 to 28 ms) to predonation levels.
Conclusion: Corrected carotid artery flow time decreased after acute blood loss. In the setting of acute hypovolemia, a passive leg raise restored corrected carotid artery flow time to predonation levels. Further investigation of corrected carotid artery flow time as a predictor of volume responsiveness is warranted.
C1 [Mackenzie, David C.] Maine Med Ctr, Dept Emergency Med, Portland, ME 04102 USA.
[Mackenzie, David C.] Tufts Univ, Sch Med, Boston, MA 02111 USA.
[Khan, Noman A.; Glazier, Scott; Chang, Yuchiao; Noble, Vicki E.; Liteplo, Andrew S.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
[Stowell, Christopher P.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Blehar, David] Univ Massachusetts, Sch Med, Dept Emergency Med, Worcester, MA USA.
RP Mackenzie, DC (reprint author), Maine Med Ctr, Dept Emergency Med, Portland, ME 04102 USA.
EM DMackenzie@mmc.org
OI Mackenzie, David/0000-0002-5535-9964
NR 10
TC 2
Z9 2
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-0644
J9 ANN EMERG MED
JI Ann. Emerg. Med.
PD SEP
PY 2015
VL 66
IS 3
BP 277
EP 282
DI 10.1016/j.annemergmed.2015.04.014
PG 6
WC Emergency Medicine
SC Emergency Medicine
GA CR1JW
UT WOS:000361082100015
PM 26003002
ER
PT J
AU Zhou, HY
Tapias, LF
Gaissert, HA
Muniappan, A
Wright, CD
Wain, JC
Donahue, DM
Morse, CR
Mathisen, DJ
Lanuti, M
AF Zhou, Haiyu
Tapias, Luis F.
Gaissert, Henning A.
Muniappan, Ashok
Wright, Cameron D.
Wain, John C.
Donahue, Dean M.
Morse, Christopher R.
Mathisen, Douglas J.
Lanuti, Michael
TI Lymph Node Assessment and Impact on Survival in Video-Assisted
Thoracoscopic Lobectomy or Segmentectomy
SO ANNALS OF THORACIC SURGERY
LA English
DT Article
ID CELL LUNG-CANCER; PROGNOSTIC-FACTOR; NUMBER; DISSECTION;
LYMPHADENECTOMY; THORACOTOMY; METASTASIS; VALIDATION; RESECTION; RATIO
AB Background. The objective of this study was to evaluate the influence of total number of resected lymph nodes, lymph node ratio, and the number of lymph node stations sampled on prognosis in patients with early stage non-small cell lung cancer (NSCLC) treated with video-assisted thoracoscopic surgery (VATS).
Methods. Five hundred and fifty patients who underwent VATS lobectomy or segmentectomy for early clinical stage NSCLC were retrospectively analyzed from 2006 to 2012. Disease-free survival (DFS) and overall survival (OS) were compared for cutoff values of total number of resected lymph nodes (RNs) and lymph node stations (LNS) using Kaplan-Meier methods and Cox proportional hazard models.
Results. Lobectomy was performed in 493 (90%) patients with a median follow-up of 2.7 years. Median age was 68 (range, 29 to 92 years) and 342 (62%) were female. Pathologic stage I, II, and III was observed in 434 (79%), 80 (14.5%) and 36 (6.5%) patients, respectively. The N0, N1, and N2 pathologic nodal status was observed in 485 (88%), 38 (7%), and 27 (5%) patients, respectively. Nodal upstaging was observed in 11.3% (59 of 550) in the total cohort and 15% (49 of 332) in patients who underwent LNS greater than 3 compared with 5% (10 of 218) in patients with LNS 3 or less (p < 0.01). Multivariate analysis identified LNS greater than 3 as a negative independent predictor for DFS (hazard ratio 2.36, p = 0.003) and OS (hazard ratio 1.77, p = 0.046).
Conclusions. Sampling greater than 3 LNS and greater than 10 RNs was associated with an increase in nodal upstaging. Only LNS greater than 3 was found to be an independent predictor of mortality in VATS lobectomy and segmentectomy in clinical early-stage NSCLC. (C) 2015 by The Society of Thoracic Surgeons
C1 Guangdong Gen Hosp, Dept Thorac Surg, Guangzhou, Guangdong, Peoples R China.
Southern Med Univ, Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Thorac Surg, Boston, MA USA.
RP Lanuti, M (reprint author), Massachusetts Gen Hosp, Div Thorac Surg, 55 Fruit St,Blake 1570, Boston, MA 02114 USA.
EM mlanuti@mgh.harvard.edu
FU Division of Thoracic Surgery at the Massachusetts General Hospital
FX Financial support for this study was provided by the Division of
Thoracic Surgery at the Massachusetts General Hospital. We would like to
acknowledge our data manager and research coordinator, Sheila Knoll and
Diane Davies, respectively, for their diligence and dedication toward
compiling and maintaining the Thoracic Surgery Database.
NR 29
TC 7
Z9 8
U1 3
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
EI 1552-6259
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD SEP
PY 2015
VL 100
IS 3
BP 910
EP 917
DI 10.1016/j.athoracsur.2015.04.034
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA CQ9VF
UT WOS:000360962600029
PM 26165483
ER
PT J
AU O'Brien, SM
Jacobs, JP
Pasquali, SK
Gaynor, JW
Karamlou, T
Welke, KF
Filardo, G
Han, JM
Kim, S
Shahian, DM
Jacobs, ML
AF O'Brien, Sean M.
Jacobs, Jeffrey P.
Pasquali, Sara K.
Gaynor, J. William
Karamlou, Tara
Welke, Karl F.
Filardo, Giovanni
Han, Jane M.
Kim, Sunghee
Shahian, David M.
Jacobs, Marshall L.
TI The Society of Thoracic Surgeons Congenital Heart Surgery Database
Mortality Risk Model: Part 1-Statistical Methodology
SO ANNALS OF THORACIC SURGERY
LA English
DT Article
ID SURGICAL REGISTRY DATABASE; PREOPERATIVE FACTORS; ADJUSTMENT; EACTS
AB Background. This study's objective was to develop a risk model incorporating procedure type and patient factors to be used for case-mix adjustment in the analysis of hospital-specific operative mortality rates after congenital cardiac operations.
Methods. Included were patients of all ages undergoing cardiac operations, with or without cardiopulmonary bypass, at centers participating in The Society of Thoracic Surgeons Congenital Heart Surgery Database during January 1, 2010, to December 31, 2013. Excluded were isolated patent ductus arteriosus closures in patients weighing less than or equal to 2.5 kg, centers with more than 10% missing data, and patients with missing data for key variables. Data from the first 3.5 years were used for model development, and data from the last 0.5 year were used for assessing model discrimination and calibration. Potential risk factors were proposed based on expert consensus and selected after empirically comparing a variety of modeling options.
Results. The study cohort included 52,224 patients from 86 centers with 1,931 deaths (3.7%). Covariates included in the model were primary procedure, age, weight, and 11 additional patient factors reflecting acuity status and comorbidities. The C statistic in the validation sample was 0.858. Plots of observed-vs-expected mortality rates revealed good calibration overall and within subgroups, except for a slight overestimation of risk in the highest decile of predicted risk. Removing patient preoperative factors from the model reduced the C statistic to 0.831 and affected the performance classification for 12 of 86 hospitals.
Conclusions. The risk model is well suited to adjust for case mix in the analysis and reporting of hospital-specific mortality for congenital heart operations. Inclusion of patient factors added useful discriminatory power and reduced bias in the calculation of hospital-specific mortality metrics. (C) 2015 by The Society of Thoracic Surgeons
C1 [O'Brien, Sean M.; Kim, Sunghee] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA.
[Jacobs, Jeffrey P.; Jacobs, Marshall L.] Johns Hopkins All Childrens Heart Inst, Tampa, FL USA.
[Jacobs, Jeffrey P.; Jacobs, Marshall L.] Johns Hopkins All Childrens Heart Inst, Orlando, FL USA.
[Jacobs, Jeffrey P.; Jacobs, Marshall L.] Johns Hopkins Univ, Sch Med, Dept Surg, Div Cardiac Surg, Baltimore, MD 21205 USA.
[Jacobs, Jeffrey P.; Jacobs, Marshall L.] Florida Hosp Children, Orlando, FL USA.
[Pasquali, Sara K.] Univ Michigan, CS Mott Childrens Hosp, Dept Pediat & Communicable Dis, Ann Arbor, MI 48109 USA.
[Gaynor, J. William] Childrens Hosp Philadelphia, Dept Surg, Div Cardiothorac Surg, Philadelphia, PA 19104 USA.
[Karamlou, Tara] Univ Calif San Francisco, Benioff Childrens Hosp, Div Pediat Cardiac Surg, San Francisco, CA 94143 USA.
[Welke, Karl F.] Univ Illinois, Coll Med Peoria, Childrens Hosp Illinois, Sect Congenital Cardiovasc Surg, Peoria, IL USA.
[Filardo, Giovanni] Baylor Hlth Care Syst, Inst Hlth Care Res & Improvement, Dallas, TX USA.
[Han, Jane M.] Soc Thorac Surg, Chicago, IL USA.
[Shahian, David M.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Shahian, David M.] Massachusetts Gen Hosp, Ctr Qual & Safety, Boston, MA 02114 USA.
[Shahian, David M.] Harvard Univ, Sch Med, Boston, MA USA.
RP O'Brien, SM (reprint author), Duke Clin Res Inst, Rm 0311,Terrace Level,2400 Pratt St, Durham, NC 27705 USA.
EM sean.m.obrien@duke.edu
FU NHLBI NIH HHS [R01 HL122261]
NR 18
TC 19
Z9 19
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
EI 1552-6259
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD SEP
PY 2015
VL 100
IS 3
BP 1054
EP 1062
DI 10.1016/j.athoracsur.2015.07.014
PG 9
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA CQ9VF
UT WOS:000360962600048
PM 26245502
ER
PT J
AU Jacobs, JP
O'Brien, SM
Pasquali, SK
Gaynor, JW
Mayer, JE
Karamlou, T
Welke, KF
Filardo, G
Han, JM
Kim, S
Quintessenza, JA
Pizarro, C
Tchervenkov, CI
Lacour-Gayet, F
Mavroudis, C
Backer, CL
Austin, EH
Fraser, CD
Tweddell, JS
Jonas, RA
Edwards, FH
Grover, FL
Prager, RL
Shahian, DM
Jacobs, ML
AF Jacobs, Jeffrey P.
O'Brien, Sean M.
Pasquali, Sara K.
Gaynor, J. William
Mayer, John E., Jr.
Karamlou, Tara
Welke, Karl F.
Filardo, Giovanni
Han, Jane M.
Kim, Sunghee
Quintessenza, James A.
Pizarro, Christian
Tchervenkov, Christo I.
Lacour-Gayet, Francois
Mavroudis, Constantine
Backer, Carl L.
Austin, Erle H., III
Fraser, Charles D.
Tweddell, James S.
Jonas, Richard A.
Edwards, Fred H.
Grover, Frederick L.
Prager, Richard L.
Shahian, David M.
Jacobs, Marshall L.
TI The Society of Thoracic Surgeons Congenital Heart Surgery Database
Mortality Risk Model: Part 2-Clinical Application
SO ANNALS OF THORACIC SURGERY
LA English
DT Article; Proceedings Paper
CT 61st Annual Meeting of the Southern-Thoracic-Surgical-Association
CY NOV 05-08, 2014
CL Tucson, AZ
SP So Thorac Surg Assoc
ID EMPIRICALLY BASED TOOL; CARDIAC-SURGERY; OPERATIONS; OUTCOMES; DISEASE
AB Background. The empirically derived 2014 Society of Thoracic Surgeons Congenital Heart Surgery Database Mortality Risk Model incorporates adjustment for procedure type and patient-specific factors. The purpose of this report is to describe this model and its application in the assessment of variation in outcomes across centers.
Methods. All index cardiac operations in The Society of Thoracic Surgeons Congenital Heart Surgery Database (January 1, 2010, to December 31, 2013) were eligible for inclusion. Isolated patent ductus arteriosus closures in patients weighing less than or equal to 2.5 kg were excluded, as were centers with more than 10% missing data and patients with missing data for key variables. The model includes the following covariates: primary procedure, age, any prior cardiovascular operation, any noncardiac abnormality, any chromosomal abnormality or syndrome, important preoperative factors (mechanical circulatory support, shock persisting at time of operation, mechanical ventilation, renal failure requiring dialysis or renal dysfunction (or both), and neurological deficit), any other preoperative factor, prematurity (neonates and infants), and weight (neonates and infants). Variation across centers was assessed. Centers for which the 95% confidence interval for the observed-to-expected mortality ratio does not include unity are identified as lower-performing or higher-performing programs with respect to operative mortality.
Results. Included were 52,224 operations from 86 centers. Overall discharge mortality was 3.7% (1,931 of 52,224). Discharge mortality by age category was neonates, 10.1% (1,129 of 11,144); infants, 3.0% (564 of 18,554), children, 0.9% (167 of 18,407), and adults, 1.7% (71 of 4,119). For all patients, 12 of 86 centers (14%) were lower-performing programs, 67 (78%) were not outliers, and 7 (8%) were higher-performing programs.
Conclusions. The 2014 Society of Thoracic Surgeons Congenital Heart Surgery Database Mortality Risk Model facilitates description of outcomes (mortality) adjusted for procedural and for patient-level factors. Identification of low-performing and high-performing programs may be useful in facilitating quality improvement efforts. (C) 2015 by The Society of Thoracic Surgeons
C1 [Jacobs, Jeffrey P.; Quintessenza, James A.; Mavroudis, Constantine; Jacobs, Marshall L.] Johns Hopkins Childrens Heart Inst, St Petersburg, FL 33701 USA.
[Jacobs, Jeffrey P.; Quintessenza, James A.; Mavroudis, Constantine; Jacobs, Marshall L.] Johns Hopkins Univ, Sch Med, Dept Surg, Div Cardiac Surg, Baltimore, MD 21205 USA.
[Jacobs, Jeffrey P.; Quintessenza, James A.; Mavroudis, Constantine; Jacobs, Marshall L.] Florida Hosp Children, Orlando, FL USA.
[O'Brien, Sean M.; Kim, Sunghee] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA.
[Pasquali, Sara K.] Univ Michigan, CS Mott Childrens Hosp, Dept Pediat & Communicable Dis, Ann Arbor, MI 48109 USA.
[Gaynor, J. William] Childrens Hosp Philadelphia, Dept Surg, Div Cardiothorac Surg, Philadelphia, PA 19104 USA.
[Mayer, John E., Jr.] Harvard Univ, Sch Med, Boston Childrens Hosp, Dept Cardiac Surg, Boston, MA USA.
[Karamlou, Tara] Univ Calif San Francisco, Benioff Childrens Hosp, Div Pediat Cardiac Surg, San Francisco, CA 94143 USA.
[Welke, Karl F.] Univ Illinois, Coll Med, Childrens Hosp Illinois, Sect Congenital Cardiovasc Surg, Peoria, IL 61656 USA.
[Filardo, Giovanni] Baylor Hlth Care Syst, Inst Hlth Care Res & Improvement, Dallas, TX USA.
[Han, Jane M.] Soc Thorac Surg, Chicago, IL USA.
[Pizarro, Christian] Nemours Alfred I duPont Hosp, Wilmington, DE USA.
[Tchervenkov, Christo I.] McGill Univ, Montreal Childrens Hosp, Montreal, PQ H3H 1P3, Canada.
[Lacour-Gayet, Francois] Royal Brompton Hosp, London SW3 6LY, England.
[Backer, Carl L.] Northwestern Univ, Feinberg Sch Med, Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA.
[Austin, Erle H., III] Univ Louisville, Kosair Childrens Hosp, Louisville, KY 40292 USA.
[Fraser, Charles D.] Texas Childrens Hosp, Baylor Coll Med, Houston, TX 77030 USA.
[Tweddell, James S.] Childrens Hosp Wisconsin, Milwaukee, WI 53201 USA.
[Jonas, Richard A.] Childrens Natl Med Ctr, Washington, DC 20010 USA.
[Edwards, Fred H.] Univ Florida, Coll Med Jacksonville, Jacksonville, FL USA.
[Grover, Frederick L.] Univ Colorado Denver, Sch Med, Aurora, CO USA.
[Prager, Richard L.] Univ Michigan, Ann Arbor, MI 48109 USA.
[Shahian, David M.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Shahian, David M.] Massachusetts Gen Hosp, Ctr Qual & Safety, Boston, MA 02114 USA.
[Shahian, David M.] Harvard Univ, Sch Med, Boston, MA USA.
RP Jacobs, JP (reprint author), Johns Hopkins Childrens Heart Inst, Cardiac Surg, 601 Fifth St South,Ste 607, St Petersburg, FL 33701 USA.
EM jeffjacobs@msn.com
FU NCATS NIH HHS [UL1 TR000430]; NHLBI NIH HHS [R01 HL122261]
NR 16
TC 18
Z9 18
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
EI 1552-6259
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD SEP
PY 2015
VL 100
IS 3
BP 1063
EP 1070
DI 10.1016/j.athoracsur.2015.07.011
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA CQ9VF
UT WOS:000360962600049
PM 26245504
ER
PT J
AU Goldberg, JB
Sundt, TM
AF Goldberg, Joshua B.
Sundt, Thoralf M., III
TI More Data Are Needed to Determine an Association Between Transfusions
and Coronary Artery Bypass Graft Occlusion
SO ANNALS OF THORACIC SURGERY
LA English
DT Letter
ID SAPHENOUS-VEIN; THERAPY
C1 [Goldberg, Joshua B.; Sundt, Thoralf M., III] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Cardiac Surg, Boston, MA 02114 USA.
RP Goldberg, JB (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Cardiac Surg, 55 Fruit St, Boston, MA 02114 USA.
EM jgoldberg0@partners.org
NR 4
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
EI 1552-6259
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD SEP
PY 2015
VL 100
IS 3
BP 1135
EP 1135
PG 1
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA CQ9VF
UT WOS:000360962600080
PM 26354661
ER
PT J
AU Di Eusanio, M
Nienaber, CA
Sundt, TM
Patel, HJ
Trimarchi, S
Myrmel, T
Eagle, KA
AF Di Eusanio, Marco
Nienaber, Christoph A.
Sundt, Thoralf M.
Patel, Himanshu J.
Trimarchi, Santi
Myrmel, Truls
Eagle, Kim A.
TI Type A Aortic Dissection: The Controversy of the Root Replacement Reply
SO ANNALS OF THORACIC SURGERY
LA English
DT Letter
C1 [Di Eusanio, Marco] G Mazzini Hosp, Cardiovasc Dept, Cardiac Surg Unit, I-64100 Teramo, Italy.
[Nienaber, Christoph A.] Univ Rostock, Dept Internal Med, D-18055 Rostock, Germany.
[Sundt, Thoralf M.] Massachusetts Gen Hosp, Thorac Aort Ctr, Boston, MA 02114 USA.
[Patel, Himanshu J.] Univ Michigan Hlth Syst, Cardiac Surg, Ann Arbor, MI USA.
[Trimarchi, Santi] IRCCS Policlin San Donato, Thorac Aort Res Ctr, San Donato Milanese, Italy.
[Myrmel, Truls] Univ Tromso Hosp, Dept Thorac & Cardiovasc Surg, N-9012 Tromso, Norway.
[Eagle, Kim A.] Univ Michigan Hlth Syst, Cardiovasc Ctr, Ann Arbor, MI USA.
RP Di Eusanio, M (reprint author), G Mazzini Hosp, Cardiovasc Dept, Cardiac Surg Unit, Piazza Italia, I-64100 Teramo, Italy.
EM marco.dieusanio@aslteramo.it
RI Trimarchi, Santi/J-7361-2016
OI Trimarchi, Santi/0000-0001-5996-3264
NR 2
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
EI 1552-6259
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD SEP
PY 2015
VL 100
IS 3
BP 1137
EP 1138
PG 3
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA CQ9VF
UT WOS:000360962600083
PM 26354663
ER
PT J
AU Akca, BI
Chang, EW
Kling, S
Ramier, A
Scarcelli, G
Marcos, S
Yun, SH
AF Akca, B. Imran
Chang, Ernest W.
Kling, Sabine
Ramier, Antoine
Scarcelli, Giuliano
Marcos, Susana
Yun, Seok H.
TI Observation of sound-induced corneal vibrational modes by optical
coherence tomography
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID OCULAR RESPONSE ANALYZER; COLLAGEN CROSS-LINKING; BIOMECHANICAL
PROPERTIES; ELASTOGRAPHY; KERATOCONUS; MICROSCOPY; ELASTICITY; OCT
AB The mechanical stability of the cornea is critical for maintaining its normal shape and refractive function. Here, we report an observation of the mechanical resonance modes of the cornea excited by sound waves and detected by using phase-sensitive optical coherence tomography. The cornea in bovine eye globes exhibited three resonance modes in a frequency range of 50-400 Hz. The vibration amplitude of the fundamental mode at 80-120 Hz was similar to 8 mu m at a sound pressure level of 100 dB (2 Pa). Vibrography allows the visualization of the radially symmetric profiles of the resonance modes. A dynamic finite-element analysis supports our observation. (C)c 2015 Optical Society of America
C1 [Akca, B. Imran; Chang, Ernest W.; Ramier, Antoine; Scarcelli, Giuliano; Yun, Seok H.] Wellman Ctr Photomed, Boston, MA 02140 USA.
[Akca, B. Imran; Chang, Ernest W.; Ramier, Antoine; Scarcelli, Giuliano; Yun, Seok H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02140 USA.
[Kling, Sabine; Marcos, Susana] CSIC, Inst Opt, E-28006 Madrid, Spain.
[Ramier, Antoine] Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Scarcelli, Giuliano] Univ Maryland, Dept Bioengn, College Pk, MD 20742 USA.
RP Akca, BI (reprint author), Wellman Ctr Photomed, 40 Blossom St, Boston, MA 02140 USA.
RI Akca, Imran/A-2280-2016
FU National Institutes of Health [R01-EY025454, P41-EB015903, UL1-RR025758,
R21EY023043, K25EB015885]; National Science Foundation [1264356];
European Research Council [ERC-2011 AdG-294099]; Spanish Government
[FIS2011-25637, FIS2014-56643-R, FPI-BES-2009-024560]
FX This work was supported by National Institutes of Health (R01-EY025454,
P41-EB015903, UL1-RR025758, R21EY023043, K25EB015885), National Science
Foundation (1264356), European Research Council (ERC-2011 AdG-294099),
and Spanish Government (FIS2011-25637; FIS2014-56643-R and
FPI-BES-2009-024560).
NR 26
TC 4
Z9 4
U1 0
U2 9
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD SEP 1
PY 2015
VL 6
IS 9
BP 3313
EP 3319
DI 10.1364/BOE.6.003313
PG 7
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
Medical Imaging
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
Medical Imaging
GA CQ8VR
UT WOS:000360888400018
PM 26417503
ER
PT J
AU Merrick, GS
Wallner, KE
Galbreath, RW
Butler, WM
Fiano, R
Orio, PF
Adamovich, E
AF Merrick, Gregory S.
Wallner, Kent E.
Galbreath, Robert W.
Butler, Wayne M.
Fiano, Ryan
Orio, Peter F., III
Adamovich, Edward
TI Is supplemental external beam radiation therapy necessary for patients
with higher risk prostate cancer treated with Pd-103? Results of two
prospective randomized trials
SO BRACHYTHERAPY
LA English
DT Article
DE Brachytherapy; Higher risk; Supplemental external beam radiation
therapy; Prospective randomized trial
ID BIOCHEMICAL FAILURE; BRACHYTHERAPY; DOSIMETRY; OUTCOMES; GY
AB PURPOSE: To determine the necessity and/or dose of supplemental external beam radiotherapy (EBRT) in conjunction with palladium-103 (Pd-103) brachytherapy for high-risk prostate cancer patients.
METHODS AND MATERIALS: Trial 44/20 randomized patients to 44 Gy plus 90 Gy Pd-103 vs. 20 Gy with 115 Gy Pd-103, and the subsequent trial randomized patients to the 20 Gy arm vs. 125 Gy Pd-103 without EBRT (20/0 trial). Eligibility criteria included clinically organ-confined disease with Gleason scores 7-9 and/or a pretreatment prostate-specific antigen (PSA) 10-20 ng/mL. The brachytherapy prescription dose was prescribed to the prostate gland with generous periprostatic margins. Biochemical failure (BF) was defined as a PSA >0.40 ng/mL after nadir. Median Day 0 minimum dose covering 90% of the prostate volume (D-90) was >121.0% of the prescription dose. Multiple parameters were evaluated for effect on outcomes.
RESULTS: In 44/20 trial, 13-year BF, prostate cancer specific mortality (PCSM), and overall mortality (OM) were 8.2%, 4.0%, and 42.8% vs. 8.0%, 1.0%. and 40.3% for the 44 and 20 Gy arms. In 20/0 trial, 8-year BF, PCSM, and OM were 2.1%, 0%, and 14.4% vs. 3.6%, 0%, and 16.1% in the 20 vs. 0 Gy arms. When stratified by either pretreatment PSA or by Gleason score, supplemental EBRT dose did not impact BF, PCSM, or OM. In multivariate analysis, BF was most closely related to percent positive biopsies and prostate volume. In both trials, patients with biochemically controlled disease had a median PSA of <0.02 ng/mL.
CONCLUSIONS: With high-quality brachytherapy dose distributions, supplemental EBRT did not influence BF or PCSM for patients with intermediate-risk disease. The number of patients with Gleason score 8-9 was too small to determine the role of supplemental EBRT in that cohort. (C) 2015 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
C1 [Merrick, Gregory S.; Galbreath, Robert W.; Butler, Wayne M.; Fiano, Ryan] Wheeling Jesuit Univ, Schiffier Canc Ctr, Dept Radiat Oncol, Wheeling, WV 26003 USA.
[Merrick, Gregory S.] Wheeling Hosp, Dept Urol, Wheeling, WV 26003 USA.
[Wallner, Kent E.] Puget Sound Hlth Care Syst, Dept Radiat Oncol, Seattle, WA USA.
[Galbreath, Robert W.] Ohio Univ Eastern, St Clairsville, OH USA.
[Orio, Peter F., III] Harvard Univ, Sch Med, Dana Farber Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA USA.
[Adamovich, Edward] Wheeling Hosp, Dept Pathol, Wheeling, WV 26003 USA.
RP Merrick, GS (reprint author), Wheeling Hosp, Schiffler Canc Ctr, 1 Med Pk, Wheeling, WV 26003 USA.
EM gmerrick@urologicresearchinstitute.org
NR 19
TC 5
Z9 5
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1538-4721
EI 1873-1449
J9 BRACHYTHERAPY
JI Brachytherapy
PD SEP-OCT
PY 2015
VL 14
IS 5
BP 677
EP 685
DI 10.1016/j.brachy.2015.05.001
PG 9
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA CR1JG
UT WOS:000361080400013
PM 26051802
ER
PT J
AU Karabanov, A
Ziemann, U
Hamada, M
George, MS
Quartarone, A
Classen, J
Massimini, M
Rothwell, J
Siebner, HR
AF Karabanov, Anke
Ziemann, Ulf
Hamada, Masashi
George, Mark S.
Quartarone, Angelo
Classen, Joseph
Massimini, Marcello
Rothwell, John
Siebner, Hartwig Roman
TI Consensus Paper: Probing Homeostatic Plasticity of Human Cortex With
Non-invasive Transcranial Brain Stimulation (vol 8, pg 442, 2015)
SO BRAIN STIMULATION
LA English
DT Correction
C1 [Karabanov, Anke; Siebner, Hartwig Roman] Univ Copenhagen, Hvidovre Hosp, Danish Res Ctr Magnet Resonance, DK-2650 Hvidovre, Denmark.
[Ziemann, Ulf] Univ Tubingen, Dept Neurol & Stroke, Tubingen, Germany.
[Ziemann, Ulf] Univ Tubingen, Hertie Inst Clin Brain Res, Tubingen, Germany.
[Hamada, Masashi] Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England.
[George, Mark S.] Med Univ S Carolina, Brain Stimulat Lab, Charleston, SC 29425 USA.
[George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
[Quartarone, Angelo] Univ Messina, Dept Neurosci, I-98100 Messina, Italy.
[Classen, Joseph] Univ Hosp Leipzig, Dept Neurol, Leipzig, Germany.
[Massimini, Marcello] Univ Milan, Dept Clin Sci, I-20122 Milan, Italy.
[Rothwell, John] UCL, Inst Neurol, Sobell Dept Motor Neurosci & Movement Disorders, London, England.
[Siebner, Hartwig Roman] Univ Copenhagen, Bispebjerg Hosp, Dept Neurol, Copenhagen, Denmark.
RP Karabanov, A (reprint author), Univ Copenhagen, Hvidovre Hosp, Danish Res Ctr Magnet Resonance, Kettegaard Alle 30, DK-2650 Hvidovre, Denmark.
EM ankenk@drcmr.dk
NR 1
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1935-861X
EI 1876-4754
J9 BRAIN STIMUL
JI Brain Stimul.
PD SEP-OCT
PY 2015
VL 8
IS 5
BP 92
EP 92
DI 10.1016/j.brs.2015.06.016
PG 1
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA CR0ME
UT WOS:000361012000028
ER
PT J
AU Mir-Moghtadaei, A
Caballero, R
Fried, P
Fox, MD
Lee, K
Giacobbe, P
Daskalakis, ZJ
Blumberger, DM
Downar, J
AF Mir-Moghtadaei, Arsalan
Caballero, Ruth
Fried, Peter
Fox, Michael D.
Lee, Katherine
Giacobbe, Peter
Daskalakis, Zafiris J.
Blumberger, Daniel M.
Downar, Jonathan
TI Concordance Between BeamF3 and MRI-neuronavigated Target Sites for
Repetitive Transcranial Magnetic Stimulation of the Left Dorsolateral
Prefrontal Cortex
SO BRAIN STIMULATION
LA English
DT Article
DE Neuronavigation; Prefrontal cortex; Transcranial magnetic stimulation;
Magnetic resonance imaging; Scalp
ID TREATMENT-RESISTANT DEPRESSION; OBSESSIVE-COMPULSIVE DISORDER;
POSTTRAUMATIC-STRESS-DISORDER; TREATING MAJOR DEPRESSION; THETA-BURST
STIMULATION; SHAM-CONTROLLED TRIAL; DOUBLE-BLIND; RANDOMIZED-TRIAL;
FUNCTIONAL CONNECTIVITY; WORKING-MEMORY
AB Background: The dorsolateral prefrontal cortex (DLPFC) is a common target for repetitive transcranial magnetic stimulation (rTMS) in major depression, but the conventional "5 cm rule" misses DLPFC in >1/3 cases. Another heuristic, BeamF3, locates the F3 EEG site from scalp measurements. MRI-guided neuronavigation is more onerous, but can target a specific DLPFC stereotaxic coordinate directly. The concordance between these two approaches has not previously been assessed.
Objective: To quantify the discrepancy in scalp site between BeamF3 versus MRI-guided neuronavigation for left DLPFC.
Methods: Using 100 pre-treatment MRIs from subjects undergoing left DLPFC-rTMS, we localized the scalp site at minimum Euclidean distance from a target MNI coordinate (X - 38 Y + 44 Z + 26) derived from our previous work. We performed nasion-inion, tragusetragus, and head-circumference measurements on the same subjects' MRIs, and applied the BeamF3 heuristic. We then compared the distance between BeamF3 and MRI-guided scalp sites.
Results: BeamF3-to-MRI-guided discrepancies were <0.65 cm in 50% of subjects, <0.99 cm in 75% of subjects, and <1.36 cm in 95% of subjects. The angle from midline to the scalp site did not differ significantly using MRI-guided versus BeamF3 methods. However, the length of the radial arc from vertex to target site was slightly but significantly longer (mean 0.35 cm) with MRI-guidance versus BeamF3.
Conclusions: The BeamF3 heuristic may provide a reasonable approximation to MRI-guided neuronavigation for locating left DLPFC in a majority of subjects. A minor optimization of the heuristic may yield additional concordance. (C) 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
C1 [Mir-Moghtadaei, Arsalan; Lee, Katherine] Univ Toronto, Fac Arts & Sci, Toronto, ON M5S 1A1, Canada.
[Caballero, Ruth; Fried, Peter; Fox, Michael D.] Harvard Univ, Beth Israel Deaconess Med Ctr, Berenson Allen Ctr Noninvas Brain Stimulat, Dept Neurol,Med Sch, Boston, MA 02215 USA.
[Fox, Michael D.] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Fox, Michael D.] Harvard Univ, Athinoula A Martinos Ctr Biomed Imaging, Sch Med, Boston, MA USA.
[Caballero, Ruth] Univ Politecn Madrid, Bioengn & Telemed Ctr, ETSI Telecomunicac, E-28040 Madrid, Spain.
[Daskalakis, Zafiris J.; Blumberger, Daniel M.; Downar, Jonathan] Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada.
[Giacobbe, Peter; Daskalakis, Zafiris J.; Blumberger, Daniel M.; Downar, Jonathan] Univ Toronto, Dept Psychiat, Toronto, ON M5S 1A1, Canada.
[Daskalakis, Zafiris J.; Blumberger, Daniel M.] Ctr Addict & Mental Hlth, Temerty Ctr Therapeut Brain Intervent, Toronto, ON, Canada.
[Giacobbe, Peter; Downar, Jonathan] Univ Hlth Network, MRI Guided rTMS Clin, Toronto, ON M5T 2S8, Canada.
RP Downar, J (reprint author), Univ Hlth Network, MRI Guided rTMS Clin, 399 Bathurst St 7M-415, Toronto, ON M5T 2S8, Canada.
EM jonathan.downar@uhn.ca
RI Downar, Jonathan/I-9002-2016
OI Downar, Jonathan/0000-0002-5140-174X
FU Canadian Institutes of Health Research [MOP136801]; Brain Canada;
Temerty Family through the Centre for Addiction and Mental Health (CAMH)
Foundation; Edgestone Foundation through the Toronto General and Western
Hospital Foundation
FX The authors acknowledge support for this research from the Canadian
Institutes of Health Research (MOP136801), Brain Canada, the Temerty
Family through the Centre for Addiction and Mental Health (CAMH)
Foundation, and the Edgestone Foundation through the Toronto General and
Western Hospital Foundation.
NR 48
TC 8
Z9 8
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1935-861X
EI 1876-4754
J9 BRAIN STIMUL
JI Brain Stimul.
PD SEP-OCT
PY 2015
VL 8
IS 5
BP 965
EP 973
DI 10.1016/j.brs.2015.05.008
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA CR0ME
UT WOS:000361012000017
PM 26115776
ER
PT J
AU Karabanov, A
Ziemann, U
Hamada, M
George, MS
Quartarone, A
Classen, J
Massimini, M
Rothwell, J
Siebner, HR
AF Karabanov, Anke
Ziemann, Ulf
Hamada, Masashi
George, Mark S.
Quartarone, Angelo
Classen, Joseph
Massimini, Marcello
Rothwell, John
Siebner, Hartwig Roman
TI Consensus Paper: Probing Homeostatic Plasticity of Human Cortex With
Non-invasive Transcranial Brain Stimulation
SO BRAIN STIMULATION
LA English
DT Article
ID HUMAN MOTOR CORTEX; LONG-TERM POTENTIATION; THETA-BURST STIMULATION;
PAIRED ASSOCIATIVE STIMULATION; BIDIRECTIONAL SYNAPTIC PLASTICITY;
PARKINSONS-DISEASE PATIENTS; DEPRESSION-LIKE PLASTICITY; LOW-FREQUENCY
STIMULATION; FOCAL HAND DYSTONIA; LTP-LIKE PLASTICITY
AB Homeostatic plasticity is thought to stabilize neural activity around a set point within a physiologically reasonable dynamic range. Over the last ten years, a wide range of non-invasive transcranial brain stimulation (NTBS) techniques have been used to probe homeostatic control of cortical plasticity in the intact human brain. Here, we review different NTBS approaches to study homeostatic plasticity on a systems level and relate the findings to both, physiological evidence from in vitro studies and to a theoretical framework of homeostatic function. We highlight differences between homeostatic and other non-homeostatic forms of plasticity and we examine the contribution of sleep in restoring synaptic homeostasis. Finally, we discuss the growing number of studies showing that abnormal homeostatic plasticity may be associated to a range of neuropsychiatric diseases. (C) 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
C1 [Karabanov, Anke; Siebner, Hartwig Roman] Univ Copenhagen, Hvidovre Hosp, Danish Res Ctr Magnet Resonance, DK-2650 Hvidovre, Denmark.
[Ziemann, Ulf] Univ Tubingen, Dept Neurol & Stroke, Hertie Inst Clin Brain Res, Tubingen, Germany.
[Hamada, Masashi] Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England.
[George, Mark S.] Med Univ S Carolina, Brain Stimulat Lab, Charleston, SC 29425 USA.
[George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
[Quartarone, Angelo] Univ Messina, Dept Neurosci, I-98100 Messina, Italy.
[Classen, Joseph] Univ Hosp Leipzig, Dept Neurol, Leipzig, Germany.
[Massimini, Marcello] Univ Milan, Dept Clin Sci, I-20122 Milan, Italy.
[Rothwell, John] UCL, Inst Neurol, Sobell Dept Motor Neurosci & Movement Disorders, London, England.
[Siebner, Hartwig Roman] Univ Copenhagen, Bispebjerg Hosp, Dept Neurol, Copenhagen, Denmark.
RP Karabanov, A (reprint author), Kettegaard Alle 30, DK-2650 Hvidovre, Denmark.
EM ankenk@drcmr.dk
OI Rothwell, John/0000-0003-1367-6467; QUARTARONE,
Angelo/0000-0003-1485-6590; Massimini, Marcello/0000-0003-2271-957X
FU Swedish Research Council [2011-38769-82837-71]
FX AK was supported by the Swedish Research Council (2011-38769-82837-71).
NR 162
TC 6
Z9 6
U1 6
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1935-861X
EI 1876-4754
J9 BRAIN STIMUL
JI Brain Stimul.
PD SEP-OCT
PY 2015
VL 8
IS 5
BP 993
EP 1006
DI 10.1016/j.brs.2015.06.017
PG 14
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA CR0ME
UT WOS:000361012000029
PM 26598772
ER
PT J
AU Hirsch, J
DePalma, G
Tsai, TT
Sands, LP
Leung, JM
AF Hirsch, J.
DePalma, G.
Tsai, T. T.
Sands, L. P.
Leung, J. M.
TI Impact of intraoperative hypotension and blood pressure fluctuations on
early postoperative delirium after non-cardiac surgery
SO BRITISH JOURNAL OF ANAESTHESIA
LA English
DT Article
DE arterial blood pressure; delirium; hypotension
ID IMPAIRED CEREBRAL AUTOREGULATION; OBSTRUCTIVE SLEEP-APNEA; RISK-FACTORS;
ELDERLY-PATIENTS; HIP FRACTURE; HALOPERIDOL PROPHYLAXIS;
PROGNOSTIC-SIGNIFICANCE; COGNITIVE DYSFUNCTION; PREDISPOSING FACTORS;
SURGICAL-PATIENTS
AB Introduction: Postoperative delirium is common in older patients. Despite its prognostic significance, the pathophysiology is incompletely understood. Although many risk factors have been identified, no reversible factors, particularly ones potentially modifiable by anaesthetic management, have been identified. The goal of this prospective cohort study was to investigate whether intraoperative hypotension was associated with postoperative delirium in older patients undergoing major non-cardiac surgery.
Methods: Study subjects were patients >65 years of age, undergoing major non-cardiac surgery, who were enrolled in an ongoing prospective observational study of the pathophysiology of postoperative delirium. Intraoperative blood pressure was measured and predefined criteria were used to define hypotension. Delirium was measured by the Confusion Assessment Method on the first two postoperative days. Data were analysed using t-tests, two-sample proportion tests and ordered logistic regression multivariable models, including correction for multiple comparisons.
Results: Data from 594 patients with a mean age of 73.6 years (SD 6.2) were studied. Of these 178 (30%) developed delirium on day 1 and 176 (30%) on day 2. Patients developing delirium were older, more often female, had lower preoperative cognitive scores, and underwent longer operations. Relative hypotension (decreases by 20, 30, or 40%) or absolute hypotension [mean arterial pressure (MAP)<50 mm Hg] were not significantly associated with postoperative delirium, nor was the duration of hypotension (MAP<50 mm Hg). Conversely, intraoperative blood pressure variance was significantly associated with postoperative delirium.
Discussion: These results showed that increased blood pressure fluctuation, not absolute or relative hypotension, was predictive of postoperative delirium.
C1 [Hirsch, J.; Tsai, T. T.; Leung, J. M.] Univ Calif San Francisco, Dept Anaesthesia & Perioperat Care, San Francisco, CA 94143 USA.
[DePalma, G.; Sands, L. P.] Purdue Univ, Dept Stat, W Lafayette, IN 47907 USA.
RP Hirsch, J (reprint author), Univ Calif San Francisco, San Francisco VAMC, San Francisco Anesthesiol Serv, Dept Anaesthesia & Perioperat Care, 4150 Clement St,Mail 129, San Francisco, CA 94121 USA.
EM jan.hirsch@ucsf.edu
RI Sands, Laura/E-8919-2015
OI Sands, Laura/0000-0003-2446-4486
FU Anesthesia Patient Safety Foundation (Indianapolis, IN, USA); National
Institutes of Health of the United States (NIH) [1RO1AG031795-05]
FX This work was supported by funding from the Anesthesia Patient Safety
Foundation (Indianapolis, IN, USA), and the National Institutes of
Health of the United States (NIH 1RO1AG031795-05) (to J.M.L.).
NR 71
TC 16
Z9 18
U1 5
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0007-0912
EI 1471-6771
J9 BRIT J ANAESTH
JI Br. J. Anaesth.
PD SEP
PY 2015
VL 115
IS 3
BP 418
EP 426
DI 10.1093/bja/aeu458
PG 9
WC Anesthesiology
SC Anesthesiology
GA CR2WL
UT WOS:000361191400015
PM 25616677
ER
PT J
AU Jin, K
Park, S
Teo, WW
Korangath, P
Cho, SS
Yoshida, T
Gyorffy, B
Goswami, CP
Nakshatri, H
Cruz, LA
Zhou, WQ
Ji, HK
Su, Y
Ekram, M
Wu, ZS
Zhu, T
Polyak, K
Sukumar, S
AF Jin, Kideok
Park, Sunju
Teo, Wei Wen
Korangath, Preethi
Cho, Sean Soonweng
Yoshida, Takahiro
Gyorffy, Balazs
Goswami, Chirayu Pankaj
Nakshatri, Harikrishna
Cruz, Leigh-Ann
Zhou, Weiqiang
Ji, Hongkai
Su, Ying
Ekram, Muhammad
Wu, Zhengsheng
Zhu, Tao
Polyak, Kornelia
Sukumar, Saraswati
TI HOXB7 Is an ER alpha Cofactor in the Activation of HER2 and Multiple ER
Target Genes Leading to Endocrine Resistance
SO CANCER DISCOVERY
LA English
DT Article
ID BREAST-CANCER CELLS; ESTROGEN-RECEPTOR MODULATORS; TAMOXIFEN RESISTANCE;
TRANSCRIPTION FACTOR; CLINICAL-PRACTICE; BINDING-SITES; EXPRESSION;
THERAPY; PHOSPHORYLATION; MECHANISMS
AB Why breast cancers become resistant to tamoxifen despite continued expression of the estrogen receptor-alpha (ER alpha) and what factors are responsible for high HER2 expression in these tumors remains an enigma. HOXB7 chromatin immunoprecipitation analysis followed by validation showed that HOXB7 physically interacts with ER alpha, and that the HOXB7-ER alpha complex enhances transcription of many ER alpha target genes, including HER2. Investigating strategies for controlling HOXB7, our studies revealed that MYC, stabilized via phosphorylation mediated by EGFR-HER2 signaling, inhibits transcription of miR-196a, a HOXB7 repressor. This leads to increased expression of HOXB7, ER target genes, and HER2. Repressing MYC using small-molecule inhibitors reverses these events and causes regression of breast cancer xenografts. The MYC-HOXB7-HER2 signaling pathway is eminently targetable in endocrine-resistant breast cancer.
SIGNIFICANCE: HOXB7 acts as an ER alpha cofactor regulating a myriad of ER target genes, including HER2, in tamoxifen-resistant breast cancer. HOXB7 expression is controlled by MYC via transcriptional regulation of the HOXB7 repressor miR-196a; consequently, antagonists of MYC cause reversal of selective ER modulator resistance both in vitro and in vivo. (C) 2015 AACR.
C1 [Jin, Kideok; Park, Sunju; Teo, Wei Wen; Korangath, Preethi; Cho, Sean Soonweng; Yoshida, Takahiro; Cruz, Leigh-Ann; Sukumar, Saraswati] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Breast Canc Program, Baltimore, MD USA.
[Gyorffy, Balazs] Semmelweis Univ, MTA TTK Lendulet Canc Biomarker Res Grp, H-1085 Budapest, Hungary.
[Yoshida, Takahiro] Semmelweis Univ, Dept Pediat 2, H-1085 Budapest, Hungary.
[Goswami, Chirayu Pankaj; Nakshatri, Harikrishna] Indiana Univ, Ctr Computat Biol & Bioinformat, Bloomington, IN USA.
[Zhou, Weiqiang; Ji, Hongkai] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA.
[Su, Ying; Ekram, Muhammad; Polyak, Kornelia] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Wu, Zhengsheng; Zhu, Tao] Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230026, Anhui, Peoples R China.
[Wu, Zhengsheng; Zhu, Tao] Univ Sci & Technol China, Sch Life Sci, Hefei 230026, Anhui, Peoples R China.
RP Sukumar, S (reprint author), Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, 1650 Orleans St,CRB 1,Room 143, Baltimore, MD 21231 USA.
EM saras@jhmi.edu
FU Susan G. Komen Foundation Leadership Grant [SAC110050]; Department of
Defense Center of Excellence [W81XWH-04-1-0595]; SKCCC Core Grant [P30
CA006973]; Susan G. Komen Foundation Postdoctoral Fellowship [KG101506];
OTKA [K108655]; Susan G. Komen Foundation [SAC110025]; NIH [R01HG006282]
FX This work was supported by Susan G. Komen Foundation Leadership Grant
SAC110050 (to S. Sukumar), Department of Defense Center of Excellence
W81XWH-04-1-0595 (to S. Sukumar), SKCCC Core Grant P30 CA006973 (to S.
Sukumar), Susan G. Komen Foundation Postdoctoral Fellowship KG101506 (to
K. Jin), the OTKA K108655 Grant (to B. Gyorffy), Susan G. Komen
Foundation Grant SAC110025 (to H. Nakshatri), and NIH R01HG006282 (to H.
Nakshatri).
NR 68
TC 7
Z9 7
U1 0
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2159-8274
EI 2159-8290
J9 CANCER DISCOV
JI Cancer Discov.
PD SEP
PY 2015
VL 5
IS 9
BP 944
EP 959
DI 10.1158/2159-8290.CD-15-0090
PG 16
WC Oncology
SC Oncology
GA CQ8DA
UT WOS:000360835200025
PM 26180042
ER
PT J
AU Tricker, EM
Xu, CX
Uddin, S
Capelletti, M
Ercan, D
Ogino, A
Pratilas, CA
Rosen, N
Gray, NS
Wong, KK
Janne, PA
AF Tricker, Erin M.
Xu, Chunxiao
Uddin, Sharmeen
Capelletti, Marzia
Ercan, Dalia
Ogino, Atsuko
Pratilas, Christine A.
Rosen, Neal
Gray, Nathanael S.
Wong, Kwok-Kin
Jaenne, Pasi A.
TI Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in
EGFR-Mutant Lung Cancer
SO CANCER DISCOVERY
LA English
DT Article
ID TYROSINE KINASE INHIBITORS; ACQUIRED-RESISTANCE; GEFITINIB; MUTATION;
ACTIVATION; T790M; AMPLIFICATION; MECHANISM; ERLOTINIB; THERAPY
AB Irreversible pyrimidine-based EGFR inhibitors, including WZ4002, selectively inhibit both EGFR-activating and EGFR inhibitor-resistant T790M mutations more potently than wild-type EGFR. Although this class of mutant-selective EGFR inhibitors is effective clinically in lung cancer patients harboring EGFR(T790M), prior preclinical studies demonstrate that acquired resistance can occur through genomic alterations that activate ERK1/2 signaling. Here, we find that ERK1/2 reactivation occurs rapidly following WZ4002 treatment. Concomitant inhibition of ERK1/2 by the MEK inhibitor trametinib prevents ERK1/2 reactivation, enhances WZ4002-induced apoptosis, and inhibits the emergence of resistance in WZ4002-sensitive models known to acquire resistance via both T790M-dependent and T790M-independent mechanisms. Resistance to WZ4002 in combination with trametinib eventually emerges due to AKT/mTOR reactivation. These data suggest that initial cotargeting of EGFR and MEK could significantly impede the development of acquired resistance in EGFR-mutant lung cancer.
SIGNIFICANCE: Patients with EGFR-mutant lung cancer develop acquired resistance to EGFR and mutant-selective EGFR tyrosine kinase inhibitors. Here, we show that cotargeting EGFR and MEK can prevent the emergence of a broad variety of drug resistance mechanisms in vitro and in vivo and may be a superior therapeutic regimen for these patients. (C) 2015 AACR.
C1 [Tricker, Erin M.; Xu, Chunxiao; Capelletti, Marzia; Ercan, Dalia; Ogino, Atsuko; Wong, Kwok-Kin; Jaenne, Pasi A.] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02215 USA.
[Tricker, Erin M.; Xu, Chunxiao; Capelletti, Marzia; Ercan, Dalia; Ogino, Atsuko; Wong, Kwok-Kin; Jaenne, Pasi A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Uddin, Sharmeen; Pratilas, Christine A.] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA.
[Uddin, Sharmeen; Pratilas, Christine A.; Rosen, Neal] Mem Sloan Kettering Canc Ctr, Program Mol Pharmacol & Chem, New York, NY 10021 USA.
[Rosen, Neal] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA.
[Gray, Nathanael S.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Gray, Nathanael S.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA.
[Wong, Kwok-Kin; Jaenne, Pasi A.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Wong, Kwok-Kin; Jaenne, Pasi A.] Harvard Univ, Sch Med, Boston, MA USA.
[Wong, Kwok-Kin; Jaenne, Pasi A.] Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02215 USA.
RP Janne, PA (reprint author), Dana Farber Canc Inst, 450 Brookline Ave,HIM223, Boston, MA 02215 USA.
EM Pasi_Janne@dfci.harvard.edu
FU NIH [RO1CA114465, R01CA135257, PO1CA154303]
FX This study was supported by grants from the NIH RO1CA114465 (to P.A.
Janne), R01CA135257 (to P.A. Janne), and PO1CA154303 (to P.A. Janne,
N.S. Gray, and K.-K. Wong).
NR 39
TC 30
Z9 31
U1 1
U2 12
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2159-8274
EI 2159-8290
J9 CANCER DISCOV
JI Cancer Discov.
PD SEP
PY 2015
VL 5
IS 9
BP 960
EP 971
DI 10.1158/2159-8290.CD-15-0063
PG 12
WC Oncology
SC Oncology
GA CQ8DA
UT WOS:000360835200026
PM 26036643
ER
PT J
AU Cottini, F
Hideshima, T
Suzuki, R
Tai, YT
Bianchini, G
Richardson, PG
Anderson, KC
Tonon, G
AF Cottini, Francesca
Hideshima, Teru
Suzuki, Rikio
Tai, Yu-Tzu
Bianchini, Giampaolo
Richardson, Paul G.
Anderson, Kenneth C.
Tonon, Giovanni
TI Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma
SO CANCER DISCOVERY
LA English
DT Article
ID ONCOGENE-INDUCED SENESCENCE; MULTIPLE-MYELOMA; C-MYC; GENOMIC
INSTABILITY; REPLICATION STRESS; CANCER-CELLS; CHROMOSOMAL INSTABILITY;
EXPRESSION PROFILES; PARP INHIBITORS; MOUSE MODEL
AB Ongoing DNA damage is a common feature of epithelial cancers. Here, we show that tumor cells derived from multiple myeloma, a disease of clonal plasma cells, demonstrate DNA-replicative stress, leading to DNA damage. We identified a poor-prognosis subset of multiple myeloma with extensive chromosomal instability and replicative stress, which rely on ATR to compensate for DNA-replicative stress; conversely, silencing of ATR or treatment with a specific ATR inhibitor triggers multiple myeloma cell apoptosis. We show that oncogenes, such as MYC, induce DNA damage in multiple myeloma cells not only by increased replicative stress, but also via increased oxidative stress, and that reactive oxygen species-inducer piperlongumine triggers further DNA damage and apoptosis. Importantly, ATR inhibition combined with piperlongumine triggers synergistic multiple myeloma cytotoxicity. This synthetic lethal approach, enhancing oxidative stress while concomitantly blocking replicative stress response, provides a novel combination targeted therapy to address an unmet medical need in this subset of multiple myeloma.
SIGNIFICANCE: Multiple myeloma remains an incurable disease. We have identified a subset of multiple myeloma patients with poor prognosis, whose tumors present chromosomal instability, replicative and oxidative stress, and DNA damage. We define a synthetic lethal approach enhancing oxidative stress while targeting replicative stress response, inducing tumor cell apoptosis in this patient subset. Cancer (C) 2015 AACR.
C1 [Cottini, Francesca; Hideshima, Teru; Suzuki, Rikio; Tai, Yu-Tzu; Richardson, Paul G.; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
[Cottini, Francesca; Tonon, Giovanni] IRCCS, San Raffaele Sci Inst, Div Expt Oncol, Funct Genom Canc Unit, Milan, Italy.
[Bianchini, Giampaolo] Hosp San Raffaele, IRCCS, Dept Med Oncol, I-20132 Milan, Italy.
RP Tonon, G (reprint author), Ist Sci San Raffaele, Via Olgettina 60, I-20132 Milan, Italy.
EM kenneth_anderson@dfci.harvard.edu; tonon.giovanni@hsr.it
FU Associazione Italiana per la Ricerca sul Cancro (AIRC Investigator
Grants and Special Program Molecular Clinical Oncology) [9965]; NIH [NIH
SPORE P50 100707, P01 78378, R01 50947]
FX This work was supported by the Associazione Italiana per la Ricerca sul
Cancro (AIRC Investigator Grants and Special Program Molecular Clinical
Oncology, 5 per mille no. 9965; to G. Tonon). K.C. Anderson is an
American Cancer Society Clinical Research Professor and is supported by
the NIH grants NIH SPORE P50 100707, P01 78378, and R01 50947.
NR 57
TC 12
Z9 12
U1 1
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2159-8274
EI 2159-8290
J9 CANCER DISCOV
JI Cancer Discov.
PD SEP
PY 2015
VL 5
IS 9
BP 972
EP 987
DI 10.1158/2159-8290.CD-14-0943
PG 16
WC Oncology
SC Oncology
GA CQ8DA
UT WOS:000360835200027
PM 26080835
ER
PT J
AU Putt, M
Hahn, VS
Januzzi, JL
Sawaya, H
Sebag, IA
Plana, JC
Picard, MH
Carver, JR
Halpern, EF
Kuter, I
Passeri, J
Cohen, V
Banchs, J
Martin, RP
Gerszten, RE
Scherrer-Crosbie, M
Ky, B
AF Putt, Mary
Hahn, Virginia Shalkey
Januzzi, James L.
Sawaya, Heloisa
Sebag, Igal A.
Plana, Juan Carlos
Picard, Michael H.
Carver, Joseph R.
Halpern, Elkan F.
Kuter, Irene
Passeri, Jonathan
Cohen, Victor
Banchs, Jose
Martin, Randolph P.
Gerszten, Robert E.
Scherrer-Crosbie, Marielle
Ky, Bonnie
TI Longitudinal Changes in Multiple Biomarkers Are Associated with
Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin,
Taxanes, and Trastuzumab
SO CLINICAL CHEMISTRY
LA English
DT Article
ID PLACENTAL GROWTH-FACTOR; HIGH-DOSE CHEMOTHERAPY; HEART-FAILURE; ADJUVANT
TRASTUZUMAB; PROGNOSTIC VALUE; TROPONIN-I; CARDIAC DYSFUNCTION;
OXIDATIVE STRESS; EUROPEAN-SOCIETY; ECHOCARDIOGRAPHY
AB BACKGROUND: Biomarkers may play an important role in identifying patients at risk for cancer therapy cardiotoxicity. Our objectives were to define the patterns of change in biomarkers with cancer therapy and their associations with cardiotoxicity.
METHODS: In a multicenter cohort of 78 breast cancer patients undergoing doxorubicin and trastuzumab therapy, 8 biomarkers were evaluated at baseline and every 3 months over a maximum follow-up of 15 months. These biomarkers, hypothesized to be mechanistically relevant to cardiotoxicity, included high-sensitivity cardiac troponin I (hs-cTnI), high-sensitivity C-reactive protein (hsCRP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), growth differentiation factor 15 (GDF-15), myeloperoxidase (MPO), placental growth factor (PlGF), soluble fms-like tyrosine kinase receptor-1 (sFlt-1), and galectin 3 (gal-3). We determined if biomarker increases were associated with cardiotoxicity at the same visit and the subsequent visit over the entire course of therapy. Cardiotoxicity was defined by the Cardiac Review and Evaluation Criteria; alternative definitions were also considered.
RESULTS: Across the entire cohort, all biomarkers except NT-proBNP and gal-3 demonstrated increases by 3 months; these increases persisted for GDF-15, PlGF, and hs-cTnI at 15 months. Increases in MPO, PlGF, and GDF-15 were associated with cardiotoxicity at the same visit [MPO hazard ratio 1.38 (95% CI 1.10-1.71), P = 0.02; PlGF 3.78 (1.30-11.0), P = 0.047; GDF-15 1.71 (1.15-2.55), P = 0.01] and the subsequent visit. MPO was robust to alternative outcome definitions.
CONCLUSIONS: Increases in MPO are associated with cardiotoxicity over the entire course of doxorubicin and trastuzumab therapy. Assessment with PlGF and GDF-15 may also be of value. These findings motivate validation studies in additional cohorts. (C) 2015 American Association for Clinical Chemistry
C1 [Putt, Mary; Hahn, Virginia Shalkey; Carver, Joseph R.; Ky, Bonnie] Univ Penn, Philadelphia, PA 19104 USA.
[Januzzi, James L.; Sawaya, Heloisa; Picard, Michael H.; Halpern, Elkan F.; Kuter, Irene; Passeri, Jonathan; Gerszten, Robert E.; Scherrer-Crosbie, Marielle] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Januzzi, James L.; Sawaya, Heloisa; Picard, Michael H.; Halpern, Elkan F.; Kuter, Irene; Passeri, Jonathan; Gerszten, Robert E.; Scherrer-Crosbie, Marielle] Harvard Univ, Sch Med, Boston, MA USA.
[Sebag, Igal A.; Cohen, Victor] Sir Mortimer B Davis Jewish Hosp, Montreal, CA USA.
[Sebag, Igal A.; Cohen, Victor] McGill Univ, Montreal, CA USA.
[Plana, Juan Carlos] Baylor Coll Med, Houston, TX 77030 USA.
[Banchs, Jose] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Martin, Randolph P.] Piedmont Heart Inst, Atlanta, GA USA.
RP Ky, B (reprint author), Univ Penn, Sch Med, Smilow Translat Res Ctr, 3400 Civic Ctr Blvd,11-105, Philadelphia, PA 19104 USA.
EM bonnie.ky@uphs.upenn.edu
OI Picard, Michael/0000-0002-9264-3243
FU Siemens; Thermo Fisher; Singulex; Siemens HealthCare Diagnostics; Abbott
Laboratories; Roman Desanctis Distinguished Scholar Award; NHLBI
Proteomics Center [HHSN268201000033C]; Susan G. Komen for the Cure
Foundation [KG 080818]; Claflin Distinguished Scholar Award; Clinical
Innovation Award; Kynett Focus Junior Faculty Investigator Award;
NIH/NHLBI [R01 HL118018]
FX This study received support from Siemens, Thermo Fisher, and Singulex,
as well as assay support provided by Siemens HealthCare Diagnostics and
Abbott Laboratories. J. Januzzi, the Roman Desanctis Distinguished
Scholar Award; R.E. Gerszten, NHLBI Proteomics Center contract
HHSN268201000033C; M. Scherrer-Crosbie, investigator-initiated grant
from the Susan G. Komen for the Cure Foundation (KG 080818), Claflin
Distinguished Scholar Award, and Clinical Innovation Award; B. Ky, the
Kynett Focus Junior Faculty Investigator Award and R01 HL118018 from
NIH/NHLBI.
NR 35
TC 11
Z9 13
U1 1
U2 3
PU AMER ASSOC CLINICAL CHEMISTRY
PI WASHINGTON
PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA
SN 0009-9147
EI 1530-8561
J9 CLIN CHEM
JI Clin. Chem.
PD SEP
PY 2015
VL 61
IS 9
BP 1164
EP 1172
DI 10.1373/clinchem.2015.241232
PG 9
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA CR1TD
UT WOS:000361107000009
PM 26220066
ER
PT J
AU Rotrnan, JA
Plodkowski, AJ
Hayes, SA
de Groot, PM
Shepard, JAO
Munden, RF
Ginsberg, MS
AF Rotrnan, Jessica A.
Plodkowski, Andrew J.
Hayes, Sara A.
de Groot, Patricia M.
Shepard, Jo-Anne O.
Munden, Reginald F.
Ginsberg, Michelle S.
TI Postoperative complications after thoracic surgery for lung cancer
SO CLINICAL IMAGING
LA English
DT Review
DE CT; Chest; Lung cancer; Surgery
ID POSTPNEUMONECTOMY BRONCHOPLEURAL FISTULA; RESPIRATORY-DISTRESS-SYNDROME;
PULMONARY RESECTION; WEDGE RESECTION; CT FINDINGS; ESOPHAGOPLEURAL
FISTULA; IMAGING FEATURES; SLEEVE LOBECTOMY; BRONCHIAL STUMP; STAGE IA
AB Lung cancer is the leading cause of cancer-related deaths in the United States. Several surgical techniques are currently used as part of the standard of care for early-stage lung cancer. Differentiating normal postoperative changes from complications is essential in the management of these patients. This article will review the various surgical approaches used, ranging from wedge resection to pneumonectomy, and will outline their expected postsurgical changes. Early and late postsurgical complications will be described, some of which are unique to the type of surgery performed. In addition, local tumor recurrence is a form of postoperative complication and must be distinguished from typical postoperative or postradiation change. Knowledge of both common and uncommon postoperative complications is crucial in the follow-up of lung cancer patients. Summary Statement Familiarity with the appearance of postoperative complications in lung cancer patients is vital to distinguish it from the normal postoperative or postradiation appearance in follow-up imaging. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Rotrnan, Jessica A.] NY Presbyterian Weill Cornell Med Ctr, Dept Radiol, New York, NY 10065 USA.
[Plodkowski, Andrew J.; Hayes, Sara A.; Ginsberg, Michelle S.] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10065 USA.
[de Groot, Patricia M.] Univ Texas MD Anderson Canc Ctr, Dept Radiol, Houston, TX 77030 USA.
[Shepard, Jo-Anne O.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Munden, Reginald F.] Houston Methodist Hosp, Dept Radiol, Houston, TX 77030 USA.
RP Ginsberg, MS (reprint author), Mem Sloan Kettering Canc Ctr, Dept Radiol, 1275 York Ave, New York, NY 10065 USA.
EM rotmanj@mskcc.org; plodkowa@mskcc.org; hayess@mskcc.org;
PDeGroot@mdanderson.org; jshepard@partners.org;
rfmunden@houstonmethodist.org; ginsberm@mskcc.org
OI Plodkowski, Andrew/0000-0002-3772-370X
NR 90
TC 0
Z9 0
U1 2
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0899-7071
EI 1873-4499
J9 CLIN IMAG
JI Clin. Imaging
PD SEP-OCT
PY 2015
VL 39
IS 5
BP 735
EP 749
DI 10.1016/j.clinimag.2015.05.013
PG 15
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CQ7IT
UT WOS:000360776900002
ER
PT J
AU Baheti, AD
Sewatkar, R
Hornick, JL
Saboo, SS
Jagannathan, JP
Ramaiya, NH
Tirumani, SH
AF Baheti, Akshay D.
Sewatkar, Rani
Hornick, Jason L.
Saboo, Sachin S.
Jagannathan, Jyothi P.
Ramaiya, Nikhil H.
Tirumani, Sree Harsha
TI Imaging features of primary and recurrent intrathoracic synovial
sarcoma: a single-institute experience
SO CLINICAL IMAGING
LA English
DT Article
DE Synovial sarcoma; Intrathoracic; Pleural; Pulmonary
ID RETROSPECTIVE ANALYSIS; PROGNOSTIC-FACTORS; PRIMARY PULMONARY;
MULTICENTER
AB Objective: The objective was to study the imaging features of primary and metastatic intrathoracic synovial sarcoma (ISS).
Materials and methods: We reviewed the imaging of 42 patients with ISS (31 pleural, 7 intrapulmonary, 4 mediastinal), with baseline imaging of 19 patients and follow-up imaging in all.
Results: Primary tumors (n=19) were well circumscribed (15/19), homogeneous or heterogeneously enhancing, with mean size 9.1 cm (range: 1.8-25 cm). Recurrent/metastatic disease developed in 28/42 patients (67%). Lung was the most common site of metastases (21/28), with most of them predominantly pleural (11/21). On pathology, 30 patients had monophasic tumors, and 6 each had biphasic tumors and poorly differentiated tumors.
Conclusion: Intrathoracic SS most commonly presents as a large heterogeneous pleural mass without associated adenopathy. Lung metastases are often pleural based and ipsilateral. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Baheti, Akshay D.; Saboo, Sachin S.; Jagannathan, Jyothi P.; Ramaiya, Nikhil H.; Tirumani, Sree Harsha] Harvard Univ, Dana Farber Canc Inst, Dept Imaging, Boston, MA 02215 USA.
[Baheti, Akshay D.; Sewatkar, Rani; Saboo, Sachin S.; Jagannathan, Jyothi P.; Ramaiya, Nikhil H.; Tirumani, Sree Harsha] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Hornick, Jason L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Saboo, Sachin S.] Univ Texas SW Med Ctr Dallas, Dept Radiol, Dallas, TX 75390 USA.
RP Baheti, AD (reprint author), Dept Imaging, 450 Brookline Ave, Boston, MA 02215 USA.
EM akshaybaheti@gmail.com
NR 23
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0899-7071
EI 1873-4499
J9 CLIN IMAG
JI Clin. Imaging
PD SEP-OCT
PY 2015
VL 39
IS 5
BP 803
EP 808
DI 10.1016/j.clinimag.2015.04.004
PG 6
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CQ7IT
UT WOS:000360776900013
PM 25963243
ER
PT J
AU Hassanzadeh, E
Chang, CY
Huang, AJ
Shaqdan, K
Mansouri, M
Aran, S
Abujudeh, HH
AF Hassanzadeh, Elmira
Chang, Connie Y.
Huang, Ambrose J.
Shaqdan, Khalid
Mansouri, Mohammad
Aran, Shima
Abujudeh, Hani H.
TI CT and MRI manifestations of luxatio erecta humeri and a review of the
literature
SO CLINICAL IMAGING
LA English
DT Article
DE Luxatio erecta humeri; Inferior shoulder dislocation; MRI; Cr
arthrogram; MR arthrogram; CT scan
AB Aim: We aimed to study luxatio erecta humeri using advanced imaging modalities.
Method: Patients with luxatio erecta humeri and a subsequent magnetic resonance imaging (MRI) and/or computed tomography (CT) scan were included in this study.
Results: Among 10 identified cases, we detected 2 rotator cuff, 4 labral, and 2 inferior glenohumeral ligament tears as well as 2 glenohumeral cartilage defects. We observed six comminuted displaced greater tuberosity fractures, four anterior inferior glenoid fractures, and four impaction fractures of humeral head.
Conclusion: This study provides detailed radiologic findings associated with luxatio erecta humeri using MRI and CT. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Hassanzadeh, Elmira; Chang, Connie Y.; Huang, Ambrose J.; Shaqdan, Khalid; Mansouri, Mohammad; Aran, Shima; Abujudeh, Hani H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA 02114 USA.
RP Abujudeh, HH (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, 55 Fruit St, Boston, MA 02114 USA.
EM ehassanzadeh@partners.org; cychang@partners.org; ajhuang@partners.org;
kshaqdan@partners.org; mmansouri1@mgh.harvard.edu;
aran.shima@mgh.harvard.edu; Habujudeh@partners.org
RI Mansouri, Mohammad/M-4774-2016
OI Mansouri, Mohammad/0000-0002-7472-1287
NR 16
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0899-7071
EI 1873-4499
J9 CLIN IMAG
JI Clin. Imaging
PD SEP-OCT
PY 2015
VL 39
IS 5
BP 876
EP 879
DI 10.1016/j.clinimag.2015.04.009
PG 4
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CQ7IT
UT WOS:000360776900027
PM 25979120
ER
PT J
AU McNamara, P
Minsky, A
Pae, V
Harris, E
Pace-Schott, E
Auerbach, S
AF McNamara, Patrick
Minsky, April
Pae, Victoria
Harris, Erica
Pace-Schott, Edward
Auerbach, Sanford
TI Aggression in Nightmares and Unpleasant Dreams and in People Reporting
Recurrent Nightmares
SO DREAMING
LA English
DT Article
DE nightmares; content analysis; sex differences; dreams; aggression
ID SLEEP; PSYCHOPATHOLOGY; PREVALENCE; DISORDERS
AB We used unique data sets from Dreamboard and Survey Monkey to test the hypothesis that aggression levels would vary significantly with content of recurrent nightmares, nonrecurrent nightmares, and unpleasant dreams. Exactly 475 nightmares and 433 unpleasant dreams were collected from Dreamboard users, while 135 nightmares were collected from individuals who reported having recurrent nightmares via a SurveyMonkey survey. Results demonstrated that physical aggression and anxiety levels were significantly higher for nightmares from individuals who reported recurrent nightmares relative to nightmares from people not reporting recurrent nightmares who in turn reported nightmares, which evidenced higher physical aggression levels relative to unpleasant dreams. Use of personal pronouns, verbs, and social terms were significantly reduced in recurrent nightmares relative to regular nightmares and unpleasant dreams. Aggressors were most often supernatural agents in recurrent nightmares; unfamiliar males in regular nightmares and familiar males in unpleasant dreams. Physical aggression against the dreamer was the most common theme in nightmares while interpersonal conflict was the most common theme in unpleasant dreams. Nightmares associated with awakenings evidenced significantly higher levels of aggression relative to nightmares not associated with awakenings. People with recurrent nightmares were 3 times more likely to report a relative on their maternal side with recurrent nightmares. We conclude that levels of physical aggression within the dream and targeted against the dreamer distinguishes recurrent from nonrecurrent nightmares and unpleasant dreams.
C1 [McNamara, Patrick; Auerbach, Sanford] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA.
[McNamara, Patrick] Northcent Univ, Grad Sch, Prescott Valley, AZ USA.
[Minsky, April] VA New England Hlth Care Syst, Dept Neurol, Boston, MA 02130 USA.
[Pae, Victoria] Boston Univ, Dept Psychol, Boston, MA 02215 USA.
[Harris, Erica] Naval Hlth Res Ctr, Hlth & Behav Sci 163, San Diego, CA USA.
[Pace-Schott, Edward] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
[Pace-Schott, Edward] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
RP McNamara, P (reprint author), VA New England Hlth Care Syst, Dept Neurol, 150 South Huntington Ave,A9-45, Boston, MA 02130 USA.
EM mcnamar@bu.edu
NR 27
TC 1
Z9 1
U1 3
U2 12
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 1053-0797
EI 1573-3351
J9 DREAMING
JI Dreaming
PD SEP
PY 2015
VL 25
IS 3
BP 190
EP 205
DI 10.1037/a0039273
PG 16
WC Psychology, Multidisciplinary
SC Psychology
GA CR0EW
UT WOS:000360992200002
ER
PT J
AU Kesselheim, AS
Campbell, EG
Schneeweiss, S
Rausch, P
Lappin, BM
Zhou, EH
Seeger, JD
Brownstein, JS
Woloshin, S
Schwartz, LM
Toomey, T
Dal Pan, GJ
Avorn, J
AF Kesselheim, Aaron S.
Campbell, Eric G.
Schneeweiss, Sebastian
Rausch, Paula
Lappin, Brian M.
Zhou, Esther H.
Seeger, John D.
Brownstein, John S.
Woloshin, Steven
Schwartz, Lisa M.
Toomey, Timothy
Dal Pan, Gerald J.
Avorn, Jerry
TI Methodological Approaches to Evaluate the Impact of FDA Drug Safety
Communications (vol 38, pg 565, 2015)
SO DRUG SAFETY
LA English
DT Correction
C1 [Kesselheim, Aaron S.; Schneeweiss, Sebastian; Seeger, John D.; Toomey, Timothy; Avorn, Jerry] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Program Regulat Therapeut & Law PORTAL, Boston, MA 02120 USA.
[Kesselheim, Aaron S.; Campbell, Eric G.; Schneeweiss, Sebastian; Seeger, John D.; Brownstein, John S.; Toomey, Timothy; Avorn, Jerry] Harvard Univ, Sch Med, Boston, MA 02120 USA.
[Campbell, Eric G.] Massachusetts Gen Hosp, Mongan Inst Hlth Policy Res, Boston, MA 02114 USA.
[Rausch, Paula] Food & Drug Adm, Ctr Drug Evaluat & Res, Off Commun, Silver Spring, MD 20993 USA.
[Lappin, Brian M.] Food & Drug Adm, Off Commissioner, Off Planning, Silver Spring, MD 20993 USA.
[Zhou, Esther H.] Food & Drug Adm, Ctr Drug Evaluat & Res, Off Surveillance & Epidemiol, Silver Spring, MD 20993 USA.
[Brownstein, John S.] Childrens Hosp, Childrens Hosp Epidemiol Grp, Boston, MA 02115 USA.
[Woloshin, Steven; Schwartz, Lisa M.] Dartmouth Inst Hlth Policy & Clin Practice, Ctr Med & Media, Lebanon, NH USA.
[Dal Pan, Gerald J.] Food & Drug Adm, Ctr Drug Evaluat & Res, Off Surveillance & Epidemiol, Silver Spring, MD 20993 USA.
RP Kesselheim, AS (reprint author), Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Program Regulat Therapeut & Law PORTAL, Suite 3030,1620 Tremont St, Boston, MA 02120 USA.
EM akesselheim@partners.org
RI Schneeweiss, Sebastian/C-2125-2013
NR 1
TC 0
Z9 0
U1 0
U2 1
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 0114-5916
EI 1179-1942
J9 DRUG SAFETY
JI Drug Saf.
PD SEP
PY 2015
VL 38
IS 9
BP 845
EP 845
DI 10.1007/s40264-015-0329-1
PG 1
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy;
Toxicology
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy;
Toxicology
GA CQ9ME
UT WOS:000360938200009
PM 26201399
ER
PT J
AU Steffel, J
Giugliano, RP
Braunwald, E
Murphy, SA
Atar, D
Heidbuchel, H
Camm, AJ
Antman, EM
Ruff, CT
AF Steffel, J.
Giugliano, R. P.
Braunwald, E.
Murphy, S. A.
Atar, D.
Heidbuchel, H.
Camm, A. J.
Antman, E. M.
Ruff, C. T.
TI Edoxaban vs. warfarin in patients with atrial fibrillation on
amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial
SO EUROPEAN HEART JOURNAL
LA English
DT Article
DE Edoxaban; Anticoagulation; Amiodarone; Atrial fibrillation
ID ORAL THROMBIN INHIBITOR; FACTOR XA INHIBITOR; DABIGATRAN ETEXILATE;
CARDIOVASCULAR DRUGS; P-GLYCOPROTEIN
AB Background In the ENGAGE AF-TIMI 48 trial, the higher-dose edoxaban (HDE) regimen had a similar incidence of ischaemic stroke compared with warfarin, whereas a higher incidence was observed with the lower-dose regimen (LDE). Amiodarone increases edoxaban plasma levels via P-glycoprotein inhibition. The current pre-specified exploratory analysis was performed to determine the effect of amiodarone on the relative efficacy and safety profile of edoxaban.
Methods and results At randomization, 2492 patients (11.8%) were receiving amiodarone. The primary efficacy endpoint of stroke or systemic embolic event was significantly lower with LDE compared with warfarin in amiodarone treated patients vs. patients not on amiodarone (hazard ratio [HR] 0.60, 95% confidence intervals [CIs] 0.36-0.99 and HR 1.20, 95% CI 1.03-1.40, respectively; P interaction < 0.01). In patients randomized to HDE, no such interaction for efficacy was observed (HR 0.73, 95% CI 0.46-1.17 vs. HR 0.89, 95% CI 0.75-1.05, P interaction = 0.446). Major bleeding was similar in patients on LDE (HR 0.35, 95% CI 0.21-0.59 vs. HR 0.53, 95% CI 0.46-0.61, P interaction = 0.131) and HDE (HR 0.94, 95% CI 0.65-1.38 vs. HR 0.79, 95% CI 0.69-0.90, P interaction = 0.392) when compared with warfarin, independent of amiodarone use.
Conclusions Patients randomized to the LDE treated with amiodarone at the time of randomization demonstrated a significant reduction in ischaemic events vs. warfarin when compared with those not on amiodarone, while preserving a favourable bleeding profile. In contrast, amiodarone had no effect on the relative efficacy and safety of HDE.
C1 [Steffel, J.] Univ Heart Ctr Zurich, Dept Cardiol, Zurich, Switzerland.
[Giugliano, R. P.; Braunwald, E.; Murphy, S. A.; Antman, E. M.; Ruff, C. T.] Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, Boston, MA 02115 USA.
[Atar, D.] Univ Oslo, Oslo Univ Hosp Ulleval, Dept Cardiol B, Oslo, Norway.
[Heidbuchel, H.] Hasselt Univ, Hasselt, Belgium.
[Heidbuchel, H.] Jessa Hosp, Ctr Heart, Hasselt, Belgium.
[Camm, A. J.] St Georges Univ London, Div Clin Sci, London SW17 0RE, England.
RP Ruff, CT (reprint author), Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, 350 Longwood Ave,1st Floor Off, Boston, MA 02115 USA.
EM cruff@partners.org
FU Daiichi Sankyo Pharma Development
FX The ENGAGE AF-TIMI 48 study was supported by Daiichi Sankyo Pharma
Development.
NR 16
TC 15
Z9 15
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
EI 1522-9645
J9 EUR HEART J
JI Eur. Heart J.
PD SEP 1
PY 2015
VL 36
IS 33
BP 2239
EP 2245
DI 10.1093/eurheartj/ehv201
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CR3BR
UT WOS:000361205800015
PM 25971288
ER
PT J
AU Kortman, GAM
Mulder, MLM
Richters, TJW
Shanmugam, NKN
Trebicka, E
Boekhorst, J
Timmerman, HM
Roelofs, R
Wiegerinck, ET
Laarakkers, CM
Swinkels, DW
Bolhuis, A
Cherayil, BJ
Tjalsma, H
AF Kortman, Guus A. M.
Mulder, Michelle L. M.
Richters, Thijs J. W.
Shanmugam, Nanda K. N.
Trebicka, Estela
Boekhorst, Jos
Timmerman, Harro M.
Roelofs, Rian
Wiegerinck, Erwin T.
Laarakkers, Coby M.
Swinkels, Dorine W.
Bolhuis, Albert
Cherayil, Bobby J.
Tjalsma, Harold
TI Low dietary iron intake restrains the intestinal inflammatory response
and pathology of enteric infection by food-borne bacterial pathogens
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
DE Caenorhabditis elegans; gut microbiome; intestinal pathogens; iron
supplementation; lipocalin-2
ID GELATINASE-ASSOCIATED LIPOCALIN; CITROBACTER-RODENTIUM INFECTION;
INDUCED COLITIS; GUT MICROBIOTA; ULCERATIVE-COLITIS; CONTROLLED-TRIAL;
BOWEL-DISEASE; RAT MODEL; MICE; SUPPLEMENTATION
AB Orally administrated iron is suspected to increase susceptibility to enteric infections among children in infection endemic regions. Here we investigated the effect of dietary iron on the pathology and local immune responses in intestinal infection models. Mice were held on iron-deficient, normal iron, or high iron diets and after 2 weeks they were orally challenged with the pathogen Citrobacter rodentium. Microbiome analysis by pyrosequencing revealed profound iron-and infection-induced shifts in microbiota composition. Fecal levels of the innate defensive molecules and markers of inflammation lipocalin-2 and calprotectin were not influenced by dietary iron intervention alone, but were markedly lower in mice on the iron-deficient diet after infection. Next, mice on the iron-deficient diet tended to gain more weight and to have a lower grade of colon pathology. Furthermore, survival of the nematode Caenorhabditis elegans infected with Salmonella enterica serovar Typhimurium was prolonged after iron deprivation. Together, these data show that iron limitation restricts disease pathology upon bacterial infection. However, our data also showed decreased intestinal inflammatory responses of mice fed on high iron diets. Thus additionally, our study indicates that the effects of iron on processes at the intestinal host-pathogen interface may highly depend on host iron status, immune status, and gut microbiota composition.
C1 [Kortman, Guus A. M.; Mulder, Michelle L. M.; Richters, Thijs J. W.; Roelofs, Rian; Wiegerinck, Erwin T.; Laarakkers, Coby M.; Swinkels, Dorine W.; Tjalsma, Harold] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Mol Life Sci, Dept Lab Med Translat Metab Lab, NL-6500 HB Nijmegen, Netherlands.
[Mulder, Michelle L. M.; Richters, Thijs J. W.; Shanmugam, Nanda K. N.; Trebicka, Estela; Cherayil, Bobby J.] Massachusetts Gen Hosp, Mucosal Immunol & Biol Res Ctr, Boston, MA 02114 USA.
[Boekhorst, Jos; Timmerman, Harro M.] NIZO Food Res BV, Ede, Netherlands.
[Bolhuis, Albert] Univ Bath, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England.
RP Swinkels, DW (reprint author), Radboud Univ Nijmegen, Med Ctr, Dept Lab Med TML 830, POB 9101, NL-6500 HB Nijmegen, Netherlands.
EM dorine.swinkels@radboudumc.nl
RI Kortman, Guus/F-9690-2010; Swinkels, D.W./H-8098-2014
OI Bolhuis, Albert/0000-0001-9307-0515;
FU Dutch Digestive Diseases Foundation [WO 10-53, 12-02s, 12-03s]; U.S.
National Institutes of Health [R01 AI089700]; Radboud Honours programme;
Dutch Cancer foundation (KWF)
FX We thank our colleagues and collaborators Anne-Claire Martines, Saskia
van Schalkwijk, and Bas Dutilh for useful discussions and/or technical
assistance. We are also grateful to Dr. Haining Shi for assistance with
scoring of colon histopathology. This work was in part supported by the
Dutch Digestive Diseases Foundation (project WO 10-53). B.J.C. was
supported by a U.S. National Institutes of Health grant (R01 AI089700).
M.L.M.M. and T.J.W.R. were in part supported by scholarships from the
Radboud Honours programme, the Dutch Digestive Diseases foundation
(12-02s and 12-03s), and the Dutch Cancer foundation (KWF).
NR 72
TC 6
Z9 6
U1 2
U2 16
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD SEP
PY 2015
VL 45
IS 9
BP 2553
EP 2567
DI 10.1002/eji.201545642
PG 15
WC Immunology
SC Immunology
GA CQ9GK
UT WOS:000360921200012
PM 26046550
ER
PT J
AU Degani-Costa, LH
Levarge, B
Digumarthy, SR
Eisman, AS
Harris, RS
Lewis, GD
AF Degani-Costa, Luiza H.
Levarge, Barbara
Digumarthy, Subba R.
Eisman, Aaron S.
Harris, R. Scott
Lewis, Gregory D.
TI Pulmonary vascular response patterns during exercise in interstitial
lung disease
SO EUROPEAN RESPIRATORY JOURNAL
LA English
DT Article
ID ARTERIAL-HYPERTENSION; SYSTEMIC-SCLEROSIS; FIBROSIS; PREVALENCE;
DIAGNOSIS
AB When overt pulmonary hypertension arises in interstitial lung disease (ILD), it contributes to exercise intolerance. We sought to determine the functional significance of abnormal pulmonary arterial pressure (PAP) responses to exercise in ILD.
27 ILD patients and 11 age-matched controls underwent invasive cardiopulmonary exercise testing (iCPET). Mean PAP (mPAP) was indexed to cardiac output (Q'T) during exercise, with a mPAP-Q'T slope >= 3 mmHg.min.L-1 defined as an abnormal pulmonary vascular response.
All control subjects had mPAP-Q'T slopes <3 mmHg.min.L-1 (mean +/- SEM 1.5 +/- 0.1 mmHg.min.L-1). 15 ILD patients had mPAP-Q'T slopes >= 3 mmHg.min.L-1 (4.1 +/- 0.2 mmHg.min.L-1) and were labelled as having ILD plus pulmonary vascular dysfunction (PVD). Subjects without pulmonary hypertension and with mPAP-Q'T slopes <3 mmHg.min.L-1 (1.9 +/- 0.2 mmHg.min.L-1) were labelled as ILD minus PVD (n=12). ILD+PVD and ILD-PVD patients did not differ in terms of age, sex, body mass index, pulmonary function testing or degree of exercise oxygen desaturation. Peak oxygen consumption was lower in ILD+PVD than in ILD-PVD (13.0 +/- 0.9 versus 17 +/- 1.1 mL.kg(-1).min(-1), p=0.012) and controls (19.8 +/- 1.7 mL.kg(-1).min(-1), p=0.003). ILD+PVD patients had increased dead space volume (V-D)/tidal volume (V-T) and minute ventilation/carbon dioxide production at the anaerobic threshold.
In ILD, mPAP-Q'T slope >= 3 mmHg.min.L-1 is associated with lower peak oxygen consumption, increased V-D/V-T and inefficient ventilation. While noninvasive parameters were unable to predict those with abnormal pulmonary vascular responses to exercise, iCPET-derived mPAP-Q'T slope may aid in identifying physiologically significant, early pulmonary vascular disease in ILD.
C1 [Degani-Costa, Luiza H.] Univ Fed Sao Paulo, Div Resp, Paulista Sch Med, Sao Paulo, Brazil.
[Degani-Costa, Luiza H.; Levarge, Barbara; Harris, R. Scott; Lewis, Gregory D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pulm & Crit Care Unit, Boston, MA USA.
[Digumarthy, Subba R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Thorac Imaging & Intervent Div, Boston, MA USA.
[Eisman, Aaron S.; Lewis, Gregory D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA.
RP Lewis, GD (reprint author), Cardiac Unit Associates, 55 Fruit St, Boston, MA 02114 USA.
EM glewis@partners.org
FU Hassenfeld Clinical Scholar Award; National Heart, Lung, and Blood
Institute grant [R01HL119154]
FX This work was supported by the Hassenfeld Clinical Scholar Award (G.D.
Lewis) and National Heart, Lung, and Blood Institute grant R01HL119154
(G.D. Lewis). Funding information for this article has been deposited
with FundRef.
NR 29
TC 7
Z9 7
U1 0
U2 4
PU EUROPEAN RESPIRATORY SOC JOURNALS LTD
PI SHEFFIELD
PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND
SN 0903-1936
EI 1399-3003
J9 EUR RESPIR J
JI Eur. Resp. J.
PD SEP
PY 2015
VL 46
IS 3
BP 738
EP 749
DI 10.1183/09031936.00191014
PG 12
WC Respiratory System
SC Respiratory System
GA CQ6BM
UT WOS:000360689400024
PM 25976688
ER
PT J
AU Willard-Grace, R
Dube, K
Hessler, D
O'Brien, B
Earnest, G
Gupta, R
Shunk, R
Grumbach, K
AF Willard-Grace, Rachel
Dube, Kate
Hessler, Danielle
O'Brien, Bridget
Earnest, Gillian
Gupta, Reena
Shunk, Rebecca
Grumbach, Kevin
TI Panel Management, Team Culture, and Worklife Experience
SO FAMILIES SYSTEMS & HEALTH
LA English
DT Article
DE burnout; panel management; patient care team; primary health care; team
culture
ID CENTERED MEDICAL HOME; RANDOMIZED-CONTROLLED-TRIAL; PRIMARY-CARE;
INTERNAL-MEDICINE; LOWER BURNOUT; PATIENT-CARE; LOW-INCOME; PHYSICIANS;
SATISFACTION; PROGRAM
AB Burnout and professional dissatisfaction are threats to the primary care workforce. We investigated the relationship between panel management capability, team culture, cynicism, and perceived "do-ability" of primary care among primary care providers (PCPs) and staff in primary care practices. We surveyed 326 PCPs and 142 staff members in 10 county-administered, 6 university-run, and 3 Veterans Affairs primary care clinics in a large urban area in 2013. Predictor variables included capability for performing panel management and perception of team culture. Outcome variables included 2 work experience measures-the Maslach Burnout Inventory cynicism scale and a 1-item measure of the "do-ability" of primary care this year compared with last year. Generalized Estimation Equation (GEE) models were used to account for clustering at the clinic level. Greater panel management capability and higher team culture were associated with lower cynicism among PCPs and staff and higher reported "do-ability" of primary care among PCPs. Panel management capability and team culture interacted to predict the 2 work experience outcomes. Among PCPs and staff reporting high team culture, there was little association between panel management capability and the outcomes, which were uniformly positive. However, there was a strong relationship between greater panel management capability and improved work experience outcomes for PCPs and staff reporting low team culture. Team-based processes of care such as panel management may be an important strategy to protect against cynicism and dissatisfaction in primary care, particularly in settings that are still working to improve their team culture.
C1 [Willard-Grace, Rachel; Dube, Kate; Hessler, Danielle; Grumbach, Kevin] Univ Calif San Francisco, Dept Family & Community Med, Ctr Excellence Primary Care, San Francisco, CA 94114 USA.
[O'Brien, Bridget; Earnest, Gillian; Shunk, Rebecca] San Francisco VA Med Ctr, Ctr Excellence Primary Care Educ, San Francisco, CA USA.
[O'Brien, Bridget; Gupta, Reena] Univ Calif San Francisco, San Francisco Gen Hosp, Div Gen Internal Med, San Francisco, CA 94114 USA.
[Gupta, Reena] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Family & Community Med, Ctr Excellence Primary Care, San Francisco, CA 94114 USA.
RP Willard-Grace, R (reprint author), Univ Calif San Francisco, Dept Family & Community Med, Ctr Excellence Primary Care, 995 Potrero Ave,Ward 83, San Francisco, CA 94114 USA.
EM willardr@fcm.ucsf.edu
RI Grumbach, Kevin/L-9222-2016;
OI Willard-Grace, Rachel/0000-0002-1876-555X
FU California Medicaid Waiver Delivery System Reform Incentive Program;
University of California, San Francisco Medical Center; San Francisco
Department of Public Health; UCSF Medical Center
FX This research was supported by funding from the California Medicaid
Waiver Delivery System Reform Incentive Program to San Francisco General
Hospital and the University of California, San Francisco Medical Center.
This research is the result of close partnership with the leadership and
staff of 19 primary care clinics across San Francisco. Without the
wisdom, expertise, and candid feedback of their clinic leadership,
clinicians, and frontline staff, this survey would not have been
possible. The study team thanks the San Francisco Department of Public
Health and the UCSF Medical Center for their support of this project in
conjunction with primary care reforms undertaken for the Centers for
Medicare and Medicaid Services Incentive Program for these health
systems under the Section 1115 California Medicaid Waiver. We
acknowledge the UCSF Clinical & Translational Science Institute and Dr.
Christy Boscardin's consultations on preliminary statistical analysis.
NR 40
TC 2
Z9 2
U1 0
U2 5
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 1091-7527
EI 1939-0602
J9 FAM SYST HEALTH
JI Fam. Syst. Health
PD SEP
PY 2015
VL 33
IS 3
BP 231
EP 241
DI 10.1037/fsh0000113
PG 11
WC Health Care Sciences & Services; Family Studies; Public, Environmental &
Occupational Health
SC Health Care Sciences & Services; Family Studies; Public, Environmental &
Occupational Health
GA CR0FA
UT WOS:000360992600007
PM 25730504
ER
PT J
AU Parikh, S
Goldstein, A
Koenig, MK
Scaglia, F
Enns, GM
Saneto, R
Anselm, I
Cohen, BH
Falk, MJ
Greene, C
Gropman, AL
Haas, R
Hirano, M
Morgan, P
Sims, K
Tarnopolsky, M
Van Hove, JLK
Wolfe, L
DiMauro, S
AF Parikh, Sumit
Goldstein, Amy
Koenig, Mary Kay
Scaglia, Fernando
Enns, Gregory M.
Saneto, Russell
Anselm, Irina
Cohen, Bruce H.
Falk, Marni J.
Greene, Carol
Gropman, Andrea L.
Haas, Richard
Hirano, Michio
Morgan, Phil
Sims, Katherine
Tarnopolsky, Mark
Van Hove, Johan L. K.
Wolfe, Lynne
DiMauro, Salvatore
TI Diagnosis and management of mitochondrial disease: a consensus statement
from the Mitochondrial Medicine Society
SO GENETICS IN MEDICINE
LA English
DT Review
DE consensus criteria; Delphi method; mitochondrial disease; mitochondrial
medicine; Mitochondrial Medicine Society
ID KEARNS-SAYRE-SYNDROME; CEREBRAL FOLATE-DEFICIENCY; EXOME SEQUENCING
REVEALS; DNA DEPLETION SYNDROME; COMPLEX-I DEFICIENCY; COMPARATIVE
GENOMIC HYBRIDIZATION; RESPIRATORY-CHAIN DEFICIENCIES; CLINICAL-PRACTICE
PROTOCOL; BRAIN-STEM INVOLVEMENT; RAT-LIVER MITOCHONDRIA
AB Purpose: The purpose of this statement is to review the literature regarding mitochondrial disease and to provide recommendations for optimal diagnosis and treatment. This statement is intended for physicians who are engaged in diagnosing and treating these patients.
Methods: The Writing Group members were appointed by the Mitochondrial Medicine Society. The panel included members with expertise in several different areas. The panel members utilized a comprehensive review of the literature, surveys, and the Delphi method to reach consensus. We anticipate that this statement will need to be updated as the field continues to evolve.
Results: Consensus-based recommendations are provided for the diagnosis and treatment of mitochondrial disease.
Conclusion: The Delphi process enabled the formation of consensus-based recommendations. We hope that these recommendations will help standardize the evaluation, diagnosis, and care of patients with suspected or demonstrated mitochondrial
C1 [Parikh, Sumit] Cleveland Clin, Childrens Hosp, Ctr Child Neurol, Dept Neurol, Cleveland, OH 44106 USA.
[Goldstein, Amy] Childrens Hosp Pittsburgh, Dept Pediat, Div Child Neurol, Pittsburgh, PA 15213 USA.
[Koenig, Mary Kay] Univ Texas Med Sch Houston, Div Child & Adolescent Neurol, Dept Pediat, Houston, TX USA.
[Scaglia, Fernando] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
[Scaglia, Fernando] Texas Childrens Hosp, Houston, TX 77030 USA.
[Enns, Gregory M.] Stanford Univ, Lucile Packard Childrens Hosp, Div Med Genet, Dept Pediat, Palo Alto, CA 94304 USA.
[Saneto, Russell] Univ Washington, Seattle Childrens Hosp, Dept Neurol, Seattle, WA 98195 USA.
[Saneto, Russell] Univ Washington, Dept Pediat, Seattle Childrens Hosp, Seattle, WA 98195 USA.
[Anselm, Irina] Boston Childrens Hosp, Dept Neurol, Boston, MA USA.
[Cohen, Bruce H.] Childrens Hosp Med Ctr Akron, Dept Pediat, NeuroDev Sci Ctr, Akron, OH USA.
[Falk, Marni J.] Childrens Hosp Philadelphia, Dept Pediat, Div Human Genet, Philadelphia, PA 19104 USA.
[Falk, Marni J.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Greene, Carol] Univ Maryland, Med Ctr, Dept Pediat, Baltimore, MD 21201 USA.
[Gropman, Andrea L.] Childrens Natl Med Ctr, Dept Neurol, Washington, DC 20010 USA.
[Gropman, Andrea L.] George Washington Univ Hlth Sci, Washington, DC USA.
[Haas, Richard] UCSD Med Ctr, Dept Neurosci & Pediat, La Jolla, CA USA.
[Haas, Richard] Rady Childrens Hosp, La Jolla, CA USA.
[Hirano, Michio] Columbia Univ, Med Ctr, Dept Neurol, New York, NY USA.
[Morgan, Phil] Seattle Childrens Hosp, Dept Anesthesiol, Seattle, WA USA.
[Sims, Katherine] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA.
[Sims, Katherine] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Tarnopolsky, Mark] McMaster Univ, Dept Pediat & Med, Hamilton, ON, Canada.
[Van Hove, Johan L. K.] Childrens Hosp Colorado, Dept Pediat Clin Genet & Metab, Denver, CO USA.
[Wolfe, Lynne] NIH, Bethesda, MD 20892 USA.
[DiMauro, Salvatore] Columbia Univ, Med Ctr, Dept Neurol, New York, NY USA.
RP Parikh, S (reprint author), Cleveland Clin, Childrens Hosp, Ctr Child Neurol, Dept Neurol, Cleveland, OH 44106 USA.
EM parikhs@ccf.org
FU RAPTOR Pharmaceuticals
FX G.M.E. has received unrestricted research gift funds from Edison
Pharmaceuticals. M.J.F. is a consultant for Mitokyne, research
collaborator for Cardero, and a research grant awardee of RAPTOR
Pharmaceuticals, and is on the Scientific and Medical Advisory Board for
the United Mitochondrial Disease Foundation. A.G. is a consultant for
Stealth Peptides. A.L.G. is a consultant for GeneDx. S.P. conducts
research for Edison Pharmaceuticals and the North American Mitochondrial
Disease Consortium (NAMDC), and is on the Scientific and Medical
Advisory Board for the United Mitochondrial Disease Foundation. R.S.
conducts research studies for Edison Pharmaceuticals and is part of the
NAMDC. F.S. works for a medical college department that owns a
Mitochondrial Diagnostic Laboratory and conducts research studies for
Edison and Raptor Pharmaceuticals. M.T. is president and CEO of
Exerkine, which develops mitochondrial therapies, and receives speaker
honoraria from Prevention Genetics and Genzyme.
NR 164
TC 23
Z9 24
U1 2
U2 14
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1098-3600
EI 1530-0366
J9 GENET MED
JI Genet. Med.
PD SEP
PY 2015
VL 17
IS 9
BP 689
EP 701
DI 10.1038/gim.2014.177
PG 13
WC Genetics & Heredity
SC Genetics & Heredity
GA CQ8YY
UT WOS:000360898500002
PM 25503498
ER
PT J
AU Morshed, SA
Davies, TF
AF Morshed, S. A.
Davies, T. F.
TI Graves' Disease Mechanisms: The Role of Stimulating, Blocking, and
Cleavage Region TSH Receptor Antibodies
SO HORMONE AND METABOLIC RESEARCH
LA English
DT Article
DE Graves' disease; thyroid; TSH-receptor antibodies; TSH; signaling
ID HUMAN THYROTROPIN RECEPTOR; SIGNALING CASCADES; CRYSTAL-STRUCTURE;
MURINE MODEL; T-CELLS; AUTOIMMUNITY; AUTOANTIBODY; ACTIVATION;
EXPRESSION; IMMUNE
AB The immunologic processes involved in Graves' disease (GD) have one unique characteristic - the autoantibodies to the TSH receptor (TSHR) which have both linear and conformational epitopes. Three types of TSHR antibodies (stimulating, blocking, and cleavage) with different functional capabilities have been described in GD patients, which induce different signaling effects varying from thyroid cell proliferation to thyroid cell death. The establishment of animal models of GD by TSHR antibody transfer or by immunization with TSHR antigen has confirmed its pathogenic role and, therefore, GD is the result of a breakdown in TSHR tolerance. Here we review some of the characteristics of TSHR antibodies with a special emphasis on new developments in our understanding of what were previously called "neutral" antibodies and which we now characterize as autoantibodies to the "cleavage" region of the TSHR ectodomain.
C1 [Morshed, S. A.; Davies, T. F.] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, Thyroid Res Unit, New York, NY 10029 USA.
RP Morshed, SA (reprint author), Room 2F-26 VA Med Ctr,130 West Kingsbridge Rd, New York, NY 10468 USA.
EM syed.morshed@mssm.edu
FU NIH [DK069713, DK052464]; VA Merit Award Program
FX This work was supported in part by NIH grants DK069713, DK052464 and the
VA Merit Award Program.
NR 49
TC 8
Z9 8
U1 1
U2 7
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0018-5043
EI 1439-4286
J9 HORM METAB RES
JI Horm. Metab. Res.
PD SEP
PY 2015
VL 47
IS 10
BP 727
EP 734
DI 10.1055/s-0035-1559633
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CR2GV
UT WOS:000361145500006
PM 26361259
ER
PT J
AU Branch-Elliman, W
Strymish, J
Kudesia, V
Rosen, AK
Gupta, K
AF Branch-Elliman, Westyn
Strymish, Judith
Kudesia, Valmeek
Rosen, Amy K.
Gupta, Kalpana
TI Natural Language Processing for Real-Time Catheter-Associated Urinary
Tract Infection Surveillance: Results of a Pilot Implementation Trial
SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
LA English
DT Article
ID ELECTRONIC MEDICAL-RECORDS; CARE-ASSOCIATED INFECTIONS; HEALTH;
IDENTIFICATION; PNEUMONIA; HOSPITALS
AB BACKGROUND. Incidence of catheter-associated urinary tract infection (CAUTI) is a quality benchmark. To streamline conventional detection methods, an electronic surveillance system augmented with natural language processing (NLP), which gathers data recorded in clinical notes without manual review, was implemented for real-time surveillance.
OBJECTIVE. To assess the utility of this algorithm for identifying indwelling urinary catheter days and CAUTI. setting. Large, urban tertiary care Veterans Affairs hospital.
METHODS. All patients admitted to the acute care units and the intensive care unit from March 1, 2013, through November 30, 2013, were included. Standard surveillance, which includes electronic and manual data extraction, was compared with the NLP-augmented algorithm.
RESULTS. The NLP-augmented algorithm identified 27% more indwelling urinary catheter days in the acute care units and 28% fewer indwelling urinary catheter days in the intensive care unit. The algorithm flagged 24 CAUTI versus 20 CAUTI by standard surveillance methods; the CAUTI identified were overlapping but not the same. The overall positive predictive value was 54.2%, and overall sensitivity was 65% (90.9% in the acute care units but 33% in the intensive care unit). Dissimilarities in the operating characteristics of the algorithm between types of unit were due to differences in documentation practice. Development and implementation of the algorithm required substantial upfront effort of clinicians and programmers to determine current language patterns.
CONCLUSIONS. The NLP algorithm was most useful for identifying simple clinical variables. Algorithm operating characteristics were specific to local documentation practices. The algorithm did not perform as well as standard surveillance methods.
C1 [Branch-Elliman, Westyn] Eastern Colorado Vet Affairs VA Healthcare Sys, Dept Med, Denver, CO USA.
[Branch-Elliman, Westyn] Univ Colorado, Sch Med, Dept Med, Denver, CO USA.
[Strymish, Judith; Kudesia, Valmeek; Gupta, Kalpana] VA Boston Healthcare Syst, Dept Med, Boston, MA USA.
[Strymish, Judith] Harvard Univ, Sch Med, Boston, MA USA.
[Kudesia, Valmeek] Boston VA Med Ctr, Massachusetts Vet Epidemiol & Informat Ctr, Boston, MA USA.
[Rosen, Amy K.; Gupta, Kalpana] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Rosen, Amy K.; Gupta, Kalpana] VA Boston Healthcare Syst, Ctr Healthcare Org & Implementat Res, Boston, MA USA.
[Rosen, Amy K.] Boston Univ, Sch Med, Dept Surg, Boston, MA 02118 USA.
RP Branch-Elliman, W (reprint author), ECHCS, Infect Prevent, 1055 Clermont Ave,Mailstop 111L, Denver, CO 80220 USA.
EM westyn.branch-elliman@ucdenver.edu
FU Patient Safety Center of Inquiry "Measurement to Advance Patient
Safety", Boston, Massachusetts [XVA 68-023]
FX Patient Safety Center of Inquiry "Measurement to Advance Patient
Safety," grant number XVA 68-023, Boston, Massachusetts.
NR 18
TC 0
Z9 0
U1 1
U2 5
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0899-823X
EI 1559-6834
J9 INFECT CONT HOSP EP
JI Infect. Control Hosp. Epidemiol.
PD SEP
PY 2015
VL 36
IS 9
BP 1004
EP 1010
DI 10.1017/ice.2015.122
PG 7
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA CQ9FD
UT WOS:000360917200002
PM 26022228
ER
PT J
AU Young-Xu, Y
Kuntz, JL
Gerding, DN
Neily, J
Mills, P
Dubberke, ER
Olsen, MA
Kelly, CP
Mahe, C
AF Young-Xu, Yinong
Kuntz, Jennifer L.
Gerding, Dale N.
Neily, Julia
Mills, Peter
Dubberke, Erik R.
Olsen, Margaret A.
Kelly, Ciaran P.
Mahe, Cedric
TI Clostridium difficile Infection Among Veterans Health Administration
Patients
SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
LA English
DT Article
ID TERM-CARE FACILITY; ASYMPTOMATIC CARRIERS; EPIDEMIOLOGY; DISEASE;
SURVEILLANCE; RESIDENTS; BURDEN; SYSTEM
AB OBJECTIVE. To report on the prevalence and incidence of Clostridium difficile infection (CDI) from 2009 to 2013 among Veterans Healthcare Administration patients
DESIGN. A retrospective descriptive analysis of data extracted from a large electronic medical record (EMR) database
SETTING. Data were acquired from VHA healthcare records from 2009 to 2013 that included outpatient clinical visits, long-term care, and hospitalized care as well as pharmacy and laboratory information.
RESULTS. In 2009, there were 10,207 CDI episodes, and in 2013, there were 12,143 CDI episodes, an increase of 19.0%. The overall CDI rate increased by 8.4% from 193 episodes per 100,000 patient years in 2009 to 209 episodes per 100,000 patient years in 2013. Of the CDI episodes identified in 2009, 58% were identified during a hospitalization, and 42% were identified in an outpatient setting. In 2013, 44% of the CDI episodes were identified in an outpatient setting.
CONCLUSION. This is one of the largest studies that has utilized timely EMR data to describe the current CDI epidemiology at the VHA. Despite an aging population with greater burden of comorbidity than the general US population, our data show that VHACDI rates stabilized between 2011 and 2013 following increases likely attributable to the introduction of the more sensitive nucleic acid amplification tests (NAATs). The findings in this report will help establish an accurate benchmark against which both current and future VA CDI prevention initiatives can be measured.
C1 [Young-Xu, Yinong; Neily, Julia; Mills, Peter] Natl Ctr Patient Safety, Dept Vet Affairs, White River Jct, VT USA.
[Young-Xu, Yinong; Mills, Peter] Geisel Sch Med Dartmouth, Hanover, NH USA.
[Kuntz, Jennifer L.] Kaiser Permanente Northwest Ctr Hlth Res, Portland, OR USA.
[Gerding, Dale N.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA.
[Gerding, Dale N.] Loyola Univ Chicago, Stritch Sch Med, Maywood, IL USA.
[Dubberke, Erik R.; Olsen, Margaret A.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.
[Olsen, Margaret A.] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA.
[Kelly, Ciaran P.] Harvard Univ, Beth Israel Deaconess Med Ctr, Div Gastroenterol, Sch Med, Boston, MA 02215 USA.
[Mahe, Cedric] Sanofi Pasteur, Lyon, France.
RP Young-Xu, Y (reprint author), VAMC, 10A4E,215 North Main St, White River Jct, VT 05009 USA.
EM Yinong.Young-Xu@va.gov
FU Sanofi-Pasteur, Lyon, France
FX This research was supported by an unrestricted research grant from
Sanofi-Pasteur, Lyon, France.
NR 24
TC 2
Z9 2
U1 1
U2 3
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0899-823X
EI 1559-6834
J9 INFECT CONT HOSP EP
JI Infect. Control Hosp. Epidemiol.
PD SEP
PY 2015
VL 36
IS 9
BP 1038
EP 1045
DI 10.1017/ice.2015.138
PG 8
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA CQ9FD
UT WOS:000360917200007
PM 26047207
ER
PT J
AU van Driel, B
Wang, GX
Liao, GX
Halibozek, PJ
Keszei, M
O'Keeffe, MS
Bhan, AK
Wang, N
Terhorst, C
AF van Driel, Boaz
Wang, Guoxing
Liao, Gongxian
Halibozek, Peter J.
Keszei, Marton
O'Keeffe, Michael S.
Bhan, Atul K.
Wang, Ninghai
Terhorst, Cox
TI The cell surface receptor Slamf6 modulates innate immune responses
during Citrobacter rodentium-induced colitis
SO INTERNATIONAL IMMUNOLOGY
LA English
DT Article
DE Citrobacter rodentium; IL-22; innate; mucosal immunology; Slamf6
ID CD4(+) T-CELLS; ENTERIC BACTERIAL PATHOGENS; HOST-DEFENSE;
B-LYMPHOCYTES; INFECTION; IL-22; MICE; SAP; MACROPHAGES; MUCOSAL
AB Slamf6 exacerbates colitis caused by a Gram(-) bacterium.The homophilic cell surface receptors CD150 (Slamf1) and CD352 (Slamf6) are known to modulate adaptive immune responses. Although the T(h)17 response was enhanced inSlamf6(-/-) C57BL/6 mice upon oral infection withCitrobacter rodentium, the pathologic consequences are indistinguishable from an infection of wild-type C57BL/6 mice. Using a reporter-based binding assay, we show that Slamf6 can engage structures on the outer cell membrane of several Gram(-) bacteria. Therefore, we examined whether Slamf6, like Slamf1, is also involved in innate responses to bacteria and regulates peripheral inflammation by assessing the outcome ofC. rodentium infections inRag(-/-) mice. Surprisingly, the pathology and immune responses in the lamina propria ofC. rodentium-infectedSlamf6(-/-) Rag(-/-) mice were markedly reduced as compared with those ofRag(-/-) mice. Infiltration of inflammatory phagocytes into the lamina propria was consistently lower inSlamf6(-/-) Rag(-/-) mice than inRag(-/-) animals. Concomitant with the reduced systemic translocation of the bacteria was an enhanced production of IL-22, suggesting that Slamf6 suppresses a mucosal protective program. Furthermore, administering a mAb (330) that inhibits bacterial interactions with Slamf6 toRag(-/-) mice ameliorated the infection compared with a control antibody. We conclude that Slamf6-mediated interactions of colonic innate immune cells with specific Gram(-) bacteria reduce mucosal protection and enhance inflammation, contributing to lethal colitis that is caused byC. rodentium infections inRag(-/-) mice.
C1 [van Driel, Boaz; Wang, Guoxing; Liao, Gongxian; Halibozek, Peter J.; Keszei, Marton; O'Keeffe, Michael S.; Wang, Ninghai; Terhorst, Cox] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Immunol,Dept Med, Boston, MA 02115 USA.
[Bhan, Atul K.] Harvard Univ, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
RP Terhorst, C (reprint author), 3 Blackfan Circle,Room CLS 938, Boston, MA 02115 USA.
EM cterhors@bidmc.harvard.edu
RI Keszei, Marton/F-3295-2014
OI Keszei, Marton/0000-0002-1158-2179
FU National Institutes of Health [RO1 NIH AI-15066]
FX National Institutes of Health (RO1 NIH AI-15066 to C.T.).
NR 34
TC 3
Z9 3
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0953-8178
EI 1460-2377
J9 INT IMMUNOL
JI Int. Immunol.
PD SEP
PY 2015
VL 27
IS 9
BP 447
EP 457
DI 10.1093/intimm/dxv029
PG 11
WC Immunology
SC Immunology
GA CR3GX
UT WOS:000361220800004
PM 25957267
ER
PT J
AU Hwang, YC
Hayashi, T
Fujimoto, WY
Kahn, SE
Leonetti, DL
McNeely, MJ
Boyko, EJ
AF Hwang, Y-C
Hayashi, T.
Fujimoto, W. Y.
Kahn, S. E.
Leonetti, D. L.
McNeely, M. J.
Boyko, E. J.
TI Visceral abdominal fat accumulation predicts the conversion of
metabolically healthy obese subjects to an unhealthy phenotype
SO INTERNATIONAL JOURNAL OF OBESITY
LA English
DT Article
ID JAPANESE-AMERICAN MEN; IMPAIRED GLUCOSE-TOLERANCE; BODY-MASS INDEX;
CARDIOVASCULAR-DISEASE; RISK-FACTORS; ALL-CAUSE; PREVALENCE;
ASSOCIATION; METAANALYSIS; DEFINITION
AB BACKGROUND: A proportion of obese subjects appear metabolically healthy (MHO) but little is known about the natural history of MHO and factors predicting its future conversion to metabolically unhealthy obese (MUO).
OBJECTIVES: The aim was to determine prospectively the frequency of conversion of MHO to MUO and the clinical variables that independently predicted this conversion, with a particular focus on the role of body composition.
METHODS: We identified 85 Japanese Americans with MHO (56 men, 29 women), aged 34-73 years (mean age 49.8 years) who were followed at 2.5, 5 and 10 years after enrollment with measurements of metabolic characteristics, lifestyle and abdominal and thigh fat areas measured by computed tomography. Obesity was defined using the Asian body mass index criterion of >= 25 kg m(-2). Metabolically healthy was defined as the presence of <= 2 of 5 metabolic syndrome components proposed by the National Cholesterol Education Program Adult Treatment Panel III, while metabolically unhealthy was defined as >= 3 components.
RESULTS: Over 10 years of follow-up, 55 MHO individuals (64.7%) converted to MUO. Statistically significant univariate predictors of conversion included dyslipidemia, greater insulin resistance and greater visceral abdominal (VAT) and subcutaneous abdominal fat area (SAT). In multivariate analysis, VAT (odds ratio per 1-s.d. increment (95% confidence interval) 2.04 (1.11-3.72), P = 0.021), high-density lipoprotein (HDL) cholesterol (0.24 (0.11-0.53), P<0.001), fasting plasma insulin (2.45 (1.07-5.62), P = 0.034) and female sex (5.37 (1.14-25.27), P = 0.033) were significantly associated with future conversion to MUO. However, SAT was not an independent predictor for future conversion to MUO.
CONCLUSIONS: In this population, MHO was a transient state, with nearly two-thirds developing MUO over 10 years, with higher conversion to MUO independently associated with VAT, female sex, higher fasting insulin level and lower baseline HDL cholesterol level.
C1 [Hwang, Y-C; Boyko, E. J.] VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA 98101 USA.
[Hwang, Y-C] Kyung Hee Univ, Sch Med, Kyung Hee Univ Hosp Gangdong, Div Endocrinol & Metab,Dept Med, Seoul, South Korea.
[Hayashi, T.] Osaka City Univ, Grad Sch Med, Dept Prevent Med & Environm Hlth, Osaka 558, Japan.
[Fujimoto, W. Y.; Kahn, S. E.; McNeely, M. J.; Boyko, E. J.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
[Kahn, S. E.] VA Puget Sound Hlth Care Syst, Hosp & Specialty Med Serv, Seattle, WA 98101 USA.
[Leonetti, D. L.] Univ Washington, Dept Anthropol, Seattle, WA 98195 USA.
RP Boyko, EJ (reprint author), VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA.
EM eboyko@uw.edu
RI Hayashi, Tomoshige/N-8508-2015;
OI Kahn, Steven/0000-0001-7307-9002
FU Diabetes Research Center [DK-17047]; Clinical Nutrition Research Unit
[DK-35816]; General Clinical Research Center at the University of
Washington [RR-00037]; VA Puget Sound Health Care System; King County
Japanese American community; National Institutes of Health [DK-31170,
HL-49293, DK-017047]
FX This work was supported by facilities and services provided by the
Diabetes Research Center (DK-17047), Clinical Nutrition Research Unit
(DK-35816), and the General Clinical Research Center (RR-00037) at the
University of Washington. VA Puget Sound Health Care System provided
support for Drs Boyko and Kahn's involvement in this research. We are
grateful to the King County Japanese American community for support and
cooperation. Funding was through National Institutes of Health grants
DK-31170, HL-49293 and DK-017047. The funding entities had no role in
the conduct of this study or interpretation of its results.
NR 32
TC 15
Z9 15
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0307-0565
EI 1476-5497
J9 INT J OBESITY
JI Int. J. Obes.
PD SEP
PY 2015
VL 39
IS 9
BP 1365
EP 1370
DI 10.1038/ijo.2015.75
PG 6
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA CR0BY
UT WOS:000360984400005
PM 25920773
ER
PT J
AU Newman, JC
AF Newman, John C.
TI Copyright and Bedside Cognitive Testing Why We Need Alternatives to the
Mini-Mental State Examination
SO JAMA INTERNAL MEDICINE
LA English
DT Editorial Material
C1 Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Div Geriatr, San Francisco, CA 94121 USA.
RP Newman, JC (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Div Geriatr, 4150 Clement St, San Francisco, CA 94121 USA.
EM newman@ucsf.edu
RI Newman, John/L-8112-2013
FU NIA NIH HHS [K08AG048354]
NR 8
TC 6
Z9 6
U1 1
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD SEP
PY 2015
VL 175
IS 9
BP 1459
EP 1460
DI 10.1001/jamainternmed.2015.2159
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA CR1CH
UT WOS:000361059900010
PM 26053392
ER
PT J
AU Campbell, EG
Vogeli, C
Rao, SR
Abraham, M
Pierson, R
Applebaum, S
AF Campbell, Eric G.
Vogeli, Christine
Rao, Sowmya R.
Abraham, Melissa
Pierson, Roz
Applebaum, Sandra
TI Industry Relationships Among Academic Institutional Review Board Members
Changes From 2005 Through 2014
SO JAMA INTERNAL MEDICINE
LA English
DT Review
ID CONFLICTS-OF-INTEREST; FINANCIAL RELATIONSHIPS; PHYSICIANS; DISCLOSURE;
CARE
AB IMPORTANCE For the past decade, more attention and concern has been directed toward financial relationships between the life science industry and physicians. Relationships between industry and institutional review board (IRB) members represent an important subclass that has the potential to broadly influence decisions regarding medical research.
OBJECTIVES To study the nature, extent, and perceived consequences of industry relationships among IRB members in academic health centers and to compare our results with findings from 2005.
DESIGN, SETTING, AND PARTICIPANTS A survey mailed to IRB members from the 115 most research-intensive medical schools and teaching hospitals in the United States from January 16 through May 16, 2014. The survey included questions identical to those used in 2005. Data analysis was conducted from June through October 2014.
MAIN OUTCOMES AND MEASURES The frequency of industry relationships among IRB members and the perceived effect of those relationships on IRB-related activities.
RESULTS We found no significant change in the percentage of IRB members with an industry relationship from 2005 through 2014 (2005: 37.2%; 95% CI, 32.7%-42.0%; 2014: 32.1%; 95% CI, 28.0%-36.4%; P = .09). However, since 2005, the percentage of members who felt another member did not properly disclose a financial relationship decreased from 10.8% (95% CI, 8.0%-14.4%) to 6.7%(95% CI, 4.7%-9.4%) (P = .04), as did the percentage who felt pressure from their institution or department to approve a protocol (2005: 18.6%; 95% CI, 15.0%-22.9%; 2014: 10.0%; 95% CI, 7.6%-13.0%; P < .001). The percentage of members with a conflict of interest who voted on protocols with which they have a conflict has not changed, although the percentage who said they always disclose relationships increased significantly from 54.9% in 2005 (95% CI, 42.2%-66.9%) to 80.0% in 2014 (95% CI, 65.3%-89.4%) (P = .01). We also found evidence of anti-industry bias in the presentation of protocols to the IRB.
CONCLUSIONS AND RELEVANCE The results show significant positive progress in the reporting and management of conflicts of interest among IRB members in academic health centers since 2005 after adjusting for other factors. Additional attention should be focused on deterring IRB members from inappropriately voting on or presenting protocols in a biased manner.
C1 [Campbell, Eric G.; Vogeli, Christine; Abraham, Melissa] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA.
[Campbell, Eric G.; Vogeli, Christine] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Abraham, Melissa] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Campbell, Eric G.; Vogeli, Christine] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Abraham, Melissa] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
[Rao, Sowmya R.] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Worcester, MA USA.
[Rao, Sowmya R.] Bedford Vet Affairs Med Ctr, Ctr Healthcare Org & Implementat Res, Bedford, MA USA.
[Pierson, Roz; Applebaum, Sandra] Nielsen Co, New York, NY USA.
RP Campbell, EG (reprint author), Massachusetts Gen Hosp, Mongan Inst Hlth Policy, 50 Staniford St,Ste 901,Ninth Floor, Boston, MA 02114 USA.
EM ecampbell@partners.org
FU National Institute of General Medical Sciences, National Institutes of
Health [1R01 GM100026-01]
FX This study was funded by grant 1R01 GM100026-01 from the National
Institute of General Medical Sciences, National Institutes of Health (Dr
Campbell).
NR 25
TC 2
Z9 2
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD SEP
PY 2015
VL 175
IS 9
BP 1500
EP 1506
DI 10.1001/jamainternmed.2015.3167
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA CR1CH
UT WOS:000361059900019
PM 26168043
ER
PT J
AU Park, ER
Gareen, IF
Japuntich, S
Lennes, I
Hyland, K
DeMello, S
Sicks, JD
Rigotti, NA
AF Park, Elyse R.
Gareen, Ilana F.
Japuntich, Sandra
Lennes, Inga
Hyland, Kelly
DeMello, Sarah
Sicks, JoRean D.
Rigotti, Nancy A.
TI Primary Care Provider-Delivered Smoking Cessation Interventions and
Smoking Cessation Among Participants in the National Lung Screening
Trial
SO JAMA INTERNAL MEDICINE
LA English
DT Article
ID POPULATION-BASED SURVEY; SERVICES TASK-FORCE; COMPUTED-TOMOGRAPHY;
HEALTH-CARE; CANCER; PHYSICIANS; SMOKERS; SATISFACTION; PERCEPTIONS;
HMOS
AB IMPORTANCE
The National Lung Screening Trial (NLST) found a reduction in lung cancer mortality among participants screened with low-dose computed tomography vs chest radiography. In February 2015, Medicare announced its decision to cover annual lung screening for patients with a significant smoking history. These guidelines promote smoking cessation treatment as an adjunct to screening, but the frequency and effectiveness of clinician-delivered smoking cessation interventions delivered after lung screening are unknown.
OBJECTIVE
To determine the association between the reported clinician-delivered 5As (ask, advise, assess, assist [talk about quitting or recommend stop-smoking medications or recommend counseling], and arrange follow-up) after lung screening and smoking behavior changes. DESIGN, SETTING, AND PARTICIPANTS A matched case-control study (caseswere quitters and controls were continued smokers) of 3336 NLST participants who were smokers at enrollment examined participants' rates and patterns of 5A delivery after a lung screen and reported smoking cessation behaviors.
MAIN OUTCOMES AND MEASURES
Prevalence of the clinician-delivered 5As and associated smoking cessation after lung screening.
RESULTS
Delivery of the 5As 1 year after screening were as follows: ask, 77.2%; advise, 75.6%; assess, 63.4%; assist, 56.4%; and arrange follow-up, 10.4%. Receipt of ask, advise, and assess was not significantly associated with quitting in multivariate models that adjusted for sociodemographic characteristics, medical history, screening results, nicotine dependence, and motivation to quit. Assist was associated with a 40% increase in the odds of quitting (odds ratio, 1.40; 95% CI, 1.21-1.63), and arrange was associated with a 46% increase in the odds of quitting (odds ratio, 1.46; 95% CI, 1.19-1.79).
CONCLUSIONS AND RELEVANCE
Assist and arrange follow-up delivered by primary care providers to smokers who were participating in the NLST were associated with increased quitting; less intensive interventions (ask, advise, and assess) were not. However, rates of assist and arrange follow-up were relatively low. Our findings confirm the need for and benefit of clinicians taking more active intervention steps in helping patients who undergo screening to quit smoking.
C1 [Park, Elyse R.; Hyland, Kelly; Rigotti, Nancy A.] Massachusetts Gen Hosp, Tobacco Res & Treatment Ctr, Boston, MA 02114 USA.
[Park, Elyse R.; Hyland, Kelly] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA.
[Gareen, Ilana F.; DeMello, Sarah; Sicks, JoRean D.] Brown Univ, Sch Publ Hlth, Ctr Stat Sci, Providence, RI 02912 USA.
[Gareen, Ilana F.] Brown Univ, Dept Epidemiol, Sch Publ Hlth, Providence, RI 02912 USA.
[Japuntich, Sandra] Vet Affairs Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA.
[Lennes, Inga] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Rigotti, Nancy A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Gen Internal Med,Dept Med, Boston, MA USA.
RP Park, ER (reprint author), Massachusetts Gen Hosp, 50 Staniford St,Ninth Floor, Boston, MA 02114 USA.
EM epark@mgh.harvard.edu
RI Gareen, Ilana/I-2816-2014
OI Gareen, Ilana/0000-0002-0457-5595
FU American Cancer Society's Mentored Research Scholar Award program
[MRSG-005-05-CPPB]; ACRIN-NLST [U01 CA079778, U01 CA080098]; Veterans
Affairs Clinical Sciences Research and Development Award program
[1IK2CX000918-01A1]
FX This project was funded by grant MRSG-005-05-CPPB from the American
Cancer Society's Mentored Research Scholar Award program (Dr Park);
grants U01 CA079778 and U01 CA080098 from the ACRIN-NLST; and, in part,
by grant 1IK2CX000918-01A1 from the Veterans Affairs Clinical Sciences
Research and Development Award program (Dr Japuntich).
NR 35
TC 18
Z9 18
U1 2
U2 8
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD SEP
PY 2015
VL 175
IS 9
BP 1509
EP 1516
DI 10.1001/jamainternmed.2015.2391
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA CR1CH
UT WOS:000361059900021
PM 26076313
ER
PT J
AU Ong, MK
AF Ong, Michael K.
TI Tobacco Cessation-We Can Do Better
SO JAMA INTERNAL MEDICINE
LA English
DT Editorial Material
ID SMOKING-CESSATION
C1 [Ong, Michael K.] Univ Calif Los Angeles, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90024 USA.
[Ong, Michael K.] Vet Affairs Greater Los Angeles HealthCare Syst, Los Angeles, CA USA.
RP Ong, MK (reprint author), Univ Calif Los Angeles, Div Gen Internal Med & Hlth Serv Res, 10940 Wilshire Blvd,Ste 700, Los Angeles, CA 90024 USA.
EM michael.ong@ucla.edu
NR 8
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD SEP
PY 2015
VL 175
IS 9
BP 1516
EP 1517
DI 10.1001/jamainternmed.2015.2402
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA CR1CH
UT WOS:000361059900022
PM 26075733
ER
PT J
AU Zeliadt, SB
Heffner, JL
Sayre, G
Klein, DE
Simons, C
Williams, J
Reinke, LF
Au, DH
AF Zeliadt, Steven B.
Heffner, Jaimee L.
Sayre, George
Klein, Deborah E.
Simons, Carol
Williams, Jennifer
Reinke, Lynn F.
Au, David H.
TI Attitudes and Perceptions About Smoking Cessation in the Context of Lung
Cancer Screening
SO JAMA INTERNAL MEDICINE
LA English
DT Article
ID SERVICES TASK-FORCE; COMPUTED-TOMOGRAPHY; PULMONARY NODULES; QUALITATIVE
RESEARCH; RISK PERCEPTIONS; COGNITIVE-DISSONANCE; TRIAL PARTICIPANTS;
FOLLOW-UP; DISCUSSIONS; DEPENDENCE
AB IMPORTANCE
Broad adoption of lung cancer screeningmay inadvertently lead to negative population health outcomes if it is perceived as a substitute for smoking cessation. OBJECTIVE To understand views on smoking cessation from current smokers in the context of being offered lung cancer screening as a routine service in primary care.
DESIGN, SETTING, AND PARTICIPANTS
As an ancillary study to the launch of a lung cancer screening program at 7 sites in the Veterans Health Administration, 45 in-depth semi-structured qualitative interviews about health beliefs related to smoking and lung cancer screening were administered from May 29 to September 22, 2014, by telephone to 37 current smokers offered lung cancer screening by their primary care physician. Analysis was conducted from June 15, 2014, to March 29, 2015.
MAIN OUTCOMES AND MEASURES
Attitudes and perceptions about the importance of smoking cessation in the context of lung cancer screening.
RESULTS
Lung cancer screening prompted most current smokers to reflect for the first time on what smoking means for their current and future health. However, 17 of 35 (49%) participants described mechanisms whereby screening lowered their motivation for cessation, including the perception that undergoing an imaging test yields the same health benefits as smoking cessation. Other misperceptions include the belief that everyone who participates in screening will benefit; the belief that screening and being able to return for additional screening offers protection from lung cancer; the perception by some individuals that findings from screenings have saved their lives by catching their cancer early when indeterminate findings are identified that can be monitored rather than immediately treated; and a reinforced belief in some individuals that a cancer-free screening test result indicates that they are among the lucky ones who will avoid the harms of smoking.
CONCLUSIONS AND RELEVANCE
In this qualitative, lung cancer screening prompted many current smokers to reflect on their health and may serve as a potential opportunity to engage patients in discussions about smoking cessation. However, several concerning pathways were identified in which screening, when offered as part of routine care and described as having proven efficacy, may negatively influence smoking cessation. Health care professionals should be aware that the opportunity for early detection of lung cancer may be interpreted as a way of avoiding the harms of smoking. To promote cessation, discussions should focus on the emotional response to screening rather than clinical details (eg, nodule size) and address misperceptions about the value of early detection so that screening does not lower motivation to quit smoking.
C1 [Zeliadt, Steven B.; Sayre, George; Simons, Carol; Williams, Jennifer; Reinke, Lynn F.; Au, David H.] VA Puget Sound Hlth Care Syst, Ctr Innovat Vet Ctr & Value Driven Care, Seattle, WA 98108 USA.
[Zeliadt, Steven B.; Sayre, George] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Heffner, Jaimee L.] Fred Hutchinson Canc Res Ctr, Tobacco & Hlth Behav Sci Res Grp, Seattle, WA 98104 USA.
[Klein, Deborah E.] Swedish Med Ctr, Swedish Med Grp, Seattle, WA USA.
[Reinke, Lynn F.; Au, David H.] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA.
RP Zeliadt, SB (reprint author), VA Puget Sound Hlth Care Syst, Ctr Innovat Vet Ctr & Value Driven Care, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM steven.zeliadt@va.gov
FU Centers for Disease Control and Prevention's Health Promotion and
Disease Prevention Research Centers Program through a Special Interest
Project (Low Dose CT Lung Cancer Screening: Informed Decision Making and
Smoking Cessation) [DP9001911-05S2, SIP13-038]
FX This study was supported by grant DP9001911-05S2 from the Centers for
Disease Control and Prevention's Health Promotion and Disease Prevention
Research Centers Program through a Special Interest Project (SIP13-038:
Low Dose CT Lung Cancer Screening: Informed Decision Making and Smoking
Cessation). This material is the result of work supported by resources
from VA Puget Sound Health Care System.
NR 39
TC 14
Z9 14
U1 2
U2 6
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD SEP
PY 2015
VL 175
IS 9
BP 1530
EP 1537
DI 10.1001/jamainternmed.2015.3558
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA CR1CH
UT WOS:000361059900025
PM 26214612
ER
PT J
AU Cai, JX
Campbell, EJ
Richter, JM
AF Cai, Jennifer X.
Campbell, Emily J.
Richter, James M.
TI Concordance of Outpatient Esophagogastroduodenoscopy of the Upper
Gastrointestinal Tract With Evidence-Based Guidelines
SO JAMA INTERNAL MEDICINE
LA English
DT Letter
ID BARRETTS-ESOPHAGUS; SURVEILLANCE; PHYSICIANS; ENDOSCOPY
C1 [Cai, Jennifer X.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
[Campbell, Emily J.; Richter, James M.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA.
RP Richter, JM (reprint author), Massachusetts Gen Hosp, Div Gastroenterol, 55 Fruit St, Boston, MA 02114 USA.
EM jrichter@mgh.harvard.edu
NR 6
TC 1
Z9 1
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD SEP
PY 2015
VL 175
IS 9
BP 1563
EP 1564
DI 10.1001/jamainternmed.2015.3533
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA CR1CH
UT WOS:000361059900033
PM 26192987
ER
PT J
AU He, WJ
Jimenez, F
Martinez, H
Harper, NL
Manoharan, MS
Carrillo, A
Ingale, P
Liu, YG
Ahuja, SS
Clark, RA
Rather, CG
Ramirez, DA
Andrews, CP
Jacobs, RL
Ahuja, SK
AF He, Weijing
Jimenez, Fabio
Martinez, Hernan
Harper, Nathan L.
Manoharan, Muthu Saravanan
Carrillo, Andrew
Ingale, Puraskar
Liu, Ya-Guang
Ahuja, Seema S.
Clark, Robert A.
Rather, Cynthia G.
Ramirez, Daniel A.
Andrews, Charles P.
Jacobs, Robert L.
Ahuja, Sunil K.
TI Cockroach sensitization mitigates allergic rhinoconjunctivitis symptom
severity in patients allergic to house dust mites and pollen
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Article
DE Cockroach sensitization; allergen challenge chamber; allergic
rhinoconjunctivitis; T-cell activation; aeroallergens; house dust mite;
skin prick test; pollen
ID INNATE LYMPHOID-CELLS; CHALLENGE CHAMBER; CD4/CD8 RATIO; HYGIENE
HYPOTHESIS; IMMUNE; ACTIVATION; EXPOSURE; RESPONSES; ASTHMA; DISEASE
AB Background: Modifiers of symptom severity in patients with allergic rhinoconjunctivitis (AR) are imprecisely characterized. The hygiene hypothesis implicates childhood microbial exposure as a protective factor. Cockroach sensitization (C+) might be a proxy for microbial exposure.
Objective: We sought to determine whether C+ assayed by means of skin prick tests influenced AR symptom severity in controlled and natural settings.
Methods: Total symptom scores (TSSs) were recorded by 21 participants with house dust mite allergy (M+) in the natural setting and during repeated exposures of 3 hours per day to house dust mite allergen in an allergen challenge chamber (ACC). In M+ participants the peripheral blood and nasal cells were assayed for T-cell activation and transcriptomic profiles (by using RNA sequencing), respectively. Participants allergic to mountain cedar (n = 21), oak (n = 34), and ragweed (n = 23) recorded TSSs during separate out-of-season exposures to these pollens (any pollen sensitization [P+]) in the ACC; a subset recorded TSSs in the pollination seasons.
Results: The hierarchy of TSSs (highest to lowest) among M+ participants tracked the following skin prick test sensitization statuses: M+P+C- > M+P+C+ > M+P-C- > M+P-C+. In nasal cells and peripheral blood the immune/inflammatory responses were rapidly resolved in M+P+C+ compared with M+P+C- participants. Among those allergic to pollen, C+ was associated with a lower TSS during pollen challenges and the pollination season. After aggregated analysis of all 4 ACC studies, C+ status was associated with a 2.8-fold greater likelihood of a lower TSS compared with C- status (odds ratio, 2.78; 95% CI, 1.18-6.67; P = .02).
Conclusions: C+ status is associated with mitigation of AR symptom severity in adults with AR.
C1 [He, Weijing; Jimenez, Fabio; Martinez, Hernan; Harper, Nathan L.; Manoharan, Muthu Saravanan; Carrillo, Andrew; Ingale, Puraskar; Liu, Ya-Guang; Ahuja, Seema S.; Clark, Robert A.; Ahuja, Sunil K.] South Texas Vet Hlth Care Syst, Vet Adm Ctr Personalized Med, San Antonio, TX USA.
[He, Weijing; Jimenez, Fabio; Martinez, Hernan; Harper, Nathan L.; Manoharan, Muthu Saravanan; Carrillo, Andrew; Ingale, Puraskar; Liu, Ya-Guang; Ahuja, Seema S.; Clark, Robert A.; Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA.
[Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA.
[Jimenez, Fabio; Martinez, Hernan; Harper, Nathan L.] Biomed Res Fdn South Texas, San Antonio, TX USA.
[Rather, Cynthia G.; Ramirez, Daniel A.; Andrews, Charles P.; Jacobs, Robert L.] Biogen Res Chamber, San Antonio, TX USA.
RP Ahuja, SK (reprint author), 7400 Merton Minter Blvd,Room W200, San Antonio, TX 78229 USA.
EM ahujas@uthscsa.edu
OI Ingale, Puraskar/0000-0003-2769-878X
FU Doris Duke Distinguished Clinical Scientist Award; Burroughs Wellcome
Clinical Scientist in Transitional Research Award; Max and Minnie
Tomerlin Voelcker Award; Center for Personalized Medicine at the South
Texas Veterans Health Care System [CX00875-01AI]
FX S.K.A. received support from the following grants: the Doris Duke
Distinguished Clinical Scientist Award, the Burroughs Wellcome Clinical
Scientist in Transitional Research Award, the Max and Minnie Tomerlin
Voelcker Award, and the Center for Personalized Medicine (CX00875-01AI)
at the South Texas Veterans Health Care System. R.L.J., C.P.A., and
D.A.R., are co-owners of Biogenics Research Chamber and have not
received financial support. C.G.R. is the Executive Director of Chamber
Operations.
NR 40
TC 5
Z9 5
U1 0
U2 5
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD SEP
PY 2015
VL 136
IS 3
BP 658
EP 666
DI 10.1016/j.jaci.2015.02.041
PG 9
WC Allergy; Immunology
SC Allergy; Immunology
GA CQ9EA
UT WOS:000360913300018
PM 26026342
ER
PT J
AU Chou, J
Massaad, MJ
Cangemi, B
Bainter, W
Platt, C
Badran, YR
Raphael, BP
Kamin, DS
Goldsmith, JD
Pai, SY
Al-Herz, W
Geha, RS
AF Chou, Janet
Massaad, Michel J.
Cangemi, Brittney
Bainter, Wayne
Platt, Craig
Badran, Yousef R.
Raphael, Bram P.
Kamin, Daniel S.
Goldsmith, Jeffrey D.
Pai, Sung-Yun
Al-Herz, Waleed
Geha, Raif S.
TI A novel mutation in ICOS presenting as hypogammaglobulinemia with
susceptibility to opportunistic pathogens
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Letter
ID COMMON VARIABLE IMMUNODEFICIENCY; DEFICIENCY; CELLS; CD4
C1 [Chou, Janet; Massaad, Michel J.; Cangemi, Brittney; Bainter, Wayne; Platt, Craig; Badran, Yousef R.; Geha, Raif S.] Boston Childrens Hosp, Div Immunol, Boston, MA 02115 USA.
[Raphael, Bram P.; Kamin, Daniel S.] Boston Childrens Hosp, Div Gastroenterol Hepatol & Nutr, Boston, MA USA.
[Raphael, Bram P.; Kamin, Daniel S.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Goldsmith, Jeffrey D.] Boston Childrens Hosp, Dept Pathol, Boston, MA USA.
[Goldsmith, Jeffrey D.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Pai, Sung-Yun] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA.
[Pai, Sung-Yun] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Al-Herz, Waleed] Kuwait Univ, Fac Med, Dept Pediat, Kuwait, Kuwait.
RP Chou, J (reprint author), Boston Childrens Hosp, Div Immunol, Boston, MA 02115 USA.
EM Raif.Geha@childrens.harvard.edu
FU NIAID NIH HHS [AI-094017, P01AI-076210]
NR 12
TC 4
Z9 4
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD SEP
PY 2015
VL 136
IS 3
BP 794
EP +
DI 10.1016/j.jaci.2014.12.1940
PG 4
WC Allergy; Immunology
SC Allergy; Immunology
GA CQ9EA
UT WOS:000360913300032
PM 25678089
ER
PT J
AU Clair, AJ
Inneh, IA
Iorio, R
Berend, KR
Della Valle, CJ
Healy, WL
Pelligrini, VD
AF Clair, Andrew James
Inneh, Ifeoma A.
Iorio, Richard
Berend, Keith R.
Della Valle, Craig J.
Healy, William L.
Pelligrini, Vincent D.
TI Can Administrative Data Be Used to Analyze Complications Following Total
Joint Arthroplasty?
SO JOURNAL OF ARTHROPLASTY
LA English
DT Article; Proceedings Paper
CT 24th Annual Meeting of the American Association of Hip and Knee Surgeons
(AAHKS)
CY NOV 06-09, 2014
CL Dallas, TX
DE total knee arthroplasty; total hip arthroplasty; complications;
healthcare quality; administrative data
ID TOTAL KNEE ARTHROPLASTY; MEDIAL COLLATERAL LIGAMENT; OUTCOMES RESEARCH;
TOTAL HIP; DATABASES; INJURY
AB We hypothesized that the Centers for Medicare and Medicaid Services Limited Dataset (CMS-LDS) could be used to validate the complications associated with total hip and knee arthroplasty (THA and TKA) endorsed by the Hip and Knee Societies. Using ICD-9 procedure and diagnosis codes, cases were extracted from the first three quarters of the 2009 CMS-LDS to allow all complications within 90-days be captured in the same calendar year. We were unable to validate the Hip and Knee Societies' complications as we could not connect readmissions or outpatient visits to index admissions. In addition, well-known complications were not detected, raising concerns about coding accuracy and stratification. Furthermore, the assignment of outpatient and inpatient codes allows for duplication of complications which may falsely elevate the true incidence. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Clair, Andrew James; Inneh, Ifeoma A.; Iorio, Richard] NYU, Langone Med Ctr, Hosp Joint Dis, Dept Orthopaed Surg, New York, NY 10003 USA.
[Berend, Keith R.] Joint Implant Surg Inc, New Albany, OH USA.
[Della Valle, Craig J.] Rush Univ, Med Ctr, Dept Orthopaed Surg, Chicago, IL 60612 USA.
[Healy, William L.] Massachusetts Gen Hosp, Newton Wellesley Hosp, Kaplan Joint Ctr, Boston, MA 02114 USA.
[Pelligrini, Vincent D.] Med Univ S Carolina, Dept Orthopaed, Charleston, SC 29425 USA.
[Pelligrini, Vincent D.] Med Univ Hosp Author, Musculoskeletal Serv Line, Charleston, SC USA.
RP Clair, AJ (reprint author), NYU, Langone Med Ctr, Hosp Joint Dis, Dept Orthopaed Surg, 301 East 17th St, New York, NY 10003 USA.
OI Iorio, Richard/0000-0001-8083-8687
NR 18
TC 4
Z9 4
U1 0
U2 1
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 0883-5403
EI 1532-8406
J9 J ARTHROPLASTY
JI J. Arthroplast.
PD SEP
PY 2015
VL 30
IS 9
SU S
BP 17
EP 20
DI 10.1016/j.arth.2015.01.060
PG 4
WC Orthopedics
SC Orthopedics
GA CQ9HB
UT WOS:000360923200005
PM 26187386
ER
PT J
AU Dwyer, MK
Lee, JA
McCarthy, JC
AF Dwyer, Maureen K.
Lee, Jo-Ann
McCarthy, Joseph C.
TI Cartilage Status at Time of Arthroscopy Predicts Failure in Patients
With Hip Dysplasia
SO JOURNAL OF ARTHROPLASTY
LA English
DT Article; Proceedings Paper
CT 24th Annual Meeting of the American Association of Hip and Knee Surgeons
(AAHKS)
CY NOV 06-09, 2014
CL Dallas, TX
DE hip arthroscopy; dysplasia; predictors; hip; cartilage
ID BERNESE PERIACETABULAR OSTEOTOMY; ACETABULAR DYSPLASIA; PRESERVATION
SURGERY; LABRUM; IMPINGEMENT; DISEASE; JOINT
AB The purpose of our study was to determine whether chondral damage at the time of arthroscopy predicted conversion to THA in patients with dysplasia. We identified 166 patients with dysplasia who underwent hip arthroscopy. Forty-seven went on to receive THA. The articular cartilage of three regions of the acetabulum and femoral head were assessed for signs of chondral damage (absent, mild, or severe]). A stepwise multivariable logistic regression analysis revealed mild damage on the posterior femoral head (P=0.001) and severe damage on the anterior acetabulum (P=0.007) made a significant contribution to the predictor. The presence of mild posterior femoral head chondral changes was indicative of more global cartilage damage in this series of patients. Our findings show that chondral damage on the posterior femoral head and anterior acetabulum is a strong predictor of ultimate conversion to THA in dysplastic patients. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Dwyer, Maureen K.; Lee, Jo-Ann; McCarthy, Joseph C.] Newton Wellesley Hosp, Kaplan Joint Ctr, Newton, MA 02462 USA.
[Dwyer, Maureen K.; McCarthy, Joseph C.] Massachusetts Gen Hosp, Dept Orthoped, Boston, MA 02114 USA.
RP Dwyer, MK (reprint author), Newton Wellesley Hosp, Kaplan Joint Ctr, 2000 Washington St,Green Bldg,Ste 361, Newton, MA 02462 USA.
NR 18
TC 4
Z9 4
U1 0
U2 0
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 0883-5403
EI 1532-8406
J9 J ARTHROPLASTY
JI J. Arthroplast.
PD SEP
PY 2015
VL 30
IS 9
SU S
BP 121
EP 124
DI 10.1016/j.arth.2014.12.034
PG 4
WC Orthopedics
SC Orthopedics
GA CQ9HB
UT WOS:000360923200028
PM 26059500
ER
PT J
AU Ferraresi, C
Parizotto, NA
de Sousa, MVP
Kaippert, B
Huang, YY
Koiso, T
Bagnato, VS
Hamblin, MR
AF Ferraresi, Cleber
Parizotto, Nivaldo Antonio
Pires de Sousa, Marcelo Victor
Kaippert, Beatriz
Huang, Ying-Ying
Koiso, Tomoharu
Bagnato, Vanderlei Salvador
Hamblin, Michael R.
TI Light-emitting diode therapy in exercise-trained mice increases muscle
performance, cytochrome c oxidase activity, ATP and cell proliferation
SO JOURNAL OF BIOPHOTONICS
LA English
DT Article
DE LLLT; LEDT; muscle performance; muscle recovery; ATP
ID BIPHASIC DOSE-RESPONSE; LEVEL LASER THERAPY; SKELETAL-MUSCLE; OXIDATIVE
STRESS; PHOTOTHERAPY; MECHANISMS; RADIATION; RATS; IRRADIATION; FATIGUE
AB Light-emitting diode therapy (LEDT) applied over the leg, gluteus and lower-back muscles of mice using a LED cluster (630nm and 850nm, 80mW/cm(2), 7.2J/cm(2)) increased muscle performance (repetitive climbing of a ladder carrying a water-filled tube attached to the tail), ATP and mitochondrial metabolism; oxidative stress and proliferative myocyte markers in mice subjected to acute and progressive strength training. Six bi-daily training sessions LEDT-After and LEDT-Before-After regimens more than doubled muscle performance and increased ATP more than tenfold. The effectiveness of LEDT on improving muscle performance and recovery suggest applicability for high performance sports and in training programs.
[GRAPHICS]
Positioning of the mice and light-emitting diode therapy (LEDT) applied on mouse legs, gluteus and lower-back muscles without contact.
C1 [Ferraresi, Cleber; Parizotto, Nivaldo Antonio] Univ Fed Sao Carlos, Dept Phys Therapy, Lab Electrothermophototherapy, BR-13560 Sao Carlos, SP, Brazil.
[Ferraresi, Cleber; Parizotto, Nivaldo Antonio] Univ Fed Sao Carlos, Postgrad Program Biotechnol, BR-13560 Sao Carlos, SP, Brazil.
[Ferraresi, Cleber; Bagnato, Vanderlei Salvador] Univ Sao Paulo, Phys Inst Sao Carlos, Opt Grp, Sao Carlos, SP, Brazil.
[Ferraresi, Cleber; Pires de Sousa, Marcelo Victor; Kaippert, Beatriz; Huang, Ying-Ying; Koiso, Tomoharu; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Pires de Sousa, Marcelo Victor] Univ Sao Paulo, Inst Phys, Lab Radiat Dosimetry & Med Phys, BR-05508 Sao Paulo, Brazil.
[Kaippert, Beatriz] Univ Fed Rio de Janeiro, BR-21941 Rio De Janeiro, Brazil.
[Huang, Ying-Ying; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Koiso, Tomoharu] Tohoku Univ, Grad Sch Biomed Engn, Sendai, Miyagi 980, Japan.
[Hamblin, Michael R.] Harvard MIT Div Hlth Sci & Technol, Cambridge, MA USA.
RP Hamblin, MR (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, 40 Blossom St, Boston, MA 02114 USA.
EM mhamblin@partners.org
RI Ferraresi, Cleber/B-2458-2014; Sao Carlos Institute of Physics,
IFSC/USP/M-2664-2016; USP, CePOF/J-3608-2015
FU FAPESP [2010/07194-7, 2012/05919-0]; US NIH [R01AI050875]
FX Cleber Ferraresi would like to thank FAPESP for his Ph.D. scholarships
(numbers 2010/07194-7 and 2012/05919-0). MR Hamblin was supported by US
NIH grant R01AI050875. We acknowledge Andrea L. Brissette for
administrative assistance and Jenny Zhao for assistance with the core
laboratory of histopathology, microscopy and digital imaging of the
Wellman Center for Photomedicine, Massachusetts General Hospital.
NR 38
TC 12
Z9 12
U1 1
U2 11
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY
SN 1864-063X
EI 1864-0648
J9 J BIOPHOTONICS
JI J. Biophotonics
PD SEP
PY 2015
VL 8
IS 9
BP 740
EP 754
DI 10.1002/jbio.201400087
PG 15
WC Biochemical Research Methods; Biophysics; Optics
SC Biochemistry & Molecular Biology; Biophysics; Optics
GA CR1CK
UT WOS:000361060200006
PM 25378263
ER
PT J
AU Wolf, LA
Delao, AM
Perhats, C
Clark, PR
Moon, MD
Baker, KM
Carman, MJ
Zavotsky, KE
Lenehan, G
AF Wolf, Lisa A.
Delao, Altair M.
Perhats, Cydne
Clark, Paul R.
Moon, Michael D.
Baker, Kathy M.
Carman, Margaret J.
Zavotsky, Kathleen E.
Lenehan, Gail
TI EXPLORING THE MANAGEMENT OF DEATH: EMERGENCY NURSES' PERCEPTIONS OF
CHALLENGES AND FACILITATORS IN THE PROVISION OF END-OF-LIFE CARE IN THE
EMERGENCY DEPARTMENT
SO JOURNAL OF EMERGENCY NURSING
LA English
DT Article
DE Mixed methods; End-of-life care; Emergency department; Nursing.
ID UNDERGRADUATE NURSING-STUDENTS; EMOTIONAL INTELLIGENCE; SUPPORTIVE
BEHAVIORS; DYING PATIENTS; OBSTACLES; ATTITUDES; IMPACT
AB Introduction: The importance of end-of-life (EOL) care for dying patients and their families is well described; however, little research has been performed in emergency settings. The purpose of this study was to explore emergency nurses' perceptions of challenges and facilitators in the care of patients at the EOL.
Methods: A mixed-methods design using survey data (N = 1,879) and focus group data (N = 17). Data were collected on questions regarding care of the EOL patient in the emergency department, specifically nurses' perceptions of the care of these patients; educational content needs; barriers to safe and effective care; and the availability of resources.
Results: High scores on the quantitative survey showed a high mean level of consistently positive attitudes and beliefs toward caring for dying patients and their families and loved ones (131.26 +/- 10.88). Analysis of the focus group transcripts uncovered 9 themes, reflecting concerns around comfort and challenges with EOL care, appropriate training for nurses, and the availability of resources to provide this type of care in the emergency setting. Also noted was dissonance between the nature of emergency care and the nature of EOL care.
Discussion: Emergency nurses are comfortable providing EOL care in the emergency setting but note that challenges to providing good care include lack of space, time, and staff. Other challenges involve the mismatch between the goals of emergency care and those of EOL care, as well as the emotional burden of caring for the dying, especially when the appropriate resources are lacking.
C1 [Wolf, Lisa A.; Delao, Altair M.; Perhats, Cydne] Emergency Nurses Assoc, Inst Emergency Nursing Res, Des Plaines, IL 60016 USA.
[Clark, Paul R.] Norton Healthcare Inst Nursing, Syst Educ, Louisville, KY USA.
[Moon, Michael D.] Univ Incarnate Word, San Antonio, TX USA.
[Baker, Kathy M.] VCU Hlth Syst, Richmond, VA USA.
[Carman, Margaret J.] Duke Univ, Sch Nursing, Durham, NC USA.
[Zavotsky, Kathleen E.] Robert Wood Johnson Univ Hosp, Nursing Res Adv Practice & Educ, New Brunswick, NJ USA.
[Lenehan, Gail] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Wolf, LA (reprint author), Emergency Nurses Assoc, 915 Lee St, Des Plaines, IL 60016 USA.
EM lwolf@ena.org
OI Clark, Paul/0000-0003-4990-875X
NR 27
TC 1
Z9 1
U1 6
U2 21
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0099-1767
EI 1527-2966
J9 J EMERG NURS
JI J. Emerg. Nurs.
PD SEP
PY 2015
VL 41
IS 5
BP E23
EP E33
DI 10.1016/j.jen.2015.05.018
PG 11
WC Emergency Medicine; Nursing
SC Emergency Medicine; Nursing
GA CQ9GA
UT WOS:000360919800001
PM 26232873
ER
PT J
AU Aoki, EM
Abdala, R
de Oliveira, JX
Arita, ES
Cortes, ARG
AF Aoki, Eduardo Massaharu
Abdala-Junior, Reinaldo
de Oliveira, Jefferson Xavier
Arita, Emiko Saito
Gonzalez Cortes, Arthur Rodriguez
TI Reliability and Reproducibility of Manual and Automated Volumetric
Measurements of Periapical Lesions
SO JOURNAL OF ENDODONTICS
LA English
DT Article
DE Cone-beam computed tomography; periapical lesions; region growing;
segmentation; volumetric measurements
ID BEAM COMPUTED-TOMOGRAPHY; APICAL PERIODONTITIS; BONE DEFECTS; ACCURACY;
CT; RADIOGRAPHY; SOFTWARE; IMPLANTS; TEETH; SCANS
AB Introduction: The present study aimed to test the reliability and reproducibility of 2 methods: manual and automated segmentation (using a threshold-based region growing algorithm) for measuring the volume of periapical lesions. Methods: A total of 43 cone-beam computed tomographic scans (14 men and 29 women, mean age of 54.6 +/- 8.5 years) were analyzed by 3 observers. Intraobserver reproducibility and inter-observer reliability were assessed using the intraclass correlation coefficient. Parametric correlation between manual and automated volumetric measurements was performed. In addition, the Student t test was also used to compare the mean time required for manual and automated volumetric measurements. Results: Automated segmentation showed slightly higher intraclass correlation coefficient values for all observers. A strong significant correlation was found between manual and automated volumetric measurements performed by the 3 observers. A significant difference in the mean procedure time was also found between both methods (P = .001). Conclusions: Within the limitations of this study, the present results suggest that automated segmentation with a region growing algorithm is faster and slightly more reliable to calculate the volume of periapical lesions.
C1 [Aoki, Eduardo Massaharu; Abdala-Junior, Reinaldo; de Oliveira, Jefferson Xavier; Arita, Emiko Saito] Univ Sao Paulo, Sch Dent, Dept Stomatol, Sao Paulo, Brazil.
[Gonzalez Cortes, Arthur Rodriguez] Massachusetts Gen Hosp, Dept Radiol, Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
[Gonzalez Cortes, Arthur Rodriguez] Harvard Univ, Sch Med, Boston, MA USA.
RP Cortes, ARG (reprint author), Massachusetts Gen Hosp, Dept Radiol, Martinos Ctr, Room 2103,149 13th St, Charlestown, MA 02129 USA.
EM acortes@nmr.mgh.harvard.edu
RI Cortes, Arthur/C-8738-2013
OI Cortes, Arthur/0000-0001-6591-7256
FU National Council for Scientific and Technological Development
CNPq-Science Without Borders, Brazil [232643/2013-0]
FX A postdoctoral scholarship was granted to A.R.G.C by the National
Council for Scientific and Technological Development CNPq-Science
Without Borders, Brazil (no. 232643/2013-0).
NR 23
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0099-2399
EI 1878-3554
J9 J ENDODONT
JI J. Endod.
PD SEP
PY 2015
VL 41
IS 9
BP 1555
EP 1559
DI 10.1016/j.joen.2015.06.015
PG 5
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA CR1JY
UT WOS:000361082300031
PM 26234544
ER
PT J
AU Yaghmaie, F
Esmaeili, S
Francis, SA
Mostafavi, E
AF Yaghmaie, Farhad
Esmaeili, Saber
Francis, Sanjeev A.
Mostafavi, Ehsan
TI Q fever endocarditis in Iran: A case report
SO JOURNAL OF INFECTION AND PUBLIC HEALTH
LA English
DT Article
DE Q fever; Coxiella burnetii; Endocarditis; Female; Iran
ID SEROEPIDEMIOLOGICAL SURVEY; PROVINCE; SHEEP
AB In this report, we describe the first chronic case of Q fever endocarditis in a 72-year-old woman in Iran. The patient developed radiation-associated heart disease status post (sip) coronary artery bypass surgery, mitral and aortic valve replacements, and tricuspid valve repair. Endocarditis was also suspected due to a history of heart valve surgery. Blood cultures were negative, but a diagnosis of Q fever endocarditis was confirmed based on serologic titers (IgG phase I 1:32,768). The patient was treated with doxycycline and hydroxychloroquine. (C) 2015 King Saud Bin Abdulaziz University for Health Sciences. Published by Elsevier Limited. All rights reserved.
C1 [Yaghmaie, Farhad; Esmaeili, Saber; Mostafavi, Ehsan] Inst Pasteur, Dept Epidemiol, Tehran 1316943551, Iran.
[Yaghmaie, Farhad; Esmaeili, Saber; Mostafavi, Ehsan] Res Ctr Emerging & Reemerging Infect Dis, Inst Pasteur, Natl Reference Lab Plague, Tularemia & Q Fever, Hamadan, Iran.
[Francis, Sanjeev A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Cardiol,Dept Med, Boston, MA 02115 USA.
RP Mostafavi, E (reprint author), Inst Pasteur, Dept Epidemiol, 69 Pasteur Ave, Tehran 1316943551, Iran.
EM mostafaviehsan@gmail.com
RI Mostafavi, Ehsan/A-7627-2011; Esmaeili, Saber/F-2620-2017
OI Mostafavi, Ehsan/0000-0002-1997-517X; Esmaeili,
Saber/0000-0003-1920-1737
FU Pasteur Institute of Iran; Center for Disease Control of Iranian
Ministry of Health and Medical Education [582]
FX We appreciate the financial support of the Pasteur Institute of Iran and
Center for Disease Control of Iranian Ministry of Health and Medical
Education (Grant No. 582). We would like to express our gratitude to the
Massachusetts General Hospital personnel, especially Seth R. Glassman
(specializing in infectious disease medicine), for their help in the
primary diagnosis and management of this case.
NR 13
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 1876-0341
EI 1876-035X
J9 J INFECT PUBLIC HEAL
JI J. Infect. Public Health
PD SEP-OCT
PY 2015
VL 8
IS 5
BP 498
EP 501
DI 10.1016/j.jiph.2014.12.004
PG 4
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA CQ8NV
UT WOS:000360865900014
PM 25747823
ER
PT J
AU Lincoln, SE
Kobayashi, Y
Anderson, MJ
Yang, S
Desmond, AJ
Mills, MA
Nilsen, GB
Jacobs, KB
Monzon, FA
Kurian, AW
Ford, JM
Ellisen, LW
AF Lincoln, Stephen E.
Kobayashi, Yuya
Anderson, Michael J.
Yang, Shan
Desmond, Andrea J.
Mills, Meredith A.
Nilsen, Geoffrey B.
Jacobs, Kevin B.
Monzon, Federico A.
Kurian, Allison W.
Ford, James M.
Ellisen, Leif W.
TI A Systematic Comparison of Traditional and Multigene Panel Testing for
Hereditary Breast and Ovarian Cancer Genes in More Than 1000 Patients
SO JOURNAL OF MOLECULAR DIAGNOSTICS
LA English
DT Article
ID DIFFUSE GASTRIC-CANCER; NEXT-GENERATION; COLORECTAL-CANCER; MUTATION
CARRIERS; RISK ASSESSMENT; SUSCEPTIBILITY GENE; GERMLINE MUTATIONS;
BRCA2 MUTATIONS; FAMILY-HISTORY; MUTYH MUTATION
AB Gene panels for hereditary breast and ovarian cancer risk assessment are gaining acceptance, even though the clinical utility of these panels is not yet fully defined. Technical questions remain, however, about the performance and clinical interpretation of gene panels in comparison with traditional tests. We tested 1105 individuals using a 29-gene next-generation sequencing panel and observed 100% analytical concordance with traditional and reference data on >750 comparable variants. These 750 variants included technically challenging classes of sequence and copy number variation that together represent a significant fraction (13.4%) of the pathogenic variants observed. For BRCA1 and BRCA2, we also compared variant interpretations in traditional reports to those produced using only non-proprietary resources and following criteria based on recent (2015) guidelines. We observed 99.8% net report concordance, albeit with a slightly higher variant of uncertain significance rate. In 4.5% of BRCA-negative cases, we uncovered pathogenic variants in other genes, which appear clinically relevant. Previously unseen variants requiring interpretation accumulated rapidly, even after 1000 individuals had been tested. We conclude that next-generation sequencing panel testing can provide results highly comparable to traditional testing and can uncover potentially actionable findings that may be otherwise missed. Challenges remain for the broad adoption of panel tests, some of which will be addressed by the accumulation of large public databases of annotated clinical variants.
C1 [Lincoln, Stephen E.; Kobayashi, Yuya; Anderson, Michael J.; Yang, Shan; Nilsen, Geoffrey B.; Jacobs, Kevin B.; Monzon, Federico A.] Invitae, San Francisco, CA 94107 USA.
[Desmond, Andrea J.; Ellisen, Leif W.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Mills, Meredith A.; Kurian, Allison W.; Ford, James M.] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
[Ellisen, Leif W.] Harvard Univ, Sch Med, Boston, MA USA.
RP Lincoln, SE (reprint author), Invitae, 458 Brannan St, San Francisco, CA 94107 USA.
EM steve.lincoln@invitae.com
FU Friends Fighting Breast Cancer; Tracey Davis Memorial Fund; Breast
Cancer Research Foundation
FX Supported by The Friends Fighting Breast Cancer (L.W.E.), the Tracey
Davis Memorial Fund (L.W.E.), and the Breast Cancer Research Foundation
(A.W.K. and J.M.F.).
NR 96
TC 15
Z9 15
U1 1
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1525-1578
EI 1943-7811
J9 J MOL DIAGN
JI J. Mol. Diagn.
PD SEP
PY 2015
VL 17
IS 5
BP 533
EP 544
DI 10.1016/j.jmoldx.2015.04.009
PG 12
WC Pathology
SC Pathology
GA CQ7JB
UT WOS:000360777700009
PM 26207792
ER
PT J
AU Adams, JM
Miyamoto, S
AF Adams, Jeffrey M.
Miyamoto, Suzanne
TI The Influence of Emerging Nursing Strategy and Policy Leaders An
Interview With Dr Suzanne Miyamoto
SO JOURNAL OF NURSING ADMINISTRATION
LA English
DT Editorial Material
AB This department highlights emerging nursing leaders who have demonstrated great potential in advancing innovation and patient care leadership in practice, policy, research, education, and theory. This interview profiles Suzanne Miyamoto, PhD, RN, Senior Director of Government Affairs and Health Policy at the American Association of Colleges of Nursing.
C1 [Adams, Jeffrey M.] Ctr Innovat Care Delivery, Boston, MA USA.
[Adams, Jeffrey M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Miyamoto, Suzanne] Amer Assoc Coll Nursing, Govt Affairs & Hlth Policy, Washington, DC USA.
RP Adams, JM (reprint author), Massachusetts Gen Hosp, 275 Cambridge St,POB 432, Boston, MA 02114 USA.
EM jadams9@partners.org
NR 1
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0002-0443
EI 1539-0721
J9 J NURS ADMIN
JI J. Nurs. Adm.
PD SEP
PY 2015
VL 45
IS 9
BP 420
EP 422
DI 10.1097/NNA.0000000000000226
PG 3
WC Nursing
SC Nursing
GA CQ8JH
UT WOS:000360853200004
ER
PT J
AU Thompson, DA
Marsteller, JA
Pronovost, PJ
Gurses, A
Lubomski, LH
Goeschel, CA
Gosbee, JW
Wahr, J
Martinez, EA
AF Thompson, David A.
Marsteller, Jill A.
Pronovost, Peter J.
Gurses, Ayse
Lubomski, Lisa H.
Goeschel, Christine A.
Gosbee, John W.
Wahr, Joyce
Martinez, Elizabeth A.
TI Locating Errors Through Networked Surveillance: A Multimethod Approach
to Peer Assessment, Hazard Identification, and Prioritization of Patient
Safety Efforts in Cardiac Surgery
SO JOURNAL OF PATIENT SAFETY
LA English
DT Article
ID BLOOD-STREAM INFECTIONS; INTENSIVE-CARE; FAILURES; SCIENCE; QUALITY;
HEALTH; IMPACT; FOCUS; RISK
AB Objectives
The objectives were to develop a scientifically sound and feasible peer-to-peer assessment model that allows health-care organizations to evaluate patient safety in cardiovascular operating rooms and to establish safety priorities for improvement.
Methods
The locating errors through networked surveillance study was conducted to identify hazards in cardiac surgical care. A multidisciplinary team, composed of organizational sociology, organizational psychology, applied social psychology, clinical medicine, human factors engineering, and health services researchers, conducted the study. We used a transdisciplinary approach, which integrated the theories, concepts, and methods from each discipline, to develop comprehensive research methods. Multiple data collection was involved: focused literature review of cardiac surgery-related adverse events, retrospective analysis of cardiovascular events from a national database in the United Kingdom, and prospective peer assessment at 5 sites, involving survey assessments, structured interviews, direct observations, and contextual inquiries. A nominal group methodology, where one single group acts to problem solve and make decisions was used to review the data and develop a list of the top priority hazards.
Results
The top 6 priority hazard themes were as follows: safety culture, teamwork and communication, infection prevention, transitions of care, failure to adhere to practices or policies, and operating room layout and equipment.
Conclusions
We integrated the theories and methods of a diverse group of researchers to identify a broad range of hazards and good clinical practices within the cardiovascular surgical operating room. Our findings were the basis for a plan to prioritize improvements in cardiac surgical care. These study methods allowed for the comprehensive assessment of a high-risk clinical setting that may translate to other clinical settings.
C1 [Thompson, David A.; Marsteller, Jill A.; Pronovost, Peter J.; Gurses, Ayse; Lubomski, Lisa H.; Goeschel, Christine A.] Johns Hopkins Med, Armstrong Inst Patient Safety & Qual, Baltimore, MD USA.
[Thompson, David A.; Marsteller, Jill A.; Pronovost, Peter J.; Gurses, Ayse; Lubomski, Lisa H.; Goeschel, Christine A.; Martinez, Elizabeth A.] Johns Hopkins Univ, Sch Med, Baltimore, MD 21202 USA.
[Thompson, David A.; Marsteller, Jill A.; Pronovost, Peter J.; Goeschel, Christine A.] Univ Maryland, Sch Nursing, Baltimore, MD 21201 USA.
[Thompson, David A.; Marsteller, Jill A.; Pronovost, Peter J.; Gurses, Ayse; Goeschel, Christine A.] Bloomberg Sch Publ Hlth, Baltimore, MD USA.
[Gosbee, John W.; Wahr, Joyce] Univ Michigan, Sch Med, Ann Arbor, MI USA.
[Martinez, Elizabeth A.] Harvard Univ, Massachusetts Gen Hosp, Boston, MA 02115 USA.
RP Thompson, DA (reprint author), Johns Hopkins Univ, Sch Med, Armstrong Inst Patient Safety & Qual, 750 E Pratt St,15th Floor, Baltimore, MD 21202 USA.
EM dthomps1@jhmi.edu
FU National Institutes of Health, RAND; Commonwealth Fund; Michigan Health
& Hospital Association Keystone Center for Quality and Patient Safety;
Agency for Healthcare Research and Quality; SCA Foundation; Agency for
Healthcare Research and Quality (K08) [HS013904-02]
FX P.J.P has received grant funding from the National Institutes of Health,
RAND, and The Commonwealth Fund; is on the Leigh [speakers] Bureau and
received honoraria from various hospitals to speak on quality and
patient safety; is a consultant for the Association for Professionals in
Infection Control and Epidemiology, Inc.; is a board member for the
Cantel Medical and receives book royalties from Penguin Group. L.H.L.
received contract funding from Michigan Health & Hospital Association
Keystone Center for Quality and Patient Safety and consulted for the
Society for Pediatric Anesthesia. C.A.G. received grant funding from
Agency for Healthcare Research and Quality and has received honoraria
from various nonprofit agencies to speak on quality, health policy, and
patient safety. This work was completed as part of the FOCUS initiative.
The FOCUS Initiative is a collaborative project of the Society of
Cardiovascular Anesthesiologists (SCA), the SCA Foundation, and the
Johns Hopkins University Quality and Safety Research group. FOCUS is
funded exclusively by the SCA Foundation; the following received support
for this research: Drs. Thompson, Marsteller, Lubomski, Goeschel, and
Pronovost. Dr. Martinez was supported by the Agency for Healthcare
Research and Quality (K08 grant no. HS013904-02).
NR 30
TC 0
Z9 0
U1 5
U2 15
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1549-8417
J9 J PATIENT SAF
JI J. Patient Saf.
PD SEP
PY 2015
VL 11
IS 3
BP 143
EP 151
DI 10.1097/PTS.0000000000000059
PG 9
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA CQ6EX
UT WOS:000360698300003
PM 24686159
ER
PT J
AU Geng, CR
Tang, XB
Qian, W
Guan, FD
Johns, J
Yu, HY
Gong, CH
Shu, DY
Chen, D
AF Geng, Changran
Tang, Xiaobin
Qian, Wei
Guan, Fada
Johns, Jesse
Yu, Haiyan
Gong, Chunhui
Shu, Diyun
Chen, Da
TI Calculations of S values and effective dose for the radioiodine carrier
and surrounding individuals based on Chinese hybrid reference phantoms
using the Monte Carlo technique
SO JOURNAL OF RADIOLOGICAL PROTECTION
LA English
DT Article
DE Monte Carlo; computational phantoms; radioiodine; S values; effective
dose
ID COMPUTATIONAL PHANTOMS; ADULT MALE; DOSIMETRY; FEMALE; I-131; FAMILY;
SCHEMA; MODEL
AB The S values for the thyroid as the radioiodine source organ to other target organs were investigated using Chinese hybrid reference phantoms and the Monte Carlo code MCNP5. Two radioiodine isotopes I-125 and I-131 uniformly distributed in the thyroid were investigated separately. We compared our S values for I-131 in Chinese phantoms with previous studies using other types of phantoms: Oak Ridge National Laboratory (ORNL) stylized phantoms, International Commission on Radiological Protection (ICRP) voxel phantoms, and University of Florida (UF) phantoms. Our results are much closer to the UF phantoms. For each specific target organ, the S value for I-131 is larger than for I-125 in both male and female phantoms. In addition, the S values and effective dose to surrounding face-to-face exposed individuals, including different genders and ages (10- and 15-year-old juniors, and adults) from an adult male radioiodine carrier were also investigated. The target organ S values and effective dose for surrounding individuals obey the inverse square law with the distance between source and target phantoms. The obtained effective dose data in Chinese phantoms are comparable to the results in a previous study using the UF phantoms. The data generated in this study can serve as the reference to make recommendations for radiation protection of the Chinese patients or nuclear workers.
C1 [Geng, Changran; Tang, Xiaobin; Qian, Wei; Yu, Haiyan; Gong, Chunhui; Shu, Diyun; Chen, Da] Nanjing Univ Aeronaut & Astronaut, Dept Nucl Sci & Engn, Nanjing 211106, Jiangsu, Peoples R China.
[Geng, Changran; Tang, Xiaobin; Yu, Haiyan; Gong, Chunhui; Shu, Diyun; Chen, Da] Collaborat Innovat Ctr Radiat Med Jiangsu Higher, Suzhou 215123, Peoples R China.
[Geng, Changran] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Geng, Changran] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Guan, Fada] Univ Texas MD Anderson Canc Ctr, Dept Radiat Phys, Houston, TX 77030 USA.
[Johns, Jesse] Nimbus Innovat LLC, Temple, TX 76501 USA.
RP Geng, CR (reprint author), Nanjing Univ Aeronaut & Astronaut, Dept Nucl Sci & Engn, Nanjing 211106, Jiangsu, Peoples R China.
EM tangxiaobin@nuaa.edu.cn
RI Tang, Xiaobin/I-7601-2014;
OI Tang, Xiaobin/0000-0003-3308-0468; GUAN, FADA/0000-0001-8477-7391
FU National Natural Science Foundation of China [11475087]; Jiangsu
Innovation Program for Graduate Education [KYLX_0265]; Fundamental
Research Funds for the Central Universities [NS2014060]; Priority
Academic Program Development of Jiangsu Higher Education Institutions
FX This work was supported by National Natural Science Foundation of China
(No. 11475087), the funding of Jiangsu Innovation Program for Graduate
Education (No. KYLX_0265), the Fundamental Research Funds for the
Central Universities (No. NS2014060), and a project funded by the
Priority Academic Program Development of Jiangsu Higher Education
Institutions. We thank Dr Choonsik Lee et al for sharing the data for
ICRP phantoms.
NR 27
TC 0
Z9 0
U1 1
U2 9
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0952-4746
EI 1361-6498
J9 J RADIOL PROT
JI J. Radiol. Prot.
PD SEP
PY 2015
VL 35
IS 3
BP 707
EP 717
DI 10.1088/0952-4746/35/3/707
PG 11
WC Environmental Sciences; Public, Environmental & Occupational Health;
Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical
Imaging
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Nuclear Science & Technology; Radiology, Nuclear Medicine &
Medical Imaging
GA CR2FN
UT WOS:000361141800018
PM 26344387
ER
PT J
AU Singh, JA
Qu, HY
Yazdany, J
Chatham, W
Dall'era, M
Shewchuk, RM
AF Singh, Jasvinder A.
Qu, Haiyan
Yazdany, Jinoos
Chatham, Winn
Dall'era, Maria
Shewchuk, Richard M.
TI Barriers to Medication Decision Making in Women with Lupus Nephritis: A
Formative Study using Nominal Group Technique
SO JOURNAL OF RHEUMATOLOGY
LA English
DT Article
DE SYSTEMIC LUPUS ERYTHEMATOSUS; MEDICATION DECISION MAKING; MINORITIES;
RACE; BARRIERS; CHALLENGES
ID ERYTHEMATOSUS PATIENTS; PATIENT PREFERENCES; TREATMENT ADHERENCE;
RHEUMATIC-DISEASE; HEALTH-CARE; DISABILITIES; AMERICAN; IDENTIFY;
QUALITY; COHORT
AB Objective. To assess the perspectives of women with lupus nephritis on barriers to medication decision making.
Methods. We used the nominal group technique (NGT), a structured process to elicit ideas from participants, for a formative assessment. Eight NGT meetings were conducted in English and moderated by an expert NGT researcher at 2 medical centers. Participants responded to the question: "What sorts of things make it hard for people to decide to take the medicines that doctors prescribe for treating their lupus kidney disease?" Patients nominated, discussed, and prioritized barriers to decisional processes involving medications for treating lupus nephritis.
Results. Fifty-one women with lupus nephritis with a mean age of 40.6 +/- 13.3 years and disease duration of 11.8 +/- 8.3 years participated in 8 NGT meetings: 26 African Americans (4 panels), 13 Hispanics (2 panels), and 12 whites (2 panels). Of the participants, 36.5% had obtained at least a college degree and 55.8% needed some help in reading health materials. Of the 248 responses generated (range 19-37 responses/panel), 100 responses (40%) were perceived by patients as having relatively greater importance than other barriers in their own decision-making processes. The most salient perceived barriers, as indicated by percent-weighted votes assigned, were known/anticipated side effects (15.6%), medication expense/ability to afford medications (8.2%), and the fear that the medication could cause other diseases (7.8%).
Conclusion. Women with lupus nephritis identified specific barriers to decisions related to medications. Information relevant to known/anticipated medication side effects and medication cost will form the basis of a patient guide for women with systemic lupus erythematosus, currently under development.
C1 [Singh, Jasvinder A.] Univ Alabama Birmingham, Med Serv, Birmingham Vet Affairs VA Med Ctr, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.; Chatham, Winn] Univ Alabama Birmingham, Dept Med, Sch Med, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.; Chatham, Winn] Univ Alabama Birmingham, Div Epidemiol, Sch Publ Hlth, Birmingham, AL 35294 USA.
[Qu, Haiyan; Shewchuk, Richard M.] Univ Alabama Birmingham, Dept Hlth Serv Adm, Sch Hlth Profess, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA.
[Yazdany, Jinoos; Dall'era, Maria] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
RP Singh, JA (reprint author), Univ Alabama Birmingham, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA.
EM Jasvinder.md@gmail.com
FU Patient-Centered Outcomes Research Institute [CE-1304-6631]; Agency for
Health Quality and Research Center for Education and Research on
Therapeutics [U19 HS021110]; National Institute of Arthritis and
Musculoskeletal and Skin Diseases [P50 AR060772, U34 AR062891]; National
Institute on Aging [U01 AG018947]; National Cancer Institute [U10
CA149950]; US National Institutes of Health [K23 AR060259]; Rosalind
Russell Medical Research Center for Arthritis
FX This material is the result of work supported by the research contract
CE-1304-6631 from the Patient-Centered Outcomes Research Institute. J.A.
Singh is also supported by the resources and the use of facilities at
the VA Medical Center at Birmingham, Alabama, USA, and research grants
from these US agencies: Agency for Health Quality and Research Center
for Education and Research on Therapeutics U19 HS021110, National
Institute of Arthritis and Musculoskeletal and Skin Diseases P50
AR060772 and U34 AR062891, National Institute on Aging U01 AG018947, and
the National Cancer Institute U10 CA149950. J.Yazdany is also supported
by the US National Institutes of Health K23 AR060259 and the Rosalind
Russell Medical Research Center for Arthritis.
NR 33
TC 4
Z9 4
U1 0
U2 3
PU J RHEUMATOL PUBL CO
PI TORONTO
PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA
SN 0315-162X
EI 1499-2752
J9 J RHEUMATOL
JI J. Rheumatol.
PD SEP
PY 2015
VL 42
IS 9
BP 1616
EP 1623
DI 10.3899/jrheum.150168
PG 8
WC Rheumatology
SC Rheumatology
GA CQ6SF
UT WOS:000360733600014
PM 26178276
ER
PT J
AU Raske, ME
Dempsey, ME
Dillman, JR
Dory, CE
Garber, M
Hayes, LL
Iyer, RS
Kulkarni, AV
Myseros, JS
Rice, HE
Rigsby, CK
Ryan, ME
Strouse, PJ
Westra, SJ
Wootton-Gorges, SL
Coley, BD
Karmazyn, B
AF Raske, Molly E.
Dempsey, Molly E.
Dillman, Jonathan R.
Dory, Christopher E.
Garber, Matthew
Hayes, Laura L.
Iyer, Ramesh S.
Kulkarni, Abhaya V.
Myseros, John S.
Rice, Henry E.
Rigsby, Cynthia K.
Ryan, Maura E.
Strouse, Peter J.
Westra, Sjirk J.
Wootton-Gorges, Sandra L.
Coley, Brian D.
Karmazyn, Boaz
TI ACR Appropriateness Criteria Vomiting in Infants up to 3 Months of Age
SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY
LA English
DT Article
DE Appropriateness Criteria; vomiting; newborn; infant; diagnostic imaging
ID HYPERTROPHIC PYLORIC-STENOSIS; PEDIATRIC GASTROESOPHAGEAL-REFLUX;
NORTH-AMERICAN-SOCIETY; INTESTINAL MALROTATION; SONOGRAPHIC DIAGNOSIS;
PH PROBE; CHILDREN; ULTRASONOGRAPHY; SCINTIGRAPHY; ROTATION
AB Vomiting is a commonly reported symptom in infants less than three months of age. There are a multitude of pathologies to consider, both within and outside the gastrointestinal tract. In addition to conducting a thorough history and physical examination, a clinician formulates a reasonable differential diagnosis by consideration of two main factors: the infant's age and the characterization of the vomit as bilious or nonbilious. In this endeavor, the clinician is able to determine if an imaging study is needed and, if so, the urgency of the request. A review of the appropriate imaging evaluation of vomiting infants in the newborn to three-month-old age group is provided by organizing the discussion around the following three clinical scenarios: bilious vomiting, intermittent nonbilious vomiting since birth, and new-onset bilious vomiting.
The ACR Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every three years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances in which evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.
C1 [Raske, Molly E.] Childrens Hosp & Clin Minnesota, Minneapolis, MN 55404 USA.
[Dempsey, Molly E.] Texas Scottish Rite Hosp Children, Dallas, TX 75219 USA.
[Dillman, Jonathan R.; Strouse, Peter J.] Univ Michigan, CS Mott Childrens Hosp, Ann Arbor, MI 48109 USA.
[Dory, Christopher E.] Childrens Hosp, San Diego, CA USA.
[Garber, Matthew] Div Gen & Hosp Pediat, Columbia, SC USA.
[Garber, Matthew] Amer Acad Pediat, Elk Grove Village, IL USA.
[Hayes, Laura L.] Childrens Healthcare Atlanta, Atlanta, GA USA.
[Iyer, Ramesh S.] Seattle Childrens Hosp, Seattle, WA USA.
[Kulkarni, Abhaya V.] Hosp Sick Children, Toronto, ON M5G 1X8, Canada.
[Kulkarni, Abhaya V.; Myseros, John S.] Amer Assoc Neurol Surg, Rolling Meadows, IL USA.
[Kulkarni, Abhaya V.; Myseros, John S.] Congress Neurol Surg, Schaumburg, IL USA.
[Myseros, John S.] Childrens Natl Med Ctr, Washington, DC 20010 USA.
[Rice, Henry E.] Duke Univ, Med Ctr, Durham, NC USA.
[Rice, Henry E.] Amer Pediat Surg Assoc, Deerfield, IL USA.
[Rigsby, Cynthia K.; Ryan, Maura E.] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL USA.
[Westra, Sjirk J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Wootton-Gorges, Sandra L.] Univ Calif Davis, Sacramento, CA 95817 USA.
[Coley, Brian D.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA.
[Karmazyn, Boaz] Indiana Univ, James Whitcomb Riley Hosp Children, Indianapolis, IN USA.
RP Raske, ME (reprint author), Childrens Hosp & Clin Minnesota, 2525 Chicago Ave, Minneapolis, MN 55404 USA.
EM molly.raske@childrensmn.org
OI Coley, Brian/0000-0003-0354-4727
NR 44
TC 0
Z9 0
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1546-1440
J9 J AM COLL RADIOL
JI J. Am. Coll. Radiol.
PD SEP
PY 2015
VL 12
IS 9
BP 915
EP 922
DI 10.1016/j.jacr.2015.05.023
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CQ8QU
UT WOS:000360874300013
PM 26254159
ER
PT J
AU Kattapuram, TM
Sheth, RA
Ganguli, S
Mueller, PR
Walker, TG
AF Kattapuram, Taj M.
Sheth, Rahul A.
Ganguli, Suvranu
Mueller, Peter R.
Walker, T. Gregory
TI Interventional Radiology Symposium for Medical Students: Raising
Awareness, Understanding, and Interest
SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY
LA English
DT Editorial Material
ID IR
C1 [Kattapuram, Taj M.; Sheth, Rahul A.; Ganguli, Suvranu; Mueller, Peter R.; Walker, T. Gregory] Massachusetts Gen Hosp, Dept Intervent Radiol, Boston, MA 02114 USA.
RP Kattapuram, TM (reprint author), Massachusetts Gen Hosp, Dept Intervent Radiol, Gray 290, Boston, MA 02114 USA.
EM tkattapuram@mgh.harvard.edu
NR 7
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1546-1440
J9 J AM COLL RADIOL
JI J. Am. Coll. Radiol.
PD SEP
PY 2015
VL 12
IS 9
BP 968
EP 971
DI 10.1016/j.jacr.2015.03.046
PG 4
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CQ8QU
UT WOS:000360874300025
PM 26123737
ER
PT J
AU Kattapuram, TM
Liu, RW
AF Kattapuram, Taj M.
Liu, Raymond W.
TI Transitioning From Leadership in Training to Leadership in Practice:
Advice for Graduating Members-in-Training
SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY
LA English
DT Editorial Material
C1 [Kattapuram, Taj M.; Liu, Raymond W.] Massachusetts Gen Hosp, Dept Intervent Radiol, Boston, MA 02114 USA.
RP Kattapuram, TM (reprint author), Massachusetts Gen Hosp, Dept Intervent Radiol, Gray 290, Boston, MA 02114 USA.
EM tkattapuram@mgh.harvard.edu
NR 5
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1546-1440
J9 J AM COLL RADIOL
JI J. Am. Coll. Radiol.
PD SEP
PY 2015
VL 12
IS 9
BP 983
EP 984
DI 10.1016/j.jacr.2015.04.023
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CQ8QU
UT WOS:000360874300031
PM 26355208
ER
PT J
AU Tan, TC
Scherrer-Crosbie, M
AF Tan, Timothy C.
Scherrer-Crosbie, Marielle
TI Does Trastuzumab Cause Cardiotoxicity in the Treatment of Patients with
Breast Cancer? Reply
SO JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY
LA English
DT Letter
ID EJECTION FRACTION; CARDIAC TOXICITY
C1 [Tan, Timothy C.] Massachusetts Gen Hosp, Cardiac Ultrasound Lab, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
RP Tan, TC (reprint author), Massachusetts Gen Hosp, Cardiac Ultrasound Lab, Boston, MA 02114 USA.
NR 10
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0894-7317
J9 J AM SOC ECHOCARDIOG
JI J. Am. Soc. Echocardiogr.
PD SEP
PY 2015
VL 28
IS 9
BP 1129
EP 1130
DI 10.1016/j.echo.2015.07.024
PG 3
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CQ9LY
UT WOS:000360937600016
PM 26354553
ER
PT J
AU Murugan, VA
Kalra, MK
Rehani, M
Digumarthy, SR
AF Murugan, Venkatesh A.
Kalra, Mannudeep K.
Rehani, Madan
Digumarthy, Subba R.
TI Lung Cancer Screening Computed Tomography Radiation and Protocols
SO JOURNAL OF THORACIC IMAGING
LA English
DT Review
DE lung cancer screening protocols; low-dose computed tomography; CT
radiation dose
ID STATISTICAL ITERATIVE RECONSTRUCTION; FILTERED BACK-PROJECTION; LOW-DOSE
CT; TUBE CURRENT MODULATION; CHEST CT; IMAGE-QUALITY;
COST-EFFECTIVENESS; ABDOMINAL CT; SPIRAL CT; REDUCTION
AB Recent studies have supported the use of low-dose computed tomography (LDCT) of the chest as a screening tool for lung cancer. Several professional organizations have now included LDCT screening in high-risk populations in their guidelines. The United States Preventive Services Task Force has added LDCT to its lung cancer-screening guidelines as of December 2013. Recently, the Centers for Medicare and Medicaid Services acknowledged that the evidence for LDCT lung cancer screening is adequate, provided that eligibility criteria are met. As widespread use of LDCT is anticipated, the radiation dose associated with LDCT needs to be optimized. The American College of Radiology-Society of Thoracic Radiology collaboration and the National Comprehensive Cancer Care Network recently provided some guidelines for LDCT utilization for lung cancer screening. There are several scanning and image reconstruction techniques that can be used for reducing radiation dose in LDCT lung cancer screening. This review article presents protocols and guidelines for use of LDCT in lung cancer screening and describes our early experience in implementing LDCT at our institution.
C1 [Murugan, Venkatesh A.] Massachusetts Gen Hosp, Dept Imaging, Boston, MA 02114 USA.
[Murugan, Venkatesh A.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Murugan, VA (reprint author), Massachusetts Gen Hosp, Dept Imaging, Boston, MA 02114 USA.
EM varumuganmurugan@mgh.harvard.edu
NR 59
TC 0
Z9 0
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0883-5993
EI 1536-0237
J9 J THORAC IMAG
JI J. Thorac. Imaging
PD SEP
PY 2015
VL 30
IS 5
BP 283
EP 289
DI 10.1097/RTI.0000000000000150
PG 7
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CQ9WP
UT WOS:000360966200001
PM 25856411
ER
PT J
AU Kulvatunyou, N
Pandit, V
Moutamn, S
Inaba, K
Chouliaras, K
DeMoya, M
Naraghi, L
Kalb, B
Arif, H
Sravanthi, R
Joseph, B
Gries, L
Tang, AL
Rhee, P
AF Kulvatunyou, Narong
Pandit, Viraj
Moutamn, Sadoun
Inaba, Kenji
Chouliaras, Konstantinos
DeMoya, Marc
Naraghi, Leily
Kalb, Bobby
Arif, Hina
Sravanthi, Reddy
Joseph, Bellal
Gries, Lynn
Tang, Andrew L.
Rhee, Peter
TI A multi-institution prospective observational study of small bowel
obstruction: Clinical and computerized tomography predictors of which
patients may require early surgery
SO JOURNAL OF TRAUMA AND ACUTE CARE SURGERY
LA English
DT Article
DE Small bowel obstruction; adhesion; predictors; CT scan
ID SOLUBLE CONTRAST AGENT; CT; NEED; INTERVENTION; METAANALYSIS; OPERATION;
ISCHEMIA; CRITERIA; MODEL
AB BACKGROUND: For patients with adhesive small bowel obstruction (ASBO), early surgery after a failed trial of nonoperative treatment can improve outcome. However, deciding which patients require early surgery is difficult, given the lack of specific clinical or radiographic signs. The study goals were to identify clinical and computed tomography (CT) predictors of which patients may need early surgery and to evaluate the utility of the common CT findings.
METHODS: This was a multi-institution prospective observational study for patients who were admitted with ASBO. Patients were excluded if their SBO were not managed conservative initially; were within 30 days postoperatively; were caused by external hernias, small bowel tumor, or intussusception; and were related to Crohn's disease. Clinical and laboratory variables were collected prospectively. CT findings were interpreted by a blinded designated radiologist. To identify significant predictors, we performed a multivariable regression analysis.
RESULTS: During 22 months, we enrolled 200 patients with ASBO. Patients' mean (SD) age was 60 (18) years; 50% were male. Fifty-two patients (26%) underwent surgery. Of those who underwent surgery, the median duration of nonoperative treatment was 1.5 days (interquartile range, 1-2.5 days). In the regression model, we identified no flatus (odds ratio [OR], 3.28; 95% confidence interval [CI], 1.51-7.12; p = 0.003), presence of free fluid on CT (OR, 2.59; 95% CI, 1.13-5.90; p = 0.023), and high-grade obstruction by CT (OR, 2.44; 95% CI, 1.10-5.43; p = 0.028) to be significant predictors for ASBO patients who may need early surgery.
CONCLUSION: In this study, we prospectively derived one clinical and two CT predictors which ASBO patients may benefit from an early surgical intervention. However, a future study to validate these predictors is needed. (J Trauma Acute Care Surg. 2015;79: 393-398. Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.)
C1 [Kulvatunyou, Narong; Pandit, Viraj; Moutamn, Sadoun; Gries, Lynn; Tang, Andrew L.; Rhee, Peter] Univ Arizona, Dept Surg, Div Acute Care Surg, Tucson, AZ 85727 USA.
[Kalb, Bobby; Arif, Hina] Univ Arizona, Dept Radiol, Tucson, AZ 85727 USA.
[Inaba, Kenji; Chouliaras, Konstantinos] Univ So Calif, Dept Surg, Div Acute Care Surg, Los Angeles, CA USA.
[Sravanthi, Reddy] Univ So Calif, Dept Radiol, Los Angeles, CA USA.
[DeMoya, Marc; Naraghi, Leily] Massachusetts Gen Hosp, Dept Surg, Div Acute Care Surg, Boston, MA 02114 USA.
RP Kulvatunyou, N (reprint author), Univ Arizona, Dept Surg, Div Acute Care Surg, 1501 N Campbell Ave,Rm 5411,POB 245063, Tucson, AZ 85727 USA.
EM nkulvatunyou@surgery.arizona.edu
NR 20
TC 2
Z9 2
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2163-0755
EI 2163-0763
J9 J TRAUMA ACUTE CARE
JI J. Trauma Acute Care Surg.
PD SEP
PY 2015
VL 79
IS 3
BP 393
EP 398
DI 10.1097/TA.0000000000000759
PG 6
WC Critical Care Medicine; Surgery
SC General & Internal Medicine; Surgery
GA CQ4JV
UT WOS:000360571900012
PM 26307871
ER
PT J
AU Cauley, CE
Panizales, MT
Reznor, G
Haynes, AB
Havens, JM
Kelley, E
Mosenthal, AC
Cooper, Z
AF Cauley, Christy E.
Panizales, Maria T.
Reznor, Gally
Haynes, Alex B.
Havens, Joaquim M.
Kelley, Edward
Mosenthal, Anne C.
Cooper, Zara
TI Outcomes after emergency abdominal surgery in patients with advanced
cancer: Opportunities to reduce complications and improve palliative
care
SO JOURNAL OF TRAUMA AND ACUTE CARE SURGERY
LA English
DT Article
DE Advanced cancer; emergency surgery; palliative care
ID QUALITY-OF-LIFE; SURGICAL QUALITY; POSTOPERATIVE COMPLICATIONS;
TREATMENT PREFERENCES; AMERICAN-COLLEGE; MENTAL-HEALTH; DEATH; END;
MORTALITY; DISCUSSIONS
AB BACKGROUND: There is increasing emphasis on the appropriateness and quality of acute surgical care for patients with serious illness and at the end of life. However, there is a lack of evidence regarding outcomes after emergent major abdominal surgery among patients with advanced cancer to guide treatment decisions. This analysis sought to characterize adverse outcomes (mortality, complications, institutional discharge) and to identify factors independently associated with 30-day mortality among patients with disseminated cancer who undergo emergent abdominal surgery for intestinal obstruction or perforation.
METHODS: This is a retrospective cohort study of 875 disseminated cancer patients undergoing emergency surgery for perforation (n = 499) or obstruction (n = 376) at hospitals participating in the American College of Surgeons' National Surgical Quality Improvement Program from 2005 to 2012. Predictors of 30-day mortality were identified using multivariate logistic regression.
RESULTS: Among patients who underwent surgery for perforation, 30-day mortality was 34%, 67% had complications, and 52% were discharged to an institution. Renal failure, septic shock, ascites, dyspnea at rest, and dependent functional status were independent preoperative predictors of death at 30 days. When complications were considered, postoperative respiratory complications and age (75-84 years) were also predictors of mortality.
Patients who had surgery for obstruction had a 30-day mortality rate of 18% (n = 68), 41% had complications, and 60% were discharged to an institution. Dependent functional status and ascites were independent predictors of death at 30 days. In addition to these predictors, postoperative predictors of mortality included respiratory and cardiac complications. Few patients (4%) had do-not-resuscitate orders before surgery.
CONCLUSION: Emergency abdominal operations in patients with disseminated cancer are highly morbid, and many patients die soon after surgery. High rates of complications and low rates of preexisting do-not-resuscitate orders highlight the need for targeted interventions to reduce complications and integrate palliative approaches into the care of these patients. (J Trauma Acute Care Surg. 2015;79: 399-406. Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.)
C1 [Cauley, Christy E.; Haynes, Alex B.; Cooper, Zara] Brigham & Womens Hosp, Ariadne Labs, Boston, MA 02115 USA.
[Reznor, Gally; Havens, Joaquim M.; Kelley, Edward; Cooper, Zara] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA.
[Reznor, Gally; Havens, Joaquim M.; Cooper, Zara] Brigham & Womens Hosp, Ctr Surg & Publ Hlth, Boston, MA 02115 USA.
[Cauley, Christy E.; Haynes, Alex B.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Haynes, Alex B.] Codman Ctr Clin Effectiveness Surg, Boston, MA USA.
[Panizales, Maria T.] Partners Healthcare Int, Boston, MA USA.
[Mosenthal, Anne C.] Rutgers State Univ, Dept Surg, Newark, NJ 07102 USA.
RP Cauley, CE (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM zcooper@partners.org
FU National Cancer Institute at the National Institutes of Health
[R25CA092203]
FX C.E.C. is currently receiving a grant (R25CA092203) from the National
Cancer Institute at the National Institutes of Health.
NR 37
TC 5
Z9 5
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2163-0755
EI 2163-0763
J9 J TRAUMA ACUTE CARE
JI J. Trauma Acute Care Surg.
PD SEP
PY 2015
VL 79
IS 3
BP 399
EP 406
DI 10.1097/TA.0000000000000764
PG 8
WC Critical Care Medicine; Surgery
SC General & Internal Medicine; Surgery
GA CQ4JV
UT WOS:000360571900013
PM 26307872
ER
PT J
AU Deipolyi, AR
Al-Ansari, S
Khademhosseini, A
Oklu, R
AF Deipolyi, Amy R.
Al-Ansari, Shehab
Khademhosseini, Ali
Oklu, Rahmi
TI Occlusion of the Internal Iliac Artery Is Associated with Smaller
Prostate and Decreased Urinary Tract Symptoms
SO JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY
LA English
DT Article
ID EMBOLIZATION; HYPERPLASIA; VOLUME; PREVALENCE; PROJECT; LUTS; CT
AB Purpose: To characterize the relationship of proximal internal iliac artery (HA) occlusion or embolization on prostate volume (PV) and the presence of lower urinary tract symptoms (LUTS) or benign prostatic hyperplasia (BPH).
Materials and Methods: The study included 2 parts: Part 1 comprised 99 men >= 50 years old who underwent abdominopelvic computed tomography angiography for lower extremity claudication assessed in a retrospective cohort design; Part 2 comprised 18 patients who underwent iatrogenic IIA embolization during endovascular aneurysm repair assessed by a within-subjects approach. Prostate volume and IIA origin diameter were measured; IIA occlusion was noted. Chart review documented body mass index, LUTS, impotence, and buttock claudication.
Results: Of 99 men in Part 1, 60 had no IIA occlusion, and 39 had IIA occlusion (17 unilateral, 22 bilateral). Prostate volume differed significantly between groups (no IIA occlusion, 27.3 mL; unilateral HA occlusion, 20.7 mL; bilateral IIA occlusion, 17.1 mL; P = .001). Men without IIA occlusion had more LUTS (27%) than men with IIA occlusion (10%; P = .04). The number of men with complaints of impotence or buttock claudication was similar in both groups (40% vs 46%; P > .05). Multiple regression showed that age and IIA occlusion were independent predictors of PV (P < 0.05), whereas body mass index was not (P > .05), and that HA occlusion was the only independent predictor of LUTS/BPH (P < .05). Among the 18 men in Part 2, PV declined by 29% after ernbolization (P = .00001); 6 men had improvement or resolution of LUTS.
Conclusion: Proximal IIA occlusion is associated with nearly one-third reduction in PV and decreased findings of LUTS/BPH.
C1 [Deipolyi, Amy R.; Al-Ansari, Shehab; Oklu, Rahmi] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Vasc & Intervent Radiol, Boston, MA 02114 USA.
[Khademhosseini, Ali; Oklu, Rahmi] Harvard Univ, Sch Med, Brigham & Womens Hosp, Biomat Innovat Res Ctr,Dept Med, Cambridge, MA 02138 USA.
[Khademhosseini, Ali] MIT, Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Khademhosseini, Ali] Harvard Univ, Wyss Inst Biol Inspired Engn, Boston, MA 02114 USA.
RP Oklu, R (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Vasc & Intervent Radiol, 55 Fruit St,290 Gray Bigelow, Boston, MA 02114 USA.
EM roklu@mgh.harvard.edu
OI Khademhosseini, Ali/0000-0001-6322-8852; Deipolyi,
Amy/0000-0003-3144-386X
NR 21
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1051-0443
EI 1535-7732
J9 J VASC INTERV RADIOL
JI J. Vasc. Interv. Radiol.
PD SEP
PY 2015
VL 26
IS 9
BP 1305
EP 1310
DI 10.1016/j.jvir.2015.04.019
PG 6
WC Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular
Disease
SC Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System &
Cardiology
GA CR1KV
UT WOS:000361084600009
PM 26065926
ER
PT J
AU Andrabi, Y
Saadeh, TS
Uppot, RN
Arellano, RS
Sahani, DV
AF Andrabi, Yasir
Saadeh, Thomas S.
Uppot, Raul N.
Arellano, Ronald S.
Sahani, Dushyant V.
TI Impact of Dose-Modified Protocols on Radiation Doses in Patients
Undergoing CT Examinations following Image-Guided Catheter Placement
SO JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY
LA English
DT Article
ID STATISTICAL ITERATIVE RECONSTRUCTION; FILTERED BACK-PROJECTION;
PERCUTANEOUS DRAINAGE; ABSCESS DRAINAGE; PELVIC ABSCESSES; MULTIDETECTOR
CT; TUBE CURRENT; EXPOSURE; QUALITY; ALGORITHMS
AB Purpose: To investigate the impact of dose-modified'(DM) scan protocols on decreasing radiation exposure from computed tomography (CT) scans obtained following image-guided catheter procedures.
Materials and Methods: In this retrospective analysis, between December 2012 and June 2014, 192 patients (mean age, 60.7 y; 102 men) who underwent abdomen/pelvis CT examinations for catheter placement follow-up were included. The standard-dose (SD) baseline CT parameters included tube potential of 120 kVp, tube current of 75-550 mA, and noise index (NI) of 18-22. Weight-based scan parameters applied for follow-up CT were based on two reconstruction algorithms: filtered back projection (FBP; 120 kVp, 75-350 mA, NI = 30) and iterative reconstruction technique (IRT; 100/120 kVp, 75-250/350 mA, NI = 35). Two readers reviewed image quality (IQ) of follow-up and baseline CT examinations for 22 randomly sampled patients. Radiation doses were retrieved by dose monitoring software.
Results: Compared with baseline, DM follow-up CT protocols enabled substantial (62.4%) dose reductions (mean CT dose indexes: 4.1 mGy at follow-up, 10.9 mGy at baseline; P<.0001). Doses were significantly lower for IRT follow-up CT examinations compared with FBP (mean CT dose indexes: IRT, 3.6 mGy; FBP, 4.6 mGy; P<.05). In 47 patients with more than one follow-up CT examination (mean, 3.1 examinations per patient; range, 2-6), the observed cumulative radiation dose (CRD) was 42.1% lower than the expected CRD (observed, 1,437.9 mGy.cm; expected, 2,483.6 mGy.cm; P<.0001). Subjective IQ scores were acceptable for follow-up CT examinations (follow-up, 3.6; baseline, 4; P<.05).
Conclusions: DM CT eXaminations enable substantial dose reduction (62.4%) for each follow-up examination compared with SD baseline scans, without any IQ concerns. Use of IRT decreases dose by an additional 22%. The CRD is lowered by 42% in patients undergoing multiple DM follow-up CT examinations.
C1 [Andrabi, Yasir; Saadeh, Thomas S.; Uppot, Raul N.; Arellano, Ronald S.; Sahani, Dushyant V.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol,Div Abdominal Imaging & Intervent, Boston, MA 02114 USA.
RP Sahani, DV (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol,Div Abdominal Imaging & Intervent, 55 Fruit St,White 270, Boston, MA 02114 USA.
NR 32
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1051-0443
EI 1535-7732
J9 J VASC INTERV RADIOL
JI J. Vasc. Interv. Radiol.
PD SEP
PY 2015
VL 26
IS 9
BP 1339
EP 1346
DI 10.1016/j.jvir.2015.05.029
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular
Disease
SC Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System &
Cardiology
GA CR1KV
UT WOS:000361084600016
PM 26190187
ER
PT J
AU Seay, K
Khajoueinejad, N
Zheng, JH
Kiser, P
Ochsenbauer, C
Kappes, JC
Herold, B
Goldstein, H
AF Seay, Kieran
Khajoueinejad, Nazanin
Zheng, Jian Hua
Kiser, Patrick
Ochsenbauer, Christina
Kappes, John C.
Herold, Betsy
Goldstein, Harris
TI The Vaginal Acquisition and Dissemination of HIV-1 Infection in a Novel
Transgenic Mouse Model Is Facilitated by Coinfection with Herpes Simplex
Virus 2 and Is Inhibited by Microbicide Treatment
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; TENOFOVIR DISOPROXIL FUMARATE; FEMALE
GENITAL-TRACT; SUB-SAHARAN AFRICA; HUMANIZED BLT MICE; TYPE-2 INFECTION;
DENDRITIC CELLS; NEUTRALIZING ANTIBODIES; PREEXPOSURE PROPHYLAXIS;
MUCOSAL TRANSMISSION
AB Epidemiological studies have demonstrated that herpes simplex virus 2 (HSV-2) infection significantly increases the risk of HIV-1 acquisition, thereby contributing to the expanding HIV-1 epidemic. To investigate whether HSV-2 infection directly facilitates mucosal HIV-1 acquisition, we used our transgenic hCD4/R5/cT1 mouse model which circumvents major entry and transcription blocks preventing murine HIV-1 infection by targeting transgenic expression of human CD4, CCR5, and cyclin T1 genes to CD4(+) T cells and myeloid-committed cells. Productive infection of mucosal leukocytes, predominantly CD4(+) T cells, was detected in all hCD4/R5/cT1 mice intravaginally challenged with an HIV-1 infectious molecular clone, HIV-Du151.2(env)-NLuc, which expresses an env gene (C.Du151.2) cloned from an acute heterosexually infected woman and a NanoLuc luciferase reporter gene. Lower genital tract HIV-1 infection after HIV-Du151.2(env)-NLuc intravaginal challenge was increased similar to 4-fold in hCD4/R5/cT1 mice coinfected with HSV-2. Furthermore, HIV-1 dissemination to draining lymph nodes was detected only in HSV-2-coinfected mice. HSV-2 infection stimulated local infiltration and activation of CD4(+) T cells and dendritic cells, likely contributing to the enhanced HIV-1 infection and dissemination in HSV-2-coinfected mice. We then used this model to demonstrate that a novel gel containing tenofovir disoproxil fumarate (TDF), the more potent prodrug of tenofovir (TFV), but not the TFV microbicide gel utilized in the recent CAPRISA 004, VOICE (Vaginal and Oral Interventions to Control the Epidemic), and FACTS 001 clinical trials, was effective as preexposure prophylaxis (PrEP) to completely prevent vaginal HIV-1 infection in almost half of HSV-2-coinfected mice. These results also support utilization of hCD4/R5/cT1 mice as a highly reproducible immunocompetent preclinical model to evaluate HIV-1 acquisition across the female genital tract.
IMPORTANCE
Multiple epidemiological studies have reported that genital herpes simplex virus 2 (HSV-2) infection increases the risk of HIV-1 sexual acquisition by severalfold. Understanding the underlying mechanisms by which HSV-2 facilitates HIV-1 infection and optimizing the efficacy of therapies to inhibit HIV-1 infection during HSV-2 coinfection should contribute to reducing HIV-1 transmission. Using our novel transgenic hCD4/R5/cT1 mouse model infectible with HIV-1, we demonstrated that HSV-2 infection enhances vaginal transmission and dissemination of HIV-1 infection while stimulating recruitment and activation of CD4(+) T cells and dendritic cells in the lower genital tract. HIV acquisition by hCD4/R5/cT1 mice vaginally coinfected with HSV-2 could be completely prevented in almost half the mice by preexposure prophylaxis (PrEP) with a novel gel containing tenofovir disoproxil fumarate (TDF), the tenofovir prodrug, but not with the tenofovir microbicide gel utilized in CAPRISA-004, VOICE, and FACTS-001 clinical trials. The hCD4/R5/cT1 mice represent a new preclinical mouse model to evaluate vaginal HIV-1 acquisition.
C1 [Seay, Kieran; Khajoueinejad, Nazanin; Herold, Betsy; Goldstein, Harris] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA.
[Khajoueinejad, Nazanin; Zheng, Jian Hua; Herold, Betsy; Goldstein, Harris] Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10467 USA.
[Kiser, Patrick] Northwestern Univ, Dept Biomed Engn, McCormick Sch Engn, Evanston, IL 60208 USA.
[Ochsenbauer, Christina; Kappes, John C.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
[Kappes, John C.] Birmingham Vet Affairs Med Ctr, Res Serv, Birmingham, AL USA.
RP Goldstein, H (reprint author), Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA.
EM harris.goldstein@einstein.yu.edu
RI Kiser, Patrick/C-2843-2014
OI Kiser, Patrick/0000-0002-3868-7122
FU National Institute of Drug Abuse at the National Institutes of Health
[DA033788]; Einstein-Montefiore Center for AIDS Research [P30-AI51519];
University of Alabama at Birmingham Center for AIDS Research
[P30-AI277670]; National Institute of Allergy and Infectious Diseases at
the National Institutes of Health [AI065309, T32-AI007501]; NIH Center
for HIV-1/AIDS Vaccine Immunology (CHAVI) [UO1-AI067854]; Charles
Michael Chair in Autoimmune Diseases; VHA Merit Review Award
FX This work was supported by the National Institute of Drug Abuse at the
National Institutes of Health (DA033788), the Einstein-Montefiore Center
for AIDS Research (P30-AI51519), the University of Alabama at Birmingham
Center for AIDS Research (P30-AI277670), the National Institute of
Allergy and Infectious Diseases at the National Institutes of Health
(AI065309 and T32-AI007501 to K.S.), NIH Center for HIV-1/AIDS Vaccine
Immunology (CHAVI) (UO1-AI067854 to J.C.K. and C.O.), the Charles
Michael Chair in Autoimmune Diseases (to H.G.), and a VHA Merit Review
Award (to J.C.K.).
NR 63
TC 5
Z9 5
U1 0
U2 10
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD SEP
PY 2015
VL 89
IS 18
BP 9559
EP 9570
DI 10.1128/JVI.01326-15
PG 12
WC Virology
SC Virology
GA CQ6HE
UT WOS:000360704400036
PM 26157126
ER
PT J
AU Toyoda, M
Ogata, Y
Mahiti, M
Maeda, Y
Kuang, XMT
Miura, T
Jessen, H
Walker, BD
Brockman, MA
Brumme, ZL
Ueno, T
AF Toyoda, Mako
Ogata, Yoko
Mahiti, Macdonald
Maeda, Yosuke
Kuang, Xiaomei T.
Miura, Toshiyuki
Jessen, Heiko
Walker, Bruce D.
Brockman, Mark A.
Brumme, Zabrina L.
Ueno, Takamasa
TI Differential Ability of Primary HIV-1 Nef Isolates To Downregulate HIV-1
Entry Receptors
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN-LEUKOCYTE ANTIGEN; TYPE-1 NEF;
INDUCED CD4; T-CELLS; ELITE CONTROLLERS; DYNAMIC-RANGE; INFECTION;
RESISTANCE; PROTEIN
AB HIV-1 Nef downregulates the viral entry receptor CD4 as well as the coreceptors CCR5 and CXCR4 from the surface of HIV-infected cells, and this leads to promotion of viral replication through superinfection resistance and other mechanisms. Nef sequence motifs that modulate these functions have been identified via in vitro mutagenesis with laboratory HIV-1 strains. However, it remains unclear whether the same motifs contribute to Nef activity in patient-derived sequences and whether these motifs may differ in Nef sequences isolated at different infection stages and/or from patients with different disease phenotypes. Here, nef clones from 45 elite controllers (EC), 46 chronic progressors (CP), and 43 acute progressors (AP) were examined for their CD4, CCR5, and CXCR4 downregulation functions. Nef clones from EC exhibited statistically significantly impaired CD4 and CCR5 downregulation ability and modestly impaired CXCR4 downregulation activity compared to those from CP and AP. Nef's ability to downregulate CD4 and CCR5 correlated positively in all cohorts, suggesting that they are functionally linked in vivo. Moreover, impairments in Nef's receptor downregulation functions increased the susceptibility of Nef-expressing cells to HIV-1 infection. Mutagenesis studies on three functionally impaired EC Nef clones revealed that multiple residues, including those at novel sites, were involved in the alteration of Nef functions and steady-state protein levels. Specifically, polymorphisms at highly conserved tryptophan residues (e.g., Trp-57 and Trp-183) and immune escape-associated sites were responsible for reduced Nef functions in these clones. Our results suggest that the functional modulation of primary Nef sequences is mediated by complex polymorphism networks.
IMPORTANCE
HIV-1 Nef, a key factor for viral pathogenesis, downregulates functionally important molecules from the surface of infected cells, including the viral entry receptor CD4 and coreceptors CCR5 and CXCR4. This activity enhances viral replication by protecting infected cells from cytotoxicity associated with superinfection and may also serve as an immune evasion strategy. However, how these activities are maintained under selective pressure in vivo remains elusive. We addressed this question by analyzing functions of primary Nef clones isolated from patients at various infection stages and with different disease phenotypes, including elite controllers, who spontaneously control HIV-1 viremia to undetectable levels. The results indicated that downregulation of HIV-1 entry receptors, particularly CCR5, is impaired in Nef clones from elite controllers. These functional impairments were driven by rare Nef polymorphisms and adaptations associated with cellular immune responses, underscoring the complex molecular pathways responsible for maintaining and attenuating viral protein function in vivo.
C1 [Toyoda, Mako; Ogata, Yoko; Mahiti, Macdonald; Ueno, Takamasa] Kumamoto Univ, Ctr AIDS Res, Kumamoto, Japan.
[Maeda, Yosuke] Kumamoto Univ, Fac Life Sci, Dept Microbiol, Kumamoto, Japan.
[Kuang, Xiaomei T.; Brockman, Mark A.; Brumme, Zabrina L.] Simon Fraser Univ, Burnaby, BC V5A 1S6, Canada.
[Miura, Toshiyuki] Univ Tokyo, Tokyo, Japan.
[Jessen, Heiko] Jessen Praxis, Berlin, Germany.
[Walker, Bruce D.] Ragon Inst Massachusetts Gen Hosp Massachusetts I, Boston, MA USA.
[Walker, Bruce D.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
[Walker, Bruce D.] Howard Hughes Med Inst, Chevy Chase, MD USA.
[Brockman, Mark A.; Brumme, Zabrina L.] British Columbia Ctr Excellence HIV AIDS, Vancouver, BC, Canada.
[Ueno, Takamasa] Kumamoto Univ, Int Res Ctr Med Sci, Kumamoto, Japan.
RP Ueno, T (reprint author), Kumamoto Univ, Ctr AIDS Res, Kumamoto, Japan.
EM uenotaka@kumamoto-u.ac.jp
RI Ueno, Takamasa/F-5788-2013;
OI Ueno, Takamasa/0000-0003-4852-4236; Brockman, Mark/0000-0001-6432-1426
FU Bill and Melinda Gates Foundation; Schwartz Foundation; Harvard
University Center for AIDS Research; Ministry of Education, Science,
Sports, and Culture of Japan; Japan Agency for Medical Research and
Development, AMED (Research Program on HIV/AIDS); Otsuka Toshimi
Scholarship Foundation; Canadian Association for HIV Research;
Bristol-Myers Squibb Canada; ViiV Healthcare; Canadian Institutes for
Health Research; Michael Smith Foundation for Health Research
FX We thank Philip Mwimanzi, Hirohito Ootsuka, Michiyo Tokunaga, and Hua
Qian for their technical contributions to the initial stage of this
study and Martin Markowitz for access to clinical specimens. We also
acknowledge and thank the International HIV Controllers Study group,
funded by the Bill and Melinda Gates Foundation, the Schwartz
Foundation, and the Harvard University Center for AIDS Research.; This
study was supported in part by a grant-in-aid for scientific research
from the Ministry of Education, Science, Sports, and Culture of Japan
and by a grant from the Japan Agency for Medical Research and
Development, AMED (Research Program on HIV/AIDS) (to T.U.). M.M. is
supported by the Otsuka Toshimi Scholarship Foundation. X.T.K. was
supported by a Master's scholarship from the Canadian Association for
HIV Research in partnership with Bristol-Myers Squibb Canada and ViiV
Healthcare. M.A.B. holds a Canada Research Chair in Viral Pathogenesis
and Immunity from the Canada Research Chairs Program. Z.L.B. is the
recipient of a New Investigator Award from the Canadian Institutes for
Health Research and a Scholar Award from the Michael Smith Foundation
for Health Research.
NR 54
TC 6
Z9 6
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD SEP
PY 2015
VL 89
IS 18
BP 9639
EP 9652
DI 10.1128/JVI.01548-15
PG 14
WC Virology
SC Virology
GA CQ6HE
UT WOS:000360704400043
PM 26178998
ER
PT J
AU Panzer, SE
Laskowski, J
Renner, B
Kulik, L
Ljubanovic, D
Huber, KM
Zhong, WX
Pickering, MC
Holers, VM
Thurman, JM
AF Panzer, Sarah E.
Laskowski, Jennifer
Renner, Brandon
Kulik, Liudmila
Ljubanovic, Danica
Huber, Kendra M.
Zhong, Weixiong
Pickering, Matthew C.
Holers, V. Michael
Thurman, Joshua M.
TI IgM exacerbates glomerular disease progression in complement-induced
glomerulopathy
SO KIDNEY INTERNATIONAL
LA English
DT Article
DE complement; glomerulonephritis; immunology
ID NEPHROTIC SYNDROME; MESANGIAL HYPERCELLULARITY; REPERFUSION INJURY;
NATURAL ANTIBODY; CELL; MICE; DEFICIENT; GLOMERULONEPHRITIS; ACTIVATION;
DEPOSITION
AB Although glomerular immunoglobulin M (IgM) deposition occurs in a variety of glomerular diseases, the mechanism of deposition and its clinical significance remain controversial. Some have theorized IgM becomes passively trapped in areas of glomerulosclerosis. However, recent studies found that IgM specifically binds damaged glomeruli. Therefore, we tested whether natural IgM binds to neo-epitopes exposed after insults to the glomerulus and exacerbates disease in mice deficient in the complement regulatory protein factor H; a model of non-sclerotic and nonimmune-complex glomerular disease. Immunofluorescence microscopy demonstrated mesangial and capillary loop deposition of IgM, whereas ultrastructural analysis found IgM deposition on endothelial cells and subendothelial areas. Factor H-deficient mice lacking B cells were protected from renal damage, as evidenced by milder histologic lesions on light and electron microscopy. IgM, but not IgG, from wild-type mice bound to cultured murine mesangial cells. Furthermore, injection of purified IgM into mice lacking B cells bound within the glomeruli and induced proteinuria. A monoclonal natural IgM-recognizing phospholipids also bound to glomeruli in vivo and induced albuminuria. Thus, our results indicate specific IgM antibodies bind to glomerular epitopes and that IgM contributes to the progression of glomerular damage in this mouse model of non-sclerotic glomerular disease.
C1 [Panzer, Sarah E.] Univ Wisconsin, Div Nephrol, Dept Med, Madison, WI 53705 USA.
[Laskowski, Jennifer; Renner, Brandon; Kulik, Liudmila; Huber, Kendra M.; Holers, V. Michael; Thurman, Joshua M.] Univ Colorado Denver, Dept Med, Aurora, CO USA.
[Ljubanovic, Danica] Univ Hosp Dubrava, Dept Pathol, Zagreb, Croatia.
[Zhong, Weixiong] Univ Wisconsin, Dept Pathol, Madison, WI 53705 USA.
[Zhong, Weixiong] William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Serv, Madison, WI USA.
[Pickering, Matthew C.] Univ London Imperial Coll Sci Technol & Med, Ctr Complement & Inflammat Res, London, England.
RP Panzer, SE (reprint author), Univ Wisconsin, Div Nephrol, Dept Med, 1685 Highland Ave,Suite 5000, Madison, WI 53705 USA.
EM sepanzer@medicine.wisc.edu
FU KIDNEEDS Foundation; National Institutes of Health [F32DK096711-01, R01
DK076690]
FX ZThis work was supported in part by the KIDNEEDS Foundation (JMT) and
National Institutes of Health grants F32DK096711-01 (SEP) and R01
DK076690 (JMT).
NR 34
TC 11
Z9 11
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0085-2538
EI 1523-1755
J9 KIDNEY INT
JI Kidney Int.
PD SEP
PY 2015
VL 88
IS 3
BP 528
EP 537
DI 10.1038/ki.2015.120
PG 10
WC Urology & Nephrology
SC Urology & Nephrology
GA CR1JA
UT WOS:000361079800017
PM 25945405
ER
PT J
AU Freeman, MC
Kolappa, K
de Almeida, JMC
Kleinman, A
Makhashvili, N
Phakathi, S
Saraceno, B
Thornicroft, G
AF Freeman, Melvyn Colin
Kolappa, Kavitha
de Almeida, Jose Miguel Caldas
Kleinman, Arthur
Makhashvili, Nino
Phakathi, Sifiso
Saraceno, Benedetto
Thornicroft, Graham
TI Reversing hard won victories in the name of human rights: a critique of
the General Comment on Article 12 of the UN Convention on the Rights of
Persons with Disabilities
SO LANCET PSYCHIATRY
LA English
DT Editorial Material
ID MENTAL-HEALTH LAW
AB The UN Convention on the Rights of Persons with Disabilities (CRPD) is a major milestone in safeguarding the rights of persons with disabilities. However, the General Comment on Article 12 of the CRPD threatens to undermine critical rights for persons with mental disabilities, including the enjoyment of the highest attainable standard of health, access to justice, the right to liberty, and the right to life. Stigma and discrimination might also increase. Much hinges on the Committee on the Rights of Persons with Disabilities' view that all persons have legal capacity at all times irrespective of mental status, and hence involuntary admission and treatment, substitute decision-making, and diversion from the criminal justice system are deemed indefensible. The General Comment requires urgent consideration with the full participation of practitioners and a broad range of user and family groups.
C1 [Freeman, Melvyn Colin; Phakathi, Sifiso] Natl Dept Hlth, ZA-0001 Pretoria, South Africa.
[Freeman, Melvyn Colin] Univ Witwatersrand, Johannesburg, South Africa.
[Kolappa, Kavitha] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[de Almeida, Jose Miguel Caldas; Saraceno, Benedetto] Univ Nova Lisboa, Fac Ciencias Med, P-1200 Lisbon, Portugal.
[Kleinman, Arthur] Harvard Univ, Sch Med, Boston, MA USA.
[Makhashvili, Nino] Ilia State Univ, Tbilisi, Rep of Georgia.
[Thornicroft, Graham] Kings Coll London, Inst Psychiat Psychol & Neurosci, Ctr Global Mental Hlth, London WC2R 2LS, England.
RP Freeman, MC (reprint author), Natl Dept Hlth, Private Bag X828, ZA-0001 Pretoria, South Africa.
EM Freemm@health.gov.za
RI Thornicroft, Graham/B-4027-2010; Faculdade de Ciencias Medicas, Nova
Medical School/K-6209-2013
OI Thornicroft, Graham/0000-0003-0662-0879;
NR 15
TC 12
Z9 12
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2215-0374
J9 LANCET PSYCHIAT
JI Lancet Psychiatry
PD SEP
PY 2015
VL 2
IS 9
BP 844
EP 850
DI 10.1016/S2215-0366(15)00218-7
PG 7
WC Psychiatry
SC Psychiatry
GA CQ9WY
UT WOS:000360967200034
PM 26236004
ER
PT J
AU Abbatiello, SE
Schilling, B
Mani, DR
Zimmerman, LJ
Hall, SC
Maclean, B
Albertolle, M
Allen, S
Burgess, M
Cusack, MP
Gosh, M
Hedrick, V
Held, JM
Inerowicz, HD
Jackson, A
Keshishian, H
Kinsinger, CR
Lyssand, J
Makowski, L
Mesri, M
Rodriguez, H
Rudnick, P
Sadowski, P
Sedransk, N
Shaddox, K
Skates, SJ
Kuhn, E
Smith, D
Whiteaker, JR
Whitwell, C
Zhang, S
Borchers, CH
Fisher, SJ
Gibson, BW
Liebler, DC
MacCoss, MJ
Neubert, TA
Paulovich, AG
Regnier, FE
Tempst, P
Carr, SA
AF Abbatiello, Susan E.
Schilling, Birgit
Mani, D. R.
Zimmerman, Lisa J.
Hall, Steven C.
Maclean, Brendan
Albertolle, Matthew
Allen, Simon
Burgess, Michael
Cusack, Michael P.
Gosh, Mousumi
Hedrick, Victoria
Held, Jason M.
Inerowicz, H. Dorota
Jackson, Angela
Keshishian, Hasmik
Kinsinger, Christopher R.
Lyssand, John
Makowski, Lee
Mesri, Mehdi
Rodriguez, Henry
Rudnick, Paul
Sadowski, Pawel
Sedransk, Nell
Shaddox, Kent
Skates, Stephen J.
Kuhn, Eric
Smith, Derek
Whiteaker, Jeffery R.
Whitwell, Corbin
Zhang, Shucha
Borchers, Christoph H.
Fisher, Susan J.
Gibson, Bradford W.
Liebler, Daniel C.
MacCoss, Michael J.
Neubert, Thomas A.
Paulovich, Amanda G.
Regnier, Fred E.
Tempst, Paul
Carr, Steven A.
TI Large-Scale Interlaboratory Study to Develop, Analytically Validate and
Apply Highly Multiplexed, Quantitative Peptide Assays to Measure
Cancer-Relevant Proteins in Plasma
SO MOLECULAR & CELLULAR PROTEOMICS
LA English
DT Article
ID MONITORING MASS-SPECTROMETRY; LOW-ABUNDANCE PROTEINS; ABSOLUTE
QUANTIFICATION; BIOMARKER DISCOVERY; TARGETED PROTEOMICS;
ISOTOPE-DILUTION; STANDARDS; MS; PROTEOLYSIS; PERFORMANCE
AB There is an increasing need in biology and clinical medicine to robustly and reliably measure tens to hundreds of peptides and proteins in clinical and biological samples with high sensitivity, specificity, reproducibility, and repeatability. Previously, we demonstrated that LC-MRM-MS with isotope dilution has suitable performance for quantitative measurements of small numbers of relatively abundant proteins in human plasma and that the resulting assays can be transferred across laboratories while maintaining high reproducibility and quantitative precision. Here, we significantly extend that earlier work, demonstrating that 11 laboratories using 14 LC-MS systems can develop, determine analytical figures of merit, and apply highly multiplexed MRM-MS assays targeting 125 peptides derived from 27 cancer-relevant proteins and seven control proteins to precisely and reproducibly measure the analytes in human plasma. To ensure consistent generation of high quality data, we incorporated a system suitability protocol (SSP) into our experimental design. The SSP enabled real-time monitoring of LC-MRM-MS performance during assay development and implementation, facilitating early detection and correction of chromatographic and instrumental problems. Low to sub-nanogram/ml sensitivity for proteins in plasma was achieved by one-step immunoaffinity depletion of 14 abundant plasma proteins prior to analysis. Median intra- and interlaboratory reproducibility was <20%, sufficient for most biological studies and candidate protein biomarker verification. Digestion recovery of peptides was assessed and quantitative accuracy improved using heavy-isotope-labeled versions of the proteins as internal standards. Using the highly multiplexed assay, participating laboratories were able to precisely and reproducibly determine the levels of a series of analytes in blinded samples used to simulate an interlaboratory clinical study of patient samples. Our study further establishes that LC-MRM-MS using stable isotope dilution, with appropriate attention to analytical validation and appropriate quality control measures, enables sensitive, specific, reproducible, and quantitative measurements of proteins and peptides in complex biological matrices such as plasma.
C1 [Abbatiello, Susan E.; Mani, D. R.; Burgess, Michael; Keshishian, Hasmik; Kuhn, Eric; Carr, Steven A.] Broad Inst & Harvard, Cambridge, MA 02142 USA.
[Schilling, Birgit; Cusack, Michael P.; Held, Jason M.; Gibson, Bradford W.] Buck Inst Res Aging, Novato, CA 94945 USA.
[Zimmerman, Lisa J.; Shaddox, Kent; Whitwell, Corbin; Liebler, Daniel C.] Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA.
[Zimmerman, Lisa J.; Shaddox, Kent; Whitwell, Corbin; Liebler, Daniel C.] Vanderbilt Ingram Canc Ctr, Jim Ayers Inst Precancer Detect & Diag, Nashville, TN 37232 USA.
[Hall, Steven C.; Albertolle, Matthew; Allen, Simon; Fisher, Susan J.] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA.
[Maclean, Brendan; MacCoss, Michael J.] Univ Washington, Sch Med, Dept Genome Sci, Seattle, WA USA.
[Gosh, Mousumi; Tempst, Paul] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA.
[Hedrick, Victoria; Inerowicz, H. Dorota; Regnier, Fred E.] Purdue Univ, W Lafayette, IN 47907 USA.
[Jackson, Angela; Smith, Derek; Borchers, Christoph H.] Univ Victoria, Genome BC Prote Ctr, Victoria, BC V8Z 7X8, Canada.
[Kinsinger, Christopher R.; Mesri, Mehdi; Rodriguez, Henry; Neubert, Thomas A.] NCI, NIH, Bethesda, MD 20892 USA.
[Lyssand, John; Sadowski, Pawel; Neubert, Thomas A.] NYU, Skirball Inst, Kimmel Ctr Biol & Med, New York, NY 10016 USA.
[Rudnick, Paul] NIST, Gaithersburg, MD 20899 USA.
[Sedransk, Nell] Natl Inst Stat Sci, Res Triangle Pk, NC 27709 USA.
[Skates, Stephen J.] Massachusetts Gen Hosp, Biostat Ctr, Boston, MA 02114 USA.
[Whiteaker, Jeffery R.; Zhang, Shucha; Paulovich, Amanda G.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA.
RP Carr, SA (reprint author), Broad Inst & Harvard, Cambridge, MA 02142 USA.
EM scarr@broad.mit.edu
OI Tempst, Paul/0000-0002-6680-3987; Held, Jason/0000-0001-8024-2736
FU National Cancer Institute, NCI Clinical Proteomic Technologies for
Cancer initiative [U24 CA126476, U24 126477, U24 126480, U24 CA126485,
U24 126479]; NCI [U24CA160034]; Vanderbilt University Center via NCI
[U24CA159988]; National Institute of Standards and Technology
[70NANB9H9001]; NCRR Shared Instrumentation program [S10 RR027953, S10
RR024604]; National Institute of Statistical Sciences; Canary Foundation
FX This work was supported by grants from the National Cancer Institute
(U24 CA126476, U24 126477, U24 126480, U24 CA126485, and U24 126479),
part of NCI Clinical Proteomic Technologies for Cancer
(http://proteomics.cancer.gov) initiative. A component of this
initiative is the Clinical Proteomic Technology Assessment for Cancer
(CPTAC) Network and teams, which include the Broad Institute of MIT and
Harvard (with the Fred Hutchinson Cancer Research Center, Massachusetts
General Hospital, the University of North Carolina at Chapel Hill, the
University of Victoria, and the Plasma Proteome Institute), Memorial
Sloan-Kettering Cancer Center (with the Skirball Institute at New York
University), Purdue University (with Monarch Life Sciences, Indiana
University, Indiana University-Purdue University Indianapolis, and the
Hoosier Oncology Group), University of California, San Francisco (with
the Buck Institute for Research on Aging, Lawrence Berkeley National
Laboratory, and the University of Texas M.D. Anderson Cancer Center),
and Vanderbilt University School of Medicine (with the University of
Texas M.D. Anderson Cancer Center, the University of Washington, and the
University of Arizona). The Broad Institute and Fred Hutchinson Cancer
Research Center also acknowledge CPTAC phase 2 support from NCI
U24CA160034, as does the Vanderbilt University Center via NCI
U24CA159988. The UCSF CPTAC team gratefully acknowledges the support of
the Canary Foundation for providing funds to purchase a 4000 QTRAP mass
spectrometer. The Vanderbilt CPTAC team was additionally supported by
Cooperative Agreement No. 70NANB9H9001 from the National Institute of
Standards and Technology. B.W.G. and T.A.N. acknowledge support from the
NCRR Shared Instrumentation program for instrumentation (grants S10
RR027953 and S10 RR024604, respectively). The NCI CPTAC also supported
the work by the National Institute of Statistical Sciences.
NR 59
TC 42
Z9 42
U1 8
U2 35
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 1535-9476
EI 1535-9484
J9 MOL CELL PROTEOMICS
JI Mol. Cell. Proteomics
PD SEP
PY 2015
VL 14
IS 9
BP 2357
EP 2374
DI 10.1074/mcp.M114.047050
PG 18
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA CQ7YO
UT WOS:000360823000006
PM 25693799
ER
PT J
AU Keshishian, H
Burgess, MW
Gillette, MA
Mertins, P
Clauser, KR
Mani, DR
Kuhn, EW
Farrell, LA
Gerszten, RE
Carr, SA
AF Keshishian, Hasmik
Burgess, Michael W.
Gillette, Michael A.
Mertins, Philipp
Clauser, Karl R.
Mani, D. R.
Kuhn, Eric W.
Farrell, Laurie A.
Gerszten, Robert E.
Carr, Steven A.
TI Multiplexed, Quantitative Workflow for Sensitive Biomarker Discovery in
Plasma Yields Novel Candidates for Early Myocardial Injury
SO MOLECULAR & CELLULAR PROTEOMICS
LA English
DT Article
ID ACUTE CORONARY SYNDROMES; MASS-SPECTROMETRY; LTQ ORBITRAP; LABEL-FREE;
PROTEOME; PROTEINS; QUANTIFICATION; CHROMATOGRAPHY; STRATEGY; DISEASE
AB We have developed a novel plasma protein analysis platform with optimized sample preparation, chromatography, and MS analysis protocols. The workflow, which utilizes chemical isobaric mass tag labeling for relative quantification of plasma proteins, achieves far greater depth of proteome detection and quantification while simultaneously having increased sample throughput than prior methods. We applied the new workflow to a time series of plasma samples from patients undergoing a therapeutic, "planned" myocardial infarction for hypertrophic cardiomyopathy, a unique human model in which each person serves as their own biologic control. Over 5300 proteins were confidently identified in our experiments with an average of 4600 proteins identified per sample (with two or more distinct peptides identified per protein) using iTRAQ four-plex labeling. Nearly 3400 proteins were quantified in common across all 16 patient samples. Compared with a previously published label-free approach, the new method quantified almost fivefold more proteins/sample and provided a six-to nine-fold increase in sample analysis throughput. Moreover, this study provides the largest high-confidence plasma proteome dataset available to date. The reliability of relative quantification was also greatly improved relative to the label-free approach, with measured iTRAQ ratios and temporal trends correlating well with results from a 23-plex immunoMRM (iMRM) assay containing a subset of the candidate proteins applied to the same patient samples. The functional importance of improved detection and quantification was reflected in a markedly expanded list of significantly regulated proteins that provided many new candidate biomarker proteins. Preliminary evaluation of plasma sample labeling with TMT six-plex and ten-plex reagents suggests that even further increases in multi-plexing of plasma analysis are practically achievable without significant losses in depth of detection relative to iTRAQ four-plex. These results obtained with our novel platform provide clear demonstration of the value of using isobaric mass tag reagents in plasma-based biomarker discovery experiments.
C1 [Keshishian, Hasmik; Burgess, Michael W.; Gillette, Michael A.; Mertins, Philipp; Clauser, Karl R.; Mani, D. R.; Kuhn, Eric W.; Gerszten, Robert E.; Carr, Steven A.] Broad Inst & Harvard, Cambridge, MA 02142 USA.
[Gillette, Michael A.; Farrell, Laurie A.; Gerszten, Robert E.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Keshishian, H (reprint author), Broad Inst & Harvard, Prote, 7 Cambridge Ctr, Cambridge, MA 02142 USA.
EM hasmik@broadinstitute.org; scarr@broad.mit.edu
FU National Institutes of Health [HHSN268201000033C]; NHLBI [R01HL096738];
NCI Clinical Proteomics Tumor Analysis Consortium initiative
[U24CA160034]; NCI Early Detection Research Network program
[5U01CA152990-05]
FX This work was supported in part by grants from National Institutes of
Health: HHSN268201000033C and R01HL096738 from NHLBI (to REG and SAC)
and Grants U24CA160034 from NCI Clinical Proteomics Tumor Analysis
Consortium initiative and 5U01CA152990-05 from the NCI Early Detection
Research Network program (to SAC).
NR 37
TC 25
Z9 25
U1 8
U2 31
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 1535-9476
EI 1535-9484
J9 MOL CELL PROTEOMICS
JI Mol. Cell. Proteomics
PD SEP
PY 2015
VL 14
IS 9
BP 2375
EP 2393
DI 10.1074/mcp.M114.046813
PG 19
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA CQ7YO
UT WOS:000360823000007
PM 25724909
ER
PT J
AU Zhang, X
AF Zhang, Xi
TI Less is More: Membrane Protein Digestion Beyond Urea-Trypsin Solution
for Next-level Proteomics
SO MOLECULAR & CELLULAR PROTEOMICS
LA English
DT Review
ID EXCHANGE-MASS-SPECTROMETRY; CYTOCHROME-C-OXIDASE; BETA(2)
ADRENERGIC-RECEPTOR; ALKYL GLYCOSIDE DETERGENTS; POROUS POLYMER
MONOLITH; X-RAY-STRUCTURE; SHOTGUN PROTEOMICS; CRYSTAL-STRUCTURE;
COUPLED RECEPTOR; SACCHAROMYCES-CEREVISIAE
AB The goal of next-level bottom-up membrane proteomics is protein function investigation, via high-coverage high-throughput peptide-centric quantitation of expression, modifications and dynamic structures at systems scale. Yet efficient digestion of mammalian membrane proteins presents a daunting barrier, and prevalent day-long urea-trypsin in-solution digestion proved insufficient to reach this goal. Many efforts contributed incremental advances over past years, but involved protein denaturation that disconnected measurement from functional states. Beyond denaturation, the recent discovery of structure/proteomics omni-compatible detergent n-dodecyl-beta-D-maltopyranoside, combined with pepsin and PNGase F columns, enabled breakthroughs in membrane protein digestion: a 2010 DDM-low-TCEP (DLT) method for H/D-exchange (HDX) using human G protein-coupled receptor, and a 2015 flow/detergent-facilitated protease and de-PTM digestions (FDD) for integrative deep sequencing and quantitation using full-length human ion channel complex. Distinguishing protein solubilization from denaturation, protease digestion reliability from theoretical specificity, and reduction from alkylation, these methods shifted day(s)-long paradigms into minutes, and afforded fully automatable (HDX)-protein-peptide-(tandem mass tag)-HPLC pipelines to instantly measure functional proteins at deep coverage, high peptide reproducibility, low artifacts and minimal leakage. Promoting-not destroying-structures and activities harnessed membrane proteins for the next-level streamlined functional proteomics. This review analyzes recent advances in membrane protein digestion methods and highlights critical discoveries for future proteomics.
C1 [Zhang, Xi] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Zhang, Xi] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA USA.
RP Zhang, X (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 32 Fruit St, Boston, MA 02114 USA.
EM xi.zhang.edu@gmail.com
OI Zhang, Xi/0000-0003-2755-7901
FU National Institute of General Medical Sciences [GM 58448]
FX This work was supported in part by the National Institute of General
Medical Sciences (GM 58448, K.W.M.).
NR 83
TC 5
Z9 5
U1 9
U2 40
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 1535-9476
EI 1535-9484
J9 MOL CELL PROTEOMICS
JI Mol. Cell. Proteomics
PD SEP
PY 2015
VL 14
IS 9
BP 2441
EP 2453
DI 10.1074/mcp.R114.042572
PG 13
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA CQ7YO
UT WOS:000360823000012
PM 26081834
ER
PT J
AU Wang, SJ
Huttmann, G
Zhang, ZX
Vogel, A
Birngruber, R
Tangutoori, S
Hasan, T
Rahmanzadeh, R
AF Wang, Sijia
Huettmann, Gereon
Zhang, Zhenxi
Vogel, Alfred
Birngruber, Reginald
Tangutoori, Shifalika
Hasan, Tayyaba
Rahmanzadeh, Ramtin
TI Light-Controlled Delivery of Monoclonal Antibodies for Targeted
Photoinactivation of Ki-67
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE liposome; nuclear localization sequence (NLS); nanotechnology; endosomal
entrapment; photodynamic therapy
ID ASSISTED LASER INACTIVATION; INTRACELLULAR DELIVERY; PHOTODYNAMIC
THERAPY; SINGLET-OXYGEN; CELL-PROLIFERATION; CANCER-THERAPY;
OVARIAN-CANCER; IN-VITRO; BPD-MA; TRANSLOCATION
AB The selective inhibition of intracellular and nuclear molecules such as Ki-67 holds great promise for the treatment of cancer and other diseases. However, the choice of the target protein and the intracellular delivery of the functional agent remain crucial challenges. Main hurdles are (a) an effective delivery into cells, (b) endosomal escape of the delivered agents, and (c) an effective, externally triggered destruction of cells. Here we show a light-controlled two-step approach for selective cellular delivery and cell elimination of proliferating cells. Three different cell-penetrating nano constructs, including liposomes, conjugates with the nuclear localization sequence (NLS), and conjugates with the cell penetrating peptide Pep-1, delivered the light activatable antibody conjugate TuBB-9-FITC, which targets the proliferation associated protein Ki-67. HeLa cells were treated with the photosensitizer benzoporphyrin monoacid derivative (BPD) and the antibody constructs. In the first optically controlled step, activation of BPD at 690 nm triggered a controlled endosomal escape of the TuBB-9-FITC constructs. In more than 75% of Ki-67 positive, irradiated cells TuBB-9-FITC antibodies relocated within 24 h from cytoplasmic organelles to the cell nucleus and bound to Ki-67. After a second light irradiation at 490 nm, which activated FITC, cell viability decreased to approximately 13%. Our study shows an effective targeting strategy, which uses light-controlled endosomal escape and the light inactivation of Ki-67 for cell elimination. The fact that liposomal or peptide-assisted delivery give similar results leads to the additional conclusion that an effective mechanism for endosomal escape leaves greater variability for the choice of the delivery agent.
C1 [Wang, Sijia; Zhang, Zhenxi] Xi An Jiao Tong Univ, Sch Life Sci & Technol, Inst Biomed Analyt Technol & Instrumentat, Key Lab Biomed Informat Engn,Minist Educ, Xran 710049, Peoples R China.
[Wang, Sijia; Huettmann, Gereon; Vogel, Alfred; Birngruber, Reginald; Rahmanzadeh, Ramtin] Univ Lubeck, Inst Biomed Opt, D-23562 Lubeck, Germany.
[Tangutoori, Shifalika; Hasan, Tayyaba] Harvard Univ, Sch Med, Wellman Ctr Photomed, Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Rahmanzadeh, R (reprint author), Univ Lubeck, Inst Biomed Opt, Peter Monnik Weg 4, D-23562 Lubeck, Germany.
EM rahmanzadeh@bmo.uni-luebeck.de
RI Vogel, Alfred/D-9852-2011; Rahmanzadeh, Ramtin/L-7941-2016; Birngruber,
Reginald/Q-2342-2016; Huttmann, Gereon/A-9072-2012
FU German Research Foundation (DFG) [Ra1771/3-1]; National Natural Science
Foundation of China [61120106013]
FX This work was supported by the German Research Foundation (DFG, Grant
No. Ra1771/3-1) and The National Natural Science Foundation of China
(No. 61120106013).
NR 43
TC 4
Z9 4
U1 7
U2 30
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD SEP
PY 2015
VL 12
IS 9
BP 3272
EP 3281
DI 10.1021/acs.molpharmaceut.5b00260
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA CR1LR
UT WOS:000361086800017
PM 26226545
ER
PT J
AU Guda, S
Brendel, C
Renella, R
Du, P
Bauer, DE
Canver, MC
Grenier, JK
Grimson, AW
Kamran, SC
Thornton, J
de Boer, H
Root, DE
Milsom, MD
Orkin, SH
Gregory, RI
Williams, DA
AF Guda, Swaroopa
Brendel, Christian
Renella, Raffaele
Du, Peng
Bauer, Daniel E.
Canver, Matthew C.
Grenier, Jennifer K.
Grimson, Andrew W.
Kamran, Sophia C.
Thornton, James
de Boer, Helen
Root, David E.
Milsom, Michael D.
Orkin, Stuart H.
Gregory, Richard I.
Williams, David A.
TI miRNA-embedded shRNAs for Lineage-specific BCL11A Knockdown and
Hemoglobin F Induction
SO MOLECULAR THERAPY
LA English
DT Article
ID LYMPHOID DEVELOPMENT; MICRORNA BIOGENESIS; GENE-EXPRESSION;
GAMMA-GLOBIN; RNAI; CELLS; TOXICITY; VECTORS; DICER; MICE
AB RNA interference (RNAi) technology using short hairpin RNAs (shRNAs) expressed via RNA polymerase (pol) III promoters has been widely exploited to modulate gene expression in a variety of mammalian cell types. For certain applications, such as lineage-specific knockdown, embedding targeting sequences into pol II-driven microRNA (miRNA) architecture is required. Here, using the potential therapeutic target BCL11A, we demonstrate that pol III-driven shRNAs lead to significantly increased knockdown but also increased cytotoxcity in comparison to pol II-driven miRNA adapted shRNAs (shRNA(miR)) in multiple hematopoietic cell lines. We show that the two expression systems yield mature guide strand sequences that differ by a 4 bp shift. This results in alternate seed sequences and consequently influences the efficacy of target gene knockdown. Incorporating a corresponding 4 bp shift into the guide strand of shRNA(miR)s resulted in improved knockdown efficiency of BCL11A. This was associated with a significant de-repression of the hemoglobin target of BCL11A, human gamma-globin or the murine homolog Hbb-y. Our results suggest the requirement for optimization of shRNA sequences upon incorporation into a miRNA backbone. These findings have important implications in future design of shRNA(miR)s for RNAi-based therapy in hemoglobinopathies and other diseases requiring lineage-specific expression of gene silencing sequences.
C1 [Guda, Swaroopa; Brendel, Christian; Renella, Raffaele; Du, Peng; Bauer, Daniel E.; Thornton, James; de Boer, Helen; Orkin, Stuart H.; Gregory, Richard I.; Williams, David A.] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.
[Guda, Swaroopa; Brendel, Christian; Renella, Raffaele; Bauer, Daniel E.; Canver, Matthew C.; Kamran, Sophia C.; Orkin, Stuart H.; Williams, David A.] Harvard Univ, Sch Med, Boston, MA USA.
[Renella, Raffaele; Bauer, Daniel E.; Orkin, Stuart H.; Williams, David A.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Du, Peng; Thornton, James; Gregory, Richard I.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Stem Cell Program,Boston Childrens Hosp,Harvard S, Boston, MA 02115 USA.
[Grenier, Jennifer K.; Root, David E.] Broad Inst Harvard & MIT, Genet Perturbat Platform, Cambridge, MA USA.
[Grimson, Andrew W.] Cornell Univ, Dept Mol Biol & Genet, Coll Arts & Sci, Ithaca, NY USA.
[Kamran, Sophia C.; Orkin, Stuart H.] Howard Hughes Med Inst, Boston, MA 02115 USA.
[Milsom, Michael D.] German Canc Res Ctr, Div Stem Cells & Canc, Heidelberg Inst Stem Cell Technol & Expt Med, Heidelberg, Germany.
RP Williams, DA (reprint author), Boston Childrens Hosp, Div Hematol Oncol, 300 Longwood Ave,Karp 08125-3, Boston, MA 02115 USA.
EM DAWilliams@childrens.harvard.edu
OI Kamran, Sophia/0000-0001-9283-6515
FU Howard Hughes Medical Institute; NHLBI NIH HHS [U01 HL117720,
U01HL117720-01]; NIDDK NIH HHS [F30 DK103359, F30DK103359-01A1, K08
DK093705]
NR 47
TC 19
Z9 18
U1 2
U2 11
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1525-0016
EI 1525-0024
J9 MOL THER
JI Mol. Ther.
PD SEP
PY 2015
VL 23
IS 9
BP 1465
EP 1474
DI 10.1038/mt.2015.113
PG 10
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
Research & Experimental
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
Experimental Medicine
GA CR1PF
UT WOS:000361096600009
PM 26080908
ER
PT J
AU Procopio, MG
Laszlo, C
Al Labban, D
Kim, DE
Bordignon, P
Jo, SH
Goruppi, S
Menietti, E
Ostano, P
Ala, U
Provero, P
Hoetzenecker, W
Neel, V
Kilarski, WW
Swartz, MA
Brisken, C
Lefort, K
Dotto, GP
AF Procopio, Maria-Giuseppina
Laszlo, Csaba
Al Labban, Dania
Kim, Dong Eun
Bordignon, Pino
Jo, Seung-Hee
Goruppi, Sandro
Menietti, Elena
Ostano, Paola
Ala, Ugo
Provero, Paolo
Hoetzenecker, Wolfram
Neel, Victor
Kilarski, Witold W.
Swartz, Melody A.
Brisken, Cathrin
Lefort, Karine
Dotto, G. Paolo
TI Combined CSL and p53 downregulation promotes cancer-associated
fibroblast activation
SO NATURE CELL BIOLOGY
LA English
DT Article
ID CARCINOMA-ASSOCIATED FIBROBLASTS; MULTIFOCAL EPITHELIAL TUMORS;
SQUAMOUS-CELL CARCINOMAS; TRANSCRIPTION COMPLEX; FIELD CANCERIZATION;
SECRETORY PHENOTYPE; SENESCENT CELLS; LUNG-CANCER; NOTCH;
MICROENVIRONMENT
AB Stromal fibroblast senescence has been linked to ageing-associated cancer risk. However, density and proliferation of cancer-associated fibroblasts (CAFs) are frequently increased. Loss or downmodulation of the Notch effector CSL (also known as RBP-J kappa) in dermal fibroblasts is sufficient for CAF activation and ensuing keratinocyte-derived tumours. We report that CSL silencing induces senescence of primary fibroblasts from dermis, oral mucosa, breast and lung. CSL functions in these cells as a direct repressor of multiple senescence-and CAF-effector genes. It also physically interacts with p53, repressing its activity. CSL is downmodulated in stromal fibroblasts of premalignant skin actinic keratosis lesions and squamous cell carcinomas, whereas p53 expression and function are downmodulated only in the latter, with paracrine FGF signalling as the probable culprit. Concomitant loss of CSL and p53 overcomes fibroblast senescence, enhances expression of CAF effectors and promotes stromal and cancer cell expansion. The findings support a CAF activation-stromal co-evolution model under convergent CSL-p53 control.
C1 [Procopio, Maria-Giuseppina; Laszlo, Csaba; Al Labban, Dania; Kim, Dong Eun; Bordignon, Pino; Menietti, Elena; Lefort, Karine; Dotto, G. Paolo] Univ Lausanne, Dept Biochem, CH-1066 Epalinges, Switzerland.
[Jo, Seung-Hee; Goruppi, Sandro; Dotto, G. Paolo] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Boston, MA 02129 USA.
[Ostano, Paola] Edo & Elvo Tempia Valenta Fdn, Canc Genom Lab, I-13900 Biella, Italy.
[Ala, Ugo; Provero, Paolo] Univ Turin, Dept Mol Biotechnol & Life Sci, I-10126 Turin, Italy.
[Hoetzenecker, Wolfram] Univ Zurich, Dept Dermatol, CH-8091 Zurich, Switzerland.
[Neel, Victor] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA.
[Kilarski, Witold W.; Swartz, Melody A.] Ecole Polytech Fed Lausanne, Inst Bioengn, CH-1015 Lausanne, Switzerland.
[Brisken, Cathrin] Ecole Polytech Fed Lausanne, Swiss Inst Expt Canc Res ISREC, CH-1015 Lausanne, Switzerland.
[Lefort, Karine] Univ Hosp CHUV, Sect Dermatol, Dept Med, CH-1011 Lausanne, Switzerland.
RP Dotto, GP (reprint author), Univ Lausanne, Dept Biochem, CH-1066 Epalinges, Switzerland.
EM Paolo.Dotta@unil.ch
RI Swartz, Melody/F-9563-2011; Ala, Ugo/K-2029-2016; Kilarski,
Witold/G-8673-2012
OI Ala, Ugo/0000-0001-5408-6397; Kilarski, Witold/0000-0003-0734-4749
FU Swiss National Science Foundation [310030_156191/1]; National Institutes
of Health [R01AR039190, R01AR064786]; European Research Council
[26075083]; OncoSuisse [OCS-2922-02-2012, KFS-3301-08-2013]; Lauretana
S.P.A.
FX We thank R. Bernards, R. Agami, W. Raffoul, J. P. Rival, J. M. Joseph,
U. Just, F. Martinon and T. Petrova for vectors or cells, F. De Sousa e
Melo and B. Hu for early contributions, K. Harshman for RNA-Seq and
ChIP-Seq analysis and C. Pasche and T. Proust for technical help. The
work was supported by grants from the Swiss National Science Foundation
(310030_156191/1), National Institutes of Health (R01AR039190;
R01AR064786; the content not necessarily representing the offcial views
of NIH), European Research Council (26075083) and OncoSuisse
(OCS-2922-02-2012 and KFS-3301-08-2013). P. Ostano was supported by a
grant from Lauretana S.P.A.
NR 68
TC 23
Z9 23
U1 3
U2 26
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-7392
EI 1476-4679
J9 NAT CELL BIOL
JI Nat. Cell Biol.
PD SEP
PY 2015
VL 17
IS 9
BP 1193
EP +
DI 10.1038/ncb3228
PG 15
WC Cell Biology
SC Cell Biology
GA CR1VQ
UT WOS:000361113700013
PM 26302407
ER
PT J
AU Geva-Zatorsky, N
Alvarez, D
Hudak, JE
Reading, NC
Erturk-Hasdemir, D
Dasgupta, S
von Andrian, UH
Kasper, DL
AF Geva-Zatorsky, Naama
Alvarez, David
Hudak, Jason E.
Reading, Nicola C.
Erturk-Hasdemir, Deniz
Dasgupta, Suryasarathi
von Andrian, Ulrich H.
Kasper, Dennis L.
TI In vivo imaging and tracking of host-microbiota interactions via
metabolic labeling of gut anaerobic bacteria
SO NATURE MEDICINE
LA English
DT Article
ID BACTEROIDES-FRAGILIS; IMMUNE-SYSTEM; DENDRITIC CELLS; T-CELLS;
POLYSACCHARIDE; DISEASE; MACROPHAGES; HOMEOSTASIS; INDUCTION; DIVERSITY
AB The intestine is densely populated by anaerobic commensal bacteria. These microorganisms shape immune system development, but understanding of host-commensal interactions is hampered by a lack of tools for studying the anaerobic intestinal environment. We applied metabolic oligosaccharide engineering and bioorthogonal click chemistry to label various commensal anaerobes, including Bacteroides fragilis, a common and immunologically important commensal. We studied the dissemination of B. fragilis after acute peritonitis and characterized the interactions of the intact microbe and its polysaccharide components in myeloid and B cell lineages. We were able to assess the distribution and colonization of labeled B. fragilis along the intestine, as well as niche competition after coadministration of multiple species of the microbiota. We also fluorescently labeled nine additional commensals (eight anaerobic and one microaerophilic) from three phyla common in the gut-Bacteroidetes, Firmicutes and Proteobacteria-as well as one aerobic pathogen (Staphylococcus aureus). This strategy permits visualization of the anaerobic microbial niche by various methods, including intravital two-photon microscopy and non-invasive whole-body imaging, and can be used to study microbial colonization and host-microbe interactions in real time.
C1 [Geva-Zatorsky, Naama; Alvarez, David; Hudak, Jason E.; Reading, Nicola C.; Erturk-Hasdemir, Deniz; Dasgupta, Suryasarathi; von Andrian, Ulrich H.; Kasper, Dennis L.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA 02163 USA.
[von Andrian, Ulrich H.] Ragon Inst Massachusetts Gen Hosp Massachusetts I, Cambridge, MA USA.
RP Kasper, DL (reprint author), Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA 02163 USA.
EM dennis_kasper@hms.harvard.edu
FU Neurobiology Imaging Facility; Neural Imaging Center as part of NINDS
P30 Core Center grant [NS072030]; NIH [1 S10 OD016401]; BCH/PCMM; US
National Institutes of Health [PO1 AI1112521, RO1 AI111595, 5T32
HL066987]; Ragon Institute at MGH; EMBO Long-Term Fellowship [ALTF
251-2011]; Human Frontiers Science Program [LT000079/2012]; UNESCO
L'Oreal National and International Women in Science Award; Fulbright
Award; Weizmann Institute of Science-National Postdoctoral Award Program
for Advancing Women in Science; Cancer Research Institute Irvington
Fellowship Program; departmental Kirschstein-NRSA training grant; Ragon
Institute at MIT; Ragon Institute at Harvard; [U19AI095261]
FX We thank the Neurobiology Imaging Facility for consultation and
instrument availability that supported this work. This facility is
supported in part by the Neural Imaging Center as part of NINDS P30 Core
Center grant NS072030. We also thank N. Barteneva of the Flow and
Imaging Cytometry Resource for help in whole-body imaging on the IVIS
Spectrum (funded by grants NIH 1 S10 OD016401 and BCH/PCMM); J. Czupryna
and M. Guerra from PerkinElmer for consultation and expert advice; C.
Araneo (Division of Immunology Flow Cytometry Core Facility, HMS) and L.
Comstock for helpful discussions, comments and reagents; and members of
the Kasper and von Andrian labs for helpful discussions.; This work was
also partly supported by the US National Institutes of Health (grants
PO1 AI1112521, RO1 AI111595 (to U.H.v.A.) and 5T32 HL066987 (to D.A.)).
Additional support to U.H.v.A. was provided by U19AI095261 and the Ragon
Institute at MGH, MIT and Harvard. N.G.-Z. was supported by an EMBO
Long-Term Fellowship (ALTF 251-2011), the Human Frontiers Science
Program (LT000079/2012), a UNESCO L'Oreal National and International
Women in Science Award, a Fulbright Award and the Weizmann Institute of
Science-National Postdoctoral Award Program for Advancing Women in
Science. J.E.H. was supported by the Cancer Research Institute Irvington
Fellowship Program. N.C.R. was supported by a departmental
Kirschstein-NRSA training grant.
NR 37
TC 20
Z9 20
U1 5
U2 43
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD SEP
PY 2015
VL 21
IS 9
BP 1091
EP +
DI 10.1038/nm.3929
PG 12
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
Medicine
GA CQ9US
UT WOS:000360961300024
PM 26280120
ER
PT J
AU Yan, G
Tsekenis, G
Barzel, B
Slotine, JJ
Liu, YY
Barabasi, AL
AF Yan, Gang
Tsekenis, Georgios
Barzel, Baruch
Slotine, Jean-Jacques
Liu, Yang-Yu
Barabasi, Albert-Laszlo
TI Spectrum of controlling and observing complex networks
SO NATURE PHYSICS
LA English
DT Article
ID DYNAMICS; CONTROLLABILITY; STABILITY; SYSTEMS; ORGANIZATION
AB Recent studies have made important advances in identifying sensor or driver nodes, through which we can observe or control a complex system. But the observational uncertainty induced by measurement noise and the energy required for control continue to be significant challenges in practical applications. Here we show that the variability of control energy and observational uncertainty for different directions of the state space depend strongly on the number of driver nodes. In particular, we find that if all nodes are directly driven, control is energetically feasible, as the maximum energy increases sublinearly with the system size. If, however, we aim to control a system through a single node, control in some directions is energetically prohibitive, increasing exponentially with the system size. For the cases in between, the maximum energy decays exponentially when the number of driver nodes increases. We validate our findings in several model and real networks, arriving at a series of fundamental laws to describe the control energy that together deepen our understanding of complex systems.
C1 [Yan, Gang; Tsekenis, Georgios; Barabasi, Albert-Laszlo] Northeastern Univ, Ctr Complex Network Res, Boston, MA 02115 USA.
[Yan, Gang; Tsekenis, Georgios; Barabasi, Albert-Laszlo] Northeastern Univ, Dept Phys, Boston, MA 02115 USA.
[Barzel, Baruch] Bar Ilan Univ, Dept Math, IL-52900 Ramat Gan, Israel.
[Slotine, Jean-Jacques] MIT, Dept Engn Mech, Cambridge, MA 02139 USA.
[Slotine, Jean-Jacques] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA.
[Liu, Yang-Yu] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Div Network Med, Boston, MA 02115 USA.
[Liu, Yang-Yu; Barabasi, Albert-Laszlo] Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02115 USA.
[Barabasi, Albert-Laszlo] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA.
[Barabasi, Albert-Laszlo] Cent European Univ, Ctr Network Sci, H-1051 Budapest, Hungary.
RP Barabasi, AL (reprint author), Northeastern Univ, Ctr Complex Network Res, Boston, MA 02115 USA.
EM alb@neu.edu
RI Yan, Gang/B-9020-2009; Liu, Yang-Yu/G-8885-2011
OI Yan, Gang/0000-0001-6196-2615; Liu, Yang-Yu/0000-0003-2728-4907
FU Army Research Laboratories (ARL) Network Science (NS) Collaborative
Technology Alliance (CTA) [ARL NS-CTA W911NF-09-2-0053]; DARPA Social
Media in Strategic Communications project [W911NF-12-C-002]; John
Templeton Foundation: Mathematical and Physical Sciences [PFI-777];
European Commission [FP7 317532 (MULTIPLEX), 641191 (CIMPLEX)]
FX We thank E. Guney, C. Song, J. Gao, M. T. Angulo, S. P. Cornelius, B.
Coutinho and A. Li for discussions. This work was supported by Army
Research Laboratories (ARL) Network Science (NS) Collaborative
Technology Alliance (CTA) grant ARL NS-CTA W911NF-09-2-0053; DARPA
Social Media in Strategic Communications project under agreement number
W911NF-12-C-002; the John Templeton Foundation: Mathematical and
Physical Sciences grant number PFI-777; European Commission grant
numbers FP7 317532 (MULTIPLEX) and 641191 (CIMPLEX).
NR 54
TC 22
Z9 23
U1 10
U2 41
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1745-2473
EI 1745-2481
J9 NAT PHYS
JI Nat. Phys.
PD SEP
PY 2015
VL 11
IS 9
BP 779
EP 786
DI 10.1038/NPHYS3422
PG 8
WC Physics, Multidisciplinary
SC Physics
GA CQ6IY
UT WOS:000360709200024
ER
PT J
AU Preusser, M
Lim, M
Hafler, DA
Reardon, DA
Sampson, JH
AF Preusser, Matthias
Lim, Michael
Hafler, David A.
Reardon, David A.
Sampson, John H.
TI Prospects of immune checkpoint modulators in the treatment of
glioblastoma
SO NATURE REVIEWS NEUROLOGY
LA English
DT Review
ID CELL LUNG-CANCER; NEWLY-DIAGNOSED GLIOBLASTOMA; TUMOR-INFILTRATING
LYMPHOCYTES; RESPONSE ASSESSMENT CRITERIA; PRIMARY BRAIN-TUMORS; LIGAND
1 PD-L1; ADVANCED MELANOMA; NIVOLUMAB ANTI-PD-1; ANTITUMOR IMMUNITY;
CTLA-4 BLOCKADE
AB Glioblastoma is the most common primary brain tumour in adults. Prognosis is poor: even with the current gold-standard first-line treatment-maximal safe resection and combination of radiotherapy with temozolomide chemotherapy-the median overall survival time is only approximately 15-17 months, because the tumour recurs in virtually all patients, and no commonly accepted standard treatment for recurrent disease exists. Several targeted agents have failed to improve patient outcomes in glioblastoma. Immunotherapy with immune checkpoint inhibitors such as ipilimumab, nivolumab, and pembrolizumab has provided relevant clinical improvements in other advanced tumours for which conventional therapies have had limited success, making immunotherapy an appealing strategy in glioblastoma. This Review summarizes current knowledge on immune checkpoint modulators and evaluates their potential role in glioblastoma on the basis of preclinical studies and emerging clinical data. Furthermore, we discuss challenges that need to be considered in the clinical development of drugs that target immune checkpoint pathways in glioblastoma, such as specific properties of the immune system in the CNS, issues with radiological response assessment, and potential interactions with established and emerging treatment strategies.
C1 [Preusser, Matthias] Med Univ Vienna, Dept Med 1, A-1090 Vienna, Austria.
[Preusser, Matthias] Med Univ Vienna, Ctr Comprehens Canc, CNS Tumours Unit, A-1090 Vienna, Austria.
[Lim, Michael] Johns Hopkins Univ, Sch Med, Baltimore, MD 21287 USA.
[Hafler, David A.] Yale Univ, Dept Neurol, Sch Med, Yale New Haven Hosp, New Haven, CT 06520 USA.
[Reardon, David A.] Dana Farber Canc Inst, Ctr Neurooncol, Boston, MA 02215 USA.
[Sampson, John H.] Duke Univ, Sch Med, Div Neurosurg, Durham, NC 27705 USA.
RP Sampson, JH (reprint author), Duke Univ, Sch Med, Div Neurosurg, 220 Sands Bldg,Res Dr, Durham, NC 27705 USA.
EM john.sampson@duke.edu
OI Preusser, Matthias/0000-0003-3541-2315
FU National Multiple Sclerosis Society Collaborative Research Centre Award
[CA1061-A18]; NIH grants [P01 AI045757, U19 AI046130, U19 AI070352, P01
AI039671, R01-CA177476-02, R01-NS086943-01, P50-CA190991-01,
2R25-NS065731-06]; Nancy Taylor Foundation for Chronic Diseases; Penates
Foundation; Accelerate Brain Cancer Cure; Pediatric Brain Tumor
Foundation; Bristol-Myers Squibb
FX M. Daniels from inScience Communications in Philadelphia, PA, USA,
provided editorial support for writing this article, comprising
compilation of tables, management of the reference database, and editing
of the manuscript text before submission. The editorial support was
funded by Bristol-Myers Squibb. D.A.H. has received the National
Multiple Sclerosis Society Collaborative Research Centre Award
CA1061-A-18, NIH grants P01 AI045757, U19 AI046130, U19 AI070352, and
P01 AI039671, and research support from the Nancy Taylor Foundation for
Chronic Diseases and the Penates Foundation. J.H.S. has received the NIH
grants R01-CA177476-02, R01-NS086943-01, P50-CA190991-01, and
2R25-NS065731-06, and research support from the Accelerate Brain Cancer
Cure and Pediatric Brain Tumor Foundation.
NR 112
TC 29
Z9 29
U1 11
U2 33
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-4758
EI 1759-4766
J9 NAT REV NEUROL
JI Nat. Rev. Neurol.
PD SEP
PY 2015
VL 11
IS 9
BP 504
EP 514
DI 10.1038/nrneurol.2015.139
PG 11
WC Clinical Neurology
SC Neurosciences & Neurology
GA CQ9WZ
UT WOS:000360967300005
PM 26260659
ER
PT J
AU Wu, H
Zhang, Y
AF Wu, Hao
Zhang, Yi
TI Charting oxidized methylcytosines at base resolution
SO NATURE STRUCTURAL & MOLECULAR BIOLOGY
LA English
DT Article
ID EMBRYONIC STEM-CELLS; DNA METHYLATION PATTERNS; GENOME-WIDE ANALYSIS;
TET PROTEINS; MAMMALIAN DEVELOPMENT; GENE BODIES;
5-HYDROXYMETHYLCYTOSINE; 5-FORMYLCYTOSINE; DEMETHYLATION;
5-CARBOXYLCYTOSINE
AB DNA cytosine methylation is a key epigenetic mark that is required for normal mammalian development. Iterative oxidation of 5-methylcytosine (5mC) by the TET family of DNA dioxygenases generates three oxidized nucleotides: 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC). Recent advances in genomic mapping techniques have suggested that these oxidized cytosines not only function in the process of active reversal of 5mC but also may possess unique regulatory functions in the mammalian genome.
C1 [Wu, Hao; Zhang, Yi] Brigham & Womens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA.
[Wu, Hao; Zhang, Yi] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA USA.
[Wu, Hao; Zhang, Yi] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA.
RP Zhang, Y (reprint author), Brigham & Womens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA.
EM yzhang@genetics.med.harvard.edu
FU US National Institutes of Health [GM68804, U01DK089565]; Jane Coffin
Childs Memorial Fund for Medical Research; US National Human Genome
Research Institute [K99HG007982]; Investigator of the Howard Hughes
Medical Institute
FX We thank L.M. Tuesta for critical reading of the manuscript. This work
was supported by US National Institutes of Health grants GM68804 and
U01DK089565 (to Y.Z.). H.W. was supported by a postdoctoral fellowship
from the Jane Coffin Childs Memorial Fund for Medical Research and is
currently supported by the US National Human Genome Research Institute
(K99HG007982). Y.Z. is supported as an Investigator of the Howard Hughes
Medical Institute.
NR 57
TC 6
Z9 6
U1 1
U2 7
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1545-9993
EI 1545-9985
J9 NAT STRUCT MOL BIOL
JI Nat. Struct. Mol. Biol.
PD SEP
PY 2015
VL 22
IS 9
BP 1
EP 6
DI 10.1038/nsmb.3071
PG 6
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA CQ9KK
UT WOS:000360933200007
PM 26333715
ER
PT J
AU Park, E
Kim, N
Ficarro, SB
Zhang, Y
Lee, BI
Cho, A
Kim, K
Park, AKJ
Park, WY
Murray, B
Meyerson, M
Beroukhim, R
Marto, JA
Cho, J
Eck, MJ
AF Park, Eunyoung
Kim, Nayoung
Ficarro, Scott B.
Zhang, Yi
Lee, Byung Il
Cho, Ahye
Kim, Kihong
Park, Angela K. J.
Park, Woong-Yang
Murray, Bradley
Meyerson, Matthew
Beroukhim, Rameen
Marto, Jarrod A.
Cho, Jeonghee
Eck, Michael J.
TI Structure and mechanism of activity-based inhibition of the EGF receptor
by Mig6
SO NATURE STRUCTURAL & MOLECULAR BIOLOGY
LA English
DT Article
ID GROWTH-FACTOR RECEPTOR; LUNG-CANCER; NEGATIVE REGULATOR; TARGETED
THERAPIES; TUMOR-SUPPRESSOR; GENOMIC ANALYSIS; KINASE DOMAIN;
GLIOBLASTOMA; MUTANTS; PROTEIN
AB Mig6 is a feedback inhibitor that directly binds, inhibits and drives internalization of ErbB-family receptors. Mig6 selectively targets activated receptors. Here we found that the epidermal growth factor receptor (EGFR) phosphorylates Mig6 on Y394 and that this phosphorylation is primed by prior phosphorylation of an adjacent residue, Y395, by Src. Crystal structures of human EGFR-Mig6 complexes reveal the structural basis for enhanced phosphorylation of primed Mig6 and show how Mig6 rearranges after phosphorylation by EGFR to effectively irreversibly inhibit the same receptor that catalyzed its phosphorylation. This dual phosphorylation site allows Mig6 to inactivate EGFR in a manner that requires activation of the target receptor and that can be modulated by Src. Loss of Mig6 is a driving event in human cancer; analysis of 1,057 gliomas reveals frequent focal deletions of ERRFI1, the gene that encodes Mig6, in EGFR-amplified glioblastomas.
C1 [Park, Eunyoung; Ficarro, Scott B.; Zhang, Yi; Lee, Byung Il; Beroukhim, Rameen; Marto, Jarrod A.; Eck, Michael J.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
[Park, Eunyoung; Marto, Jarrod A.; Eck, Michael J.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Kim, Nayoung; Cho, Ahye; Park, Angela K. J.; Park, Woong-Yang; Cho, Jeonghee] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Samsung Genome Inst, Seoul, South Korea.
[Kim, Nayoung; Cho, Ahye; Kim, Kihong; Park, Angela K. J.; Park, Woong-Yang; Cho, Jeonghee] Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol, Seoul, South Korea.
[Ficarro, Scott B.; Zhang, Yi; Marto, Jarrod A.] Dana Farber Canc Inst, Blais Prote Ctr, Boston, MA 02115 USA.
[Lee, Byung Il] Natl Canc Ctr, Res Inst, Div Convergence Technol, Biomol Funct Res Branch, Goyang, South Korea.
[Murray, Bradley; Meyerson, Matthew; Beroukhim, Rameen] Broad Inst Harvard & MIT, Cambridge, MA USA.
[Meyerson, Matthew; Beroukhim, Rameen] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Meyerson, Matthew] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Beroukhim, Rameen] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
RP Eck, MJ (reprint author), Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
EM jeong.cho@skku.edu; eck@crystal.harvard.edu
FU US National Institutes of Health (NIH); NIH [CA116020, CA154303,
CA156021, CA178860]; Samsung Medical Center; Basic Science Research
Program of the National Research Foundation of Korea, Ministry of
Science, ICT and Future Planning [2013065771]
FX We thank L. Cantley and M. Begley for helpful discussions and sharing
unpublished data, and R. McNally for critical reading of the manuscript.
We thank P. Cole, D. Leahy and Z. Wang for helpful discussions and for
testing the effect of phospho-Mig6 species on the activity of
transmembrane EGFR (Supplementary Fig. 4e). We thank P. Janne
(Dana-Farber Cancer Institute) for providing cells. We thank beamline
personnel at the Northeast Collaborative Access Team at the Advanced
Photon Source, Argonne National Laboratory (NE-CAT) for assistance with
data collection and processing. NE-CAT is supported by grants from the
US National Institutes of Health (NIH). This work was supported in part
by NIH grants CA116020 (M.J.E. and M.M.), CA154303 (M.J.E. and M.M.),
CA156021 (J.A.M.) and CA178860 (J.A.M.). This work was also supported in
part by grants from Samsung Medical Center (J.C.) and the Basic Science
Research Program of the National Research Foundation of Korea, Ministry
of Science, ICT and Future Planning (grant 2013065771; J.C.).
NR 59
TC 9
Z9 9
U1 3
U2 6
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1545-9993
EI 1545-9985
J9 NAT STRUCT MOL BIOL
JI Nat. Struct. Mol. Biol.
PD SEP
PY 2015
VL 22
IS 9
BP 703
EP U84
DI 10.1038/nsmb.3074
PG 11
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA CQ9KK
UT WOS:000360933200013
PM 26280531
ER
PT J
AU Gadd, MA
AF Gadd, Michele A.
TI Changing Beliefs and Practices in Women With Breast Cancer in China
SO ONCOLOGIST
LA English
DT Editorial Material
C1 Massachusetts Gen Hosp, Ctr Canc, Div Surg Oncol, Gillette Ctr Womens Canc, Boston, MA 02114 USA.
RP Gadd, MA (reprint author), Massachusetts Gen Hosp, Ctr Canc, Div Surg Oncol, Gillette Ctr Womens Canc, 55 Fruit St, Boston, MA 02114 USA.
EM MGadd@partners.org
NR 6
TC 0
Z9 0
U1 0
U2 1
PU ALPHAMED PRESS
PI DURHAM
PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA
SN 1083-7159
EI 1549-490X
J9 ONCOLOGIST
JI Oncologist
PD SEP
PY 2015
VL 20
IS 9
BP 979
EP 980
DI 10.1634/theoncologist.2015-0249
PG 2
WC Oncology
SC Oncology
GA CQ9ZB
UT WOS:000360975000004
PM 26253558
ER
PT J
AU Seah, DS
Scott, S
Guo, H
Najita, J
Lederman, R
Frank, E
Sohl, J
Stadler, Z
Silverman, S
Peppercorn, J
Winer, E
Come, S
Lin, NU
AF Seah, Davinia S.
Scott, Sarah
Guo, Hao
Najita, Julie
Lederman, Ruth
Frank, Elizabeth
Sohl, Jessica
Stadler, Zsofia
Silverman, Stuart
Peppercorn, Jeffrey
Winer, Eric
Come, Steve
Lin, Nancy U.
TI Variation in the Attitudes of Medical Oncologists Toward Research
Biopsies in Patients With Metastatic Breast Cancer
SO ONCOLOGIST
LA English
DT Article
DE Research biopsies; Physicians; Attitudes; Metastatic breast cancer
ID CLINICAL-TRIALS; FEASIBILITY; EXPERIENCE; MUTATIONS; OUTCOMES; SAFETY;
RISKS; HELP
AB Background. Tissue from research biopsies provides access to insights into tumor biology. We aimed to determine medical oncologists' (MOs') attitudes toward research biopsies in patients with metastatic breast cancer (MBC).
Materials and Methods. A total of 309 breast MOs from National Cancer Institute (NCI)-designated cancer centers were invited to complete a self-administered survey about their attitudes toward approaching patients for research purpose-only biopsies (RPOBs), performed as a standalone procedure, or additional biopsies, performed with a clinically indicated biopsy. The MOs were asked to predict what proportion of their MBC patients would consider undergoing research biopsies.
Results. Of the 309 MOs, 221 (72%) responded. Of these 221 MOs, 30 were ineligible, leaving 191 eligible responders. Nearly all the MOs reported they were comfortable approaching patients regarding research biopsies of blood or skin. One fifth of MOs were uncomfortable approaching patients for RPOBs of the breast. One half of MOs were uncomfortable approaching patients for RPOBs of the liver. A significant variation was found in the perceptions by MOs of their patients' willingness to undergo research biopsies. The factors associated with increased comfort in approaching patients for research biopsies included fewer years in practice, caring for patients who had undergone recent research biopsies, and the predicted willingness of patients to consent to biopsies. The risk of a biopsy and biopsy-related pain were the most common reasons for reluctance to refer patients for research biopsies.
Conclusion. Significant variation exists, even at NCI centers, in the comfort level of MOs in approaching MBC patients for research biopsies. MOs' attitudes toward research biopsies might be a modifiable factor in increasing tissue collection for research.
C1 [Seah, Davinia S.; Guo, Hao; Najita, Julie; Lederman, Ruth; Frank, Elizabeth; Sohl, Jessica; Winer, Eric; Lin, Nancy U.] Dana Farber Canc Inst, Boston, MA 02215 USA.
[Scott, Sarah; Come, Steve] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Stadler, Zsofia] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Silverman, Stuart] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Peppercorn, Jeffrey] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Lin, NU (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM nlin@partners.org
RI Guo, Hao/E-8921-2015
OI Guo, Hao/0000-0003-1658-0989
FU Metastatic Research Fund; Susan G. Komen For the Cure fund; Friends of
Dana-Farber Cancer Institute
FX The study was funded by the Metastatic Research Fund (an anonymous donor
to Eric Winer and Nancy U. Lin), the Susan G. Komen For the Cure fund,
and the Friends of Dana-Farber Cancer Institute. These results were
presented at the 36th Annual San Antonio Breast Cancer Symposium as a
poster presentation, San Antonio, Texas, December 10-14, 2013.
NR 19
TC 2
Z9 2
U1 0
U2 1
PU ALPHAMED PRESS
PI DURHAM
PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA
SN 1083-7159
EI 1549-490X
J9 ONCOLOGIST
JI Oncologist
PD SEP
PY 2015
VL 20
IS 9
BP 992
EP 1000
DI 10.1634/theoncologist.2015-0112
PG 9
WC Oncology
SC Oncology
GA CQ9ZB
UT WOS:000360975000008
PM 26240134
ER
PT J
AU Goyal, L
Govindan, A
Sheth, RA
Nardi, V
Blaszkowsky, LS
Faris, JE
Clark, JW
Ryan, DP
Kwak, EL
Allen, JN
Murphy, JE
Saha, SK
Hong, TS
Wo, JY
Ferrone, CR
Tanabe, KK
Chong, DQ
Deshpande, V
Borger, DR
Iafrate, AJ
Bardeesy, N
Zheng, H
Zhu, AX
AF Goyal, Lipika
Govindan, Aparna
Sheth, Rahul A.
Nardi, Valentina
Blaszkowsky, Lawrence S.
Faris, Jason E.
Clark, Jeffrey W.
Ryan, David P.
Kwak, Eunice L.
Allen, Jill N.
Murphy, Janet E.
Saha, Supriya K.
Hong, Theodore S.
Wo, Jennifer Y.
Ferrone, Cristina R.
Tanabe, Kenneth K.
Chong, Dawn Q.
Deshpande, Vikram
Borger, Darrell R.
Iafrate, A. John
Bardeesy, Nabeel
Zheng, Hui
Zhu, Andrew X.
TI Prognosis and Clinicopathologic Features of Patients With Advanced Stage
Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic
Cholangiocarcinoma
SO ONCOLOGIST
LA English
DT Article
DE Cholangiocarcinoma; Isocitrate dehydrogenase; Prognosis; Metastatic;
Phenotype
ID PRIMARY SCLEROSING CHOLANGITIS; ACUTE MYELOID-LEUKEMIA; BILIARY-TRACT
CANCER; ONCOMETABOLITE 2-HYDROXYGLUTARATE; MUTATIONS; LEWIS;
DIFFERENTIATION; CA19-9; CHEMOTHERAPY; BIOMARKER
AB Background. Conflicting data exist regarding the prognostic impact of the isocitrate dehydrogenase (IDH) mutation in intrahepatic cholangiocarcinoma (ICC), and limited data exist in patients with advanced-stage disease. Similarly, the clinical phenotype of patients with advanced IDH mutant (IDHm) ICC has not been characterized. In this study, we report the correlation of IDH mutation status with prognosis and clinicopathologic features in patients with advanced ICC.
Methods. Patients with histologically confirmed advanced ICC who underwent tumor mutational profiling as a routine part of their care between 2009 and 2014 were evaluated. Clinical and pathological data were collected by retrospective chart review for patients with IDHm versus IDH wild-type (IDHwt) ICC. Pretreatment tumor volume was calculated on computed tomography or magnetic resonance imaging.
Results. Of the 104 patients with ICC who were evaluated, 30 (28.8%) had an IDH mutation (25.0% IDH1, 3.8% IDH2). The median overall survival did not differ significantly between IDHm and IDHwt patients (15.0 vs. 20.1 months, respectively; p = .17). The pretreatment serum carbohydrate antigen 19-9 (CA19-9) level in IDHm and IDHwt patients was 34.5 and 118.0 U/mL, respectively (p = .04). Age at diagnosis, sex, histologic grade, and pattern of metastasis did not differ significantly by IDH mutation status.
Conclusion. The IDH mutation was not associated with prognosis in patients with advanced ICC. The clinical phenotypes of advanced IDHm and IDHwt ICC were similar, but patients with IDHm ICC had a lower median serum CA19-9 level at presentation.
C1 [Goyal, Lipika; Govindan, Aparna; Sheth, Rahul A.; Nardi, Valentina; Blaszkowsky, Lawrence S.; Faris, Jason E.; Clark, Jeffrey W.; Ryan, David P.; Kwak, Eunice L.; Allen, Jill N.; Murphy, Janet E.; Saha, Supriya K.; Hong, Theodore S.; Wo, Jennifer Y.; Ferrone, Cristina R.; Tanabe, Kenneth K.; Chong, Dawn Q.; Deshpande, Vikram; Borger, Darrell R.; Iafrate, A. John; Bardeesy, Nabeel; Zheng, Hui; Zhu, Andrew X.] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
RP Zhu, AX (reprint author), Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA.
EM azhu@partners.org
FU Agios; Novartis
FX Jason E. Faris: N-of-One, Merrimack Pharmaceuticals (C/A), Agios (RF);
David P. Ryan: Uptodate, McGraw Hill (H); Eunice L. Kwak: Amgen (C/A);
Theodore S. Hong: Eisai (C/A), Novartis (RF); A. John Iafrate: ArcherDx
(IP, OI). The other authors indicated no financial relationships.
NR 40
TC 7
Z9 7
U1 2
U2 7
PU ALPHAMED PRESS
PI DURHAM
PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA
SN 1083-7159
EI 1549-490X
J9 ONCOLOGIST
JI Oncologist
PD SEP
PY 2015
VL 20
IS 9
BP 1019
EP 1027
DI 10.1634/theoncologist.2015-0210
PG 9
WC Oncology
SC Oncology
GA CQ9ZB
UT WOS:000360975000011
PM 26245674
ER
PT J
AU Diver, EJ
Foster, R
Rueda, BR
Growdon, WB
AF Diver, Elisabeth J.
Foster, Rosemary
Rueda, Bo R.
Growdon, Whitfield B.
TI The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer
SO ONCOLOGIST
LA English
DT Article
DE Endometrial cancer; HER2; Uterine serous carcinoma; Resistance
ID METASTATIC BREAST-CANCER; EPIDERMAL-GROWTH-FACTOR;
GYNECOLOGIC-ONCOLOGY-GROUP; PHASE-III TRIAL; SURGICALLY STAGED PATIENTS;
FACTOR-RECEPTOR; SEROUS CARCINOMA; TRASTUZUMAB RESISTANCE; TYROSINE
KINASE; ADJUVANT TRASTUZUMAB
AB Endometrial cancer is the mostcommon gynecologic cancer in the United States, diagnosed in more than 50,000 women annually. While the majority ofwomenpresent with low-grade tumors that are cured with surgery and adjuvant radiotherapy, a significant subset of women experience recurrence and do not survive their disease. A disproportionate number of the more than 8,000 annual deaths attributed to endometrial cancer are due to high-grade uterine cancers, highlighting the need for new therapies that target molecular alterations specific to this subset of tumors. Numerous correlative scientific investigations have demonstrated that the HER2 (ERBB2) gene is amplified in 17%-33% of carcinosarcoma, uterine serous carcinoma, and a subset of high-grade endometrioid endometrial tumors. In breast cancer, this potent signature has directed women to anti-HER2-targeted therapies such as trastuzumab and lapatinib. In contrast to breast cancer, therapy with trastuzumab alone revealed no responses in women with recurrent HER2 overexpressing endometrial cancer, suggesting that these tumors may possess acquired or innate trastuzumab resistance mechanisms. This review explores the literature surrounding HER2 expression in endometrial cancer, focusing on trastuzumab and other anti-HER2 therapy and resistance mechanisms characterized in breast cancer but germane to endometrial tumors. Understanding resistance pathwayswill suggest combination therapies that target both HER2 and key oncogenic escape pathways in endometrial cancer.
C1 Massachusetts Gen Hosp, Vincent Ctr Reprod Biol, Dept Obstet & Gynecol, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Div Gynecol Oncol, Dept Obstet & Gynecol, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
RP Growdon, WB (reprint author), Massachusetts Gen Hosp, Vincent Ctr Reprod Biol, Vincent Dept Obstet & Gynecol, THR 901,55 Fruit St, Boston, MA 02114 USA.
EM wgrowdon@partners.org
NR 151
TC 5
Z9 5
U1 0
U2 2
PU ALPHAMED PRESS
PI DURHAM
PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA
SN 1083-7159
EI 1549-490X
J9 ONCOLOGIST
JI Oncologist
PD SEP
PY 2015
VL 20
IS 9
BP 1058
EP 1068
DI 10.1634/theoncologist.2015-0149
PG 11
WC Oncology
SC Oncology
GA CQ9ZB
UT WOS:000360975000016
PM 26099744
ER
PT J
AU Nishino, M
Boswell, EN
Hatabu, H
Ghobrial, IM
Ramaiya, NH
AF Nishino, Mizuki
Boswell, Erica N.
Hatabu, Hiroto
Ghobrial, Irene M.
Ramaiya, Nikhil H.
TI Drug-Related Pneumonitis During Mammalian Target of Rapamycin Inhibitor
Therapy: Radiographic Pattern-Based Approach in Waldenstrom
Macroglobulinemia as a Paradigm
SO ONCOLOGIST
LA English
DT Article
DE Mammalian target of rapamycin inhibitor; mTOR; Pneumonitis; Drug
toxicity; Computed tomography; Waldenstrom macroglobulinemia
ID RENAL-CELL CARCINOMA; HIGH-RESOLUTION CT; IDIOPATHIC INTERSTITIAL
PNEUMONIAS; INDUCED LUNG-DISEASE; PHASE-II TRIAL; MULTIPLE-MYELOMA;
TEMSIROLIMUS; RITUXIMAB; EVEROLIMUS; LYMPHOMA
AB Background. This study determined the frequency of drug-related pneumonitis during mammalian target of rapamycin (mTOR) inhibitor therapy in Waldenstrom macroglobulinemia patients and investigated the imaging characteristics and radiographic patterns of pneumonitis.
Materials and Methods. A total of 40 patients (23 men, 17 women; 43-84 years old) with Waldenstrom macroglobulinemia treated in 2 trials of the mTOR inhibitor everolimus were retrospectively studied. Chest computed tomography (CT) scans during therapy were reviewed for abnormalities suspicious for drug-related pneumonitis by the consensus of three radiologists, evaluating the extent, distributions, and specific findings. The radiographic patterns of pneumonitis were classified using the American Thoracic Society/European Respiratory Society classification of interstitial pneumonia.
Results. Drug-related pneumonitis was noted in 23 patients (58%). The median time from the initiation of therapy to the onset of pneumonitis was 5.7 months. Lower lungs were involved in all 23 patients, with a higher extent than in the other zones (p<.001). The distribution was peripheral and lower in 11 patients (48%) and mixed and multifocal in 10 (44%). The findings were bilateral in 20 patients (87%). Ground glass opacities (GGOs) and reticular opacities were present in all 23 patients, with consolidation in 12, traction bronchiectasis in 2, and centrilobular nodularity in 1. The pattern of pneumonitis was classified as cryptogenic organizing pneumonia (COP) in 16 (70%) and nonspecific interstitial pneumonia (NSIP) in 7 (30%), with overlapping features of COP and NSIP in 7 patients.
Conclusion. Drug-related pneumonitis was noted on CT in 58% of Waldenstrom macroglobulinemia patients treated with mTOR inhibitor therapy. Mostcommon findings were bilateral GGOs and reticular opacities, with or without consolidation, in peripheral and lower lungs, demonstrating COP and NSIP patterns.
C1 [Nishino, Mizuki; Hatabu, Hiroto; Ramaiya, Nikhil H.] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA.
[Boswell, Erica N.; Ghobrial, Irene M.] Brigham & Womens Hosp, Dept Med Oncol, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02215 USA.
RP Nishino, M (reprint author), Dana Farber Canc Inst, Dept Radiol, 450 Brookline Ave, Boston, MA 02215 USA.
EM Mizuki_Nishino@dfci.harvard.edu
FU National Cancer Institute [1K23CA157631]
FX M.N. was supported by National Cancer Institute Grant 1K23CA157631.
NR 28
TC 6
Z9 6
U1 0
U2 1
PU ALPHAMED PRESS
PI DURHAM
PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA
SN 1083-7159
EI 1549-490X
J9 ONCOLOGIST
JI Oncologist
PD SEP
PY 2015
VL 20
IS 9
BP 1077
EP 1083
DI 10.1634/theoncologist.2015-0033
PG 7
WC Oncology
SC Oncology
GA CQ9ZB
UT WOS:000360975000018
PM 26205737
ER
PT J
AU Zhou, J
Zhang, XF
Wang, YH
Guan, YH
AF Zhou, Jing
Zhang, Xiaofeng
Wang, Yuhua
Guan, Yinghui
TI PU.1 affects proliferation of the human acute myeloid leukemia U937 cell
line by directly regulating MEIS1
SO ONCOLOGY LETTERS
LA English
DT Article
DE PU.1; MEIS1; leukemia; transcription
ID TRANSCRIPTION FACTOR PU.1; HEMATOPOIETIC STEM-CELLS; PROGENITORS;
EXPRESSION; DIFFERENTIATION; COMMITMENT; MUTATIONS; TARGETS; ALPHA;
HOXA9
AB The transcription factor PU.1 is a member of the ETS family, which is expressed in a wide variety of hematopoietic lineages. Accumulating evidence has indicated that PU.1 plays a key role in hematopoiesis, and reduced expression of PU.1 leads to the pathogenesis of human myeloid leukemia. As a multi-functional factor, PU.1 is also required for mixed lineage leukemia (MLL) stem cell potential and the development of MLL. However, the function of PU.1 in human non-MLL leukemia and its molecular mechanism remains poorly understood. In the present study, PU.1 siRNA was demonstrated to efficiently inhibit the transcription level of oncogene MEIS1 in the human acute myeloid non-MLL leukemia U937 cell line. In addition, PU.1, as a positive regulator of MEIS1, performed a crucial role in maintaining cell proliferation. Using electrophoretic mobility shift assay, chromatin immunoprecipitation analysis and luciferase reporter assay, previously unexplored evidence that PU.1 activated the MEIS1 promoter through a conserved binding motif in vitro and in vivo was further defined. Overall, the present study provides insight into the molecular mechanism of the contribution of PU.1 to the pathogenesis of non-MLL U937 cells, which is mediated by direct regulation of MEIS1 transcription. The present data reveal the possibility of developing an alternative therapy for non-MLL leukemia by targeting PU.1-mediated MEIS1 gene activation.
C1 [Zhou, Jing] Chinese Acad Sci, Beijing Inst Genom, Lab Genome Variat & Precis Biomed, Beijing 100101, Peoples R China.
[Zhou, Jing; Wang, Yuhua] Forsyth Inst, Dept Immunol & Infect Dis, Cambridge, MA 02142 USA.
[Zhang, Xiaofeng] Univ Massachusetts, Dept Chem, Boston, MA 02125 USA.
[Wang, Yuhua] Shanghai Jiao Tong Univ, Sch Med, Coll Stomatol, Shanghai Key Lab Stomatol,Dept Prosthodont,People, Shanghai 200011, Peoples R China.
[Guan, Yinghui] Jilin Univ, Resp Dept, Branch 2, Hosp 1, Changchun 130021, Jilin, Peoples R China.
RP Zhou, J (reprint author), Forsyth Inst, Dept Immunol & Infect Dis, 245 First St, Cambridge, MA 02142 USA.
EM Jzhou@forsyth.org; gyinghui@sina.com
RI Zhou, jing/B-4718-2016
FU National Natural Science Foundation of China [81100381]
FX This study was supported by the National Natural Science Foundation of
China (grant no., 81100381).
NR 29
TC 1
Z9 1
U1 0
U2 1
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD SEP
PY 2015
VL 10
IS 3
BP 1912
EP 1918
DI 10.3892/ol.2015.3404
PG 7
WC Oncology
SC Oncology
GA CQ9GZ
UT WOS:000360923000120
ER
PT J
AU Lippok, N
Villiger, M
Bouma, BE
AF Lippok, Norman
Villiger, Martin
Bouma, Brett E.
TI Degree of polarization (uniformity) and depolarization index:
unambiguous depolarization contrast for optical coherence tomography
SO OPTICS LETTERS
LA English
DT Article
ID MUELLER MATRIX; SYSTEM
AB The degree of polarization (uniformity) has attracted increased interest as a functional contrast in optical coherence tomography (OCT). However, its computation from a single polarization state suggests an ambiguity that is strongly dependent on a sample's orientation. We here propose an improved metric to present depolarization with respect to the optical system rather than the propagating field. Using numerical simulations and optical frequency domain imaging, we evaluate the conventional DOP(U) for different polarization states and compare its performance with the unambiguous depolarization index. (C) 2015 Optical Society of America
C1 [Lippok, Norman; Villiger, Martin; Bouma, Brett E.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Lippok, Norman; Villiger, Martin; Bouma, Brett E.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Bouma, Brett E.] Harvard Massachusetts Inst Technol, Program Hlth Sci & Technol, Cambridge, MA 02142 USA.
RP Lippok, N (reprint author), Harvard Univ, Sch Med, Boston, MA 02115 USA.
EM nlippok@mgh.harvard.edu
FU National Institute of Health [P41 EB015903]; Terumo Corporation
FX National Institute of Health (P41 EB015903); Terumo Corporation.
NR 15
TC 4
Z9 4
U1 5
U2 11
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 0146-9592
EI 1539-4794
J9 OPT LETT
JI Opt. Lett.
PD SEP 1
PY 2015
VL 40
IS 17
BP 3954
EP 3957
DI 10.1364/OL.40.003954
PG 4
WC Optics
SC Optics
GA CQ7UM
UT WOS:000360810200009
PM 26368685
ER
PT J
AU Beach, MC
Roter, DL
Saha, S
Korthuis, PT
Eggly, S
Cohn, J
Sharp, V
Moore, RD
Wilson, IB
AF Beach, Mary Catherine
Roter, Debra L.
Saha, Somnath
Korthuis, P. Todd
Eggly, Susan
Cohn, Jonathan
Sharp, Victoria
Moore, Richard D.
Wilson, Ira B.
TI Impact of a brief patient and provider intervention to improve the
quality of communication about medication adherence among HIV patients
SO PATIENT EDUCATION AND COUNSELING
LA English
DT Article
DE Communication skills training; HIV/AIDS; Medication adherence
ID ANTIRETROVIRAL THERAPY; CARE; SATISFACTION; PHYSICIANS; OUTCOMES;
INFECTION; HIV/AIDS; DIALOGUE; RECALL
AB Introduction: Medication adherence is essential in HIV care, yet provider communication about adherence is often suboptimal. We designed this study to improve patient-provider communication about HIV medication adherence.
Methods: We randomized 26 providers at three HIV care sites to receive or not receive a one-hour communication skills training based on motivational interviewing principles applied to medication adherence. Prior to routine office visits, non-adherent patients of providers who received the training were coached to discuss adherence with their providers. Patients of providers who did not receive the training providers were not coached. We audio-recorded and coded patient-provider interactions using the roter interaction analysis system (RIAS).
Results: There was more dialogue about therapeutic regimen in visits with intervention patients and providers (167 vs 128, respectively, p=.004), with the majority of statements coming from providers. These visits also included more brainstorming solutions to nonadherence (41% vs. 22%, p=0.026). Intervention compared with control visit providers engaged in more positive talk (44 vs. 38 statements, p=0.039), emotional talk (26 vs. 18 statements, p<0.001), and probing of patient opinion (3 vs. 2 statements, p=0.009).
Conclusion: A brief provider training combined with patient coaching sessions, improved provider communication behaviors and increased dialogue regarding medication adherence. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
C1 [Beach, Mary Catherine] Johns Hopkins Univ, Berman Inst Bioeth, Baltimore, MD 21287 USA.
[Beach, Mary Catherine; Roter, Debra L.; Moore, Richard D.] Johns Hopkins Sch Med, Dept Med, Baltimore, MD USA.
[Beach, Mary Catherine; Roter, Debra L.; Moore, Richard D.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, Baltimore, MD 21287 USA.
[Beach, Mary Catherine] Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD USA.
[Saha, Somnath] Portland VA Med Ctr, Portland, OR USA.
[Saha, Somnath; Korthuis, P. Todd] Oregon Hlth & Sci Univ, Dept Med, Portland, OR USA.
[Eggly, Susan; Cohn, Jonathan] Wayne State Univ, Dept Med, Detroit, MI 48202 USA.
[Wilson, Ira B.] Brown Univ, Sch Publ Hlth, Dept Hlth Serv Policy & Practice, Providence, RI 02912 USA.
RP Beach, MC (reprint author), Johns Hopkins Univ, Gen Internal Med, 2024 East Monument St, Baltimore, MD 21287 USA.
EM mcbeach@jhmi.edu
RI Wilson, Ira/F-9190-2016;
OI Wilson, Ira/0000-0002-0246-738X; Eggly, Susan/0000-0002-8137-6098
FU Health Resources Service Administration; Agency for Healthcare Research
and Quality [AHRQ 290-01-0012, K08HS013903-05]; National Institute of
Drug Abuse [K23 DA019809]; Department of Veterans Affairs; Robert Wood
Johnson Generalist Physician Faculty Scholars Awards
FX This research was supported by a contract from the Health Resources
Service Administration and the Agency for Healthcare Research and
Quality (AHRQ 290-01-0012). In addition, Dr. Korthuis. was supported by
the National Institute of Drug Abuse (K23 DA019809), Dr. Saha was
supported by the Department of Veterans Affairs, Dr. Beach was supported
by the Agency for Healthcare Research and Quality (K08HS013903-05) and
both Drs. Beach and Saha were supported by Robert Wood Johnson
Generalist Physician Faculty Scholars Awards. None of the funders had a
role in the design and conduct of this analysis, nor was it subject to
their final approval. None of the authors have any relevant financial
conflicts of interest.
NR 33
TC 7
Z9 7
U1 3
U2 8
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0738-3991
J9 PATIENT EDUC COUNS
JI Patient Educ. Couns.
PD SEP
PY 2015
VL 98
IS 9
BP 1078
EP 1083
DI 10.1016/j.pec.2015.05.011
PG 6
WC Public, Environmental & Occupational Health; Social Sciences,
Interdisciplinary
SC Public, Environmental & Occupational Health; Social Sciences - Other
Topics
GA CQ8PH
UT WOS:000360870200006
PM 26021185
ER
PT J
AU Kolappa, K
Kern, DE
AF Kolappa, Kavitha
Kern, David E.
TI One good hand
SO PATIENT EDUCATION AND COUNSELING
LA English
DT Article
DE Narrative medicine; Patient-centered care; Medical education;
Physician-patient relations; Patient compliance; Empathy; Holistic
health; Cost-effectiveness; Healthcare delivery; Career choice
C1 [Kolappa, Kavitha] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Kern, David E.] Johns Hopkins Univ, Sch Med, Div Gen Internal Med, Johns Hopkins Bayview Med Ctr, Baltimore, MD 21218 USA.
RP Kern, DE (reprint author), Johns Hopkins Bayview Med Ctr, Div Gen Internal Med, MFL Ctr Tower,Suite 2300,5200 Eastern Ave, Baltimore, MD 21224 USA.
EM dkernl@jhmi.edu
OI Kolappa, Kavitha/0000-0002-5464-4683
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0738-3991
J9 PATIENT EDUC COUNS
JI Patient Educ. Couns.
PD SEP
PY 2015
VL 98
IS 9
BP 1164
EP 1166
DI 10.1016/j.pec.2015.06.010
PG 3
WC Public, Environmental & Occupational Health; Social Sciences,
Interdisciplinary
SC Public, Environmental & Occupational Health; Social Sciences - Other
Topics
GA CQ8PH
UT WOS:000360870200019
PM 26138157
ER
PT J
AU Kim, GE
Seidler, E
Kimball, AB
AF Kim, Grace E.
Seidler, Elizabeth
Kimball, Alexa Boer
TI Effect of Age at Diagnosis on Chronic Quality of Life and Long-Term
Outcomes of Individuals with Psoriasis
SO PEDIATRIC DERMATOLOGY
LA English
DT Article
ID OBSTRUCTIVE SLEEP-APNEA; INDEX; CONSEQUENCES; ADOLESCENTS; MECHANISMS;
CHILDREN
AB Psoriasis is a skin disorder that frequently begins in the pediatric and young adult population but imposes physical and psychosocial burdens over a lifetime. The objective of this retrospective cohort study was to evaluate the effect of age at diagnosis on the lifetime outcomes of psoriasis patients. Individuals with psoriasis (N=114) completed a questionnaire regarding disabilities, relationships, education, finances, and medical outcomes. Responses were compared among quartiles of age at diagnosis and regression analyses were performed. Those diagnosed at a younger age were more likely to have a greater lifetime Dermatology Life Quality Index (LT DLQI) (p<0.001), have felt depressed (p=0.003), believe that psoriasis had caused their depression (p<0.001), experience lifetime sleep problems (p=0.004), use recreational drugs (p<0.001), hide their psoriasis over their lifetime (p<0.001), and experience more severe lifetime discrimination in social settings (p=0.002). Early onset psoriasis is associated with depression, social discrimination, and greater LT DLQI.
C1 [Kim, Grace E.; Kimball, Alexa Boer] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Seidler, Elizabeth] Emory Univ, Sch Med, Atlanta, GA USA.
[Kimball, Alexa Boer] Massachusetts Gen Hosp, Clin Unit Res Trials & Outcomes Skin, Boston, MA 02114 USA.
RP Kimball, AB (reprint author), 50 Staniford St,240, Boston, MA 02114 USA.
EM harvardskinstudies@partners.org
FU Alpha Omega Alpha Carolyn L. Kuckein Student Research Fellowship
FX This study was supported in part by an Alpha Omega Alpha Carolyn L.
Kuckein Student Research Fellowship. The funder was not involved in any
aspect of the study.
NR 26
TC 3
Z9 3
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0736-8046
EI 1525-1470
J9 PEDIATR DERMATOL
JI Pediatr. Dermatol.
PD SEP-OCT
PY 2015
VL 32
IS 5
BP 656
EP 662
DI 10.1111/pde.12416
PG 7
WC Dermatology; Pediatrics
SC Dermatology; Pediatrics
GA CR2TR
UT WOS:000361184000026
PM 25556559
ER
PT J
AU Sheldon, LK
Blonquist, TM
Hilaire, DM
Hong, FX
Berry, DL
AF Sheldon, Lisa Kennedy
Blonquist, Traci M.
Hilaire, Dany M.
Hong, Fangxin
Berry, Donna L.
TI Patient cues and symptoms of psychosocial distress: what predicts
assessment and treatment of distress by oncology clinicians?
SO PSYCHO-ONCOLOGY
LA English
DT Article
DE distress; cancer; symptoms; communication; psychosocial factors;
oncology
ID CANCER-PATIENTS; RANDOMIZED-TRIAL; DEPRESSION; ANXIETY; CARE
AB Objective: Psychosocial concerns arise after a cancer diagnosis and during treatment requiring oncology clinicians to initiate discussions to identify distress. This study examined patient-clinician communication about psychosocial concerns and predictors of assessment and treatment/referral for distress.
Methods: Secondary analysis of existing dataset coded to explore patient-clinician communication during ambulatory visits in two comprehensive cancer centers was carried out. Sample included adult patients with various cancers and stages. Dataset included audio-recordings and symptom/QOL reports 4-6weeks after starting treatment from all distressed patients (n=66) in parent study and random sample of nondistressed patients (n=23). Distressed patients had moderate-to-severe depression (Patient Health Questionnaire-9 scores 10) and/or poor emotional functioning (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire emotional function scores <50). Audio-recordings were coded to describe patient-clinician communication about psychosocial concerns using the coding scheme from the parent study plus Medical Interview Aural Rating System.
Results: The remaining patients gave 222 cues of psychosocial concerns: 183 from 46 distressed patients and 39 from nine nondistressed patients. Distressed patients were younger, were female, had higher symptom burden, and/or gave more cues. Significantly, more distressed patients had at least one cue/visit. Clinicians initiated 62% of discussions overall with no statistical difference between distressed and nondistressed groups. More explicit cues and more than four cues predicted treatment/referral for distress.
Conclusions: Distressed patients were younger, were female, had higher symptom burden, and/or gave more verbal cues. Clinicians responded to explicit and more frequent cues by providing treatment and/or referrals for distress. Further exploration is needed regarding clinician factors related to assessment of psychosocial concerns. Copyright (c) 2014 John Wiley & Sons, Ltd.
C1 [Sheldon, Lisa Kennedy; Hilaire, Dany M.] Univ Massachusetts, Boston, MA 02125 USA.
[Blonquist, Traci M.; Hong, Fangxin; Berry, Donna L.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Berry, Donna L.] Harvard Univ, Sch Med, Boston, MA USA.
RP Sheldon, LK (reprint author), Univ Massachusetts, Coll Nursing & Hlth Sci, 100 Morrissey Blvd, Boston, MA 02125 USA.
EM lisa.kennedysheldon@umb.edu
OI Sheldon, Lisa Kennedy/0000-0002-5958-8529
FU Oncology Nursing Society Foundation; National Institute of Nursing
Research [2R01 NR008726]
FX This research was supported by a grant from the Oncology Nursing Society
Foundation. The parent study was supported by the National Institute of
Nursing Research (2R01 NR008726). This study was reviewed as exempt by
the Institutional Review Board of the University of Massachusetts
Boston.
NR 33
TC 0
Z9 0
U1 2
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD SEP
PY 2015
VL 24
IS 9
BP 1020
EP 1027
DI 10.1002/pon.3689
PG 8
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA CR0FD
UT WOS:000360992900005
PM 25288344
ER
PT J
AU Meyer, F
Fletcher, K
Prigerson, HG
Braun, IM
Maciejewski, PK
AF Meyer, Fremonta
Fletcher, Kalen
Prigerson, Holly G.
Braun, Ilana M.
Maciejewski, Paul K.
TI Advanced cancer as a risk for major depressive episodes
SO PSYCHO-ONCOLOGY
LA English
DT Article
DE cancer; oncology; depression; etiology; epidemiology
ID NATIONAL COMORBIDITY SURVEY; STRESSFUL LIFE EVENTS; REPLICATION NCS-R;
QUALITY-OF-LIFE; BREAST-CANCER; MENTAL-DISORDERS; PALLIATIVE CARE;
DISTRESS; WOMEN; PREVALENCE
AB Objective Major depression adversely affects health communication, quality of life, and survival in patients with advanced cancer. Prior research provides limited insight into how patients with advanced cancer differ from the general population in risk for developing a major depressive episode (MDE). This study aims to determine whether advanced cancer poses distinct risks for initial and recurrent MDEs.
Methods Advanced cancer patients (N=628) from Coping with Cancer were compared with propensity-weighted general population controls (N=9282) from the National Comorbidity Survey Replication.
Results Patients with advanced cancer were more likely than comparisons to have an initial MDE [OR=27.3, 95% CI=(14.8-50.4); p<0.001] but no more likely than comparisons to have a recurrent MDE [OR=1.5, 95% CI=(0.9-2.6); p=0.160]. Nearly two thirds (64.4%) of current MDEs in patients were initial onset; the vast majority (91.8%) of current MDEs in comparisons were recurrent.
Conclusions Advanced cancer increases risk of an initial MDE but appears not to enhance risk of a recurrent MDE. This suggests the importance of screening widely for depression in patients with advanced cancer as opposed to targeting screening to presumably high-risk subgroups of those with psychiatric histories. Copyright (c) 2014 John Wiley & Sons, Ltd.
C1 [Meyer, Fremonta; Braun, Ilana M.] Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02115 USA.
[Meyer, Fremonta; Braun, Ilana M.] Harvard Univ, Sch Med, Boston, MA USA.
[Meyer, Fremonta; Braun, Ilana M.] Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Boston, MA 02115 USA.
[Fletcher, Kalen] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Prigerson, Holly G.; Maciejewski, Paul K.] Weill Cornell Med Coll, Dept Med, Ctr Res End Life Care, New York, NY 10065 USA.
[Prigerson, Holly G.; Maciejewski, Paul K.] Weill Cornell Med Coll, Dept Radiol, New York, NY 10065 USA.
RP Maciejewski, PK (reprint author), Weill Cornell Med Coll, Dept Med, Ctr Res End Life Care, 525 East 68th St,Box 141, New York, NY 10065 USA.
EM pam2056@med.cornell.edu
FU National Institute of Mental Health [MH63892, MH60220]; National Cancer
Institute [CA106370]
FX This research was supported by the National Institute of Mental Health
(MH63892, Prigerson) and the National Cancer Institute (CA106370,
Prigerson). The National Comorbidity Survey Replication was sponsored by
the National Institute of Mental Health (MH60220).
NR 39
TC 1
Z9 1
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD SEP
PY 2015
VL 24
IS 9
BP 1080
EP 1087
DI 10.1002/pon.3722
PG 8
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA CR0FD
UT WOS:000360992900013
PM 25389107
ER
PT J
AU Sporn, NJ
Smith, KB
Pirl, WF
Lennes, IT
Hyland, KA
Park, ER
AF Sporn, Nora J.
Smith, Kelly B.
Pirl, William F.
Lennes, Inga T.
Hyland, Kelly A.
Park, Elyse R.
TI Sexual health communication between cancer survivors and providers: how
frequently does it occur and which providers are preferred?
SO PSYCHO-ONCOLOGY
LA English
DT Article
DE cancer; oncology; survivorship care; survivorship clinic; sexual health;
patient-provider communication
ID PRIMARY-CARE PHYSICIANS; QUALITY-OF-LIFE; ERECTILE DYSFUNCTION;
GYNECOLOGIC CANCER; TESTICULAR CANCER; FOLLOW-UP; INTIMACY; NEEDS;
ONCOLOGISTS; DEPRESSION
AB BackgroundSexual health concerns in cancer survivors are often unaddressed by providers. Study objectives were to assess cancer survivors' reported rates of communication with oncology providers about sexual health, preference for such communication with their oncology or primary care providers (PCPs), and factors associated with these communication rates and preferences.
MethodsSixty-six patients attending a cancer survivorship clinic were asked how often their oncologist addressed and initiated discussion about sexual functioning and whether they wanted their oncologist or PCP to ask about their sexual health. We also assessed whether various sociodemographic characteristics and levels of depression, anxiety, and sexual satisfaction were associated with survivors' sexual health communication rates and preferences.
Results41% of patients wanted their oncologist to ask about sexual health and 58% of patients wanted their PCP to ask about sexual health. Over 90% of patients reported that their oncologist infrequently addressed sexual health concerns and that their oncologist was unlikely to initiate such discussions. Education level influenced whether patients wanted their oncologist to ask about sexual health. Age, education level, and insurance type influenced whether patients wanted their PCP to ask about sexual health. Levels of depression, anxiety, and sexual satisfaction were not associated with communication rates or preferences.
ConclusionsPatients attending a survivorship clinic reported infrequent communication about sexual health with their oncology providers, despite wanting their providers to ask about sexual health concerns. Copyright (c) 2014 John Wiley & Sons, Ltd.
C1 [Sporn, Nora J.] Univ Kansas, Dept Psychol, Lawrence, KS 66045 USA.
[Smith, Kelly B.] Univ British Columbia, Dept Obstet & Gynaecol, Vancouver, BC V5Z 1M9, Canada.
[Pirl, William F.; Park, Elyse R.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Pirl, William F.; Lennes, Inga T.; Hyland, Kelly A.; Park, Elyse R.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Hyland, Kelly A.; Park, Elyse R.] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA.
RP Sporn, NJ (reprint author), Univ Kansas, Dept Psychol, 325 Fraser Hall,1415 Jayhawk Blvd, Lawrence, KS 66045 USA.
EM nsporn@ku.edu
FU Massachusetts General Hospital Cancer Center; Michael Smith Foundation
for Health Research; Canadian Pain Society
FX This study was supported by internal funds from the Massachusetts
General Hospital Cancer Center.; Dr. Smith has received postdoctoral
fellowship awards from the Michael Smith Foundation for Health Research
and the Canadian Pain Society.
NR 40
TC 9
Z9 9
U1 2
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD SEP
PY 2015
VL 24
IS 9
BP 1167
EP 1173
DI 10.1002/pon.3736
PG 7
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA CR0FD
UT WOS:000360992900024
PM 25534170
ER
PT J
AU Fortenbaugh, FC
DeGutis, J
Germine, L
Wilmer, JB
Grosso, M
Russo, K
Esterman, M
AF Fortenbaugh, Francesca C.
DeGutis, Joseph
Germine, Laura
Wilmer, Jeremy B.
Grosso, Mallory
Russo, Kathryn
Esterman, Michael
TI Sustained Attention Across the Life Span in a Sample of 10,000:
Dissociating Ability and Strategy
SO PSYCHOLOGICAL SCIENCE
LA English
DT Article
DE sustained attention; response inhibition; development; aging; life span
ID COGNITIVE NEUROSCIENCE; INHIBITORY CONTROL; REACTION-TIME; RISK-TAKING;
BEHAVIOR; AGE; PERFORMANCE; FAILURES; MIND
AB Normal and abnormal differences in sustained visual attention have long been of interest to scientists, educators, and clinicians. Still lacking, however, is a clear understanding of how sustained visual attention varies across the broad sweep of the human life span. In the present study, we filled this gap in two ways. First, using an unprecedentedly large 10,430-person sample, we modeled age-related differences with substantially greater precision than have prior efforts. Second, using the recently developed gradual-onset continuous performance test (gradCPT), we parsed sustained-attention performance over the life span into its ability and strategy components. We found that after the age of 15 years, the strategy and ability trajectories saliently diverge. Strategy becomes monotonically more conservative with age, whereas ability peaks in the early 40s and is followed by a gradual decline in older adults. These observed life-span trajectories for sustained attention are distinct from results of other life-span studies focusing on fluid and crystallized intelligence.
C1 [Fortenbaugh, Francesca C.; DeGutis, Joseph; Grosso, Mallory; Russo, Kathryn; Esterman, Michael] VA Boston Healthcare Syst, GRECC & Res Serv, Dept Vet Affairs, Boston, MA 02130 USA.
[Fortenbaugh, Francesca C.] Harvard Univ, Sch Med, Dept Psychiat, Cambridge, MA 02138 USA.
[DeGutis, Joseph] Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA.
[Germine, Laura] Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA.
[Germine, Laura] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Wilmer, Jeremy B.] Wellesley Coll, Dept Psychol, Wellesley, MA 02181 USA.
[Esterman, Michael] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA.
RP Fortenbaugh, FC (reprint author), VA Boston Healthcare Syst, 150 S Huntington Ave 182 JP, Boston, MA 02130 USA.
EM francescafortenbaugh@gmail.com
OI Esterman, Michael/0000-0002-9000-3920; Germine,
Laura/0000-0001-8690-8412
FU Department of Veterans Affairs; Department of Veterans Affairs Clinical
Sciences Research and Development Service [1IK2CX000706-01A2]; Brachman
Hoffman Fellowship
FX This research was partially supported by the Department of Veterans
Affairs. F. C. Fortenbaugh has an Advanced Geriatric Fellowship from the
Department of Veterans Affairs. M. Esterman has a Career Development
award from the Department of Veterans Affairs Clinical Sciences Research
and Development Service (1IK2CX000706-01A2). J. B. Wilmer has a Brachman
Hoffman Fellowship.
NR 40
TC 8
Z9 8
U1 4
U2 19
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0956-7976
EI 1467-9280
J9 PSYCHOL SCI
JI Psychol. Sci.
PD SEP
PY 2015
VL 26
IS 9
BP 1497
EP 1510
DI 10.1177/0956797615594896
PG 14
WC Psychology, Multidisciplinary
SC Psychology
GA CR2OY
UT WOS:000361171200016
PM 26253551
ER
PT J
AU Sauser, K
Vickery, KD
Davis, MM
AF Sauser, Kori
Vickery, Katherine Diaz
Davis, Matthew M.
TI Bottleneck or Magnifying Glass? Monitoring the Health-Care System's
Vital Signs through Emergency Departments
SO PUBLIC HEALTH REPORTS
LA English
DT Editorial Material
ID REHOSPITALIZATIONS; IMPACT
AB At this time of dynamic changes in the U.S. health-care system, the emergency department (ED) has a unique vantage point from which to monitor the pulse of Americans' health and to ensure that vulnerable groups are not the victims of unintended consequences of policy and system changes. The ED has a vital, pluripotent role in the U.S. health-care system: It is a primary site of acute unscheduled care and the chief source of hospital admissions, it serves as a diagnostic center, and it is an essential strand of federal, state, and community safety nets.' With such an array of roles, the ED forms a key intersection, where clinical, social, and financial issues converge and often bottleneck. At this privileged but pressurized site, the ED is a place where early effects of policy changes may be detected, diagnosed, and addressed. Yet, the opportunity for the ED to serve this monitoring function is frequently missed. Development of a coordinated network of EDs acting as monitoring points would leverage the natural, timely advantage of the ED and its unique position in the U.S. health-care system. High-yield opportunities for taking a pulse on how our system is caring for its most vulnerable patient groups might be found in tracking ED utilization patterns, rates of left-without-being-seen patients, ED revisit rates, and rates of psychiatric boarding. By monitoring these indicators in real time, system-level alerts can capitalize on the convergence and magnification of issues in the ED by collecting data that are relevant on many levels for hospitals, health systems, and local, state, and national jurisdictions. Such a system could illuminate key issues, inform innovative solutions, and provide opportunities for early intervention.
C1 [Sauser, Kori] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
[Sauser, Kori] Harvard Univ, Sch Med, Dept Emergency Med, Boston, MA USA.
[Vickery, Katherine Diaz] Hennepin Healthcare Syst, Hennepin Cty Med Ctr, Dept Med, Minneapolis, MN USA.
[Vickery, Katherine Diaz] Hennepin Healthcare Syst, Hennepin Cty Med Ctr, Dept Family Med, Minneapolis, MN USA.
[Vickery, Katherine Diaz] Minneapolis Med Res Fdn Inc, Minneapolis, MN USA.
[Vickery, Katherine Diaz] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA.
[Davis, Matthew M.] Univ Michigan, Robert Wood Johnson Fdn, Clin Scholars Program, Ann Arbor, MI 48109 USA.
[Davis, Matthew M.] Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA.
[Davis, Matthew M.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA.
[Davis, Matthew M.] Univ Michigan, Inst Healthcare Policy & Innovat, Ann Arbor, MI 48109 USA.
[Davis, Matthew M.] Univ Michigan, Gerald R Ford Sch Publ Policy, Ann Arbor, MI 48109 USA.
RP Sauser, K (reprint author), Massachusetts Gen Hosp, Dept Emergency Med, Zero Emerson Pl,Ste 3B, Boston, MA 02114 USA.
EM ksauser@mgh.harvard.edu
OI Sauser-Zachrison, Kori/0000-0001-8160-3257
NR 20
TC 1
Z9 1
U1 2
U2 4
PU ASSOC SCHOOLS PUBLIC HEALTH
PI WASHINGTON
PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA
SN 0033-3549
J9 PUBLIC HEALTH REP
JI Public Health Rep.
PD SEP-OCT
PY 2015
VL 130
IS 5
BP 431
EP 434
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA CR1KX
UT WOS:000361084800004
PM 26327719
ER
PT J
AU Hasegawa, K
Stoll, SJ
Ahn, J
Bittner, JC
Camargo, CA
AF Hasegawa, Kohei
Stoll, Samantha J.
Ahn, Jason
Bittner, Jane C.
Camargo, Carlos A., Jr.
TI Prevalence of eosinophilia in hospitalized patients with asthma
exacerbation
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Acute asthma; Hospitalization; Prevalence; Eosinophilia; Asthma
phenotypes; Biologic therapies
ID MULTICENTER; MEPOLIZUMAB; PHENOTYPES; ONSET; CARE
AB Background: Recent studies have identified the "eosinophilic phenotype" of asthma that is characterized by persistent eosinophilic inflammation and frequent exacerbations. However, the prevalence of eosinophilia in patients hospitalized for asthma exacerbation is not known.
Methods: We performed a pilot study in two sites participating in a multicenter chart review project of children and adults hospitalized for asthma exacerbation during 2012-2013. The pilot study investigated the prevalence of blood eosinophilia in this patient population. Eosinophilia was defined as a count of >= 300 cells/microliter at some time during the hospitalization.
Results: Among 80 patients hospitalized for asthma exacerbation, 47 (59%) underwent CBC with differential and had data on blood eosinophil count. These 47 comprised the analytic cohort. The median patient age was 32 years (IQR, 24-44 years), and 51% were female. Overall, 40% (95% CI, 26%-56%) of patients had eosinophilia. Although statistical power was limited, there were no statistically significant differences in patient characteristics or hospital course between patients with eosinophilia and those without (all P > 0.05).
Conclusion: Our pilot study showed that 40% of patients hospitalized for asthma exacerbation had eosinophilia. The clinical meaning of this biomarker in the emergency department/inpatient setting requires further study in much larger samples with long-term follow-up; such studies appear feasible. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Hasegawa, Kohei; Stoll, Samantha J.; Ahn, Jason; Bittner, Jane C.; Camargo, Carlos A., Jr.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA USA.
[Stoll, Samantha J.; Ahn, Jason] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Emergency Med, Boston, MA 02115 USA.
RP Hasegawa, K (reprint author), Massachusetts Gen Hosp, Dept Emergency Med, 326 Cambridge St,Suite 410, Boston, MA 02114 USA.
EM khasegawa1@partners.org
FU Novartis Pharmaceuticals Corporation
FX The study was supported, in part, by Novartis Pharmaceuticals
Corporation to Massachusetts General Hospital (PI: Camargo). The sponsor
had no role in the conduct of the study, or collection, management,
analysis or interpretation of the data, nor preparation, review, or
approval of the manuscript.
NR 16
TC 7
Z9 7
U1 0
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD SEP
PY 2015
VL 109
IS 9
BP 1230
EP 1232
DI 10.1016/j.rmed.2015.07.011
PG 3
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA CQ9HY
UT WOS:000360925800018
PM 26198894
ER
PT J
AU Cui, J
Kawai, T
Irani, Z
AF Cui, Jie
Kawai, Tasuo
Irani, Zubin
TI Catheter-directed Thrombolysis in Acute Superior Vena Cava Syndrome
Caused by Central Venous Catheters
SO SEMINARS IN DIALYSIS
LA English
DT Article
ID ARTERIOVENOUS GRAFTS; HEMODIALYSIS-PATIENTS; HERO; OUTCOMES; ACCESS
AB Indwelling central venous catheters have been reported to increase the risk of superior venous cava (SVC) syndrome. This case report describes the development of acute SVC syndrome in a 28-year-old woman with end-stage renal disease implanted with a left-side hemodialysis reliable outflow graft and a right-side double lumen hemodialysis catheter via internal jugular veins. Her symptoms were not alleviated after catheter removal and systemic anticoagulation therapy. She was eventually treated with catheter-directed thrombolysis and a predischarge computer tomographic venogram on postthrombolytic procedure day 7 showed patent central veins and patient remained asymptomatic. This case demonstrates that catheter-directed thrombolysis can be safely employed to treat refractory catheter-induced acute SVC syndrome in end-stage renal disease patients.
C1 [Cui, Jie] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Nephrol, Boston, MA 02115 USA.
[Kawai, Tasuo] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Transplant Surg, Boston, MA 02115 USA.
[Irani, Zubin] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Vasc Imaging & Intervent,Dept Radiol, Boston, MA 02115 USA.
RP Irani, Z (reprint author), MGH Intervent Radiol, 55 Fruits St, Boston, MA 02114 USA.
EM zirani@mgh.harvard.edu
FU American Society of Nephrology
FX The authors thank Linda Romano RN for her assistance with patient's care
coordination. Dr. Cui is supported by Ben J. Lipps Research Fellowship
from American Society of Nephrology.
NR 10
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0894-0959
EI 1525-139X
J9 SEMIN DIALYSIS
JI Semin. Dial.
PD SEP-OCT
PY 2015
VL 28
IS 5
BP 548
EP 551
DI 10.1111/sdi.12362
PG 4
WC Urology & Nephrology
SC Urology & Nephrology
GA CQ7SG
UT WOS:000360803600016
PM 25827021
ER
PT J
AU Brouwers, HB
Battey, TWK
Musial, HH
Ciura, VA
Falcone, GJ
Ayres, AM
Vashkevich, A
Schwab, K
Viswanathan, A
Anderson, CD
Greenberg, SM
Pomerantz, SR
Ortiz, CJ
Goldstein, JN
Gonzalez, RG
Rosand, J
Romero, JM
AF Brouwers, H. Bart
Battey, Thomas W. K.
Musial, Hayley H.
Ciura, Viesha A.
Falcone, Guido J.
Ayres, Alison M.
Vashkevich, Anastasia
Schwab, Kristin
Viswanathan, Anand
Anderson, Christopher D.
Greenberg, Steven M.
Pomerantz, Stuart R.
Ortiz, Claudia J.
Goldstein, Joshua N.
Gonzalez, R. Gilberto
Rosand, Jonathan
Romero, Javier M.
TI Rate of Contrast Extravasation on Computed Tomographic Angiography
Predicts Hematoma Expansion and Mortality in Primary Intracerebral
Hemorrhage
SO STROKE
LA English
DT Article
DE cerebral hemorrhage; CT angiography; intracerebral hemorrhage; mortality
ID ACTIVATED FACTOR-VII; SPOT SIGN SCORE; GROWTH
AB Background and Purpose-In primary intracerebral hemorrhage, the presence of contrast extravasation after computed tomographic angiography (CTA), termed the spot sign, predicts hematoma expansion and mortality. Because the biological underpinnings of the spot sign are not fully understood, we investigated whether the rate of contrast extravasation, which may reflect the rate of bleeding, predicts expansion and mortality beyond the simple presence of the spot sign.
Methods-Consecutive intracerebral hemorrhage patients with first-pass CTA followed by a 90-second delayed postcontrast CT (delayed CTA) were included. CTAs were reviewed for spot sign presence by 2 blinded readers. Spot sign volumes on first-pass and delayed CTA and intracerebral hemorrhage volumes were measured using semiautomated software. Extravasation rates were calculated and tested for association with hematoma expansion and mortality using uni- and multivariable logistic regressions.
Results-One hundred and sixty-two patients were included, 48 (30%) of whom had >= 1 spot sign. Median spot sign volume was 0.04 mL on first-pass CTA and 0.4 mL on delayed CTA. Median extravasation rate was 0.23 mL/min overall and 0.30 mL/min among expanders versus 0.07 mL/min in nonexpanders. Extravasation rates were also significantly higher in patients who died in hospital: 0.27 mL/min versus 0.04 mL/min. In multivariable analysis, the extravasation rate was independently associated with in-hospital mortality (odds ratio, 1.09 [95% confidence interval, 1.04-1.18], P=0.004), 90-day mortality (odds ratio, 1.15 [95% confidence interval, 1.08-1.27]; P=0.0004), and hematoma expansion (odds ratio, 1.03 [95% confidence interval, 1.01-1.08]; P=0.047).
Conclusions-Contrast extravasation rate, or spot sign growth, further refines the ability to predict hematoma expansion and mortality. Our results support the hypothesis that the spot sign directly measures active bleeding in acute intracerebral hemorrhage.
C1 [Brouwers, H. Bart] Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Dept Neurosurg, NL-3584 CX Utrecht, Netherlands.
[Brouwers, H. Bart; Battey, Thomas W. K.; Musial, Hayley H.; Falcone, Guido J.; Anderson, Christopher D.; Rosand, Jonathan] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Human Genet Res, Boston, MA USA.
[Brouwers, H. Bart; Falcone, Guido J.; Viswanathan, Anand; Anderson, Christopher D.; Goldstein, Joshua N.; Rosand, Jonathan] Harvard Univ, Sch Med, Dept Neurol,Div Neurocrit Care & Emergency Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Brouwers, H. Bart; Battey, Thomas W. K.; Musial, Hayley H.; Falcone, Guido J.; Ayres, Alison M.; Vashkevich, Anastasia; Schwab, Kristin; Viswanathan, Anand; Anderson, Christopher D.; Greenberg, Steven M.; Goldstein, Joshua N.; Rosand, Jonathan] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Hemorrhag Stroke Res Grp, Boston, MA USA.
[Brouwers, H. Bart; Battey, Thomas W. K.; Musial, Hayley H.; Falcone, Guido J.; Ayres, Alison M.; Vashkevich, Anastasia; Schwab, Kristin; Viswanathan, Anand; Anderson, Christopher D.; Greenberg, Steven M.; Goldstein, Joshua N.; Rosand, Jonathan] Harvard Univ, Massachusetts Gen Hosp, Sch Med, J Philip Kistler Stroke Res Ctr, Boston, MA USA.
[Ciura, Viesha A.; Pomerantz, Stuart R.; Ortiz, Claudia J.; Gonzalez, R. Gilberto; Romero, Javier M.] Harvard Univ, Sch Med, Dept Radiol, Neuroradiol Serv,Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Goldstein, Joshua N.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA.
RP Brouwers, HB (reprint author), Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Dept Neurosurg, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.
EM H.B.Brouwers-4@umcutrecht.nl
RI Goldstein, Joshua/H-8953-2016; Falcone, Guido/L-2287-2016;
OI Falcone, Guido/0000-0002-6407-0302; Anderson,
Christopher/0000-0002-0053-2002
FU National Institutes of Health-National Institute of Neurological
Disorders and Stroke (NIH-NINDS) [R01NS073344, R01NS059727,
5K23NS059774]; NIH-NINDS SPOTRIAS fellowship [P50NS051343]
FX All funding entities had no involvement in study design, data
collection, analysis, and interpretation, writing of the article, and in
the decision to submit for publication. The project described was
supported by National Institutes of Health-National Institute of
Neurological Disorders and Stroke (NIH-NINDS) grants R01NS073344,
R01NS059727, and 5K23NS059774. Drs Brouwers and Falcone were supported
by the NIH-NINDS SPOTRIAS fellowship grant P50NS051343.
NR 23
TC 6
Z9 6
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD SEP
PY 2015
VL 46
IS 9
BP 2498
EP 2503
DI 10.1161/STROKEAHA.115.009659
PG 6
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA CQ9FZ
UT WOS:000360919700028
PM 26243220
ER
PT J
AU Andersson, C
Preis, SR
Beiser, A
DeCarli, C
Wollert, KC
Wang, TJ
Januzzi, JL
Vasan, RS
Seshadri, S
AF Andersson, Charlotte
Preis, Sarah R.
Beiser, Alexa
DeCarli, Charles
Wollert, Kai C.
Wang, Thomas J.
Januzzi, James L., Jr.
Vasan, Ramachandran S.
Seshadri, Sudha
TI Associations of Circulating Growth Differentiation Factor-15 and ST2
Concentrations With Subclinical Vascular Brain Injury and Incident
Stroke
SO STROKE
LA English
DT Article
DE follow-up studies; growth differentiation factor-15; magnetic resonance
imaging; neuroimaging; stroke
ID FACTOR-15/MACROPHAGE INHIBITORY CYTOKINE-1; ACUTE CORONARY SYNDROME;
RISK STRATIFICATION; SOLUBLE ST2; CARDIOVASCULAR EVENTS; MULTIPLE
BIOMARKERS; EJECTION FRACTION; COGNITIVE DECLINE; ISCHEMIC-STROKE;
HEART-FAILURE
AB Background and Purpose-Growth differentiation factor-15 (GDF-15) and soluble (s)ST2 are markers of cardiac and vascular stress. We investigated the associations between circulating concentrations of these biomarkers and incident stroke and subclinical vascular brain injury in a sample from the Framingham Offspring cohort.
Methods-We followed 3374 stroke-and dementia-free individuals (mean age, 59.0+/-9.7 years; 53% women) attending the Framingham Offspring sixth examination cycle 11.8+/-3.0 years for incident stroke. A subsample of 2463 individuals underwent brain magnetic resonance imaging and neuropsychological testing approximate to 4.0+/-1.7 years after the sixth examination.
Results-After adjustment for traditional cardiovascular risk factors, B-type natriuretic peptide, high-sensitivity C-reactive protein, and urine albumin levels, higher stress biomarker levels were associated cross-sectionally with lower brain volumes (beta coefficients for intracranial volume comparing fourth [Q4] versus first biomarker [Q1] quartiles: -0.71% for GDF-15; P=0.002 and 0.47% for sST2; P=0.02) and worse performance on the visual reproduction test (beta coefficients for Q4 versus Q1: -0.62 for GDF-15; P=0.009 and -0.40 for sST2; P=0.04). Higher GDF-15 concentrations were also associated with greater log-transformed white-matter hyperintensity volumes (beta for Q4 versus Q1=0.19; P=0.01). Prospectively, a total of 203 (6%) individuals developed incident stroke/transient ischemic attack during follow-up. After multivariable adjustment, sST2 remained significantly associated with stroke/transient ischemic attack, hazard ratio for Q4 versus Q1 of 1.76, 95% confidence interval of 1.06 to 2.92, and P=0.03.
Conclusions-Circulating GDF-15 and sST2 are associated with subclinical brain injury and cognitive impairment. Higher sST2 concentrations are also associated with incident stroke, suggesting potential links between cardiac stress biomarkers and brain injury.
C1 [Andersson, Charlotte; Beiser, Alexa; Wang, Thomas J.; Vasan, Ramachandran S.; Seshadri, Sudha] Framingham Heart Dis Epidemiol Study, Framingham, MA 01702 USA.
[Andersson, Charlotte] Univ Copenhagen, Gentofte Hosp, Dept Cardiol, DK-1168 Copenhagen, Denmark.
[Preis, Sarah R.; Beiser, Alexa] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02215 USA.
[Beiser, Alexa; Seshadri, Sudha] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02215 USA.
[Vasan, Ramachandran S.] Boston Univ, Sch Med, Sect Prevent Med & Cardiol, Boston, MA 02215 USA.
[DeCarli, Charles] Univ Calif Davis, Dept Neurol, Sacramento, CA 95817 USA.
[Wollert, Kai C.] Hannover Med Sch, Dept Cardiol & Angiol, Div Mol & Translat Cardiol, Hannover, Germany.
[Wang, Thomas J.] Vanderbilt Univ, Div Cardiovasc Med, Nashville, TN 37235 USA.
[Januzzi, James L., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA.
RP Andersson, C (reprint author), Framingham Heart Dis Epidemiol Study, 73 Mt Wayte Ave, Framingham, MA 01702 USA.
EM ca@heart.dk
OI Seshadri, Sudha/0000-0001-6135-2622; Ramachandran,
Vasan/0000-0001-7357-5970; Beiser, Alexa/0000-0001-8551-7778
FU National Institutes of Health Heart, Lung and Blood Institute
[N01-HC-25195]; National Institute on Neurological Diseases and Stroke
[NS17950]; National Institute on Aging [AG081220, AG016495]; Critical
Diagnostics; Danish agency for science, technology, and innovation
[FSS-11-120873]; Desanctis Clinical Scholar Endowment; Hutter Family
Professorship; NIA [AG10129]
FX This study was funded by the National Institutes of Health Heart, Lung
and Blood Institute (contract no. N01-HC-25195, PI, Vasan) with
additional support from the National Institute on Neurological Diseases
and Stroke (NS17950) and the National Institute on Aging (AG081220,
AG016495). The ST2 assays were provided with in-kind support from
Critical Diagnostics. Dr Andersson was supported by an independent
research grant from the Danish agency for science, technology, and
innovation (grant number, FSS-11-120873). Dr Januzzi was supported in
part by the Desanctis Clinical Scholar Endowment and the Hutter Family
Professorship and NIA AG10129.
NR 41
TC 4
Z9 4
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD SEP
PY 2015
VL 46
IS 9
BP 2568
EP 2575
DI 10.1161/STROKEAHA.115.009026
PG 8
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA CQ9FZ
UT WOS:000360919700039
PM 26219649
ER
PT J
AU Han, LJ
Cai, W
Mao, LL
Liu, J
Li, PY
Leak, RK
Xu, Y
Hu, XM
Chen, J
AF Han, Lijuan
Cai, Wei
Mao, Leilei
Liu, Jia
Li, Peiying
Leak, Rehana K.
Xu, Yun
Hu, Xiaoming
Chen, Jun
TI Rosiglitazone Promotes White Matter Integrity and Long-Term Functional
Recovery After Focal Cerebral Ischemia
SO STROKE
LA English
DT Article
DE bromodeoxyuridine; inflammation; polarization; stroke; white matter
ID ACTIVATED-RECEPTOR-GAMMA; MICROGLIA/MACROPHAGE POLARIZATION DYNAMICS;
TRAUMATIC BRAIN-INJURY; PPAR-GAMMA; OLIGODENDROCYTE DIFFERENTIATION;
INTRACEREBRAL HEMORRHAGE; AGONIST ROSIGLITAZONE; NEUROPROTECTION; CELLS;
PROGENITORS
AB Background and Purpose-Oligodendrogenesis is essential for white matter repair after stroke. Although agonists of peroxisome proliferator-activated receptors. confer neuroprotection in models of cerebral ischemia, it is not known whether this effect extends to white matter protection. This study tested the hypothesis that the peroxisome proliferator-activated receptors. agonist rosiglitazone enhances oligodendrogenesis and improves long-term white matter integrity after ischemia/reperfusion.
Methods-Male adult C57/BL6 mice (25-30 g) were subjected to 60-minute middle cerebral artery occlusion and reperfusion. Rosiglitazone (3 mg/kg) was injected intraperitoneally once daily for 14 days beginning 2 hours after reperfusion. Sensorimotor and cognitive functions were evaluated <= 21 days after middle cerebral artery occlusion. Immunostaining was used to assess infarct volume, myelin loss, and microglial activation. Bromodeoxyuridine (BrdU) was injected for measurements of proliferating NG2(+) oligodendrocyte precursor cells (OPCs) and newly generated adenomatous polyposis coli(+) oligodendrocytes. Mixed glial cultures were used to confirm the effect of rosiglitazone on oligodendrocyte differentiation and microglial polarization.
Results-Rosiglitazone significantly reduced brain tissue loss, ameliorated white matter injury, and improved sensorimotor and cognitive functions for at least 21 days after middle cerebral artery occlusion. Rosiglitazone enhanced OPC proliferation and increased the numbers of newly generated mature oligodendrocytes after middle cerebral artery occlusion. Rosiglitazone treatment also reduced the numbers of Iba1(+)/CD16(+) M1 microglia and increased the numbers of Iba1(+)/CD206(+) M2 microglia after stroke. Glial culture experiments confirmed that rosiglitazone promoted oligodendrocyte differentiation, perhaps by promoting microglial M2 polarization.
Conclusions-Rosiglitazone treatment improves long-term white matter integrity after cerebral ischemia, at least, in part, by promoting oligodendrogenesis and facilitating microglial polarization toward the beneficial M2 phenotype.
C1 [Han, Lijuan; Xu, Yun] Nanjing Univ, Sch Med, Drum Tower Hosp, Dept Neurol, Nanjing 21008, Jiangsu, Peoples R China.
[Han, Lijuan; Cai, Wei; Mao, Leilei; Hu, Xiaoming; Chen, Jun] Univ Pittsburgh, Sch Med, Dept Neurol, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15213 USA.
[Liu, Jia; Li, Peiying; Hu, Xiaoming; Chen, Jun] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200433, Peoples R China.
[Liu, Jia; Li, Peiying; Hu, Xiaoming; Chen, Jun] Fudan Univ, Inst Brain Sci, Shanghai 200433, Peoples R China.
[Cai, Wei] Sun Yat Sen Univ, Affiliated Hosp 3, Multiple Sclerosis Ctr, Dept Neurol, Guangzhou 510275, Guangdong, Peoples R China.
[Leak, Rehana K.] Duquesne Univ, Div Pharmaceut Sci, Pittsburgh, PA 15219 USA.
[Hu, Xiaoming; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
RP Chen, J (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA.
EM xuyun20042001@aliyun.com; chenj2@upmc.edu
OI Leak, Rehana/0000-0003-2817-7417
FU National institutes of Health/National Institute of neurological
disorders and stroke [NS095671, NS045048, NS036736, NS089534, NS092618];
US Department of Veterans Affairs Research Career Scientist Award and
RRD Merit Review [I01RX000420]; American Heart Association
[13SDG14570025]; Chinese Scholarship Council; China Natural Science
Foundation [81230026, 81171085]; Science and Technology Commission of
Shanghai Municipality [13ZR1452200]; National Natural Science Foundation
[81400956]
FX This work was supported by the National institutes of Health/National
Institute of neurological disorders and stroke grants NS095671,
NS045048, NS036736, and NS089534 (to Dr Chen) and NS092618 (to Dr Hu),
US Department of Veterans Affairs Research Career Scientist Award and
RR&D Merit Review I01RX000420 (to Dr Chen), and grant 13SDG14570025 from
the American Heart Association (to Dr Hu). Dr Han was supported by
predoctoral fellowship from the Chinese Scholarship Council. Dr Xu was
supported by China Natural Science Foundation grants (No. 81230026 and
No. 81171085). Dr Li was supported by the Science and Technology
Commission of Shanghai Municipality (13ZR1452200) and National Natural
Science Foundation grant (No. 81400956).
NR 36
TC 11
Z9 11
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD SEP
PY 2015
VL 46
IS 9
BP 2628
EP 2636
DI 10.1161/STROKEAHA.115.010091
PG 9
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA CQ9FZ
UT WOS:000360919700046
PM 26243225
ER
PT J
AU Esposito, E
Hayakawa, K
Maki, T
Arai, K
Lo, EH
AF Esposito, Elga
Hayakawa, Kazuhide
Maki, Takakuni
Arai, Ken
Lo, Eng H.
TI Effects of Postconditioning on Neurogenesis and Angiogenesis During the
Recovery Phase After Focal Cerebral Ischemia
SO STROKE
LA English
DT Article
DE brain ischemia; infarction; ischemic postconditioning; neurogenesis;
stroke
ID BRAIN-INJURY; STROKE; RATS
AB Background and Purpose-Postconditioning may be a clinically feasible way to protect the brain after a stroke. However, its effects during the recovery phase post stroke remain to be fully elucidated. Here, we examine the hypothesis that ischemic postconditioning amplifies neurogenesis and angiogenesis during stroke recovery.
Methods-Male Sprague-Dawley rats were subjected to 100-minute transient middle cerebral artery occlusion (MCAO) or postconditioning (100-minute middle cerebral artery occlusion plus 10-minute reperfusion plus 10-minute reocclusion). After 2 weeks, infarct volumes, behavioral outcomes, and immunohistochemical markers of neurogenesis and angiogenesis were quantified.
Results-Postconditioning significantly reduced infarction and improved neurological outcomes. Concomitantly, brains subjected to postconditioning showed an increase in doublecortin/BrdU and collagen-IV/Ki67-positive cells.
Conclusions-These results suggest that therapeutic effects of postconditioning may involve the promotion of neurogenesis and angiogenic remodeling during the recovery phase after focal cerebral ischemia.
C1 Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
RP Lo, EH (reprint author), Massachusetts Gen Hosp, E Bldg 149,13th St, Charlestown, MA 02129 USA.
EM eesposito@partners.org; lo@helix.mgh.harvard.edu
FU National Institutes of Health; Rappaport Foundation
FX This work was supported in part by grants from the National Institutes
of Health and the Rappaport Foundation.
NR 13
TC 7
Z9 8
U1 4
U2 14
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD SEP
PY 2015
VL 46
IS 9
BP 2691
EP 2694
DI 10.1161/STROKEAHA.115.009070
PG 4
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA CQ9FZ
UT WOS:000360919700059
PM 26243221
ER
PT J
AU Bader, MK
Wavra, T
Laux, C
Guanci, MM
Figueroa, SA
Brophy, GM
Kurczewski, L
Livesay, SL
AF Bader, Mary Kay
Wavra, Teresa
Laux, Chris
Guanci, Mary McKenna
Figueroa, Stephen A.
Brophy, Gretchen M.
Kurczewski, Lisa
Livesay, Sarah L.
TI Clinical Q & A: Translating Therapeutic Temperature Management from
Theory to Practice
SO THERAPEUTIC HYPOTHERMIA AND TEMPERATURE MANAGEMENT
LA English
DT Article
ID TRAUMATIC BRAIN-INJURY; CARDIAC-ARREST; MODERATE HYPOTHERMIA; SHIVERING
THRESHOLD; MILD HYPOTHERMIA; NORMOTHERMIA; METAANALYSIS; INDUCTION;
REDUCE; HEAD
C1 [Bader, Mary Kay; Wavra, Teresa] Mission Hosp, Mission Viejo, CA 92691 USA.
[Laux, Chris] Univ Washington, Harborview Med Ctr, Operat Manager Cardiac Serv, Seattle, WA 98104 USA.
[Guanci, Mary McKenna] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Figueroa, Stephen A.] Univ Texas SW Med Ctr Dallas, Div Neurocrit Care, Dallas, TX 75390 USA.
[Brophy, Gretchen M.] Virginia Commonwealth Univ, Pharmacotherapy & Outcomes Sci & Neurosurg, Richmond, VA USA.
[Kurczewski, Lisa] Virginia Commonwealth Univ Hlth Syst, Dept Pharm Serv, Crit Care, Richmond, VA USA.
[Livesay, Sarah L.] Rush Univ, Coll Nursing, Chicago, IL 60612 USA.
RP Bader, MK (reprint author), Mission Hosp, Mission Viejo, CA 92691 USA.
NR 30
TC 1
Z9 1
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2153-7658
EI 2153-7933
J9 THER HYPOTHERMIA TEM
JI Ther. Hypothermia Temp. Manag.
PD SEP 1
PY 2015
VL 5
IS 3
BP 177
EP 181
DI 10.1089/ther.2015.29002.mkb
PG 5
WC Critical Care Medicine
SC General & Internal Medicine
GA CR1UC
UT WOS:000361109600011
ER
PT J
AU Calabrese, R
Gerami-Naini, B
Maione, AG
Smith, AE
Carpinito, G
Tomic-Canic, M
Veves, A
Mooney, DJ
Garlick, JA
AF Calabrese, R.
Gerami-Naini, B.
Maione, A. G.
Smith, A. E.
Carpinito, G.
Tomic-Canic, M.
Veves, A.
Mooney, D. J.
Garlick, J. A.
TI Reprogramming Diabetic Foot Ulcer-Derived Fibroblasts to Restore
Regenerative Potential: From iPSCs to Bioengineered 3D Tissues
SO TISSUE ENGINEERING PART A
LA English
DT Meeting Abstract
CT 4th TERMIS World Congress
CY SEP 08-11, 2015
CL Boston, MA
SP TERMIS
C1 [Calabrese, R.; Gerami-Naini, B.; Maione, A. G.; Smith, A. E.; Carpinito, G.; Garlick, J. A.] Tufts Dent Sch Med, Dept Oral & Maxillofacial Pathol Oral Med & Crani, Boston, MA USA.
[Tomic-Canic, M.] Univ Miami, Miller Sch Med, Dept Dermatol & Cutaneous Surg, Miami, FL 33136 USA.
[Veves, A.] Beth Israel Deaconess Med Ctr, Microcirculat Lab, Boston, MA 02215 USA.
[Veves, A.] Beth Israel Deaconess Med Ctr, Joslin Beth Israel Deaconess Foot Ctr, Boston, MA 02215 USA.
[Mooney, D. J.] Harvard Univ, Sch Engn & Appl Sci, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937-3341
EI 1937-335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD SEP 1
PY 2015
VL 21
SU 1
BP S86
EP S86
PG 1
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
Biology
SC Cell Biology; Biotechnology & Applied Microbiology
GA CP9HR
UT WOS:000360205200338
ER
PT J
AU Du, D
Liu, Z
Niu, W
Weng, D
Lim, TC
Wang, L
Kurisawa, M
Spector, M
AF Du, D.
Liu, Z.
Niu, W.
Weng, D.
Lim, T. C.
Wang, L.
Kurisawa, M.
Spector, M.
TI An Injectable Multifunctional Dual-Phase Microsphere-Reinforced Gelatin
Matrix Permissive of Mesenchymal Stem Cell Infiltration for
Musculoskeletal Soft Tissue Repair
SO TISSUE ENGINEERING PART A
LA English
DT Meeting Abstract
CT 4th TERMIS World Congress
CY SEP 08-11, 2015
CL Boston, MA
SP TERMIS
C1 [Du, D.; Liu, Z.; Niu, W.; Weng, D.; Lim, T. C.; Spector, M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, VA Boston Healthcare Syst, Boston, MA 02115 USA.
[Du, D.; Liu, Z.] Harbin Med Univ, Sino Russian Inst Hard Tissue Dev & Regenerat, Harbin, Peoples R China.
[Lim, T. C.] MIT, Boston, MA USA.
[Wang, L.; Kurisawa, M.] Inst Bioengn & Nanotechnol, Singapore, Singapore.
RI KURISAWA, MOTOICHI/C-1325-2014
OI KURISAWA, MOTOICHI/0000-0003-2413-6933
NR 0
TC 0
Z9 0
U1 1
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937-3341
EI 1937-335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD SEP 1
PY 2015
VL 21
SU 1
BP S298
EP S298
PG 1
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
Biology
SC Cell Biology; Biotechnology & Applied Microbiology
GA CP9HR
UT WOS:000360205202258
ER
PT J
AU Frohlich, EM
Prantil-Baun, R
Alonso, J
Arnaout, AM
Charest, JL
AF Frohlich, E. M.
Prantil-Baun, R.
Alonso, J.
Arnaout, A. M.
Charest, J. L.
TI A Microphysiological 3D Model of the Renal Proximal Tubule to Evaluate
Regenerative Therapies
SO TISSUE ENGINEERING PART A
LA English
DT Meeting Abstract
CT 4th TERMIS World Congress
CY SEP 08-11, 2015
CL Boston, MA
SP TERMIS
C1 [Frohlich, E. M.] Draper Lab, Micro Nano Syst Dev, Cambridge, MA USA.
[Prantil-Baun, R.; Charest, J. L.] Draper Lab, Biomed Microsyst, Cambridge, MA USA.
[Alonso, J.; Arnaout, A. M.] Massachusetts Gen Hosp, Div Nephrol, Charlestown, MA USA.
NR 0
TC 0
Z9 0
U1 2
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937-3341
EI 1937-335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD SEP 1
PY 2015
VL 21
SU 1
BP S27
EP S27
PG 1
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
Biology
SC Cell Biology; Biotechnology & Applied Microbiology
GA CP9HR
UT WOS:000360205200099
ER
PT J
AU Gonzalez-Andrades, M
Cruzat, A
Mauris, J
Alonso-Pastor, L
Dohlman, C
Argueso, P
AF Gonzalez-Andrades, M.
Cruzat, A.
Mauris, J.
Alonso-Pastor, L.
Dohlman, C.
Argueso, P.
TI A Novel Human Epithelial In Vitro Wound Healing Assay for the Evaluation
of Materials and Growth Factors Used in Corneal Tissue Engineering
SO TISSUE ENGINEERING PART A
LA English
DT Meeting Abstract
CT 4th TERMIS World Congress
CY SEP 08-11, 2015
CL Boston, MA
SP TERMIS
C1 [Gonzalez-Andrades, M.; Cruzat, A.; Dohlman, C.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Ophthalmol, Boston, MA USA.
[Mauris, J.; Argueso, P.] Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA USA.
[Alonso-Pastor, L.] MIT, Changing Places Res Grp, Media Lab, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937-3341
EI 1937-335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD SEP 1
PY 2015
VL 21
SU 1
BP S203
EP S204
PG 2
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
Biology
SC Cell Biology; Biotechnology & Applied Microbiology
GA CP9HR
UT WOS:000360205201395
ER
PT J
AU Grottkau, BE
Pang, Y
AF Grottkau, B. E.
Pang, Y.
TI Stem Cell Transplantation into Epiphysis of Piglet Perthes' Model
Promoted Restoration of Femoral Head Sphericity
SO TISSUE ENGINEERING PART A
LA English
DT Meeting Abstract
CT 4th TERMIS World Congress
CY SEP 08-11, 2015
CL Boston, MA
SP TERMIS
C1 [Grottkau, B. E.; Pang, Y.] Massachusetts Gen Hosp, Orthopaed, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937-3341
EI 1937-335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD SEP 1
PY 2015
VL 21
SU 1
BP S37
EP S37
PG 1
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
Biology
SC Cell Biology; Biotechnology & Applied Microbiology
GA CP9HR
UT WOS:000360205200140
ER
PT J
AU Hahn, S
Yang, J
Yeom, J
Choi, M
Yun, S
AF Hahn, S.
Yang, J.
Yeom, J.
Choi, M.
Yun, S.
TI Bioengineered Cell-Based Sensing and Therapy using Smart Hydrogels
SO TISSUE ENGINEERING PART A
LA English
DT Meeting Abstract
CT 4th TERMIS World Congress
CY SEP 08-11, 2015
CL Boston, MA
SP TERMIS
C1 [Hahn, S.; Yang, J.; Yeom, J.] Pohang Univ Sci & Technol POSTECH, Dept Mat Sci & Engn, Pohang, South Korea.
[Choi, M.; Yun, S.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Cambridge, MA USA.
[Choi, M.; Yun, S.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937-3341
EI 1937-335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD SEP 1
PY 2015
VL 21
SU 1
BP S54
EP S55
PG 2
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
Biology
SC Cell Biology; Biotechnology & Applied Microbiology
GA CP9HR
UT WOS:000360205200210
ER
PT J
AU Kim, D
AF Kim, D.
TI A 3d Human Neural Cell Culture System for Modeling Alzheimer's Disease
SO TISSUE ENGINEERING PART A
LA English
DT Meeting Abstract
CT 4th TERMIS World Congress
CY SEP 08-11, 2015
CL Boston, MA
SP TERMIS
C1 [Kim, D.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neurol, Charlestown, MA USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937-3341
EI 1937-335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD SEP 1
PY 2015
VL 21
SU 1
BP S78
EP S78
PG 1
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
Biology
SC Cell Biology; Biotechnology & Applied Microbiology
GA CP9HR
UT WOS:000360205200304
ER
PT J
AU Kim, S
Lee, S
Choi, H
AF Kim, S.
Lee, S.
Choi, H.
TI Noninvasive Trafficking of Scaffold Degradation and Tissue Regeneration
SO TISSUE ENGINEERING PART A
LA English
DT Meeting Abstract
CT 4th TERMIS World Congress
CY SEP 08-11, 2015
CL Boston, MA
SP TERMIS
C1 [Kim, S.; Lee, S.] WFIRM, Winston Salem, NC USA.
[Choi, H.] BIDMC, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937-3341
EI 1937-335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD SEP 1
PY 2015
VL 21
SU 1
BP S356
EP S356
PG 1
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
Biology
SC Cell Biology; Biotechnology & Applied Microbiology
GA CP9HR
UT WOS:000360205202487
ER
PT J
AU Lee, J
Parekkadan, B
AF Lee, J.
Parekkadan, B.
TI Implantable Microenvironments for Studying Human Tumor Metastasis
SO TISSUE ENGINEERING PART A
LA English
DT Meeting Abstract
CT 4th TERMIS World Congress
CY SEP 08-11, 2015
CL Boston, MA
SP TERMIS
C1 [Lee, J.] Univ Massachusetts, Inst Appl Life Sci, Dept Chem Engn, Amherst, MA 01003 USA.
[Parekkadan, B.] Massachusetts Gen Hosp, Ctr Engn Med, Dept Surg, Boston, MA 02114 USA.
[Parekkadan, B.] Shriners Hosp Children, Boston, MA USA.
[Parekkadan, B.] Harvard Univ, Stem Cell Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937-3341
EI 1937-335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD SEP 1
PY 2015
VL 21
SU 1
BP S223
EP S223
PG 1
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
Biology
SC Cell Biology; Biotechnology & Applied Microbiology
GA CP9HR
UT WOS:000360205201472
ER
PT J
AU Lim, T
Mandeville, E
Weng, D
Wang, L
Kurisawa, M
Leite-Morris, K
Lo, E
Spector, M
AF Lim, T.
Mandeville, E.
Weng, D.
Wang, L.
Kurisawa, M.
Leite-Morris, K.
Lo, E.
Spector, M.
TI Injectable Gelatin Matrix to Enable Reconstruction of Deep Brain Lesion
Cavity with Endogenous Neural Stem Cells
SO TISSUE ENGINEERING PART A
LA English
DT Meeting Abstract
CT 4th TERMIS World Congress
CY SEP 08-11, 2015
CL Boston, MA
SP TERMIS
C1 [Lim, T.] MIT, Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Lim, T.; Weng, D.; Spector, M.] VA Boston Healthcare Syst, Tissue Engn Lab, Boston, MA USA.
[Mandeville, E.; Lo, E.] Massachusetts Gen Hosp, Neurol & Radiol, Boston, MA 02114 USA.
[Weng, D.; Spector, M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
[Wang, L.; Kurisawa, M.] Inst Bioengn & Nanotechnol, Singapore, Singapore.
[Leite-Morris, K.] VA Boston Healthcare Syst, Neuropharmacol Lab, Boston, MA USA.
RI KURISAWA, MOTOICHI/C-1325-2014
OI KURISAWA, MOTOICHI/0000-0003-2413-6933
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937-3341
EI 1937-335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD SEP 1
PY 2015
VL 21
SU 1
BP S298
EP S298
PG 1
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
Biology
SC Cell Biology; Biotechnology & Applied Microbiology
GA CP9HR
UT WOS:000360205202257
ER
PT J
AU Ma, D
Yao, Y
Hui, Z
Pang, Y
Grottkau, BE
AF Ma, D.
Yao, Y.
Hui, Z.
Pang, Y.
Grottkau, B. E.
TI 3D Bioprinting Malignant Tumor Micro-tissues for Cancer Research
SO TISSUE ENGINEERING PART A
LA English
DT Meeting Abstract
CT 4th TERMIS World Congress
CY SEP 08-11, 2015
CL Boston, MA
SP TERMIS
C1 [Ma, D.; Yao, Y.; Hui, Z.; Pang, Y.; Grottkau, B. E.] Massachusetts Gen Hosp, Orthopaed, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 2
U2 8
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937-3341
EI 1937-335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD SEP 1
PY 2015
VL 21
SU 1
BP S214
EP S214
PG 1
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
Biology
SC Cell Biology; Biotechnology & Applied Microbiology
GA CP9HR
UT WOS:000360205201436
ER
PT J
AU Mishra, R
Roux, BM
Posukonis, M
Bodamer, E
Brey, EM
Fisher, JP
Dean, D
AF Mishra, R.
Roux, B. M.
Posukonis, M.
Bodamer, E.
Brey, E. M.
Fisher, J. P.
Dean, D.
TI Effect of HUVEC/hMSC Pre-culture on Vascularization of Fibrin-Loaded
Poly(propylene Fumarate) Scaffolds In Vitro and In Vivo
SO TISSUE ENGINEERING PART A
LA English
DT Meeting Abstract
CT 4th TERMIS World Congress
CY SEP 08-11, 2015
CL Boston, MA
SP TERMIS
C1 [Mishra, R.; Posukonis, M.; Bodamer, E.; Dean, D.] Ohio State Univ, Plast Surg, Columbus, OH 43210 USA.
[Roux, B. M.; Brey, E. M.] IIT, Biomed Engn, Chicago, IL 60616 USA.
[Roux, B. M.; Brey, E. M.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv, Hines, IL 60141 USA.
[Fisher, J. P.] Univ Maryland, Bioengn, College Pk, MD 20742 USA.
NR 0
TC 0
Z9 0
U1 5
U2 9
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937-3341
EI 1937-335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD SEP 1
PY 2015
VL 21
SU 1
BP S361
EP S361
PG 1
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
Biology
SC Cell Biology; Biotechnology & Applied Microbiology
GA CP9HR
UT WOS:000360205202506
ER
PT J
AU Niu, W
Weng, D
Alshihri, AA
Lim, T
Wang, L
Kurisawa, M
Spector, M
AF Niu, W.
Weng, D.
Alshihri, A. A.
Lim, T.
Wang, L.
Kurisawa, M.
Spector, M.
TI Behavior of Bone Marrow Mesenchymal Stem Cells in Injectable
Gelatin-Hyaluronan Matrices
SO TISSUE ENGINEERING PART A
LA English
DT Meeting Abstract
CT 4th TERMIS World Congress
CY SEP 08-11, 2015
CL Boston, MA
SP TERMIS
C1 [Niu, W.; Weng, D.; Spector, M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, VA Boston Healthcare Syst, Boston, MA 02115 USA.
[Alshihri, A. A.] Harvard Univ, Sch Dent Med, VA Boston Healthcare Syst, Boston, MA 02115 USA.
[Alshihri, A. A.] King Saud Univ, Riyadh, Saudi Arabia.
[Lim, T.] MIT, VA Boston Healthcare Syst, Boston, MA USA.
[Lim, T.; Wang, L.; Kurisawa, M.] Inst Bioengn & Nanotechnol, Singapore, Singapore.
RI KURISAWA, MOTOICHI/C-1325-2014
OI KURISAWA, MOTOICHI/0000-0003-2413-6933
NR 0
TC 0
Z9 0
U1 1
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937-3341
EI 1937-335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD SEP 1
PY 2015
VL 21
SU 1
BP S308
EP S308
PG 1
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
Biology
SC Cell Biology; Biotechnology & Applied Microbiology
GA CP9HR
UT WOS:000360205202296
ER
PT J
AU Niu, W
Kong, Q
Weng, D
Wang, L
Kurisawa, M
Spector, M
AF Niu, W.
Kong, Q.
Weng, D.
Wang, L.
Kurisawa, M.
Spector, M.
TI Fibroblast Behavior in an Injectable Covalently Cross-Linkable Gelatin
Matrix Incorporating Select Growth Factors
SO TISSUE ENGINEERING PART A
LA English
DT Meeting Abstract
CT 4th TERMIS World Congress
CY SEP 08-11, 2015
CL Boston, MA
SP TERMIS
C1 [Niu, W.; Kong, Q.; Weng, D.; Spector, M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, VA Boston Healthcare Syst, Boston, MA 02115 USA.
[Kong, Q.] West China Hosp, Chengdu, Peoples R China.
[Wang, L.; Kurisawa, M.] Inst Bioengn & Nanotechnol, Singapore, Singapore.
RI KURISAWA, MOTOICHI/C-1325-2014
OI KURISAWA, MOTOICHI/0000-0003-2413-6933
NR 1
TC 0
Z9 0
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937-3341
EI 1937-335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD SEP 1
PY 2015
VL 21
SU 1
BP S290
EP S290
PG 1
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
Biology
SC Cell Biology; Biotechnology & Applied Microbiology
GA CP9HR
UT WOS:000360205202227
ER
PT J
AU Rajappa, R
Rokkappanavar, S
Wang, L
Kurisawa, M
Spector, M
AF Rajappa, R.
Rokkappanavar, S.
Wang, L.
Kurisawa, M.
Spector, M.
TI PDGF-BB-Loaded Injectable Gelatin Matrix in Conjunction with
Extracorporeal Shock Waves for Periodontal Tissue Regeneration:
In-eVitro Assessment
SO TISSUE ENGINEERING PART A
LA English
DT Meeting Abstract
CT 4th TERMIS World Congress
CY SEP 08-11, 2015
CL Boston, MA
SP TERMIS
C1 [Rajappa, R.; Rokkappanavar, S.; Spector, M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, VA Boston Healthcare Syst, Boston, MA 02115 USA.
[Wang, L.; Kurisawa, M.] Inst Bioengn & Nanotechnol, Singapore, Singapore.
RI KURISAWA, MOTOICHI/C-1325-2014
OI KURISAWA, MOTOICHI/0000-0003-2413-6933
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937-3341
EI 1937-335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD SEP 1
PY 2015
VL 21
SU 1
BP S411
EP S411
PG 1
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
Biology
SC Cell Biology; Biotechnology & Applied Microbiology
GA CP9HR
UT WOS:000360205202709
ER
PT J
AU Randolph, M
Edwards, S
Meppelink, A
Gill, TJ
AF Randolph, M.
Edwards, S.
Meppelink, A.
Gill, T. J.
TI Meniscal Regeneration using a Bovine Dermal Collagen Matrix
SO TISSUE ENGINEERING PART A
LA English
DT Meeting Abstract
CT 4th TERMIS World Congress
CY SEP 08-11, 2015
CL Boston, MA
SP TERMIS
C1 [Randolph, M.; Edwards, S.; Meppelink, A.] Massachusetts Gen Hosp, Lab Musculoskeletal Tissue Engn, Boston, MA 02114 USA.
[Gill, T. J.] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937-3341
EI 1937-335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD SEP 1
PY 2015
VL 21
SU 1
BP S224
EP S225
PG 2
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
Biology
SC Cell Biology; Biotechnology & Applied Microbiology
GA CP9HR
UT WOS:000360205201478
ER
PT J
AU Roux, BM
Gandhi, JK
Brey, EM
AF Roux, B. M.
Gandhi, J. K.
Brey, E. M.
TI Evaluation of MSC Source on Angiogenesis in 3D Co-Culture
SO TISSUE ENGINEERING PART A
LA English
DT Meeting Abstract
CT 4th TERMIS World Congress
CY SEP 08-11, 2015
CL Boston, MA
SP TERMIS
C1 [Roux, B. M.; Gandhi, J. K.; Brey, E. M.] IIT, Biomed Engn, Chicago, IL 60616 USA.
[Roux, B. M.; Gandhi, J. K.; Brey, E. M.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv, Hines, IL 60141 USA.
NR 0
TC 0
Z9 0
U1 3
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937-3341
EI 1937-335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD SEP 1
PY 2015
VL 21
SU 1
BP S156
EP S157
PG 2
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
Biology
SC Cell Biology; Biotechnology & Applied Microbiology
GA CP9HR
UT WOS:000360205201212
ER
PT J
AU Wang, Y
Ortega-Martinez, A
Gutierrez-Herrera, E
Farinelli, WA
Doukas, AG
Anderson, RR
Franco, W
AF Wang, Y.
Ortega-Martinez, A.
Gutierrez-Herrera, E.
Farinelli, W. A.
Doukas, A. G.
Anderson, R. R.
Franco, W.
TI A Non-contact Wide Field Method to Evaluate Epithelialization: UV
Fluorescence Excitation Imaging
SO TISSUE ENGINEERING PART A
LA English
DT Meeting Abstract
CT 4th TERMIS World Congress
CY SEP 08-11, 2015
CL Boston, MA
SP TERMIS
C1 [Wang, Y.; Ortega-Martinez, A.; Farinelli, W. A.; Doukas, A. G.; Anderson, R. R.; Franco, W.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed,Dept Dermatol, Boston, MA USA.
[Gutierrez-Herrera, E.] Univ Nacl Autonoma Mexico, Ctr Ciencias Aplicadas & Desarrollo Tecnol, Mexico City 04510, DF, Mexico.
NR 0
TC 1
Z9 1
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937-3341
EI 1937-335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD SEP 1
PY 2015
VL 21
SU 1
BP S374
EP S375
PG 2
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
Biology
SC Cell Biology; Biotechnology & Applied Microbiology
GA CP9HR
UT WOS:000360205202559
ER
PT J
AU Weng, D
Niu, W
Du, D
Wang, L
Kurisawa, M
Spector, M
AF Weng, D.
Niu, W.
Du, D.
Wang, L.
Kurisawa, M.
Spector, M.
TI Physical Properties of Enzymatically Cross-Linked Injectable Gelatin
Matrices
SO TISSUE ENGINEERING PART A
LA English
DT Meeting Abstract
CT 4th TERMIS World Congress
CY SEP 08-11, 2015
CL Boston, MA
SP TERMIS
C1 [Weng, D.; Niu, W.; Du, D.; Spector, M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
[Weng, D.; Niu, W.; Du, D.; Spector, M.] VA Boston Healthcare Syst, Boston, MA USA.
[Du, D.] Harbin Med Univ, Orthoped Surg, Harbin, Peoples R China.
[Wang, L.; Kurisawa, M.] Inst Bioengn & Nanotechnol, Singapore, Singapore.
RI KURISAWA, MOTOICHI/C-1325-2014
OI KURISAWA, MOTOICHI/0000-0003-2413-6933
NR 0
TC 0
Z9 0
U1 2
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937-3341
EI 1937-335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD SEP 1
PY 2015
VL 21
SU 1
BP S324
EP S325
PG 2
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
Biology
SC Cell Biology; Biotechnology & Applied Microbiology
GA CP9HR
UT WOS:000360205202361
ER
PT J
AU Yao, Y
Hui, Z
Ma, D
Grottkau, BE
Pang, Y
AF Yao, Y.
Hui, Z.
Ma, D.
Grottkau, B. E.
Pang, Y.
TI A Novel 3D Bioprinted Angiogenesis System for High-throughput Screening
SO TISSUE ENGINEERING PART A
LA English
DT Meeting Abstract
CT 4th TERMIS World Congress
CY SEP 08-11, 2015
CL Boston, MA
SP TERMIS
C1 [Yao, Y.; Hui, Z.; Ma, D.; Grottkau, B. E.; Pang, Y.] Massachusetts Gen Hosp, Orthopaed, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937-3341
EI 1937-335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD SEP 1
PY 2015
VL 21
SU 1
BP S321
EP S321
PG 1
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
Biology
SC Cell Biology; Biotechnology & Applied Microbiology
GA CP9HR
UT WOS:000360205202347
ER
PT J
AU Knowlton, S
Onal, S
Yu, CH
Zhao, JJ
Tasoglu, S
AF Knowlton, Stephanie
Onal, Sevgi
Yu, Chu Hsiang
Zhao, Jean J.
Tasoglu, Savas
TI Bioprinting for cancer research
SO TRENDS IN BIOTECHNOLOGY
LA English
DT Review
ID LAYER-BY-LAYER; MICROSCALE HYDROGELS; IN-VITRO; FREEFORM FABRICATION;
TISSUE CONSTRUCTS; PROSTATE-CANCER; CELL-MIGRATION; LIVING CELLS; TUMOR;
SCAFFOLDS
AB Bioprinting offers the ability to create highly complex 3D architectures with living cells. This cutting-edge technique has significantly gained popularity and applicability in several fields. Bioprinting methods have been developed to effectively and rapidly pattern living cells, biological macromolecules, and biomaterials. These technologies hold great potential for applications in cancer research. Bioprinted cancer models represent a significant improvement over previous 2D models by mimicking 3D complexity and facilitating physiologically relevant cell-cell and cell-matrix interactions. Here we review bioprinting methods based on inkjet, microextrusion, and laser technologies and compare 3D cancer models with 2D cancer models. We discuss bioprinted models that mimic the tumor microenvironment, providing a platform for deeper understanding of cancer pathology, anticancer drug screening, and cancer treatment development.
C1 [Knowlton, Stephanie; Onal, Sevgi; Tasoglu, Savas] Univ Connecticut, Dept Biomed Engn, Storrs, CT 06269 USA.
[Yu, Chu Hsiang; Tasoglu, Savas] Univ Connecticut, Dept Mech Engn, Storrs, CT 06269 USA.
[Zhao, Jean J.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Zhao, Jean J.] Dana Farber Canc Inst, Canc Biol, Boston, MA 02215 USA.
RP Tasoglu, S (reprint author), Univ Connecticut, Dept Biomed Engn, 260 Glenbrook Rd, Storrs, CT 06269 USA.
EM savas@engr.uconn.edu
FU UConn Research Excellence Program Award
FX S.T. acknowledges the UConn Research Excellence Program Award.
NR 89
TC 26
Z9 27
U1 13
U2 75
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0167-7799
J9 TRENDS BIOTECHNOL
JI Trends Biotechnol.
PD SEP
PY 2015
VL 33
IS 9
BP 504
EP 513
DI 10.1016/j.tibtech.2015.06.007
PG 10
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA CQ9RH
UT WOS:000360952200004
PM 26216543
ER
PT J
AU Curreri, SA
Fung, C
Beard, CJ
AF Curreri, Stephanie A.
Fung, Chunkit
Beard, Clair J.
TI Secondary malignant neoplasms in testicular cancer survivors
SO UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
LA English
DT Article
DE Testicular cancer; Radiation therapy; Chemotherapy; Diagnostic imaging;
Second cancer
ID COMPUTED-TOMOGRAPHY; 2ND MALIGNANCIES; CHEMOTHERAPY; RISK; RADIATION;
PLATINUM; SEMINOMA; TUMORS; SURVEILLANCE; CISPLATIN
AB Background: Testicular cancer is the most common cancer among men aged 15 to 40 years, and the incidence of testicular cancer is steadily increasing. Despite successful treatment outcomes and the rate of survival at 5 to 10 years being 95%, survivors can experience late effects of both their cancer and the treatment they received, including secondary malignant neoplasms (SMNs). We discuss the development of non germ cell SMNs that develop after diagnosis and treatment of testicular cancer and their effect on mortality.
Results: Patients diagnosed with testicular cancer frequently choose postoperative surveillance if they are diagnosed with clinical stage I disease. These patients may experience an increased risk for developing SMNs following radiation exposure from diagnostic imaging. Similarly. radiotherapy for testicular cancer is associated with increased risks of developing both solid tumors and leukemia. Studies have reported that patients exposed to higher doses of radiation have an increased risk of developing SMNs when compared with patients who received lower doses of radiation. Patients treated with chemotherapy also experience an increased risk of developing SMNs following testicular cancer. though the risk following chemotherapy and radiation therapy combined is not well described. A large population-based study concluded that the rate ratios for both cancer-specific and all-cause mortality for SMNs among testicular cancer survivors were not significantly different from those of matched first cancers.
Conclusions: Although it is known that patients who receive adjuvant chemotherapy or radiotherapy or who undergo routine diagnostic or follow-up imaging for a primary testicular cancer are at an increased risk for developing SMNs, the extent of this risk is largely unknown. It is critically important that research be conducted to determine this risk and its contributing factors as accurately as possible. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Curreri, Stephanie A.; Beard, Clair J.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Fung, Chunkit] Univ Rochester, Med Ctr, Rochester, NY 14642 USA.
RP Curreri, SA (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
EM scurreri@lroc.harvard.edu
OI Lynch, Stephanie/0000-0002-2200-1579
NR 31
TC 1
Z9 1
U1 2
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1078-1439
EI 1873-2496
J9 UROL ONCOL-SEMIN ORI
JI Urol. Oncol.-Semin. Orig. Investig.
PD SEP
PY 2015
VL 33
IS 9
BP 392
EP 398
DI 10.1016/j.urolonc.2015.05.002
PG 7
WC Oncology; Urology & Nephrology
SC Oncology; Urology & Nephrology
GA CR0TV
UT WOS:000361037000024
PM 26072728
ER
PT J
AU Preston, MA
Feldman, AS
Coen, JJ
McDougal, WS
Smith, MR
Paly, JJ
Carrasquillo, R
Wu, CL
Dahl, DM
Barrisford, GW
Blute, ML
Zietman, AI
AF Preston, Mark A.
Feldman, Adam S.
Coen, John J.
McDougal, W. Scott
Smith, Matthew R.
Paly, Jonathan J.
Carrasquillo, Robert
Wu, Chin-Lee
Dahl, Douglas M.
Barrisford, Glen W.
Blute, Michael L.
Zietman, Anthony I.
TI Active surveillance for low-risk prostate cancer: Need for intervention
and survival at 10 years
SO UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
LA English
DT Article
DE Prostate cancel; Active surveillance; Survival; Intervention
ID OVERDIAGNOSIS; EXPERIENCE; MORTALITY; SELECTION; TRIGGERS; OUTCOMES;
BIOPSY; PSA
AB Introduction: To describe the need for treatment and cancer-specific and overall survival in a contemporary active surveillance (AS) cohort.
Patients and methods: Historical cohort study of men diagnosed with localized prostate cancer between 1997 and 2009 and managed with AS at a tertiary care center. Inclusion criteria were Gleason score <= 6 (Gleason score of 7 in select patients), <= 3/12 cores positive, and prostate-specific antigen (PSA) level <20 ng/ml. Survival analyses were conducted using the Kaplan-Meier method.
Results: A total of 469 men with median age at diagnosis of 68.1 years (interquartile range [IQR]: 62.5-73.4) were followed up for a median of 4.8 years (IQR: 3.4-7.3). Median PSA level at diagnosis was 5.1 ng/ml (IQR: 4.0-6.9), with 94% of them having PSA level <10 ng/ml. Overall, 98.3% (461/469) of patients had a Gleason score of 6 and 1.7% (8/469) had a Gleason score of 3 + 4 = 7, and 94.0% (441/469) had T1c stage disease. Freedom from treatment was 77% at 5 years and 62% at 10 years. A total of 116 (24.7%) patients received treatment during the course of surveillance. Reasons for treatment included 44.8% (52/116) for pathologic reclassification, 30.2% (35/116) for PSA progression, 12.1% (14/116) for patient preference, 5.2% (6/116) for digital rectal examination progression, and 4.3% (5/116) for metastatic disease. Of the patients treated, 59 (50.1%) received radiation, 26 (22.4%) underwent surgery, 17 (14.7%) received brachytherapy, and 14 (12.1%) received androgen-deprivation therapy. Cancer-specific survival was 100% at 5 and 10 years. Overall survival was 95% at 5 years and 88% at 10 years.
Conclusion: In a contemporary cohort of men with low-risk prostate cancer. AS allowed avoidance of treatment most of them. Common reasons for change in management were Gleason upgrading and volume progression on prostate rebiopsy. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Preston, Mark A.] Brigham & Womens Hosp, Dept Surg, Div Urol, Boston, MA 02115 USA.
[Feldman, Adam S.; McDougal, W. Scott; Wu, Chin-Lee; Dahl, Douglas M.; Barrisford, Glen W.; Blute, Michael L.] Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA.
[Coen, John J.; Paly, Jonathan J.; Zietman, Anthony I.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Smith, Matthew R.] Massachusetts Gen Hosp, Div Med Oncol, Boston, MA 02114 USA.
[Carrasquillo, Robert] Boston Med Ctr, Dept Urol, Boston, MA USA.
RP Feldman, AS (reprint author), Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA.
EM afeldman@partners.org
FU Prostate Cancer Foundation Young Investigator Award; Department of
Defense Prostate Cancer Research Program Physician Research Training
Award [W81XWH-13-1-0328]
FX This work was in part funded by the Prostate Cancer Foundation Young
Investigator Award (A.S.F.) and the Department of Defense Prostate
Cancer Research Program Physician Research Training Award, Award no.
W81XWH-13-1-0328 (A.S.F.).
NR 29
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1078-1439
EI 1873-2496
J9 UROL ONCOL-SEMIN ORI
JI Urol. Oncol.-Semin. Orig. Investig.
PD SEP
PY 2015
VL 33
IS 9
DI 10.1016/j.urolonc.2015.04.015
PG 8
WC Oncology; Urology & Nephrology
SC Oncology; Urology & Nephrology
GA CR0TV
UT WOS:000361037000004
ER
PT J
AU Chou, LB
Lerner, LB
Harris, AHS
Brandon, AJ
Girod, S
Butler, LM
AF Chou, Loretta B.
Lerner, Lori B.
Harris, Alex H. S.
Brandon, Ashley J.
Girod, Sabine
Butler, Lesley M.
TI Cancer Prevalence among a Cross-sectional Survey of Female Orthopedic,
Urology, and Plastic Surgeons in the United States
SO WOMENS HEALTH ISSUES
LA English
DT Article
ID US RADIOLOGIC TECHNOLOGISTS; C-ARM FLUOROSCOPY; RADIATION-EXPOSURE;
BREAST-CANCER; MEDICAL RADIATION; RISK; CARCINOGENS; MORTALITY; WOMEN
AB Background: Exposure to ionizing radiation from fluoroscopy performed during surgery, although low and within established limits, remains a health concern among surgeons. Estimates of breast cancer prevalence among women across surgery specialties with different patterns of fluoroscopy use are needed to evaluate this concern.
Methods: Female U.S. surgeons in urology, plastics, and orthopedics were identified using national directories and mailed surveys to collect information on occupational and medical history, including cancer diagnoses. Standardized prevalence ratios (SPRs) and 95% CIs were calculated by dividing the observed number of cancers among female surgeons in each specialty by the expected number, based on the gender-specific, age-specific, and race-specific cancer prevalence statistics in the general U.S. population.
Results: Standard fluoroscopy use more than once per week was common among urologists (54%) and orthopedists (37%); the same frequency of mini fluoroscopy use was only common among orthopedics (31%) and hardly ever used by urologists. Plastic surgeons reported very infrequent use of any fluoroscopy. For orthopedic surgeons, a significantly greater than expected prevalence of any cancer (SPR, 1.85; 95% CI, 1.19-2.76) and breast cancer (SPR, 2.90; 95% CI, 1.66-4.71) were observed. There was no difference between the observed and expected prevalence of any cancer or breast cancer for urology or plastics.
Conclusions: Using the first available cancer prevalence data comparing female surgeons across three specialties, we report that orthopedic surgeons have a greater than expected prevalence of cancer that may or may not be owing to occupational exposure to ionizing radiation. Copyright (C) 2015 by the Jacobs Institute of Women's Health. Published by Elsevier Inc.
C1 [Chou, Loretta B.; Harris, Alex H. S.] Stanford Sch Med, Dept Orthopaed Surg, Redwood City, CA 94063 USA.
[Lerner, Lori B.; Brandon, Ashley J.] VA Boston Healthcare Syst, Dept Surg, Boston, MA USA.
[Girod, Sabine] Stanford Univ, Dept Oral Med & Maxillofacial Surg, Palo Alto, CA 94304 USA.
[Butler, Lesley M.] Univ Pittsburgh, Inst Canc, Div Canc Control & Populat Sci, Pittsburgh, PA USA.
[Butler, Lesley M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA.
RP Chou, LB (reprint author), Stanford Sch Med, Dept Orthopaed Surg, 450 Broadway St, Redwood City, CA 94063 USA.
EM lchou@stanford.edu
NR 33
TC 2
Z9 2
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1049-3867
EI 1878-4321
J9 WOMEN HEALTH ISS
JI Womens Health Iss.
PD SEP-OCT
PY 2015
VL 25
IS 5
BP 476
EP 481
DI 10.1016/j.whi.2015.05.005
PG 6
WC Public, Environmental & Occupational Health; Women's Studies
SC Public, Environmental & Occupational Health; Women's Studies
GA CR1CM
UT WOS:000361060400009
PM 26265543
ER
PT J
AU Saadi, A
Bond, BE
Percac-Lima, S
AF Saadi, Altaf
Bond, Barbara E.
Percac-Lima, Sanja
TI Bosnian, Iraqi, and Somali Refugee Women Speak: A Comparative
Qualitative Study of Refugee Health Beliefs on Preventive Health and
Breast Cancer Screening
SO WOMENS HEALTH ISSUES
LA English
DT Article
ID AFRICAN-AMERICANS VIEWS; IMMIGRANT WOMEN; UNITED-STATES; CARE;
DISPARITIES; BARRIERS; TRUSTWORTHINESS; ETHNICITY; ATTITUDES; SURVIVAL
AB Introduction: The low uptake of preventive services in disadvantaged communities is a continuing challenge to public health. Women refugee communities are particularly vulnerable populations, and disparities in both preventive care and breast cancer screening have been documented sparsely. The objective of this qualitative study was to explore Bosnian, Iraqi, and Somali women refugees' beliefs about preventive care and breast cancer screening to inform future community interventions and best practices.
Methods: In an urban community health center, 57 interviews with Bosnian, Somali, and Iraqi women refugees were conducted by native language speakers. Interview transcripts were coded and analyzed according to best practices for thematic and content analysis. The responses of three groups were compared.
Findings: Similarities across participants included barriers to care such as fear of pain and diagnosis, modesty, and work and childcare commitments; facilitative factors such as outreach efforts, appointment reminders, and personal contact from health providers; perceptions of how the American medical infrastructure compared with inadequacies in their home countries; and positive attitude toward U.S. health professionals. Differences that emerged among groups were: varying degrees of medical exposure to doctors in home countries, the impact of war on health systems; and understanding preventive breast care.
Conclusion: Taken together, duration of time in United States and prior exposure to Western medicine account for differences in refugee women's knowledge of preventive care. Understanding population-specific health beliefs, health information, and behavior are crucial for designing tailored prevention programs for refugee women. Copyright (C) 2015 by the Jacobs Institute of Women's Health. Published by Elsevier Inc.
C1 [Saadi, Altaf] Massachusetts Gen Hosp, Partners Neurol Residency, Boston, MA 02114 USA.
[Saadi, Altaf] Brigham & Womans Hosp, Boston, MA USA.
[Bond, Barbara E.] Bridgewater State Univ, Sch Social Work, Bridgewater, MA USA.
[Percac-Lima, Sanja] Massachusetts Gen Hosp, Chelsea HealthCare Ctr, Chelsea, MA USA.
RP Saadi, A (reprint author), Massachusetts Gen Hosp, Partners Neurol Residency, 55 Fruit St, Boston, MA 02114 USA.
EM asaadi@partners.org
FU Susan G. Komen MA Affiliate foundation; MGH Center for Community Health
Improvement; Cancer Control Career Development Award for Primary Care
Physicians from the American Cancer Society [CCCDAA-14-012-01-CCCDA];
Lazarex Cancer Foundation
FX Funding: This work was funded by Susan G. Komen MA Affiliate foundation
and MGH Center for Community Health Improvement. Dr. Percac-Lima is
supported in part by Cancer Control Career Development Award for Primary
Care Physicians, CCCDAA-14-012-01-CCCDA from the American Cancer Society
and in part by grant from Lazarex Cancer Foundation.
NR 39
TC 0
Z9 0
U1 3
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1049-3867
EI 1878-4321
J9 WOMEN HEALTH ISS
JI Womens Health Iss.
PD SEP-OCT
PY 2015
VL 25
IS 5
BP 501
EP 508
DI 10.1016/j.whi.2015.06.005
PG 8
WC Public, Environmental & Occupational Health; Women's Studies
SC Public, Environmental & Occupational Health; Women's Studies
GA CR1CM
UT WOS:000361060400012
PM 26219676
ER
PT J
AU Lehavot, K
O'Hara, R
Washington, DL
Yano, EM
Simpson, TL
AF Lehavot, Keren
O'Hara, Ruth
Washington, Donna L.
Yano, Elizabeth M.
Simpson, Tracy L.
TI Posttraumatic Stress Disorder Symptom Severity and Socioeconomic Factors
Associated with Veterans Health Administration Use among Women Veterans
SO WOMENS HEALTH ISSUES
LA English
DT Article
ID FEMALE VETERANS; PTSD RISK; CARE; VALIDITY; SAMPLE; RELIABILITY;
DEPRESSION; PROJECT; NEED
AB Background: The Veterans Health Administration (VA) has historically focused on treating men. Although women veterans' VA use is increasing, they remain more likely than male veterans to receive their care in non-VA settings. To date, there is limited research on factors associated with VA use among women. We examined the relationship between demographic, civilian, military, and health-related variables with past-year VA use among women veterans.
Methods: Women veterans were recruited over the internet to participate in an anonymous national survey (n = 617) in 2013. An empirically derived decision tree was computed using signal detection software for iterative receiver operator characteristics (ROC) to identify variables with the best sensitivity/specificity balance associated with past-year VA use.
Results: ROC analysis indicated that 85% of participants with high posttraumatic stress disorder (PTSD) and depressive symptoms and who were younger than 54 years of age used VA in the past year. Of those who were 54 years of age or older and had very high PTSD symptoms, 94% used the VA in the last year. By contrast, only 40% of participants with relatively lower PTSD symptoms had VA past-year use, although among these individuals, VA past-year use increased to 65% for those with a relatively lower income.
Conclusions: Findings suggest that greater PTSD symptoms, depressive symptoms, and low income correlate with VA use, with very high PTSD symptoms in older groups, high PTSD symptoms coupled with high depressive symptoms in younger groups, and low income in those with lower PTSD symptoms each associated with greater past-year VA use. Ensuring PTSD assessment and treatment, and addressing socioeconomic factors, may be key strategies for health care delivered directly or through contract with VA facilities. Published by Elsevier Inc.
C1 [Lehavot, Keren] VA Puget Sound Hlth Care Syst, HSR&D, Ctr Innovat COIN, Seattle, WA 98108 USA.
[Lehavot, Keren; Simpson, Tracy L.] VA Puget Sound Hlth Care Syst, MIRECC, Seattle, WA 98108 USA.
[Lehavot, Keren; Simpson, Tracy L.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[O'Hara, Ruth] Palo Alto VA Hlth Care Syst, Sierra Pacific Mental Illness Res Educ & Clin Ctr, Palo Alto, CA USA.
[O'Hara, Ruth] Stanford Univ, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA.
[Washington, Donna L.; Yano, Elizabeth M.] VA Greater Los Angeles Healthcare Syst, VA Hlth Serv Res & Dev HSR&D, Ctr Study Healthcare Innovat Implementat & Policy, Sepulveda, CA USA.
[Washington, Donna L.; Yano, Elizabeth M.] VA Greater Los Angeles Healthcare Syst, VA Hlth Serv Res & Dev HSR&D, Ctr Study Healthcare Innovat Implementat & Policy, Los Angeles, CA USA.
[Washington, Donna L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Yano, Elizabeth M.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA.
[Simpson, Tracy L.] VA Puget Sound Hlth Care Syst, CESATE, Seattle, WA 98108 USA.
RP Lehavot, K (reprint author), VA Puget Sound Hlth Care Syst, 116-POC,1660 S Columbian Way, Seattle, WA 98108 USA.
EM klehavot@uw.edu
FU VISN-20 Mental Illness Research, Education, and Clinical Center
(MIRECC); VA CSR&D Career Development Award [IK2 CX000867]; VA HSR&D
Service Senior Research Career Scientist award [RCS 05-195]
FX This research was supported by a research grant to Drs. Lehavot and
Simpson from the VISN-20 Mental Illness Research, Education, and
Clinical Center (MIRECC). Dr. Lehavot's effort was supported by a VA
CSR&D Career Development Award (IK2 CX000867) and Dr. Yano's effort was
supported by a VA HSR&D Service Senior Research Career Scientist award
(Project # RCS 05-195).
NR 40
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1049-3867
EI 1878-4321
J9 WOMEN HEALTH ISS
JI Womens Health Iss.
PD SEP-OCT
PY 2015
VL 25
IS 5
BP 535
EP 541
DI 10.1016/j.whi.2015.05.003
PG 7
WC Public, Environmental & Occupational Health; Women's Studies
SC Public, Environmental & Occupational Health; Women's Studies
GA CR1CM
UT WOS:000361060400016
PM 26123641
ER
PT J
AU Callegari, LS
Borrero, S
Reiber, GE
Nelson, KM
Zephyrin, L
Sayre, GG
Katon, JG
AF Callegari, Lisa S.
Borrero, Sonya
Reiber, Gayle E.
Nelson, Karin M.
Zephyrin, Laurie
Sayre, George G.
Katon, Jodie G.
TI Reproductive Life Planning in Primary Care: A Qualitative Study of Women
Veterans' Perceptions
SO WOMENS HEALTH ISSUES
LA English
DT Article
ID SHARED DECISION-MAKING; VA HEALTH-CARE; UNITED-STATES; PRECONCEPTION
HEALTH; PREFERENCES; RECOMMENDATIONS; CONTRACEPTION; EXPERIENCES;
PREGNANCY; MILITARY
AB Background: Women veterans using Veterans Administration (VA) health care have high rates of medical and mental health comorbidities, placing them at increased risk of poor outcomes from unplanned pregnancy. Reproductive life planning is a strategy recommended by the U.S. Centers of Disease Control and Prevention that could promote healthy pregnancies and reduce unplanned pregnancy in the VA. However, no data exist on women veterans' perceptions of reproductive life planning discussions.
Methods: We trained six VA primary care physicians at two VA Women's Health Clinics to conduct reproductive life planning discussions with veterans aged 18 to 44 during primary care visits. After the visit, we performed semi-structured telephone interviews with consenting veterans to explore perceptions of 1) reproductive life planning content and 2) provider-patient communication in reproductive life planning discussions. Interviews were audio-recorded, transcribed, and analyzed using content analysis.
Results: We interviewed 27 veterans with a mean age of 31 years (range, 22-42). Women veterans perceived generally reproductive life planning discussions as important opportunities to discuss reproductive goals with providers and to obtain new and relevant information about contraception, planning healthy pregnancies, and available VA reproductive health services. Perceptions of reproductive life planning content were influenced by women's pregnancy intentions. Perceptions related to provider-patient communication included preferences for provider-initiated discussions and nonjudgmental counseling that incorporates patients' values and preferences.
Conclusions: Women veterans perceived reproductive life planning as valuable and important to their health. Reproductive life planning has the potential to enhance patient-centered delivery of reproductive health services in VA primary care. Published by Elsevier Inc.
C1 [Callegari, Lisa S.; Reiber, Gayle E.; Nelson, Karin M.; Sayre, George G.; Katon, Jodie G.] Dept Vet Affairs VA Puget Sound Hlth Care Syst Hl, Seattle, WA USA.
[Callegari, Lisa S.] Univ Washington, Sch Med, Dept Obstet & Gynecol, Seattle, WA 98195 USA.
[Borrero, Sonya] VA Pittsburgh Hlth Care Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Borrero, Sonya] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA.
[Reiber, Gayle E.] Univ Washington, Dept Epidemiol, Sch Publ Hlth, Seattle, WA 98195 USA.
[Reiber, Gayle E.; Nelson, Karin M.; Sayre, George G.; Katon, Jodie G.] Univ Washington, Dept Hlth Serv, Sch Publ Hlth, Seattle, WA 98195 USA.
[Nelson, Karin M.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
[Zephyrin, Laurie] Womens Hlth Serv, VA Off Patient Care Serv, Washington, DC USA.
[Zephyrin, Laurie] NYU, Dept Obstet & Gynecol, Langone Sch Med, New York, NY 10016 USA.
RP Callegari, LS (reprint author), VA Puget Sound Hlth Care Syst, Seattle HSR&D Ctr, 1660 S Columbian Way S-152, Seattle, WA 98108 USA.
EM lisa.callegari@va.gov
FU Department of Veterans Affairs (VA) National Office of Patient Care
Services, Office of Women's Health and Office of Public Health; VA
Health Services Research and Development Postdoctoral Fellowship [TPM
61-041]
FX The authors acknowledge Marie Lutton for her assistance with patient
recruitment, interviewing, and data management. The authors also
acknowledge the generous VA clinicians and veterans who donated their
time to participate in the project. This study was supported by a
quality improvement grant from the Department of Veterans Affairs (VA)
National Office of Patient Care Services, Office of Women's Health and
Office of Public Health. L.S.C. was supported by a VA Health Services
Research and Development Postdoctoral Fellowship (TPM 61-041).
NR 36
TC 3
Z9 3
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1049-3867
EI 1878-4321
J9 WOMEN HEALTH ISS
JI Womens Health Iss.
PD SEP-OCT
PY 2015
VL 25
IS 5
BP 548
EP 554
DI 10.1016/j.whi.2015.05.002
PG 7
WC Public, Environmental & Occupational Health; Women's Studies
SC Public, Environmental & Occupational Health; Women's Studies
GA CR1CM
UT WOS:000361060400018
PM 26123640
ER
PT J
AU Dichter, ME
Wagner, C
Goldberg, EB
Iverson, KM
AF Dichter, Melissa E.
Wagner, Clara
Goldberg, Erica B.
Iverson, Katherine M.
TI Intimate Partner Violence Detection and Care in the Veterans Health
Administration: Patient and Provider Perspectives
SO WOMENS HEALTH ISSUES
LA English
DT Article
ID WOMEN VETERANS; INTERVENTIONS; COMMUNICATION; DISCLOSURE; FRAMEWORK;
SURVIVORS
AB Background: Women veterans experience high rates of intimate partner violence (IPV), with associated negative health impacts. The Veterans Health Administration (VHA) has recently developed plans to implement routine IPV screening and provide IPV-related follow-up services for VHA patients. Previous research has examined barriers and facilitators to health care provider screening for IPV. The next step is to examine patients' disclosure of IPV experiences to health care providers and effective response to such disclosures. We sought to identify VHA patients' and providers' perspectives on how to facilitate effective IPV detection and care in VHA.
Methods: We conducted semistructured, qualitative interviews with 25 female veteran patients and 15 VHA health care providers. We used an inductive approach to analyzing interview transcripts and identifying themes that constituted study findings.
Results: Themes fell in to two broad categories: 1) barriers to disclosure and 2) barriers to an adequate response to disclosure and providing follow-up care. Barriers to disclosure of IPV to health care providers included lack of provider inquiry, lack of comfort, and concerns about the consequences of disclosure and lack of privacy. Patients and providers both indicated a need for expanded resources to respond to IPV in VHA.
Conclusions: Findings support current plans for IPV program implementation in VHA and point to recommendations for practice and implications for further research. Published by Elsevier Inc.
C1 [Dichter, Melissa E.; Wagner, Clara; Goldberg, Erica B.] VA Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
[Iverson, Katherine M.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA.
[Iverson, Katherine M.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA.
RP Dichter, ME (reprint author), Philadelphia VA Med Ctr, VA Ctr Hlth Equ Res & Promot, 3900 Woodland Ave,Bldg 4100 Annex, Philadelphia, PA 19104 USA.
EM Melissa.Dichter@va.gov
FU Department of Veterans Affairs VISN 4 Center for Evaluation of Patient
Aligned Care Teams [CEPACT 12-005]; Drs. Dichter's and Iverson's VA
Health Services Research and Development (HSR&D) Career Development
Awards [CDA 10-202, CDA 10-029]
FX This research was supported by the Department of Veterans Affairs VISN 4
Center for Evaluation of Patient Aligned Care Teams (CEPACT 12-005; PI:
Dichter) and as part of Drs. Dichter's and Iverson's VA Health Services
Research and Development (HSR&D) Career Development Awards (Dichter: CDA
10-202; Iverson: CDA 10-029).
NR 36
TC 2
Z9 2
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1049-3867
EI 1878-4321
J9 WOMEN HEALTH ISS
JI Womens Health Iss.
PD SEP-OCT
PY 2015
VL 25
IS 5
BP 555
EP 560
DI 10.1016/j.whi.2015.06.006
PG 6
WC Public, Environmental & Occupational Health; Women's Studies
SC Public, Environmental & Occupational Health; Women's Studies
GA CR1CM
UT WOS:000361060400019
PM 26227208
ER
PT J
AU Maezawa, Y
Paltser, G
Tsui, H
Cheung, R
Wu, P
Nicholas, AP
Dosch, HM
AF Maezawa, Y.
Paltser, G.
Tsui, H.
Cheung, R.
Wu, P.
Nicholas, A. P.
Dosch, H. -M.
TI 2-Chloroacetamidine, a novel immunomodulator, suppresses antigen-induced
mouse airway inflammation
SO ALLERGY
LA English
DT Article
DE animal model; asthma; protein citrullination; T cell
ID PEPTIDYLARGININE-DEIMINASE; CITRULLINATED PROTEINS; T-CELLS; ASTHMA;
PATHOGENESIS; INVOLVEMENT; EXPRESSION; APOPTOSIS; RESPONSES; FEATURES
AB BackgroundCitrullination is a presently under-recognized posttranslational protein modification catalyzed by PAD enzymes. Immune responses to citrullinated neo-epitopes are identified in a growing number of inflammatory and autoimmune diseases. However, the involvement of hypercitrullination in the pathogenesis of bronchial asthma is still unknown.
MethodsAs main experimental tool, we examined the effect of 2-chloroacetamidine (2CA), a PAD enzyme inhibitor, on OVA-immunized and airway-challenged BALB/c mice; a commonly used model of allergic airway inflammation. We also measured the effect of 2CA on exvivo lymphocytes and cell lines.
ResultsIn vivo, 2CA dramatically suppressed lung tissue hypercitrullination, inflammatory cell recruitment, and airway-Th2 cytokine secretion. 2CA also suppressed systemic OVA-specific and total IgE production dramatically, effectively preventing de novo and diminishing established disease without measurably impacting general immunocompetence. In vitro, 2CA markedly inhibited the proliferation of mouse and human T cells with cell cycle block and apoptosis during a limited, postactivation phase.
Conclusions2CA acts as narrow-spectrum immunosuppressant that selectively targets lymphocyte populations involved in active inflammatory tissue lesions. If hypercitrullination is generated in patients with asthma, 2CA may represent a novel disease modulator for human asthmatics/allergic diseases.
C1 [Maezawa, Y.; Paltser, G.; Tsui, H.; Cheung, R.; Wu, P.; Dosch, H. -M.] Univ Toronto, Hosp Sick Children, Res Inst, Neurosci & Mental Hlth, Toronto, ON M5G 1X8, Canada.
[Nicholas, A. P.] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA.
[Nicholas, A. P.] Univ Alabama Birmingham, Ctr Neuroimmunol, Birmingham, AL USA.
[Nicholas, A. P.] Birmingham VA Med Ctr, Birmingham, AL USA.
RP Dosch, HM (reprint author), Univ Toronto, Hosp Sick Children, NMH Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.
EM michael.dosch@me.com
NR 25
TC 0
Z9 0
U1 2
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD SEP
PY 2015
VL 70
IS 9
BP 1130
EP 1138
DI 10.1111/all.12651
PG 9
WC Allergy; Immunology
SC Allergy; Immunology
GA CQ2QW
UT WOS:000360447200011
PM 25969859
ER
PT J
AU Meara, JG
Leather, AJM
Hagander, L
Alkire, BC
Alonso, N
Ameh, EA
Bickler, SW
Conteh, L
Dare, AJ
Davies, J
Merisier, ED
El-Halabi, S
Farmer, PE
Gawande, A
Gillies, R
Greenberg, SLM
Grimes, CE
Gruen, RL
Ismail, EA
Kamara, TB
Lavy, C
Lundeg, G
Mkandawire, NC
Raykar, NP
Riesel, JN
Rodas, E
Rose, J
Roy, N
Shrime, MG
Sullivan, R
Verguet, S
Watters, D
Weiser, TG
Wilson, IH
Yamey, G
Yip, W
AF Meara, John G.
Leather, Andrew J. M.
Hagander, Lars
Alkire, Blake C.
Alonso, Nivaldo
Ameh, Emmanuel A.
Bickler, Stephen W.
Conteh, Lesong
Dare, Anna J.
Davies, Justine
Merisier, Eunice Derivois
El-Halabi, Shenaaz
Farmer, Paul E.
Gawande, Atul
Gillies, Rowan
Greenberg, Sarah L. M.
Grimes, Caris E.
Gruen, Russell L.
Ismail, Edna Adan
Kamara, Thaim Buya
Lavy, Chris
Lundeg, Ganbold
Mkandawire, Nyengo C.
Raykar, Nakul P.
Riesel, Johanna N.
Rodas, Edgar
Rose, John
Roy, Nobhojit
Shrime, Mark G.
Sullivan, Richard
Verguet, Stephane
Watters, David
Weiser, Thomas G.
Wilson, Iain H.
Yamey, Gavin
Yip, Winnie
TI Global Surgery 2030: evidence and solutions for achieving health,
welfare, and economic development
SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
LA English
DT Article
C1 [Meara, John G.; Greenberg, Sarah L. M.; Raykar, Nakul P.; Riesel, Johanna N.] Harvard Univ, Sch Med, Boston Childrens Hosp, Program Global Surg & Social Change,Dept Global H, Boston, MA 02163 USA.
[Shrime, Mark G.] Harvard Univ, Sch Med, Boston Childrens Hosp, Dept Otol & Laryngol, Boston, MA USA.
[Meara, John G.; Greenberg, Sarah L. M.; Raykar, Nakul P.; Riesel, Johanna N.] Harvard Univ, Sch Med, Boston Childrens Hosp, Boston, MA USA.
[Alkire, Blake C.] Harvard Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Boston, MA USA.
[Shrime, Mark G.] Harvard Univ, Sch Med, Off Global Surg, Boston, MA USA.
[Farmer, Paul E.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Global Hlth & Social Med,Div Global Hlth Equ, Boston, MA USA.
[Farmer, Paul E.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Farmer, Paul E.] Partners Hlth, Boston, MA USA.
[Gawande, Atul; Rose, John] Brigham & Womens Hosp, Ctr Surg & Publ Hlth, Boston, MA 02115 USA.
[Gawande, Atul] Harvard Univ, TH Chan Sch Publ Hlth, Ariadne Labs, Boston, MA 02115 USA.
[Raykar, Nakul P.] Harvard Univ, Beth Israel Deaconess Med Ctr, Dept Surg, TH Chan Sch Publ Hlth, Boston, MA 02215 USA.
[Riesel, Johanna N.] Harvard Univ, Massachusetts Gen Hosp, Dept Surg, TH Chan Sch Publ Hlth, Boston, MA 02115 USA.
[Verguet, Stephane] Harvard Univ, TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA.
[Leather, Andrew J. M.; Dare, Anna J.; Grimes, Caris E.] Kings Hlth Partners, Kings Ctr Global Hlth, London, England.
[Leather, Andrew J. M.; Dare, Anna J.; Grimes, Caris E.] Kings Coll London, London WC2R 2LS, England.
[Conteh, Lesong] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, London, England.
[Davies, Justine] The Lancet, London, England.
[Sullivan, Richard] Kings Coll London, Kings Ctr Global Hlth, Kings Hlth Partners Integrated Canc Ctr, Inst Canc Policy, London WC2R 2LS, England.
[Hagander, Lars] Lund Univ, Clin Sci Lund, Dept Pediat, Pediat Surg & Global Pediat, Lund, Sweden.
[Alonso, Nivaldo] Univ Sao Paulo, Dept Plast Surg, Sao Paulo, Brazil.
[Ameh, Emmanuel A.] Natl Hosp, Dept Surg, Div Peadiatr Surg, Abuja, Nigeria.
[Bickler, Stephen W.] Rady Childrens Hosp, San Diego, CA USA.
[Rose, John] Univ Calif San Diego, Dept Surg, San Diego, CA 92103 USA.
[Merisier, Eunice Derivois] Dept Minist Hlth, Gressier, Ouest, Haiti.
[El-Halabi, Shenaaz] Minist Hlth, Gaborone, Botswana.
[Gillies, Rowan] Royal N Shore Hosp, St Leonards, NSW 2065, Australia.
[Greenberg, Sarah L. M.] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Gruen, Russell L.] Alfred Hosp, Melbourne, Vic, Australia.
[Gruen, Russell L.] Monash Univ, Melbourne, Vic 3004, Australia.
[Gruen, Russell L.] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore 639798, Singapore.
[Watters, David] Royal Australasian Coll Surg, East Melbourne, Vic, Australia.
[Watters, David] Deakin Univ, Melbourne, Vic, Australia.
[Ismail, Edna Adan] Edna Adan Univ Hosp, Hargeisa, Somaliland, England.
[Kamara, Thaim Buya] Connaught Hosp, Freetown, Sierra Leone.
[Lavy, Chris] Univ Oxford, Dept Orthopaed Rheumatol & Musculoskeletal Sci, Oxford, England.
[Yip, Winnie] Univ Oxford, Blavatnik Sch Govt, Oxford, England.
[Lundeg, Ganbold] Mongolian Natl Univ Med Sci, Ulaanbaatar, Mongol Peo Rep.
[Mkandawire, Nyengo C.] Univ Malawi, Coll Med, Dept Surg, Blantyre, Malawi.
[Mkandawire, Nyengo C.] Flinders Univ S Australia, Sch Med, Adelaide, SA 5001, Australia.
[Rodas, Edgar] Univ Cuenca, Cinterandes Fdn, Cuenca, Ecuador.
[Rodas, Edgar] Univ Azuay, Cuenca, Ecuador.
[Roy, Nobhojit] BARC Hosp, Bombay, Maharashtra, India.
[Shrime, Mark G.] Harvard Interfac Initiat Hlth Policy, Cambridge, MA USA.
[Weiser, Thomas G.] Stanford Univ, Sch Med, Dept Surg, Stanford, CA 94305 USA.
[Wilson, Iain H.] Royal Devon & Exeter Natl Hlth Serv Fdn Trust, Dept Anaesthesia, Exeter, Devon, England.
[Yamey, Gavin] Univ Calif San Francisco, Global Hlth Grp, Evidence Policy Initiat, San Francisco, CA 94143 USA.
RP Meara, JG (reprint author), Harvard Univ, Sch Med, Boston Childrens Hosp, Program Global Surg & Social Change,Dept Global H, Boston, MA 02163 USA.
EM john.meara@childrens.harvard.edu
NR 1
TC 0
Z9 0
U1 3
U2 7
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9378
EI 1097-6868
J9 AM J OBSTET GYNECOL
JI Am. J. Obstet. Gynecol.
PD SEP
PY 2015
VL 213
IS 3
BP 338
EP 340
DI 10.1016/j.ajog.2015.04.010
PG 3
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA CQ4CL
UT WOS:000360551700011
PM 25985722
ER
PT J
AU Creanga, AA
Bateman, BT
Butwick, AJ
Raleigh, L
Maeda, A
Kuklina, E
Callaghan, WM
AF Creanga, Andreea A.
Bateman, Brian T.
Butwick, Alexander J.
Raleigh, Lindsay
Maeda, Ayumi
Kuklina, Elena
Callaghan, William M.
TI Morbidity associated with cesarean delivery in the United States: is
placenta accreta an increasingly important contributor?
SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
LA English
DT Article
DE cesarean delivery; United States
ID MATERNAL MORBIDITY; ABNORMAL PLACENTATION; HYSTERECTOMY; COMPLICATIONS;
MORTALITY; OUTCOMES; TERM
AB OBJECTIVE: The purpose of this study was to examine cesarean delivery morbidity and its predictors in the United States.
STUDY DESIGN: We used 2000-2011 Nationwide Inpatient Sample data to identify cesarean deliveries and records with 12 potential cesarean delivery complications, including placenta accreta. We estimated cesarean delivery morbidity rates and rate changes from 2000-2011, and fitted Poisson regression models to assess the relative incidence of morbidity among repeat vs primary cesarean deliveries and explore its predictors.
RESULTS: From 2000-2011, 76 in 1000 cesarean deliveries (97 in 1000 primary and 48 in 1000 repeat cesarean deliveries) were accompanied by >= 1 of 12 complications. The unadjusted composite cesarean delivery morbidity rate increased by 3.6% only among women with a primary cesarean delivery (P < .001); the unadjusted rate of placenta accreta increased by 30.8% only among women with a repeat cesarean deliveries (P = .025). The adjusted rate of overall composite cesarean delivery morbidity decreased by 1% annually from 2000-2011 (P < .001). Compared with women with a primary cesarean delivery, those women who underwent a repeat cesarean delivery were one-half as likely (incidence rate ratio, 0.50; 95% CI, 0.49-0.50) to experience a complication, but 2.13 (95% CI, 1.98-2.29) times more likely to have a placenta accreta diagnosis. Both cesarean delivery morbidity and placenta accreta were positively associated with age >30 years, non-Hispanic black race/ethnicity, the presence of a chronic medical condition, and delivery in urban, teaching, or larger hospitals.
CONCLUSION: Overall, cesarean delivery morbidity declined modestly from 2000-2011, but placenta accreta became an increasingly important contributor to repeat cesarean delivery morbidity. Clinicians should maintain a high index of suspicion for abnormal placentation and make adequate preparations for patients who need cesarean deliveries.
C1 [Creanga, Andreea A.; Kuklina, Elena; Callaghan, William M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30329 USA.
[Bateman, Brian T.] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA.
[Bateman, Brian T.] Harvard Univ, Sch Med, Boston, MA USA.
[Bateman, Brian T.; Maeda, Ayumi] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesiol Crit Care & Pain Med, Boston, MA USA.
[Butwick, Alexander J.; Raleigh, Lindsay] Stanford Univ, Sch Med, Dept Anesthesia, Stanford, CA 94305 USA.
RP Creanga, AA (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30329 USA.
EM acreanga@cdc.gov
OI Butwick, Alexander/0000-0002-2048-0879
NR 29
TC 6
Z9 6
U1 0
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9378
EI 1097-6868
J9 AM J OBSTET GYNECOL
JI Am. J. Obstet. Gynecol.
PD SEP
PY 2015
VL 213
IS 3
AR 384.e1
DI 10.1016/j.ajog.2015.05.002
PG 11
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA CQ4CL
UT WOS:000360551700027
PM 25957019
ER
PT J
AU Pilliod, RA
Page, JM
Burwick, RM
Kaimal, AJ
Cheng, YW
Caughey, AB
AF Pilliod, Rachel A.
Page, Jessica M.
Burwick, Richard M.
Kaimal, Anjali J.
Cheng, Yvonne W.
Caughey, Aaron B.
TI The risk of fetal death in nonanomalous pregnancies affected by
polyhydramnios
SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
LA English
DT Article; Proceedings Paper
CT 35th Annual Scientific Pregnancy Meeting of the
Society-for-Maternal-Fetal-Medicine (SMFM)
CY FEB 02-07, 2015
CL San Diego, CA
SP Soc Maternal Fetal Med
DE antenatal testing; intrauterine fetal demise; polyhydramnios; stillbirth
ID HYDRAMNIOS
AB OBJECTIVE: The objective of the study was to evaluate the ongoing risk of intrauterine fetal demise (IUFD) in nonanomalous pregnancies affected by polyhydramnios.
STUDY DESIGN: We analyzed a retrospective cohort of all singleton, nonanomalous births in California between 2005 and 2008 as recorded in a statewide birth certificate registry. We included all births between 24+0 and 41+6 weeks' gestational age, excluding multiple gestations, major congenital anomalies, and pregnancies affected by oligohydramnios. Polyhydramnios was identified by International Classification of Diseases, ninth revision, codes. chi(2) tests were used to compare the dichotomous outcomes, and multivariable logistic regression analyses were then performed to control for potential confounders. We analyzed the data for pregnancies affected and unaffected by polyhydramnios. The IUFD risk was expressed as a rate per 10,000.
RESULTS: The risk of IUFD in pregnancies affected by polyhydramnios was greater at every gestational age compared with unaffected pregnancies. The IUFD risk in pregnancies affected by polyhydramnios was more than 7 times higher than unaffected pregnancies at 37 weeks at a rate of 18.0 (95% confidence interval [CI], 9.0-32.6) vs 2.4 (95% CI, 2.0-2.5) and was 11-fold higher by 40 weeks' gestational age at a rate of 66.3 (95% CI, 10.8-68.6) vs 6.0 (95% CI, 5.1-6.3) in unaffected pregnancies. When adjusted for multiple confounding variables, the presence of polyhydramnios remained associated with an increased odds of IUFD in nonanomalous singleton pregnancies, with an adjusted odds ratio of 5.5 (95% CI, 4.1-7.6).
CONCLUSION: Ongoing risk of IUFD is greater in low-risk pregnancies affected by polyhydramnios at all gestational ages compared with unaffected pregnancies with the greatest increase in risk at term. Although further study is needed to explore the underlying etiology of polyhydramnios in these cases, the identification of polyhydramnios alone may warrant increased antenatal surveillance.
C1 [Pilliod, Rachel A.] Brigham & Womens Hosp, Dept Obstet & Gynecol, Boston, MA 02115 USA.
[Kaimal, Anjali J.] Massachusetts Gen Hosp, Div Maternal Fetal Med, Dept Obstet & Gynecol, Boston, MA 02114 USA.
[Page, Jessica M.] Univ Utah, Sch Med, Dept Obstet & Gynecol, Salt Lake City, UT 84132 USA.
[Burwick, Richard M.; Caughey, Aaron B.] Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Div Maternal Fetal Med, Portland, OR 97201 USA.
[Cheng, Yvonne W.] Univ Calif Davis, Div Maternal Fetal Med, Dept Obstet & Gynecol, Sch Med, Sacramento, CA 95817 USA.
RP Pilliod, RA (reprint author), Brigham & Womens Hosp, Dept Obstet & Gynecol, 75 Francis St, Boston, MA 02115 USA.
EM rpilliod@partners.org
NR 17
TC 1
Z9 1
U1 2
U2 6
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9378
EI 1097-6868
J9 AM J OBSTET GYNECOL
JI Am. J. Obstet. Gynecol.
PD SEP
PY 2015
VL 213
IS 3
AR 410.e1
DI 10.1016/j.ajog.2015.05.022
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA CQ4CL
UT WOS:000360551700041
PM 25981851
ER
PT J
AU Kao, CS
Cornejo, KM
Ulbright, TM
Young, RH
AF Kao, Chia-Sui
Cornejo, Kristine M.
Ulbright, Thomas M.
Young, Robert H.
TI Juvenile Granulosa Cell Tumors of the Testis A Clinicopathologic Study
of 70 Cases With Emphasis on Its Wide Morphologic Spectrum
SO AMERICAN JOURNAL OF SURGICAL PATHOLOGY
LA English
DT Article
DE testis; juvenile granulosa cell tumor; sex cord-stromal tumor; infants;
immunohistochemistry
ID CORD-STROMAL TUMORS; PREPUBERTAL TESTICULAR-TUMORS; CLINICAL BEHAVIOR;
INFANTILE TESTIS; DIAGNOSIS; CHILDREN; REGISTRY; FOXL2; DIFFERENTIATION;
MANAGEMENT
AB The clinical and pathologic features of 70 juvenile granulosa cell tumors (JGCTs) of the testis are presented. The patients were from 30 weeks gestational age to 10 years old; 60 of 67 (90%) whose ages are known to us were 6 months old or younger. Sixty-two underwent gonadectomy, 6 wedge excision, and 2 only biopsy. Twenty-six tumors were left sided and 22 right sided. Six occurred in an undescended testis and 2 in dysgenetic gonads. The most common presentation was a testicular mass (65%), followed by an enlarging testis (25%). Six of 14 patients in whom it was measured had elevated serum -fetoprotein (AFP), likely physiologically, and 1 had gynecomastia. The tumors measured 0.5 to 5 cm (mean, 1.7 cm; median, 1.5 cm) and were most commonly well circumscribed and typically yellow-tan; approximately 2/3 had a cystic component, whereas 1/3 were entirely solid. Microscopic examination typically showed a lobular growth, punctuated in 67 cases by variably sized and shaped follicles containing material that was basophilic (21%), eosinophilic (44%), or of both characters (35%); 3 lacked follicles. In nonfollicular areas, the tumor cells typically grew diffusely but occasionally had a corded arrangement (26%) or reticular appearance (29%). The stroma was either fibrous or fibromyxoid; hemorrhage associated with hemosiderin-laden macrophages was focally seen in 16%. The tumor cells were mostly small to medium sized with round to oval nuclei containing inconspicuous nucleoli and moderate to abundant, but occasionally scant, pale to lightly eosinophilic, sometimes vacuolated, cytoplasm; nuclear grooves were infrequent (6%). Focal columnar morphology was seen in 27% of the tumors. Mitoses were plentiful in 37%, and apoptosis was prominent in 46%. Intratubular tumor was seen in 43% and entrapped seminiferous tubules in 70%. Lymphovascular invasion was present in 2 cases, rete testis involvement in 4, and necrosis in 1. Rare features/patterns included: regressed tumor with hyalinization and prominent blood vessels (13%), papillary growth (4%), basaloid morphology (1%), spindle cell predominance (1%), microcystic foci (1%), adult granulosa cell-like (1%) patterns, and hyaline globules (1%). Inhibin (16/18), calretinin (8/9), WT1 (6/7), FOXL2 (12/12), SF-1 (12/12), and SOX9 (6/11) were positive, whereas SALL4 and glypican-3 were consistently negative in the neoplastic granulosa cells. Only 1 of 10 tumors was focally positive for -fetoprotein. JGCT is a rare neoplasm with a wide morphologic spectrum that also occurs rarely in undescended testes and dysgenetic gonads. The solid and reticular patterns may pose diagnostic challenges, but the lobular appearance and follicular differentiation are characteristic. Immunohistochemical stains may aid in its distinction from other tumors of young male individuals, particularly yolk sac tumor, a neoplasm that peaks at a somewhat later age. Twenty-four patients with follow-up, including 4 of 6 patients treated with wedge resection/biopsy, had no evidence of disease (2 to 348 mo; mean, 83 mo; median, 61 mo). One additional patient was alive at 260 months, but the disease status is unknown. The benign clinical course of all cases of JGCT with follow-up, despite often frequent mitotic activity, supports testis sparing surgery when technically feasible.
C1 [Kao, Chia-Sui; Cornejo, Kristine M.; Young, Robert H.] Massachusetts Gen Hosp, James Homer Wright Pathol Labs, Boston, MA 02114 USA.
[Kao, Chia-Sui; Cornejo, Kristine M.; Young, Robert H.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Ulbright, Thomas M.] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA.
RP Young, RH (reprint author), Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St,Warren 215, Boston, MA 02114 USA.
EM rhyoung@partners.org
NR 37
TC 3
Z9 3
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0147-5185
EI 1532-0979
J9 AM J SURG PATHOL
JI Am. J. Surg. Pathol.
PD SEP
PY 2015
VL 39
IS 9
BP 1159
EP 1169
DI 10.1097/PAS.0000000000000450
PG 11
WC Pathology; Surgery
SC Pathology; Surgery
GA CQ4QP
UT WOS:000360590000001
PM 26076062
ER
PT J
AU Khor, TS
Lauwers, GY
Odze, RD
Srivastava, A
AF Khor, Tze S.
Lauwers, Gregory Y.
Odze, Robert D.
Srivastava, Amitabh
TI "Mass-forming" Variant of Ischemic Colitis Is A Distinct Entity With
Predilection for the Proximal Colon
SO AMERICAN JOURNAL OF SURGICAL PATHOLOGY
LA English
DT Article
DE ischemia; colon; colitis; carcinoma; malignancy
ID CARCINOMA; PATTERNS; OUTCOMES; CANCER
AB We systematically evaluated the clinicopathologic features and outcome of a rare, unusual variant of ischemic colitis that presents as a mass lesion mimicking malignancy on imaging or colonoscopy. A retrospective search was performed for cases with a histologic diagnosis of ischemic colitis and a clinical impression of malignancy. Of the 23 patients initially identified, 4 were excluded because clinical and histologic review showed mucosal prolapse (n=1), discrete colon polyp (n=2), and a diverticular mass (n=1) without concern for malignancy. The mass-forming variant of ischemic colitis (n=19) was seen predominantly in elderly (mean age 71.8 y) women (63.2%) with a striking predilection for the right colon (13/19), particularly the cecum (n=6). Abdominal pain (52.6%) and hematochezia (26.3%) were the most common presenting symptoms. A computed tomography scan showed segmental thickening suspicious for malignancy in 6/8 patients. Colonoscopy revealed an exophytic (n=16) or stricturing (n=3) mass with a mean size of 4.67 cm. Mucosal biopsies showed features typical for ischemic colitis in all cases. A colectomy was performed in 4 cases. In 2, the mass-like appearance was due to marked submucosal and mural edema, whereas in the other 2 cases, with a malignant stricture-like lesion, marked submucosal fibrosis and cholesterol emboli were present. No malignancy was identified on follow-up in any patient (mean 39.9 mo). Follow-up colonoscopy was performed in 7 patients 1 to 32 weeks after initial presentation and showed resolution of the mass in all cases. Awareness of this rare variant of ischemic colitis will prevent unnecessary resections in these patients.
C1 [Khor, Tze S.] PathWest Lab Med, Dept Anat Pathol, Nedlands, WA, Australia.
[Lauwers, Gregory Y.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Odze, Robert D.; Srivastava, Amitabh] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
RP Srivastava, A (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.
EM asrivastava@partners.org
FU A&A Saw Medical Research Fellowship from the University of Western
Australia, WA, Australia
FX T.S.K. was supported by an A&A Saw Medical Research Fellowship from the
University of Western Australia, WA, Australia. The authors have
disclosed that they have no significant relationships with, or financial
interest in, any commercial companies pertaining to this article.
NR 26
TC 1
Z9 1
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0147-5185
EI 1532-0979
J9 AM J SURG PATHOL
JI Am. J. Surg. Pathol.
PD SEP
PY 2015
VL 39
IS 9
BP 1275
EP 1281
DI 10.1097/PAS.0000000000000438
PG 7
WC Pathology; Surgery
SC Pathology; Surgery
GA CQ4QP
UT WOS:000360590000014
PM 26034865
ER
PT J
AU Shih, A
Lauwers, GY
Balabaud, C
Bioulac-Sage, P
Misdraji, J
AF Shih, Angela
Lauwers, Gregory Y.
Balabaud, Charles
Bioulac-Sage, Paulette
Misdraji, Joseph
TI Simultaneous Occurrence of Focal Nodular Hyperplasia and
HNF1A-inactivated Hepatocellular Adenoma A Collision Tumor Simulating a
Composite FNH-HCA
SO AMERICAN JOURNAL OF SURGICAL PATHOLOGY
LA English
DT Article
DE liver; mixed tumor; collision tumor; focal nodular hyperplasia;
hepatocellular adenoma
ID ORAL-CONTRACEPTIVES; SUBTYPE CLASSIFICATION; GLUTAMINE-SYNTHETASE; LIVER
ADENOMA; CARCINOMA; INACTIVATION; ASSOCIATION; EXPRESSION; VARIANT
AB Mixed focal nodular hyperplasia (FNH) and hepatocellular adenoma (HCA) within a single tumor mass is rarely reported, and most of these cases are examples of tumors with features intermediate between FNH and HCA. Although a few reported cases are probably examples of true mixed tumors, none was evaluated immunohistochemically or confirmed by molecular analysis. We report a mixed FNH and HCA arising in a woman with several HNF1A-inactivated adenomas. Our case is the first case of mixed FNH and HNF1A-inactivated HCA documented by immunohistochemistry.
C1 [Shih, Angela; Lauwers, Gregory Y.; Misdraji, Joseph] Harvard Univ, Massachusetts Gen Hosp, Sch Med, James Homer Wright Pathol Labs, Boston, MA USA.
[Balabaud, Charles; Bioulac-Sage, Paulette] Univ Bordeaux, INSERM, U1053, Bordeaux, France.
[Bioulac-Sage, Paulette] CHU Bordeaux, Pellegrin Hosp, Dept Pathol, Bordeaux, France.
RP Misdraji, J (reprint author), Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St,Warren Bldg 105, Boston, MA 02114 USA.
EM jmisdraji@partners.org
NR 31
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0147-5185
EI 1532-0979
J9 AM J SURG PATHOL
JI Am. J. Surg. Pathol.
PD SEP
PY 2015
VL 39
IS 9
BP 1296
EP 1300
DI 10.1097/PAS.0000000000000477
PG 5
WC Pathology; Surgery
SC Pathology; Surgery
GA CQ4QP
UT WOS:000360590000017
PM 26274031
ER
PT J
AU Nanji, KC
Orser, BA
AF Nanji, Karen C.
Orser, Beverley A.
TI Managing Ebola: Lessons Learned from the SARS Epidemic
SO ANESTHESIA AND ANALGESIA
LA English
DT Letter
C1 [Nanji, Karen C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med,Dept Anaesth, Boston, MA 02115 USA.
[Orser, Beverley A.] Sunnybrook Hlth Sci Ctr, Dept Anesthesia, Toronto, ON M4N 3M5, Canada.
[Orser, Beverley A.] Univ Toronto, Dept Anesthesia, Toronto, ON, Canada.
RP Nanji, KC (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med,Dept Anaesth, Boston, MA 02115 USA.
EM knanji@partners.org
NR 3
TC 0
Z9 0
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD SEP
PY 2015
VL 121
IS 3
BP 834
EP 835
DI 10.1213/ANE.0000000000000748
PG 2
WC Anesthesiology
SC Anesthesiology
GA CQ1MA
UT WOS:000360360600008
PM 26287305
ER
PT J
AU Zhang, Q
Gray, PJ
AF Zhang, Qing
Gray, Phillip J.
TI From bench to bedside: bipolar androgen therapy in a pilot clinical
study
SO ASIAN JOURNAL OF ANDROLOGY
LA English
DT Editorial Material
ID METASTATIC PROSTATE-CANCER; CASTRATION; ENZALUTAMIDE; CHEMOTHERAPY;
RECEPTOR
AB Prostate cancer remains a leading cause of cancer death in Europe and the United States and is an emerging problem in Asia despite significant improvements in available treatments over the last few decades. Androgen deprivation therapy (ADT) has been the core treatment of advance-staged disease since the discovery of prostate cancer's androgen dependence in 1941 by Huggins et al.(1) Options for initial medical treatment include gonadotropin-releasing hormone analogues such as leuprolide (LHRH agonist) and degarelix (LHRH antagonist) and androgen receptor (AR) binding agents such as bicalutamide. Although most patients will initially respond to either surgical or medical castration, there is almost always progression to castration-resistant prostate cancer (CRPC) necessitating treatment with more novel agents.(2) However, even drugs such as abiraterone and enzalutamide, two next-generation agents used commonly in metastatic CRPC, have failed to demonstrate persistent efficacy in most patients.(3,4)
C1 [Zhang, Qing] Singapore Gen Hosp, Dept Internal Med, Singapore, Singapore.
[Gray, Phillip J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA 02115 USA.
RP Gray, PJ (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA 02115 USA.
EM pjgray@partners.org
NR 13
TC 1
Z9 1
U1 1
U2 2
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
INDIA
SN 1008-682X
EI 1745-7262
J9 ASIAN J ANDROL
JI Asian J. Androl.
PD SEP-OCT
PY 2015
VL 17
IS 5
BP 767
EP 768
DI 10.4103/1008-682X.151390
PG 2
WC Andrology; Urology & Nephrology
SC Endocrinology & Metabolism; Urology & Nephrology
GA CQ5FN
UT WOS:000360628800016
PM 25814159
ER
PT J
AU Zhao, JY
An, Q
Goldberg, J
Quyyumi, AA
Vaccarino, V
AF Zhao, Jinying
An, Qiang
Goldberg, Jack
Quyyumi, Arshed A.
Vaccarino, Viola
TI Promoter methylation of glucocorticoid receptor gene is associated with
subclinical atherosclerosis: A monozygotic twin study
SO ATHEROSCLEROSIS
LA English
DT Article
DE DNA methylation; NR3C1; Subclinical atherosclerosis; Monozygotic twins
ID SEROTONIN TRANSPORTER GENE; PITUITARY-ADRENAL AXIS; FLOW-MEDIATED
DILATION; DNA METHYLATION; EPIGENETIC INHERITANCE;
CARDIOVASCULAR-DISEASE; ENDOTHELIAL FUNCTION; BRACHIAL-ARTERY;
HEART-DISEASE; RISK
AB Objective: Endothelial dysfunction assessed by brachial artery flow-mediated dilation (FMD) is a marker of early atherosclerosis. Glucocorticoid receptor gene (NR3C1) regulates many biological processes, including stress response, behavioral, cardiometabolic and immunologic functions. Genetic variants in NR3C1 have been associated with atherosclerosis and related risk factors. This study investigated the association of NR3C1 promoter methylation with FMD, independent of genetic and family-level environmental factors.
Methods: We studied 84 middle-aged, male-male monozygotic twin pairs recruited from the Vietnam Era Twin Registry. Brachial artery FMD was measured by ultrasound. DNA methylation levels at 22 CpG residues in the NR3C1 exon 1F promoter region were quantified by bisulfite pyrosequencing in genomic DNA isolated from peripheral blood leukocytes. Co-twin control analyses were conducted to examine the association of methylation variation with FMD, adjusting for smoking, physical activity, body mass index, lipids, blood pressure, fasting glucose, and depressive symptoms. Multiple testing was corrected using the false discovery rate.
Results: Mean methylation level across the 22 studied CpG sites was 2.02%. Methylation alterations at 12 out of the 22 CpG residues were significantly associated with FMD. On average, a 1% increase in the intra-pair difference in mean DNA methylation was associated with 2.83% increase in the intra-pair difference in FMD (95% CI: 1.46-4.20; P < 0.0001) after adjusting for risk factors and multiple testing.
Conclusion: Methylation variation in NR3C1 exon 1F promoter significantly influences subclinical atherosclerosis, independent of genetic, early family environmental and other risk factors. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
C1 [Zhao, Jinying; An, Qiang] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, New Orleans, LA 70112 USA.
[Goldberg, Jack] VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA.
[Goldberg, Jack] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Quyyumi, Arshed A.] Emory Univ, Sch Med, Dept Med, Atlanta, GA USA.
[Vaccarino, Viola] Emory Univ, Sch Publ Hlth, Dept Epidemiol, Atlanta, GA USA.
RP Zhao, JY (reprint author), Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, 1440 Canal St,Suite 2000-SL18, New Orleans, LA 70112 USA.
EM jzhao5@tulane.edu
FU NIH [R01MH097018, R21HL092363, K01AG034259, K24HL077506, R01HL68630,
R01AG026255]; United States Department of Veterans Affairs
FX This study was supported by NIH grants R01MH097018, R21HL092363, and
K01AG034259 (Dr. Zhao), and grants K24HL077506, R01HL68630 and
R01AG026255 (Dr. Vaccarino).; The United States Department of Veterans
Affairs has provided financial support for the development and
maintenance of the Vietnam Era Twin (VET) Registry. Numerous
organizations have provided invaluable assistance in the conduct of this
study, including: Department of Defense; National Personnel Records
Center, National Archives and Records Administration; the Internal
Revenue Service; National Institutes of Health; National Opinion
Research Center; National Research Council, National Academy of
Sciences; the Institute for Survey Research, Temple University. Most
importantly, the authors gratefully acknowledge the continued
cooperation and participation of the members of the VET Registry and
their families. Without their contribution this research would not have
been possible.
NR 48
TC 2
Z9 2
U1 0
U2 6
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD SEP
PY 2015
VL 242
IS 1
BP 71
EP 76
DI 10.1016/j.atherosclerosis.2015.07.007
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA CP7WU
UT WOS:000360100900012
PM 26186654
ER
PT J
AU Quispe, R
Manalac, RJ
Faridi, KF
Blaha, MJ
Toth, PP
Kulkarni, KR
Nasir, K
Virani, SS
Banach, M
Blumenthal, RS
Martin, SS
Jones, SR
AF Quispe, Renato
Manalac, Raoul J.
Faridi, Kamil F.
Blaha, Michael J.
Toth, Peter P.
Kulkarni, Krishnaji R.
Nasir, Khurram
Virani, Salim S.
Banach, Maciej
Blumenthal, Roger S.
Martin, Seth S.
Jones, Steven R.
TI Relationship of the triglyceride to high-density lipoprotein cholesterol
(TG/HDL-C) ratio to the remainder of the lipid profile: The Very Large
Database of Lipids-4 (VLDL-4) study
SO ATHEROSCLEROSIS
LA English
DT Article
DE Triglycerides; High-density lipoprotein cholesterol; TG/HDL-C ratio;
Lipids; Cut-off points; Remnant lipoprotein particle cholesterol
ID CORONARY-ARTERY-DISEASE; ISCHEMIC-HEART-DISEASE; LOW-GRADE INFLAMMATION;
HDL-CHOLESTEROL; CARDIOVASCULAR-DISEASE; DIABETES-MELLITUS;
POSTMENOPAUSAL WOMEN; REMNANT CHOLESTEROL; LDL-CHOLESTEROL;
MYOCARDIAL-INFARCTION
AB Background: High levels of the triglycerides to high-density lipoprotein cholesterol (TG/HDL-C) ratio are associated with obesity, metabolic syndrome, and insulin resistance.
Objectives: We evaluated variability in the remaining lipid profile, especially remnant lipoprotein particle cholesterol (RLP-C) and its components (very low-density lipoprotein cholesterol subfraction 3 and intermediate-density lipoprotein cholesterol), with variability in the TG/HDL-C ratio in a very large study cohort representative of the general U.S. population.
Methods: We examined data from 1,350,908 US individuals who were clinically referred for lipoprotein cholesterol ultracentrifugation (Atherotech, Birmingham, AL) from 2009 to 2011. Demographic information other than age and sex was not available. Changes to the remaining lipid profile across percentiles of the TG/HDL-C ratio were quantified, as well as by three TG/HDL-C cut-off points previously proposed in the literature: 2.5 (male) and 2 (female), 3.75 (male) and 3 (female), and 3.5 (male and female).
Results: The mean age of our study population was 58.7 years, and 48% were men. The median TG/HDL-C ratio was 2.2. Across increasing TG/HDL-C ratios, we found steadily increasing levels of RLP-C, non-HDL-C and LDL density. Among the lipid parameters studied, RLP-C and LDL density had the highest relative increase when comparing individuals with elevated TG/HDL-C levels to those with lower TG/HDL-C levels using established cut-off points. Approximately 47% of TG/HDL-C ratio variance was attributable to RLP-C.
Conclusions: In the present analysis, a higher TG/HDL-C ratio was associated with an increasingly atherogenic lipid phenotype, characterized by higher RLP-C along with higher non-HDL-C and LDL density. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
C1 [Quispe, Renato; Manalac, Raoul J.; Faridi, Kamil F.; Blaha, Michael J.; Toth, Peter P.; Nasir, Khurram; Blumenthal, Roger S.; Martin, Seth S.; Jones, Steven R.] Johns Hopkins Ciccarone Ctr Prevent Heart Dis, Baltimore, MD 21287 USA.
[Toth, Peter P.] CGH Med Ctr, Dept Prevent Cardiol, Sterling, IL USA.
[Toth, Peter P.] Univ Illinois, Coll Med, Peoria, IL 61656 USA.
[Kulkarni, Krishnaji R.] Atherotech Diagnost Lab, Birmingham, AL USA.
[Nasir, Khurram] Univ Miami, South Beach Prevent Cardiol Ctr, Miami, FL USA.
[Virani, Salim S.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Virani, Salim S.] Baylor Coll Med, Dept Med, Sect Cardiovasc Res, Houston, TX 77030 USA.
[Banach, Maciej] Med Univ Lodz, Dept Hypertens, Lodz, Poland.
RP Quispe, R (reprint author), Johns Hopkins Ciccarone Ctr Prevent Heart Dis, 600 N Wolfe St,Blalock 524-C, Baltimore, MD 21287 USA.
EM jquispe1@jhmi.edu
RI Banach, Maciej/A-1271-2009;
OI Banach, Maciej/0000-0001-6690-6874; Virani, Salim/0000-0001-9541-6954
FU Atherotech
FX Dr. Blaha served on an Advisory Board for Pfizer. Dr. Toth reports
consulting for Amgen, AstraZeneca, Atherotech, GlaxoSmithKline, Kowa,
Liposcience, and Merck; serving on the speakers bureau for Amarin,
AstraZeneca, Genzyme, Kowa, Merck. Dr. Kulkarni is a research director
at Atherotech Diagnostics Lab; owns uncashable stocks for Atherotech
Diagnostics Labs; and receives modest royalties from the University of
Alabama at Birmingham. Dr. Nasir served on an Advisory Board for Quest
Diagnostic. Dr Jones reports serving on the medical advisory board for,
and receiving grant funding from, Atherotech. Drs. Quispe, Manalac,
Faridi, Virani, Banach, Blumenthal, and Martin have nothing to disclose.
NR 60
TC 7
Z9 8
U1 0
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD SEP
PY 2015
VL 242
IS 1
BP 243
EP 250
DI 10.1016/j.atherosclerosis.2015.06.057
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA CP7WU
UT WOS:000360100900039
PM 26232164
ER
PT J
AU Prudente, S
Bailetti, D
Mendonca, C
Mannino, GC
Fontana, A
Andreozzi, F
Hastings, T
Mercuri, L
Alberico, F
Basile, G
Copetti, M
Sesti, G
Doria, A
Trischitta, V
AF Prudente, Sabrina
Bailetti, Diego
Mendonca, Christine
Mannino, Gaia Chiara
Fontana, Andrea
Andreozzi, Francesco
Hastings, Timothy
Mercuri, Luana
Alberico, Federica
Basile, Giorgio
Copetti, Massimiliano
Sesti, Giorgio
Doria, Alessandro
Trischitta, Vincenzo
TI Infrequent TRIB3 coding variants and coronary artery disease in type 2
diabetes
SO ATHEROSCLEROSIS
LA English
DT Article
DE Insulin sensitivity; Insulin signaling; Coronary artery disease; Type 2
diabetes mellitus; Infrequent variants
ID INSULIN SIGNALING GENES; HUMAN ENDOTHELIAL-CELLS; OF-FUNCTION MUTATIONS;
HEART-DISEASE; CARDIOVASCULAR EVENTS; GLUCOSE-HOMEOSTASIS; R84 VARIANT;
RISK; ASSOCIATION; RESISTANCE
AB Objective: Genes that modulate insulin sensitivity may also be involved in shaping the risk of coronary artery disease (CAD). The relatively common TRIB3 Q84R polymorphism (rs2295490) has been associated with abnormal insulin signaling, endothelial dysfunction, insulin resistance, and pro-atherogenic phenotypes. The aim of our study was to investigate the association between low-frequency TRIB3 coding variants and CAD in patients with type 2 diabetes (T2D).
Methods: Three caseecontrol studies for CAD from Italy and US were analyzed, for a total of 1565 individuals, all with type 2 diabetes. Infrequent variants were identified by re-sequencing TRIB3 exons in 140 "extreme cases" and 140 "super-controls" and then genotyped in all study subjects.
Results: TRIB3 infrequent variants (n = 8), considered according to a collapsing rare variants framework, were significantly associated with CAD in diabetic patients from Italy (n = 700, OR = 0.43, 95% CI 0.20-0.91; p = 0.027), but not from the US (n = 865, OR = 1.22, 95% CI 0.69-2.18; p = 0.49). In the Italian sets, the association was especially strong among individuals who also carried the common R84 variant.
Conclusion: Although preliminary, our finding suggests a role of TRIB3 low-frequency variants on CAD among Italian patients with T2D. Further studies are needed to address the role of TRIB3 infrequent variants in other populations of both European and non-European ancestries. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
C1 [Prudente, Sabrina; Bailetti, Diego; Mercuri, Luana; Alberico, Federica; Basile, Giorgio; Trischitta, Vincenzo] IRCSS Casa Sollievo Sofferenza Mendel Lab, San Giovanni Rotondo, Italy.
[Bailetti, Diego; Basile, Giorgio; Trischitta, Vincenzo] Univ Roma La Sapienza, Dept Expt Med, Rome, Italy.
[Mendonca, Christine; Mannino, Gaia Chiara; Hastings, Timothy; Doria, Alessandro] Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA.
[Mannino, Gaia Chiara; Andreozzi, Francesco; Sesti, Giorgio] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Catanzaro, Italy.
[Fontana, Andrea; Copetti, Massimiliano] IRCCS Casa Sollievo Sofferenza, Unit Biostat, San Giovanni Rotondo, Italy.
[Doria, Alessandro] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Trischitta, Vincenzo] IRCSS Casa Sollievo Sofferenza, Res Unit Diabet & Endocrine Dis, San Giovanni Rotondo, Italy.
RP Prudente, S (reprint author), CSS Mendel Inst, Viale Regina Margherita 261, I-00198 Rome, Italy.
EM s.prudente@css-mendel.it; vincenzo.trischitta@uniroma1.it
RI Prudente, Sabrina/H-2886-2016; Trischitta, Vincenzo/K-1487-2016;
Mannino, Gaia/K-1580-2016; Copetti, Massimiliano/K-3186-2016; Fontana,
Andrea/J-8584-2016;
OI Prudente, Sabrina/0000-0001-9220-8981; Trischitta,
Vincenzo/0000-0003-1174-127X; Mannino, Gaia/0000-0002-6341-4572;
Copetti, Massimiliano/0000-0002-7960-5947; Fontana,
Andrea/0000-0002-6660-5315; Andreozzi, Francesco/0000-0001-9375-1513
FU Italian Ministry of Health (Ricerca Corrente); National Institutes of
Health [R01 HL073168, P30 DK036836]; European Union [279171-1 MEDIGENE]
FX This work was supported by the Italian Ministry of Health (Ricerca
Corrente 2014 and 2015 to SP and VT), the National Institutes of Health
(grants R01 HL073168 to AD and P30 DK036836 to the Joslin Diabetes
Research Center [Advanced Genomics and Genetics Core]) and the European
Union (FP7 2007-2013, grant 279171-1 MEDIGENE to VT).
NR 26
TC 2
Z9 2
U1 1
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD SEP
PY 2015
VL 242
IS 1
BP 334
EP 339
DI 10.1016/j.atherosclerosis.2015.07.030
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA CP7WU
UT WOS:000360100900052
PM 26253791
ER
PT J
AU Kim, E
Zeng, DL
Zhou, XH
AF Kim, Eunhee
Zeng, Donglin
Zhou, Xiao-Hua
TI Semiparametric transformation models for multiple continuous biomarkers
in ROC analysis
SO BIOMETRICAL JOURNAL
LA English
DT Article
DE Biomarkers; ROC analysis; Nonparametric maximum likelihood estimation;
Semiparametric efficiency; Transformation models
ID OPERATING CHARACTERISTIC CURVE; MAXIMUM-LIKELIHOOD-ESTIMATION;
CENSORED-DATA; EM ALGORITHM; INFERENCE; SUBJECT; MARKERS;
CLASSIFICATION; DISEASE; LIMITS
AB Recent technological advances continue to provide noninvasive and more accurate biomarkers for evaluating disease status. One standard tool for assessing the accuracy of diagnostic tests is the receiver operating characteristic (ROC) curve. Few statistical methods exist to accommodate multiple continuous-scale biomarkers in the framework of ROC analysis. In this paper, we propose a method to integrate continuous-scale biomarkers to optimize classification accuracy. Specifically, we develop semiparametric transformation models formultiple biomarkers. We assume that unknown and marker-specific transformations of biomarkers follow a multivariate normal distribution. Our models accommodate biomarkers subject to limits of detection and account for the dependence among biomarkers by including a subject-specific random effect. We also propose a diagnostic measure using an optimal linear combination of the transformed biomarkers. Our diagnostic rule does not depend on any monotone transformation of biomarkers and is not sensitive to extreme biomarker values. Nonparametric maximum likelihood estimation (NPMLE) is used for inference. We show that the parameter estimators are asymptotically normal and efficient. We illustrate our semiparametric approach using data from the Endometriosis, Natural History, Diagnosis, and Outcomes (ENDO) study.
C1 [Kim, Eunhee] Brown Univ, Dept Biostat, Providence, RI 02912 USA.
[Kim, Eunhee] Brown Univ, Ctr Stat Sci, Providence, RI 02912 USA.
[Zeng, Donglin] Univ N Carolina, Dept Biostat, Chapel Hill, NC 27599 USA.
[Zhou, Xiao-Hua] Univ Washington, VA Puget Sound Hlth Care Syst, HSRD Ctr Excellence, Seattle, WA 98198 USA.
[Zhou, Xiao-Hua] Univ Washington, Dept Biostat, Seattle, WA 98198 USA.
RP Kim, E (reprint author), Brown Univ, Dept Biostat, Providence, RI 02912 USA.
EM ekim@stat.brown.edu
FU Intramural Research Program of the Eunice Kennedy Shriver National
Institute of Child and Human Development, National Institute of Heath
[NO1-DK-6-3428, NO1-DK-6-3427, 10001406-02]
FX The authors thank Zhen Chen for his valuable comments and suggestions
and Youdan Wang for providing programming support. This research was
supported in part by the Intramural Research Program of the Eunice
Kennedy Shriver National Institute of Child and Human Development,
National Institute of Heath (contracts #NO1-DK-6-3428; NO1-DK-6-3427;
10001406-02; 10001406-02).
NR 37
TC 0
Z9 0
U1 3
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0323-3847
EI 1521-4036
J9 BIOMETRICAL J
JI Biom. J.
PD SEP
PY 2015
VL 57
IS 5
BP 808
EP 833
DI 10.1002/bimj.201400043
PG 26
WC Mathematical & Computational Biology; Statistics & Probability
SC Mathematical & Computational Biology; Mathematics
GA CQ7CA
UT WOS:000360759200006
PM 26138227
ER
PT J
AU Sajatovic, M
Levin, JB
Sams, J
Cassidy, KA
Akagi, K
Aebi, ME
Ramirez, LF
Safren, SA
Tatsuoka, C
AF Sajatovic, Martha
Levin, Jennifer B.
Sams, Johnny
Cassidy, Kristin A.
Akagi, Kouri
Aebi, Michelle E.
Ramirez, Luis F.
Safren, Steven A.
Tatsuoka, Curtis
TI Symptom severity, self-reported adherence, and electronic pill
monitoring in poorly adherent patients with bipolar disorder
SO BIPOLAR DISORDERS
LA English
DT Article
DE adherence; bipolar disorder; compliance; depression; mania; mood
stabilizer
ID PSYCHIATRIC RATING-SCALE; MEDICATION ADHERENCE; MOOD STABILIZERS; I
DISORDER; LITHIUM; NONADHERENCE; HOSPITALIZATION; DEPRESSION;
GUIDELINES; ATTITUDES
AB ObjectivesThis analysis of screening and baseline data from an ongoing trial examined self-report versus automated adherence monitoring and assessed the relationship between bipolar disorder (BD) symptoms and adherence in 104 poorly adherent individuals.
MethodsAdherence was measured with the Tablets Routine Questionnaire (TRQ) and the Medication Event Monitoring System (MEMS). Symptoms were measured with the Montgomery-angstrom sberg Depression Rating Scale (MADRS), the Young Mania Rating Scale (YMRS), and the Brief Psychiatric Rating Scale (BPRS).
ResultsThe mean age of the sample was 46.3years [standard deviation (SD)=9.41 years], with 72% (n=75) women and 71% (n=74) African American subjects. Adherence improved from screening to baseline, with a mean missed drug proportion measured by TRQ of 61.43% (SD=26.48%) versus a baseline mean of 46.61% (SD=30.55%). The mean proportion of missed medication using MEMS at baseline was 66.43% (SD=30.40%). The correlation between TRQ and MEMS was 0.47. The correlation between a single index drug and all BD medications was 0.95. Symptoms were generally positively correlated with TRQ (worse adherence=more severe symptoms), but in most instances was only at a trend level (p>0.05), with the exception of the correlations between baseline TRQ and MADRS and BPRS, which were positive (r=0.20 and r=0.21, respectively) and significant (p0.05).
ConclusionsIn patients with BD, monitoring increased adherence by 15%. MEMS identified 20% more non-adherence than self-report. Using a standard procedure to identify a single index drug for adherence monitoring may be one way to assess global adherence in patients with BD receiving polypharmacy treatment. Greater BD symptom severity may be a clinical indicator to assess for adherence problems.
C1 [Sajatovic, Martha; Levin, Jennifer B.; Sams, Johnny; Cassidy, Kristin A.; Akagi, Kouri; Ramirez, Luis F.] Case Western Reserve Univ, Sch Med, Dept Psychiat, Cleveland, OH 44106 USA.
[Sajatovic, Martha; Levin, Jennifer B.; Sams, Johnny; Aebi, Michelle E.; Tatsuoka, Curtis] Univ Hosp Case Med Ctr, Neurol & Behav Outcomes Ctr, Cleveland, OH USA.
[Sajatovic, Martha; Tatsuoka, Curtis] Case Western Reserve Univ, Sch Med, Dept Neurol, Cleveland, OH 44106 USA.
[Safren, Steven A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
RP Sajatovic, M (reprint author), Case Western Reserve Univ, Sch Med, Dept Psychiat, WO Walker Bldg,7th Floor 10524 Euclid Ave, Cleveland, OH 44106 USA.
EM martha.sajatovic@uhhospitals.org
FU National Institute of Mental Health (NIMH) [NIMH 1R01MH093321-01A1];
Clinical and Translational Science Award (CTSC) [UL1TR 00043]
FX This study was supported by a grant from the National Institute of
Mental Health (NIMH) grant NIMH 1R01MH093321-01A1 (Principal
Investigator: MS) and by the Clinical and Translational Science Award
(CTSC) - UL1TR 00043 for REDCap.
NR 48
TC 3
Z9 3
U1 2
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-5647
EI 1399-5618
J9 BIPOLAR DISORD
JI Bipolar Disord.
PD SEP
PY 2015
VL 17
IS 6
BP 653
EP 661
DI 10.1111/bdi.12326
PG 9
WC Clinical Neurology; Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA CQ8DB
UT WOS:000360835300008
PM 26529124
ER
PT J
AU Freer, PE
Slanetz, PJ
Haas, JS
Tung, NM
Hughes, KS
Armstrong, K
Semine, AA
Troyan, SL
Birdwell, RL
AF Freer, Phoebe E.
Slanetz, Priscilla J.
Haas, Jennifer S.
Tung, Nadine M.
Hughes, Kevin S.
Armstrong, Katrina
Semine, A. Alan
Troyan, Susan L.
Birdwell, Robyn L.
TI Breast cancer screening in the era of density notification legislation:
summary of 2014 Massachusetts experience and suggestion of an
evidence-based management algorithm by multi-disciplinary expert panel
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Screening; Density; Dense breasts; Mammography; Supplemental screening
ID MAMMOGRAPHIC DENSITY; DIGITAL MAMMOGRAPHY; COMMUNITY PRACTICE; ELEVATED
RISK; WOMEN; ACCURACY; MRI; ULTRASOUND; COHORT; US
AB Stemming from breast density notification legislation in Massachusetts effective 2015, we sought to develop a collaborative evidence-based approach to density notification that could be used by practitioners across the state. Our goal was to develop an evidence-based consensus management algorithm to help patients and health care providers follow best practices to implement a coordinated, evidence-based, cost-effective, sustainable practice and to standardize care in recommendations for supplemental screening. We formed the Massachusetts Breast Risk Education and Assessment Task Force (MA-BREAST) a multi-institutional, multi-disciplinary panel of expert radiologists, surgeons, primary care physicians, and oncologists to develop a collaborative approach to density notification legislation. Using evidence-based data from the Institute for Clinical and Economic Review, the Cochrane review, National Comprehensive Cancer Network guidelines, American Cancer Society recommendations, and American College of Radiology appropriateness criteria, the group collaboratively developed an evidence-based best-practices algorithm. The expert consensus algorithm uses breast density as one element in the risk stratification to determine the need for supplemental screening. Women with dense breasts and otherwise low risk (< 15 % lifetime risk), do not routinely require supplemental screening per the expert consensus. Women of high risk (> 20 % lifetime) should consider supplemental screening MRI in addition to routine mammography regardless of breast density. We report the development of the multi-disciplinary collaborative approach to density notification. We propose a risk stratification algorithm to assess personal level of risk to determine the need for supplemental screening for an individual woman.
C1 [Freer, Phoebe E.] Massachusetts Gen Hosp, MGH Imaging, Div Breast Imaging, Boston, MA 02114 USA.
[Slanetz, Priscilla J.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Breast Imaging, Boston, MA 02215 USA.
[Haas, Jennifer S.] Brigham & Womens Hosp, Div Gen Internal Med, Boston, MA 02115 USA.
[Tung, Nadine M.] Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02215 USA.
[Hughes, Kevin S.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Armstrong, Katrina] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Semine, A. Alan] Newton Wellesley Hosp, Dept Radiol, Washington, DC USA.
[Troyan, Susan L.] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA.
[Birdwell, Robyn L.] Brigham & Womens Hosp, Dept Radiol, Div Breast Imaging, Boston, MA 02115 USA.
RP Freer, PE (reprint author), Massachusetts Gen Hosp, MGH Imaging, Div Breast Imaging, Boston, MA 02114 USA.
EM phoebefreer@gmail.com; pslanetz@bidmc.harvard.edu; jhaas@partners.org;
ntung@bidmc.harvard.edu; kshughes@partners.org;
Karmstrong6@mgh.harvard.edu; asemine@partners.org; stroyan@partners.org;
rbirdwell@partners.org
OI Freer, Phoebe/0000-0001-6886-7100
FU NCI NIH HHS [U54 CA163307]
NR 46
TC 3
Z9 3
U1 0
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD SEP
PY 2015
VL 153
IS 2
BP 455
EP 464
DI 10.1007/s10549-015-3534-9
PG 10
WC Oncology
SC Oncology
GA CQ5TU
UT WOS:000360669400023
PM 26290416
ER
PT J
AU Foley, O
Dizon, D
Schmeler, K
del Carmen, M
AF Foley, Olivia
Dizon, Don
Schmeler, Kathleen
del Carmen, Marcela
TI Development of a Breast Cancer Advocacy and Access Health Program in
Nicaragua
SO BREAST JOURNAL
LA English
DT Letter
C1 [Foley, Olivia; del Carmen, Marcela] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Vincent Obstet & Gynecol, Boston, MA USA.
[Dizon, Don] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Hematol Oncol, Boston, MA USA.
[Schmeler, Kathleen] Univ Texas MD Anderson Canc Ctr, Div Gynecol Oncol, Houston, TX 77030 USA.
RP del Carmen, M (reprint author), Massachusetts Gen Hosp, Div Gynecol Oncol, Vincent Obstet & Gynecol, 55 Fruit St,Yawkey 9 E, Boston, MA 02114 USA.
EM mdelcarmen@partners.org
NR 5
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1075-122X
EI 1524-4741
J9 BREAST J
JI Breast J.
PD SEP-OCT
PY 2015
VL 21
IS 5
BP 570
EP 571
DI 10.1111/tbj.12459
PG 2
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA CQ7FK
UT WOS:000360768200024
PM 26190769
ER
PT J
AU Kieran, MW
Chi, S
Goldman, S
Onar-Thomas, A
Poussaint, TY
Vajapeyam, S
Fahey, F
Wu, SJ
Turner, DC
Stewart, CF
Moses, M
Packer, RJ
Jakacki, R
Banerjee, A
Boyett, JM
Fouladi, M
Kun, L
AF Kieran, Mark W.
Chi, Susan
Goldman, Stewart
Onar-Thomas, Arzu
Poussaint, Tina Young
Vajapeyam, Sridhar
Fahey, Frederic
Wu, Shengjie
Turner, David C.
Stewart, Clinton F.
Moses, Marsha
Packer, Roger J.
Jakacki, Regina
Banerjee, Anu
Boyett, James M.
Fouladi, Maryam
Kun, Larry
TI A phase I trial and PK study of cediranib (AZD2171), an orally
bioavailable pan-VEGFR inhibitor, in children with recurrent or
refractory primary CNS tumors
SO CHILDS NERVOUS SYSTEM
LA English
DT Article
DE AZD2171; Recentin; Cediranib; Antiangiogenesis; Pediatric brain tumor
ID TYROSINE KINASE INHIBITOR; CONTINUAL REASSESSMENT METHOD; BEVACIZUMAB
PLUS IRINOTECAN; BRAIN-STEM GLIOMA; METRONOMIC CHEMOTHERAPY;
GLIOBLASTOMA PATIENTS; PROSTATE-CANCER; F-18-FDG PET; SOLID TUMORS;
GROWTH
AB Cediranib (AZD2171), an oral pan-vascular endothelial growth factor (VEGF) inhibitor, was evaluated in this phase I study to determine its toxicity profile, dose-limiting toxicities (DLTs), maximum-tolerated dose (MTD), pharmacokinetics, and pharmacodynamics in children and adolescents with recurrent or refractory primary central nervous system (CNS) tumors.
Children and adolescents < 22 years were enrolled into one of two strata: stratum I-those not receiving enzyme-inducing anticonvulsant drugs (EIACD) and stratum II-those receiving EIACDs. Dose-level selection was based on the continual reassessment method (CRM).
Thirty-six eligible patients with median age of 12.7 years (range, 5.4-21.7 years) in stratum I (24 males) and 12 patients (7 males) in stratum II with median age of 13.4 years (range, 8.9-19.5 years) were initially assessed over a 4-week DLT evaluation period, modified to 6 weeks during the study. An MTD of 32 mg/m(2)/day was declared; however, excessive toxicities (transaminitis, proteinuria, diarrhea, hemorrhage, palmer-planter syndrome, reversible posterior leukoencephalopathy) in the expansion cohort treated at this dose suggested that it might not be tolerated over a longer time period. An expansion cohort at 20 mg/m(2)/day also demonstrated poor longer-term tolerability. Diffusion and perfusion MRI and PET imaging variables as well as biomarker analysis were performed and correlated with outcome. At 20 mg/m(2)/day, the median plasma area under the concentration-time curve at steady state was lower than that observed in adults at similar dosages.
While the MTD of once daily oral cediranib in children with recurrent or progressive CNS tumors was initially defined as 32 mg/m(2)/day, this dose and 20 mg/m(2)/day were not considered tolerable over a protracted time period.
C1 [Kieran, Mark W.; Chi, Susan] Dana Farber Canc Inst, Dept Pediat Oncol, Pediat Neurooncol, Boston, MA 02215 USA.
[Kieran, Mark W.; Chi, Susan] Boston Childrens Hosp, Div Pediat Hematol Oncol, Boston, MA 02215 USA.
[Poussaint, Tina Young; Vajapeyam, Sridhar; Fahey, Frederic] Boston Childrens Hosp, Dept Radiol, Boston, MA 02215 USA.
[Kieran, Mark W.; Moses, Marsha] Boston Childrens Hosp, Dept Surg, Vasc Biol Program, Boston, MA 02215 USA.
[Goldman, Stewart] Lurie Childrens Hosp, Dept Hematol Oncol, Chicago, IL USA.
[Onar-Thomas, Arzu; Wu, Shengjie; Boyett, James M.] St Jude Childrens Res Hosp, Dept Biostat, Memphis, TN 38105 USA.
[Turner, David C.; Stewart, Clinton F.] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA.
[Kun, Larry] St Jude Childrens Res Hosp, Radiol Sci, Memphis, TN 38105 USA.
[Packer, Roger J.] Childrens Natl Hlth Syst, Ctr Neurosci & Behav Med, Brain Tumor Inst, Washington, DC USA.
[Jakacki, Regina] Childrens Hosp Pittsburgh, Pediat Hematol Oncol, Pittsburgh, PA 15213 USA.
[Banerjee, Anu] Univ San Francisco, Pediat Oncol, San Francisco, CA 94117 USA.
[Fouladi, Maryam] Cincinnati Childrens Hosp Med Ctr, Div Hematol Oncol, Cincinnati, OH 45229 USA.
RP Kieran, MW (reprint author), Dana Farber Canc Inst, Dept Pediat Oncol, Pediat Neurooncol, 450 Brookline Ave,Rm D3154, Boston, MA 02215 USA.
EM mark_kieran@dfci.harvard.edu
FU NIH for the Pediatric Brain Tumor Consortium [U01 CA81457]; American
Lebanese Syrian Associated Charities; Stop & Shop Pediatric Brain Tumor
Program at the Dana-Farber Cancer Institute; Boston Children's Hospital
FX This work was supported in part by NIH grant U01 CA81457 for the
Pediatric Brain Tumor Consortium, American Lebanese Syrian Associated
Charities, and the Stop & Shop Pediatric Brain Tumor Program at the
Dana-Farber Cancer Institute and Boston Children's Hospital.
NR 32
TC 0
Z9 0
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0256-7040
EI 1433-0350
J9 CHILD NERV SYST
JI Childs Nerv. Syst.
PD SEP
PY 2015
VL 31
IS 9
BP 1433
EP 1445
DI 10.1007/s00381-015-2812-5
PG 13
WC Clinical Neurology; Pediatrics; Surgery
SC Neurosciences & Neurology; Pediatrics; Surgery
GA CQ8FI
UT WOS:000360841500003
PM 26188774
ER
PT J
AU Qadri, YJ
Bortsov, AV
Orrey, DC
Swor, RA
Peak, DA
Jones, JS
Rathlev, NK
Lee, DC
Domeier, RM
Hendry, PL
Mclean, SA
AF Qadri, Yawar J.
Bortsov, Andrey V.
Orrey, Danielle C.
Swor, Robert A.
Peak, David A.
Jones, Jeffrey S.
Rathlev, Niels K.
Lee, David C.
Domeier, Robert M.
Hendry, Phyllis L.
Mclean, Samuel A.
TI Genetic Polymorphisms in the Dopamine Receptor 2 Predict Acute Pain
Severity After Motor Vehicle Collision
SO CLINICAL JOURNAL OF PAIN
LA English
DT Article
DE dopamine; DRD2; SLC6A3; genetic association; acute trauma
ID PATIENT-CONTROLLED ANALGESIA; DRD2 NCOI ALLELES; PARKINSONS-DISEASE;
TRANSPORTER GENE; ASSOCIATION; MIGRAINE; METOCLOPRAMIDE; SUSCEPTIBILITY;
ALCOHOL; HUMANS
AB Objectives:Dopaminergic signaling is implicated in nociceptive pathways. These effects are mediated largely through dopamine receptors and modulated in part by dopamine transporters. This study tested the hypothesis that genetic variants in the genes encoding dopamine receptor 2 (DRD2) and the dopamine active transporter (SLC6A3) influence acute pain severity after motor vehicle collision.Materials and Methods:European Americans presenting to the emergency department after motor vehicle collision were recruited. Overall pain intensity in emergency department was assessed using a 0 to 10 numeric rating scale. DNA was extracted from blood samples and genotyping of single-nucleotide polymorphisms (SNPs) in the DRD2 and SLC6A3 gene was performed.Results:A total of 948 patients completed evaluation. After correction for multiple comparisons, SNP rs6276 at DRD2 showed significant association with pain scores, with individuals with the A/A genotype reporting lower mean pain scores (5.3; 95% confidence interval [CI], 5.1-5.5) than those with A/G (5.9; 95% CI, 5.6-6.1) or G/G (5.7; 95% CI, 5.2-6.2) genotypes (P=0.0027). Secondary analyses revealed an interaction between sex and DRD2 SNPs rs4586205 and rs4648318 on pain scores: females with 2 minor alleles had increased pain intensity, whereas males with 2 minor alleles had less pain than individuals with a major allele (interaction P=0.0019).Discussion:Genetic variants in DRD2 are associated with acute pain after a traumatic stressful event. These results suggest that dopaminergic agents may be useful for the treatment of individuals with acute posttraumatic pain as part of a multimodal opioid-sparing analgesic regimen.
C1 [Qadri, Yawar J.; Bortsov, Andrey V.; Orrey, Danielle C.; Mclean, Samuel A.] Univ N Carolina, Dept Anesthesiol, Chapel Hill, NC USA.
[Swor, Robert A.] William Beaumont Hosp, Dept Emergency Med, Royal Oak, MI 48072 USA.
[Jones, Jeffrey S.] Spectrum Hlth Syst, Dept Emergency Med, Grand Rapids, MI USA.
[Domeier, Robert M.] St Joseph Mercy Hlth Syst, Dept Emergency Med, Ypsilanti, MI USA.
[Peak, David A.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
[Rathlev, Niels K.] Bay State Med Ctr, Dept Emergency Med, Springfield, MA USA.
[Lee, David C.] N Shore Univ Hosp, Dept Emergency Med, Manhasset, NY USA.
[Hendry, Phyllis L.; Mclean, Samuel A.] Univ Florida, Dept Emergency Med, Jacksonville, FL USA.
RP Mclean, SA (reprint author), Univ N Carolina, Sch Med, Dept Anesthesiol, Wing C CB 7010, Chapel Hill, NC 27599 USA.
EM smclean@aims.unc.edu
OI McLean, Samuel/0000-0001-9482-3582
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases of
the National Institutes of Health, Bethesda, MD [R01AR056328]
FX Research reported in this publication was supported by the National
Institute of Arthritis and Musculoskeletal and Skin Diseases of the
National Institutes of Health, Bethesda, MD; under Award Number
R01AR056328. The content is solely the responsibility of the authors and
does not necessarily represent the official views of the National
Institutes of Health. The authors declare no conflict of interest.
NR 61
TC 1
Z9 1
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0749-8047
EI 1536-5409
J9 CLIN J PAIN
JI Clin. J. Pain
PD SEP
PY 2015
VL 31
IS 9
BP 768
EP 775
DI 10.1097/AJP.0000000000000167
PG 8
WC Anesthesiology; Clinical Neurology
SC Anesthesiology; Neurosciences & Neurology
GA CQ1GZ
UT WOS:000360346600002
ER
PT J
AU Anderson, JE
Steiner, RW
Mekeel, KL
Chang, DC
Hemming, AW
Halldorson, JB
AF Anderson, Jamie E.
Steiner, Robert W.
Mekeel, Kristin L.
Chang, David C.
Hemming, Alan W.
Halldorson, Jeffrey B.
TI ECD kidney transplantation outcomes are improved when matching donors to
recipients using a novel creatinine clearance match ratio (CCMR)
SO CLINICAL TRANSPLANTATION
LA English
DT Article
DE creatinine clearance; end-stage renal disease; extended criteria donor;
kidney transplantation; surgical outcomes
ID GRAFT FUNCTION; ALLOGRAFT SURVIVAL; SERUM CREATININE; WEIGHT; SIZE;
PREDICTION; IMPACT; INDEX; AGE
AB Improved outcomes have been associated with various methods of size matching between expanded criteria (ECD) donors and recipients. A novel method for improved functional based matching was developed utilizing manipulation of Cockcroft-Gault estimated creatinine clearances for donor and recipient. We hypothesized that optimal clearance-based matches would have superior outcomes for both immediate graft function and long-term graft survival. For the analysis, recipients of ECD kidneys in the Scientific Registry of Transplant Recipients (SRTR) transplanted between October 1, 1987 and August 31, 2011 were included. Univariate and multivariate analyses predicted the hazard ratio of graft failure and the odds ratio of requiring dialysis within the first week. A total of 25,640 ECD kidney transplants were analyzed. On multivariate analysis, higher creatinine clearance match ratio (CCMR) was associated with increased graft failure and odds of requiring dialysis within the first week (comparing highest ratio quintile versus lowest ratio quintile: HR 1.43, p<0.001; OR 2.08, p<0.001). This study suggests that ECD kidneys have improved outcomes when the recipient/donor CCMR is optimized.
C1 [Anderson, Jamie E.; Mekeel, Kristin L.; Hemming, Alan W.; Halldorson, Jeffrey B.] Univ Calif San Diego, Dept Surg, San Diego, CA 92103 USA.
[Steiner, Robert W.] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA.
[Chang, David C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, Boston, MA USA.
RP Halldorson, JB (reprint author), Univ Calif San Diego, 200 W Arbor Dr 8400, San Diego, CA 92103 USA.
EM jhalldorson@ucsd.edu
NR 22
TC 1
Z9 2
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0902-0063
EI 1399-0012
J9 CLIN TRANSPLANT
JI Clin. Transplant.
PD SEP
PY 2015
VL 29
IS 9
BP 738
EP 746
DI 10.1111/ctr.12555
PG 9
WC Surgery; Transplantation
SC Surgery; Transplantation
GA CQ7NG
UT WOS:000360790300005
PM 25918902
ER
PT J
AU Veldman, PB
Dye, PK
Holiman, JD
Mayko, ZM
Sales, CS
Straiko, MD
Stoeger, CG
Terry, MA
AF Veldman, Peter B.
Dye, Philip K.
Holiman, Jeffrey D.
Mayko, Zachary M.
Sales, Christopher S.
Straiko, Michael D.
Stoeger, Christopher G.
Terry, Mark A.
TI Stamping an S on DMEK Donor Tissue to Prevent Upside-Down Grafts:
Laboratory Validation and Detailed Preparation Technique Description
SO CORNEA
LA English
DT Article
DE DMEK; endothelial keratoplasty; donor tissue preparation; S-stamp;
upside-down graft
ID MEMBRANE ENDOTHELIAL KERATOPLASTY; CORNEAL TISSUE; EYE; REJECTION; RISK
AB Purpose:To report endothelial cell loss (ECL) caused by a novel S-stamp preparation technique for Descemet membrane endothelial keratoplasty (DMEK).Methods:Six cadaveric human corneas were prepared for DMEK transplantation using a single standardized technique, including the application of a dry ink gentian violet S-stamp to the stromal side of Descemet membrane. Endothelial cell death was evaluated and quantified using computerized analysis of vital dye staining.Results:ECL caused by the S-stamp was 0.6% (range 0.1%-1.0%), which comprised less than one-tenth of the total ECL caused by our preparation of the DMEK graft from the start to finish, including recovery, prestripping, S-stamping, and trephination (13.7% total ECL, range 9.9%-17.6%).Conclusions:Our novel S-stamp donor tissue preparation technique is intuitive to learn and holds the promise of preventing iatrogenic primary graft failure due to upside-down grafts without causing unacceptable increases in ECL.
C1 [Veldman, Peter B.] Massachusetts Eye & Ear Infirm, Cornea Serv, Boston, MA 02114 USA.
[Veldman, Peter B.; Sales, Christopher S.; Straiko, Michael D.; Terry, Mark A.] Devers Eye Inst, Cornea Serv, Portland, OR USA.
[Dye, Philip K.; Holiman, Jeffrey D.; Mayko, Zachary M.; Stoeger, Christopher G.] Lions Vis Gift, Portland, OR USA.
RP Veldman, PB (reprint author), Massachusetts Eye & Ear Infirm, Cornea Serv, 243 Charles St, Boston, MA 02114 USA.
EM peterbveldman@gmail.com
NR 18
TC 7
Z9 7
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0277-3740
EI 1536-4798
J9 CORNEA
JI Cornea
PD SEP
PY 2015
VL 34
IS 9
BP 1175
EP 1178
DI 10.1097/ICO.0000000000000522
PG 4
WC Ophthalmology
SC Ophthalmology
GA CQ1HT
UT WOS:000360348600034
PM 26147839
ER
PT J
AU Roberts, DA
Steensma, DP
AF Roberts, Daniel A.
Steensma, David P.
TI Outlook and Management of Patients with Myelodysplastic Syndromes Failed
by Hypomethylating Agents
SO CURRENT HEMATOLOGIC MALIGNANCY REPORTS
LA English
DT Review
DE Myelodysplastic syndromes; Azacitidine; Decitabine; DNA
methyltransferase inhibitor
ID ACUTE MYELOID-LEUKEMIA; STEM-CELL TRANSPLANTATION; LOW-DOSE CYTARABINE;
AZACITIDINE TREATMENT FAILURE; INTERNATIONAL WORKING GROUP; ACUTE
MYELOGENOUS LEUKEMIA; PHASE-III; ELDERLY-PATIENTS; INTENSIVE
CHEMOTHERAPY; RISK STRATIFICATION
AB The DNA hypomethylating agents (HMAs) azacitidine and decitabine are currently the most frequently administered disease-modifying therapies for patients with higher-risk myelodysplastic syndromes (MDS). However, azacitidine and decitabine are not curative, the median response duration is 11-15 months, and only 10-20 % of patients experience complete hematologic and cytogenetic response. Moreover, once an HMA fails the patient, the prognosis is poor, with a median survival of less than 6 months unless the patient undergoes hematopoietic stem cell transplantation (HSCT). Recent insights into the genetic basis of MDS have enhanced biological understanding and prognostication accuracy, but these developments have not yet led to regulatory approval of new therapies. While there are multiple potential approaches to patients with MDS for whom HMAs have failed, including supportive care alone, cytotoxic therapy, lenalidomide, histone deacetylase inhibitors, and HSCT, favorable responses to these approaches are limited and new therapies are greatly needed. Here, we review clinical and biological data about the population of patients failed by HMAs, evaluate currently available approaches to patients in this clinical situation, and discuss prospects for development of novel active agents.
C1 [Roberts, Daniel A.] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA.
[Steensma, David P.] Dana Farber Canc Inst, Dept Med Oncol, Div Hematol Malignancies, Boston, MA 02215 USA.
[Steensma, David P.] Harvard Univ, Sch Med, Boston, MA 02215 USA.
RP Steensma, DP (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Div Hematol Malignancies, 450 Brookline Ave, Boston, MA 02215 USA.
EM david_steensma@dfci.harvard.edu
NR 89
TC 1
Z9 1
U1 0
U2 2
PU CURRENT MEDICINE GROUP
PI PHILADELPHIA
PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA
SN 1558-8211
EI 1558-822X
J9 CURR HEMATOL MALIG R
JI Curr. Hematol. Malig. Rep.
PD SEP
PY 2015
VL 10
IS 3
BP 318
EP 328
DI 10.1007/s11899-015-0273-2
PG 11
WC Oncology; Hematology
SC Oncology; Hematology
GA CQ4BK
UT WOS:000360548900016
PM 26126600
ER
PT J
AU D'Eon, SA
Pober, DM
Tinsley, LJ
Hastings, SM
King, GL
Keenan, HA
AF D'Eon, S. A.
Pober, D. M.
Tinsley, L. J.
Hastings, S. M.
King, G. L.
Keenan, H. A.
TI Lower mortality with physical activity in type 1 diabetes of extreme
duration: Joslin 50-Year Medalist study
SO DIABETOLOGIA
LA English
DT Meeting Abstract
CT 51st Annual Meeting of the
European-Association-for-the-Study-of-Diabetes (EASD)
CY SEP 14-18, 2015
CL Stockholm, SWEDEN
SP European Assoc Study Diabet
C1 [D'Eon, S. A.; Pober, D. M.; Tinsley, L. J.; Hastings, S. M.; King, G. L.; Keenan, H. A.] Joslin Diabet Ctr, Vasc Cell, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 1
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
EI 1432-0428
J9 DIABETOLOGIA
JI Diabetologia
PD SEP
PY 2015
VL 58
SU 1
MA 308
BP S155
EP S155
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CP3ZE
UT WOS:000359820900309
ER
PT J
AU Dahlstrom, EH
Todd, J
Sandholm, N
Salem, R
Forsblom, C
Tolonen, N
Harjutsalo, V
Hirschorn, J
Florez, JC
Groop, PH
AF Dahlstrom, E. H.
Todd, J.
Sandholm, N.
Salem, R.
Forsblom, C.
Tolonen, N.
Harjutsalo, V.
Hirschorn, J.
Florez, J. C.
Groop, P. -H.
TI Genetic exploration of a causal role of dyslipidaemia on diabetic
nephropathy in type 1 diabetes
SO DIABETOLOGIA
LA English
DT Meeting Abstract
CT 51st Annual Meeting of the
European-Association-for-the-Study-of-Diabetes (EASD)
CY SEP 14-18, 2015
CL Stockholm, SWEDEN
SP European Assoc Study Diabet
C1 [Dahlstrom, E. H.; Sandholm, N.; Forsblom, C.; Tolonen, N.; Harjutsalo, V.; Groop, P. -H.] Folkhalsan Inst Genet, Helsinki, Finland.
[Dahlstrom, E. H.; Sandholm, N.; Forsblom, C.; Tolonen, N.; Harjutsalo, V.; Groop, P. -H.] Abdominal Ctr Nephrol, Helsinki, Finland.
[Todd, J.; Salem, R.; Hirschorn, J.] Boston Childrens Hosp, Div Endocrinol, Boston, MA USA.
[Todd, J.; Salem, R.; Hirschorn, J.] Harvard Univ, Sch Med, Dept Pediat, Cambridge, MA 02138 USA.
[Florez, J. C.] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA.
[Florez, J. C.] Massachusetts Gen Hosp, Ctr Human Genet Res, Dept Med, Boston, MA 02114 USA.
[Florez, J. C.] Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
EI 1432-0428
J9 DIABETOLOGIA
JI Diabetologia
PD SEP
PY 2015
VL 58
SU 1
MA 1096
BP S527
EP S527
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CP3ZE
UT WOS:000359820903063
ER
PT J
AU De Jesus, DF
Kulkarni, RN
AF De Jesus, D. F.
Kulkarni, R. N.
TI Metabolic reprogramming in male offspring in a non-dietary model of
liver insulin resistance
SO DIABETOLOGIA
LA English
DT Meeting Abstract
CT 51st Annual Meeting of the
European-Association-for-the-Study-of-Diabetes (EASD)
CY SEP 14-18, 2015
CL Stockholm, SWEDEN
SP European Assoc Study Diabet
C1 [De Jesus, D. F.; Kulkarni, R. N.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Islet Cell & Regenerat Biol, Boston, MA 02115 USA.
[De Jesus, D. F.] Univ Porto, GABBA Grad Program Areas Basic & Appl Biol, Abel Salazar Biomed Sci Inst, P-4100 Oporto, Portugal.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
EI 1432-0428
J9 DIABETOLOGIA
JI Diabetologia
PD SEP
PY 2015
VL 58
SU 1
MA 239
BP S120
EP S121
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CP3ZE
UT WOS:000359820900240
ER
PT J
AU Grunberg, JR
Hoffmann, JM
Hedjazifar, S
Nerstedt, A
Jenndahl, L
Castellot, J
Wei, L
Skrtic, SM
Backhed, F
Syed, I
Saghetelian, A
Kahn, B
Hammarstedt, A
Smith, U
AF Grunberg, J. R.
Hoffmann, J. M.
Hedjazifar, S.
Nerstedt, A.
Jenndahl, L.
Castellot, J.
Wei, L.
Skrtic, S. Moverare
Backhed, F.
Syed, I.
Saghetelian, A.
Kahn, B.
Hammarstedt, A.
Smith, U.
TI Increased brown fat and insulin sensitivity in obese mice overexpressing
WISP2 in the adipose tissue
SO DIABETOLOGIA
LA English
DT Meeting Abstract
CT 51st Annual Meeting of the
European-Association-for-the-Study-of-Diabetes (EASD)
CY SEP 14-18, 2015
CL Stockholm, SWEDEN
SP European Assoc Study Diabet
C1 [Castellot, J.] Tufts Univ, Sch Med, Dept Integrat Physiol & Pathobiol, Medford, MA USA.
[Wei, L.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Syed, I.; Kahn, B.] Harvard Univ, Sch Med, Boston, MA USA.
[Saghetelian, A.] Salk Inst, San Diego, CA 92186 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
EI 1432-0428
J9 DIABETOLOGIA
JI Diabetologia
PD SEP
PY 2015
VL 58
SU 1
MA 210
BP S105
EP S106
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CP3ZE
UT WOS:000359820900211
ER
PT J
AU Hillary, KA
Khamaisi, M
Tinsley, LJ
Hastings, SM
D'Eon, S
Pober, D
Sun, JK
King, GL
AF Hillary, K. A.
Khamaisi, M.
Tinsley, L. J.
Hastings, S. M.
D'Eon, S.
Pober, D.
Sun, J. K.
King, G. L.
TI Protection from diabetic retinopathy, but not nephropathy
SO DIABETOLOGIA
LA English
DT Meeting Abstract
CT 51st Annual Meeting of the
European-Association-for-the-Study-of-Diabetes (EASD)
CY SEP 14-18, 2015
CL Stockholm, SWEDEN
SP European Assoc Study Diabet
C1 [Hillary, K. A.; Khamaisi, M.; Tinsley, L. J.; Hastings, S. M.; D'Eon, S.; Pober, D.; King, G. L.] Joslin Diabet Ctr, Vasc Cell Biol, Boston, MA 02215 USA.
[Sun, J. K.] Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
EI 1432-0428
J9 DIABETOLOGIA
JI Diabetologia
PD SEP
PY 2015
VL 58
SU 1
MA 228
BP S114
EP S115
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CP3ZE
UT WOS:000359820900229
ER
PT J
AU Kaplan, LM
Maggs, D
Liao, A
Chiquette, E
AF Kaplan, L. M.
Maggs, D.
Liao, A.
Chiquette, E.
TI Sustained effects of duodenal-jejunal bypass liner on weight loss and
glycaemic control
SO DIABETOLOGIA
LA English
DT Meeting Abstract
CT 51st Annual Meeting of the
European-Association-for-the-Study-of-Diabetes (EASD)
CY SEP 14-18, 2015
CL Stockholm, SWEDEN
SP European Assoc Study Diabet
C1 [Kaplan, L. M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Kaplan, L. M.] Harvard Univ, Sch Med, Boston, MA USA.
[Maggs, D.; Liao, A.; Chiquette, E.] GI Dynam, Lexington, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
EI 1432-0428
J9 DIABETOLOGIA
JI Diabetologia
PD SEP
PY 2015
VL 58
SU 1
MA 906
BP S437
EP S437
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CP3ZE
UT WOS:000359820902164
ER
PT J
AU Sandholm, N
Ahlqvist, E
Deshmukh, H
Van Zuydam, N
Rayner, NW
Harjutsalo, V
Marcovecchio, ML
Cooper, J
McKnight, AJ
Salem, RM
Lajer, M
Tregouet, D
Hiraki, LT
Pezzolesi, M
Forsblom, C
AF Sandholm, N.
Ahlqvist, E.
Deshmukh, H.
Van Zuydam, N.
Rayner, N. W.
Harjutsalo, V.
Marcovecchio, M. L.
Cooper, J.
McKnight, A. J.
Salem, R. M.
Lajer, M.
Tregouet, D.
Hiraki, L. T.
Pezzolesi, M.
Forsblom, C.
TI Genome-wide association studies on kidney complications in patients with
type 1 diabetes
SO DIABETOLOGIA
LA English
DT Meeting Abstract
CT 51st Annual Meeting of the
European-Association-for-the-Study-of-Diabetes (EASD)
CY SEP 14-18, 2015
CL Stockholm, SWEDEN
SP European Assoc Study Diabet
C1 [Sandholm, N.; Forsblom, C.] Univ Helsinki, Folkhalsan Inst Genet, Folkhalsan Res Ctr, FIN-00014 Helsinki, Finland.
[Sandholm, N.; Forsblom, C.] Univ Helsinki, Abdominal Ctr Nephrol, FIN-00014 Helsinki, Finland.
Helsinki Univ Hosp, Helsinki, Finland.
[Ahlqvist, E.] Lund Univ, Skane Univ Hosp, Malmo, Sweden.
[Deshmukh, H.] Univ Dundee, Dundee DD1 4HN, Scotland.
[Van Zuydam, N.; Rayner, N. W.] Wellcome Trust Ctr Human Genet, Oxford, England.
[Harjutsalo, V.] Natl Inst Hlth & Welf, Helsinki, Finland.
[Marcovecchio, M. L.; Cooper, J.] Univ Cambridge, Cambridge CB2 1TN, England.
[McKnight, A. J.] Queens Univ Belfast, Belfast BT7 1NN, Antrim, North Ireland.
[Salem, R. M.] Broad Inst, Cambridge, MA USA.
[Lajer, M.] Steno Diabet Ctr, DK-2820 Gentofte, Denmark.
[Tregouet, D.] INSERM, UMR S 1166, Paris, France.
[Hiraki, L. T.] Hosp Sick Children, Toronto, ON M5G 1X8, Canada.
[Pezzolesi, M.] Joslin Diabet Ctr, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
EI 1432-0428
J9 DIABETOLOGIA
JI Diabetologia
PD SEP
PY 2015
VL 58
SU 1
MA 179
BP S90
EP S91
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CP3ZE
UT WOS:000359820900180
ER
PT J
AU Skupien, J
Smiles, AM
Galecki, AT
Mychaleckyj, JC
Pezzolesi, MG
Krolewski, AS
AF Skupien, J.
Smiles, A. M.
Galecki, A. T.
Mychaleckyj, J. C.
Pezzolesi, M. G.
Krolewski, A. S.
TI Synergistic effect of genetic susceptibility and poor glycaemic control
on renal decline in patients with type 1 diabetes and proteinuria
SO DIABETOLOGIA
LA English
DT Meeting Abstract
CT 51st Annual Meeting of the
European-Association-for-the-Study-of-Diabetes (EASD)
CY SEP 14-18, 2015
CL Stockholm, SWEDEN
SP European Assoc Study Diabet
C1 [Skupien, J.] Jagiellonian Univ, Coll Med, Dept Metab Dis, Krakow, Poland.
[Skupien, J.; Smiles, A. M.; Pezzolesi, M. G.; Krolewski, A. S.] Joslin Diabet Ctr, Sect Genet & Epidemiol, Boston, MA 02215 USA.
[Galecki, A. T.] Univ Michigan, Ann Arbor, MI 48109 USA.
[Mychaleckyj, J. C.] Univ Virginia, Charlottesville, VA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
EI 1432-0428
J9 DIABETOLOGIA
JI Diabetologia
PD SEP
PY 2015
VL 58
SU 1
MA 180
BP S91
EP S91
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CP3ZE
UT WOS:000359820900181
ER
PT J
AU Solheim, MH
Winnay, JN
Molven, A
Njolstad, PR
Kahn, CR
AF Solheim, M. H.
Winnay, J. N.
Molven, A.
Njolstad, P. R.
Kahn, C. R.
TI Impaired PI 3-kinase signalling in a mouse model of SHORT syndrome
SO DIABETOLOGIA
LA English
DT Meeting Abstract
CT 51st Annual Meeting of the
European-Association-for-the-Study-of-Diabetes (EASD)
CY SEP 14-18, 2015
CL Stockholm, SWEDEN
SP European Assoc Study Diabet
C1 [Solheim, M. H.; Winnay, J. N.; Kahn, C. R.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA.
[Solheim, M. H.; Molven, A.; Njolstad, P. R.] Univ Bergen, Dept Clin Sci, KG Jebsen Ctr Diabetes Res, Bergen, Norway.
[Molven, A.] Univ Bergen, Dept Clin Sci, Gade Lab Pathol, Bergen, Norway.
[Njolstad, P. R.] Haukeland Hosp, Dept Pediat, N-5021 Bergen, Norway.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
EI 1432-0428
J9 DIABETOLOGIA
JI Diabetologia
PD SEP
PY 2015
VL 58
SU 1
MA 34
BP S17
EP S17
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CP3ZE
UT WOS:000359820900035
ER
PT J
AU Zhu, X
Waldron, R
Lugea, A
Li, L
AF Zhu, X.
Waldron, R.
Lugea, A.
Li, L.
TI Insulin and IGF-1 promote pancreatic stellate cells activation and
galectin-3 expression: potential role in promotion of pancreatic cancer
SO DIABETOLOGIA
LA English
DT Meeting Abstract
CT 51st Annual Meeting of the
European-Association-for-the-Study-of-Diabetes (EASD)
CY SEP 14-18, 2015
CL Stockholm, SWEDEN
SP European Assoc Study Diabet
C1 [Zhu, X.; Li, L.] Southeast Univ, Dept Endocrinol, Affiliated ZhongDa Hosp, Nanjing, Jiangsu, Peoples R China.
[Waldron, R.; Lugea, A.; Li, L.] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
[Waldron, R.; Lugea, A.; Li, L.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90048 USA.
NR 0
TC 0
Z9 0
U1 3
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
EI 1432-0428
J9 DIABETOLOGIA
JI Diabetologia
PD SEP
PY 2015
VL 58
SU 1
MA 699
BP S334
EP S334
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CP3ZE
UT WOS:000359820901388
ER
PT J
AU Karaosmanoglu, AD
Onur, MR
Shirkhoda, A
Ozmen, M
Hahn, PF
AF Karaosmanoglu, Ali Devrim
Onur, Mehmet Ruhi
Shirkhoda, Ali
Ozmen, Mustafa
Hahn, Peter F.
TI Unusual benign solid neoplasms of the kidney: cross-sectional imaging
findings
SO DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY
LA English
DT Article
AB Kidney neoplasms are common diseases with varying prognoses depending on the subtype of the tumor. The most common solid lesion of the kidney is renal cell carcinoma, and the treatment is typically surgical removal. With increasing use of cross-sectional imaging in the last two decades, the detection of renal lesions has significantly increased, especially in asymptomatic patients who are scanned for other reasons. In this article, we present the imaging findings of rare solid benign primary kidney neoplasms including renal leiomyoma, reninoma, carcinoid tumor, metanephric adenoma, solitary fibrous tumor of the kidney, lipomatous hemangiopericytoma of the kidney, renal schwannoma, inflammatory myofibroblastic tumor of the kidney, extramedullary hematopoiesis in the kidney, and extranodal renal Rosai-Dorfman disease. Accurate preoperative or prebiopsy diagnoses of these lesions are unusual; however, informed radiologists may sometimes be able to favorably change the patient management and treatment.
C1 [Karaosmanoglu, Ali Devrim; Onur, Mehmet Ruhi; Ozmen, Mustafa] Hacettepe Univ, Sch Med, Dept Radiol, Ankara, Turkey.
[Shirkhoda, Ali] Univ Calif Irvine, Sch Med, Dept Radiol, Irvine, CA 92717 USA.
[Hahn, Peter F.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA USA.
RP Onur, MR (reprint author), Hacettepe Univ, Sch Med, Dept Radiol, Ankara, Turkey.
EM ruhionur@yahoo.com
NR 15
TC 1
Z9 1
U1 0
U2 7
PU TURKISH SOC RADIOLOGY
PI ANKARA
PA HOSDERE CAD, GUZELKENT SOK, CANKAYA EVLERI, F-2, ANKARA, 06540, TURKEY
SN 1305-3825
EI 1305-3612
J9 DIAGN INTERV RADIOL
JI Diagn. Interv. Radiol.
PD SEP-OCT
PY 2015
VL 21
IS 5
BP 376
EP 381
DI 10.5152/dir.2015.14545
PG 6
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CQ4CE
UT WOS:000360551000003
PM 26200482
ER
PT J
AU Khalilzadeh, O
Rahimian, M
Batchu, V
Vadvala, HV
Novelline, RA
Choy, G
AF Khalilzadeh, Omid
Rahimian, Maryam
Batchu, Vinay
Vadvala, Harshna V.
Novelline, Robert A.
Choy, Garry
TI Effectiveness of second-opinion radiology consultations to reassess the
cervical spine CT scans: a study on trauma patients referred to a
tertiary-care hospital
SO DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY
LA English
DT Article
ID INJURIES
AB PURPOSE
A second opinion is a valuable resource in confirming proper medical diagnosis and treatment. This study evaluates the effectiveness of second-opinion radiology consultations to reassess the cervical spine computed tomography (CT) scans of the trauma patients referred to our hospital.
METHODS
Cervical spine CT scans of 301 consecutive adult trauma patients, who were referred to our hospital from outside institutions, were analyzed. The emergency radiologists at our institution completed the over-read reports on the CT images obtained at the outside facilities. A single radiologist compared the outside-and over-read reports and determined the discrepancy of the radiologic reports.
RESULTS
Based on the outside reports, 31% of the CT scans had cervical traumatic injury. In 92% of patients, the first-read and the over-read reports had consistent radiologic findings. About 90% of the positive, and 93% of the negative radiologic findings, were reported consistently in the over-read reports. Our analysis showed that the over-read reporting resulted in reassurance of negative findings in 63%; confirmation of positive findings in 29%; clearing a false diagnosis in 3%; and detection of a missed diagnosis in 5%. A rescan was done in 80% of patients with inconsistent and 20% of patients with consistent findings (P < 0.05). The most common missed radiologic findings in the first-reports were transverse and spinous process fractures and the most common misdiagnoses were dens fractures.
CONCLUSION
For a service offering second-opinion consultations on cervical spine trauma, review of outside CT studies improves diagnosis and benefits patient care.
C1 [Choy, Garry] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
RP Choy, G (reprint author), Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
EM gchoy@partners.org
NR 18
TC 0
Z9 0
U1 0
U2 1
PU TURKISH SOC RADIOLOGY
PI ANKARA
PA HOSDERE CAD, GUZELKENT SOK, CANKAYA EVLERI, F-2, ANKARA, 06540, TURKEY
SN 1305-3825
EI 1305-3612
J9 DIAGN INTERV RADIOL
JI Diagn. Interv. Radiol.
PD SEP-OCT
PY 2015
VL 21
IS 5
BP 423
EP 427
DI 10.5152/dir.2015.15003
PG 5
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CQ4CE
UT WOS:000360551000012
PM 26200483
ER
PT J
AU Prakash, SR
Herrmann, BS
Milojcic, R
Rauch, SD
Guinan, JJ
AF Prakash, S. R.
Herrmann, Barbara S.
Milojcic, Rupprecht
Rauch, Steven D.
Guinan, John J.
TI Evaluating Inhibition of Motoneuron Firing From Electromyogram Data to
Assess Vestibular Output Using Vestibular Evoked Myogenic Potentials
SO EAR AND HEARING
LA English
DT Article
DE cVEMP; Electromyogram; EMG; oVEMP; VEMP; Vestibulocollic reflex
ID MOTOR-UNIT; STERNOCLEIDOMASTOID MUSCLE; ISOMETRIC CONTRACTIONS; EMG;
MODEL; GENERATION; NERVE; NOISE; NORMALIZATION; RECRUITMENT
AB Objectives: Vestibular evoked myogenic potentials (VEMPs) are due to vestibular responses producing brief inhibitions of muscle contractions that are detectable in electromyographic (EMG) responses. VEMP amplitudes are traditionally measured by the peak to peak amplitude of the averaged EMG response (VEMPpp) or by a normalized VEMPpp (nVEMPpp). However, a brief EMG inhibition does not satisfy the statistical assumptions for the average to be the optimal processing strategy. Here, it is postulated that the inhibition depth of motoneuron firing is the desired metric for showing the influence of the vestibular system on the muscle system. The authors present a metric called VEMPid that estimates this inhibition depth from the EMG data obtained in a usual VEMP data acquisition. The goal of this article was to compare how well VEMPid, VEMPpp, and nVEMPpp track inhibition depth.
Design: To find a robust method to compare VEMPid, VEMPpp, and nVEMPpp, realistic physiological models for the inhibition of VEMP EMG signals were made using VEMP data from four measurement sessions on each of the five normal subjects. Each of the resulting 20 EMG-production models was adjusted to match the EMG autocorrelation of an individual subject and session. Simulated VEMP traces produced by these models were used to compare how well VEMPid, VEMPpp, and nVEMPpp tracked model inhibition depth.
Results: Applied to simulated and real VEMP data, VEMPid showed good test-retest consistency and greater sensitivity at low stimulus levels than VEMPpp or nVEMPpp. For large-amplitude responses, nVEMPpp and VEMPid were equivalent in their consistency across subjects and sessions, but for low-amplitude responses, VEMPid was superior. Unnormalized VEMPpp was always worse than nVEMPpp or VEMPid.
Conclusions: VEMPid provides a more reliable measurement of vestibular function at low sound levels than the traditional nVEMPpp, without requiring a change in how VEMP tests are performed. The calculation method for VEMPid should be applicable whenever an ongoing muscle contraction is briefly inhibited by an external stimulus.
C1 [Prakash, S. R.; Herrmann, Barbara S.; Guinan, John J.] MIT, Harvard Mit Div Hlth Sci & Technol, Speech & Hearing Biosci & Technol Program, Cambridge, MA 02139 USA.
[Prakash, S. R.; Herrmann, Barbara S.; Milojcic, Rupprecht; Rauch, Steven D.; Guinan, John J.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
[Prakash, S. R.; Milojcic, Rupprecht; Rauch, Steven D.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA.
[Herrmann, Barbara S.] Massachusetts Eye & Ear Infirm, Dept Audiol, Boston, MA 02114 USA.
[Guinan, John J.] Massachusetts Eye & Ear Infirm, Eaton Peabody Labs, Boston, MA 02114 USA.
RP Guinan, JJ (reprint author), Massachusetts Eye & Ear Infirm, Eaton Peabody Labs, Boston, MA 02114 USA.
EM jjg@epl.meei.harvard.edu
NR 50
TC 0
Z9 0
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0196-0202
EI 1538-4667
J9 EAR HEARING
JI Ear Hear.
PD SEP-OCT
PY 2015
VL 36
IS 5
BP 591
EP 604
DI 10.1097/AUD.0000000000000158
PG 14
WC Audiology & Speech-Language Pathology; Otorhinolaryngology
SC Audiology & Speech-Language Pathology; Otorhinolaryngology
GA CQ5GI
UT WOS:000360630900011
PM 25811931
ER
PT J
AU Tsvetkov, P
Mendillo, ML
Zhao, JH
Carette, JE
Merrill, PH
Cikes, D
Varadarajan, M
van Diemen, FR
Penninger, JM
Goldberg, AL
Brummelkamp, TR
Santagata, S
Lindquist, S
AF Tsvetkov, Peter
Mendillo, Marc L.
Zhao, Jinghui
Carette, Jan E.
Merrill, Parker H.
Cikes, Domagoj
Varadarajan, Malini
van Diemen, Ferdy R.
Penninger, Josef M.
Goldberg, Alfred L.
Brummelkamp, Thijn R.
Santagata, Sandro
Lindquist, Susan
TI Compromising the 19S proteasome complex protects cells from reduced flux
through the proteasome
SO ELIFE
LA English
DT Article
ID EMBRYONIC STEM-CELLS; 26S PROTEASOME; HEAT-SHOCK;
SACCHAROMYCES-CEREVISIAE; STATIONARY-PHASE; OXIDATIVE STRESS; 20S
PROTEASOMES; CANCER-CELLS; DEGRADATION; INHIBITORS
AB Proteasomes are central regulators of protein homeostasis in eukaryotes. Proteasome function is vulnerable to environmental insults, cellular protein imbalance and targeted pharmaceuticals. Yet, mechanisms that cells deploy to counteract inhibition of this central regulator are little understood. To find such mechanisms, we reduced flux through the proteasome to the point of toxicity with specific inhibitors and performed genome-wide screens for mutations that allowed cells to survive. Counter to expectation, reducing expression of individual subunits of the proteasome's 19S regulatory complex increased survival. Strong 19S reduction was cytotoxic but modest reduction protected cells from inhibitors. Protection was accompanied by an increased ratio of 20S to 26S proteasomes, preservation of protein degradation capacity and reduced proteotoxic stress. While compromise of 19S function can have a fitness cost under basal conditions, it provided a powerful survival advantage when proteasome function was impaired. This means of rebalancing proteostasis is conserved from yeast to humans.
C1 [Tsvetkov, Peter; Varadarajan, Malini; Santagata, Sandro; Lindquist, Susan] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.
[Mendillo, Marc L.; Lindquist, Susan] MIT, Howard Hughes Med Inst, Dept Biol, Cambridge, MA 02139 USA.
[Zhao, Jinghui; Goldberg, Alfred L.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA USA.
[Carette, Jan E.] Stanford Univ, Dept Microbiol & Immunol, Sch Med, Stanford, CA 94305 USA.
[Merrill, Parker H.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Cikes, Domagoj; Penninger, Josef M.] Austrian Acad Sci, Inst Mol Biotechnol, A-1010 Vienna, Austria.
[van Diemen, Ferdy R.; Brummelkamp, Thijn R.] Netherlands Canc Inst, Dept Biochem, Amsterdam, Netherlands.
[Santagata, Sandro] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Santagata, Sandro] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
RP Santagata, S (reprint author), Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.
EM ssantagata@bics.bwh.harvard.edu; lindquist_admin@wi.mit.edu
RI Penninger, Josef/I-6860-2013
OI Penninger, Josef/0000-0002-8194-3777
FU EMBO [ALTF 739-2011]; National Institutes of Health (NIH) [K08NS064168];
The Medical Foundation (TMF)
FX EMBO ALTF 739-2011 Peter Tsvetkov; National Institutes of Health (NIH)
K08NS064168 Sandro Santagata; The Medical Foundation (TMF) Charles A.
King Trust Peter Tsvetkov
NR 79
TC 6
Z9 6
U1 0
U2 7
PU ELIFE SCIENCES PUBLICATIONS LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050-084X
J9 ELIFE
JI eLife
PD SEP 1
PY 2015
VL 4
AR e08467
DI 10.7554/eLife.08467
PG 22
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA CQ5QT
UT WOS:000360661200001
ER
PT J
AU Wang, YH
Scadden, DT
AF Wang, Ying-Hua
Scadden, David T.
TI Harnessing the apoptotic programs in cancer stem-like cells
SO EMBO REPORTS
LA English
DT Review
DE apoptosis; cancer stem cells; cancer therapy
ID ACUTE MYELOID-LEUKEMIA; TRAIL-INDUCED APOPTOSIS; TUMOR-INITIATING CELLS;
HEPATOCELLULAR-CARCINOMA CELLS; SMALL-MOLECULE INHIBITORS; DR5
MONOCLONAL-ANTIBODY; BCL-2 FAMILY PROTEINS; HUMAN GLIOMA-CELLS;
LUNG-CANCER; DOWN-REGULATION
AB Elimination of malignant cells is an unmet challenge for most human cancer types even with therapies targeting specific driver mutations. Therefore, a multi-pronged strategy to alter cancer cell biology on multiple levels is increasingly recognized as essential for cancer cure. One such aspect of cancer cell biology is the relative apoptosis resistance of tumor-initiating cells. Here, we provide an overview of the mechanisms affecting the apoptotic process in tumor cells emphasizing the differences in the tumor-initiating or stem-like cells of cancer. Further, we summarize efforts to exploit these differences to design therapies targeting that important cancer cell population.
C1 [Wang, Ying-Hua; Scadden, David T.] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA.
[Wang, Ying-Hua; Scadden, David T.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Wang, Ying-Hua; Scadden, David T.] Harvard Stem Cell Inst, Cambridge, MA USA.
[Wang, Ying-Hua; Scadden, David T.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
RP Scadden, DT (reprint author), Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA.
EM dscadden@mgh.harvard.edu
NR 167
TC 2
Z9 3
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-221X
EI 1469-3178
J9 EMBO REP
JI EMBO Rep.
PD SEP
PY 2015
VL 16
IS 9
BP 1084
EP 1098
PG 15
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA CQ6LP
UT WOS:000360716200008
PM 26253117
ER
PT J
AU Lal, D
Pernhorst, K
Klein, KM
Reif, P
Tozzi, R
Toliat, MR
Winterer, G
Neubauer, B
Nurnberg, P
Rosenow, F
Becker, F
Lerche, H
Kunz, WS
Kurki, MI
Hoffmann, P
Becker, AJ
Perucca, E
Zara, F
Sander, T
Weber, YG
AF Lal, Dennis
Pernhorst, Katharina
Klein, Karl Martin
Reif, Philipp
Tozzi, Rossana
Toliat, Mohammad R.
Winterer, Georg
Neubauer, Bernd
Nuernberg, Peter
Rosenow, Felix
Becker, Felicitas
Lerche, Holger
Kunz, Wolfram S.
Kurki, Mitja I.
Hoffmann, Per
Becker, Albert J.
Perucca, Emilio
Zara, Federico
Sander, Thomas
Weber, Yvonne G.
TI Extending the phenotypic spectrum of RBFOX1 deletions: Sporadic focal
epilepsy
SO EPILEPSIA
LA English
DT Article
DE Copy number variation; Idiopathic; Genetic; Cryptogenic; Magnet
resonance imaging negative; Lesional
ID GENERALIZED EPILEPSY; MODEL; DISEASE; BRAIN; RISK
AB Partial deletions of the RBFOX1 gene encoding the neuronal splicing regulator have been reported in a range of neurodevelopmental diseases including idiopathic/genetic generalized epilepsy (IGE/GGE), childhood focal epilepsy, and self-limited childhood benign epilepsy with centrotemporal spikes (BECTS, rolandic epilepsy), and autism. The protein regulates alternative splicing of many neuronal transcripts involved in the homeostatic control of neuronal excitability. Herein, we examined whether structural deletions affecting RBFOX1 exons confer susceptibility to common forms of juvenile and adult focal epilepsy syndromes. We screened 807 unrelated patients with sporadic focal epilepsy, and we identified seven hemizygous exonic RBFOX1 deletions in patients with sporadic focal epilepsy (0.9%) in comparison to one deletion found in 1,502 controls. The phenotypes of the patients carrying RBFOX1 deletions comprise magnetic resonance imaging (MRI)-negative epilepsy of unknown etiology with frontal and temporal origin (n=5) and two patients with temporal lobe epilepsy with hippocampal sclerosis. The epilepsies were largely pharmacoresistant but not associated with intellectual disability. Our study extends the phenotypic spectrum of RBFOX1 deletions as a risk factor for focal epilepsy and suggests that exonic RBFOX1 deletions are involved in the broad spectrum of focal and generalized epilepsies.
C1 [Lal, Dennis; Toliat, Mohammad R.; Winterer, Georg; Nuernberg, Peter; Sander, Thomas] Univ Cologne, Cologne Excellence Cluster Cellular Stress Respon, D-50931 Cologne, Germany.
[Lal, Dennis; Neubauer, Bernd] Univ Med Ctr Giessen & Marburg, Dept Neuropediat, Giessen, Germany.
[Lal, Dennis] Univ Cologne, Cologne Ctr Genom, D-50931 Cologne, Germany.
[Pernhorst, Katharina; Becker, Albert J.] Univ Bonn, Dept Neuropathol, Bonn, Germany.
[Klein, Karl Martin; Reif, Philipp; Rosenow, Felix] Univ Marburg, Dept Neurol, Marburg, Germany.
[Tozzi, Rossana; Perucca, Emilio] C Mondino Natl Neurol Inst, Pavia, Italy.
[Becker, Felicitas; Lerche, Holger; Weber, Yvonne G.] Univ Tubingen, Hertie Inst Clin Brain Res, Dept Neurol & Epileptol, D-72076 Tubingen, Germany.
[Kunz, Wolfram S.] Univ Bonn, Life & Brain Ctr, Bonn, Germany.
[Kurki, Mitja I.] Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA.
[Kurki, Mitja I.] Broad Inst Harvard & MIT, Cambridge, MA USA.
[Kurki, Mitja I.] Kuopio Univ Hosp, NeuroCtr, Neurosurg, SF-70210 Kuopio, Finland.
[Hoffmann, Per] Univ Bonn, Inst Human Genet, Bonn, Germany.
[Hoffmann, Per] Univ Basel Hosp, Div Med Genet, CH-4031 Basel, Switzerland.
[Hoffmann, Per] Univ Basel, Dept Biomed, Basel, Switzerland.
[Perucca, Emilio] Univ Pavia, Dept Internal Med & Therapeut, I-27100 Pavia, Italy.
[Zara, Federico] Ist Giannina Gaslini, Neurogenet Lab, Neuromuscular Dis Unit, I-16148 Genoa, Italy.
RP Weber, YG (reprint author), Univ Tubingen, Hertie Inst Clin Brain Res, Dept Neurol & Epileptol, Hoppe SeylerStr 3, D-72076 Tubingen, Germany.
EM Yvonne.weber@uni-tuebingen.de
RI Becker, Albert/F-6248-2012;
OI Klein, Karl Martin/0000-0002-6654-1665
FU Italian League against Epilepsy (LICE); European Community [LSHCT-2006-
037315]; Klaus-Dieter Scharf Research Project Marburg; Stiftung P.E.
Kempkes Marburg
FX This study was supported by grants from the Italian League against
Epilepsy (LICE) and from the European Community's Sixth Framework
Programme (Integrated Project EPICURE, contract number: LSHCT-2006-
037315). In addition to the authors, the following investigators from
Italian centers participated in the study: Umberto Aguglia, Angelo
Labate, Institute of Neurology, University Magna Graecia, Catanzaro;
Fabrizio Balestrieri, Unit of Neurology, Palagi Hospital, Firenze;
Amedeo Bianchi, Division of Neurology, Ospedale S Donato, Arezzo;
Francesca Beccaria, Giuseppe Capovilla, Epilepsy Center, Department of
Child Neuropsychiatry, C. Poma Hospital, Mantova; Paolo Benna, Rossella
Colonna, Elisa Montalenti, Division of Neurology, University of Turin;
Clementina Boniver, Marilena Vecchi, Division of Pediatric Neurology,
University of Padua; Roberto Campostrini, Paolo Forleo, Epilepsy Center,
Ospedale Misericordia e Dolce, Prato; Maria P. Canevini, Rosanna
Chifari, Epilepsy Center, S. Paolo Hospital, Milan; Barbara Chiocchetti,
Giancarlo Muscas, Eleonora Rosati, 3rd Neurology Division and Epilepsy
Center, Careggi Hospital, Florence; Patrizia D'Alessandro, Epilepsy
Centre, Unit of Neurophysiopathology, Perugia; Christine Durisotti, Pier
Gaetano Garofalo, Epilepsy Center, Civil Hospital, Vicenza; Maurizio
Elia, Oasi Institute for Research on Mental Retardation and Brain Aging
(IRCCS), Troina; Cinzia Fattore, C. Mondino National Neurological
Institute, Pavia; Roberto Gaggero, Maria Maddalena Mancardi, Division of
Neuropsychiatry, Istituto G. Gaslini, Genova; Antonio Gambardella,
Institute of Neurology, University Magna Grecia, Catanzaro, Italy; Anna
T. Giallonardo, Gabriella Egeo, Department of Neurological Sciences,
Policlinico Umberto I, Sapienza University of Rome; Alfonso Iudice,
Stella Jensen, Department of Neurosciences, University of Pisa; Angela
La Neve, Nicola Specchio, Epilepsy Center, Neurology Hospital Amaducci,
University of Bari; Ida Manna, Francesca Condino, Institute of
Neurological Sciences, National Research Council, Mangone-Cosenza;
Daniela Marino, Raffaele Rocchi, Gian Paolo Vatti, Epilepsy Centre,
University of Siena; Roberto Michelucci, Stefania Testoni, Division of
Neurology, Bellaria Hospital, Bologna; Roberta Paravidino, Laboratory of
Human Genetics, E.O. Ospedali Galliera, Genoa; Pasquale Striano,
Laboratory of Neurogenetics, Neuromuscular Disease Unit, Istituto G.
Gaslini, Genoa; Francesca Vanadia, Service of Neuropsychiatry, Ospedale
Civico, Palermo; Gaetano Zaccara, Unit of Neurology, Palagi Hospital,
Firenze; Claudio Zucca, Clinical Neurophysiology Unit, E. Medear
Scientific Institute, Lecco, Italy. This study was supported by the
Klaus-Dieter Scharf Research Project Marburg and the Stiftung P.E.
Kempkes Marburg.
NR 12
TC 3
Z9 3
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0013-9580
EI 1528-1167
J9 EPILEPSIA
JI Epilepsia
PD SEP
PY 2015
VL 56
IS 9
BP E129
EP E133
DI 10.1111/epi.13076
PG 5
WC Clinical Neurology
SC Neurosciences & Neurology
GA CQ7PF
UT WOS:000360795400003
PM 26174448
ER
PT J
AU Martin, NE
AF Martin, Neil E.
TI Doing It Right: How, Not Whether, To Perform Prostate-specific Antigen
Screening
SO EUROPEAN UROLOGY
LA English
DT Editorial Material
ID TASK-FORCE RECOMMENDATION; FOLLOW-UP; CANCER
C1 Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA 02115 USA.
RP Martin, NE (reprint author), Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, ASB 1,L2,75 Francis St, Boston, MA 02115 USA.
EM nmartin@lroc.harvard.edu
RI Martin, Neil/E-2193-2014
OI Martin, Neil/0000-0002-8164-8516
NR 9
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0302-2838
EI 1873-7560
J9 EUR UROL
JI Eur. Urol.
PD SEP
PY 2015
VL 68
IS 3
BP 361
EP 362
DI 10.1016/j.eururo.2015.02.035
PG 2
WC Urology & Nephrology
SC Urology & Nephrology
GA CQ4JZ
UT WOS:000360572300011
PM 25794459
ER
PT J
AU DiPaola, RS
Chen, YH
Bubley, GJ
Stein, MN
Hahn, NM
Carducci, MA
Lattime, EC
Gulley, JL
Arlen, PM
Butterfield, LH
Wilding, G
AF DiPaola, Robert S.
Chen, Yu-Hui
Bubley, Glenn J.
Stein, Mark N.
Hahn, Noah M.
Carducci, Michael A.
Lattime, Edmund C.
Gulley, James L.
Arlen, Philip M.
Butterfield, Lisa H.
Wilding, George
TI A National Multicenter Phase 2 Study of Prostate-specific Antigen (PSA)
Pox Virus Vaccine with Sequential Androgen Ablation Therapy in Patients
with PSA Progression: ECOG 9802
SO EUROPEAN UROLOGY
LA English
DT Article
DE Prostate cancer; Pox virus; Vaccine; PSA
ID DEPRIVATION THERAPY; ONCOLOGY-GROUP; CANCER; IMMUNOTHERAPY; SURVIVAL;
IMPACT; TRIAL
AB Background: E9802 was a phase 2 multi-institution study conducted to evaluate the safety and effectiveness of vaccinia and fowlpox prostate-specific antigen (PSA) vaccine (step 1) followed by combination with androgen ablation therapy (step 2) in patients with PSA progression without visible metastasis.
Objective: To test the hypothesis that vaccine therapy in this early disease setting will be safe and have a biochemical effect that would support future studies of immunotherapy in patients with minimal disease burden.
Design, setting, and participants: Patients who had PSA progression following local therapy were treated with PROSTVAC-V (vaccinia)/TRICOM on cycle 1 followed by PROSTVAC-F (fowlpox)/TRICOM for subsequent cycles in combination with granulocyte- macrophage colony-stimulating factor (step 1). Androgen ablation was added on progression (step 2).
Outcome measurements and statistical analysis: Step 1 primary end points included progression at 6 mo and characterization of change in PSA velocity pretreatment to post-treatment. Step 2 end points included PSA response with combined vaccine and androgen ablation.
Results and limitations: In step 1, 25 of 40 eligible patients (63%) were progression free at 6mo after registration (90% confidence interval [CI], 48-75). The median pretreatment PSA velocity was 0.13 log(PSA)/mo, in contrast to median postregistration velocity of 0.09 log(PSA)/mo (p = 0.02), which is an increase in median PSA doubling time from 5.3 mo to 7.7 mo. No grade >= 4 treatment-related toxicity was observed. In the 27 patients eligible and treated for step 2, 20 patients achieved a complete response (CR) at 7 mo (CR rate: 74%; 90% CI, 57-87). Although supportive of larger studies in the cooperative group setting, this study is limited by the small number of patients and the absence of a control group as in a phase 3 study.
Conclusions: A viral PSA vaccine can be administered safely in the multi-institutional cooperative group setting to patients with minimal disease volume alone and combined withandrogenablation, supporting the feasibility of futurephase 3studies in thispopulation.
Patient summary: These data support consideration of vaccine therapy earlier in the course of prostate cancer progression with minimal disease burden in future studies of vaccine approaches in earlier stages of disease. (C) 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.
C1 [DiPaola, Robert S.; Stein, Mark N.; Lattime, Edmund C.] Rutgers Canc Inst New Jersey, New Brunswick, NJ 08901 USA.
[Chen, Yu-Hui] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Bubley, Glenn J.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Hahn, Noah M.] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA.
[Carducci, Michael A.] Johns Hopkins Univ, Baltimore, MD USA.
[Gulley, James L.; Arlen, Philip M.] NCI, Bethesda, MD 20892 USA.
[Butterfield, Lisa H.] Univ Pittsburgh, Pittsburgh, PA USA.
[Wilding, George] Univ Wisconsin, UW Carbone Canc Ctr, Madison, WI USA.
RP DiPaola, RS (reprint author), Rutgers Canc Inst New Jersey, 195 Little Albany St, New Brunswick, NJ 08901 USA.
EM Robert.DiPaola@rutgers.edu
RI Gulley, James/K-4139-2016
OI Gulley, James/0000-0002-6569-2912
FU Public Health Service [CA23318, CA66636, CA21115, CA80775, CA49883,
CA16116, CA21076]; National Cancer Institute (NCI), National Institutes
of Health; Department of Health and Human Services
FX This study was conducted by the ECOG-ACRIN Cancer Research Group (Robert
L. Comis, MD, and Mitchell D. Schnall, MD, PhD, group cochairs) and
supported in part by Public Health Service Grants CA23318, CA66636,
CA21115, CA80775, CA49883, CA16116, CA21076, and from the National
Cancer Institute (NCI), National Institutes of Health, and the
Department of Health and Human Services. Its content is solely the
responsibility of the authors and does not necessarily represent the
official views of the NCI. Only the first step of the study (step 1:
vaccine alone) was presented at the Genitourinary American Society of
Clinical Oncology Annual Meeting 2009; step 2 data (combined androgen
ablation and vaccine) has not been presented.
NR 19
TC 4
Z9 4
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0302-2838
EI 1873-7560
J9 EUR UROL
JI Eur. Urol.
PD SEP
PY 2015
VL 68
IS 3
BP 365
EP 371
DI 10.1016/j.eururo.2014.12.010
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA CQ4JZ
UT WOS:000360572300013
PM 25533418
ER
PT J
AU Martin, NE
AF Martin, Neil E.
TI Improving What Matters
SO EUROPEAN UROLOGY
LA English
DT Editorial Material
ID LOCALIZED PROSTATE-CANCER; MORTALITY; OUTCOMES; TRIAL; MEN
C1 Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA 02115 USA.
RP Martin, NE (reprint author), Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, 75 Francis St,ASB 1,L2, Boston, MA 02115 USA.
EM nmartin@lroc.harvard.edu
RI Martin, Neil/E-2193-2014
OI Martin, Neil/0000-0002-8164-8516
NR 10
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0302-2838
EI 1873-7560
J9 EUR UROL
JI Eur. Urol.
PD SEP
PY 2015
VL 68
IS 3
BP 384
EP 385
DI 10.1016/j.eururo.2015.05.004
PG 2
WC Urology & Nephrology
SC Urology & Nephrology
GA CQ4JZ
UT WOS:000360572300016
PM 26004798
ER
PT J
AU Nguyen, PL
D'Amico, AV
AF Nguyen, Paul L.
D'Amico, Anthony V.
TI Toward Personalizing the Use of Androgen Deprivation Therapy to Maximize
Benefit and Minimize Harm
SO EUROPEAN UROLOGY
LA English
DT Editorial Material
ID PROSTATE-CANCER; CARDIOVASCULAR-DISEASE
C1 [Nguyen, Paul L.; D'Amico, Anthony V.] Harvard Univ, Sch Med, Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA 02115 USA.
RP Nguyen, PL (reprint author), Harvard Univ, Sch Med, Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, 75 Francis St, Boston, MA 02115 USA.
EM pnguyen@LROC.harvard.edu
NR 11
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0302-2838
EI 1873-7560
J9 EUR UROL
JI Eur. Urol.
PD SEP
PY 2015
VL 68
IS 3
BP 397
EP 398
DI 10.1016/j.eururo.2014.12.019
PG 2
WC Urology & Nephrology
SC Urology & Nephrology
GA CQ4JZ
UT WOS:000360572300018
PM 25542627
ER
PT J
AU Kroeger, N
Pantuck, AJ
Wells, JC
Lawrence, N
Broom, R
Kim, JJ
Srinivas, S
Yim, J
Bjarnason, GA
Templeton, A
Knox, J
Bernstein, E
Smoragiewicz, M
Lee, J
Rini, BI
Vaishampayan, UN
Woodm, LA
Beuselinck, B
Donskov, F
Choueiri, TK
Heng, DY
AF Kroeger, Nils
Pantuck, Allan J.
Wells, J. Connor
Lawrence, Nicola
Broom, Reuben
Kim, Jenny J.
Srinivas, Sandy
Yim, Jessica
Bjarnason, Georg A.
Templeton, Arnoud
Knox, Jennifer
Bernstein, Ezra
Smoragiewicz, Martin
Lee, Jae
Rini, Brian I.
Vaishampayan, Ulka N.
Woodm, Lori A.
Beuselinck, Benoit
Donskov, Frede
Choueiri, Toni K.
Heng, Daniel Y.
TI Characterizing the Impact of Lymph Node Metastases on the Survival
Outcome for Metastatic Renal Cell Carcinoma Patients Treated with
Targeted Therapies
SO EUROPEAN UROLOGY
LA English
DT Article
DE Lymph node metastases; Lymph nodes; Targeted therapies; Treatment
response; Survival outcome; Renal cell carcinoma
ID DATABASE CONSORTIUM; RADICAL NEPHRECTOMY; PROGNOSTIC-FACTORS;
DISSECTION; LYMPHADENECTOMY; VALIDATION; CANCER; MODEL
AB Background: It is unknown whether lymph node metastases (LNM) and their localization negatively affect clinical outcome in metastatic renal cell carcinoma (mRCC) patients.
Objective: To evaluate the clinicopathological features, survival outcome, and treatment response in mRCC patients with LNM versus those without LNM after treatment with targeted therapies (TT).
Design, setting, and participants: Patients (n = 2996) were first analyzed without consideration of lymph node (LN) localization or histologic subtype. Additional analyses (n = 1536) were performed in subgroups of patients with supradiaphragmatic (SPD) LNM, subdiaphragmatic (SBD) LNM, and patients with LNM in both locations (SPD+/SBD+) without histologic considerations, and then separately in clear cell RCC (ccRCC) and non-clear cell RCC (nccRCC) patients, respectively.
Outcome measurements and statistical analysis: The primary outcome was overall survival (OS) and the secondary outcome was progression-free survival (PFS).
Results and limitations: All patients with LNM had worse PFS (p = 0.001) and OS (p < 0.001) compared to those without LNM. Compared to patients without LNM (PFS 8.8 mo; OS 25.1 mo), any SBD LNM involvement was associated with worse PFS (SBD, 6.8 mo; p = 0.003; SPD+/SBD+, 5.5 mo; p < 0.001) and OS (SBD, 16.2 mo; p < 0.001; SPD+/SBD+, 11.5 mo; p < 0.001). Both SBD and SPD+/SBD+ LNM were retained as independent prognostic factors in multivariate analyses (MVA) for PFS (p = 0.006 and p = 0.022, respectively) and OS (both p < 0.001), while SPD LNM was not an independent risk factor. Likewise, in ccRCC, SBD LNM (19.8 mo) and SPD+/SBD+ LNM (12.85 mo) patients had the worst OS. SPD+/SBD+LNM (p = 0.006) and SBD LNM (p = 0.028) were independent prognostic factors for OS in MVA, while SPD LNM was not significant (p = 0.301). The study is limited by its retrospective design and the lack of pathologic evaluation of LNM in all cases.
Conclusions: The metastatic spread of RCC to SBD lymph nodes is associated with poor prognosis in mRCC patients treated with TT.
Patient summary: The presence of lymph node metastases below the diaphragm is associated with shorter survival outcome when metastatic renal cell carcinoma (mRCC) patients are treated with targeted therapies. Clinical trials should evaluate whether surgical removal of regional lymph nodes at the time of nephrectomy may improve outcomes in high-risk RCC patients. (C) 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.
C1 [Kroeger, Nils; Wells, J. Connor; Heng, Daniel Y.] Univ Calgary, Tom Baker Canc Ctr, Dept Med Oncol, Calgary, AB T2N 4N2, Canada.
[Kroeger, Nils] Univ Med, Dept Urol, Greifswald, Germany.
[Kroeger, Nils; Pantuck, Allan J.; Bernstein, Ezra] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Inst Urol Oncol, Los Angeles, CA 90095 USA.
[Lawrence, Nicola; Broom, Reuben] Auckland City Hosp, Auckland, New Zealand.
[Kim, Jenny J.] Johns Hopkins Univ Hosp, Dept Med Oncol, Baltimore, MD 21287 USA.
[Srinivas, Sandy] Stanford Med Ctr, Div Oncol, Stanford, CA USA.
[Yim, Jessica; Bjarnason, Georg A.] Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada.
[Templeton, Arnoud; Knox, Jennifer] Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Dept Med Oncol, Toronto, ON, Canada.
[Smoragiewicz, Martin] Univ British Columbia, British Columbia Canc Agcy, Dept Med Oncol, Vancouver, BC V5Z 1M9, Canada.
[Lee, Jae] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea.
[Rini, Brian I.] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA.
[Vaishampayan, Ulka N.] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
[Woodm, Lori A.] Dalhousie Univ, Queen Elizabeth II Hlth Sci Ctr, Halifax, NS, Canada.
[Beuselinck, Benoit] Katholieke Univ Leuven, Dept Gen Med Oncol, Leuven, Belgium.
[Beuselinck, Benoit] Katholieke Univ Leuven, Leuven Canc Inst, Univ Hosp Leuven, Expt Oncol Lab, Leuven, Belgium.
[Donskov, Frede] Aarhus Univ Hosp, Dept Oncol, DK-8000 Aarhus, Denmark.
[Choueiri, Toni K.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Heng, DY (reprint author), Univ Calgary, Tom Baker Canc Ctr, 1331 29th St NW, Calgary, AB T2N 4N2, Canada.
EM daniel.heng@albertahealthservices.ca
OI Bjarnason, Georg Arnold/0000-0001-6903-5357; Donskov,
Frede/0000-0002-8449-863X
FU Trust family; Loker Pinard and Michael Brigham Funds for Kidney Cancer
Research at the Dana-Farber Cancer Institute
FX Dr. Choueiri is supported in part by the Trust family and the Loker
Pinard and Michael Brigham Funds for Kidney Cancer Research at the
Dana-Farber Cancer Institute. Dr. Kroeger thanks Dr. Klatte, Department
of Urology, Medical University of Vienna, for statistical advice.
NR 23
TC 5
Z9 5
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0302-2838
EI 1873-7560
J9 EUR UROL
JI Eur. Urol.
PD SEP
PY 2015
VL 68
IS 3
BP 506
EP 515
DI 10.1016/j.eururo.2014.11.054
PG 10
WC Urology & Nephrology
SC Urology & Nephrology
GA CQ4JZ
UT WOS:000360572300035
PM 25524810
ER
PT J
AU Ambrecht, LA
Perlman, JI
McDonnell, JF
Zhai, YG
Qiao, L
Bu, P
AF Ambrecht, Lindsay A.
Perlman, Jay I.
McDonnell, James F.
Zhai, Yougang
Qiao, Liang
Bu, Ping
TI Protection of retinal function by sulforaphane following retinal
ischemic injury
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Sulforaphane; Retinal ischemic reperfusion injury; Electroretinography;
Neuroprotection; Retinal morphology
ID NRF2-DEPENDENT PHASE-2 ENZYME; REPERFUSION INJURY; INDUCTION; NEURONS;
ELEMENT; DAMAGE; NRF2; MICE
AB Sulforaphane, a precursor of glucosinolate in cruciferous vegetables such as broccoli and cauliflower, has been shown to protect brain ischemic injury. In this study, we examined the effect of systemic administration of sulforaphane on retinal ischemic reperfusion injury. Intraocular pressure was elevated in two groups of C57BL/6 mice (n = 8 per group) for 45 min to induce retinal ischemic reperfusion injury. Following retinal ischemic reperfusion injury, vehicle (I% DMSO saline) or sulforaphane (25 mg/kg/day) was administered intraperitoneally daily for 5 days. Scotopic electroretinography (ERG) was used to quantify retinal function prior to and one-week after retinal ischemic insult. Retinal morphology was examined one week after ischemic insult. Following ischemic reperfusion injury, ERG a- and b-wave amplitudes were significantly reduced in the control mice. Sulforaphane treatment significantly attenuated ischemic-induced loss of retinal function as compared to vehicle treated mice. In vehicle treated mice, ischemic reperfusion injury produced marked thinning of the inner retinal layers, but the thinning of the inner retinal layers appeared significantly less with sulforaphane treatment. Thus, sulforaphane may be beneficial in the treatment of retinal disorders with ischemic reperfusion injury. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Ambrecht, Lindsay A.; Perlman, Jay I.; McDonnell, James F.; Bu, Ping] Loyola Univ Chicago, Dept Ophthalmol, Maywood, IL 60153 USA.
[Perlman, Jay I.] Loyola Univ Chicago, Dept Pathol, Maywood, IL 60153 USA.
[Zhai, Yougang; Qiao, Liang] Loyola Univ Chicago, Dept Microbiol & Immunol, Maywood, IL 60153 USA.
[Bu, Ping] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv, Hines, IL 60141 USA.
[Perlman, Jay I.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Surg Serv, Hines, IL 60141 USA.
RP Bu, P (reprint author), Loyola Univ Chicago, Dept Ophthalmol, 2160 S First Ave, Maywood, IL 60153 USA.
EM pbu@luc.edu
FU Richard A. Perritt Charitable Foundation; Illinois Society for the
Prevention of Blindness; American Society of Cataract and Refractive
Surgery
FX The authors thank Dr. Xiaorong Liu for her suggestions. This work was
supported by The Richard A. Perritt Charitable Foundation, Illinois
Society for the Prevention of Blindness, and American Society of
Cataract and Refractive Surgery.
NR 21
TC 3
Z9 4
U1 2
U2 3
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD SEP
PY 2015
VL 138
BP 66
EP 69
DI 10.1016/j.exer.2015.06.030
PG 4
WC Ophthalmology
SC Ophthalmology
GA CQ7IV
UT WOS:000360777100008
PM 26142954
ER
PT J
AU Gonzalez, T
Chiodo, C
AF Gonzalez, Tyler
Chiodo, Christopher
TI ICD 10: A Primer for the Orthopedic Foot and Ankle Surgeon
SO FOOT & ANKLE INTERNATIONAL
LA English
DT Review
DE ICD 10; foot and ankle; orthopedic surgery; codes; billing
AB The use of the 10th Revision of the International Classification of Diseases (ICD-10) will likely be required as of October 2015. ICD-10 was developed to increase the specificity and accuracy of disease and injury reporting. The number of diagnostic codes in this system has increased substantially, and approximately half of all ICD-10 codes are related to the musculoskeletal system, whereas 25% of all codes are related to fractures. For most foot and ankle injuries, the new code structure includes location, laterality, degree of healing, and encounter type. At the provider level, navigating this system will initially be a complex task. Understanding the ICD-10 code structure, properly training appropriate staff, and financially preparing for implementation will minimize potential practice disruption.
C1 [Gonzalez, Tyler] Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA.
[Chiodo, Christopher] Brigham & Womens Hosp, Faulkner Hosp, Div Foot & Ankle Surg, Brigham Foot & Ankle Ctr, Boston, MA 02130 USA.
RP Chiodo, C (reprint author), Brigham & Womens Hosp, Faulkner Hosp, Div Foot & Ankle Surg, Brigham Foot & Ankle Ctr, 1153 Ctr St Suite 56, Boston, MA 02130 USA.
EM cchiodo@partners.org
NR 6
TC 0
Z9 0
U1 0
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1071-1007
EI 1944-7876
J9 FOOT ANKLE INT
JI Foot Ankle Int.
PD SEP
PY 2015
VL 36
IS 9
BP 1110
EP 1116
DI 10.1177/1071100715600286
PG 7
WC Orthopedics
SC Orthopedics
GA CQ5DU
UT WOS:000360624300018
PM 26276133
ER
PT J
AU Osborn-Heaford, HL
Murthy, S
Gu, LL
Larson-Casey, JL
Ryan, AJ
Shi, L
Glogauer, M
Neighbors, JD
Hohl, R
Carter, AB
AF Osborn-Heaford, Heather L.
Murthy, Shubha
Gu, Linlin
Larson-Casey, Jennifer L.
Ryan, Alan J.
Shi, Lei
Glogauer, Michael
Neighbors, Jeffrey D.
Hohl, Raymond
Carter, A. Brent
TI Targeting the isoprenoid pathway to abrogate progression of pulmonary
fibrosis
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Macrophage; Reactive oxygen species; Mitochondria; Pulmonary fibrosis;
Rac1; Isoprenoid; Pathway
ID COA REDUCTASE INHIBITOR; OXIDATIVE STRESS; EXTRACELLULAR-MATRIX;
IN-VIVO; MACROPHAGES; RAC1; FIBROBLASTS; ACTIVATION; APOPTOSIS; SURVIVAL
AB Fibrotic remodeling in lung injury is a major cause of morbidity. The mechanism that mediates the ongoing fibrosis is unclear, and there is no available treatment to abate the aberrant repair. Reactive oxygen species (ROS) have a critical role in inducing fibrosis by modulating extracellular matrix deposition. Specifically, mitochondrial hydrogen peroxide (H2O2) production by alveolar macrophages is directly linked to pulmonary fibrosis as inhibition of mitochondrial H2O2 attenuates the fibrotic response in mice. Prior studies indicate that the small GTP-binding protein, Rac1, directly mediates H2O2 generation in the mitochondrial intermembrane space. Geranylgeranylation of the C-terminal cysteine residue (Cys(189)) is required for Rac1 activation and mitochondria! import. We hypothesized that impairment of geranylgeranylation would limit mitochondrial oxidative stress and, thus, abrogate progression of pulmonary fibrosis. By targeting the isoprenoid pathway with a novel agent, digeranyl bisphosphonate (DGBP), which impairs geranylgeranylation, we demonstrate that Rac1 mitochondrial import, mitochondrial oxidative stress, and progression of the fibrotic response to lung injury are significantly attenuated. These observations reveal that targeting the isoprenoid pathway to alter Rac1 geranylgeranylation halts the progression of pulmonary fibrosis after lung injury. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Osborn-Heaford, Heather L.; Murthy, Shubha; Ryan, Alan J.; Hohl, Raymond; Carter, A. Brent] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA.
[Gu, Linlin; Larson-Casey, Jennifer L.; Carter, A. Brent] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
[Larson-Casey, Jennifer L.; Carter, A. Brent] Univ Iowa, Free Rad & Radiat Biol Program, Iowa City, IA 52242 USA.
[Shi, Lei; Carter, A. Brent] Univ Iowa, Human Toxicol Program, Iowa City, IA 52242 USA.
[Glogauer, Michael] Univ Toronto, Canadian Inst Hlth Res Grp Matrix Dynam, Toronto, ON, Canada.
[Neighbors, Jeffrey D.] Univ Iowa, Dept Chem, Iowa City, IA 52242 USA.
[Hohl, Raymond] Univ Iowa, Dept Pharmacol, Iowa City, IA 52242 USA.
[Carter, A. Brent] Iowa City VA Healthcare Syst, Iowa City, IA USA.
[Carter, A. Brent] Birmingham VAMC, Birmingham, AL USA.
RP Carter, AB (reprint author), Univ Alabama Birmingham, Dept Med, Birmingham VAMC, 1918 Univ Blvd,404 MCLM, Birmingham, AL 35294 USA.
EM bcarter1@uab.edu
OI Larson-Casey, Jennifer L./0000-0001-7238-7986
FU National Institutes of Health [2R01ES015981-07, R01ES014871]; Department
of Veterans Affairs, Veterans Health Administration, Office of Research
and Development, Biomedical Laboratory Research and Development
[1BX001135-01]
FX This work was supported, in whole or in part, by National Institutes of
Health Grants 2R01ES015981-07 and R01ES014871. This work was also
supported by a Merit Review from the Department of Veterans Affairs,
Veterans Health Administration, Office of Research and Development,
Biomedical Laboratory Research and Development Grant 1BX001135-01.
NR 58
TC 2
Z9 2
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD SEP
PY 2015
VL 86
BP 47
EP 56
DI 10.1016/j.freeradbiomed.2015.04.031
PG 10
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA CQ4JA
UT WOS:000360569700005
PM 25958207
ER
PT J
AU Gelaye, B
Barrios, YV
Zhong, QY
Rondon, MB
Borba, CPC
Sanchez, SE
Henderson, DC
Williams, MA
AF Gelaye, Bizu
Barrios, Yasmin V.
Zhong, Qiu-Yue
Rondon, Marta B.
Borba, Christina P. C.
Sanchez, Sixto E.
Henderson, David C.
Williams, Michelle A.
TI Association of poor subjective sleep quality with suicidal ideation
among pregnant Peruvian women
SO GENERAL HOSPITAL PSYCHIATRY
LA English
DT Article
DE Sleep quality; Suicide ideation; Suicide; Depression; Pregnancy
ID RISK-FACTORS; ANXIETY DISORDERS; MAJOR DEPRESSION; POSTPARTUM WOMEN;
PRETERM BIRTH; LATE-LIFE; COHORT; BEHAVIOR; PERIOD; ADULTS
AB Objective: To examine the independent and joint relationships of poor subjective sleep quality and antepartum depression with suicidal ideation among pregnant women.
Methods: A cross-sectional study was conducted among 641 pregnant women attending prenatal care clinics in Lima, Peru. Antepartum depression and suicidal ideation were assessed using the Patient Health Questionnaire-9 scale. Antepartum subjective sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI). Logistic regression procedures were performed to estimate odds ratios (aOR) and 95% confidence intervals (95% CI) adjusted for confounders.
Results: Overall, the prevalence of suicidal ideation in this cohort was 16.8% and poor subjective sleep quality was more common among women endorsing suicidal ideation as compared to their counterparts who did not (47.2% vs. 24.8%, P<.001). After adjustment for confounders including maternal depression, poor subjective sleep quality (defined using the recommended criteria of PSQI global score of >5 vs. <= 5) was associated with a 1.7-fold increased odds of suicidal ideation (aOR=1.67; 95% CI 1.02-2.71). When assessed as a continuous variable, each 1-unit increase in the global PSQI score resulted in an 18% increase in odds for suicidal ideation, even after adjusting for depression (aOR=1.18; 95% CI 1.08-1.28). Women with both poor subjective sleep quality and depression had a 3.5-fold increased odds of suicidal ideation (aOR=3.48; 95% CI 1.96-6.18) as compared with those who had neither risk factor.
Conclusion: Poor subjective sleep quality was associated with increased odds of suicidal ideation. Replication of these findings may promote investments in studies designed to examine the efficacy of sleep-focused interventions to treat pregnant women with sleep disorders and suicidal ideation. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Gelaye, Bizu; Barrios, Yasmin V.; Zhong, Qiu-Yue; Henderson, David C.; Williams, Michelle A.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Rondon, Marta B.] Cayetano Heredia Peruvian Univ, Dept Med, Lima, Peru.
[Borba, Christina P. C.; Henderson, David C.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Borba, Christina P. C.; Henderson, David C.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Sanchez, Sixto E.] Univ Peruana Ciencias Aplicadas, Lima, Peru.
[Sanchez, Sixto E.] Asociac Civil PROESA, Lima, Peru.
RP Gelaye, B (reprint author), Harvard Univ, TH Chan Sch Publ Hlth, Dept Epidemiol, 677 Huntington Ave,K505F, Boston, MA 02115 USA.
EM bgelaye@hsph.harvard.edu
OI Gelaye, Bizu/0000-0001-7934-548X
FU National Institutes of Health (NIH) [R01-HD-059835, T37-MD000149,
K01MH100428]
FX This research was supported by an award from the National Institutes of
Health (NIH; R01-HD-059835, T37-MD000149 and K01MH100428). The NIH had
no further role in study design; in the collection, analysis and
interpretation of data; in the writing of the report; and in the
decision to submit the paper for publication. The authors wish to thank
the dedicated staff members of Asociacion Civil Proyectos en Salud
(PROESA), Peru and Instituto Especializado Materno Perinatal, Peru, for
their expert technical assistance with this research.
NR 74
TC 6
Z9 6
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0163-8343
EI 1873-7714
J9 GEN HOSP PSYCHIAT
JI Gen. Hosp. Psych.
PD SEP-OCT
PY 2015
VL 37
IS 5
BP 441
EP 447
DI 10.1016/j.genhosppsych.2015.04.014
PG 7
WC Psychiatry
SC Psychiatry
GA CQ4HD
UT WOS:000360564500010
PM 25983188
ER
PT J
AU Gatchel, J
Legesse, B
Tayeb, S
Murray, E
Price, B
AF Gatchel, Jennifer
Legesse, Benalfew
Tayeb, Safwan
Murray, Evan
Price, Bruce
TI Neurosyphilis in psychiatric practice: a case-based discussion of
clinical evaluation and diagnosis
SO GENERAL HOSPITAL PSYCHIATRY
LA English
DT Article
DE Neurosyphilis; Tabes dorsalis; Psychotic disorder; RPR
ID MANIFESTATIONS; SYPHILIS
AB Objective: Neurosyphilis can present with a wide range of neuropsychiatric symptoms. Hence, psychiatrists need to be familiar with tests for syphilis screening and how to interpret syphilis serologic tests.
Methods: We present four cases of patients with positive syphilis tests encountered in a psychiatric hospital.
Results: Two cases were treated for neurosyphilis, while the other two cases did not have active syphilis infection despite positive results.
Conclusion: We thus highlight the challenges encountered by psychiatrists in screening for and diagnosing cases of neurosyphilis. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Gatchel, Jennifer] MGH McLean Adult Psychiat Residency Program, Boston, MA USA.
[Gatchel, Jennifer] Massachusetts Gen Hosp, Dept Psychopharmacol, Boston, MA 02114 USA.
[Legesse, Benalfew] Harvard Univ, Sch Med, Dept Psychiat, Belmont, MA 02178 USA.
[Legesse, Benalfew] McLean Hosp, Dept Psychiat, Boston, MA USA.
[Tayeb, Safwan] King Abdulaziz Univ, Jeddah 21413, Saudi Arabia.
[Murray, Evan; Price, Bruce] Harvard Univ, Sch Med, Dept Neurol, Belmont, MA 02178 USA.
[Murray, Evan; Price, Bruce] McLean Hosp, Dept Neurol, Boston, MA USA.
[Murray, Evan; Price, Bruce] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Murray, Evan] Manchester VA Med Ctr, Traumat Brain Injury Serv, Manchester, NH USA.
RP Legesse, B (reprint author), Harvard Univ, Sch Med, Dept Psychiat, Belmont, MA 02178 USA.
EM blegesse@partners.org
OI Gatchel, Jennifer/0000-0002-3892-9742
FU Jr. Foundation
FX We would like to thank the Sidney R. Baer, Jr. Foundation for fellowship
training support.
NR 16
TC 1
Z9 1
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0163-8343
EI 1873-7714
J9 GEN HOSP PSYCHIAT
JI Gen. Hosp. Psych.
PD SEP-OCT
PY 2015
VL 37
IS 5
BP 459
EP 463
DI 10.1016/j.genhosppsych.2015.04.012
PG 5
WC Psychiatry
SC Psychiatry
GA CQ4HD
UT WOS:000360564500013
PM 26022384
ER
PT J
AU Fei, Q
Yang, XQ
Jiang, H
Wang, Q
Yu, YY
Yu, YL
Yi, W
Zhou, SL
Chen, TP
Lu, C
Atadja, P
Liu, XS
Li, E
Zhang, Y
Shou, JY
AF Fei, Qi
Yang, Xiaoqin
Jiang, Hua
Wang, Qian
Yu, Yanyan
Yu, Yiling
Yi, Wei
Zhou, Shaolian
Chen, Taiping
Lu, Chris
Atadja, Peter
Liu, Xiaole Shirley
Li, En
Zhang, Yong
Shou, Jianyong
TI SETDB1 modulates PRC2 activity at developmental genes independently of
H3K9 trimethylation in mouse ES cells
SO GENOME RESEARCH
LA English
DT Article
ID EMBRYONIC STEM-CELLS; HISTONE METHYLTRANSFERASE ESET; TRANSCRIPTIONAL
NETWORK; RECOMBINANT HISTONES; METHYLATION; POLYCOMB; PLURIPOTENCY;
REGULATORS; MAINTENANCE; CHROMATIN
AB SETDB1, a histone methyltransferase responsible for methylation of histone H3 lysine 9 (H3K9), is involved in maintenance of embryonic stem (ES) cells and early embryonic development of the mouse. However, how SETDB1 regulates gene expression during development is largely unknown. Here, we characterized genome-wide SETDB1 binding and H3K9 trimethylation (H3K9me3) profiles in mouse ES cells and uncovered two distinct classes of SETDB1 binding sites, termed solo and ensemble peaks. The solo peaks were devoid of H3K9me3 and enriched near developmental regulators while the ensemble peaks were associated with H3K9me3. A subset of the SETDB1 solo peaks, particularly those near neural development-related genes, was found to be associated with Polycomb Repressive Complex 2 (PRC2) as well as PRC2-interacting proteins JARID2 and MTF2. Genetic deletion of Setdb1 reduced EZH2 binding as well as histone 3 lysine 27 (H3K27) trimethylation level at SETDB1 solo peaks and facilitated neural differentiation. Furthermore, we found that H3K27me3 inhibits SETDB1 methyltransferase activity. The currently identified reciprocal action between SETDB1 and PRC2 reveals a novel mechanism underlying ES cell pluripotency and differentiation regulation.
C1 [Fei, Qi; Jiang, Hua; Yu, Yanyan; Yu, Yiling; Yi, Wei; Zhou, Shaolian; Lu, Chris; Atadja, Peter; Li, En; Shou, Jianyong] China Novartis Inst BioMed Res, Shanghai 201203, Peoples R China.
[Yang, Xiaoqin; Wang, Qian; Zhang, Yong] Tongji Univ, Sch Life Sci & Technol, Shanghai Key Lab Signaling & Dis Res, Shanghai 200092, Peoples R China.
[Chen, Taiping] Novartis Inst BioMed Res, Cambridge, MA 02139 USA.
[Liu, Xiaole Shirley] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
RP Shou, JY (reprint author), Lilly China Res & Dev Ctr, Shanghai 201203, Peoples R China.
EM yzhang@tongji.edu.cn; shou_jian_yong@lilly.com
RI Zhang, Yong/B-4838-2011
OI Zhang, Yong/0000-0001-6316-2734
FU China Novartis Institutes for BioMedical Research; National Natural
Science Foundation of China [31371288, 31322031]; Shanghai Rising-Star
Program [13QH1402200]
FX We thank Thomas Jenuwein for the H3K9me3 antibody for our initial study.
We also thank Drs. Song Shi, Shannon Chuai, and Haiyan Xu for insightful
discussion and suggestions. We thank Dr. Tengfei Zhang for critical
reading of the paper. We thank Drs. Teddy Yang and Kehao Zhao for help
with making the nucleosomes and Drs. Ling Li and Justin Gu for the help
with the in vitro methylation assay. This project is sponsored by China
Novartis Institutes for BioMedical Research. The fourteenth author
(Y.Z.) is partially supported by the National Natural Science Foundation
of China (31371288, 31322031) and the Shanghai Rising-Star Program
(13QH1402200).
NR 44
TC 3
Z9 3
U1 1
U2 12
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 1088-9051
EI 1549-5469
J9 GENOME RES
JI Genome Res.
PD SEP
PY 2015
VL 25
IS 9
BP 1325
EP 1335
DI 10.1101/gr.177576.114
PG 11
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Genetics & Heredity
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Genetics & Heredity
GA CQ6NK
UT WOS:000360721000007
PM 26160163
ER
PT J
AU Mimiaga, MJ
Biello, K
Reisner, SL
Crane, HM
Wilson, J
Grasso, C
Kitahata, MM
Mathews, WC
Mayer, KH
Safren, SA
AF Mimiaga, Matthew J.
Biello, Katie
Reisner, Sari L.
Crane, Heidi M.
Wilson, Johannes
Grasso, Chris
Kitahata, Mari M.
Mathews, Wm. Christopher
Mayer, Kenneth H.
Safren, Steven A.
TI Latent Class Profiles of Internalizing and Externalizing Psychosocial
Health Indicators Are Differentially Associated With Sexual Transmission
Risk: Findings From the CFAR Network of Integrated Clinical Systems
(CNICS) Cohort Study of HIV-Infected Men Engaged in Primary Care in the
United States
SO HEALTH PSYCHOLOGY
LA English
DT Article
DE externalizing; HIV; internalizing; men who have sex with men; sexual
risk
ID RESEARCH DOMAIN CRITERIA; SUBSTANCE USE; NEGATIVE AFFECT; ANTIRETROVIRAL
THERAPY; PSYCHIATRIC-DISORDERS; LONGITUDINAL DATA; ANAL INTERCOURSE;
DSM-IV; BEHAVIOR; CLASSIFICATION
AB Objective: To examine whether latent class indicators of negative affect and substance use emerged as distinct psychosocial risk profiles among HIV-infected men, and if these latent classes were associated with high-risk sexual behaviors that may transmit HIV. Methods: Data were from HIV-infected men who reported having anal intercourse in the past 6 months and received routine clinical care at 4 U.S. sites in the Centers for AIDS Research Network of Integrated Clinical Systems cohort (n = 1,210). Latent class membership was estimated using binary indicators for anxiety, depression, alcohol and/or drug use during sex, and polydrug use. Generalized estimating equations modeled whether latent class membership was associated with HIV sexual transmission risk in the past 6 months. Results: Three latent classes of psychosocial indicators emerged: (a) internalizing (15.3%; high probability of anxiety and major depression); (b) externalizing (17.8%; high probability of alcohol and/or drug use during sex and polydrug use); (c) low psychosocial distress (67.0%; low probability of all psychosocial factors examined). Internalizing and externalizing latent class membership were associated with HIV sexual transmission risk, compared to low psychosocial class membership; externalizing class membership was also associated with higher sexual transmission risk compared to internalizing class membership. Conclusions: Distinct patterns of psychosocial health characterize this sexually active HIV-infected male patient population and are strongly associated with HIV sexual transmission risk. Public Health intervention efforts targeting HIV sexual risk transmission may benefit from considering symptom clusters that share internalizing or externalizing properties.
C1 [Mimiaga, Matthew J.; Safren, Steven A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA 02114 USA.
[Mimiaga, Matthew J.; Biello, Katie; Reisner, Sari L.; Wilson, Johannes; Grasso, Chris; Mayer, Kenneth H.; Safren, Steven A.] Fenway Hlth, Boston, MA USA.
[Biello, Katie; Reisner, Sari L.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Crane, Heidi M.; Kitahata, Mari M.] Univ Washington, Sch Med, Div Infect Dis, Seattle, WA 98195 USA.
[Mathews, Wm. Christopher] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
[Mayer, Kenneth H.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Infect Dis, Boston, MA 02114 USA.
RP Mimiaga, MJ (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, One Bowdoin Sq,7th Floor, Boston, MA 02114 USA.
EM mmimiaga@hsph.harvard.edu
FU CNICS [R24AI067039]; PROMIS HIV grant [U01AR057954]; [R34DA031028];
[K24 MH094214]
FX This work was supported in part by R34DA031028 (Matthew J. Mimiaga) and
the CNICS grant R24AI067039 (Saag). Patient Reported Outcome collection
in CNICS is also supported in part by the PROMIS HIV grant U01AR057954
(Heidi M. Crane). The content is solely the responsibility of the
authors and does not necessarily represent the official views of the
National Institutes of Health. Steven A. Safren is supported by K24
MH094214.
NR 64
TC 3
Z9 3
U1 2
U2 6
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0278-6133
EI 1930-7810
J9 HEALTH PSYCHOL
JI Health Psychol.
PD SEP
PY 2015
VL 34
IS 9
BP 951
EP 959
DI 10.1037/hea0000189
PG 9
WC Psychology, Clinical; Psychology
SC Psychology
GA CQ4OO
UT WOS:000360584600008
PM 25642839
ER
PT J
AU Leatherman, BD
Khalid, A
Lee, S
McMains, K
Peltier, J
Platt, MP
Stachler, RJ
Toskala, E
Tropper, G
Venkatraman, G
Lin, SY
AF Leatherman, Bryan D.
Khalid, Ayesha
Lee, Stella
McMains, Kevin
Peltier, Jacques
Platt, Michael P.
Stachler, Robert J.
Toskala, Elina
Tropper, Guy
Venkatraman, Giri
Lin, Sandra Y.
TI Dosing of sublingual immunotherapy for allergic rhinitis: evidence-based
review with recommendations
SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY
LA English
DT Article
DE type I allergy; subcutaneous immunotherapy; evidence-based medicine;
aeroallergens; allergic conjunctivitis; allergy injections; asthma;
sublingual immunotherapy
ID HOUSE-DUST-MITE; PLACEBO-CONTROLLED TRIAL; RANDOMIZED CONTROLLED-TRIAL;
DOUBLE-BLIND-PLACEBO; SUB-LINGUAL IMMUNOTHERAPY; NORTH-AMERICAN ADULTS;
QUALITY-OF-LIFE; GRASS-POLLEN; SWALLOW IMMUNOTHERAPY; BIRCH POLLEN
AB BackgroundSince the mid 1980s, the clinical use of sublingual immunotherapy (SLIT) has dramatically increased. However, 1 of the primary barriers to providing SLIT is lack of a published dosing recommendations. The purpose of this work is to provide a range of effective SLIT dosing based upon a rigorous review of the existing evidence base. An appendix with SLIT dosing recommendations is also included.
MethodsA comprehensive search of the past 25 years of the medical literature using PubMed was performed for specific antigens. Inclusion criteria for articles included: randomized, placebo-controlled studies of SLIT, studies with clinical allergic rhinitis outcomes, and dosing units available to determine the micrograms per month of major allergen administered. The extracted data was used to compile a range of effective SLIT dosing for individual antigens.
ResultsSeventy-five articles met the inclusion criteria, providing a range of effective dosing for some allergens. There was commonly a wide range in doses for particular antigens between the individual studies. For some antigens, there was significant overlap in dosage amount between studies showing efficacy and lack of efficacy. Clinical trials meeting inclusion criteria are not available for many allergens.
ConclusionThis study provided a comprehensive review of the published sublingual dosing ranges for specific antigens. The review provided a range of effective sublingual doses for some allergens, whereas for other allergens there was insufficient published data to determine specific doses. Recommendations for SLIT dosing were produced based on the data revealed in the review and expert opinion.
C1 [Leatherman, Bryan D.] Coastal Sinus & Allergy Ctr, Gulfport, MS 39503 USA.
[Leatherman, Bryan D.] Coastal Ear Nose & Throat Associates, Gulfport, MS USA.
[Khalid, Ayesha] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
[Lee, Stella] Univ Pittsburgh, Med Ctr, Div Sinonasal Disorders & Allergy, Dept Otolaryngol Head & Neck Surg, Pittsburgh, PA USA.
[McMains, Kevin] South Texas Vet Hlth Care Syst, Otolaryngol, San Antonio, TX USA.
[Peltier, Jacques] North Oaks ENT & Allergy, Hammond, LA USA.
[Platt, Michael P.] Boston Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Boston, MA 02215 USA.
[Stachler, Robert J.] Henry Ford Med Grp, Sterling Hts, MI USA.
[Toskala, Elina] Temple Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Philadelphia, PA 19122 USA.
[Tropper, Guy] Avant Garde Med Care, Boucherville, PQ, Canada.
[Venkatraman, Giri] Dartmouth Hitchcock Med Ctr, Lebanon, NH USA.
[Lin, Sandra Y.] Johns Hopkins Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD USA.
RP Leatherman, BD (reprint author), 9000 Lorraine Rd, Gulfport, MS 39503 USA.
EM Leathermanmd@coastalent.net
FU AAOA
FX Funding sources for the study: This article is a product of a work group
appointed by the American Academy of Otolaryngic Allergy (AAOA). Funding
in the form of facilitating a face-to-face meeting was provided by the
AAOA.
NR 88
TC 3
Z9 3
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2042-6976
EI 2042-6984
J9 INT FORUM ALLERGY RH
JI Int. Forum Allergy Rhinol.
PD SEP
PY 2015
VL 5
IS 9
BP 773
EP 783
DI 10.1002/alr.21561
PG 11
WC Otorhinolaryngology
SC Otorhinolaryngology
GA CQ8BY
UT WOS:000360832400002
PM 26097218
ER
PT J
AU Xu, WF
Li, HZ
Ji, ZG
Yan, WG
Zhang, YS
Zhang, XB
Li, Q
AF Xu, Weifeng
Li, Hanzhong
Ji, Zhigang
Yan, Weigang
Zhang, Yushi
Zhang, Xuebin
Li, Qian
TI Transumbilical laparoendoscopic single-site surgery versus conventional
laparoscopy for the resection of retroperitoneal paragangliomas
SO INTERNATIONAL JOURNAL OF UROLOGY
LA English
DT Article
DE laparoscopy; paraganglioma; pheochromocytoma; transumbilical
laparoendoscopic single-site surgery
ID CLINICAL-EXPERIENCE; PHEOCHROMOCYTOMA; ADRENALECTOMY; UROLOGY
AB ObjectivesTo compare transumbilical laparoendoscopic single-site surgery with conventional laparoscopy for the resection of retroperitoneal paragangliomas.
MethodsIn the present case-control study, we compared 11 transumbilical laparoendoscopic single-site surgery procedures with 22 conventional laparoscopy procedures carried out to treat retroperitoneal paragangliomas between June 2004 and October 2013 at Peking Union Medical Hospital, Beijing, China. Operative time, estimated intraoperative blood loss, blood transfusions, intraoperative hypertension, intraoperative hypotension, highest intraoperative systolic blood pressure, lowest intraoperative systolic blood pressure, postoperative fatigue time, postoperative systematic inflammation reaction syndrome, 24-h postoperative visual analog scale scores, postoperative hospital stay duration, and postoperative complications were recorded and analyzed.
ResultsThere were no significant differences in patient characteristics. All surgical procedures were successfully completed in both groups. Minor complications occurred in one case in the laparoendoscopic single-site surgery group and in two cases in the conventional laparoscopy group. In the laparoendoscopic single-site surgery group, the operative time was longer than that in the conventional laparoscopy group (P=0.001). There were no significant differences in terms of intraoperative hypertension, intraoperative hypotension, highest intraoperative systolic blood pressure, lowest intraoperative systolic blood pressure, estimated blood loss, postoperative fatigue time, postoperative hospital stay or systematic inflammation reaction syndrome between the two groups. The 24-h postoperative visual analog scale score was lower in the laparoendoscopic single-site surgery group (P=0.002). No recurrence or metastases were observed over the duration of the postoperative follow up.
ConclusionsIn properly selected patients, transumbilical laparoendoscopic single-site surgery is a feasible, safe and effective procedure for the surgical treatment of retroperitoneal paragangliomas.
C1 [Xu, Weifeng; Li, Hanzhong; Ji, Zhigang; Yan, Weigang; Zhang, Yushi; Zhang, Xuebin] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Urol, Beijing 100730, Peoples R China.
[Li, Qian] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
RP Li, HZ (reprint author), Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Urol, Beijing 100730, Peoples R China.
EM lihanzhongcn@163.com
NR 30
TC 0
Z9 0
U1 2
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0919-8172
EI 1442-2042
J9 INT J UROL
JI Int. J. Urol.
PD SEP
PY 2015
VL 22
IS 9
BP 844
EP 849
DI 10.1111/iju.12834
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA CQ7CR
UT WOS:000360760900010
PM 26119870
ER
PT J
AU Kohli, P
Pinto-Plata, V
Divo, M
Malhotra, A
Harris, RS
Lazaar, A
Flynn, A
Tal-Singer, R
Panettieri, RA
Celli, B
AF Kohli, Puja
Pinto-Plata, Victor
Divo, Miguel
Malhotra, Atul
Harris, R. Scott
Lazaar, Aili
Flynn, Aiden
Tal-Singer, Ruth
Panettieri, Reynold A., Jr.
Celli, Bartolome
TI Functional Capacity, Health Status, and Inflammatory Biomarker Profile
in a Cohort of Patients With Chronic Obstructive Pulmonary Disease
SO JOURNAL OF CARDIOPULMONARY REHABILITATION AND PREVENTION
LA English
DT Article
DE biomarkers; chronic obstructive pulmonary disease; health-related
quality of life; pulmonary rehabilitation
ID 6-MIN WALK DISTANCE; QUALITY-OF-LIFE; CHRONIC RESPIRATORY-DISEASE;
SYSTEMIC INFLAMMATION; ECLIPSE COHORT; COPD; MORTALITY; ASSOCIATION;
REHABILITATION; DEPRESSION
AB PURPOSE: Prior research has shown a significant relationship between 6-minute walking distance (6MWD) and health-related quality of life (HRQOL) in patients with chronic obstructive pulmonary disease (COPD). However, few studies have examined this relationship above and below the 350-m threshold that prognosticates survival and whether serum biomarkers could provide insight into the causes of quality-of-life differences above and below this threshold.
METHODS: Measures of lung function, 6MWD, and HRQOL were compared in patients with COPD. Differences in HRQOL domains and serum biomarkers were compared in patients whose 6MWD were > or < 350 m.
RESULTS: In patients walking < 350 m, scores in the physical domains of the SF-36 and the St. George's Respiratory Questionnaire (SGRQ) were significantly different from scores of their counterparts with greater 6MWD. However, there was no association between any biomarkers and the physical domains of the SF-36 and the SGRQ. In patients walking < 350 m, only the IL-8 levels were associated with lower scores in SF-36 domains of emotional role, pain, vitality, and mental health (average r = -0.702; P = .01). In contrast, in patients walking > 350 m, surfactant protein D levels were associated with higher SF-36 scores in general pain, vitality, and social functioning (average r = 0.42; P = .04).
CONCLUSIONS: In COPD, there is an association between 6MWD and the physical domains of the SF-36 and SGRQ in those patients walking < 350 m. The physical differences between patients walking < or > 350 m are not related to systemic inflammation. The association between interleukin 8 with nonphysical domains in patients with 6MWD < 350 m suggests that inflammation may play a larger role in the perceptive domain than previously recognized.
C1 [Kohli, Puja; Pinto-Plata, Victor; Divo, Miguel; Celli, Bartolome] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Pulm & Crit Care Med, Boston, MA 02115 USA.
[Kohli, Puja; Harris, R. Scott] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Pulm & Crit Care Med, Boston, MA USA.
[Malhotra, Atul] Univ Calif San Diego, Sch Med, Div Pulm & Crit Care Med, Div Sleep Med, San Diego, CA 92103 USA.
[Lazaar, Aili; Flynn, Aiden; Tal-Singer, Ruth] GalaxoSmithKline, COPD Clin Discovery, King Of Prussia, PA USA.
[Panettieri, Reynold A., Jr.] Univ Penn, Sch Med, Div Pulm Allergy & Crit Care, Philadelphia, PA 19104 USA.
RP Celli, B (reprint author), PBB Clin 3, 75 Francis St, Boston, MA 02115 USA.
EM BCelli@copdnet.org
FU GalaxoSmithKline
FX Support for this research was provided by an unrestricted grant from
GalaxoSmithKline. Jane Gilbert contributed to the data analysis of the
manuscript.
NR 42
TC 1
Z9 1
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1932-7501
EI 1932-751X
J9 J CARDIOPULM REHABIL
JI J. Cardiopulm. Rehabil. Prev.
PD SEP-OCT
PY 2015
VL 35
IS 5
BP 348
EP 355
DI 10.1097/HCR.0000000000000123
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CQ5QN
UT WOS:000360660600007
PM 26309192
ER
PT J
AU Dukkipati, SR
Woollett, I
McElderry, HT
Bohmer, MC
Doshi, SK
Gerstenfeld, EP
Horton, R
D'Avila, A
Haines, DE
Valderrabano, M
Mangrum, JM
Ruskin, JN
Natale, A
Reddy, VY
AF Dukkipati, Srinivas R.
Woollett, Ian
McElderry, H. Thomas
Boehmer, Marie-Christine
Doshi, Shephal K.
Gerstenfeld, Edward P.
Horton, Rodney
D'Avila, Andre
Haines, David E.
Valderrabano, Miguel
Mangrum, J. Michael
Ruskin, Jeremy N.
Natale, Andrea
Reddy, Vivek Y.
TI Pulmonary Vein Isolation Using the Visually Guided Laser Balloon:
Results of the US Feasibility Study
SO JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY
LA English
DT Article
DE atrial fibrillation; catheter ablation; laser; pulmonary veins; visual
guidance
ID PAROXYSMAL ATRIAL-FIBRILLATION; ENDOSCOPIC ABLATION SYSTEM; CATHETER
ABLATION; FOLLOW-UP; 2ND-GENERATION CRYOBALLOON; MULTICENTER;
EXPERIENCE; EFFICACY; LESSONS; SAFETY
AB Visually Guided PV Isolation
IntroductionVisually guided laser balloon (VGLB) ablation is unique in that the operator delivers ablative energy under direct visual guidance. In this multicenter study, we sought to determine the feasibility, efficacy, and safety of performing pulmonary vein isolation (PVI) using this VGLB.
MethodsPatients with symptomatic, drug-refractory paroxysmal atrial fibrillation (AF) underwent PVI using the VGLB with the majority of operators conducting their first-ever clinical VGLB cases. The primary effectiveness endpoint was defined as freedom from treatment failure that included: Occurrence of symptomatic AF episodes 1 minutes beyond the 90-day blanking, the inability to isolate 1 superior and 2 total PVs, occurrence of left atrial flutter or atrial tachycardia, or left atrial ablation/surgery during follow-up.
ResultsA total of 86 patients (mean age 5610 years, 67% male) were treated with the VGLB at 10 US centers. Mean fluoroscopy, ablation, and procedure times were 39.8 +/- 24.3 minutes, 205.2 +/- 61.7 minutes, and 253.5 +/- 71.3 minutes, respectively. Acute PVI was achieved in 314/323 (97.2%) of targeted PVs. Of 84 patients completing follow-up, the primary effectiveness endpoint was achieved in 50 (60%) patients. Freedom from symptomatic or asymptomatic AF was 61%. The primary adverse event rate was 16.3% (8.1% pericarditis, phrenic nerve injury 5.8%, and cardiac tamponade 3.5%). There were no cerebrovascular events, atrioesophageal fistulas, or significant PV stenosis.
ConclusionsThis multicenter study of operators in the early stage of the learning curve demonstrates that PVI can be achieved with the VGLB with a reasonable safety profile and an efficacy similar to radiofrequency ablation.
C1 [Dukkipati, Srinivas R.; Boehmer, Marie-Christine; D'Avila, Andre; Reddy, Vivek Y.] Icahn Sch Med Mt Sinai, Helmsley Electrophysiol Ctr, New York, NY 10029 USA.
[Woollett, Ian] Sentara Cardiovasc Res Inst, Norfolk, VA USA.
[McElderry, H. Thomas] Univ Alabama Birmingham, Birmingham, AL USA.
[Doshi, Shephal K.] Pacific Heart Inst, Santa Monica, CA USA.
[Gerstenfeld, Edward P.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA.
[Haines, David E.] William Beaumont Hosp, Royal Oak, MI 48072 USA.
[Valderrabano, Miguel] Methodist Hosp, Houston, TX 77030 USA.
[Mangrum, J. Michael] Univ Virginia, Charlottesville, VA USA.
[Ruskin, Jeremy N.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Horton, Rodney; Natale, Andrea] Texas Cardiac Arrhythmia Inst, Austin, TX USA.
RP Dukkipati, SR (reprint author), Icahn Sch Med Mt Sinai, Helmsley Electrophysiol Ctr, One Gustave L Levy Pl,Box 1030, New York, NY 10029 USA.
EM srinivas.dukkipati@mountsinai.org
FU CardioFocus; Hansen Medical; Boston Scientific; CardioInsight; Cardiome;
Gilead Sciences; Medtronic; Pfizer
FX Drs. Woollett, McElderry, Doshi, Mangrum, Haines, and Reddy report
participation on a research grant supported by CardioFocus. Drs.
Dukkipati and McElderry report compensation for participation on a
speaker's bureau and honoraria relevant to this topic; in addition, Dr.
McElderry serves as consultant/advisory board member for Boston
Scientific, ACT Med, Vytron US, St. Jude Medical, and Biosense Webster.
Dr. Reddy serves as consultant/advisory board member for CardioFocus.
Dr. Valderrabano reports research grants supported by Hansen Medical and
Boston Scientific. Dr. Ruskin reports consultant fees from
CardioInsight, Cardiome, Gilead Sciences, Medtronic, and Pfizer;
honorarium from Sanofi Aventis; equity interest in InfoBionic and
Portola. Other authors: No disclosures.
NR 20
TC 2
Z9 2
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1045-3873
EI 1540-8167
J9 J CARDIOVASC ELECTR
JI J. Cardiovasc. Electrophysiol.
PD SEP
PY 2015
VL 26
IS 9
BP 944
EP 949
DI 10.1111/jce.12727
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CQ7VM
UT WOS:000360813600005
ER
PT J
AU Sadowska, GB
Chen, XD
Zhang, JY
Lim, YP
Cummings, EE
Makeyev, O
Besio, WG
Gaitanis, J
Padbury, JF
Banks, WA
Stonestreet, BS
AF Sadowska, Grazyna B.
Chen, Xiaodi
Zhang, Jiyong
Lim, Yow-Pin
Cummings, Erin E.
Makeyev, Oleksandr
Besio, Walter G.
Gaitanis, John
Padbury, James F.
Banks, William A.
Stonestreet, Barbara S.
TI Interleukin-1 beta transfer across the blood-brain barrier in the ovine
fetus
SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
LA English
DT Article
DE blood-brain barrier; brain; cytokines; fetus; hypoxia-ischemia; sheep
ID NECROSIS-FACTOR-ALPHA; PROTEIN EXPRESSION; WHITE-MATTER; NEONATAL-RAT;
TRANSPORT; CYTOKINES; ISCHEMIA; INJURY; MECHANISM; MOUSE
AB Pro-inflammatory cytokines contribute to hypoxic-ischemic brain injury. Blood-brain barrier (BBB) dysfunction represents an important component of hypoxic-ischemic brain injury in the fetus. Hypoxic-ischemic injury could accentuate systemic cytokine transfer across the fetal BBB. There has been considerable conjecture suggesting that systemic cytokines could cross the BBB during the perinatal period. Nonetheless, evidence to support this contention is sparse. We hypothesized that ischemia-reperfusion increases the transfer of systemic interleukin-1 beta (IL-1 beta) across the BBB in the fetus. Ovine fetuses at 127 days of gestation were studied 4 hours after 30 minutes of bilateral carotid artery occlusion and compared with a nonischemic group. Recombinant ovine IL-1 beta protein was expressed from an IL-1 beta pGEX-2 T vector in E. coli BL-21 cells and purified. The BBB function was quantified in 12 brain regions using a blood-to-brain transfer constant with intravenous I-125-radiolabeled IL-1 beta (I-125-IL-1 beta). Interleukin-1 beta crossed the intact BBB in nonischemic fetuses. Blood-to-brain transport of I-125-IL-1 beta was higher (P < 0.05) across brain regions in fetuses exposed to ischemia-reperfusion than nonischemic fetuses. We conclude that systemic IL-1 beta crosses the intact fetal BBB, and that ischemia-reperfusion increases transfer of this cytokine across the fetal BBB. Therefore, altered BBB function after hypoxia-ischemia facilitates entry of systemic cytokines into the brain of the fetus.
C1 [Sadowska, Grazyna B.; Chen, Xiaodi; Zhang, Jiyong; Cummings, Erin E.; Padbury, James F.; Stonestreet, Barbara S.] Brown Univ, Alpert Med Sch, Women & Infants Hosp Rhode Isl, Dept Pediat, Providence, RI 02905 USA.
[Lim, Yow-Pin] ProThera Biol Inc, Providence, RI USA.
[Makeyev, Oleksandr; Besio, Walter G.] Univ Rhode Isl, Dept Elect Comp & Biomed Engn, Kingston, RI 02881 USA.
[Gaitanis, John] Brown Univ, Alpert Med Sch, Rhode Isl Hosp, Dept Neurol, Providence, RI 02905 USA.
[Banks, William A.] Univ Washington, Dept Med, Vet Affairs Puget Sound Hlth Care Syst, Div Gerontol & Geriatr Med,Geriatr Res Educ & Cli, Seattle, WA USA.
RP Stonestreet, BS (reprint author), Brown Univ, Alpert Med Sch, Women & Infants Hosp Rhode Isl, Dept Pediat, 101 Dudley St, Providence, RI 02905 USA.
EM bstonestreet@wihri.org
FU National Institute of General Medical Sciences of the National
Institutes of Health [1R01-HD-057100, P20 RR018728, P20GM103537];
American Heart Association [13POST16860015]
FX Research reported in this publication was supported by the National
Institute of General Medical Sciences of the National Institutes of
Health under award number 1R01-HD-057100, by an Institutional
Development Award (IDeA) from the National Institute of General Medical
Sciences of the National Institutes of Health under grant number P20
RR018728 and P20GM103537, and by a postdoctoral fellowship award (JZ)
from the American Heart Association under grant number 13POST16860015.
NR 46
TC 3
Z9 3
U1 1
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0271-678X
EI 1559-7016
J9 J CEREBR BLOOD F MET
JI J. Cereb. Blood Flow Metab.
PD SEP
PY 2015
VL 35
IS 9
BP 1388
EP 1395
DI 10.1038/jcbfm.2015.134
PG 8
WC Endocrinology & Metabolism; Hematology; Neurosciences
SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology
GA CQ6BN
UT WOS:000360689500002
PM 26082012
ER
PT J
AU Werner, P
Saur, D
Zeisig, V
Ettrich, B
Patt, M
Sattler, B
Jochimsen, T
Lobsien, D
Meyer, PM
Bergh, FT
Dreyer, A
Boltze, J
Classen, J
Fritzsch, D
Hoffmann, KT
Sabri, O
Barthel, H
AF Werner, Peter
Saur, Dorothee
Zeisig, Vilia
Ettrich, Barbara
Patt, Marianne
Sattler, Bernhard
Jochimsen, Thies
Lobsien, Donald
Meyer, Philipp M.
Bergh, Florian Then
Dreyer, Antje
Boltze, Johannes
Classen, Joseph
Fritzsch, Dominik
Hoffmann, Karl-Titus
Sabri, Osama
Barthel, Henryk
TI Simultaneous PET/MRI in stroke: a case series
SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
LA English
DT Article
DE Mismatch; penumbra; PET/MRI; stroke; thrombolysis
ID POSITRON-EMISSION-TOMOGRAPHY; CEREBRAL-BLOOD-FLOW; ISCHEMIC-STROKE; MRI;
PET; METABOLISM; ALTEPLASE; PENUMBRA; TRIAL; MAPS
AB Prospective studies on magnetic resonance imaging (MRI)-guided systemic thrombolysis >4.5 hours after stroke onset did not reach their primary end points. It was discussed and observed in post hoc data re-assessment that this was partly because of limited MRI accuracy to measure critical hypoperfusion. We report the first cases of simultaneous [O-15]H2O-positron emission tomography (PET)/MRI in stroke patients and an ovine model. Discrepancies between simultaneously obtained PET and MRI readouts were observed that might explain the above current limitations of stroke MRI. By offering highly complementary information, [O-15]H2O-PET/MRI might help to identify critically hypoperfused tissue resulting in an improved patient stratification in thrombolysis trials.
C1 [Werner, Peter; Zeisig, Vilia; Patt, Marianne; Sattler, Bernhard; Jochimsen, Thies; Meyer, Philipp M.; Sabri, Osama; Barthel, Henryk] Univ Leipzig, Dept Nucl Med, D-04103 Leipzig, Germany.
[Saur, Dorothee; Ettrich, Barbara; Bergh, Florian Then; Classen, Joseph] Univ Leipzig, Dept Neurol, D-04103 Leipzig, Germany.
[Lobsien, Donald; Fritzsch, Dominik; Hoffmann, Karl-Titus] Univ Leipzig, Dept Neuroradiol, D-04103 Leipzig, Germany.
[Bergh, Florian Then; Dreyer, Antje] Univ Leipzig, Univ Hosp Leipzig, Translat Ctr Regenerat Med, D-04103 Leipzig, Germany.
[Dreyer, Antje; Boltze, Johannes] Fraunhofer Inst Cell Therapy & Immunol, Leipzig, Germany.
[Boltze, Johannes] Massachusetts Gen Hosp, Charlestown, MA USA.
[Boltze, Johannes] Harvard Univ, Sch Med, Stroke & Neurovasc Regulat Lab, Charlestown, MA USA.
RP Barthel, H (reprint author), Univ Leipzig, Dept Nucl Med, Liebigstr 18, D-04103 Leipzig, Germany.
EM henryk.barthel@medizin.uni-leipzig.de
FU German Research Foundation [SA 669/9-1]; Max Planck Society
FX The work was supported by the German Research Foundation that funded the
PET/MRI system (grantcode: SA 669/9-1). The Max Planck Society co-funded
the system.
NR 18
TC 7
Z9 7
U1 1
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0271-678X
EI 1559-7016
J9 J CEREBR BLOOD F MET
JI J. Cereb. Blood Flow Metab.
PD SEP
PY 2015
VL 35
IS 9
BP 1421
EP 1425
DI 10.1038/jcbfm.2015.158
PG 5
WC Endocrinology & Metabolism; Hematology; Neurosciences
SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology
GA CQ6BN
UT WOS:000360689500008
PM 26174332
ER
PT J
AU Dong, TT
Zhang, Q
Hamblin, MR
Wu, MX
AF Dong, Tingting
Zhang, Qi
Hamblin, Michael R.
Wu, Mei X.
TI Low-level light in combination with metabolic modulators for effective
therapy of injured brain
SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
LA English
DT Article
DE hypoxia; lactate/pyruvate; low-level light; mitochondrial function; TBI
ID RAT-LIVER MITOCHONDRIA; TREATMENT STRATEGIES; TRANSCRANIAL LASER;
SPINAL-CORD; IN-VITRO; HYPOXIA; NEURONS; PYRUVATE; LACTATE; DAMAGE
AB Vascular damage occurs frequently at the injured brain causing hypoxia and is associated with poor outcomes in the clinics. We found high levels of glycolysis, reduced adenosine triphosphate generation, and increased formation of reactive oxygen species and apoptosis in neurons under hypoxia. Strikingly, these adverse events were reversed significantly by noninvasive exposure of injured brain to low-level light (LLL). Low-level light illumination sustained the mitochondrial membrane potential, constrained cytochrome c leakage in hypoxic cells, and protected them from apoptosis, underscoring a unique property of LLL. The effect of LLL was further bolstered by combination with metabolic substrates such as pyruvate or lactate both in vivo and in vitro. The combinational treatment retained memory and learning activities of injured mice to a normal level, whereas other treatment displayed partial or severe deficiency in these cognitive functions. In accordance with well-protected learning and memory function, the hippocampal region primarily responsible for learning and memory was completely protected by combination treatment, in marked contrast to the severe loss of hippocampal tissue because of secondary damage in control mice. These data clearly suggest that energy metabolic modulators can additively or synergistically enhance the therapeutic effect of LLL in energy-producing insufficient tissue-like injured brain.
C1 [Dong, Tingting; Zhang, Qi; Hamblin, Michael R.; Wu, Mei X.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Dermatol,Wellman Ctr Photomed, Boston, MA 02114 USA.
RP Wu, MX (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Dermatol,Wellman Ctr Photomed, 50 Blossom St, Boston, MA 02114 USA.
EM mwu5@mgh.harvard.edu
FU Department of Defense/Air Force Office of Scientific Research Militory
Phtomedicine Program [FA9550-11-1-0331, FA9550-13-1-0068]; Department of
Defense, CDMRP/BAA [W81XWH-13-2-0067]; [CA158756]
FX This work was supported by FA9550-11-1-0331 and FA9550-13-1-0068,
Department of Defense/Air Force Office of Scientific Research Militory
Phtomedicine Program, W81XWH-13-2-0067, Department of Defense,
CDMRP/BAA, and CA158756 to MW.
NR 39
TC 6
Z9 6
U1 1
U2 5
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0271-678X
EI 1559-7016
J9 J CEREBR BLOOD F MET
JI J. Cereb. Blood Flow Metab.
PD SEP
PY 2015
VL 35
IS 9
BP 1435
EP 1444
DI 10.1038/jcbfm.2015.87
PG 10
WC Endocrinology & Metabolism; Hematology; Neurosciences
SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology
GA CQ6BN
UT WOS:000360689500010
PM 25966949
ER
PT J
AU Roh, MR
Kim, JM
Lee, SH
Jang, HS
Park, KH
Chung, KY
Rha, SY
AF Roh, Mi Ryung
Kim, Jung Min
Lee, Sang Hee
Jang, Hong Sun
Park, Kyu Hyun
Chung, Kee Yang
Rha, Sun Young
TI Low-concentration vemurafenib induces the proliferation and invasion of
human HaCaT keratinocytes through mitogen-activated protein kinase
pathway activation
SO JOURNAL OF DERMATOLOGY
LA English
DT Article
DE human HaCaT keratinocyte; matrix metalloproteinase; mitogen-activated
protein kinase pathway; squamous cell carcinoma; vemurafenib
ID SQUAMOUS-CELL CARCINOMA; BRAF V600E MUTATION; RAF INHIBITORS; COLORECTAL
NEOPLASIA; METASTATIC MELANOMA; SKIN CARCINOGENESIS; IMPROVED SURVIVAL;
PROGRESSION; EXPRESSION; METALLOPROTEINASES
AB Cutaneous squamous cell carcinomas and keratoacanthomas commonly occur in patients treated with BRAF inhibitors. We investigated the effect of the BRAF inhibitor vemurafenib on normal immortalized human HaCaT keratinocytes to explore the mechanism of hyperproliferative cutaneous neoplasia associated with the use of BRAF inhibitors. Vemurafenib induced an increase in viable cell number in BRAF wild-type cell lines (SK-MEL-2 and HaCaT) but not in BRAF mutant cell lines (SK-MEL-24 and G361). In HaCaT keratinocytes, a low concentration (2mol/L) of vemurafenib increased cell proliferation and activated mitogen-activated protein kinase kinase/extracellular signal-regulated kinase in a CRAF-dependent manner. Invasiveness of HaCaT cells in a Matrigel assay significantly increased upon cultivation of cells with 2mol/L vemurafenib for 24h. Gelatin zymography, reverse transcription polymerase chain reaction and western blot results revealed that 2mol/L vemurafenib treatment increased matrix metalloproteinase (MMP)-2 and MMP-9 expressions and activities in HaCaT cells. These results offer additional insight into the complex mechanism of paradoxical mitogen-activated protein kinase signaling involved in hyperproliferative cutaneous neoplasias that arise after BRAF inhibition and suggest a possible role for MMP in tumor progression and invasion.
C1 [Roh, Mi Ryung; Lee, Sang Hee; Jang, Hong Sun; Chung, Kee Yang] Yonsei Univ, Coll Med, Cutaneous Biol Res Inst, Dept Dermatol, Seoul 120749, South Korea.
[Roh, Mi Ryung] Harvard Univ, Sch Med, Dept Dermatol, Massachusetts Gen Hosp,Wellman Ctr Photomed, Boston, MA 02115 USA.
[Kim, Jung Min; Park, Kyu Hyun; Rha, Sun Young] Yonsei Univ, Coll Med, Songdam Inst Canc Res, Seoul 120749, South Korea.
[Rha, Sun Young] Yonsei Univ, Coll Med, Dept Int Med, Seoul 120749, South Korea.
[Rha, Sun Young] Yonsei Univ, Coll Med, Div Med Oncol, Seoul 120749, South Korea.
RP Rha, SY (reprint author), Yonsei Univ, Yonsei Canc Ctr, Dept Internal Med, Div Med Oncol,Coll Med, 50 Yonsei Ro, Seoul 120749, South Korea.
EM rha7655@yuhs.ac
FU Basic Science Research Program through the National Research Foundation
of Korea - Ministry of Education, Science and Technology [2011-0022376];
Public Welfare and Safety Research Program through the National Research
Foundation of Korea (NRF) - Ministry of Education, Science and
Technology [2010-0020841]
FX This work was supported by the Basic Science Research Program through
the National Research Foundation of Korea, which is funded by the
Ministry of Education, Science and Technology (2011-0022376) and by the
Public Welfare and Safety Research Program through the National Research
Foundation of Korea (NRF), which is funded by the Ministry of Education,
Science and Technology (2010-0020841).
NR 35
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0385-2407
EI 1346-8138
J9 J DERMATOL
JI J. Dermatol.
PD SEP
PY 2015
VL 42
IS 9
BP 881
EP 888
DI 10.1111/1346-8138.12950
PG 8
WC Dermatology
SC Dermatology
GA CQ7EQ
UT WOS:000360766200006
PM 26047064
ER
PT J
AU Hanske, J
Sanchez, A
Schmid, M
Meyer, CP
Abdollah, F
Feldman, AS
Kibel, AS
Sammon, JD
Menon, M
Eswara, JR
Noldus, J
Trinh, QD
AF Hanske, Julian
Sanchez, Alejandro
Schmid, Marianne
Meyer, Christian P.
Abdollah, Firas
Feldman, Adam S.
Kibel, Adam S.
Sammon, Jesse D.
Menon, Mani
Eswara, Jairam R.
Noldus, Joachim
Trinh, Quoc-Dien
TI A Comparison of 30-Day Perioperative Outcomes in Open Versus Minimally
Invasive Nephroureterectomy for Upper Tract Urothelial Carcinoma:
Analysis of 896 Patients from the American College of Surgeons-National
Surgical Quality Improvement Program Database
SO JOURNAL OF ENDOUROLOGY
LA English
DT Article
ID LYMPH-NODE DISSECTION; LAPAROSCOPIC NEPHROURETERECTOMY; RADICAL
NEPHROURETERECTOMY; VENOUS THROMBOEMBOLISM; ONCOLOGIC OUTCOMES;
BLOOD-TRANSFUSION; CANCER; LYMPHADENECTOMY; METAANALYSIS; EVENTS
AB Background and Purpose: Minimally invasive surgery for nephroureterectomy (MINU) in patients with upper tract urothelial carcinoma (UTUC) is increasingly used among urologists with reported equivalent oncologic outcomes compared with open nephroureterectomy (ONU). Population-level data comparing perioperative outcomes between these approaches remain limited, however. We sought to compare perioperative outcomes between MINU and ONU in a prospectively collected national cohort of patients. Methods: Between 2006 and 2012, patients who underwent nephroureterectomy for UTUC within the American College of Surgeons-National Surgical Quality Improvement Program database were categorized into MINU or ONU. Our primary outcome of interest was 30-day perioperative complications. Secondary outcomes included use of lymph node dissection (LND), transfusion, reintervention and readmission rate, operative time, length of stay (LOS), and perioperative mortality. Multivariable logistic regression analyses were used to examine the association between outcomes and surgical approach. Results: A total of 599 (66.9%) and 297 (33.1%) patients underwent MINU and ONU, respectively. Overall, 12.7% of patients experienced a complication within 30 days postoperatively, and the rate did not differ among surgical approaches. Patients in the MINU group, however, had a decreased LOS (P<0.001). On multivariable analysis, patients receiving MINU were less likely to undergo a LND (OR 0.13; P<0.001), had decreased risk of thromboembolic complications (odds ratio [OR] 0.13; P=0.018), decreased need for transfusion (OR 0.39; P=0.001), and decreased need for operative reintervention (OR 0.24; P=0.024). Conclusions: Patients receiving MINU have similar overall complication rates compared with ONU. MINU, however, was associated with a decreased risk of blood transfusions, thromboembolic events, reintervention, and overall LOS compared with ONU. MINU should be considered as a primary approach in select groups of patients with UTUC.
C1 [Hanske, Julian; Schmid, Marianne; Meyer, Christian P.; Kibel, Adam S.; Eswara, Jairam R.; Trinh, Quoc-Dien] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Urol Surg, Boston, MA 02115 USA.
[Hanske, Julian; Schmid, Marianne; Meyer, Christian P.; Kibel, Adam S.; Eswara, Jairam R.; Trinh, Quoc-Dien] Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Surg & Publ Hlth, Boston, MA 02115 USA.
[Hanske, Julian; Noldus, Joachim] Ruhr Univ Bochum, Marien Hosp, Dept Urol, Bochum, Herne, Germany.
[Sanchez, Alejandro; Feldman, Adam S.] Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA.
[Schmid, Marianne; Meyer, Christian P.] Univ Med Ctr Hamburg Eppendorf, Dept Urol, Hamburg, Germany.
[Abdollah, Firas; Sammon, Jesse D.; Menon, Mani] Henry Ford Hlth Syst, Vattikuti Urol Inst, Ctr Outcomes Res Analyst & Evaluat, Detroit, MI USA.
RP Hanske, J (reprint author), Brigham & Womens Hosp, Div Urol Surg, 45 Francis St,ASB 2-3, Boston, MA 02115 USA.
EM j.hanske@gmx.de
FU Professor Walter Morris-Hale Distinguished Chair in Urologic Oncology at
Brigham and Women's Hospital; Vattikuti Urology Institute; Heinrich
Hertz-Stiftung
FX Quoc-Dien Trinh is supported by the Professor Walter Morris-Hale
Distinguished Chair in Urologic Oncology at Brigham and Women's Hospital
and by an unrestricted educational grant from the Vattikuti Urology
Institute. Julian Hanske is supported by a grant from the Heinrich
Hertz-Stiftung.
NR 27
TC 4
Z9 4
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0892-7790
EI 1557-900X
J9 J ENDOUROL
JI J. Endourol.
PD SEP 1
PY 2015
VL 29
IS 9
BP 1052
EP 1058
DI 10.1089/end.2015.0137
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA CQ4RA
UT WOS:000360591100013
PM 25891843
ER
PT J
AU Grob, SR
Campbell, AA
Gross, A
Cestari, DM
AF Grob, Seanna R.
Campbell, Ashley A.
Gross, Andrew
Cestari, Dean M.
TI Hemorrhage Within the Optic Nerve From a Cavernous Hemangioma of the
Optic Disc
SO JOURNAL OF NEURO-OPHTHALMOLOGY
LA English
DT Editorial Material
ID RETINA
AB A 49-year-old woman with a known right optic disc cavernous hemangioma experienced pain with eye movements and worsening of a superior visual field defect. While she retained 20/20 visual acuity in each eye, findings on magnetic resonance imaging were consistent with a hemorrhage in the anterior portion of the right intraorbital optic nerve. Her visual function stabilized spontaneously. We are unaware of previous reports of hemorrhage into the optic nerve from a cavernous hemangioma of the optic disc.
C1 [Gross, Andrew; Cestari, Dean M.] Massachusetts Eye & Ear Infirm, Neuroophthalmol, Boston, MA 02114 USA.
[Grob, Seanna R.; Campbell, Ashley A.; Gross, Andrew; Cestari, Dean M.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA.
RP Cestari, DM (reprint author), Massachusetts Eye & Ear Infirm, Neuroophthalmol, 243 Charles St, Boston, MA 02114 USA.
EM dean_cestari@meei.harvard.edu
NR 9
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1070-8022
EI 1536-5166
J9 J NEURO-OPHTHALMOL
JI J. Neuro-Ophthal.
PD SEP
PY 2015
VL 35
IS 3
BP 277
EP 279
DI 10.1097/WNO.0000000000000274
PG 3
WC Clinical Neurology; Ophthalmology
SC Neurosciences & Neurology; Ophthalmology
GA CQ4DC
UT WOS:000360553500010
PM 26132965
ER
PT J
AU Cestari, DM
Lessell, S
Mantopoulos, D
AF Cestari, Dean M.
Lessell, Simmons
Mantopoulos, Dimosthenis
TI Early Diagnosis of Subclinical Interferon Alpha-Associated Optic
Neuropathy Using Fluorescein Angiography
SO JOURNAL OF NEURO-OPHTHALMOLOGY
LA English
DT Article
ID COMBINATION THERAPY; HEPATITIS-C; RETINOPATHY; EDEMA; RIBAVIRIN
AB We report a case of a 57-year-old man who presented with decreased visual acuity in the left eye secondary to nonarteritic anterior ischemic optic neuropathy (NAION) while on therapy with interferon- for hepatitis C. Fundus fluorescein angiography revealed late leakage of both optic discs, consistent with bilateral disease. One week later, the patient developed clinical signs and symptoms consistent with NAION in the fellow eye. Fluorescein angiography may play an important role in identifying subclinical NAION in patients taking interferon-.
C1 [Cestari, Dean M.; Lessell, Simmons; Mantopoulos, Dimosthenis] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Neuroophthalmol Serv, Boston, MA USA.
[Mantopoulos, Dimosthenis] Ohio State Univ, Wexner Med Ctr, Havener Eye Inst, Dept Ophthalmol & Visual Sci, Columbus, OH 43212 USA.
RP Mantopoulos, D (reprint author), Ohio State Univ, Wexner Med Ctr, Havener Eye Inst, Dept Ophthalmol & Visual Sci, 915 Olentangy River Rd, Columbus, OH 43212 USA.
EM dimosthenis.mantopoulos@osumc.edu
NR 21
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1070-8022
EI 1536-5166
J9 J NEURO-OPHTHALMOL
JI J. Neuro-Ophthal.
PD SEP
PY 2015
VL 35
IS 3
BP 280
EP 283
DI 10.1097/WNO.0000000000000238
PG 4
WC Clinical Neurology; Ophthalmology
SC Neurosciences & Neurology; Ophthalmology
GA CQ4DC
UT WOS:000360553500011
PM 25793363
ER
PT J
AU Borchert, MS
Lessell, S
AF Borchert, Mark S.
Lessell, Simmons
TI Fanfare for the Uncommon Neuro-Ophthalmologist: A Tribute to Irma Miller
Lessell In Memoriam
SO JOURNAL OF NEURO-OPHTHALMOLOGY
LA English
DT Biographical-Item
C1 [Borchert, Mark S.] USC, Keck Sch Med, Childrens Hosp Los Angeles, Dept Ophthalmol, Los Angeles, CA 90095 USA.
[Lessell, Simmons] Harvard Univ, Sch Med, Dept Ophthalmol, Massachusetts Eye & Ear Infirm, Boston, MA USA.
RP Borchert, MS (reprint author), USC, Keck Sch Med, Childrens Hosp Los Angeles, Dept Ophthalmol, Los Angeles, CA 90095 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1070-8022
EI 1536-5166
J9 J NEURO-OPHTHALMOL
JI J. Neuro-Ophthal.
PD SEP
PY 2015
VL 35
IS 3
BP e24
EP e25
DI 10.1097/WNO.0000000000000262
PG 2
WC Clinical Neurology; Ophthalmology
SC Neurosciences & Neurology; Ophthalmology
GA CQ4DA
UT WOS:000360553300001
PM 26505049
ER
PT J
AU Wang, SY
Aldridge, MD
Gross, CP
Canavan, M
Cherlin, E
Johnson-Hurzeler, R
Bradley, E
AF Wang, Shi-Yi
Aldridge, Melissa D.
Gross, Cary P.
Canavan, Maureen
Cherlin, Emily
Johnson-Hurzeler, Rosemary
Bradley, Elizabeth
TI Geographic Variation of Hospice Use Patterns at the End of Life
SO JOURNAL OF PALLIATIVE MEDICINE
LA English
DT Article
ID CARE; CANCER; DEATH; QUALITY; INDICATORS; DEPRESSION; ENROLLMENT;
CAREGIVERS; BENEFIT; LENGTH
AB Background: Little is known about state-level variation in patterns of hospice use, an important indicator of quality of care at the end of life. Findings may identify states where targeted efforts for improving end-of-life care may be warranted. Objective: Our aim was to characterize the state-level variation in patterns of hospice use among decedents and to examine state, county, and individual factors associated with these patterns. Methods: We conducted a retrospective analysis of Medicare fee-for-service decedents. The primary outcome measures were state-level hospice use during the last 6 months of life and the state's proportion of hospice users with very short hospice enrollment (7 days), very long hospice enrollment (180 days), and hospice disenrollment prior to death. Results: In 2011, the percentage of decedents who used hospice in the last 6 months of life nationally was 47.1%, and varied across states from 20.3% in Alaska to 60.8% in Utah. Hospice utilization patterns also varied by state, with the percentage of hospice users with very short hospice enrollment ranging from 23.0% in the District of Columbia to 39.9% in Connecticut. The percentage of very long hospice use varied from 5.7% in Connecticut to 15.9% in Delaware. The percentage of hospice disenrollment ranged from 6.2% in Hawaii to 19.0% in the District of Columbia. Nationally, state-level hospice use among decedents was positively correlated with the percentage of potentially concerning patterns (including very short hospice enrollment, very long hospice enrollment, and hospice disenrollment) among hospice users (the Pearson correlation coefficient=0.52, p value<0.001). Oregon was the only state in the highest quartile of hospice use and the lowest quartiles of both very short and very long hospice enrollment. Conclusions: The percentage of decedents who use hospice may mask important state-level variation in these patterns, including the timing of hospice enrollment, a potentially important component of the quality of end-of-life care.
C1 [Wang, Shi-Yi] Yale Univ, Sch Publ Hlth, Dept Chron Dis Epidemiol, New Haven, CT 06520 USA.
[Canavan, Maureen; Cherlin, Emily; Bradley, Elizabeth] Yale Univ, Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT 06520 USA.
[Wang, Shi-Yi; Gross, Cary P.] Yale Canc Ctr, Canc Outcomes Publ Policy & Effectiveness Res COP, New Haven, CT USA.
[Wang, Shi-Yi; Gross, Cary P.] Yale Univ, Sch Med, New Haven, CT 06520 USA.
[Aldridge, Melissa D.] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY USA.
[Aldridge, Melissa D.] James J Peters VA Med Ctr, Bronx, NY USA.
[Gross, Cary P.] Yale Univ, Sch Med, Dept Internal Med, Gen Internal Med Sect, New Haven, CT 06520 USA.
[Johnson-Hurzeler, Rosemary] John D Thompson Hospice Inst Educ Training & Res, Branford, CT USA.
RP Wang, SY (reprint author), Yale Univ, Sch Publ Hlth, Dept Chron Dis Epidemiol, 60 Coll St,POB 208034, New Haven, CT 06520 USA.
EM shiyi.wang@yale.edu
FU National Cancer Institute [1R01CA116398-01A2]; John D. Thompson
Foundation; National Institute of Nursing Research [5R01NR013499]
FX This study was supported by grant 1R01CA116398-01A2 from the National
Cancer Institute (Drs. Aldridge and Bradley), the John D. Thompson
Foundation (Dr. Bradley), and grant 5R01NR013499 from the National
Institute of Nursing Research (Dr. Aldridge).
NR 23
TC 7
Z9 7
U1 2
U2 4
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-6218
EI 1557-7740
J9 J PALLIAT MED
JI J. Palliat. Med.
PD SEP 1
PY 2015
VL 18
IS 9
BP 771
EP 780
DI 10.1089/jpm.2014.0425
PG 10
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA CQ1LE
UT WOS:000360358400010
PM 26172615
ER
PT J
AU Kaafarani, HMA
AF Kaafarani, Haytham M. A.
TI The voice of the "never-complaining" staff: the impact of hospital and
residency mergers on surgical trainees
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Editorial Material
C1 Harvard Univ, Dept Surg, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Kaafarani, HMA (reprint author), Harvard Univ, Dept Surg, Sch Med, Massachusetts Gen Hosp, 165 Cambridge St,Suite 810, Boston, MA 02114 USA.
EM hkaafarani@mgh.harvard.edu
NR 4
TC 0
Z9 0
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-4804
EI 1095-8673
J9 J SURG RES
JI J. Surg. Res.
PD SEP
PY 2015
VL 198
IS 1
BP 59
EP 60
DI 10.1016/j.jss.2015.05.047
PG 2
WC Surgery
SC Surgery
GA CQ6IG
UT WOS:000360707300010
PM 26095421
ER
PT J
AU Vimalananda, VG
Gupte, G
Seraj, SM
Orlander, J
Berlowitz, D
Fincke, BG
Simon, SR
AF Vimalananda, Varsha G.
Gupte, Gouri
Seraj, Siamak M.
Orlander, Jay
Berlowitz, Dan
Fincke, Benjamin G.
Simon, Steven R.
TI Electronic consultations (e-consults) to improve access to specialty
care: A systematic review and narrative synthesis
SO JOURNAL OF TELEMEDICINE AND TELECARE
LA English
DT Review
DE remote consultation; teleconsulting; telehealth; telemedicine;
e-consults
ID CHRONIC KIDNEY-DISEASE; SAFETY-NET; REFERRALS; IMPLEMENTATION;
TECHNOLOGY; PROVIDERS; BENEFITS; SERVICE
AB Background: We define electronic consultations ("e-consults") as asynchronous, consultative, provider-to-provider communications within a shared electronic health record (EHR) or web-based platform. E-consults are intended to improve access to specialty expertise for patients and providers without the need for a face-to-face visit. Our goal was to systematically review and summarize the literature describing the use and effects of e-consults.
Methods: We searched PubMed, EMBASE, the Cochrane Library, and CINAHL for studies related to e-consults published between 1990 through December 2014. Three reviewers identified empirical studies and system descriptions, including articles on systems that used a shared EHR or web-based platform, connected providers in the same health system, were used for two-way provider communication, and were text-based.
Results: Our final review included 27 articles. Twenty-two were research studies and five were system descriptions. Eighteen originated from one of three sites with well-developed e-consult programs. Most studies reported on workflow impact, timeliness of specialty input, and/or provider perceptions of e-consults. E-consultations are used in a variety of ways within and across medical centers. They provide timely access to specialty care and are well-received by primary care providers.
Discussion: E-consults are feasible in a variety of settings, flexible in their application, and facilitate timely specialty advice. More extensive and rigorous studies are needed to inform the e-consult process and describe its effect on access to specialty visits, cost and clinical outcomes.
C1 [Vimalananda, Varsha G.; Berlowitz, Dan; Fincke, Benjamin G.; Simon, Steven R.] US Dept Vet Affairs, CHOIR, Bedford, MA USA.
[Vimalananda, Varsha G.] Boston Univ, Sch Med, Sect Endocrinol Diabet & Nutr, Boston, MA 02118 USA.
[Gupte, Gouri; Seraj, Siamak M.; Berlowitz, Dan] Boston Univ, Sch Med, Dept Hlth Policy & Management, Boston, MA 02118 USA.
[Orlander, Jay; Simon, Steven R.] VA Boston Healthcare Syst, Boston, MA USA.
[Orlander, Jay] Boston Univ, Sch Med, Gen Internal Med Sect, Boston, MA 02118 USA.
[Simon, Steven R.] Brigham & Womens Hosp, Div Gen Internal Med, Boston, MA 02115 USA.
[Simon, Steven R.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
RP Vimalananda, VG (reprint author), Edith Nourse Rogers Mem VA Med Ctr 152, CHOIR, 200 Springs Rd, Bedford, MA 01730 USA.
EM varsha.vimalananda@va.gov
FU Department of Veterans Affairs
FX The author(s) disclosed receipt of the following financial support for
the research, authorship, and/or publication of this article: This
material is based upon work supported in part by the Department of
Veterans Affairs. The views expressed in this article are those of the
authors and do not necessarily reflect the position or policy of the
Department of Veterans Affairs or the US Government.
NR 37
TC 18
Z9 18
U1 5
U2 19
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1357-633X
EI 1758-1109
J9 J TELEMED TELECARE
JI J. Telemed. Telecare
PD SEP
PY 2015
VL 21
IS 6
BP 323
EP 330
DI 10.1177/1357633X15582108
PG 8
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA CQ8HK
UT WOS:000360847500002
PM 25995331
ER
PT J
AU Conrad, MF
Carvalho, S
Ergul, E
Kwolek, CJ
Lancaster, RT
Patel, VI
Cambria, RP
AF Conrad, Mark F.
Carvalho, Stephanie
Ergul, Emel
Kwolek, Christopher J.
Lancaster, R. Todd
Patel, Virendra I.
Cambria, Richard P.
TI Late aortic remodeling persists in the stented segment after
endovascular repair of acute complicated type B aortic dissection
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Article; Proceedings Paper
CT 40th Annual Meeting of the New-England-Society-for-Vascular-Surgery
CY SEP 27-29, 2013
CL Stowe, VT
SP New England Soc Vasc Surg
ID MULTICENTER CLINICAL-TRIAL; DESCENDING THORACIC AORTA; COMPOSITE DEVICE
DESIGN; INTERNATIONAL REGISTRY; IRAD; MANAGEMENT; ANEURYSMS; OUTCOMES;
GRAFT; EXPERIENCE
AB Objective: Thoracic endovascular aortic repair (TEVAR) for acute complicated type B aortic dissection (AD) promotes early positive aortic remodeling. However, little is known about the long-term effect of TEVAR on the dissected aorta, which is the goal of this study.
Methods: Between August 2005 and August 2009, 31 patients with complicated type B AD were treated with TEVAR and had > 1-year follow-up imaging. Computed tomography angiograms obtained at 1 month, 1 year, and long term (average, 42 months) were compared with baseline scans. The largest diameters of the stented thoracic aorta, stented true lumen, and stented false lumen were recorded at each time point, as were the values in the unstented distal thoracic aorta and the abdominal aorta. Changes over time were evaluated by a mixed effect analysis of variance model of repeated measures.
Results: The average age of the cohort was 56 years, and 74% were male. Indications for TEVAR were as follows: 61% malperfusion, 32% refractory hypertension, 45% impending rupture, and 32% persistent pain; 58% had more than one indication. All patients were treated in the acute phase within 7 days of the initial presentation. The average length of aorta covered was 19 cm. Observation of the stented segment over time showed that the maximum diameter of the stented thoracic aorta was stable (P = NS), the diameter of the stented true lumen increased (P < .001), and the diameter of the stented false lumen decreased (P < .001); 84% had complete false lumen obliteration across the stented aortic segment. Observation of the uncovered thoracic aorta over time showed that the maximum diameter increased (P = .014), as did the visceral segment of the aorta (P < .001). The average growth of the visceral segment was 31% in patients with a patent false lumen vs 3% in those with a thrombosed false lumen (P = .004). One patient had aneurysmal degeneration of the false lumen and required an additional endograft at 18 months.
Conclusions: TEVAR of acute AD promotes long-term remodeling across the stented segment, with false lumen obliteration in 84% of patients. However, false lumen obliteration beyond the stented segment appears necessary to prevent late aneurysmal degeneration of the distal aorta.
C1 [Conrad, Mark F.; Carvalho, Stephanie; Ergul, Emel; Kwolek, Christopher J.; Lancaster, R. Todd; Patel, Virendra I.; Cambria, Richard P.] Harvard Univ, Massachusetts Gen Hosp, Med Sch, Div Vasc & Endovasc Surg,Dept Surg, Cambridge, MA 02138 USA.
RP Conrad, MF (reprint author), Massachusetts Gen Hosp, WACC 4,15 Parkman St, Boston, MA 02114 USA.
EM mconrad@partners.org
NR 33
TC 6
Z9 6
U1 0
U2 4
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD SEP
PY 2015
VL 62
IS 3
BP 600
EP 605
DI 10.1016/j.jvs.2015.03.064
PG 6
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA CQ1KW
UT WOS:000360357500010
PM 26054588
ER
PT J
AU Vierthaler, L
Callas, PW
Goodney, PP
Schanzer, A
Patel, VI
Cronenwett, J
Bertges, DJ
AF Vierthaler, Luke
Callas, Peter W.
Goodney, Philip P.
Schanzer, Andres
Patel, Virenda I.
Cronenwett, Jack
Bertges, Daniel J.
CA Vasc Study Grp New England
TI Determinants of survival and major amputation after peripheral
endovascular intervention for critical limb ischemia
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Article; Proceedings Paper
CT 40th Annual Meeting of the New-England-Society-for-Vascular-Surgery
CY SEP 27-29, 2013
CL Stowe, VT
SP New England Soc Vasc Surg
ID EXTREMITY BYPASS-SURGERY; LEG BASIL TRIAL; VASCULAR-SURGERY;
ARTERIAL-DISEASE; PREDICTION MODEL; FINNVASC SCORE; REVASCULARIZATION;
ANGIOPLASTY; VALIDATION; STRATIFICATION
AB Objective: Our objective was to analyze periprocedural and 1-year outcomes of peripheral endovascular intervention (PVI) for critical limb ischemia (CLI).
Methods: We reviewed 1244 patients undergoing 1414 PVIs for CLI (rest pain, 29%; tissue loss, 71%) within the Vascular Study Group of New England (VSGNE) from January 2010 to December 2011. Overall survival (OS), amputation-free survival (AFS), and freedom from major amputation at 1 year were analyzed using the Kaplan-Meier method. Cox proportional hazards models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs).
Results: The number of arteries treated during each procedure were 1 (49%), 2 (35%), 3 (12%), and >= 4 (5%). Target arterial segments and TransAtlantic Inter-Society Consensus classifications were aortoiliac, 27% (A, 48%; B, 28%; C, 12%; and D, 12%); femoral-popliteal, 48% (A, 29%; B, 34%; C, 20%; and D, 17%); and infrapopliteal, 25% (A, 17%; B, 14%; C, 25%; D, 44%). Technical success was 92%. Complications included access site hematoma (5.0%), occlusion (0.3%), and distal embolization (2.4%). Mortality and major amputation rates were 2.8% and 2.2% at 30 days, respectively. Overall percutaneous or open reintervention rate was 8.0% during the first year. At 1-year, OS, AFS, and freedom from major amputation were 87%, 87%, and 94% for patients with rest pain and 80%, 71%, and 81% for patients with tissue loss. Independent predictors of reduced 1-year OS (C index = .74) included dialysis (HR, 3.8; 95% CI, 2.8-5.1; P < .01), emergency procedure (HR, 2.5; 95% CI, 1.0-6.2; P = .05), age > 80 years (HR, 2.2; 95% CI, 1.7-2.8; P <.01), not living at home preoperatively (HR, 2.0; 95% CI, 1.4-2.8; P <.01), creatinine > 1.8 mg/dL (HR, 1.9; 95% CI, 1.3-2.8; P <.01), congestive heart failure (HR, 1.7; 95% CI, 1.3-2.2; P <.01), and chronic beta-blocker use (HR, 1.4; 95% CI, 1.0-1.9; P = .03), whereas independent preoperative ambulation (HR, 0.7; 95% CI, 0.6-0.9; P = .014) was protective. Independent predictors of major amputation (C index[. 69) at 1 year included dialysis (HR, 2.7; 95% CI, 1.6-4.5; P <.01), tissue loss (HR, 2.0; 95% CI, 1.1-3.7; P = .02), prior major contralateral amputation (HR, 2.0; 95% CI, 1.1-3.5; P = .02), nonCaucasian race (HR, 1.7; 95% CI, 1.0-2.9; P = .045), and male gender (HR, 1.6; 95% CI, 1.1-2.6; P = .03), whereas smoking (HR,.60; 95% CI, 0.4-1.0; P = .042) was protective.
Conclusions: Survival and major amputation after PVI for CLI are associated with different patient characteristics. Dialysis dependence is a common predictor that portends especially poor outcomes. These data may facilitate efforts to improve patient selection and, after further validation, enable risk-adjusted outcome reporting for CLI patients undergoing PVI.
C1 [Vierthaler, Luke; Callas, Peter W.] Univ Vermont, Coll Med, Burlington, VT 05401 USA.
[Goodney, Philip P.; Cronenwett, Jack] Dartmouth Hitchcock Med Ctr, Sect Vasc Surg, Lebanon, NH 03766 USA.
[Schanzer, Andres] Univ Massachusetts, Med Ctr, Div Vasc Surg, Worcester, MA USA.
[Patel, Virenda I.] Massachusetts Gen Hosp, Div Vasc Surg, Boston, MA 02114 USA.
[Bertges, Daniel J.] Univ Vermont, Med Ctr, Div Vasc Surg, Burlington, VT 05401 USA.
RP Bertges, DJ (reprint author), Univ Vermont, Med Ctr, Div Vasc Surg, 111 Colchester Ave,Smith 338, Burlington, VT 05401 USA.
EM daniel.bertges@vtmednet.org
FU NHLBI NIH HHS [K08 HL105676]
NR 23
TC 3
Z9 3
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD SEP
PY 2015
VL 62
IS 3
BP 655
EP U532
DI 10.1016/j.jvs.2015.04.391
PG 18
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA CQ1KW
UT WOS:000360357500020
PM 26215708
ER
PT J
AU Scali, S
Bertges, D
Neal, D
Patel, V
Eldrup-Jorgensen, J
Cronenwett, J
Beck, A
AF Scali, Salvatore
Bertges, Daniel
Neal, Daniel
Patel, Virendra
Eldrup-Jorgensen, Jens
Cronenwett, Jack
Beck, Adam
TI Heart rate variables in the Vascular Quality Initiative are not reliable
predictors of adverse cardiac outcomes or mortality after major elective
vascular surgery
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Article; Proceedings Paper
CT 39th Annual Meeting of the Southern-Association-for-Vascular-Surgery
CY JAN 14-17, 2015
CL Scottsdale, AZ
SP So Assoc Vasc Surg
ID PERIOPERATIVE CARDIOVASCULAR EVALUATION; NONCARDIAC SURGERY;
OF-CARDIOLOGY; ASSOCIATION; SOCIETY; RISK; ECHOCARDIOGRAPHY; MANAGEMENT;
DISEASE; BYPASS
AB Objective: Heart rate (HR) parameters are known indicators of cardiovascular complications after cardiac surgery, but there is little evidence of their role in predicting outcome after major vascular surgery. The purpose of this study was to determine whether arrival HR (AHR) and highest intraoperative HR are associated with mortality or major adverse cardiac events (MACEs) after elective vascular surgery in the Vascular Quality Initiative (VQI).
Methods: Patients undergoing elective lower extremity bypass (LEB), aortofemoral bypass (AFB), and open abdominal aortic aneurysm (AAA) repair in the VQI were analyzed. MACE was defined as any postoperative myocardial infarction, dysrhythmia, or congestive heart failure. Controlled HR was defined as AHR <75 beats/min on operating room arrival. Delta HR (DHR) was defined as highest intraoperative HR - AHR. Procedure-specific MACE models were derived for risk stratification, and generalized estimating equations were used to account for clustering of center effects. HR, beta-blocker exposure, cardiac risk, and their interactions were explored to determine association with MACE or 30-day mortality. A Bonferroni correction with P < .004 was used to declare significance.
Results: There were 13,291 patients reviewed (LEB, n = 8155 [62%]; AFB, n = 2629 [18%]; open AAA, n = 2629 [20%]). Rates of any preoperative beta-blocker exposure were as follows: LEB, 66.5% (n = 5412); AFB, 57% (n = 1342); and open AAA, 74.2% (n = 1949). AHR and DHR outcome association was variable across patients and procedures. AHR < 75 beats/min was associated with increased postoperative myocardial infarction risk for LEB patients across all risk strata (odds ratio [OR], 1.4; 95% confidence interval [CI], 1.03-1.9; P = .03), whereas AHR < 75 beats/min was associated with decreased dysrhythmia risk (OR, 0.42; 95% CI, 0.28-0.63; P = .0001) and 30-day death (OR, 0.50; 95% CI, 0.33-0.77; P = .001) in patients at moderate and high cardiac risk. These HR associations disappeared in controlling for beta-blocker status. For AFB and open AAA repair patients, there was no significant association between AHR and MACE or 30-day mortality, irrespective or cardiac risk or beta-blocker status. DHR and extremes of highest intraoperative HR (>90 or 100 beats/min) were analyzed among all three operations, and no consistent associations with MACE or 30-day mortality were detected.
Conclusions: The VQI AHR and highest intraoperative HR variables are highly confounded by patient presentation, operative variables, and beta-blocker therapy. The discordance between cardiac risk and HR as well as the lack of consistent correlation to outcome makes them unreliable predictors. The VQI has elected to discontinue collecting AHR and highest intraoperative HR data, given insufficient evidence to suggest their importance as an outcome measure.
C1 [Scali, Salvatore; Neal, Daniel; Beck, Adam] Univ Florida, Div Vasc Surg & Endovasc Therapy, Gainesville, FL 32610 USA.
[Bertges, Daniel] Univ Vermont, Div Vasc Surg, Burlington, VT USA.
[Patel, Virendra] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Vasc Surg, Boston, MA USA.
[Eldrup-Jorgensen, Jens] Maine Med Ctr, Div Vasc Surg, Portland, ME 04102 USA.
[Cronenwett, Jack] Dartmouth Hitchcock Med Ctr, Vasc Surg Sect, Lebanon, NH 03766 USA.
RP Scali, S (reprint author), Univ Florida, Sch Med, Div Vasc Surg & Endovasc Therapy, Surg, POB 100128,1600 SW Archer Rd,Ste NG 45, Gainesville, FL 32610 USA.
EM salvatore.scali@surgery.ufl.edu
FU NHLBI NIH HHS [5K23HL115673-02, K23 HL115673]
NR 27
TC 1
Z9 1
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD SEP
PY 2015
VL 62
IS 3
BP 710
EP U599
DI 10.1016/j.jvs.2015.03.071
PG 20
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA CQ1KW
UT WOS:000360357500028
PM 26067200
ER
PT J
AU Mehta, M
Paty, PSK
Kwolek, C
Cambria, R
Keenan, M
Feustel, P
AF Mehta, Manish
Paty, Philip S. K.
Kwolek, Christopher
Cambria, Richard
Keenan, Megan
Feustel, Paul
TI A Novel Transcarotid Artery Revascularization Procedure With Flow
Reversal: 30-Day Pivotal Results of the ROADSTER IDE Trial
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Meeting Abstract
CT 29th Annual Meeting of the Eastern-Vascular-Society
CY SEP 24-26, 2015
CL Baltimore, MD
SP Eastern Vasc Soc
C1 [Mehta, Manish; Paty, Philip S. K.] Vasc Hlth Partners, CCP, Glens Falls, NY USA.
[Kwolek, Christopher; Cambria, Richard] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Keenan, Megan] Inst Vasc Hlth & Dis, Albany, NY USA.
[Feustel, Paul] Albany Med Coll, Albany, NY 12208 USA.
NR 0
TC 1
Z9 1
U1 1
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD SEP
PY 2015
VL 62
IS 3
BP 804
EP 804
PG 1
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA CQ1KW
UT WOS:000360357500070
ER
PT J
AU Creighton, FX
Hapner, E
Klein, A
Rosen, A
Jinnah, HA
Johns, MM
AF Creighton, Francis X.
Hapner, Edie
Klein, Adam
Rosen, Ami
Jinnah, Hyder A.
Johns, Michael M.
TI Diagnostic Delays in Spasmodic Dysphonia: A Call for Clinician Education
SO JOURNAL OF VOICE
LA English
DT Article
DE Larynx; Voice; Spasmodic dysphonia; Diagnostic delay
ID CERVICAL DYSTONIA; RISK
AB Purpose. Spasmodic dysphonia (SD) is a rare but often debilitating disease. Due to lack of awareness among practitioners and lack of well-defined diagnostic criteria, it can be difficult for patients with SD to receive a diagnosis and subsequent treatment. There is currently no literature documenting the efficacy of the medical community in recognizing and diagnosing this disorder. We aimed to quantify the patients' experiences with obtaining a diagnosis of SD.
Methods. One hundred seven consecutive patients with SD completed questionnaires about their experiences with SD. Patients were recruited either during outpatient laryngology visits or during participation in a National Institutes of Health funded study investigating SD.
Results. It took patients an average of 4.43 years (53.21 months) to be diagnosed with SD after first going to a physician with vocal symptoms. Patients had to see an average of 3.95 physicians to receive a diagnosis of SD. Patients (31.4%) had been prescribed medications other than botulinum toxin to treat their symptoms. Patients (30%) attempted alternative therapies for treatment of SD, such as chiropractor or dietary modification.
Conclusions. Despite advances in diagnostic modalities in medicine, the diagnosis of SD still remains elusive. Objective criteria for the diagnosis of SD and increased clinician education are warranted to address this diagnostic delay.
C1 [Creighton, Francis X.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otolaryngol Head & Neck Surg, Boston, MA USA.
[Hapner, Edie; Klein, Adam; Johns, Michael M.] Emory Univ, Sch Med, Emory Voice Ctr, Dept Otolaryngol Head & Neck Surg, Atlanta, GA 30308 USA.
[Rosen, Ami; Jinnah, Hyder A.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30308 USA.
RP Johns, MM (reprint author), Emory Univ, Emory Voice Ctr, 550 Peachtree St 9th Fl Ste 4400, Atlanta, GA 30308 USA.
EM michael.johns2@emory.edu
FU NIH Grant [NS065701]
FX This research was supported in part by NIH Grant # NS065701.
NR 5
TC 1
Z9 1
U1 1
U2 6
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0892-1997
EI 1873-4588
J9 J VOICE
JI J. Voice
PD SEP
PY 2015
VL 29
IS 5
BP 592
EP 594
DI 10.1016/j.jvoice.2013.10.022
PG 3
WC Otorhinolaryngology
SC Otorhinolaryngology
GA CQ4EI
UT WOS:000360556700011
PM 25873547
ER
PT J
AU Ng, LC
Hanlon, C
Yimer, G
Henderson, DC
Fekadu, A
AF Ng, Lauren C.
Hanlon, Charlotte
Yimer, Getnet
Henderson, David C.
Fekadu, Abebaw
TI Ethics in global health research: the need for balance
SO LANCET GLOBAL HEALTH
LA English
DT Editorial Material
ID INTERNATIONAL RESEARCH; CAPACITY; COMMITTEES
C1 [Ng, Lauren C.; Henderson, David C.] Massachusetts Gen Hosp, Dept Psychiat, Chester M Pierce MD Div Global Psychiat, Boston, MA 02114 USA.
[Ng, Lauren C.; Henderson, David C.] Harvard Univ, Sch Med, Boston, MA USA.
[Hanlon, Charlotte; Fekadu, Abebaw] Univ Addis Ababa, Dept Psychiat, Coll Hlth Sci, Sch Med, Addis Ababa, Ethiopia.
[Yimer, Getnet] Univ Addis Ababa, Dept Pharmacol & Biochem, Coll Hlth Sci, Sch Med, Addis Ababa, Ethiopia.
[Hanlon, Charlotte] Kings Coll London, Ctr Global Mental Hlth, Inst Psychiat Psychol & Neurosci, London WC2R 2LS, England.
[Fekadu, Abebaw] Kings Coll London, Ctr Affect Disorders, Inst Psychiat Psychol & Neurosci, London WC2R 2LS, England.
[Henderson, David C.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
RP Ng, LC (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Chester M Pierce MD Div Global Psychiat, Boston, MA 02114 USA.
EM lng4@mgh.harvard.edu
FU National Institute of Mental Health [5T32MH093310]
FX This Comment was supported by grant number 5T32MH093310 from the
National Institute of Mental Health. The funder had no role in the
writing of the Comment or the decision to submit it for publication. We
declare no competing interests.
NR 9
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2214-109X
J9 LANCET GLOB HEALTH
JI Lancet Glob. Health
PD SEP
PY 2015
VL 3
IS 9
BP E516
EP E517
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA CQ4FJ
UT WOS:000360559500009
PM 26275322
ER
PT J
AU Hinton, DE
Reis, R
de Jong, J
AF Hinton, Devon E.
Reis, Ria
de Jong, Joop
TI The "Thinking a Lot" Idiom of Distress and PTSD: An Examination of Their
Relationship among Traumatized Cambodian Refugees Using the "Thinking a
Lot" Questionnaire
SO MEDICAL ANTHROPOLOGY QUARTERLY
LA English
DT Article
DE idioms of distress; "thinking a lot,"; "thinking too much,"; Cambodian
refugees; PTSD
ID REPETITIVE THOUGHT; CULTURAL SYNDROMES; RUMINATION; ATTACKS; CBT
AB Thinking a lot (TAL)also referred to as thinking too muchis a key complaint in many cultural contexts, and the current article profiles this idiom of distress among Cambodian refugees. The article also proposes a general model of how TAL generates various types of distress that then cause PTSD-type psychopathology, a model we refer to as the TAL-PTSD model. As tested in this Cambodian refugee sample, the model is supported by the following: (1) the close connection of TAL to PTSD as shown by odds ratio (OR = 19.6), correlation (r = .86), and factor loading; and (2) the mediation of most of the effect of TAL on PTSD by TAL-caused somatic symptoms, catastrophic cognitions, trauma recall, insomnia, and irritability. The questionnaire used in the present study is provided and can be used to examine TAL in other cultural and global contexts to advance the study of this commonly encountered distress form.
C1 [Hinton, Devon E.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA.
[Reis, Ria] Leiden Univ, Med Ctr, Dept Publ Hlth & Primary Care, NL-2300 RA Leiden, Netherlands.
[Reis, Ria; de Jong, Joop] Univ Amsterdam, Amsterdam Inst Social Sci Res, NL-1012 WX Amsterdam, Netherlands.
[Reis, Ria] Univ Cape Town, Childrens Inst, ZA-7700 Rondebosch, South Africa.
RP Hinton, DE (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA.
EM devon_hinton@hms.harvard.edu
NR 33
TC 5
Z9 5
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0745-5194
EI 1548-1387
J9 MED ANTHROPOL Q
JI Med. Anthropol. Q.
PD SEP
PY 2015
VL 29
IS 3
BP 357
EP 380
DI 10.1111/maq.12204
PG 24
WC Anthropology; Public, Environmental & Occupational Health; Social
Sciences, Biomedical
SC Anthropology; Public, Environmental & Occupational Health; Biomedical
Social Sciences
GA CQ7VJ
UT WOS:000360813200015
PM 25772670
ER
PT J
AU Rinne, ST
Wong, ES
Hebert, PL
Au, DH
Lindenauer, PK
Neely, EL
Sulc, CA
Liu, CF
AF Rinne, Seppo T.
Wong, Edwin S.
Hebert, Paul L.
Au, David H.
Lindenauer, Peter K.
Neely, Emily L.
Sulc, Christine A.
Liu, Chuan-Fen
TI Weekend Discharges and Length of Stay Among Veterans Admitted for
Chronic Obstructive Pulmonary Disease
SO MEDICAL CARE
LA English
DT Article
DE weekend; COPD; length of stay; efficiency; readmission
ID MYOCARDIAL-INFARCTION; HEART-FAILURE; HOSPITALS; MORTALITY; OUTCOMES;
SERVICE; DELAYS; RATES
AB Background:Discharge rates are substantially lower on weekends, though the impact on hospital length of stay (LOS) is not fully understood.Objectives:The primary objective was to examine the association of weekend discharges with hospital LOS. We also examined the association of weekend discharges with readmission, mortality, and postdischarge follow-up.Research Design and Methods:A cohort study of 25,301 patients who were admitted to Veterans Affairs hospitals for chronic obstructive pulmonary disease during October 01, 2008-September 30, 2010, including 3845 patients discharged on the weekend (Saturday or Sunday) and 21,456 discharged on weekdays (Monday through Friday).Results:There were significantly fewer discharges on the weekend (1922 per weekend day vs. 4279 per weekday, P<0.01). Inpatient status during the weekend at any point in hospitalization was associated with an increased LOS of 0.59 day [95% confidence interval (CI), 0.54-0.63 d]. Discharge on the weekend was not associated with increased odds of 30-day hospital readmission [odds ratio (OR)=1.00; 95% CI, 0.90-1.10] or lack of primary care follow-up visit within 14 days of discharge (OR=0.94; 95% CI, 0.85-1.03). However, weekend discharges were significantly associated with lower odds of mortality within 30 days after discharge (OR=0.80; 95% CI, 0.65-0.99).Conclusions:The presence of fewer weekend discharges was associated with significantly longer hospital lengths of stay. Weekend discharges were not associated with higher readmission rates and had lower rates of mortality compared with weekdays discharges. Identifying methods to increase weekend discharges may create an opportunity to improve hospital efficiency.
C1 [Rinne, Seppo T.] VA Connecticut Hlth Care Syst, West Haven, CT USA.
[Rinne, Seppo T.] Yale Univ, Dept Med, Div Pulm & Crit Care, New Haven, CT 06520 USA.
[Wong, Edwin S.; Hebert, Paul L.; Au, David H.; Neely, Emily L.; Sulc, Christine A.; Liu, Chuan-Fen] VA Puget Sound Hlth Care Syst, Dept Vet Affairs, Seattle, WA USA.
[Wong, Edwin S.; Hebert, Paul L.; Liu, Chuan-Fen] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Au, David H.] Univ Washington, Dept Med, Div Pulm & Crit Care, Seattle, WA USA.
[Lindenauer, Peter K.] Baystate Med Ctr, Dept Med, Springfield, MA 01199 USA.
RP Rinne, ST (reprint author), 950 Campbell Ave,Bldg 35a,Room 2-234, West Haven, CT 06516 USA.
EM seppo.rinne@va.gov
FU Veterans Affairs clinical research grant [IIR-09-354]
FX Supported by Veterans Affairs clinical research grant: IIR-09-354.
NR 24
TC 2
Z9 2
U1 2
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7079
EI 1537-1948
J9 MED CARE
JI Med. Care
PD SEP
PY 2015
VL 53
IS 9
BP 753
EP 757
DI 10.1097/MLR.0000000000000395
PG 5
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA CQ4QM
UT WOS:000360589700003
PM 26147865
ER
PT J
AU Toth, M
Holmes, M
Van Houtven, C
Toles, M
Weinberger, M
Silberman, P
AF Toth, Matthew
Holmes, Mark
Van Houtven, Courtney
Toles, Mark
Weinberger, Morris
Silberman, Pam
TI Rural Medicare Beneficiaries Have Fewer Follow-up Visits and Greater
Emergency Department Use Postdischarge
SO MEDICAL CARE
LA English
DT Article
DE Medicare; rural health; postacute care; readmission
ID QUALITY-OF-CARE; HEART-FAILURE; TRANSITIONAL CARE; HEALTH-CARE; HOSPITAL
READMISSIONS; 30-DAY READMISSION; ACCESS; RATES; DISCHARGE;
OPPORTUNITIES
AB Background:Hospitals are focused on improving postdischarge services for older adults, such as early follow-up care after hospitalization to reduce readmissions and unnecessary emergency department (ED) use. Rural Medicare beneficiaries face many barriers to receiving quality care, but little is known about their postdischarge care and outcomes. We hypothesize that rural Medicare beneficiaries compared with urban beneficiaries, will have fewer follow-up visits, and a greater likelihood of readmission and ED use.Methods:We conducted a retrospective analysis of elderly Medicare beneficiaries discharged home using the Medicare Current Beneficiary Survey, Cost and Use files, 2000-2010. Multivariate Cox proportional hazard models were used to assess the risk of rural residency on readmission, ED use, and follow-up care up to 30 days' postdischarge. Covariates include demographic, health, and hospital-level characteristics.Results:Compared with urban beneficiaries, Medicare beneficiaries living in isolated rural settings had a lower rate of follow-up care [hazard ratio (HR)=0.81, P<0.001]. Beneficiaries in large and small rural settings had a greater risk of an ED visit compared with urban beneficiaries (HR=1.44, P<0.001; HR=1.52, P<0.01). Rural beneficiaries did not have a greater risk of readmission, though risk of readmission was higher for beneficiaries discharged from hospitals in large and small rural settings (HR=1.33, P<0.05; HR=1.42, P<0.05).Conclusions:This study provides evidence of lower quality postdischarge care for Medicare beneficiaries in rural settings. As readmission penalties expand, hospitals serving rural beneficiaries may be disproportionately affected. This suggests a need for policies that increase follow-up care in rural settings.
C1 [Toth, Matthew; Holmes, Mark; Weinberger, Morris; Silberman, Pam] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Hlth Policy & Management, Sheps Ctr Hlth Serv Res, Chapel Hill, NC 27599 USA.
[Van Houtven, Courtney] Durham VA Med Ctr, US Dept Vet Affairs, Ctr Hlth Serv Res Primary Care, Durham, NC USA.
[Van Houtven, Courtney] Duke Univ, Med Ctr, Dept Med, Div Gen Internal Med, Durham, NC 27706 USA.
[Toles, Mark] Univ N Carolina, Sch Nursing, Chapel Hill, NC 27599 USA.
RP Toth, M (reprint author), Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Hlth Policy & Management, Sheps Ctr Hlth Serv Res, 135 Dauer Dr,1101 McGavran Greeberg Hall,CB 7411, Chapel Hill, NC 27599 USA.
EM tbmatthe@live.unc.edu
FU T-32 National Research Service Award, Sheps Center for Health Services
Research [2T32HS000032-25]; North Carolina Rural Health Research Program
[UL1-TR000083, F30-HL110483, T32-GM008719]; UNC Institute on Aging
FX Supported by a T-32 National Research Service Award, Sheps Center for
Health Services Research, Grant #: 2T32HS000032-25. Support was also
provided by the North Carolina Rural Health Research Program.
UL1-TR000083, F30-HL110483, T32-GM008719, and UNC Institute on Aging
pilot grant supported the purchase of the Medicare Current Beneficiary
Survey.
NR 47
TC 4
Z9 4
U1 3
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7079
EI 1537-1948
J9 MED CARE
JI Med. Care
PD SEP
PY 2015
VL 53
IS 9
BP 800
EP 808
DI 10.1097/MLR.0000000000000401
PG 9
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA CQ4QM
UT WOS:000360589700009
PM 26270827
ER
PT J
AU Nelson, RE
Samore, MH
Jones, M
Greene, T
Stevens, VW
Liu, CF
Graves, N
Evans, MF
Rubin, MA
AF Nelson, Richard E.
Samore, Matthew H.
Jones, Makoto
Greene, Tom
Stevens, Vanessa W.
Liu, Chuan-Fen
Graves, Nicholas
Evans, Martin F.
Rubin, Michael A.
TI Reducing Time-dependent Bias in Estimates of the Attributable Cost of
Health Care-associated Methicillin-resistant Staphylococcus aureus
Infections A Comparison of Three Estimation Strategies
SO MEDICAL CARE
LA English
DT Article
DE costs; MRSA; health care-associated infection
ID LENGTH-OF-STAY; BURDEN; IMPACT
AB Background:Previous estimates of the excess costs due to health care-associated infection (HAI) have scarcely addressed the issue of time-dependent bias.Objective:We examined time-dependent bias by estimating the health care costs attributable to an HAI due to methicillin-resistant Staphylococcus aureus (MRSA) using a unique dataset in the Department of Veterans Affairs (VA) that makes it possible to distinguish between costs that occurred before and after an HAI. In addition, we compare our results to those from 2 other estimation strategies.Methods:Using a historical cohort study design to estimate the excess predischarge costs attributable to MRSA HAIs, we conducted 3 analyses: (1) conventional, in which costs for the entire inpatient stay were compared between patients with and without MRSA HAIs; (2) post-HAI, which included only costs that occurred after an infection; and (3) matched, in which costs for the entire inpatient stay were compared between patients with an MRSA HAI and subset of patients without an MRSA HAI who were matched based on the time to infection.Results:In our post-HAI analysis, estimates of the increase in inpatient costs due to MRSA HAI were $12,559 (P<0.0001) and $24,015 (P<0.0001) for variable and total costs, respectively. The excess variable and total cost estimates were 33.7% and 31.5% higher, respectively, when using the conventional methods and 14.6% and 11.8% higher, respectively, when using matched methods.Conclusions:This is the first study to account for time-dependent bias in the estimation of incremental per-patient health care costs attributable to HAI using a unique dataset in the VA. We found that failure to account for this bias can lead to overestimation of these costs. Matching on the timing of infection can reduce this bias substantially.
C1 [Nelson, Richard E.; Samore, Matthew H.; Jones, Makoto; Stevens, Vanessa W.; Rubin, Michael A.] Vet Affairs Salt Lake City Hlth Care Syst, Salt Lake City, UT USA.
[Nelson, Richard E.; Samore, Matthew H.; Jones, Makoto; Greene, Tom; Rubin, Michael A.] Univ Utah, Sch Med, Dept Internal Med, Salt Lake City, UT USA.
[Stevens, Vanessa W.] Univ Utah, Coll Pharm, Dept Pharmacotherapy, Salt Lake City, UT 84112 USA.
[Liu, Chuan-Fen] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
[Liu, Chuan-Fen] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Graves, Nicholas] Univ Queensland, Sch Publ Hlth, Brisbane, Qld, Australia.
[Evans, Martin F.] Lexington Vet Affairs Med Ctr, Lexington, KY USA.
[Evans, Martin F.] Univ Kentucky, Dept Internal Med, Lexington, KY USA.
RP Nelson, RE (reprint author), 500 Foothill Blvd, Salt Lake City, UT 84148 USA.
EM richard.nelson@utah.edu
OI Graves, Nicholas/0000-0002-5559-3267; Stevens,
Vanessa/0000-0001-8933-5453
FU Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development, Health Services Research and Development
Service [CDA 11-210]; Centers for Disease Control and Prevention, Safety
and Healthcare Epidemiology Prevention Research Development Program
[200-2011-42039]
FX Supported by the Department of Veterans Affairs, Veterans Health
Administration, Office of Research and Development, Health Services
Research and Development Service (CDA 11-210) with R.E.N. as the
principal investigator and the Centers for Disease Control and
Prevention, Safety and Healthcare Epidemiology Prevention Research
Development Program (contract number 200-2011-42039) with M.H.S. as the
principal investigator.
NR 28
TC 4
Z9 4
U1 2
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7079
EI 1537-1948
J9 MED CARE
JI Med. Care
PD SEP
PY 2015
VL 53
IS 9
BP 827
EP 834
DI 10.1097/MLR.0000000000000403
PG 8
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA CQ4QM
UT WOS:000360589700012
PM 26225444
ER
PT J
AU Simuni, T
Caspell-Garcia, C
Coffey, C
Chahine, LM
Lasch, S
Oertel, WH
Mayer, G
Hogl, B
Postuma, R
Videnovic, A
Amara, AW
Marek, K
AF Simuni, Tanya
Caspell-Garcia, Chelsea
Coffey, Christopher
Chahine, Lama M.
Lasch, Shirley
Oertel, Wolfgang H.
Mayer, Geert
Hoegl, Birgit
Postuma, Ron
Videnovic, Aleksandar
Amara, Amy Willis
Marek, Ken
CA PPMI Sleep Working Group Behalf PP
TI Correlates of Excessive Daytime Sleepiness in De Novo Parkinson's
Disease: A Case Control Study
SO MOVEMENT DISORDERS
LA English
DT Article
DE Parkinson's disease; daytime somnolence; biomarkers
ID POSTURAL SWAY; BRAIN-STIMULATION; GAIT; LEVODOPA; PROGRESSION;
VALIDATION; INITIATION; PEOPLE; MOTOR; RISK
AB Objective: This study was undertaken to determine the frequency and correlates of excessive daytime sleepiness in de novo, untreated Parkinson's disease (PD) patients compared with the matched healthy controls. Methods: Data were obtained from the Parkinson's Progression Markers Initiative, an international study of de novo, untreated PD patients and healthy controls. At baseline, participants were assessed with a wide range of motor and nonmotor scales, including the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Excessive daytime sleepiness was assessed based on the Epworth Sleepiness scale (ESS), with a cutoff of 10. Results: Four hundred twenty-three PD subjects and 196 healthy controls were recruited into the study. Mean ESS (min, max) score was 5.8 (0, 20) for the PD subjects and 5.6 (0, 19) for healthy controls (P=0.54). Sixty-six (15.6%) PD subjects and 24 (12%) healthy controls had ESS of at least 10 (P=0.28). No difference was seen in demographic characteristics, age of onset, disease duration, PD subtype, cognitive status, or utilization of sedatives between the PD sleepiness-positive versus the negative group. The sleepiness-positive group had higher MDS-UPDRS Part I and II but not III scores, and higher depression and autonomic dysfunction scores. Sleepiness was associated with a marginal reduction of A-beta (P=0.05) but not alpha-synuclein spinal fluid levels in PD. Conclusions: This largest case control study demonstrates no difference in prevalence of excessive sleepiness in subjects with de novo untreated PD compared with healthy controls. The only clinical correlates of sleepiness were mood and autonomic dysfunction. Ongoing longitudinal analyses will be essential to further examine clinical and biological correlates of sleepiness in PD and specifically the role of dopaminergic therapy. (c) 2015 International Parkinson and Movement Disorder Society
C1 [Simuni, Tanya] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
[Caspell-Garcia, Chelsea; Coffey, Christopher] Univ Iowa, Iowa City, IA USA.
[Chahine, Lama M.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Lasch, Shirley; Marek, Ken] Inst Neurodegenerat Disorders, New Haven, CT USA.
[Oertel, Wolfgang H.] Charitable Hertie Fdn, Frankfurt, Germany.
[Mayer, Geert] Hephata Hess Diakoniezentrum eV, Hephata Klin, Geisenheim, Germany.
[Hoegl, Birgit] Med Univ Innsbruck, A-6020 Innsbruck, Austria.
[Postuma, Ron] McGill Univ, Montreal, PQ, Canada.
[Videnovic, Aleksandar] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Amara, Amy Willis] UAB Sch Med, Birmingham, AL USA.
RP Simuni, T (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Neurol, 710 North Lake Shore Dr,1126, Chicago, IL 60611 USA.
EM tsimuni@nmff.org
RI Singleton, Andrew/C-3010-2009;
OI Amara, Amy/0000-0003-0762-9656; Standaert, David/0000-0003-2921-8348
FU Michael J. Fox Foundation for Parkinson's Research (MJFF); MJFF; Abbvie;
Avid Radiopharmaceuticals; Biogen Idec; Bristol-Myers Squibb; Covance;
Eli Lilly Co.; F. Hoffman-La Roche, Ltd.; GE Healthcare; Genentech;
GlaxoSmithKline; Lundbeck; Merck; MesoScale; Piramal; Pfizer; UCB
FX P.P.M.I. is sponsored by the Michael J. Fox Foundation for Parkinson's
Research (MJFF) and is co-funded by MJFF, Abbvie, Avid
Radiopharmaceuticals, Biogen Idec, Bristol-Myers Squibb, Covance, Eli
Lilly & Co., F. Hoffman-La Roche, Ltd., GE Healthcare, Genentech,
GlaxoSmithKline, Lundbeck, Merck, MesoScale, Piramal, Pfizer and UCB.
NR 37
TC 6
Z9 7
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-3185
EI 1531-8257
J9 MOVEMENT DISORD
JI Mov. Disord.
PD SEP
PY 2015
VL 30
IS 10
BP 1371
EP 1381
DI 10.1002/mds.26248
PG 11
WC Clinical Neurology
SC Neurosciences & Neurology
GA CQ7CD
UT WOS:000360759500042
PM 26095202
ER
PT J
AU Ashokkumar, A
Kearney, M
Simpson, E
Videnovic, A
Cudkowicz, M
AF Ashokkumar, A.
Kearney, M.
Simpson, E.
Videnovic, A.
Cudkowicz, M.
TI Neurological Clinical Research Institute (NCRI) Coordinating Center
Support for Multi-Center Clinical Trials: Lessons Learned to Improve
Efficiency of Study Start Up
SO MOVEMENT DISORDERS
LA English
DT Meeting Abstract
CT 29th Annual Symposium on Etiology, Pathogenesis, and Treatment of
Parkinson Disease and Other Movement Disorders
CY SEP 12, 2015
CL Ft Myers, FL
C1 [Ashokkumar, A.; Kearney, M.; Simpson, E.; Videnovic, A.; Cudkowicz, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-3185
EI 1531-8257
J9 MOVEMENT DISORD
JI Mov. Disord.
PD SEP
PY 2015
VL 30
IS 10
MA 22
BP E7
EP E7
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA CQ7CD
UT WOS:000360759500018
ER
PT J
AU Chen, X
Umeh, CC
Maguire, M
Tainsh, R
Macklin, EA
Buys, M
Schwarzschild, MA
AF Chen, X.
Umeh, C. C.
Maguire, M.
Tainsh, R.
Macklin, E. A.
Buys, M.
Schwarzschild, M. A.
TI Serum Urate Elevation and Blood Pressure Modulation in Parkinson
disease: an Exploratory Analysis
SO MOVEMENT DISORDERS
LA English
DT Meeting Abstract
CT 29th Annual Symposium on Etiology, Pathogenesis, and Treatment of
Parkinson Disease and Other Movement Disorders
CY SEP 12, 2015
CL Ft Myers, FL
C1 [Chen, X.; Maguire, M.; Macklin, E. A.; Schwarzschild, M. A.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Umeh, C. C.] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA.
[Tainsh, R.; Buys, M.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-3185
EI 1531-8257
J9 MOVEMENT DISORD
JI Mov. Disord.
PD SEP
PY 2015
VL 30
IS 10
MA 30
BP E10
EP E10
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA CQ7CD
UT WOS:000360759500026
ER
PT J
AU Huang, Z
Li, J
Ascherio, A
Cui, L
Dou, N
Schwarzschild, MA
Wu, S
Gao, X
AF Huang, Z.
Li, J.
Ascherio, A.
Cui, L.
Dou, N.
Schwarzschild, M. A.
Wu, S.
Gao, X.
TI Urate and Rapid Eye Movement Sleep Behavior Disorder: A Community-Based
Study.
SO MOVEMENT DISORDERS
LA English
DT Meeting Abstract
CT 29th Annual Symposium on Etiology, Pathogenesis, and Treatment of
Parkinson Disease and Other Movement Disorders
CY SEP 12, 2015
CL Ft Myers, FL
C1 [Huang, Z.; Li, J.; Cui, L.; Wu, S.] Kailuan Hosp, Dept Internal Med, Tangshan, Hebei, Peoples R China.
[Huang, Z.; Dou, N.; Gao, X.] Penn State Univ, Dept Nutr Sci, University Pk, PA 16802 USA.
[Ascherio, A.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Schwarzschild, M. A.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Schwarzschild, M. A.] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-3185
EI 1531-8257
J9 MOVEMENT DISORD
JI Mov. Disord.
PD SEP
PY 2015
VL 30
IS 10
BP E1
EP E2
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA CQ7CD
UT WOS:000360759500002
ER
PT J
AU Videnovic, A
Marconi, A
Wolfe, L
Zee, PC
Klerman, EB
Turek, F
AF Videnovic, A.
Marconi, A.
Wolfe, L.
Zee, P. C.
Klerman, E. B.
Turek, F.
TI Circadian Expression of Clock Genes in Parkinson's Disease -
Implications for Disrupted Sleep and Daytime Sleepiness.
SO MOVEMENT DISORDERS
LA English
DT Meeting Abstract
CT 29th Annual Symposium on Etiology, Pathogenesis, and Treatment of
Parkinson Disease and Other Movement Disorders
CY SEP 12, 2015
CL Ft Myers, FL
C1 [Videnovic, A.] Massachusetts Gen Hosp, Movement Disorders Unit, Boston, MA 02114 USA.
[Videnovic, A.; Klerman, E. B.] Harvard Univ, Sch Med, Div Sleep Med, Boston, MA USA.
[Marconi, A.; Wolfe, L.; Zee, P. C.] Northwestern Univ, Northwestern Univ Feinberg Sch Med, Dept Neurol, Chicago, IL USA.
[Turek, F.] Northwestern Univ, Dept Neurobiol, Evanston, IL USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-3185
EI 1531-8257
J9 MOVEMENT DISORD
JI Mov. Disord.
PD SEP
PY 2015
VL 30
IS 10
BP E2
EP E2
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA CQ7CD
UT WOS:000360759500003
ER
PT J
AU Liu, JZ
van Sommeren, S
Huang, HL
Ng, SC
Alberts, R
Takahashi, A
Ripke, S
Lee, JC
Jostins, L
Shah, T
Abedian, S
Cheon, JH
Cho, J
Daryani, NE
Franke, L
Fuyuno, Y
Hart, A
Juyal, RC
Juyal, G
Kim, WH
Morris, AP
Poustchi, H
Newman, WG
Midha, V
Orchard, TR
Vahedi, H
Sood, A
Sung, JJY
Malekzadeh, R
Westra, HJ
Yamazaki, K
Yang, SK
Barrett, JC
Franke, A
Alizadeh, BZ
Parkes, M
Thelma, BK
Daly, MJ
Kubo, M
Anderson, CA
Weersma, RK
AF Liu, Jimmy Z.
van Sommeren, Suzanne
Huang, Hailiang
Ng, Siew C.
Alberts, Rudi
Takahashi, Atsushi
Ripke, Stephan
Lee, James C.
Jostins, Luke
Shah, Tejas
Abedian, Shifteh
Cheon, Jae Hee
Cho, Judy
Daryani, Naser E.
Franke, Lude
Fuyuno, Yuta
Hart, Ailsa
Juyal, Ramesh C.
Juyal, Garima
Kim, Won Ho
Morris, Andrew P.
Poustchi, Hossein
Newman, William G.
Midha, Vandana
Orchard, Timothy R.
Vahedi, Homayon
Sood, Ajit
Sung, Joseph J. Y.
Malekzadeh, Reza
Westra, Harm-Jan
Yamazaki, Keiko
Yang, Suk-Kyun
Barrett, Jeffrey C.
Franke, Andre
Alizadeh, Behrooz Z.
Parkes, Miles
Thelma, B. K.
Daly, Mark J.
Kubo, Michiaki
Anderson, Carl A.
Weersma, Rinse K.
CA Int Multiple Sclerosis Genetics Co
Int IBD Genetics Consortium
TI Association analyses identify 38 susceptibility loci for inflammatory
bowel disease and highlight shared genetic risk across populations
SO NATURE GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; KAPPA-B-ZETA; ULCERATIVE-COLITIS;
CROHNS-DISEASE; JAPANESE POPULATION; COMPLEX DISEASES; METAANALYSIS;
VARIANTS; STRATIFICATION; ARCHITECTURE
AB Ulcerative colitis and Crohn's disease are the two main forms of inflammatory bowel disease (IBD). Here we report the first transancestry association study of IBD, with genome-wide or Immunochip genotype data from an extended cohort of 86,640 European individuals and Immunochip data from 9,846 individuals of East Asian, Indian or Iranian descent. We implicate 38 loci in IBD risk for the first time. For the majority of the IBD risk loci, the direction and magnitude of effect are consistent in European and non-European cohorts. Nevertheless, we observe genetic heterogeneity between divergent populations at several established risk loci driven by differences in allele frequency (NOD2) or effect size (TNFSF15 and ATG16L1) or a combination of these factors (IL23R and IRGM). Our results provide biological insights into the pathogenesis of IBD and demonstrate the usefulness of trans-ancestry association studies for mapping loci associated with complex diseases and understanding genetic architecture across diverse populations.
C1 [Liu, Jimmy Z.; Shah, Tejas; Barrett, Jeffrey C.; Anderson, Carl A.] Wellcome Trust Sanger Inst, Hinxton, England.
[van Sommeren, Suzanne; Alberts, Rudi; Weersma, Rinse K.] Univ Groningen, Univ Med Ctr Groningen, Dept Gastroenterol & Hepatol, Groningen, Netherlands.
[van Sommeren, Suzanne; Franke, Lude; Westra, Harm-Jan] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands.
[Huang, Hailiang; Ripke, Stephan; Daly, Mark J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Analyt & Translat Genet Unit, Boston, MA USA.
[Ng, Siew C.; Sung, Joseph J. Y.] Chinese Univ Hong Kong, Dept Med & Therapeut, Inst Digest Dis, LKS Inst Hlth Sci,State Key Lab Digest Dis, Hong Kong, Hong Kong, Peoples R China.
[Takahashi, Atsushi] RIKEN, Ctr Integrat Med Sci, Lab Stat Anal, Yokohama, Kanagawa, Japan.
[Lee, James C.; Parkes, Miles] Addenbrookes Hosp, Inflammatory Bowel Dis Res Grp, Cambridge, England.
[Jostins, Luke] Univ Oxford, Wellcome Trust Ctr Human Genet, Headington, England.
[Abedian, Shifteh; Poustchi, Hossein; Vahedi, Homayon; Malekzadeh, Reza] Shariati Hosp, Digest Dis Res Inst, Tehran, Iran.
[Cheon, Jae Hee; Kim, Won Ho] Yonsei Univ, Coll Med, Dept Gastroenterol & Hepatol, Seoul, South Korea.
[Cho, Judy] Mt Sinai Hosp, Icahn Sch Med, New York, NY 10029 USA.
[Daryani, Naser E.] Emam Hosp, Dept Gastroenterol, Tehran, Iran.
[Fuyuno, Yuta; Yamazaki, Keiko; Kubo, Michiaki] RIKEN, Ctr Integrat Med Sci, Lab Genotyping Dev, Yokohama, Kanagawa, Japan.
[Hart, Ailsa] St Marks Hosp, Inflammatory Bowel Dis Unit, Harrow, Middx, England.
[Juyal, Ramesh C.] Natl Inst Immunol, New Delhi 110067, India.
[Juyal, Garima; Thelma, B. K.] Univ Delhi, Dept Genet, New Delhi, India.
[Morris, Andrew P.] Univ Liverpool, Dept Biostat, Liverpool L69 3BX, Merseyside, England.
[Newman, William G.] Univ Manchester, Manchester Ctr Genom Med, Manchester, Lancs, England.
[Newman, William G.] Cent Manchester Univ Hosp Natl Hlth Serv NHS Fdn, Manchester, Lancs, England.
[Midha, Vandana; Sood, Ajit] Dayanand Med Coll & Hosp, Dept Med, Ludhiana, Punjab, India.
[Orchard, Timothy R.] St Marys Hosp, Dept Gastroenterol & Hepatol, London, England.
[Yang, Suk-Kyun] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Gastroenterol & Hepatol, Seoul, South Korea.
[Franke, Andre] Univ Kiel, Inst Clin Mol Biol, Kiel, Germany.
[Alizadeh, Behrooz Z.] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands.
RP Anderson, CA (reprint author), Univ Groningen, Univ Med Ctr Groningen, Dept Gastroenterol & Hepatol, Groningen, Netherlands.
EM carl.anderson@sanger.ac.uk; r.k.weersma@umcg.nl
RI Ng, Siew Chien/N-4733-2015; Rioux, John/A-9599-2015; Franke,
Lude/P-7036-2016; Wijmenga, Cisca/D-2173-2009; Ellinghaus,
David/G-4467-2012; Zeissig, Sebastian/B-6297-2012; Franke,
Andre/B-2151-2010; Palmieri, Orazio/J-7697-2012; Silverberg,
Mark/B-4183-2008; Kubo, Michiaki/N-7947-2015
OI Ziad Alizadeh, Behrooz/0000-0002-1415-8007; Laukens,
Debby/0000-0002-1984-5850; Kennedy, Nicholas/0000-0003-4368-1961;
Barrett, Jeffrey/0000-0002-1152-370X; Nothen,
Markus/0000-0002-8770-2464; Gearry, Richard/0000-0002-2298-5141;
Andersen, Vibeke/0000-0002-0127-2863; Newman,
William/0000-0002-6382-4678; Ng, Siew Chien/0000-0002-6850-4454; Rioux,
John/0000-0001-7560-8326; Franke, Lude/0000-0002-5159-8802; Franke,
Andre/0000-0003-1530-5811; Huang, Hailiang/0000-0003-1461-5762; Lee,
James/0000-0001-5711-9385; Palmieri, Orazio/0000-0002-0019-7929;
FU Netherlands Organization for Scientific Research (NWO) [016.136.308];
Broad Medical Research Program of the Broad Foundation [IBD-0318];
Netherlands Organization for Scientific Research (NWO), through NWO VENI
grant [916.10.135]; NWO VIDI grant [917.14.374]; European Community's
Health Seventh Framework Programme [259867]; Department of Biotechnology
of the government of India (New Delhi, India) [BT/01/COE/07/UDSC/2008];
Tehran University of Medical Sciences, Iran; National Association for
Colitis and Crohn's Disease; Wellcome Trust; Medical Research Council
UK; Peninsular College of Medicine and Dentistry, Exeter; National
Institute for Health Research (NIHR) Biomedical Research Centre;
Wellcome Trust [WT098017, 098051]
FX R.K.W. is supported by a VIDI grant (016.136.308) from the Netherlands
Organization for Scientific Research (NWO) and the Broad Medical
Research Program of the Broad Foundation (IBD-0318). L.F. is supported
by the Netherlands Organization for Scientific Research (NWO), through
NWO VENI grant 916.10.135 and NWO VIDI grant 917.14.374. The research
leading to these results has received funding from the European
Community's Health Seventh Framework Programme (FP7/2007-2013) under
grant agreement 259867. T.B.K. is supported by Centre of Excellence
grant BT/01/COE/07/UDSC/2008 from the Department of Biotechnology of the
government of India (New Delhi, India). The collection of Iranian
samples has been supported by the Tehran University of Medical Sciences,
Iran. UK case collections were supported by the National Association for
Colitis and Crohn's Disease, the Wellcome Trust, the Medical Research
Council UK and the Peninsular College of Medicine and Dentistry, Exeter.
We also acknowledge National Institute for Health Research (NIHR)
Biomedical Research Centre awards to Guy's and St Thomas' NHS
Trust/King's College London and to Addenbrooke's Hospital/University of
Cambridge School of Clinical Medicine. A.P.M. is supported by the
Wellcome Trust under award WT098017. J.Z.L., T.S., J.C.B. and C.A.A. are
supported by the Wellcome Trust (098051).
NR 53
TC 121
Z9 121
U1 8
U2 28
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
EI 1546-1718
J9 NAT GENET
JI Nature Genet.
PD SEP
PY 2015
VL 47
IS 9
BP 979
EP +
DI 10.1038/ng.3359
PG 11
WC Genetics & Heredity
SC Genetics & Heredity
GA CQ1XQ
UT WOS:000360394100007
PM 26192919
ER
PT J
AU Stachler, MD
Taylor-Weiner, A
Peng, SY
McKenna, A
Agoston, AT
Odze, RD
Davison, JM
Nason, KS
Loda, M
Leshchiner, I
Stewart, C
Stojanov, P
Seepo, S
Lawrence, MS
Ferrer-Torres, D
Lin, J
Chang, AC
Gabriel, SB
Lander, ES
Beer, DG
Getz, G
Carter, SL
Bass, AJ
AF Stachler, Matthew D.
Taylor-Weiner, Amaro
Peng, Shouyong
McKenna, Aaron
Agoston, Agoston T.
Odze, Robert D.
Davison, Jon M.
Nason, Katie S.
Loda, Massimo
Leshchiner, Ignaty
Stewart, Chip
Stojanov, Petar
Seepo, Sara
Lawrence, Michael S.
Ferrer-Torres, Daysha
Lin, Jules
Chang, Andrew C.
Gabriel, Stacey B.
Lander, Eric S.
Beer, David G.
Getz, Gad
Carter, Scott L.
Bass, Adam J.
TI Paired exome analysis of Barrett's esophagus and adenocarcinoma
SO NATURE GENETICS
LA English
DT Article
ID CIRCULAR BINARY SEGMENTATION; HIGH-GRADE DYSPLASIA; PROSTATE-CANCER;
COPY NUMBER; GASTROESOPHAGEAL-REFLUX; NEOPLASTIC PROGRESSION; GENOMIC
INSTABILITY; PANCREATIC-CANCER; SOMATIC MUTATIONS; CLONAL EXPANSION
AB Barrett's esophagus is thought to progress to esophageal adenocarcinoma (EAC) through a stepwise progression with loss of CDKN2A followed by TP53 inactivation and aneuploidy. Here we present whole-exome sequencing from 25 pairs of EAC and Barrett's esophagus and from 5 patients whose Barrett's esophagus and tumor were extensively sampled. Our analysis showed that oncogene amplification typically occurred as a late event and that TP53 mutations often occurred early in Barrett's esophagus progression, including in non-dysplastic epithelium. Reanalysis of additional EAC exome data showed that the majority (62.5%) of EACs emerged following genome doubling and that tumors with genomic doubling had different patterns of genomic alterations, with more frequent oncogenic amplification and less frequent inactivation of tumor suppressors, including CDKN2A. These data suggest that many EACs emerge not through the gradual accumulation of tumor-suppressor alterations but rather through a more direct path whereby a TP53-mutant cell undergoes genome doubling, followed by the acquisition of oncogenic amplifications.
C1 [Stachler, Matthew D.; Agoston, Agoston T.; Odze, Robert D.; Loda, Massimo] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Stachler, Matthew D.; Agoston, Agoston T.; Odze, Robert D.; Loda, Massimo] Harvard Univ, Sch Med, Boston, MA USA.
[Stachler, Matthew D.; Peng, Shouyong; Loda, Massimo; Bass, Adam J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Taylor-Weiner, Amaro; Leshchiner, Ignaty; Stewart, Chip; Stojanov, Petar; Seepo, Sara; Lawrence, Michael S.; Gabriel, Stacey B.; Lander, Eric S.; Getz, Gad; Carter, Scott L.; Bass, Adam J.] Eli & Edythe L Broad Inst, Cambridge, MA 02142 USA.
[McKenna, Aaron] Univ Washington, Seattle, WA 98195 USA.
[Davison, Jon M.; Nason, Katie S.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
[Ferrer-Torres, Daysha; Lin, Jules; Chang, Andrew C.; Beer, David G.] Univ Michigan, Sect Thorac Surg, Ann Arbor, MI 48109 USA.
[Lander, Eric S.] MIT, Dept Biol, Cambridge, MA USA.
[Getz, Gad] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Carter, Scott L.] Harvard Univ, Brigham & Womens Hosp, Sch Med,Broad Inst Harvard & MIT, Joint Ctr Canc Precis Med,Dana Farber Canc Inst, Boston, MA 02115 USA.
[Carter, Scott L.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Carter, Scott L.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
RP Carter, SL (reprint author), Eli & Edythe L Broad Inst, Cambridge, MA 02142 USA.
EM gadgetz@broadinstitute.org; scarter@broadinstitute.org;
adam_bass@dfci.harvard.edu
FU US National Institutes of Health [T32 HL007627]; Dana-Farber/Harvard
Gastrointestinal Cancer Specialized Programs of Research Excellence
[P50CA127003]; National Human Genome Research Institute (NHGRI)
Large-Scale Sequencing Program [U54 HG0003067]; National Cancer
Institute [U54 CA163059, P01 CA098101, U54 CA163004]; Broad Institute
SPARC; American Cancer Society
FX We thank the members of the Broad Institute Genome Sequencing Platform
and the molecular laboratories at Brigham and Women's Hospital and
Massachusetts General Hospital for their assistance. We are grateful to
the patients and families who agreed to contribute their samples to
enable this research and to the physicians and hospital staff whose
efforts in collecting these samples are essential to this work. This
work was supported by US National Institutes of Health grant T32
HL007627 and the Dana-Farber/Harvard Gastrointestinal Cancer Specialized
Programs of Research Excellence P50CA127003 (M.D.S.), the National Human
Genome Research Institute (NHGRI) Large-Scale Sequencing Program (U54
HG0003067; E.S.L.), National Cancer Institute grant U54 CA163059
(D.G.B.), Broad Institute SPARC funding (A.J.B., S.L.C. and G.G.), a
Research Scholar Grant from the American Cancer Society (A.J.B.) and the
National Cancer Institute (P01 CA098101 and U54 CA163004; A.J.B.).
NR 63
TC 36
Z9 36
U1 1
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
EI 1546-1718
J9 NAT GENET
JI Nature Genet.
PD SEP
PY 2015
VL 47
IS 9
BP 1047
EP +
DI 10.1038/ng.3343
PG 12
WC Genetics & Heredity
SC Genetics & Heredity
GA CQ1XQ
UT WOS:000360394100015
PM 26192918
ER
PT J
AU Sherrill, KR
Chrastil, ER
Ross, RS
Erdema, UM
Hasselmo, ME
Stern, CE
AF Sherrill, Katherine R.
Chrastil, Elizabeth R.
Ross, Robert S.
Erdema, Ugur M.
Hasselmo, Michael E.
Stern, Chantal E.
TI Functional connections between optic flow areas and navigationally
responsive brain regions during goal-directed navigation
SO NEUROIMAGE
LA English
DT Article
DE fMRI; Hippocampus; MT; Retrosplenial cortex; V3A; V6
ID PATH-INTEGRATION; RETROSPLENIAL CORTEX; HEAD-DIRECTION; COGNITIVE MAP;
VISUAL-MOTION; NEURAL BASIS; SPATIAL NAVIGATION; TEMPORAL LOBECTOMY;
ENTORHINAL CORTEX; HIPPOCAMPUS
AB Recent computational models suggest that visual input from optic flow provides information about egocentric (navigator-centered) motion and influences firing patterns in spatially tuned cells during navigation. Computationally, self-motion cues can be extracted from optic flow during navigation. Despite the importance of optic flow to navigation, a functional link between brain regions sensitive to optic flow and brain regions important for navigation has not been established in either humans or animals. Here, we used a beta-series correlation methodology coupled with two fMRI tasks to establish this functional link during goal-directed navigation in humans. Functionally defined optic flow sensitive cortical areas V3A, V6, and hMT+ were used as seed regions. fMRI data was collected during a navigation task in which participants updated position and orientation based on self-motion cues to successfully navigate to an encoded goal location. The results demonstrate that goal-directed navigation requiring updating of position and orientation in the first person perspective involves a cooperative interaction between optic flow sensitive regions V3A, V6, and hMT+ and the hippocampus, retrosplenial cortex, posterior parietal cortex, and medial prefrontal cortex. These functional connections suggest a dynamic interaction between these systems to support goal-directed navigation. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Sherrill, Katherine R.; Chrastil, Elizabeth R.; Erdema, Ugur M.; Hasselmo, Michael E.; Stern, Chantal E.] Boston Univ, Dept Psychol & Brain Sci, Ctr Memory & Brain, Boston, MA 02215 USA.
[Sherrill, Katherine R.; Chrastil, Elizabeth R.; Stern, Chantal E.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
[Ross, Robert S.] Univ New Hampshire, Dept Psychol, Durham, NH 03824 USA.
RP Stern, CE (reprint author), Boston Univ, Ctr Memory & Brain, 2 Cummington Mall,Room 109, Boston, MA 02215 USA.
EM Chantal@bu.edu
OI Ross, Robert/0000-0002-3987-881X; Hasselmo, Michael/0000-0002-9925-6377;
Chrastil, Elizabeth/0000-0003-2544-0152
FU Office of Naval Research (ONR) Multi-disciplinary University Research
Initiative (MURI) [N00014-10-1-0936]; NCRR [P41RR14075]
FX This work was conducted with the support from the Office of Naval
Research (ONR) Multi-disciplinary University Research Initiative (MURI)
(N00014-10-1-0936). fMRI scanning was completed at the Athinoula A.
Martinos Center for Biomedical Imaging (Charlestown, MA), which receives
support from NCRR P41RR14075. We would like to thank Dr. Jesse Rissman
for providing his custom Matlab script of the functional connectivity
analysis, Randall Newmark for assisting in fMRI data collection, Deepti
Putcha for assistance with processing the optic flow data, and Dr. David
Somers from the Perceptual Neuroimaging Laboratory at Boston University
for providing the optic flow task. The authors declare no competing
financial interests.
NR 71
TC 2
Z9 2
U1 1
U2 11
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
EI 1095-9572
J9 NEUROIMAGE
JI Neuroimage
PD SEP
PY 2015
VL 118
BP 386
EP 396
DI 10.1016/j.neuroimage.2015.06.009
PG 11
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA CQ5GB
UT WOS:000360630200037
PM 26054874
ER
PT J
AU Skeide, MA
Kirsten, H
Kraft, I
Schaadt, G
Muller, B
Neef, N
Brauer, J
Wilcke, A
Emmrich, F
Boltze, J
Friederici, AD
AF Skeide, Michael A.
Kirsten, Holger
Kraft, Indra
Schaadt, Gesa
Mueller, Bent
Neef, Nicole
Brauer, Jens
Wilcke, Arndt
Emmrich, Frank
Boltze, Johannes
Friederici, Angela D.
TI Genetic dyslexia risk variant is related to neural connectivity patterns
underlying phonological awareness in children
SO NEUROIMAGE
LA English
DT Article
ID PARIETAL WHITE-MATTER; DEVELOPMENTAL DYSLEXIA; READING-ABILITY; BRAIN;
ACTIVATION; MECHANISMS; REGIONS; MOTION; ADULTS; VOLUME
AB Phonological awareness is the best-validated predictor of reading and spelling skill and therefore highly relevant for developmental dyslexia. Prior imaging genetics studies link several dyslexia risk genes to either brain-functional or brain-structural factors of phonological deficits. However, coherent evidence for genetic associations with both functional and structural neural phenotypes underlying variation in phonological awareness has not yet been provided. Here we demonstrate that rs11100040, a reported modifier of SLC2A3, is related to the functional connectivity of left fronto-temporal phonological processing areas at resting state in a sample of 9- to 12-year-old children. Furthermore, we provide evidence that rs11100040 is related to the fractional anisotropy of the arcuate fasciculus, which forms the structural connection between these areas. This structural connectivity phenotype is associated with phonological awareness, which is in turn associated with the individual retrospective risk scores in an early dyslexia screening as well as to spelling. These results suggest a link between a dyslexia risk genotype and a functional as well as a structural neural phenotype, which is associated with a phonological awareness phenotype. The present study goes beyond previous work by integrating genetic, brain-functional and brain-structural aspects of phonological awareness within a single approach. These combined findings might be another step towards a multimodal biomarker for developmental dyslexia. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Skeide, Michael A.; Kraft, Indra; Schaadt, Gesa; Neef, Nicole; Brauer, Jens; Friederici, Angela D.] Max Planck Inst Human Cognit & Brain Sci, Dept Neuropsychol, D-04103 Leipzig, Germany.
[Kirsten, Holger; Mueller, Bent; Wilcke, Arndt; Emmrich, Frank; Boltze, Johannes] Fraunhofer Inst Cell Therapy & Immunol, D-04103 Leipzig, Germany.
[Kirsten, Holger] Univ Leipzig, Inst Med Informat Stat & Epidemiol, D-04107 Leipzig, Germany.
[Kirsten, Holger] Univ Leipzig, LIFE Leipzig Res Ctr Civilizat Dis, D-04107 Leipzig, Germany.
[Schaadt, Gesa] Humboldt Univ, Dept Psychol, D-12489 Berlin, Germany.
[Emmrich, Frank; Boltze, Johannes] Translat Ctr Regenerat Med, D-04103 Leipzig, Germany.
[Boltze, Johannes] Massachusetts Gen Hosp, Charlestown, MA 02129 USA.
[Boltze, Johannes] Harvard Univ, Sch Med, Neurovasc Regulat Lab, Charlestown, MA 02129 USA.
RP Skeide, MA (reprint author), Max Planck Inst Human Cognit & Brain Sci, Stephanstr 1a, D-04103 Leipzig, Germany.
EM skeide@cbs.mpg.de
OI Muller, Bent/0000-0001-8308-6193
FU Max Planck Society; Fraunhofer Society [M.FE.A.NEPF0001]
FX This work was funded by the Max Planck Society and the Fraunhofer
Society (grant number M.FE.A.NEPF0001). We thank Alfred Anwander for
providing his expertise in diffusion-weighted magnetic resonance
imaging.
NR 59
TC 3
Z9 3
U1 4
U2 20
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
EI 1095-9572
J9 NEUROIMAGE
JI Neuroimage
PD SEP
PY 2015
VL 118
BP 414
EP 421
DI 10.1016/j.neuroimage.2015.06.024
PG 8
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA CQ5GB
UT WOS:000360630200040
PM 26080313
ER
PT J
AU Duval, T
McNab, JA
Setsompop, K
Witzel, T
Schneider, T
Huang, SY
Keil, B
Klawiter, EC
Wald, LL
Cohen-Adad, J
AF Duval, Tanguy
McNab, Jennifer A.
Setsompop, Kawin
Witzel, Thomas
Schneider, Torben
Huang, Susie Yi
Keil, Boris
Klawiter, Eric C.
Wald, Lawrence L.
Cohen-Adad, Julien
TI In vivo mapping of human spinal cord microstructure at 300 mT/m
SO NEUROIMAGE
LA English
DT Article
DE Diffusion MRI; AxCaliber; Axon diameter; Quantification; Human; Spinal
cord
ID AXON DIAMETER DISTRIBUTION; HUMAN CONNECTOME PROJECT; DIFFUSION MRI;
WHITE-MATTER; WATER DIFFUSION; HUMAN BRAIN; MAGNETIZATION-TRANSFER;
TISSUE-MICROSTRUCTURE; MULTIPLE-SCLEROSIS; MULTICOMPONENT T-1
AB The ability to characterize white matter microstructure non-invasively has important applications for the diagnosis and follow-up of several neurological diseases. There exists a family of diffusion MRI techniques, such as AxCaliber, that provide indices of axon microstructure, such as axon diameter and density. However, to obtain accurate measurements of axons with small diameters (<5 mu m), these techniques require strong gradients, i.e. an order of magnitude higher than the 40-80 mT/m currently available in clinical systems. In this study we acquired AxCaliber diffusion data at a variety of different q-values and diffusion times in the spinal cord of five healthy subjects using a 300 mT/m whole body gradient system. Acquisition and processing were optimized using state-of-the-artmethods (e.g., 64-channel coil, template-based analysis). Results consistently show an average axon diameter of 4.5 +/- 1.1 mu min the spinal cord white matter. Diameters ranged from 3.0 mu m(gracilis) to 5.9 mu m (spinocerebellar tracts). Values were similar across laterality (left-right), but statistically different across spinal cord pathways (p < 10(-5)). The observed trends are similar to those observed in animal histology. This study shows, for the first time, in vivo mapping of axon diameter in the spinal cord at 300 mT/m, thus creating opportunities for applications in spinal cord diseases. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Duval, Tanguy; Cohen-Adad, Julien] Polytech Montreal, Inst Biomed Engn, Montreal, PQ H3T 1J4, Canada.
[McNab, Jennifer A.] Stanford Univ, Dept Radiol, Stanford, CA 94305 USA.
[Setsompop, Kawin; Witzel, Thomas; Huang, Susie Yi; Keil, Boris; Wald, Lawrence L.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, AA Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Schneider, Torben] UCL Inst Neurol, Queen Sq MS Ctr, Dept Neuroinflammat, NMR Res Unit, London, England.
[Klawiter, Eric C.] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Cohen-Adad, Julien] Univ Montreal, CRIUGM, Funct Neuroimaging Unit, Montreal, PQ, Canada.
RP Cohen-Adad, J (reprint author), Polytech Montreal, Inst Biomed Engn, 2900 Edouard Montpetit Bld, Montreal, PQ H3T 1J4, Canada.
EM jcohen@polymtl.ca
RI Wald, Lawrence/D-4151-2009;
OI DUVAL, Tanguy/0000-0002-1228-5192
FU National Institutes of Health [P41EB015896]; NIH Blueprint Initiative
for Neuroscience Research [U01MH093765]; MS Society of Canada [EGID
2370]; SensoriMotor Rehabilitation Research Team (SMRRT) of the Canadian
Institute of Health Research; National MS Society [FG1892A1/1]; Fonds de
Recherche du Quebec - Sante (FRQS); Quebec BioImaging Network (QBIN);
Natural Sciences and Engineering Research Council of Canada (NSERC)
FX We would like to thank the individuals who participated in this
experiment. We also thank Marc Benhamou and Benjamin De Leener for the
creation of the atlas of white matter tracts and the development of
registration tools. This study was founded by National Institutes of
Health, NIH Blueprint Initiative for Neuroscience Research grant
U01MH093765, National Institutes of Health grant P41EB015896, the MS
Society of Canada [EGID 2370], the SensoriMotor Rehabilitation Research
Team (SMRRT) of the Canadian Institute of Health Research, the National
MS Society [FG1892A1/1], the Fonds de Recherche du Quebec - Sante
(FRQS), the Quebec BioImaging Network (QBIN) and the Natural Sciences
and Engineering Research Council of Canada (NSERC).
NR 88
TC 8
Z9 8
U1 3
U2 18
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
EI 1095-9572
J9 NEUROIMAGE
JI Neuroimage
PD SEP
PY 2015
VL 118
BP 494
EP 507
DI 10.1016/j.neuroimage.2015.06.038
PG 14
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA CQ5GB
UT WOS:000360630200047
PM 26095093
ER
PT J
AU Chen, JX
Kozin, ED
Sethi, RKV
Remenschneider, AK
Emerick, KS
Gray, ST
AF Chen, Jenny X.
Kozin, Elliott D.
Sethi, Rosh K. V.
Remenschneider, Aaron K.
Emerick, Kevin S.
Gray, Stacey T.
TI Increased Resident Research over an 18-Year Period: A Single
Institution's Experience
SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY
LA English
DT Article
DE residency; otolaryngology; work hours; research; publication
ID DUTY HOUR RESTRICTIONS; ACADEMIC OTOLARYNGOLOGY; SCHOLARLY IMPACT;
NECK-SURGERY; PUBLICATIONS; PRODUCTIVITY; PERSPECTIVES; APPLICANTS; HEAD
AB Objectives (1) To evaluate changes in the resident publications over time, including before and after duty hour restrictions, and (2) to identify factors statistically associated with publications during residency.
Study Design Retrospective review of bibliometric data.
Subjects and Methods Residents who graduated from an otolaryngology residency program from 1996 to 2013 were evaluated. Thomson Reuters Web of Science was searched to determine the number of indexed peer-reviewed publications before and after implementation of resident duty hour restrictions in 2003. Resident demographics, PhD degrees, training tracks, and postgraduation plans were collected to determine factors associated with publication rate using multivariable regression analysis.
Results During the studied period, 75 residents completed otolaryngology residency training and published a total of 294 papers, averaging 3.92 publications per resident during training. After work hour restrictions were implemented, the mean number of publications increased from 1.21 to 5.10 (P < .0001). First author publications, clinical publications, and basic science publications all increased (P < .001). In regression analysis, T32 grants ( = 6.98, standard error [SE] = 1.87, P = .0004) and the time period after duty hour restrictions were introduced ( = 4.72, SE = 1.73, P = .0083) were positively associated with resident publications. Gender, PhD degree, and pursuit of fellowship training were not associated with increased publications (P > .05).
Conclusion There has been a significant increase in resident publications over time, coinciding with the implementation of work hour restrictions. T32 grants were most predictive of increased resident publications, while PhD degrees were not significantly associated.
C1 [Chen, Jenny X.; Kozin, Elliott D.; Sethi, Rosh K. V.; Remenschneider, Aaron K.; Emerick, Kevin S.; Gray, Stacey T.] Harvard Univ,